fluorouracil has been researched along with Cancer of Colon in 3643 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 9.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer." | 9.69 | Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0." | 9.51 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022) |
| " The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death." | 9.41 | Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature. ( Guo, Y; Liu, F; Nian, J; Xu, Y; Yang, G, 2023) |
| "This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 9.24 | Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017) |
| "The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer." | 9.17 | Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. ( Chachad, S; Malhotra, G; Naidu, R; Purandare, S, 2013) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 9.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 9.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 9.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma." | 9.09 | Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. ( Fujii, S; Hatano, K; Kitayama, J; Matsuda, K; Muto, T; Nagawa, H; Nita, ME; Takenoue, T; Tsuruo, T, 2000) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 9.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 9.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 9.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 9.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs." | 9.04 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975) |
| "Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome." | 8.31 | Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report. ( Hemachudha, P; Phuenpathom, W; Pongpitakmetha, T; Rattanawong, W, 2023) |
| "Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC)." | 8.31 | Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. ( Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023) |
| "In this study, we investigated the combined treatment of 5-fluorouracil (5-FU) and Anatolian propolis extract (PE) on colorectal cancer (CRC)using in vitro and in vivo studies." | 8.31 | Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study. ( Aydogdu, G; Durmus, E; Goren, AC; Guler, EM; Hekimoglu, ER; Kanimdan, E; Kocyigit, A; Oruc, HH; Ozman, Z; Yasar, O; Yenigun, VB, 2023) |
| "To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy." | 8.12 | Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 8.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 8.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Ocular toxicity derived from the use of systemic fluorouracil has been widely described in the literature, as well as the relationship between the use of capecitabine and the appearance of conjunctivitis." | 8.12 | Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions. ( Bello Crespo, M; Gajete Pablos, MA; Gioseffi, HA; Roa García, DM; Trujillano Ruiz, A, 2022) |
| "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)." | 8.12 | Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022) |
| "The current study was set out to investigate the mechanism by which silenced long noncoding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) modulates the cell growth, migration, invasion, and drug sensitivity of breast cancer (BC) cells to 5-fluorouracil (5-Fu) with the involvement of miR-145 and p53." | 8.12 | Effect of long noncoding RNA CCAT2 on drug sensitivity to 5-fluorouracil of breast cancer cells through microRNA-145 meditated by p53. ( Cheng, W; Gu, J; Wang, J; Wang, Q; Wang, X; Wang, Y; Wu, H; Zhang, Z; Zheng, G; Zhou, D, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 8.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 8.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine." | 8.12 | [Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports]. ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022) |
| "Patients with colorectal cancer treated with 5-fluorouracil (5-FU) and irinotecan (CPT-11) exhibit a risk for chemotherapy-induced colitis (CIC) that may lead to fatal consequences." | 8.02 | Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism. ( Du, GH; Wang, L; Wang, R; Wang, SM; Wang, Z; Wei, GY; Zhang, RP; Zhu, Y, 2021) |
| " Here, we evaluated the anti-inflammatory Trimethylglycine and the Signal transducer and activator of transcription (STAT6) inhibitor AS1517499, as possible adjuvants to 5-FU in already established cancers, using a model of colitis-associated colon cancer (CAC)." | 7.96 | Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. ( Beristain-Terrazas, DL; Callejas, BE; Chirino, YI; Delgado-Buenrostro, NL; García-Castillo, V; Gutierrez-Cirlos, EB; León-Cabrera, SA; Mendoza-Rodríguez, MG; Meraz-Ríos, MA; Pérez-Plasencia, C; Rodríguez-Sosa, M; Sánchez-Barrera, CÁ; Terrazas, LI; Vaca-Paniagua, F, 2020) |
| " We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response." | 7.91 | Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019) |
| "The compound 5-fluorouracil (5-FU) is the first choice chemotherapeutic agent for the treatment of colorectal cancer (CRC), but intestinal mucositis is a primary limiting factor in anticancer therapy." | 7.88 | Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. ( Cao, L; Gao, L; Wang, C; Wang, L; Yang, S, 2018) |
| "Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells." | 7.88 | Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. ( Ahmed, F; Kondapi, AK; Kumari, S, 2018) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer." | 7.85 | Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. ( Auboeuf, D; Bash-Imam, Z; Catez, F; Dalla Venezia, N; David, A; Diaz, JJ; Dutertre, M; Lafôrets, F; Macari, F; Marcel, V; Mertani, HC; Pannequin, J; Pion, N; Polay Espinoza, M; Saurin, JC; Textoris, J; Thérizols, G; Vincent, A, 2017) |
| "The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear." | 7.85 | Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). ( Hong, YS; Kim, CW; Kim, HJ; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Yoon, YS; Yu, CS, 2017) |
| " In the present study, we examined the potential of DECPR to prevent colon cancer development in rats treated with azoxymethane (AOM) (15 mg/kg) by determining the percentage inhibition in incidence of aberrant crypt foci (ACF)." | 7.81 | The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats. ( Abd Malek, SN; Abdulla, MA; Al-Henhena, N; Awang, K; Hasanpourghadi, M; Kunasegaran, T; Looi, CY; Moghadamtousi, SZ; Mohamed, Z; Rouhollahi, E, 2015) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 7.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 7.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| "The present study investigated whether a water-soluble extract from the culture medium of Ganoderma lucidum mycelia (Japanese: Reishi or Mannentake) (designated as MAK) exerted a protective effect against induction of aberrant crypt foci (ACF) by azoxymethane (AOM) and small-intestinal damage induced by the anticancer drug 5-FU." | 7.79 | Effects of a water-soluble extract of Ganoderma lucidum mycelia on aberrant crypt foci induced by azoxymethane and small-intestinal injury by 5-FU in F344 rats. ( Kashimoto, N; Tamura, K; Ushijima, M; Watanabe, H, 2013) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 7.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 7.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)." | 7.76 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 7.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients." | 7.74 | Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. ( Easaw, JC; Vickers, MM, 2008) |
| "To clarify the potential of parathyroid hormone-related protein (PTHrP) and interleukin-6 (IL-6) as cachectic factors in a colon 26 model and the effects of capecitabine on cancer cachexia as determined by plasma levels of IL-6 and PTHrP and body weight loss." | 7.74 | Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007) |
| "This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients." | 7.74 | Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007) |
| "To investigate the inhibitive effects of triptolide (TPL) combined with 5-fluorouracil (5-FU) on colon carcinoma HT-29 cells in vitro and in vivo and their side effects." | 7.74 | Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. ( Lin, XL; Tang, XY; Tao, WH; Wei, B; Zhu, YQ, 2007) |
| "Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors." | 7.74 | Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007) |
| "We reported two cases of retroperitoneal hematoma in patients who received a combination of anticoagulant therapy and 5-fluorouracil (5-FU)." | 7.73 | Two cases of retroperitoneal hematoma caused by combination of anticoagulant therapy and 5-fluorouracil. ( Furutani, K; Furutani, S; Kashihara, K; Minato, M; Morita, N; Murase, T; Nishitani, H; Otsuka, H; Tagashira, H; Tsujikawa, T; Yoneda, K, 2005) |
| " We hypothesized that this polymorphism may modulate the cytotoxic effect of 5-fluorouracil (5FU) and methotrexate (MTX), two commonly used chemotherapeutic agents for colon and breast cancers, because the modes of action of 5FU and MTX are critically dependent on cellular composition of folates." | 7.72 | Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Sohn, KJ; Yates, Z, 2004) |
| "Canalicular obstruction may follow systemic use of 5-fluorouracil due to squamous metaplasia." | 7.71 | Squamous metaplasia of the canaliculi associated with 5-fluorouracil: a clinicopathologic case report. ( Agarwal, MR; Burnstine, MA; Esmaeli, B, 2002) |
| "This case can be considered the first documented Irinotecan-induced immune thrombocytopenia." | 7.70 | Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998) |
| "A selective inflammatory reaction involving actinic keratosis may occur in patients receiving systemic 5-fluorouracil as part of a chemotherapeutic protocol." | 7.70 | Selective inflammatory effect of systemic fluorouracil in actinic keratosis. ( Mehregan, D; Mohindra, R; Nabai, H, 1999) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| " In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer." | 7.70 | dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. ( Caradonna, SJ; Groshen, S; Ladner, RD; Lenz, HJ; Lynch, FJ; Sherrod, A; Stoehlmacher, J; Xiong, YP, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 7.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "To determine the effect of cellular proliferation and cell cycle stage on the ability of postirradiation 5-fluorouracil (5-FU) to radiosensitize cultured human colon adenocarcinoma Clone A cells." | 7.69 | 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. ( Buchholz, DJ; Lepek, KJ; Murray, D; Rich, TA, 1995) |
| "Exposure of the human colon adenocarcinoma HT29 cells to different concentrations of 5-fluorouracil (5FU) for 24 h resulted in a dose-dependent increase in the cellular glutathione (GSH) level which remained elevated up to 72 h following 5FU treatment." | 7.69 | Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. ( Boyce, HW; Chen, LT; Chen, MF, 1995) |
| "Several classes of plant polyphenols namely, flavonoids, chalcones and coumarins exhibited varying degrees of inhibition on the cell proliferation of human colon adenocarcinoma cell line 220." | 7.69 | Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. ( Das, NP; Yit, CC, 1994) |
| "To investigate the resistance against 5-fluorouracil (FU), thymidylate synthase (TS) mRNA level was measured by reverse transcription PCR (RT-PCR) technique and quantitated by a competitive-PCR method in human colon adenocarcinoma cell line, SNU-C1 and its FU resistant cell line, C1/FU." | 7.69 | [Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]. ( Aiba, K; Horikoshi, N; Minowa, S; Shibata, H; Shibata, J, 1994) |
| "The metabolism of 5-fluorouracil (5-FU) was monitored non-invasively in two xenografts, a hypopharynx carcinoma and a colon carcinoma (CSM) by 19F-magnetic resonance spectroscopy following an i." | 7.69 | 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo. ( Baumgart, F; Köpf-Maier, P; Tausch-Treml, R; Ziessow, D, 1996) |
| "Previous studies using cultured colon adenocarcinoma cells demonstrated that a mixture of the diastereoiosomers of the biologically active (6S) and inactive (6R) forms of (6RS) leucovorin or 5-formyl-H4PteGlu (LV) and recombinant human alpha2a-interferon (rIFN-alpha2a) in combination significantly increased the cytotoxicity of 5-fluorouracil (FUra) (by 10-14-fold) whereas FUra combined with single modulators was less potentiated (3-fold)." | 7.69 | Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. ( Cheshire, PJ; Houghton, JA; Morton, CL; Stewart, CF, 1995) |
| "Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule." | 7.68 | Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. ( Aschele, C; Bertino, JR; Guglielmi, AP; Melioli, GG; Mori, AM; Rosso, R; Sobrero, AF, 1993) |
| "To perform an economic evaluation of the joint use of 5-fluorouracil and levamisole as adjuvant chemotherapy in patients with fully resected Dukes' Stage C carcinoma of the colon, compared with resection and no chemotherapy." | 7.68 | A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. ( Gurney, H; Hall, J; Harnett, PR; Smith, RD, 1993) |
| "We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)." | 7.68 | In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 7.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil." | 7.68 | Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990) |
| "A human colon adenocarcinoma cell line (GC3TK-) was selected for thymidine kinase (TK) deficiency from cloned parental cells (GC3C1) by exposure to 5-bromodeoxyuridine (BrdUrd)." | 7.68 | Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. ( Germain, G; Houghton, JA; Houghton, PJ; Pennington, J; Radparvar, S; Rahman, A, 1990) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "The effect of 5-fluorouracil on the stability of DNA and the synthesis of DNA replication intermediates was analyzed in human colon adenocarcinoma cells." | 7.67 | Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. ( Lönn, S; Lönn, U, 1984) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 7.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 7.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 7.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "Parameters for inhibition of thymidylate synthase (TS) in a DMH-induced transplantable rat colon carcinoma were studied after intraperitoneal administration of bolus doxifluridine (5'-dFUR) 200 mg/kg." | 7.67 | Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. ( Almersjö, O; Berne, M; Gustavsson, B; Spears, P; Sundström, E, 1988) |
| "5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas." | 7.67 | Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Torrance, PM; Weiss, KD; Williams, LG, 1986) |
| "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 7.67 | Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. ( Jakubowski, AA; Kemeny, N, 1988) |
| "Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX." | 7.67 | Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 7.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed." | 7.67 | Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. ( Germain, G; Houghton, JA; Houghton, PJ; Torrance, PM, 1987) |
| "To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted." | 7.67 | Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985) |
| "Sequential methotrexate-5-fluorouracil (Mtx-5-Fu) reduces proliferation of human colon adenocarcinoma cells." | 7.67 | The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil. ( Lönn, S; Lönn, U, 1986) |
| "The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A." | 7.66 | In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. ( Corbett, TH; Heidelberger, C; Moran, RG; Shahinian, AH; Spears, CP, 1982) |
| "The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38)." | 7.66 | Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. ( Goto, A; Narisawa, T; Sano, M; Sato, M; Takahashi, T, 1983) |
| "A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice." | 7.66 | Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. ( Houghton, JA; Houghton, PJ, 1982) |
| "This study was designed to examine the possibilities for increasing the therapeutic index in the treatment of human colon adenocarcinomas maintained as xenografts in immune-deprived mice using combinations of methotrexate (MTX) that preceded 5-fluorouracil (FUra)." | 7.66 | The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Tice, AJ, 1982) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 7.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma." | 7.66 | Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981) |
| " Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy." | 7.30 | Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 ( Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0." | 7.11 | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022) |
| "DNA microsatellite instability was also assessed using a panel of mono- and dinucleotide markers." | 6.74 | Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. ( Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS, 2009) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 6.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 6.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 6.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "Treatment with levamisole alone had no detectable effect." | 6.67 | Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. ( Emerson, WA; Fleming, TR; Glick, JH; Goodman, PJ; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tormey, DC; Ungerleider, JS, 1990) |
| "5-Fluorouracil is a key element to the treatment of colon cancer." | 6.66 | Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. ( Allison, JD; Birnbaum, G; Khalid, U; Tanavin, T; Yang, Y, 2020) |
| "Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice." | 5.91 | The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023) |
| "Chloroquine (CQ) is an effective and safe antimalarial drug that is also used as a disease-modifying antirheumatic drug." | 5.91 | Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia. ( Ju, S; Jung, Y; Kang, C; Kim, J, 2023) |
| "The present study aimed to determine if oral methioninase (o-rMETase) combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with peritoneal-carcinomatosis formed from HCT-116 green fluorescent protein (GFP)-expressing colon-cancer cells implanted intra-peritoneally in nude mice." | 5.91 | Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis. ( Bouvet, M; Han, Q; Hoffman, RM; Kim, MJ; Park, JH, 2023) |
| "Colorectal cancer has risen to the third occurring cancer in the world." | 5.91 | The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. ( Chen, J; Chen, Q; Jin, S; Song, H; Song, X; Wang, L; Wang, Z; Xing, W; Yang, H; Zhao, W, 2023) |
| "5-Fluorouracil (5-FU) is a chemotherapy drug that treats several cancers; however, it causes severe adverse effects and multidrug resistance." | 5.91 | Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase. ( Ganesan, K; Gong, G; Tsim, KWK; Xiong, Q; Zheng, Y, 2023) |
| " The efficacy and adverse effects of maintenance treatment were compared between the two groups." | 5.72 | Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022) |
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 5.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR)." | 5.69 | An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. ( Antoniotti, C; Bensi, M; Bergamo, F; Boccaccino, A; Boquet, I; Catteau, A; Conca, V; Cremolini, C; Galon, J; Giordano, M; Leonetti, S; McGregor, K; Morano, F; Murgioni, S; Nielsen, TJ; Papiani, G; Passardi, A; Pietrantonio, F; Ross, DT; Rossini, D; Salvatore, L; Schweitzer, BL; Seitz, R; Tamburini, E; Varga, MG, 2023) |
| "The phase Ia/b trials investigated the safety and tolerability and antitumor activities of suvemcitug for pretreated advanced solid tumors and in combination with FOLFIRI (leucovorin and fluorouracil plus irinotecan) in second-line treatment of metastatic colorectal cancer using a 3 + 3 dose-escalation design." | 5.69 | Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials. ( Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y, 2023) |
| "The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer." | 5.69 | Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study." | 5.51 | [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab]. ( Colombo, A; Porretto, CM; Rosati, G, 2022) |
| "The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0." | 5.51 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022) |
| "The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin." | 5.51 | Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. ( Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME, 2022) |
| " Pretreatment with the pan-caspase inhibitor, z-VAD-FMK, attenuated the caspase-dependent apoptosis induced by circularly permuted tumor necrosis factor-related apoptosis-inducing ligand alone or combined with 5-fluorouracil." | 5.48 | Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. ( Liang, X; Sun, T; Yang, S; Zhao, R; Zhu, T, 2018) |
| "5-Fluorouracil has been considered as a cornerstone therapy for colorectal cancer; however, it suffers from low therapeutic response rate and severe side effects." | 5.46 | Apoptosis mediated chemosensitization of tumor cells to 5-fluorouracil on supplementation of fish oil in experimental colon carcinoma. ( Agnihotri, N; Kaur, S; Kumar, S; Rani, I; Sharma, B, 2017) |
| "Capecitabine is an oral prodrug of 5-fluorouracil and is commonly used oral chemotherapeutic drugs for advanced gastric and colorectal cancer." | 5.43 | Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. ( Achrekar, MS; Carvalho, MD; D'souza, A; Govindarajan, S; Gupta, S; Murugan, K; Ostwal, V, 2016) |
| "Aflibercept; a decoy receptor for vascular endothelial growth factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin calcium, fluorouracil, irinotecan hydrochloride) chemotherapy regime, was FDA approved in 2012 as second-line salvage chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. ( Chorawala, MR; Patel, RS; Thakur, A, 2023) |
| " The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death." | 5.41 | Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature. ( Guo, Y; Liu, F; Nian, J; Xu, Y; Yang, G, 2023) |
| " In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179." | 5.40 | Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014) |
| "A 77-year-old man with colon cancer and multiple metastases to the liver and lungs underwent resection of the primary tumor and D3 lymph node dissection." | 5.39 | [A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents]. ( Adachi, A; Nakajima, M; Uchisako, H; Uchiyama, T, 2013) |
| "5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers." | 5.39 | 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. ( Akpinar, B; Baran, Y; Can, G; Olsson, M; Zhivotovsky, B, 2013) |
| "5-Fluorouracil (5-FU) has a significant antineoplastic activity and has been used for the management of various malignant neoplasms." | 5.38 | Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. ( Çağdaş, M; Çalık, AN; Çeliker, E; Güzelburç, Ö; Velibey, Y, 2012) |
| "However, severe hyperbilirubinemia (grade 3/4) has not been previously reported in association with this chemotherapeutic agent." | 5.34 | Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. ( Fakih, MG; Gupta, B; LeVea, C; Litwin, A, 2007) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 5.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "Resistant HCT-8 colon cancer cell lines (HCT-8/FUI/15R and HCT-8/FUB/2R) were selected from parental sensitive HCT-8 cells by long-term and short-term exposure schedules, respectively." | 5.33 | Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules. ( Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E, 2005) |
| "Coronary artery spasm has been postulated to be involved in the mechanism of this incident Patients may present with angina, myocardial infarction, arrhythmias and/or even sudden death." | 5.31 | A case of coronary spasm induced by 5-fluorouracil. ( Celik, S; Gorgulu, S; Tezel, T, 2002) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 5.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Irinotecan and etoposide were combined using the (d x 5)2 i." | 5.29 | Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 5.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "5-Fluorouracil treatments resulted in a dose-dependent inhibition of tumor growth under the two examined schedules (five daily doses and three doses every 4 days) when administered either i." | 5.27 | 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. ( Frei, E; Goldin, A; Mantel, N; VanWinkle, TJ; Zimmerman, RJ, 1986) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 5.24 | Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017) |
| "We analyzed data from patients with stage III colon adenocarcinoma randomly assigned to groups given fluorouracil and leucovorin or IFL after surgery, from April 1999 through April 2001." | 5.19 | CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. ( Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS, 2014) |
| "The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer." | 5.17 | Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. ( Chachad, S; Malhotra, G; Naidu, R; Purandare, S, 2013) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 5.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 5.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database." | 5.12 | Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. ( Chau, KK; Choy, TS; Fu, YT; Law, CC; So, PF; Wong, KH, 2007) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 5.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "Thymidylate synthase (TS) is regarded as a parameter of 5-fluorouracil (5-FU) chemosensitivity for colorectal carcinoma." | 5.09 | Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. ( Fujii, S; Hatano, K; Kitayama, J; Matsuda, K; Muto, T; Nagawa, H; Nita, ME; Takenoue, T; Tsuruo, T, 2000) |
| "Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma." | 5.09 | [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000) |
| " After radical resection of adenocarcinoma of the colon (pT1-4 pN>0 M0 and pT3-4 pN0 M0) and perioperative chemotherapy, patients were randomised to three treatment arms: observation only (A), 5-fluorouracil (5-FU) 450 mg/m(2) plus levamisol (B), or 5-FU 600 mg/m(2) (C)." | 5.09 | Response shift in the perception of health for utility evaluation. an explorative investigation. ( Bernhard, J; Hürny, C; Lowy, A; Maibach, R, 2001) |
| "Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46." | 5.08 | [Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 5.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "We have used a relatively new trial methodology, the group sequential design, to prospectively evaluate two dose levels of bolus/infusional 5-fluorouracil (5-FU) and folinic acid in 192 consecutive-patients with advanced colorectal carcinoma." | 5.08 | Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation. ( Canney, PA; Cassidy, J; Habeshaw, T; Jodrell, DI; Mackean, MJ; McInnes, A; Paul, J; Reed, NS; Robertson, AG; Twelves, CJ; Yosef, H, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 5.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| " Moreover, sulindac has been shown to attenuate the growth and progression of colonic neoplasms in an experimental model of colon carcinoma and in patients with familial adenomatous polyposis." | 5.08 | Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma. ( Levin, B; Pazdur, R; Sinicrope, FA, 1996) |
| "One hundred twenty-two chemotherapy-naive patients with histologically confirmed colorectal adenocarcinoma were entered into a randomized trial comparing infusional fluorouracil (FU) versus cisplatin (CDDP) and FU." | 5.06 | Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. ( Bosselli, B; Botet, J; Chapman, D; Cochran, C; Israel, K; Kemeny, N; Minsky, B; Niedzwiecki, D; Rosenbluth, R; Vinciguerra, V, 1990) |
| "Seventy-four previously untreated patients with metastatic colorectal adenocarcinoma were prospectively randomized into one of three treatment regimens: (1) 5-fluorouracil (5-FU) 450 mg/m2 as an intravenous (IV) bolus daily for five days or toxicity, then 200 mg/m2 IV bolus every other day for six doses; (2) methotrexate (MTX) 50 mg/m2 in normal saline by IV infusion over four hours followed by an IV bolus of 5-FU 600 mg/m2." | 5.06 | A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. ( Burke, P; Creaven, P; Emrich, LJ; Herrera, L; Mittelman, A; Petrelli, N; Rustum, Y; Stulc, J, 1987) |
| "In this prospective randomized study the effect of oral Ftorafur was compared with that of intravenous 5-fluorouracil in patients with advanced adenocarcinoma of the stomach, colon or rectum." | 5.06 | Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. ( Bjerkeset, T; Fjøsne, HE, 1986) |
| " Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks)." | 5.06 | A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Ansari, R; Correa, J; Hui, S; Kubilis, P; Loehrer, PJ; Meyer, S; Stephens, D; Turner, S; Woodburn, R, 1988) |
| "Studies were analyzed to show the correlation of response with dose intensity of single-agent 5-fluorouracil (5-FU) against colorectal cancer, multiagent CMF (cyclophosphamide, methotrexate, 5-FU) regimens against advanced breast cancer, and adjuvant therapy in stage II breast cancer." | 5.06 | Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. ( Figueredo, A; Goodyear, M; Hryniuk, WM, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 5.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 5.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| "In a randomized, multicenter study, 168 evaluable patients with colorectal adenocarcinoma at B2, C1 or C2 stages of the Dukes, Astler and Coller classification, were treated after radical surgery with BCG and 5-fluorouracil alone (regimen A) or in combination with hydroxyurea, methyl-CCNU and mitomycin C (regimen B)." | 5.05 | Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma. ( De Vecchis, L; Lagomarsino Caprino, MC; Mazzei, T; Periti, P; Popoli, P, 1984) |
| "One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs." | 5.05 | Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980) |
| "An adjuvant program of fluorouracil for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968." | 5.04 | Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report. ( Brown, PW; Horsley, JS; Lawrence, W; Romero, C; Terz, JJ, 1978) |
| "In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks." | 5.04 | Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978) |
| "A combined intraoperative and postoperative adjuvant program of 5 minus Fluorouracil (5 FU) for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968." | 5.04 | Chemotherapy as an adjuvant to surgery for colorectal cancer. ( Brown, PW; Donaldson, M; Horsley, S; Lawrence, W; Lovett, WL; Regelson, W; Ruffner, BW; Terz, JJ, 1975) |
| "In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs." | 5.04 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975) |
| " We diagnosed 5-fluorouracil (5FU)-induced hyperammonemia." | 4.85 | [A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer]. ( Fujita, J; Hirata, T; Kinjyo, F; Kobashikawa, K; Matayoshi, R; Nakamura, M; Ohshiro, M; Takaki, R; Tamura, J, 2009) |
| " This article discusses how these new drugs are affecting nursing practice, focusing on one novel oral agent-capecitabine (Xeloda), approved for treating metastatic colorectal and breast cancer and as adjuvant therapy for stage 3 (Dukes's C) colon cancer-to illustrate." | 4.84 | How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate. ( Gibson, DE; Szetela, AB, 2007) |
| "5-Fluorouracil (5-FU) has been available for over 40 years and has been used in a wide variety of different regimens for the treatment of advanced colorectal cancer, a malignancy with a poor prognosis that is common in industrialized countries." | 4.80 | Which 5-fluorouracil regimen?--the great debate. ( Harper, P; Labianca, R; Vincent, M, 1999) |
| "Growth of human adenocarcinomas of the colon and rectum in immunoincompetent mice has allowed for a greater understanding of the interaction of 5-fluorouracil, its metabolism, and mechanism(s) of cytotoxicity under conditions of tumor growth in situ." | 4.77 | Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy. ( Hazelton, BJ; Houghton, JA; Houghton, PJ; Radparvar, S, 1989) |
| "To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen." | 4.31 | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. ( Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023) |
| "Safety and effectiveness of aflibercept with 5-fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting." | 4.31 | Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. ( Kazama, H; Terazawa, T; Uetake, H; Watanabe, J; Yamane, S; Yoshino, T, 2023) |
| "Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia." | 4.31 | Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023) |
| "5-Fluorouracil (5-FU) is one of the frequently used chemotherapeutic agents against colorectal cancer (CRC)." | 4.31 | microRNA-143 interferes the EGFR-stimulated glucose metabolism to re-sensitize 5-FU resistant colon cancer cells via targeting hexokinase 2. ( Chen, W; Chen, Y; Hui, T, 2023) |
| "Fluorouracil-induced leukoencephalopathy is a rare complication and has been reported to present as confusion, oculomotor abnormality, ataxia, and parkinsonism; however, there is no previous report of a presentation mimicking neuroleptic malignant syndrome." | 4.31 | Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report. ( Hemachudha, P; Phuenpathom, W; Pongpitakmetha, T; Rattanawong, W, 2023) |
| " 5-Fluorouracil (5FU) is widely used as the first-line treatment of colorectal cancer (CRC)." | 4.31 | Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. ( Castañeda-Patlán, MC; Macías-Silva, M; Moreno-Londoño, AP; Robles-Flores, M; Sarabia-Sánchez, MA, 2023) |
| " The use of the oral FP S-1 has been approved by the European Medicines Agency as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic CRC in whom it is not possible to continue treatment with another FP due to hand-foot syndrome (HFS) or cardiovascular toxicity (CVT)." | 4.31 | Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. ( André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E, 2023) |
| "We investigated whether or not postoperative complications (POCs) themselves have a negative survival impact or indirectly worsen the survival due to insufficient adjuvant chemotherapy in a pooled analysis of two large phase III studies performed in Japan PATIENTS AND METHODS: The study examined the patients who enrolled in 1304, phase III study comparing the efficacy of 6 and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III study to confirm the tolerability of oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients." | 4.31 | The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Yoshikawa, T, 2023) |
| "Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC)." | 4.31 | Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. ( Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023) |
| "Chemotherapy using 5-fluorouracil (5-FU) is currently considered the most effective treatment for advanced colon adenocarcinoma (COAD)." | 4.31 | FOXM1/NCAPH activates glycolysis to promote colon adenocarcinoma stemness and 5-FU resistance. ( Chen, W; Lei, Y; Tian, X; Wang, D; Wei, J, 2023) |
| "This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors." | 4.31 | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023) |
| "In this study, we investigated the combined treatment of 5-fluorouracil (5-FU) and Anatolian propolis extract (PE) on colorectal cancer (CRC)using in vitro and in vivo studies." | 4.31 | Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study. ( Aydogdu, G; Durmus, E; Goren, AC; Guler, EM; Hekimoglu, ER; Kanimdan, E; Kocyigit, A; Oruc, HH; Ozman, Z; Yasar, O; Yenigun, VB, 2023) |
| "To assess the cost-effectiveness of cetuximab in combination with chemotherapy fluorouracil, oxaliplatin, and leucovorin (FOLFOX) or fluorouracil, irinotecan and leucovorin (FOLFIRI) compared to standard chemotherapy alone as a first-line treatment for metastatic colorectal cancer (mCRC) with positive KRAS wild type patients in Indonesia." | 4.31 | Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. ( Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Nugraha, RR; Permanasari, VY; Putri, S; Saldi, SRF; Santatiwongchai, B; Sastroasmoro, S; Setiawan, E, 2023) |
| "To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy." | 4.12 | Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 4.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 4.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Ocular toxicity derived from the use of systemic fluorouracil has been widely described in the literature, as well as the relationship between the use of capecitabine and the appearance of conjunctivitis." | 4.12 | Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions. ( Bello Crespo, M; Gajete Pablos, MA; Gioseffi, HA; Roa García, DM; Trujillano Ruiz, A, 2022) |
| "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)." | 4.12 | Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022) |
| "The current study was set out to investigate the mechanism by which silenced long noncoding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) modulates the cell growth, migration, invasion, and drug sensitivity of breast cancer (BC) cells to 5-fluorouracil (5-Fu) with the involvement of miR-145 and p53." | 4.12 | Effect of long noncoding RNA CCAT2 on drug sensitivity to 5-fluorouracil of breast cancer cells through microRNA-145 meditated by p53. ( Cheng, W; Gu, J; Wang, J; Wang, Q; Wang, X; Wang, Y; Wu, H; Zhang, Z; Zheng, G; Zhou, D, 2022) |
| "The drug, 5-fluorouracil (5FU) is a standard first-line treatment for colorectal cancer (CRC) patients." | 4.12 | Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells. ( Arregui Ramos, DA; de-Freitas-Junior, JCM; Morgado-Díaz, JA; Sousa-Squiavinato, ACM; Tessmann, JW; Wagner, MS, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 4.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 4.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| " We demonstrated the combinations of doxorubicin (DOX) + artesunate, DOX + chloroquine, paclitaxel (PTX) + fluoxetine, PTX + fluphenazine, and PTX + benztropine induce significant cytotoxicity in Michigan Cancer Foundation-7 (MCF-7) breast cancer cells." | 4.12 | Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action. ( Duarte, D; Nunes, M; Ricardo, S; Vale, N, 2022) |
| "We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine." | 4.12 | [Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports]. ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022) |
| "Patients with colorectal cancer treated with 5-fluorouracil (5-FU) and irinotecan (CPT-11) exhibit a risk for chemotherapy-induced colitis (CIC) that may lead to fatal consequences." | 4.02 | Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism. ( Du, GH; Wang, L; Wang, R; Wang, SM; Wang, Z; Wei, GY; Zhang, RP; Zhu, Y, 2021) |
| " This study aimed to design a novel model of combination that combines different CNS agents and antineoplastic drugs (5-fluorouracil (5-FU) and paclitaxel (PTX)) for colorectal and breast cancer therapy, respectively." | 4.02 | Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs. ( Cardoso, A; Duarte, D; Vale, N, 2021) |
| " Here, we evaluated the anti-inflammatory Trimethylglycine and the Signal transducer and activator of transcription (STAT6) inhibitor AS1517499, as possible adjuvants to 5-FU in already established cancers, using a model of colitis-associated colon cancer (CAC)." | 3.96 | Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. ( Beristain-Terrazas, DL; Callejas, BE; Chirino, YI; Delgado-Buenrostro, NL; García-Castillo, V; Gutierrez-Cirlos, EB; León-Cabrera, SA; Mendoza-Rodríguez, MG; Meraz-Ríos, MA; Pérez-Plasencia, C; Rodríguez-Sosa, M; Sánchez-Barrera, CÁ; Terrazas, LI; Vaca-Paniagua, F, 2020) |
| " We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response." | 3.91 | Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019) |
| "Colorectal cancer is one of the primary causes of cancer-related deaths and 5-fluorouracil (5-FU) therapy remains the cornerstone of treatment in these patients." | 3.91 | RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer. ( Bachvarov, CH; Bogdanova, MK; Chaushev, BG; Conev, NV; Dimitrova, EG; Donev, IS; Georgiev, KD; Kalchev, KP; Kashlov, YK; Manev, RR; Petrov, DP; Popov, HB; Radanova, MA; Todorov, GN, 2019) |
| "The compound 5-fluorouracil (5-FU) is the first choice chemotherapeutic agent for the treatment of colorectal cancer (CRC), but intestinal mucositis is a primary limiting factor in anticancer therapy." | 3.88 | Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. ( Cao, L; Gao, L; Wang, C; Wang, L; Yang, S, 2018) |
| "Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells." | 3.88 | Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. ( Ahmed, F; Kondapi, AK; Kumari, S, 2018) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer." | 3.85 | Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. ( Auboeuf, D; Bash-Imam, Z; Catez, F; Dalla Venezia, N; David, A; Diaz, JJ; Dutertre, M; Lafôrets, F; Macari, F; Marcel, V; Mertani, HC; Pannequin, J; Pion, N; Polay Espinoza, M; Saurin, JC; Textoris, J; Thérizols, G; Vincent, A, 2017) |
| "Starting 7 days after transplantation of colonic adenocarcinoma colon-26 cells, STZ-treated and control mice were intraperitoneally administered oxaliplatin, fluorouracil, and levofolinate (FOLFOX) every 2 weeks." | 3.85 | Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil. ( Hashida, T; Ikemura, M, 2017) |
| " A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon." | 3.85 | Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE. ( Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K, 2017) |
| " It was investigated the potential use of folic acid-decorated and PEGylated poly(D,L-lactide-co-glycolide) nanoparticles (FOL-PEG-PLGA NPs) for the targeted delivery of 5-FU to colon and breast cancers." | 3.85 | Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. ( Arias, JL; Delgado, ÁV; El-Hammadi, MM; Melguizo, C; Prados, JC, 2017) |
| "The impact of microsatellite instability (MSI) on survival in stage III colon cancer treated with adjuvant 5-fluorouracil-oxaliplatin combination (FOLFOX) chemotherapy is not clear." | 3.85 | Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). ( Hong, YS; Kim, CW; Kim, HJ; Kim, JC; Kim, JE; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lim, SB; Park, IJ; Yoon, YS; Yu, CS, 2017) |
| " We silenced UBXN2A in the human osteosarcoma U2OS cell line, an enriched mortalin cancer cell, followed by a clinical dosage of the chemotherapeutic agent 5-fluorouracil (5-FU)." | 3.83 | Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. ( Abdullah, A; Chauhan, SC; Nelson, ME; Newton, SS; Rezvani, K; Sane, S; Wang, H, 2016) |
| "Three mouse cancer cell lines [CT26 mouse colon cancer cells, B16 melanoma cells and Lewis lung carcinoma (LLC)], 5 human carcinoma cell lines (human esophageal squamous cell carcinoma cell lines TE8 and HEC46 and the human pancreatic carcinoma cell lines PK-9, AsPC-1 and SUIT-2) and 5 chemotherapeutic agents [mitoxantrone (MIT), mitomycin C(MMC), 5-fluorouracil (5FU), camptothecin (CPT-11) and cisplatin (CDDP)] that are frequently used in a clinical setting for cancer treatment were utilized to investigate the surface expression level of calreticulin and HLA class I after exposure to chemotherapeutic agents." | 3.81 | The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. ( Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y, 2015) |
| " In the present study, we examined the potential of DECPR to prevent colon cancer development in rats treated with azoxymethane (AOM) (15 mg/kg) by determining the percentage inhibition in incidence of aberrant crypt foci (ACF)." | 3.81 | The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats. ( Abd Malek, SN; Abdulla, MA; Al-Henhena, N; Awang, K; Hasanpourghadi, M; Kunasegaran, T; Looi, CY; Moghadamtousi, SZ; Mohamed, Z; Rouhollahi, E, 2015) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 3.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "Adjuvant folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy for resected high-risk colon cancer is associated with a low risk of febrile neutropenia (FN)." | 3.80 | Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. ( Gill, S; Javaheri, KR; Smoragiewicz, M; Yin, Y, 2014) |
| " We describe the case of a colon cancer patient who underwent adjuvant treatment with capecitabine and oxaliplatin and was admitted to the hospital with seizures and brain edema." | 3.80 | [Blindness and symmetrical neurological deficit in a patient with colon cancer receiving adjuvant chemotherapy: is it always cancer?]. ( Fennig, S; Greenberg, G; Leshem, Y; Talianski, E; Wolf, I, 2014) |
| "Preliminary results showed that there is a significant MCV increase in patients receiving capecitabine for metastatic colon and breast cancer after 12 weeks of treatment." | 3.79 | Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer. ( Gervasi, E; Giovanardi, F; Pezzuolo, D; Prati, G; Scaltriti, L; Scarabelli, L, 2013) |
| " We aimed to investigate the effects of fish oil emulsion (FOE) rich in n-3 PUFA with the standard chemotherapeutic agents 5-fluorouracil (5-FU), oxaliplatin (OX) or irinotecan (IRI) on two human colorectal adenocarcinoma cells with different genetic backgrounds." | 3.79 | Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. ( Cai, F; Clerc, A; Dupertuis, YM; Granci, V; Lecumberri, E; Pichard, C, 2013) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 3.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| "The present study investigated whether a water-soluble extract from the culture medium of Ganoderma lucidum mycelia (Japanese: Reishi or Mannentake) (designated as MAK) exerted a protective effect against induction of aberrant crypt foci (ACF) by azoxymethane (AOM) and small-intestinal damage induced by the anticancer drug 5-FU." | 3.79 | Effects of a water-soluble extract of Ganoderma lucidum mycelia on aberrant crypt foci induced by azoxymethane and small-intestinal injury by 5-FU in F344 rats. ( Kashimoto, N; Tamura, K; Ushijima, M; Watanabe, H, 2013) |
| "Patients with Dukes' B colon cancer benefit from adjuvant chemotherapy and should be presented with this treatment option." | 3.79 | Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) ( Atkins, JN; Bear, HD; Jones, J; Mamounas, E; Rockette, H; Song, K; Wieand, S; Wolmark, N, 1999) |
| "When disseminated colorectal cancer is diagnosed the possibility of palliative chemotherapy should be conferred with an oncologist." | 3.79 | [Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer]. ( Raskov, HH; Wiboltt, K, 1999) |
| "Microsatellite instability (MSI) is a distinct molecular phenotype of colorectal cancer related to prognosis and tumour response to 5-fluorouracil (5-FU)-based chemotherapy." | 3.78 | The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. ( Cheon, JH; Hong, SP; Kim, H; Kim, NK; Kim, TI; Kim, WH; Min, BS, 2012) |
| " We describe the case of a 50-year-old man with Dukes C colon carcinoma being treated with an adjuvant FOLFOX4 (5-fluorouracil, leucovorin and oxaliplatin (85 mg/m(2) per cycle)) who developed a widespread acute pain 5 min after commencing his twelfth cycle of chemotherapy." | 3.78 | Acute pain associated with oxaliplatin infusion: case report and literature review. ( Ashley, DA; Clay, TD, 2012) |
| " We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine." | 3.78 | A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin. ( Imai, E; Ito, I; Ito, Y; Kosugi, T; Maruyama, S; Matsuo, S; Mizuno, M; Ozaki, T; Sato, W; Suzuki, Y; Tsuboi, N; Yasuda, K; Yasuda, Y, 2012) |
| "The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea." | 3.78 | [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012) |
| " Here, we aimed to investigate the role of CQ in potentiating the effect of 5-fluorouracil (5-FU), the chemotherapeutic agent of first choice for the treatment of colorectal cancer, in an animal model of colon cancer." | 3.78 | Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study. ( Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH, 2012) |
| " In this study, patient-derived tumor tissue (PDTT) xenograft models of primary colon carcinoma and lymphatic and hepatic metastases were established for assessment of the antitumor activity of FP3 in combination with capecitabine." | 3.78 | Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. ( Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z, 2012) |
| "Capecitabine, an oral prodrug of 5 -fluorouracil, is a promising treatment for colorectal, breast, and gastric cancers, but often causes hand-foot syndrome(HFS), which is the most common dose-limiting toxicity." | 3.78 | [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy]. ( Amamori, K; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamagiwa, K; Yamanda, T, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 3.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "The prognosis for patients with cancer of the colon is dubious." | 3.78 | [Adjuvant systemic chemotherapy in colon cancer]. ( Raskov, HH, 1996) |
| "Levamisole is a synthetic, orally active agent that has antihelmintic and immunomodulatory properties." | 3.77 | Levamisole in the adjuvant treatment of colon cancer. ( Hutson, PR; Mutch, RS, 1991) |
| "The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)." | 3.76 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010) |
| " In the present study we investigate the effects of HIF-1 modulation on the response of the human colon adenocarcinoma cell line HCT116 to 5-fluorouracil (5FU)." | 3.75 | Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. ( Gariboldi, MB; Marras, E; Molteni, R; Monti, E; Perletti, G; Ravizza, R, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 3.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "Five-fluorouracil (5-FU) has become the standard chemotherapeutic agent for the treatment of advanced colorectal carcinoma." | 3.75 | An analysis of chemotherapy for colorectal carcinoma. ( Mittelman, A; Petrelli, NJ, 1984) |
| "Hyperpigmentation of the hands and feet is a rare side effect with capecitabine chemotherapy and appeared to predict impending grade 2 HFS in our patients." | 3.74 | Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. ( Easaw, JC; Vickers, MM, 2008) |
| "To clarify the potential of parathyroid hormone-related protein (PTHrP) and interleukin-6 (IL-6) as cachectic factors in a colon 26 model and the effects of capecitabine on cancer cachexia as determined by plasma levels of IL-6 and PTHrP and body weight loss." | 3.74 | Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007) |
| "This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients." | 3.74 | Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007) |
| "The aim of this study is to evaluate the safety and efficacy of hepatic artery infusion (HAI) of 5-fluorouracil (5FU) for patients with liver metastases from colorectal carcinoma after radiological placement of infusion catheters." | 3.74 | Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. ( Hirayama, I; Horikoshi, H; Motegi, K; Saito, T; Sameshima, S; Sawada, T; Tomozawa, S, 2007) |
| "To investigate the inhibitive effects of triptolide (TPL) combined with 5-fluorouracil (5-FU) on colon carcinoma HT-29 cells in vitro and in vivo and their side effects." | 3.74 | Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. ( Lin, XL; Tang, XY; Tao, WH; Wei, B; Zhu, YQ, 2007) |
| "Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors." | 3.74 | Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007) |
| " For this purpose, we assessed the impact of cellular supernatants of the primary adenocarcinoma cell line CCL228, its lymph node metastasis CCL227, and four subclones resistant to different levels of 5-fluorouracil on the growth of microvascular and macrovascular endothelial cells." | 3.74 | Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro. ( Mader, RM; Schönau, KK; Steger, GG, 2007) |
| "A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer." | 3.74 | Regression of radiation-induced macular edema after systemic bevacizumab. ( Bakri, SJ; Pulido, JS; Solano, JM, 2007) |
| " Similarly, constitutive hTERT expression inhibited wild-type p53-dependent apoptosis in response to mitomycin C or 5-fluorouracil in HCT116 colon carcinoma cells carrying endogenous p53." | 3.73 | hTERT antagonizes p53-induced apoptosis independently of telomerase activity. ( Latonen, L; Rahman, R; Wiman, KG, 2005) |
| "We reported two cases of retroperitoneal hematoma in patients who received a combination of anticoagulant therapy and 5-fluorouracil (5-FU)." | 3.73 | Two cases of retroperitoneal hematoma caused by combination of anticoagulant therapy and 5-fluorouracil. ( Furutani, K; Furutani, S; Kashihara, K; Minato, M; Morita, N; Murase, T; Nishitani, H; Otsuka, H; Tagashira, H; Tsujikawa, T; Yoneda, K, 2005) |
| " injection with 5-fluorouracil/leukovorin (5-FU/LV) for 5 days (20 mg and 10 mg/kg body weight respectively)." | 3.73 | Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. ( El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V, 2005) |
| " We investigated the combination effect of 5-fluorouracil (5-FU), a first-choice drug for the treatment of colorectal cancer and adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells." | 3.72 | 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. ( Hamada, H; Kitayama, J; Nagawa, H; Shinoura, N; Uchida, H; Watanabe, T, 2003) |
| "Among the various pathophysiologic mechanisms proposed to explain the 5-fluorouracil cardiotoxicity, coronary vasospasm, occurring most frequently after the completion of the second or third dose of the cycle, has gained wide acceptance." | 3.72 | Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy. ( Giaccon, G; Mariani, G; Mastore, M, 2003) |
| " We hypothesized that this polymorphism may modulate the cytotoxic effect of 5-fluorouracil (5FU) and methotrexate (MTX), two commonly used chemotherapeutic agents for colon and breast cancers, because the modes of action of 5FU and MTX are critically dependent on cellular composition of folates." | 3.72 | Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Sohn, KJ; Yates, Z, 2004) |
| "To assess the mechanism of action of 5-fluorouracil (5-FU) apoptosis (AI) and proliferation (PI) indices were determined histochemically in colon carcinoma and normal colon tissue of 7 patients treated preoperatively with 5-FU (300 mg/m2/day for 5 days) and 11 controls." | 3.71 | Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans. ( Dervenis, C; Giannakou, N; Kozoni, V; Rigas, A; Rigas, B; Shiff, SJ, 2002) |
| "One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT." | 3.71 | [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002) |
| "Canalicular obstruction may follow systemic use of 5-fluorouracil due to squamous metaplasia." | 3.71 | Squamous metaplasia of the canaliculi associated with 5-fluorouracil: a clinicopathologic case report. ( Agarwal, MR; Burnstine, MA; Esmaeli, B, 2002) |
| "A 62-year-old male patient who developed Philadelphia chromosome-positive chronic myeloid leukemia (CML) after cisplatin and 5-fluorouracil treatment for colon adenocarcinoma is reported." | 3.71 | Chronic myeloid leukemia in a patient with colon adenocarcinoma. ( Gokel, Y; Paydas, S, 2002) |
| "5-Fluorouracil (5-FU) is a pyrimidine antimetabolite active against colorectal carcinoma and other malignancies of the digestive tract." | 3.71 | In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. ( Aquino, A; Correale, P; Cusi, MG; De Vecchis, L; Francini, G; Giorgi, G; Micheli, L; Nencini, C; Petrioli, R; Pozzessere, D; Prete, SP; Rausa, L; Sabatino, M; Sanguedolce, R; Turriziani, M, 2001) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "5-Fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FU, are representative of the chemotherapeutic agents for colorectal adenocarcinomas." | 3.71 | Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. ( Iwahashi, M; Nagata, T; Nakamori, M; Yamaue, H, 2002) |
| "This case can be considered the first documented Irinotecan-induced immune thrombocytopenia." | 3.70 | Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998) |
| "The clonogenic hybrid spheroid assay has been used to determine the toxicity of 5-fluorouracil (5-FU), alone or in combination with indomethacin, in LoVo cells (a human colon adenocarcinoma line)." | 3.70 | Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids. ( Djordjevic, B; Lange, CS; Rotman, M; Schwartz, MS, 1998) |
| "A selective inflammatory reaction involving actinic keratosis may occur in patients receiving systemic 5-fluorouracil as part of a chemotherapeutic protocol." | 3.70 | Selective inflammatory effect of systemic fluorouracil in actinic keratosis. ( Mehregan, D; Mohindra, R; Nabai, H, 1999) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| " In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer." | 3.70 | dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. ( Caradonna, SJ; Groshen, S; Ladner, RD; Lenz, HJ; Lynch, FJ; Sherrod, A; Stoehlmacher, J; Xiong, YP, 2000) |
| "Adjuvant 5-fluorouracil (5-FU)-based chemotherapy is standard treatment for stage C colorectal cancer (CRC)." | 3.70 | Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. ( Aaltonen, LA; Hemminki, A; Järvinen, H; Joensuu, H; Mecklin, JP, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 3.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "The relationship between augmentation of cytotoxic activity of 5-fluorouracil (FUra) by l-leucovorin (l-LV) and combination schedule was investigated using human colon adenocarcinoma KM 20 C cell line." | 3.69 | [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. ( Okabe, H; Takeda, S; Toko, T; Unemi, N; Yuasa, C, 1995) |
| "To determine the effect of cellular proliferation and cell cycle stage on the ability of postirradiation 5-fluorouracil (5-FU) to radiosensitize cultured human colon adenocarcinoma Clone A cells." | 3.69 | 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. ( Buchholz, DJ; Lepek, KJ; Murray, D; Rich, TA, 1995) |
| "Exposure of the human colon adenocarcinoma HT29 cells to different concentrations of 5-fluorouracil (5FU) for 24 h resulted in a dose-dependent increase in the cellular glutathione (GSH) level which remained elevated up to 72 h following 5FU treatment." | 3.69 | Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. ( Boyce, HW; Chen, LT; Chen, MF, 1995) |
| "To examine if preferential retention of somatostatin analogues observed in some tumors might be used for modulation of effects of cancer drugs by co-treatment with long acting somatostatin analogues, the effects of somatostatin analogue octreotide on the kinetics of 5-fluorouracil (FUra) and 5-fluorouridine (FUrd) metabolism were studied by 19F NMR spectroscopy in multicell tumor spheroids comprised of human colon HT-29 adenocarcinoma cells." | 3.69 | Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids. ( Chen, TB; Huzak, M; Macura, S; Vuk-Pavlović, S, 1994) |
| "Several classes of plant polyphenols namely, flavonoids, chalcones and coumarins exhibited varying degrees of inhibition on the cell proliferation of human colon adenocarcinoma cell line 220." | 3.69 | Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. ( Das, NP; Yit, CC, 1994) |
| "To investigate the resistance against 5-fluorouracil (FU), thymidylate synthase (TS) mRNA level was measured by reverse transcription PCR (RT-PCR) technique and quantitated by a competitive-PCR method in human colon adenocarcinoma cell line, SNU-C1 and its FU resistant cell line, C1/FU." | 3.69 | [Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]. ( Aiba, K; Horikoshi, N; Minowa, S; Shibata, H; Shibata, J, 1994) |
| "The metabolism of 5-fluorouracil (5-FU) was monitored non-invasively in two xenografts, a hypopharynx carcinoma and a colon carcinoma (CSM) by 19F-magnetic resonance spectroscopy following an i." | 3.69 | 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo. ( Baumgart, F; Köpf-Maier, P; Tausch-Treml, R; Ziessow, D, 1996) |
| "The present studies examined the anti-proliferative effects of diallyl disulfide (DADS) on the growth of human colon tumor cell line, HCT-15, xenografts in 6-wk-old female NCr nu/nu mice with an initial body weight of 20-22 g." | 3.69 | Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. ( Milner, JA; Sundaram, SG, 1996) |
| "The use of 5-fluorouracil (5-FU) and levamisole in patients with Stage III adenocarcinoma of the colon has now become standard." | 3.69 | Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. ( Gordon, J; Licho, R; Litofsky, NS; Ragland, R; Recht, L; Savarese, DM; Smith, TW, 1996) |
| "Chemotherapy programs using either bolus or infusional delivery were selected representing standard or commonplace regimens for the treatment of patients with breast cancer (cyclophosphamide, methotrexate, fluorouracil [CMF] or CA); colon cancer (5-fluorouracil[5-FU] infusion vs." | 3.69 | Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. ( Anderson, NR; Lokich, JJ; Moore, CL, 1996) |
| " The objective of this study was to test the effect of tamoxifen and tamoxifen in combination with other agents [5-fluorouracil (5-FU) and interferon (IFN)] against experimental liver metastases of human colorectal tumor cells xenografted into nude mice." | 3.69 | Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. ( Bender, E; Katoh, A; Mahaffey, W; Marrangoni, A; McKeating, J; Werner, A, 1996) |
| "The case history is reported of a 51-year-old man with metastatic colonic carcinoma who was receiving a continuous 5-fluorouracil infusion via a central venous catheter and who developed cardiac perforation and pericardial effusion." | 3.69 | Cardiac perforation associated with continuous infusional chemotherapy. ( Cooper, RA; James, RD; Taylor, KJ, 1996) |
| " In this study, we characterized the growth-inhibitory effects of active metabolites of sulindac in cultured colon adenocarcinoma cells by determining the contribution of apoptosis and cell cycle arrest and the requirement for cyclooxygenase (COX) inhibition and p53 involvement and compared the effects of sulindac metabolites with the chemotherapeutic drug, 5-fluorouracil (5-FU)." | 3.69 | Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. ( Ahnen, DJ; Finn, TS; Fryer, BH; Li, H; Pamukcu, R; Piazza, GA; Rahm, AK; Stoumen, AL, 1997) |
| "Previous studies using cultured colon adenocarcinoma cells demonstrated that a mixture of the diastereoiosomers of the biologically active (6S) and inactive (6R) forms of (6RS) leucovorin or 5-formyl-H4PteGlu (LV) and recombinant human alpha2a-interferon (rIFN-alpha2a) in combination significantly increased the cytotoxicity of 5-fluorouracil (FUra) (by 10-14-fold) whereas FUra combined with single modulators was less potentiated (3-fold)." | 3.69 | Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. ( Cheshire, PJ; Houghton, JA; Morton, CL; Stewart, CF, 1995) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "To explore an anti-tumor effect of indomethacin on human colon adenocarcinoma cell line HCT116, and its mechanism." | 3.69 | [Neoplasm-inhibiting effect and sensitivity-promoting effect of indomethacin in vitro]. ( Duan, C; Leng, A; Shi, J; Zhang, G, 1997) |
| "Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule." | 3.68 | Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. ( Aschele, C; Bertino, JR; Guglielmi, AP; Melioli, GG; Mori, AM; Rosso, R; Sobrero, AF, 1993) |
| "A prospective trial was conducted involving 16 patients with colorectal adenocarcinoma using a regimen of continuous-infusion octreotide acetate (Sandostatin [octreotide acetate], Sandoz, East Hanover, NJ for the treatment of severe diarrhea induced by the weekly schedule of 5-fluorouracil (5-FU) in combination with leucovorin who were refractory to opiate therapy." | 3.68 | Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. ( Creaven, P; Herrera, L; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, Y, 1993) |
| "2-fold potentiation of 5-fluorouracil (FUra) cytotoxicity by recombinant human interferon-alpha 2a (rIFN-alpha 2a) in GC3/cl colon adenocarcinoma cells that was significantly enhanced to 14-fold when FUra was combined with rIFN-alpha 2a + a mixture of the diasteroisomers of the biologically active (6S) and inactive (6R) leucovorin or 5-formyl-H4PteGlu (LV), events that were reversible by thymidine (dThd)." | 3.68 | Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. ( Adkins, DA; Houghton, JA; Morton, CL; Rahman, A, 1993) |
| "We report the fourth case of cerebral demyelinating disease associated with 5-fluorouracil and levamisole hydrochloride therapy for adenocarcinoma of the colon." | 3.68 | Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. ( Kimmel, DW; Schutt, AJ, 1993) |
| "To perform an economic evaluation of the joint use of 5-fluorouracil and levamisole as adjuvant chemotherapy in patients with fully resected Dukes' Stage C carcinoma of the colon, compared with resection and no chemotherapy." | 3.68 | A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. ( Gurney, H; Hall, J; Harnett, PR; Smith, RD, 1993) |
| ") administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) in BDF1 mice bearing murine mammary adenocarcinoma 755 and athymic mice bearing the transplantable human colon adenocarcinoma LS174T." | 3.68 | Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate. ( Hoshi, A; Iigo, M; Nakajima, Y, 1992) |
| "A cerebral demyelinating disease developed in 3 patients during adjuvant therapy with 5-fluorouracil and levamisole for adenocarcinoma of the colon." | 3.68 | Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. ( Forsyth, PA; Hook, CC; Kimmel, DW; Kvols, LK; Moertel, CG; Rodriguez, M; Rubin, J; Scheithauer, BW, 1992) |
| "Juzen-taiho-to (JTT; [Shi-quan-da-bu-tang], a Japanese modified Chinese herbal prescription) in combination with an anticancer drug UFT (5-fluorouracil derivative) prevented the body weight loss and the induction of the colonic cancer in rats treated with a chemical carcinogen 1,2-dimethylhydrazine (DMH), and suppressed markedly the activity of thymidylate synthetase (TS) involved in the de novo pathway of pyrimidine synthesis in colonic cancer induced by DMH." | 3.68 | Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. ( Kasahara, N; Kato, T; Kawasaki, T; Kudo, H; Kuwa, K; Nakayama, T; Okamoto, R; Sakamoto, S; Suzuki, S, 1991) |
| "We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)." | 3.68 | In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991) |
| "Experimental chemotherapy with 5-fluorouracil (5-FU; 60 mg/kg), 1-hexylcarbamoyl-5-fluorouracil (HCFU; 70 mg/kg), 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxym ethyl-5- fluorouracil (BOF-A2; 30 mg/kg) and UFT (20 mg/kg as tegafur with uracil at a molar ratio of 1:4) was performed using human gastric (H-111) and colon (Co-4) carcinoma strains in nude mice." | 3.68 | Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. ( Abe, O; Arisawa, Y; Fujita, S; Ishibiki, K; Josui, K; Kodaira, S; Kubota, T; Mabuchi, K; Suto, A; Yamamoto, T, 1991) |
| "We evaluated conventional pulse exposure versus continuous exposure models of 5-fluorouracil (5-FU) radiosensitization in HT-29 (human colon adenocarcinoma) and DU-145 (human prostate cancer adenocarcinoma) cell lines." | 3.68 | 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. ( Evans, RG; Kimler, BF; Smalley, SR, 1991) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 3.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "2,2'-Anhydro-5-ethyluridine (ANEUR), a potent inhibitor of uridine phosphorylase, markedly potentiated the antitumor activity of fluorouridine (FUR) against murine mammary adenocarcinoma 755 in BDF1 mice and human colon adenocarcinoma LS174T in athymic-nude mice." | 3.68 | Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine. ( De Clercq, E; Iigo, M; Nakajima, Y; Nishikata, K; Szabolcs, A; Szinai, I; Veres, Z, 1990) |
| "Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil." | 3.68 | Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990) |
| "A human colon adenocarcinoma cell line (GC3TK-) was selected for thymidine kinase (TK) deficiency from cloned parental cells (GC3C1) by exposure to 5-bromodeoxyuridine (BrdUrd)." | 3.68 | Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. ( Germain, G; Houghton, JA; Houghton, PJ; Pennington, J; Radparvar, S; Rahman, A, 1990) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "In a search for compounds related to flavoneacetic acid with activity against solid tumors, a series of methyl-, methoxy-, chloro-, nitro-, and hydroxy-substituted xanthenone-4-acetic acids have been synthesized and evaluated against subcutaneously implanted colon adenocarcinoma 38 in vivo, using a short-term histology assay as a primary screening system." | 3.67 | Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. ( Atwell, GJ; Baguley, BC; Calveley, SB; Denny, WA; Rewcastle, GW, 1989) |
| "The effect of 5-fluorouracil on the stability of DNA and the synthesis of DNA replication intermediates was analyzed in human colon adenocarcinoma cells." | 3.67 | Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. ( Lönn, S; Lönn, U, 1984) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 3.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR)." | 3.67 | Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. ( Braakhuis, BJ; de Bruijn, EA; Laurensse, EJ; Peters, GJ; Pinedo, HM; van Walsum, M, 1989) |
| "When given orally in combination with L-cysteine, 5'-deoxy-5-fluorouridine (DFUR) brought about a significant reduction in the growth of adenocarcinoma 755 and a significant prolongation of life-span in mice bearing Lewis lung carcinoma without increased toxicity to the host as compared with DFUR alone, though L-cysteine alone did not show an appreciable antitumor activity." | 3.67 | Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine. ( Araki, E; Hoshi, A; Iigo, M; Nakajima, Y, 1989) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 3.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 3.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| " Following our former report in which the combination effects of mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) were clarified, combined applications of 4 drugs, vindesine (VDS), methotrexate (MTX), cisplatin (CDDP) and 5'-DFUR against 3 lines of human breast cancer (H-62, H-31, H-71), and one line each of gastric cancer (H-55) and colon cancer (H-110) xenografted into nude mice were evaluated in comparison with CAF (cyclophosphamide, adriamycin and 5-FU) therapy which is commonly used for breast cancer." | 3.67 | [Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T, 1987) |
| "Parameters for inhibition of thymidylate synthase (TS) in a DMH-induced transplantable rat colon carcinoma were studied after intraperitoneal administration of bolus doxifluridine (5'-dFUR) 200 mg/kg." | 3.67 | Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. ( Almersjö, O; Berne, M; Gustavsson, B; Spears, P; Sundström, E, 1988) |
| "5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas." | 3.67 | Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Torrance, PM; Weiss, KD; Williams, LG, 1986) |
| "Twenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2 as a 24 h infusion for 4 consecutive days with 60 mg/m2 intravenous folinic acid administered every 6 hours." | 3.67 | Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. ( Higano, C; Mortimer, JE, 1988) |
| "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 3.67 | Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. ( Jakubowski, AA; Kemeny, N, 1988) |
| "Forty-four patients with locally recurrent or metastatic colorectal adenocarcinoma were treated with methotrexate (MTX) 100 mg/m2 i." | 3.67 | Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. ( Anderson, T; Hansen, RM; Ritch, PS, 1986) |
| "Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX." | 3.67 | Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 3.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed." | 3.67 | Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. ( Germain, G; Houghton, JA; Houghton, PJ; Torrance, PM, 1987) |
| "Bestatin enhanced the antitumor effects of mitomycin C, 5-fluorouracil and cis-dichlorodiammineplatinum against a syngeneic solid tumor of colon adenocarcinoma 26 in BALB/c mice." | 3.67 | Enhancement of antitumor effect of cytotoxic agents by bestatin. ( Abe, F; Ashizawa, J; Horinishi, H; Ishizuka, M; Matsuda, A; Shibuya, K; Takahashi, K; Takeuchi, T; Umezawa, H, 1985) |
| "To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted." | 3.67 | Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985) |
| "Sequential methotrexate-5-fluorouracil (Mtx-5-Fu) reduces proliferation of human colon adenocarcinoma cells." | 3.67 | The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil. ( Lönn, S; Lönn, U, 1986) |
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were treated with the following regimen: N5-10-methyltetrahydrofolate (MTHF) (200 mg/m2/day) and 5-fluorouracil (5-FU) (375 mg/m2/day) given concomitantly, consecutively for 5 days, every 4 weeks, in order to evaluate the potential advantage derived from the biochemical enhancement of cytotoxic activity of 5-FU by high-dose reduced folates." | 3.67 | Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. ( Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| "The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A." | 3.66 | In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. ( Corbett, TH; Heidelberger, C; Moran, RG; Shahinian, AH; Spears, CP, 1982) |
| "The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38)." | 3.66 | Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. ( Goto, A; Narisawa, T; Sano, M; Sato, M; Takahashi, T, 1983) |
| "A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice." | 3.66 | Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. ( Houghton, JA; Houghton, PJ, 1982) |
| " This ex vivo culture system was used to test the activity of 5-fluorouracil (5-FU) against four human colorectal adenocarcinoma cell lines (SW 403, SW 480, SW 620, and SW 707)." | 3.66 | Ex vivo hemodialysis culture system for assessing the activity of cancer chemotherapeutic agents. ( Leibovitz, A; Morris, NG; Quarles, JM, 1982) |
| "Twenty-five patients with advanced measurable adenocarcinoma of the colon were treated with 5-fluorouracil (FUra), 15 to 20 mg/kg/week i." | 3.66 | Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer. ( Bateman, JR; Block, JB; Chan, KK; Chlebowski, RT; Gota, CH; Weiner, JM, 1982) |
| "This study was designed to examine the possibilities for increasing the therapeutic index in the treatment of human colon adenocarcinomas maintained as xenografts in immune-deprived mice using combinations of methotrexate (MTX) that preceded 5-fluorouracil (FUra)." | 3.66 | The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Tice, AJ, 1982) |
| "Consecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl-CCNU, 6-thioguanine, and 5-fluorouracil in 89 patients." | 3.66 | Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer. ( Aroney, RS; Bell, DR; Chan, WK; Dalley, DN; Levi, JA, 1981) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 3.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "The effect of sequential methotrexate and 5-fluorouracil on the clonal growth of the human colon adenocarcinoma cell, HCT-8, and the hormone-dependent human breast carcinoma cell, 47-DN, was examined." | 3.66 | Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. ( Benz, C; Cadman, E; Choti, M; Schoenberg, M, 1980) |
| "The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma." | 3.66 | Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981) |
| "Fifty-four patients with clinical evidence of residual colorectal adenocarcinoma following surgical removal of the primary tumor were treated with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside." | 3.66 | Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study. ( Davis, S; Park, YK, 1978) |
| "Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)." | 3.65 | Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976) |
| "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity." | 3.65 | Oculomotor disturbances associated with 5-fluorouracil chemotherapy. ( Bixenman, WW; Nicholls, JV; Warwick, OH, 1977) |
| "In the present paper a test model was used to examine if human adenocarcinomas of the colon and the stomach are heterogenous as regards the sensitivity to cytosine arabinoside, melphalan, vinblastine sulphate, amethopterin and 5-fluorouracil in vitro." | 3.65 | Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. ( Dencker, H; Håkansson, L; Tropé, C, 1975) |
| "In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for patient survival." | 3.30 | Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. ( D'Anastasi, M; Decker, T; Gesenhues, AB; Heinemann, V; Heintges, T; Hesse, N; Hofmann, FO; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Link, H; Modest, DP; Moehler, M; Scheithauer, W; Stintzing, S; von Weikersthal, LF, 2023) |
| "Use of NAC for locally advanced colon cancer has been shown to improve surgical outcomes and longer term cancer outcomes." | 3.30 | Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT. ( Akerman, L; Fish, R; Quyn, AJ; Seligmann, JF; Tolan, D; West, N; Williams, CJ, 2023) |
| "Patient age, frailty and comorbidities will be considered to guide trial entry." | 3.30 | Personalizing neoadjuvant chemotherapy for locally advanced colon cancer: protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials. ( Cairns, DA; Craig, Z; Glasbey, JC; Morton, D; Platt, JR; Seligmann, J; Williams, CJM, 2023) |
| "In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated." | 3.30 | Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. ( Bergamo, F; Conca, V; Cremolini, C; Di Donato, S; Fanotto, V; Fontanini, G; Germani, MM; Giordano, M; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Niccoli, C; Passardi, A; Pietrantonio, F; Prisciandaro, M; Proietti, A; Tamburini, E; Ugolini, C; Zaniboni, A, 2023) |
| "In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs)." | 3.30 | Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. ( Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A, 2023) |
| " Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy." | 3.30 | Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 ( Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the standard therapeutic regimens as first line for these patients with objective response rate (ORR) of ~ 50% and median progression-free survival (mPFS) of 8-9 months." | 3.30 | Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. ( Ding, K; Dong, C; Fang, X; Hu, H; Li, J; Liao, X; Sun, L; Wang, J; Weng, S; Xiao, Q; Xu, D; Yuan, Y; Zhang, S; Zhong, C, 2023) |
| "Oral pain was assessed using a visual analogue scale alongside assessment of patients' perceptions and daily functional activities based on the Rotterdam Symptom Checklist." | 3.30 | Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer. ( Al-Taie, A; Koseoglu, A, 2023) |
| "The estimated cure rates for colon cancer were 0." | 3.11 | Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study. ( Fukuda, T; Hasegawa, J; Ishiguro, M; Masuda, Y; Nakamura, M; Sakamoto, J; Shibahara, H; Shiroiwa, T; Tomita, N; Yamaguchi, S, 2022) |
| "Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0." | 3.11 | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022) |
| " Patient characteristics were evaluated with multiple regression analyses for survival outcomes, using the Cox proportional hazard model and linear regression analyses for the worst grade of adverse events." | 3.11 | Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. ( Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022) |
| "Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features." | 3.11 | Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. ( Burge, M; Cohen, JD; Day, F; Dobbyn, L; Gibbs, P; Harris, M; Harris, S; Hayes, T; Hruban, R; Khattak, A; Kinzler, KW; Kosmider, S; Lahouel, K; Lee, B; Lee, M; Lennon, AM; Lo, SN; Lynam, J; McLachlan, SA; Nott, L; Papadopoulos, N; Popoli, M; Ptak, J; Shapiro, J; Silliman, N; Tie, J; Tomasetti, C; Vogelstein, B; Wang, Y; Wong, R, 2022) |
| "This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC)." | 3.11 | Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. ( Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M, 2022) |
| "Patients with stage II or stage IIIC colon cancer with positive ctDNA results (tested as standard of care with commercial testing) will be eligible for enrollment in cohort B." | 3.11 | Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. ( Dasari, A; Deming, D; George, TJ; Kopetz, S; Lieu, CH; Lin, Y; Lucas, PC; Sahin, IH; Yothers, G, 2022) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "The meta-analysis aimed to assess the clinical efficacy of chemotherapeutic triplet-drug regimen combined with anti-EGFR antibody in patients with initially unresectable metastatic colorectal cancer (mCRC)." | 3.01 | Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. ( Dong, W; Jiang, T; Jiang, X; Li, H; Li, Y; Lv, Y; Tian, M; Xiao, J; Yin, Z; Zeng, J, 2023) |
| " Skin toxicity outcomes were collected using the Common Toxicity Criteria for Adverse Events version 3." | 3.01 | Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). ( Alberts, SR; Banbury, BL; Chan, AT; Cohen, SA; George, TJ; Goldberg, RM; Harrison, TA; Hua, X; Huyghe, JR; Labadie, JD; Newcomb, PA; Penney, KL; Peters, U; Phipps, AI; Shi, Q; Sinicrope, FA; Sun, W; Yothers, G, 2021) |
| "Adjuvant treatment for stage II colon cancer remains debated." | 2.94 | "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". ( André, T; Benhaim, L; Chauvenet, M; Emile, JF; Geillon, F; Laurent Puig, P; Le Malicot, K; Lepage, C; Manfredi, S; Taïeb, J; Taly, V; Tougeron, D, 2020) |
| "Metformin use was neither associated with OS (adjusted hazard ratio [HR], 1." | 2.90 | Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. ( Adamo, V; Aglietta, M; Antista, M; Banzi, M; Barni, S; Bidoli, P; Buonadonna, A; Cavanna, L; Ciarlo, A; Cinieri, S; Clerico, M; Damiani, A; De Placido, S; Di Bartolomeo, M; Dotti, KF; Faedi, M; Ferrari, D; Ferrari, L; Ferrario, S; Frassineti, GL; Galli, F; Giordani, P; Gori, S; Iaffaioli, RV; Labianca, RF; Leonardi, F; Lonardi, S; Maiello, E; Marchetti, P; Nicolini, M; Pavesi, L; Re, GL; Rosati, G; Tamburini, E; Tronconi, MC; Vernieri, C; Zampino, MG; Zaniboni, A, 2019) |
| "Patients with resected stage III colon cancer (CC) from seven adjuvant studies with available data for disease recurrence and MMR and BRAFV600E status were analyzed." | 2.90 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. ( Alberts, S; André, T; de Gramont, A; Grothey, A; Kerr, R; Lonardi, S; Pederson, L; Shi, Q; Sinicrope, FA; Taieb, J; Van Cutsem, E; Wolmark, N; Yoshino, T; Yothers, G; Zaanan, A, 2019) |
| " Secondary endpoints were the incidence of adverse events (AEs) and the completion rate of study therapy." | 2.87 | Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study). ( Ishibashi, K; Ishida, H; Kato, H; Kato, R; Koda, K; Kosugi, C; Mori, M; Narushima, K; Oya, M; Shuto, K; Tanaka, S; Yoshimatsu, K, 2018) |
| "Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population." | 2.87 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. ( Andre, T; Boukovinas, I; Grothey, A; Iveson, T; Kerr, R; Labianca, R; Meyerhardt, JA; Meyers, JP; Niedzwiecki, D; Paul, J; Renfro, LA; Sargent, DJ; Saunders, M; Shi, Q; Shields, AF; Sobrero, AF; Souglakos, J; Taieb, J; Torri, V; Vernerey, D; Watanabe, T; Yamanaka, T; Yoshino, T, 2018) |
| "Patients with resected stage III colon cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or without cetuximab (North Central Cancer Treatment Group N0147 trial) or adjuvant FOLFOX chemotherapy with or without bevacizumab (National Surgical Adjuvant Breast and Bowel Project C-08 trial)." | 2.84 | Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. ( Alberts, SR; Allegra, CJ; Goldberg, RM; Meyers, JP; Pogue-Geile, KL; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Thibodeau, SN; Yothers, G, 2017) |
| "The treatment of colorectal cancer liver metastases has seen significant improvement in recent years and, for certain patients, the long-term survival and even cure are possible." | 2.82 | Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. ( Naher, SK; Samoon, Z; Sjoquist, KM; Zalcberg, J, 2022) |
| "Severe (grade≥3) adverse events (AEs) to 5-fluorouracil (5-FU)-based chemotherapy regimens can result in treatment delays or cessation, and, in extreme cases, life-threatening complications." | 2.82 | Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). ( Alberts, SR; Berenberg, JL; Chan, E; Diasio, RB; Gill, S; Goldberg, RM; Grothey, A; Kahlenberg, MS; Lee, AM; Nair, SG; Polite, B; Sargent, DJ; Shi, Q; Shields, AF; Sinicrope, FA, 2016) |
| "Kaplan-Meier plots from colon cancer patients showed a significant treatment benefit in patients with low maspin expression, but not for individuals with medium/high expression." | 2.80 | Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer. ( Brydøy, M; Dahl, O; Hestetun, KE; Myklebust, MP, 2015) |
| " Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery." | 2.80 | A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. ( Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015) |
| "Although colon cancer (CC) with microsatellite instability (MSI) has a more favorable prognosis than microsatellite stable (MSS) CC, the impact varies according to clinicopathological parameters." | 2.80 | Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. ( Bosman, FT; Delorenzi, M; Klingbiel, D; Roth, AD; Saridaki, Z; Tejpar, S, 2015) |
| " The median total dosage of oxaliplatin was 811." | 2.80 | Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). ( Goto, K; Hasegawa, J; Inoue, K; Ishigure, K; Kotaka, M; Manaka, D; Matsui, T; Oba, K; Ohtsu, A; Saji, S; Sakamoto, J; Shinozaki, K; Touyama, T; Watanabe, T; Yoshino, T, 2015) |
| "There were no statistically significant neuropathy differences among the study arms as measured by the primary end point or additional measures of neuropathy, including clinician-determined measurement of the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale." | 2.79 | Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). ( Atherton, P; Dakhil, SR; Fehrenbacher, L; Flynn, KA; Grothey, A; Lewis, GC; Loprinzi, CL; Qamar, R; Qin, R; Seisler, D, 2014) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| "Patients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from four randomised controlled trials (NSABP C-08, XELOXA, X-ACT, and AVANT; 8734 patients in total) were pooled and analysed." | 2.79 | Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll ( Cartwright, T; Haller, D; Lee, S; McKenna, E; O'Connell, MJ; Saif, M; Schmoll, HJ; Sun, W; Twelves, C; Yothers, G, 2014) |
| "Obesity and underweight status were associated independently with inferior outcomes in patients with colon cancer who received treatment in adjuvant chemotherapy trials." | 2.78 | Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. ( Benson, A; Degramont, A; Foster, NR; Goldberg, RM; Labianca, R; O'Connell, MJ; Sargent, DJ; Seitz, JF; Sinicrope, FA; Yothers, G, 2013) |
| " The starting dosage of capecitabine was 2000 mg/m(2)/day (days 1-14, every 3 weeks)." | 2.77 | Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. ( Bang, SM; Chang, HJ; Kang, SB; Kim, DW; Kim, JH; Kim, YJ; Lee, JS; Lee, KW, 2012) |
| "Oral capecitabine is an effective alternative to bolus 5-FU/FA as adjuvant treatment of patients with stage III colon cancer with efficacy benefits maintained at 5 years and in older patients." | 2.77 | Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. ( Cassidy, J; Díaz-Rubio, E; Gilberg, F; McKendrick, J; Scheithauer, W; Seitz, JF; Twelves, C; Van Hazel, G; Wong, A, 2012) |
| "Patients with MSI-H (n=34) colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS (n=189) colon cancer patients (5 year time to relapse: MSI-H 0." | 2.77 | Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. ( Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M, 2012) |
| "Among patients with stage III resected colon cancer, the use of cetuximab with adjuvant mFOLFOX6 compared with mFOLFOX6 alone did not result in improved disease-free survival." | 2.77 | Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. ( Alberts, SR; Chan, E; Farr, GH; Gill, S; Goldberg, RM; Grothey, A; Kahlenberg, MS; Mahoney, MR; Mooney, M; Nair, S; Pockaj, BA; Quesenberry, JT; Sargent, DJ; Shields, AF; Sinicrope, FA; Smyrk, TC; Thibodeau, SN; Webb, TA, 2012) |
| " Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)." | 2.76 | Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. ( Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011) |
| "Irinotecan (CPT-11) is a topoisomerase I inhibitor with activity in metastatic disease." | 2.76 | A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Basdanis, G; Dimopoulos, MA; Economopoulos, T; Efstratiou, I; Fountzilas, G; Kafiri, G; Kalofonos, HP; Karanikiotis, C; Karina, M; Klouvas, G; Korantzis, I; Makatsoris, T; Malettou, L; Matsiakou, F; Miliaras, D; Papadimitriou, CA; Papakostas, P; Papaspirou, I; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Xiros, N, 2011) |
| "Irinotecan RDI was >0." | 2.74 | A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). ( Becouarn, Y; Bedenne, L; Bouché, O; Bugat, R; Conroy, T; Douillard, JY; Ducreux, M; Gamelin, E; Gourgou-Bourgade, S; Kramar, A; Mineur, L; Raoul, JL; Seitz, JF; Viret, F; Ychou, M, 2009) |
| "However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs." | 2.74 | Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. ( Bjerkeset, O; Carlsen, E; Dahl, O; Eide, TJ; Fluge, Ø; Halvorsen, TB; Myrvold, HE; Podhorny, N; Tveit, KM; Vonen, B; Wiig, JN, 2009) |
| "DNA microsatellite instability was also assessed using a panel of mono- and dinucleotide markers." | 2.74 | Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. ( Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS, 2009) |
| " Pharmacokinetic analysis was performed on blood, plasma and plasma ultrafiltrable by ICP-MS (Inductively Coupled Plasma Mass Spectrometry)." | 2.74 | Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. ( Balacescu, L; Balacescu, O; Berindan-Neagoe, IB; Burz, C; Chintoanu, M; Cristea, V; Gog, A; Irimie, A; Leucuta, SE; Tanaselia, C; Ursu, M; Vlase, L, 2009) |
| "Chinese drug ZW3 for the treatment of colonic cancer could improve the main clinical symptoms, improve the QOL, increase body weight and prolong the survival time of patients, showing a favorable integral effect." | 2.74 | Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. ( Shan, ZZ; You, JL; Zhou, LY, 2009) |
| " Follow-up for potential delayed adverse effects and efficacy is ongoing." | 2.74 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009) |
| "2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens." | 2.73 | [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. ( Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM, 2008) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| " Most treatment-related adverse events (AEs) occurred at similar rates in both treatment arms." | 2.73 | Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. ( Cartwright, T; de Braud, F; Figer, A; Haller, DG; Hill, M; Lim, R; Maroun, J; McKendrick, J; Nowacki, MP; Park, YS; Price, T; Schmoll, HJ; Sirzén, F; Soler-Gonzalez, G; Tabernero, J; Topham, C; Van Cutsem, E, 2007) |
| " This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events." | 2.73 | [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007) |
| "Neurotoxicity was recorded for all patients using standard adverse event reporting." | 2.73 | Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. ( Bearden, JD; Cecchini, RS; Cella, D; Colangelo, LH; Colman, LK; Costantino, JP; Ganz, PA; Kopec, JA; Kuebler, JP; Land, SR; Lanier, KS; Murphy, K; Needles, BM; O'Connell, MJ; Pajon, ER; Seay, TE; Smith, RE; Wieand, HS; Wolmark, N, 2007) |
| "This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer." | 2.73 | Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. ( Atkins, JN; Colangelo, LH; Colman, LK; Conley, BA; Fehrenbacher, L; Findlay, MP; Flynn, PJ; Goodwin, JW; Kuebler, JP; Lanier, KS; Levine, EA; O'Connell, MJ; Petrelli, NJ; Ramanathan, RK; Seay, TE; Smith, RE; Soori, G; Wieand, HS; Wolmark, N; Yothers, G; Zapas, JL, 2007) |
| "Ninety patients with metastatic colorectal cancer were included in the study." | 2.73 | TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. ( Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM, 2007) |
| "Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only." | 2.73 | A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. ( Gnant, M; Greil, R; Herbst, F; Hofbauer, F; Jagoditsch, M; Jakesz, R; Rabl, H; Samonigg, H; Schaberl-Moser, R; Schippinger, W; Steger, GG; Thaler, J; Thödtmann, R; Tschmelitsch, J; Wohlmuth, P, 2007) |
| "Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined." | 2.73 | Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. ( Baumann, W; Ette, C; Formentini, A; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Sander, S; Staib, L, 2008) |
| "The Adjuvant Colon Cancer End Points (ACCENT) data set was analyzed using univariate and multivariate Cox proportional hazards models, stratified by study." | 2.73 | Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. ( André, T; Benedetti, JK; Campbell, ME; Goldberg, RM; Grothey, A; Haller, DG; O'Connell, MJ; Sargent, DJ; Seitz, JF, 2008) |
| "Capecitabine is a prodrug that is enzymatically converted to its active form, fluorouracil (also called 5-fluorouracil), which is commonly used as adjuvant chemotherapy in colorectal cancer patients." | 2.72 | Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature. ( Liu, S; Sun, Z; Wu, J; Zou, Y, 2021) |
| "Oral capecitabine (Xeloda) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer." | 2.72 | Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. ( Beham, A; Bertetto, O; Bustová, I; Cassidy, J; Cowell, W; Coxon, F; Díaz-Rubio, E; Douillard, JY; Dufour, P; Figer, A; Fountzilas, G; Garrison, LP; Jelic, S; Johnston, PG; Lesniewski-Kmak, K; Malzyner, A; Maughan, TS; McKendrick, JJ; Patel, KK; Scheithauer, W; Twelves, C, 2006) |
| "Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated." | 2.72 | Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. ( Hirota, T; Kodaira, S; Mori, T; Ohashi, Y, 2006) |
| "Of the total patients, 47% had stage II colon cancer, and 53% had stage III colon cancer." | 2.72 | Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. ( Colangelo, LH; Colman, LK; Giguere, JK; Jacobs, AD; Lembersky, BC; Marshall, ME; O'Connell, MJ; Petrelli, NJ; Seay, TE; Smith, RE; Soran, A; Wieand, HS; Wolmark, N; Yothers, G, 2006) |
| "Levamisole combined with 5-fluorouracil (5-FU) was previously shown to significantly reduce tumor relapses and improve patient survival when given postoperatively in patients with resected stage III colon cancer." | 2.72 | Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. ( Krook, JE; Kugler, JW; Mahoney, MR; Morton, RF; O'Connell, MJ; Rayson, S; Rowland, KM; Sargent, DJ; Shepherd, L; Windschitl, HE, 2006) |
| "Colon cancer was located in the rectosigmoid in 46." | 2.72 | Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06. ( Harlak, A; Lembersky, BC; Nesbitt, L; O'Connell, MJ; Soran, A; Wienad, HS; Wilson, JW, 2006) |
| "After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated." | 2.71 | 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. ( Arkenau, HT; Bermann, A; Porschen, R; Rettig, K; Strohmeyer, G, 2003) |
| "To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and to determine the pharmacokinetic profile of irinotecan and its metabolites." | 2.71 | Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. ( Braun, MS; Button, CJ; Cheeseman, SL; Chester, JD; Davis, T; Hall, GD; Joel, SP; Perry, J; Seymour, MT, 2003) |
| "Obesity is a risk factor for the development of colon carcinoma." | 2.71 | Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. ( Benson, AB; Catalano, PJ; Fuchs, CS; Haller, DG; Macdonald, JS; Mayer, RJ; Meyerhardt, JA, 2003) |
| "Consenting patients with presumed colorectal cancer were randomized to surgery with or without 7 days of PVI (1 g 5-FU plus 5000 units heparin in 1 litre 5 per cent dextrose infused over each 24-h period)." | 2.71 | Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). ( Donaldson, D; Gray, R; James, RD; Northover, JM; Stenning, SP; Taylor, I, 2003) |
| "Patients with stage III colon cancer were randomized to receive 5FU alone (450 mg/m2 i." | 2.71 | The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone. ( Bascioni, R; Cascinu, S; Catalano, G; Catalano, V; Cellerino, R; Giorgi, F; Marcellini, M; Mattioli, R; Pancotti, A; Pieroni, V; Piga, A; Silva, RR; Torresi, U, 2003) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 2.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 2.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "A total of 760 patients with colon cancer and 669 patients with rectal cancer were entered into this randomized clinical trial (RCT)." | 2.71 | Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-flu ( Hojyo, K; Isomoto, H; Kato, T; Kodaira, S; Kunii, Y; Kunitomo, K; Niimoto, M; Nishida, O; Ohashi, Y; Takahashi, T; Tominaga, T; Watanabe, M; Yasutomi, M, 2004) |
| "The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL)." | 2.71 | Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. ( André, T; Boni, C; Bridgewater, J; Clingan, P; de Gramont, A; Hickish, T; Mounedji-Boudiaf, L; Navarro, M; Tabah-Fisch, I; Tabernero, J; Topham, C; Zaninelli, M, 2004) |
| "5-Fluorouracil (5-FU) is a common anticancer agent used in the treatment of solid tumours, with a reported variability in the pharmacokinetic profile and inter-patient differences in efficacy and toxicity." | 2.71 | Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. ( Canaparo, R; Casale, F; Costa, M; Eandi, M; Fornari, G; Mairone, L; Muntoni, E; Pepa, CD; Serpe, L; Zara, GP, 2004) |
| "Some patients with colon cancer have a high risk of local recurrence postoperatively." | 2.71 | Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. ( Benson, AB; Donohue, JH; Fisher, B; Goldberg, RM; Gunderson, LL; Mailliard, JA; Martenson, JA; Myerson, R; Sargent, DJ; Thomas, CR; Willett, CG, 2004) |
| " We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA)." | 2.71 | A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. ( Blackey, R; Cassidy, J; Choi, L; Devlin, M; Eatock, M; Johnson, J; Morrison, R; Owen, S; Twelves, C, 2005) |
| "5-Fluorouracil (5-FU) has two major mechanisms by which it exerts its anticancer activity." | 2.71 | Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. ( Hoshino, S; Maekawa, T; Shirakusa, T; Yamashita, Y, 2005) |
| "Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer." | 2.71 | Capecitabine as adjuvant treatment for stage III colon cancer. ( Abt, M; Burris, H; Carrato, A; Cassidy, J; Cervantes, A; Fagerberg, J; Georgoulias, V; Husseini, F; Jodrell, D; Koralewski, P; Kröning, H; Maroun, J; Marschner, N; McKendrick, J; Nowacki, MP; Pawlicki, M; Rosso, R; Scheithauer, W; Schüller, J; Seitz, JF; Stabuc, B; Tujakowski, J; Twelves, C; Van Hazel, G; Wong, A; Zaluski, J, 2005) |
| "Patients with curatively resected colon cancer (stages UICC IIb and III) were stratified according to T, N, and participating center and randomized to receive a 12-month treatment using 5-FU + LEV alone or in combination with FA or IFN-alpha." | 2.71 | Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. ( Beger, HG; Kornmann, M; Kron, M; Link, KH; Redenbacher, M; Staib, L, 2005) |
| "In most cases, hyperbilirubinemia was associated with concomitant alterations in other hemolytic parameters." | 2.71 | Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. ( Cassidy, J; Filipovic-Ljeskovic, I; Jelic, S; Nikolic-Tomasevic, Z; Tomasevic, Z, 2005) |
| " In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer." | 2.70 | Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. ( Benson, AB; Catalano, PJ; Fuchs, CS; Haller, DG; Macdonald, JS; Mayer, RJ; McCollum, AD, 2002) |
| "Adjuvant chemotherapy for colon cancer has been established during the past decade." | 2.70 | Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. ( Dencausse, Y; Fritze, D; Hagmüller, E; Hartung, G; Kopp-Schneider, A; Lindemann, H; Queisser, W; Sturm, J; Wojatschek, C, 2002) |
| "5-Fluorouracil/leucovorin was not recommended as a standard adjuvant treatment for all patients with Dukes' B2 colon cancer." | 2.70 | Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. ( Marsoni, S, 2001) |
| "The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metastatic colorectal cancer (CRC) patients." | 2.70 | A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. ( Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001) |
| " It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer." | 2.70 | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. ( Ahn, JB; Chung, HC; Jeung, HC; Kim, BS; Kim, NK; Min, JS; Rha, SY; Roh, JK; Shim, KY; Yoo, NC, 2001) |
| " Both before and after the addition of OXA, the 5-FU dose was individually adjusted according to the pharmacokinetic follow-up (target steady-state plasma concentrations 2." | 2.70 | Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ( Boisdron-Celle, M; Brienza, S; Craipeau, C; Cvitkovic, E; Delva, R; Gamelin, E; Guérin-Meyer, V, 2002) |
| " In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L)." | 2.69 | Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ( Alleaume, C; Boisdron-Celle, M; Burtin, P; Cailleux, PE; Danquechin-Dorval, E; Delva, R; Dumesnil, Y; Fety, R; Gamelin, E; Geslin, J; Gesta, P; Goudier, MJ; Larra, F; Lortholary, A; Maigre, M; Maillart, P; Maillet, ML; Person-Joly, MC; Picon, L; Regimbeau, C; Robert, J; Sire, M, 1998) |
| "A group of 205 colon cancer patients (104 in the 5FU arm and 101 in the 5FU + IFNapha-2a arm) were included in the final intention-to-treat analysis." | 2.69 | 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. ( Bernardo, G; Bruni, G; Colucci, G; Danova, M; Dastoli, G; Della Vittoria Scarpati, M; Di Lauro, L; Filippelli, G; Gebbia, N; Leonardi, V; Lo Russo, V; Meli, M; Palmeri, S; Palmieri, G; Piazzi, M; Rausa, L; Russo, A; Spada, S, 1998) |
| " However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin." | 2.69 | Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv ( Apolone, G; Couvreur, ML; Curran, D; De Waele, B; Doci, R; Labianca, R; Lasser, P; Marsoni, S; Nakajima, T; Nitti, D; Pector, JC; Rauschecker, H; Rougier, P; Sahmoud, T; Wils, J, 1998) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 2.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "We examined whether patients with colon cancer undergoing surgery with or without adjuvant chemotherapy change the internal standards on which they base their quality-of-life (QL) estimation, and, if they do so, whether this reframing alters interpretation of QL findings." | 2.69 | Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK) ( Bernhard, J; Herrmann, R; Hürny, C; Laffer, U; Maibach, R, 1999) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole." | 2.69 | Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. ( , 2000) |
| "Five hundred patients with Dukes' C colon cancer were randomly assigned to adjuvant treatment for one year with 5-fluorouracil (450 mg/m2 i." | 2.69 | The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. ( Bleeker, WA; Hermans, J; Mulder, NH; Otter, R; Plukker, JT, 2000) |
| "Of 104 patients with peritoneal carcinomatosis from colon or rectal adenocarcinoma, five patients (4." | 2.69 | Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. ( Pestieau, SR; Sugarbaker, PH, 2000) |
| "To assess the clinical effect and safety of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating malignant tumor of digestive tract." | 2.69 | [Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract]. ( Wang, J; Xin, M; Zhou, C, 1998) |
| "To evaluate the efficacy of intra-arterial chemotherapy combined with hyperthermia for metastatic liver cancer, our cooperative study group carried out a randomized clinical trial comparing intra-arterial chemotherapy alone and intra-arterial chemotherapy combined with hyperthermia." | 2.68 | [A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer]. ( Hiraoka, M; Itani, K; Kondo, M; Miura, K; Noguchi, M; Tanaka, Y; Watanabe, N; Yoshikawa, T, 1995) |
| "The regimens for colon cancer were, Arm I: mitomycin C [intraoperative portal vein bolus (12 mg/m2) + postoperative, twice weekly and then three times bimonthly for six months intermittent i." | 2.68 | Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. ( , 1995) |
| "5-FU; and arm III was surgery only." | 2.68 | Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. ( Hamano, K; Kato, T; Kodaira, S; Koyama, Y; Ogawa, N; Sakabe, T; Takahashi, T; Tominaga, T; Yasutomi, M, 1996) |
| " Laboratory studies of IFN-beta suggest that this agent may offer theoretical advantages over IFN-alpha in combination with 5-FU." | 2.68 | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. ( Bradley, C; Hallam, S; Illingworth, JM; Joffe, JK; Perren, TJ; Primrose, J; Selby, PJ; Ward, U, 1997) |
| "Levamisole was administered orally (days 1-3 and 15-17) at doses from 30 to 470 mg/m2 per day." | 2.68 | A phase I study of 5-fluorouracil, leucovorin and levamisole. ( Alberti, D; Arzoomanian, R; Carbone, P; Cleary, JF; Feierabend, C; Storer, B; Wilding, G; Witt, P, 1997) |
| "Human colonic cancer is associated with multiple genetic deletions, mutations, and alterations in gene expression; in contrast, gene amplification has not been recognized as a prominent characteristic of human colonic tumors." | 2.68 | Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. ( Augenlicht, LH; Benson, A; Corner, G; Haller, D; Heerdt, BG; Multani, AS; Pathak, S; Richards, C; Ryan, L; Wadler, S, 1997) |
| "After a median follow-up of 9 years, disease progression was reported in 40% of patients in the control group, 40% in the HEP group and 29% in the HEP/5-FU group." | 2.68 | Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Can ( Couvreur, ML; Curran, D; dos Santos, JG; Lise, M; Nitti, D; Rauschecker, H; Roelofsen, F; Sahmoud, T; Stremmel, W; Wils, J, 1997) |
| "Resection of colorectal cancer and portal infusion of adjuvant chemotherapy." | 2.68 | Association between blood transfusion and survival in a randomised multicentre trial of perioperative adjuvant portal chemotherapy in patients with colorectal cancer. The Swiss Group for Clinical Cancer Research (SAKK). ( , 1997) |
| "Some 978 patients with colon cancer and 713 patients with rectal cancer were enrolled in the study, 85 (5." | 2.68 | [Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer]. ( Hojo, K; Ichihashi, H; Kato, T; Kikuchi, K; Kodaira, S; Kunii, Y; Ogawa, M; Takahashi, T; Tamada, R; Tominaga, T; Yasutomi, M, 1997) |
| "Recurrence of gastric cancer or colon cancer was observed in some patients who received 5-fluorouracil (5-FU) high-dose continuous Methotrexate (MTX)-Leucovorin (LV) therapy (FML therapy) previously." | 2.67 | [Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer]. ( Fujihara, T; Inokuchi, T; Kawano, K; Kimoto, K; Mori, F; Tamura, Y; Yoshioka, Y, 1994) |
| "In advanced colorectal cancer the addition of folinic acid (FA) has been shown to lead to increased activity, at least in terms of response rate, in comparison with 5-fluorouracil (5FU) alone." | 2.67 | Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer. ( Ambrosini, G; Barni, S; Duro, M; Fiorentini, G; Giaccon, G; Iirillo, A; Labianca, R; Oliani, C; Pancera, G; Piazza, E, 1994) |
| " Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)." | 2.67 | A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Colon cancer is one of the major health problems in industrialized countries, and its incidence appears to be increasing." | 2.67 | Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. ( Aquino, A; Armenio, S; Civitelli, S; Francini, G; Lorenzini, L; Mancini, S; Marsili, S; Marzocca, G; Petrioli, R; Tanzini, G, 1994) |
| "Eleven patients with rectum cancer and four patients with colon cancer were treated according to the following schedule: 9 million units IFN-alpha subcutaneous three times a week; 500 mg/m2 5-FU via an intravenous bolus 1 hour after the initiation of a 2-hour infusion of 500 mg/m2 of FA, once a week." | 2.67 | Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a. ( Bernhard, H; Klein, O; Knuth, A; Meyer zum Büschenfelde, KH, 1992) |
| "Three patients with isolated liver metastases and one patient with local recurrence of rectal carcinoma received regional therapy with higher 5-FU doses." | 2.67 | Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer. ( Preiss, J, 1992) |
| " The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU." | 2.67 | A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ( Anderson, JH; Cooke, TG; Kerr, DJ; McArdle, CS; Setanoians, A, 1992) |
| "Hypotension was observed in three of five patients at the highest dose level (0." | 2.67 | A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. ( Botet, J; Crown, J; Gasparetto, C; Gordon, M; Jakubowski, A; Kemeny, N; Meisenberg, B; Sheridan, C; Toner, G; Wong, G, 1991) |
| "Treatment with levamisole alone had no detectable effect." | 2.67 | Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. ( Emerson, WA; Fleming, TR; Glick, JH; Goodman, PJ; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tormey, DC; Ungerleider, JS, 1990) |
| "5-Fluorouracil is a key element to the treatment of colon cancer." | 2.66 | Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. ( Allison, JD; Birnbaum, G; Khalid, U; Tanavin, T; Yang, Y, 2020) |
| "A total of 6501 patients with stage III colon cancer who received adjuvant FOLFOX or FLOX in six randomized trials were included in the analysis." | 2.66 | Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. ( Alberts, SR; Andre, T; De Gramont, A; Goldberg, RM; Grothey, A; Kerr, RS; Lonardi, S; Marshall, JL; Pederson, LD; Salem, ME; Shi, Q; Taieb, J; Wolmark, N; Yin, J; Yoshino, T; Yothers, G, 2020) |
| "In stage III colon cancer, randomised clinical trials and meta-analyses of modulated 5-fluorouracil (5-FU) based chemotherapy versus surgery scored ESMO-MCBS grade A and randomised controlled trials (RCTs) and meta-analyses comprising oxaliplatin added to this 5-FU backbone showed a more modest additional overall survival benefit (grade A and B)." | 2.66 | Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. ( Cherny, NI; Dafni, U; de Groot, DJ; de Vries, EGE; Douillard, JY; Knapen, DG; Latino, NJ; Zygoura, P, 2020) |
| " However, the optimal protocol for neoadjuvant therapy has not been determined yet, and it remains a source of controversy about whether systemic chemotherapy combined with cetuximab can increase the surgical resection rate and obtain more clinical benefits." | 2.66 | Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy. ( Hong, L; Kong, Y; Xu, X, 2020) |
| "Eighty-two patients with colo-rectal cancers (29 colon and 53 rectum) were admitted and underwent radical resection from January 1982 to June 1984." | 2.66 | [Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial]. ( Wan, DS, 1988) |
| "Doxifluridine is an active agent in colorectal cancer." | 2.66 | A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. ( Alberto, P; Cavalli, F; Germano, G; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Spati, B; Weber, W, 1988) |
| " No serious adverse effects were observed in any of the groups." | 2.66 | [Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan]. ( Abe, O; Hattori, T; Inokuchi, K; Kasai, Y; Kikuchi, K; Komi, N; Kondo, T; Kunii, Y; Ogawa, N; Taguchi, T, 1987) |
| "Fifty-five patients with advanced colorectal cancer were entered into a randomized controlled clinical trial to evaluate order of administration and sequential methotrexate (MTX) and 5-fluorouracil (5-FU) therapy." | 2.66 | Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil. ( Coates, A; Mackintosh, J; Raghavan, D; Swanson, C; Tattersall, MH, 1987) |
| "Following curative surgery for colorectal cancer 141 patients were randomized to receive a 6 month course of 5-fluorouracil (5FU) with or without postoperative levamisole or supportive treatment only." | 2.66 | Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. ( Bell, PR; Shaw, D; Windle, R, 1987) |
| " This prospective study was undertaken to record possible adverse effects of surgery, external beam radiation therapy, and 5-fluorouracil (5-FU) chemotherapy in the treatment of large bowel cancer." | 2.66 | 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route. ( Barofsky, I; Gianola, FJ; Hancock, SL; Sugarbaker, PH; Wesley, R, 1986) |
| " Alpha-2 interferon, alone or in combination with 5-FU, is ineffective in advanced colorectal cancer." | 2.66 | Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. ( Blomgren, H; Cedermark, B; Clark, PI; Fallenius, A; Kurschel, E; Lundell, G; Niederle, N; Ohman, U; Reznek, RH; Slevin, ML, 1987) |
| " The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12." | 2.66 | Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. ( Dobbs, BR; Edwards, IR; Perrier, DG; Schaaf, LJ, 1987) |
| "Clinical studies were prospectively conducted to quantitate the toxic side-effects of 5-FU administered by either the intravenous (i." | 2.66 | Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. ( Barofsky, I; Gianola, FJ; Meyers, CE; Sugarbaker, PH; White, DE, 1986) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "Oral tegafur and I." | 2.65 | A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983) |
| " The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg." | 2.65 | [Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984) |
| "With rectal cancer, 5-year survival was 57." | 2.65 | [Evaluation of preoperative administration of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) suppository in surgical adjuvant chemotherapy for large bowel cancer]. ( Fujita, H; Kosaka, T; Miyazaki, I; Takashima, S; Ueno, K, 1984) |
| "The razoxane-treated patients experienced no significant toxicity apart from a readily reversible mild leukopenia in 52% while gastrointestinal symptoms necessitated stopping the drug in only four patients." | 2.65 | A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer. ( Cassell, PC; Ellis, H; Evans, MG; Gilbert, JM; Hellmann, K; Stoodley, BJ; Wastell, C, 1981) |
| "Every third patient with colon cancer Dukes' C and every fourth patient with rectal cancer Dukes' C survives 5 years." | 2.65 | [Background and experience of adjuvant cytostatic therapy in gastrointestinal cancer (author's transl)]. ( Bengmark, S; Eriksson, S; Hafström, L; Hugander, A, 1981) |
| "Combinations of active agents in gastric cancer hold promise as effective surgical adjuvant therapy." | 2.65 | Adjuvant chemotherapy in colon and gastric cancer. ( Haller, DG; Kisner, DL; Macdonald, JS, 1982) |
| "Fifty-three patients with colorectal cancer Dukes' B2 and C were randomized after surgery." | 2.65 | Adjuvant therapy in colorectal cancer. (A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with the methanol extraction residue of BCG, MER). ( Bartal, A; Cohen, Y; Mekori, T; Milstein, D; Robinson, E, 1979) |
| "A PR of hepatic metastases was noted in eight patients (35%) with a median and mean duration of response of 4." | 2.64 | Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. ( Buroker, T; Correa, J; Fraile, R; Samson, M; Vaitkevicius, VK, 1976) |
| "A clinical trial involving 462 colon, rectum, and breast cancer patients randomized among four different dosage regimens of 5-FU (an intravenous loading course, a weekly intravenous schedule, a nontoxic schedule, and an oral schedule) has shown a significantly better response among colon-rectum cancer patients for the intravenous loading course." | 2.64 | A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report. ( Ansfield, F; Cornell, G; Davis, H; Hill, G; Klotz, J; Minton, J; Nealon, T; Ramirez, G; Wilson, W, 1977) |
| "Fifty consecutive patients with colorectal cancer but no evidence of secondary deposits in the liver were included in an ongoing controlled clinical trial of adjuvant liver perfusion aimed at reducing the incidence of hepatic metastases." | 2.64 | Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. ( Brooman, P; Rowling, JT; Taylor, I, 1977) |
| "Twenty patients with advanced colon cancer were treated with a combination of low-dose weekly cyclophosphamide, vincristine, and methotrexate (COM) after demonstrated progression of disease with 5-fluorouracil (5-FU)." | 2.64 | Phase II trial of a combination of cyclosphamide, vincristine, and methotrexate in advanced colorectal carcinoma. ( Desai, SA; DeWys, WD; Taylor, SG, 1978) |
| "Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds." | 2.64 | Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978) |
| "Fifty-two untreated patients with colorectal cancer were randomized to receive 5-fluorouracil (5-FU) alternating either with methotrexate (MTX) or Baker's Antifol (BAF) with or without the immunostimulant, levamisole (Program I)." | 2.64 | Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole. ( Bedikian, AY; Bodey, GP; Burgess, MA; Mavligit, GM; Rodriguez, V; Valdivieso, M, 1978) |
| "Adjuvant trials in cancer treatment present special problems in statistical analysis." | 2.64 | Special problems in the evaluation of results in adjuvant trials of cancer treatment. ( Higgins, GA, 1978) |
| "route." | 2.64 | A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. ( Bruckner, HW; Hahn, RG; Moertel, CG; Schutt, AJ, 1975) |
| "The MSI phenotype in colon cancer is a good prognostic factor, with an impact probably more pronounced for stage II than stage III tumor." | 2.61 | [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?] ( Taieb, J; Zaanan, A, 2019) |
| "Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501." | 2.58 | Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. ( Alberts, SR; Folprecht, G; Goldberg, RM; Julie, C; Laurent-Puig, P; Le Malicot, K; Meyers, JP; Mini, E; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Tabernero, J; Taieb, J; Van Laethem, JL; Zaanan, A; Zawadi, A, 2018) |
| "Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer." | 2.58 | Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. ( Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J, 2018) |
| " Hyperammonemia induced by 5-FU is relatively rare, with a reported incidence of 5-9%; however, caution is required with high dosage regimens of 5-FU that are currently recommended for colorectal cancer therapy because hyperammonemia is an important side effect." | 2.58 | [A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer]. ( Funahashi, K; Kagami, S; Tamura, A; Yoshino, Y, 2018) |
| "Multimodality management of rectal cancer continues to evolve; total mesorectal excision is the cornerstone." | 2.55 | Randomized Clinical Trials in Colon and Rectal Cancer. ( George, TJ; Iqbal, A, 2017) |
| "Colon cancer is a leading cause of cancer-related death in humans." | 2.53 | Motility patterns in mouse colon: gastrointestinal dysfunction induced by anticancer chemotherapy. ( Spencer, NJ, 2016) |
| "Intussusception is relatively rare in adults, particularly in portions of the colon fixed to the retroperitoneum, such as the descending colon." | 2.53 | [A Case of Intussusception Caused by Descending Colon Cancer]. ( Hashimoto, Y; Hotta, S; Iwaki, T; Kameyama, H; Kobayashi, T; Oyamatsu, M; Sakata, J; Sato, K; Sato, Y; Shimada, Y; Wakai, T, 2016) |
| "She was diagnosed with ascending colon cancer, with portal vein tumor thromboembolism extending to the portosplenic junction." | 2.52 | [Five-Year Recurrence-Free Survival after mFOLFOX6 Administration, Right Hemicolectomy, and Lymphadenectomy for Portal Venous Tumor Thromboembolism]. ( Asayama, M; Ishikawa, H; Kawashima, Y; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015) |
| "The patient was diagnosed with acute leukoencephalopathy, and the capecitabine treatment was discontinued." | 2.50 | [Early diagnosis of capecitabine-induced acute leukoencephalopathy by using diffusion-weighted MRI]. ( Ban, T; Ikegaya, Y; Isogai, N; Kawachi, J; Miyake, K; Ogino, H; Shimoyama, R; Watanabe, K, 2014) |
| " Future strategies should focus on investigating the immunomodulatory effects of chemotherapy in conjunction with TroVax, understanding the optimal dosing and schedule of the combination, and examining potential predictive biomarkers to determine which patients may benefit from immunotherapy from those who do not." | 2.50 | TroVax in colorectal cancer. ( Cen, P; Rowe, J, 2014) |
| "We report a case of recurrent colon cancer successfully treated by mFOLFOX6 and FOLFIRI, and maintaining a complete response(CR)over the long-term." | 2.49 | [A case of recurrent colon cancer involved in multiple organs maintaining complete response over the long-term after chemotherapy]. ( Hamada, T; Ohashi, S; Ohta, K; Taniguchi, E; Yamagami, Y; Yoshikawa, M, 2013) |
| "Although 40% of patients with colon cancer are elderly, clinical trials enroll mainly younger patients." | 2.49 | Managing choices for older patients with colon cancer: adjuvant therapy. ( Goldberg, RM; Wu, C, 2013) |
| "He was diagnosed with interstitial pneumonitis induced by irinotecan or panitumumab." | 2.48 | [A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy]. ( Abe, T; Ando, M; Kato, T; Nakashima, H; Shindo, J; Shiraki, A; Yamamoto, K; Yukita, Y, 2012) |
| "The standard treatment for colon cancer is surgical excision." | 2.47 | Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease. ( , 2011) |
| "Patients with UICC stage II colon cancer and microsatellite instability (MSI) apparently experience a better prognosis but do not profit from an adjuvant CT with 5-FU/FA alone." | 2.47 | [Multimodal therapy for colon cancer: state of the art]. ( Link, KH; Weber, T, 2011) |
| "The present patient had metastatic colon cancer and was admitted to our hospital with a floating sensation and general malaise on day 4 after undergoing the last of 4 cycles of a 7th round of chemotherapy with XELOX." | 2.47 | [Recurrent autoimmune hemolytic anemia induced by XELOX chemotherapy for colon cancer]. ( Goto, H; Hara, K; Higuchi, K; Hijioka, S; Kawai, H; Kondo, S; Mizuno, N; Nakamura, M; Niwa, Y; Ogura, T; Sawaki, A; Tajika, M; Yamao, K, 2011) |
| "Among patients with resected colon cancer, black patients have worse survival than whites." | 2.47 | Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. ( Benedetti, JK; Blackstock, AW; Dignam, JJ; Goldberg, RM; O'Connell, MJ; Saltz, LB; Sargent, DJ; Wolmark, N; Yothers, G, 2011) |
| "A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | 2.46 | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
| "We report a case of renal tubular acidosis (RTA) secondary to capecitabine, oxaliplatin, and cetuximab administration in a 63-year-old woman with liver metastasis from colon carcinoma who had partial treatment response." | 2.46 | Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. ( Meirovitz, A; Sonnenblick, A, 2010) |
| "While many patients with early-stage colon cancer are cured with surgery alone, the standard of care remains a uniform approach to adjuvant chemotherapy based primarily on tumor stage." | 2.46 | Molecular markers to individualize adjuvant therapy for colon cancer. ( Gangadhar, T; Schilsky, RL, 2010) |
| "Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage." | 2.46 | Adjuvant colon cancer chemotherapy: where we are and where we'll go. ( Cinieri, S; Colucci, G; Fazio, N; Lombardi, L; Maiello, E; Morelli, F; Orlando, L; Santini, D; Silvestris, N; Tonini, G, 2010) |
| "Risk factors for colorectal cancer are mainly dietary and genetic." | 2.46 | Colorectal cancer treatment. ( Landau, D; Qureshi, A; Ross, P; Verma, A, 2010) |
| "A 43-year-old man with a history of colon cancer developed typical angina during intravenous infusion of 5-FU." | 2.46 | Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. ( Movahed, MR; Saadat, H; Taherkhani, M; Tajik, R, 2010) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "Colon cancer is a public health problem worldwide." | 2.44 | Colon cancer: update on adjuvant therapy. ( Duhoux, F; Mano, MS, 2008) |
| " As a result, both the toxicity and efficacy of over 30 anticancer agents vary by more than 50% as a function of dosing time in experimental models." | 2.44 | Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. ( Baron, B; de la Valette, V; Focan, C; Focan-Henrard, D; Giacchetti, S; Karaboué, A; Kreutz, F; Lévi, F, 2007) |
| "Adjuvant chemotherapy for colon cancer has changed significantly during the past 5 years." | 2.43 | Advances in colon cancer chemotheapy: nursing implications. ( Vega-Stromberg, T, 2005) |
| "Adjuvant chemotherapy for colon cancer and combined chemotherapy and radiation therapy (RT) for rectal cancer increases the proportion of patients cured of their disease." | 2.43 | An overview of approaches to adjuvant therapy for colorectal cancer in the United States. ( Hobday, TJ, 2005) |
| " For both breast and colon cancer, capecitabine alone or in combination with other cytotoxics is safe and effective." | 2.43 | Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. ( Ershler, WB, 2006) |
| "Colon cancer is a leading cause of cancer and cancer deaths in Western countries." | 2.43 | Adjuvant therapy for colon cancer. ( Cilley, J; Mulcahy, MF, 2006) |
| "In stage II colon cancer, treatment strategies are more debated." | 2.43 | [Adjuvant treatment of colorectal cancer]. ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006) |
| "Oral capecitabine was at least equivalent in disease-free survival to the bolus Mayo Clinic 5-FU/LV regimen for patients with resected Stage III colon cancer." | 2.43 | The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. ( Eggington, S; Paisley, S; Pandor, A; Sutcliffe, P; Tappenden, P, 2006) |
| "Capecitabine was also associated with significantly fewer fluoropyrimidine-related grade 3/4 adverse events (AEs; P < 0." | 2.43 | Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. ( Twelves, CJ, 2006) |
| "No case of epidermoid (squamous cell) cancer of the colon has been previously described in a pregnant woman." | 2.42 | [Colon cancer in pregnancy]. ( Fermeaux, V; Mathonnet, M, 2003) |
| "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability." | 2.42 | Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. ( Burzykowski, T; Buyse, M; Hamada, C; Ohashi, Y; Piedbois, P; Sakamoto, J, 2004) |
| "Patients with high-risk resected colon cancer obtain benefit from FU-based therapy across subsets of age, sex, location, T stage, nodal status, and grade." | 2.42 | Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? ( Alberts, SR; Benedetti, J; Cha, SS; Chen, W; Francini, G; Francois Seitz, J; Gill, S; Goldberg, RM; Haller, DG; Heldebrant, MP; Labianca, R; Loprinzi, CL; Sargent, DJ; Shepherd, LE; Thomé, SD, 2004) |
| "Future studies in adjuvant therapy for colon cancer will explore oxaliplatin and 5-FU with or without antiangiogenesis or anti-epidermal growth factor agents." | 2.42 | An overview of adjuvant systemic chemotherapy for colon cancer. ( Andre, T; de Gramont, A, 2004) |
| " Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment." | 2.42 | Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004) |
| "Colorectal cancer is one of the most common tumors worldwide." | 2.41 | The role of genomic instabilities in affecting treatment responses of colorectal cancer. ( Bazzoli, F; Ricciardiello, L, 2002) |
| "Forty-seven resected colon cancer specimens, four colon cancer cell lines, two xenografts by colon cancer cell lines, and human mononuclear cells were used." | 2.41 | Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. ( Hatano, K; Kitayama, J; Matsuda, K; Nagawa, H; Nita, ME; Takei, Y; Takenoue, T; Tsuruo, T; Umetani, N, 2000) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and rationally designed to undergo tumor-selective activation." | 2.41 | [Capecitabine--a review of its antitumor activity and toxicity in clinical studies]. ( Maeda, Y; Sasaki, T, 2000) |
| "Advanced colorectal cancer has traditionally been treated with 5-fluorouracil, alone or in combination with leucovorin." | 2.41 | [New drugs in the treatment of advanced colorectal cancer]. ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000) |
| "Colon cancer has clearly moved from an exclusive surgeons' stronghold to a disease where a multimodal approach will provide better and more promising results." | 2.41 | [Adjuvant therapy for colon cancer]. ( Fey, MF, 2000) |
| "The mainstay of treatment of colon cancer is 5-Fluoruracil (5-FU), which should be combined with folinic acid in case of bolus (2-4 min." | 2.41 | [Chemotherapy of colonic carcinoma in the year 2001]. ( Mross, K; Semsek, D, 2001) |
| "Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects." | 2.41 | A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. ( Francini, G; Goldberg, RM; Haller, DG; Jacobson, SD; Labianca, R; Macdonald, JS; Sargent, DJ; Seitz, JF; Shepherd, LE, 2001) |
| "In patients with stage II colon cancer it is still unclear whether adjuvant chemotherapy is effective." | 2.41 | Adjuvant chemotherapy for colon cancer. ( Boige, V; Ducreux, M, 2002) |
| "In patients with Dukes' B or C rectal cancer, combined radiation and FU increase survival and decrease local and distal recurrence." | 2.40 | Adjuvant therapy of colorectal cancer. ( Cohen, A; Kemeny, N; Saltz, L, 1997) |
| " Raltitrexed, a thymidylate synthase inhibitor, offers similar antitumoral activity together with a tolerability in comparison to standard 5-fluorouracil based chemotherapy and its simple dosage schedule also contributes to better quality of life." | 2.40 | [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer." | 2.40 | Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Pater, A; Shehata, N; Tang, SC, 1999) |
| "The majority of these cases were anal cancers with proximal extension into the rectum and were excluded." | 2.40 | Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature. ( Francis, B; Juturi, JV; Koontz, PW; Wilkes, JD, 1999) |
| "One thousand sixteen patients with B2 colon cancer entered onto five separate trials were randomized to FU + LV or observation." | 2.40 | Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. ( , 1999) |
| "Sixty-six patients with colorectal cancer were studied regarding effects of prevention of hepatic recurrence in completely performed portal infusion chemotherapy." | 2.40 | [Is portal infusion chemotherapy uneffective for hepatic recurrence after resection for colorectal cancer?]. ( Akaishi, O; Tsukikawa, S; Yabe, K; Yamaguchi, S; Yamamura, T, 1999) |
| "Raltitrexed has a different mechanism of action from two other new agents active in colorectal cancer, irinotecan and oxaliplatin, and tumours are therefore not necessarily cross-resistant." | 2.40 | Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. ( Ford, HE; Jackman, AL; Kimbell, R, 1999) |
| "In the treatment of stages 2 and 3 rectal cancer, significant reductions in local recurrence and death rates have been achieved with the combination of 5-fluorouracil and radiation therapy." | 2.39 | Role of adjuvant therapy in surgically resected colorectal carcinoma. ( Sinicrope, FA; Sugarman, SM, 1995) |
| " Preoperative radiotherapy with a dosage of 35-45 Gy can lead to downstaging of rectal cancer." | 2.39 | [Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma]. ( Eble, MJ; Kraus, TW; Raeth, U, 1994) |
| "For Dukes' C colon cancer, postoperative adjuvant chemotherapy with a combination of fluorouracil and levamisole is now recommended as standard therapy." | 2.39 | Adjuvant postoperative therapy of gastrointestinal malignancies. ( Ilson, DH; Kelsen, DP, 1994) |
| "Deoxyuridine monophosphate levels were greatly increased when cells were exposed to 5-FU alone, and were even larger with the addition of dipyridamole." | 2.38 | Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. ( Grem, JL, 1992) |
| "Some aspects of colorectal cancer remain controversial, particularly screening recommendations and monitoring of carcinoembryonic antigen levels." | 2.38 | Colorectal cancer. Recent developments and continuing controversies. ( Lee, MW, 1992) |
| "Several trials in rectal cancer show an advantage for 5-FU combined with semustine and radiation therapy in terms of disease-free survival, overall survival, or both; the contribution of semustine has been questioned and is currently being investigated." | 2.38 | Current treatment approaches in colorectal cancer. ( Grem, JL, 1991) |
| " To date, a lot of phase II studies have been conducted, but there are many distance in each clinical data concerning response rate and side effect by the difference between their clinical methods with respect to the interval between methotrexate and 5-fluorouracil, or the dosage of each drugs." | 2.37 | [Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy]. ( Murakami, M; Ota, K, 1988) |
| "Fluorouracil has been the mainstay of chemotherapy in colorectal cancer for many years." | 2.37 | Biochemical modulation of fluorouracil therapy in advanced colorectal cancer. ( Mackintosh, J; Tattersall, MH, 1987) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| "The potential impact on cancer mortality from these treatment results is obvious." | 2.36 | Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. ( DeVita, VT; Weiss, RB, 1979) |
| "Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice." | 1.91 | The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023) |
| "Capecitabine was associated with the lowest ER/hospitalization rate." | 1.91 | Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older. ( Duan, Z; Giordano, SH; Jones, E; Nguyen, TT; Zhao, H, 2023) |
| "Of patients with colon cancer treated with an initial lower 5-FU dose, 18% had a therapeutic 5-FU blood level." | 1.91 | Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion. ( Baranseh, J; Khatib, AW; Selub, SM; Shai, A; Uryvaey, A, 2023) |
| "Chloroquine (CQ) is an effective and safe antimalarial drug that is also used as a disease-modifying antirheumatic drug." | 1.91 | Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia. ( Ju, S; Jung, Y; Kang, C; Kim, J, 2023) |
| "The present study aimed to determine if oral methioninase (o-rMETase) combined with oxaliplatinum (OXA) plus 5-fluorouracil (5-FU) increases survival of mice with peritoneal-carcinomatosis formed from HCT-116 green fluorescent protein (GFP)-expressing colon-cancer cells implanted intra-peritoneally in nude mice." | 1.91 | Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis. ( Bouvet, M; Han, Q; Hoffman, RM; Kim, MJ; Park, JH, 2023) |
| "Colorectal cancer has risen to the third occurring cancer in the world." | 1.91 | The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. ( Chen, J; Chen, Q; Jin, S; Song, H; Song, X; Wang, L; Wang, Z; Xing, W; Yang, H; Zhao, W, 2023) |
| "Rhabdomyolysis was determined to be the adverse effect of oxaliplatin because out of all the drugs prescribed to the patient, this condition is listed as a side effect only in oxaliplatin's package insert." | 1.91 | [A Case of Rhabdomyolysis Caused by Oxaliplatin during Postoperative Adjuvant Chemotherapy]. ( Amano, Y; Furuhata, T; Hisatsune, Y; Katsumata, K; Kikuchi, Y; Kokuba, Y; Naito, M; Negishi, H; Oshima, R; Otsubo, T; Usui, S, 2023) |
| "5-Fluorouracil (5-FU) is a chemotherapy drug that treats several cancers; however, it causes severe adverse effects and multidrug resistance." | 1.91 | Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase. ( Ganesan, K; Gong, G; Tsim, KWK; Xiong, Q; Zheng, Y, 2023) |
| "Then, human colon cancer cells were dynamically seeded onto the 3D Stroma μTs to achieve the 3D CRC μTs." | 1.91 | Colorectal Cancer Bioengineered Microtissues as a Model to Replicate Tumor-ECM Crosstalk and Assess Drug Delivery Systems In Vitro. ( De Gregorio, V; Imparato, G; La Rocca, A; Lagreca, E; Netti, PA; Vecchione, R, 2023) |
| "To evaluate the effect of 5-fluorouracil (5-FU) combined with rutaecarpine (RUT) on the antiproliferative, anti-migratory, and apoptosis-promoting ability of colorectal cancer (CRC) cells and explore the underlying mechanism." | 1.91 | 5-Fluorouracil Combined with Rutaecarpine Synergistically Suppresses the Growth of Colon Cancer Cells by Inhibiting STAT3. ( Chan, S; Chen, J; Chen, W; Sun, R; Wang, M; Wang, X; Wang, Z; Yu, Z; Zhang, H; Zuo, X, 2023) |
| "We prospectively included patients with gastric cancer who underwent radical gastrectomy between March 14, 2017 and September 30, 2021." | 1.91 | Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy. ( Dong, Q; Gao, L; Li, E; Li, Z; Liu, Z; Ma, J; Ren, D; Shen, G; Wang, M; Xie, Q; Zhao, F; Zhao, J; Zhao, Y, 2023) |
| "FOSL1 expression in colon cancer was analyzed by bioinformatics methods, and its downstream regulatory factors were predicted." | 1.91 | FOSL1 transcriptionally regulates PHLDA2 to promote 5-FU resistance in colon cancer cells. ( Li, Y; Liu, G; Ran, R; Wang, H; Wang, Y, 2023) |
| "The role of ATF2 in colon cancer (CC) is controversial." | 1.91 | ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway. ( Erlenbach-Wuensch, K; Geppert, CI; Hampel, C; Hartmann, A; Huebner, K; Mahadevan, V; Schneider-Stock, R; Selvamani, SB; Shukla, V; Yang, H, 2023) |
| "Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018." | 1.91 | Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen. ( Han, Q; Hu, X; Li, G; Liu, Y; Liu, Z; Ni, K; Ping, H; Sun, J; Wang, G; Wang, W; Xin, R; Yan, S; Zhan, Y; Zhang, C; Zhang, Q; Zhang, X; Zhang, Z; Zhao, X, 2023) |
| "To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors." | 1.91 | Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer. ( Delgado, MG; Gomez, MF; Hubbard, JM; Ji, R; Kim, RD; Knepper, TC; Laber, DA; Meng, L; Permuth, JB; Thapa, R; Wang, X; Xie, H, 2023) |
| "BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time." | 1.91 | Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. ( Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z, 2023) |
| "This study aimed to analyze the effect of Bletilla striata polysaccharide(BSP) on endogenous metabolites in serum of tumor-bearing mice treated with 5-fluorouracil(5-FU) by untargeted metabolomics techniques and explore the mechanism of BSP in alleviating the toxic and side effects induced by 5-FU." | 1.91 | [Bletilla striata polysaccharide improves toxic and side effects induced by 5-FU: an untargeted metabolomics study]. ( Cui, YR; He, TH; Liu, P; Wang, WL; Xie, XX; Yu, J; Zhang, JT, 2023) |
| "Quercetin (Que) has been proven to enhance the chemosensitivity of multiple cancers, including colon cancer (CC)." | 1.91 | Quercetin reverses 5-fluorouracil resistance in colon cancer cells by modulating the NRF2/HO-1 pathway. ( Chen, Y; Liu, B; Tang, Z; Wang, H; Wang, L; Wang, R; Zhang, S; Zheng, X, 2023) |
| "For patients with resected stage III colon cancer, 6 months of adjuvant fluoropyrimidine-based chemotherapy has been the standard of care." | 1.91 | Changes in Prescribing Patterns in Stage III Colon Cancer. ( Ahn, DH; Alese, OB; Bekaii-Saab, TS; Draper, A; Griswold, CR; Kang, S; Larson, JJ; Ou, FS; Patel, B; Raman, P; Sonbol, MB; Ueberroth, BE; Walden, DJ; Wu, CS, 2023) |
| " We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first-line (1L) treatment in patients with RAS wild-type mCRC and the dynamics of plasma angiogenesis factors at progression during 1L treatment." | 1.91 | Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. ( Abe, Y; Asano, C; Bando, H; Denda, T; Esaki, T; Kagawa, Y; Kato, T; Kawakami, H; Matsuhashi, N; Nishina, T; Nomura, S; Satake, H; Shiozawa, M; Sunakawa, Y; Takahashi, N; Takashima, A; Taniguchi, H; Yamazaki, K; Yasui, H; Yoshino, T; Yuki, S, 2023) |
| " Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy." | 1.91 | Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers. ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023) |
| " Number of cycles, dose delays for any cause, and dose reductions for adverse events (AEs) were comparable between age classes." | 1.91 | Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study. ( Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R, 2023) |
| "Treating colon cancer cells with a DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine (DAC), led to elevated expression levels of CYP1B1 and CYP3A4 through demethylation of the promoter regions of related genes." | 1.91 | [Modulation of Expression of Drug Metabolizing Enzymes and Augmentation of Anti-cancer Drug Effects: Through Epigenetics and Three-dimensional Cancer Cell Culture Systems]. ( Ozawa, S, 2023) |
| "Silencing HCG11 inhibited colon cancer cell proliferation, migration, invasion and glucose metabolism and sensitized CRC cells to 5-FU." | 1.72 | LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis. ( Cui, Z; Deng, MH; Han, QL; Wang, Q, 2022) |
| "To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)." | 1.72 | Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. ( Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022) |
| "Fraxetin is a natural compound extracted from Fraxinus spp." | 1.72 | Fraxetin induces cell death in colon cancer cells via mitochondria dysfunction and enhances therapeutic effects in 5-fluorouracil resistant cells. ( Lee, M; Lim, W; Park, S; Song, G; Yang, C, 2022) |
| "The aim of the present work was to evaluate the in vitro effect of Manuka honey and its combination with 5-Fu, the most common drug used in the treatment of colon cancer, on the morphological and physical parameters of colonspheres enriched with cancer stem-like cells deriving from HCT-116 colon adenocarcinoma cell line and on the apoptosis rate." | 1.72 | Manuka honey in combination with 5-Fluorouracil decreases physical parameters of colonspheres enriched with cancer stem-like cells and reduces their resistance to apoptosis. ( Alvarez-Suarez, JM; Bai, W; Battino, M; Cianciosi, D; Forbes-Hernández, TY; Giampieri, F; Quinzi, D; Regolo, L; Sargenti, A; Tian, L, 2022) |
| " The efficacy and adverse effects of maintenance treatment were compared between the two groups." | 1.72 | Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022) |
| "Moreover, AKR1C3 was downregulated in colon cancer tissues compared to normal tissues." | 1.72 | ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3. ( Bai, F; Du, Y; Jin, X; Li, J; Li, X; Li, Y; Tang, J; Wang, T; Yang, L, 2022) |
| "Treatment of colon cancer cells with GZ17-6." | 1.72 | Mechanisms of GZ17-6.02 resistance. ( Booth, L; Dent, P; Von Hoff, D; West, C, 2022) |
| "Apoptosis is de-regulated in colon cancer and is one key mechanism of cancer treatment." | 1.72 | ARHGAP17 enhances 5-Fluorouracil-induced apoptosis in colon cancer cells by suppressing Rac1. ( Deng, YY; Fu, J; Pan, SL; Qin, XJ; Zhang, YH; Zhang, ZJ, 2022) |
| "It revealed a peritoneal recurrence in the pouch of Douglas." | 1.72 | [A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection]. ( Arakawa, A; Ii, Y; Irie, T; Kawaguchi, M; Kawai, M; Kobari, A; Kojima, Y; Momose, H; Sakamoto, K; Sugimoto, K; Terao, Y; Tomiki, Y; Tsukamoto, R, 2022) |
| "The selected old colon cancer patients with a high risk of recurrence gained an additional benefit with respect to prognosis from FU + oxaliplatin as AC." | 1.72 | Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis. ( Fukuda, A; Fukuoka, H; Hashimoto, S; Hisanaga, M; Nagayasu, T; Nonaka, T; Oyama, S; Sawai, T; Shiraishi, T; Sumida, Y; Takeshita, H; Tanaka, K; To, K; Tominaga, T, 2022) |
| " The most frequent grade 3/4 adverse events were: asthenia (21." | 1.72 | Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. ( Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y, 2022) |
| "Compared with no screening for DPD deficiency, DPYD genotyping increased per-patient costs by $78 and improved survival by 0." | 1.72 | Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. ( Brooks, GA; Busam, JA; Daly, AT; Tapp, S; Tosteson, ANA, 2022) |
| "Patients with colon cancer who prematurely discontinue postoperative chemotherapy may have an increased risk of disease recurrence and death." | 1.72 | The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer. ( Brown, JC; Caan, BJ; Cespedes Feliciano, EM; Cheng, E; Meyerhardt, JA, 2022) |
| "Drug resistance of colon cancer cells is the key to affect the efficacy of colon cancer chemotherapy and lead to chemotherapy failure." | 1.72 | VMP1 promotes exosome secretion and enhances 5-FU resistance in colon cancer cells. ( Chen, G; Huang, J; Wei, X; Yang, Z, 2022) |
| "CLRE could reverse 5-Fu resistance in colon cancer by inactivating TLR4/PI3K/AKT/mTORC1 pathway." | 1.72 | Curcumae longae Rhizoma (Jianghuang) extract reverses the 5-Fluoruracil resistance in colorectal cancer cells via TLR4/PI3K/Akt/mTOR pathway. ( Guo, Y; Liu, Y; Sun, X; Teng, Z; Xu, M; Zhang, M, 2022) |
| "Colorectal cancer is one of the most commonly diagnosed malignancies globally and nearly half of these patients develop metastatic colorectal cancer (mCRC)." | 1.72 | Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. ( Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW, 2022) |
| "Most frequent second cancers were prostate cancer (18." | 1.72 | Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. ( Ebert, MP; Evert, M; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Li, M; Schlitt, HJ; Teufel, A, 2022) |
| "TBG inhibits SW620 colon cancer growth, induces apoptosis SMAC-XIAP-Caspases signaling, induces cellular senescence through CDKN1a/CDKN2a-RB-E2F signaling, inhibits angiogenesis by down-regulation of HIF-1α and VEGF, and enhances the effects of 5-Fu." | 1.72 | Tenglong Buzhong granules inhibits the growth of SW620 human colon cancer. ( Bing, HU; Hongmei, AN; Jialu, Z; Jinfang, C; Lei, C; Miao, LI; Shuangshuang, W; Xiao, P, 2022) |
| " Moreover, though HE staining and organ index measurement, 2'-FL was validated to alleviate toxic effects on liver and kidney tissue when combining with 5-Fu." | 1.72 | 2'-Fucosyllactose Suppresses Angiogenesis and Alleviates Toxic Effects of 5-Fu in a HCT116 Colon Tumor-Bearing Model. ( Li, H; Wang, B; Wang, Y, 2022) |
| "5-Fluorouracil (5-FU) is a standard chemotherapeutic agent to treat solid cancers such as breast, colon, head, and neck." | 1.72 | Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model. ( Almasan, A; Gurkan-Cavusoglu, E; Ma, C, 2022) |
| "Colon cancer is a major malignant neoplasm with a low survival rate for late-stage patients." | 1.72 | Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo. ( Chang, CH; Cho, EC; Hsieh, YC; Lee, CH; Liu, HH; Liu, YR; Zheng, JH, 2022) |
| "Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis." | 1.72 | A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE Study). ( Endo, I; Ishibe, A; Misumi, T; Nakagawa, K; Ota, M; Suwa, H; Suwa, Y; Watanabe, J, 2022) |
| "In stage 3 colon cancer oncologists had an equal decision "to do or not to do" in MSI testing." | 1.72 | The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. ( Araz, M; Aykan, NF; Baykara, M; Beypinar, I; Demir, H, 2022) |
| "Colon cancer is one of the leading causes of cancer-related deaths worldwide." | 1.72 | Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years. ( Abdelaziz, LA; Gertallah, LM; Harb, OA; Taha, HF, 2022) |
| "5- Fluorouracil (5-FU) is a conventional and most effective drug used in the clinic for the treatment of CRC." | 1.72 | Sulfonamide-Functionalized Polymeric Nanoparticles for Enhanced In Vivo Colorectal Cancer Therapy. ( Andrade, SP; Campos, PP; Gontijo, SML; Guimarães, PPG; Pereira, L; Santos, RAS; Sinisterra, RD; Viana, CTR, 2022) |
| "Capecitabine monotherapy is an oncologically safe regimen compared to oxaliplatin-added regimens in elderly patients with high-risk stage II/stage III colon cancer." | 1.72 | Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II - III elderly patients with colon cancer. ( An, MS; Baik, H; Kang, SH; Kim, KH; Lee, HS; Lee, SH; Oh, MK; Park, J; Seo, SH, 2022) |
| "FOLFIRINOX and FOLFOXIRI are combination chemotherapy treatments that incorporate the same drug cocktail (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) but exploit an altered dosing regimen when used in the management of pancreatic and colorectal cancer, respectively." | 1.62 | A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. ( Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M, 2021) |
| "To identify genetic vulnerabilities of colon cancer, we performed targeted CRISPR dropout screens comprising 657 Drugbank targets and 317 epigenetic regulators on two patient-derived colon CSC-enriched spheroids." | 1.62 | CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer. ( Ahmed, M; Chen, H; Gao, S; Go, MYY; He, HH; Liu, W; O'Brien, CA; Soares, F; Sung, JJY; Wang, S; Wong, CC; Yang, Z; Yu, J; Zeng, Y, 2021) |
| " These results also validate that CLZ has significant anticancer activity both alone and in combination and support the strategy of drug repurposing coupled to drug combination for prostate cancer therapy." | 1.62 | Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines. ( Duarte, D; Vale, N, 2021) |
| " From the clinical course, we suspected that the severe adverse effects were caused due to a deficiency of DPD." | 1.62 | [A Case of Colon Cancer with Suspected DPD Deficiency Causing Severe Adverse Effects following Adjuvant Chemotherapy with Capecitabine]. ( Aoki, H; Araki, H; Arata, T; Katsuda, K; Kimura, Y; Minagi, H; Nagahisa, S; Ogawa, T; Tanakaya, K; Taniguchi, F; Watanabe, M, 2021) |
| " A latent class analysis defined the unobserved latent constructs that can be predicted as symptom clusters, considering the intensity of four types of adverse events (AEs)." | 1.62 | Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. ( Cacho Lavin, D; Calderón, C; Carmona-Bayonas, A; Gomez, D; Jimenez-Fonseca, P; Martinez Cabañez, R; Muñoz, MM, 2021) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "In patients with stage III colon cancer (CC) whose tumors demonstrate microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without oxaliplatin has not been clearly demonstrated and the prognostic value of MSI remains uncertain." | 1.62 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. ( Alberts, S; Allegra, C; André, T; Cohen, R; de Gramont, A; Erlichman, C; Fiskum, J; Goldberg, R; Grothey, A; Haller, D; Kerr, R; Lonardi, S; O'Connell, M; Seitz, JF; Shi, Q; Sinicrope, FA; Taieb, J; Wolmark, N; Yoshino, T; Yothers, G; Zaniboni, A, 2021) |
| "The colon cancer was induced by 1,2-dimethylhydrazine(DMH)/dextran sulfate sodium(DSS) in male Balb/c mice and these animals were treated with 5-FU(12." | 1.62 | Elucidation of underlying molecular mechanism of 5-Fluorouracil chemoresistance and its restoration using fish oil in experimental colon carcinoma. ( Agnihotri, N; Kaur, S; Kumar, S; Prasad, R; Rani, I; Sharma, B; Sharma, P, 2021) |
| "A 68-year-old man having a descending colon cancer with multiple metastases of up to 9." | 1.62 | [A Case of Colon Cancer with Synchronous Multiple Metastases Successfully Treated with Combined Chemotherapy]. ( Hasegawa, K; Isogai, J; Kaneko, J; Maejima, K; Maejima, S; Otomo, M; Takatsuno, Y, 2021) |
| "T4N0 colon cancer had similar oncological characteristics and survival outcomes to T3N1 colon cancer." | 1.62 | Staging Paradox and Discrepancy in Adjuvant Chemotherapy in Patients with T4N0, T1-2N1, and T3N1 Colon Cancer. ( Arita, T; Fujiwara, H; Ikoma, H; Kiuchi, J; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2021) |
| "We used pancreatic, liver and colon cancer cell lines and isolated CSCs using Aldefluor technology to analyze PARP-1 expression." | 1.62 | Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study. ( Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D, 2021) |
| "Human colon cancer cell lines, proficient (HT29) and deficient (HCT116) in MMR, were treated with 5-FU and Olaparib." | 1.62 | Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. ( Bencke Grudzinski, P; da Costa Ghignatti, PV; de Castro E Gloria, H; Guecheva, TN; Jesuíno Nogueira, L; Motta Leguisamo, N; Saffi, J, 2021) |
| "In this study, one out of five colon cancer patients were hospitalized during adjuvant chemotherapy." | 1.62 | Hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy: a real-world study. ( Abdel-Rahman, O; Koski, S; Tang, PA, 2021) |
| "Traditionally, adjuvant treatment for colon cancer has been 6 months of combination chemotherapy." | 1.62 | The Early Impact of the IDEA Collaboration Results: How the Results Changed Prescribing Practice. ( Hanna, C; Iveson, P; Iveson, T; Levasseur, A; Meyerhardt, J; Zhang, S, 2021) |
| "Only 50-70% of elderly colon cancer patients could complete the recommended 6 months of postoperative chemotherapy." | 1.62 | Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study. ( Chen, J; Chen, W; Dong, H; Wang, G; Wang, W, 2021) |
| "Using drug-resistant TP53-null colon cancer cells as a model we demonstrated that p65BTK silencing or chemical inhibition overcame the 5-fluorouracil resistance of CRC cell lines and patient-derived organoids and significantly reduced the growth of xenografted tumours." | 1.56 | BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. ( Agostini, M; Bonomo, S; Canzonieri, V; Cerrito, MG; Cialdella, A; D'Amato, F; Ferri, GL; Giovannoni, R; Grassilli, E; Helin, K; Ianzano, L; Lavitrano, M; Leone, BE; McLean, CM; Missaglia, C; Noli, B; Pisano, F; Pucciarelli, S; Romano, G; Voest, EE, 2020) |
| "Advanced colon cancer is extremely difficult to cure, underscoring the need to develop novel therapeutic agents." | 1.56 | Gercumin synergizes the action of 5-fluorouracil and oxaliplatin against chemoresistant human cancer colon cells. ( Epifano, F; Fiorito, S; Genovese, S; Majumdar, APN; Nangia-Makker, P; Preziuso, F; Slater, J, 2020) |
| "EGFR contributed to 5-FU resistance in colon cancer cells through autophagy induction, and EGFR overexpression in 5-FU resistant colon cancer was regulated by RARA." | 1.56 | Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer. ( Cui, BB; Gu, XY; Han, P; Jiang, Y; Li, MQ; Liu, YL, 2020) |
| "5-Fluorouracil (5-FU) has been commonly prescribed for patients with colorectal cancer (CRC), but resistance to 5-FU is one of the main reasons for failure in CRC." | 1.56 | Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. ( Ali, DJ; Chen, B; Liang, G; Si, K; Sun, B; Tian, T; Xiao, Z; Xu, H; Zhu, Y, 2020) |
| "SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer." | 1.56 | Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer. ( Han, JG; Wang, YB; Wang, ZJ; Wei, GH; Yi, BQ; Zeng, WG; Zhai, ZW; Zhao, BC, 2020) |
| "Colon cancer is one of the leading causes of cancer-related deaths and its five-year survival rate remains low in locally advanced or metastatic stages of colon cancer." | 1.56 | Dicoumarol suppresses HMGA2-mediated oncogenic capacities and inhibits cell proliferation by inducing apoptosis in colon cancer. ( Chen, CH; Cho, EC; Hsieh, YC; Liu, YR; Yang, PM, 2020) |
| "Total paired 70 colon cancer and adjacent normal tissues were collected from colon cancer patients." | 1.56 | Long non-coding RNA POU6F2-AS2 promotes cell proliferation and drug resistance in colon cancer by regulating miR-377/BRD4. ( Wang, Y; Xu, G; Xu, J; Zhang, M; Zhang, Y; Zhu, D; Zhu, H, 2020) |
| "Colon cancer is one of the most common and has the highest mortality rate in the world." | 1.56 | Data Mining the Prognostic Biomarkers: miRNAs Targeting the Chemotherapeutic Agent 5-Fluorouracil in Colon Cancer. ( Chen, YH; Huang, XL; Huang, ZM; Li, YL; Lin, XR; Wu, XX, 2020) |
| " We also addressed the economic feasibility of a new combined treatment of this thiosulfinate-enriched garlic extract, with oxaliplatin that could reduce the dosage and costs of a monotherapy." | 1.56 | Cost Effective Use of a Thiosulfinate-Enriched ( de la Cruz-Morcillo, MA; Galan-Moya, EM; Garcia, MT; Gracia, I; Perez-Ortiz, JM; Redondo-Calvo, FJ; Rodriguez, JF, 2020) |
| "Cytotoxicity on two colon cancer cell lines (SW480 and SW620) was measured by MTT test." | 1.56 | 6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions. ( Agrawal, S; Makuch, S; Winograd, K; Wiśniewski, J; Woźniak, M; Ziółkowski, P, 2020) |
| "Curcumin was found to be effective in the inhibition of proliferation, inducement of apoptosis and block of G0/G1 phase on 5-fluorouracil treated HCT-116 cells." | 1.56 | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress. ( Lu, Y; Yao, Q; Zhang, B; Zhang, R; Zhang, X, 2020) |
| "Ginsenoside Rg3 (Rg3) is an active ingredient isolated from ginseng." | 1.56 | Ginsenoside Rg3 enhances the anticancer effect of 5‑FU in colon cancer cells via the PI3K/AKT pathway. ( Cai, W; Chen, X; Hong, S; Huang, Y; Huang, Z; Lin, Z; Mi, X; Wang, Y, 2020) |
| " 5-fluorouracil (5-FU) is known to have erratic oral bioavailability due to first-pass metabolism." | 1.56 | Colon-specific tablets containing 5-fluorouracil microsponges for colon cancer targeting. ( Abdellatif, AAH; Ali, UF; Othman, MH; Zayed, GM, 2020) |
| "Cabozantinib is a multi-kinase inhibitor targeting MET, AXL, and VEGFR2, and has been approved for use in multiple malignancies." | 1.56 | Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway. ( Qu, B; Qu, H; Yang, S; Yin, X; Zhang, X; Zhao, H, 2020) |
| "Patients with stage III colon cancer homogeneously treated with surgery followed by FOLFOX chemotherapy between Jan 2007 and Aug 2013 were included retrospectively." | 1.51 | Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. ( Baik, SH; Cha, YJ; Kang, J; Lee, KY; Park, EJ, 2019) |
| "Gadolinium is a paramagnetic lanthanide element used in chelates, working as a contrast medium agent for an MRI system." | 1.51 | An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy. ( Jia, J; Niu, X; Song, Q; Sun, L; Wang, L; Zhang, H; Zhang, Y; Zhang, Z; Zhao, H; Zheng, C, 2019) |
| "Colon cancer is the 4th most common cancer causing death in both male and female equally, mainly caused due to the improper diet plans, consumption of the red meat and lack of exercise." | 1.51 | Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance? ( Karthika, C; Sureshkumar, R, 2019) |
| "Forty colon cancer primary tumor PDOX mouse models were divided into 4 groups of 10 mice each (total 40 mice) by measuring the tumor size." | 1.51 | Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. ( Bouvet, M; Clary, B; Han, Q; Higuchi, T; Hoffman, RM; Park, JH; Singh, SR; Sugisawa, N; Sun, Y; Yamamoto, J; Zhao, M, 2019) |
| "Sixty-two patients with metastatic colorectal cancer received aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks." | 1.51 | Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. ( Chiron, M; Denda, T; Esaki, T; Fujii, H; Hamaguchi, T; Itabashi, M; Kajiwara, T; Komatsu, Y; Kudo, T; Moriwaki, T; Nagashima, F; Nakajima, TE; Oki, E; Otsu, S; Sasaki, T; Sato, T; Sugimoto, N; Takahashi, S; Ura, T; Yamazaki, K; Yoshino, T, 2019) |
| "5‑Fluorouracil (5‑FU) is a cytotoxic anticancer drug commonly used for patients with advanced colon cancer." | 1.51 | BH3 profiling discriminates the anti‑apoptotic status of 5‑fluorouracil‑resistant colon cancer cells. ( Arihara, Y; Ishikawa, K; Kato, J; Kawano, Y; Kobune, M; Kubo, T; Miyanishi, K; Murase, K; Takada, K, 2019) |
| " Here, we investigated a safe and efficient dosing schedule of oxaliplatin in folinic acid, fluorouracil, and oxaliplatin (FOLFOX) regimen by monitoring total and free platinum concentrations in plasma." | 1.51 | Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report. ( Cai, X; Fang, W; Gu, Y; Li, X; Wang, D; Wang, J; Wang, Y; Xu, L; Zhao, F, 2019) |
| "Forty PDOX mouse models with colon cancer growing on the peritoneum were divided into 4 groups of 10 mice each by measuring the tumor size and fluorescence intensity: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, ip) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, ip); o-rMETase (100 units/day, oral 14 consecutive days); combination 5-FU + OXA and o-rMETase." | 1.51 | Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model. ( Bouvet, M; Clary, B; Han, Q; Higuchi, T; Hoffman, RM; Park, JH; Singh, SR; Sugisawa, N; Tan, Y; Yamamoto, J; Yoon, SN; Zhao, M, 2019) |
| "We report 2 cases of advanced colorectal cancer achieving complete response by FOLFOXIRI plus bevacizumab." | 1.51 | [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report]. ( Aizawa, M; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K, 2019) |
| "Capecitabine is a safe regimen in terms of oncologic outcomes compared with FL in older patients with stage II colon cancer." | 1.51 | Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study. ( Cho, S; Jeong, SY; Kim, MJ; Kwon, YH; Lee, KY; Park, JW; Park, KJ; Ryoo, SB, 2019) |
| "Among 29,687 eligible colon cancer patients, 67% were 75+ years and 45% had stage III disease." | 1.51 | Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. ( Faurot, KR; Hester, LL; Jonsson Funk, M; Lund, JL; Mayer, SE; Peacock Hinton, S; Sanoff, HK; Stürmer, T; Tan, HJ, 2019) |
| "An orthotopic murine model of colon cancer expressing human uMUC1 peptide (MC38 MUC1) was created along with the control model devoid of the antigen (MC38 neo)." | 1.51 | uMUC1-Targeting Magnetic Resonance Imaging of Therapeutic Response in an Orthotropic Mouse Model of Colon Cancer. ( Moore, A; Mukherjee, P; Richardson, R; Talebloo, N; Wang, P; Zhao, H, 2019) |
| "Colon cancer is a major health problem worldwide." | 1.51 | Activation of the PERK-ATF4 pathway promotes chemo-resistance in colon cancer cells. ( Bai, R; Feng, T; Lv, W; Shi, Z; Yu, X; Yuan, M; Zhong, H, 2019) |
| "In conclusion, miR-214 sensitizes colon cancer cells to 5-FU by targeting Hsp27, indicating a significant role for this miRNA in colon cancer chemotherapy." | 1.51 | MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27. ( Bao, Y; Du, LJ; Ma, ZH; Wan, J; Yang, GK; Yang, Y, 2019) |
| "This therapeutic approach in colon cancer could mediate 5-FU chemoresistance via modulating therapeutic targets (ie, STAT3 and Nrf2 pathways) and decreased 5-FU-related adverse effects." | 1.51 | Identification of Nrf2/STAT3 axis in induction of apoptosis through sub-G ( Aghajani, M; Mahmuodi, S; Mohammadian, J; Ramezani, F; Ramezani, M; Sabzichi, M; Tajmohammadi, I, 2019) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic drug used to treat cancer, including CRC." | 1.51 | Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer. ( Lee, JH; Lee, SW, 2019) |
| "This study explores the effect of preoperative radiotherapy combined with FOLFOX chemotherapy on patients with locally advanced colon cancer (LACC)." | 1.51 | Clinical Evaluation of Preoperative Radiotherapy Combined with FOLFOX Chemotherapy on Patients with Locally Advanced Colon Cancer. ( Guo, Z; Li, S; Qiao, W; Yu, W; Zhou, J, 2019) |
| "We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC." | 1.51 | Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer. ( Antonella, I; Antonio, C; Benedetto, C; Domenico, C; Gallelli, L; Giuseppe, S; Lidia, C; Luigi, S, 2019) |
| "After few days, despite of this dose reduction, he experienced life-threatening adverse events such as mucositis G3, diarrhea G3, neutropenia G4, thrombocytopenia G4, and hyperbilirubinemia G3 according to Common Terminology Criteria for Adverse Events v 5." | 1.51 | A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. ( Ciardiello, D; Ciardiello, F; Conzo, G; Coppola, N; De Falco, V; De Vita, F; Giunta, EF; Marinaccio, A; Martinelli, E; Napolitano, S; Natalicchio, MI; Troiani, T; Vietri, MT; Vitale, P; Vitiello, PP; Zanaletti, N, 2019) |
| "Even for right colon cancer, anti-EGFR antibodies might be effective if RAS is wild-type." | 1.51 | [Long-Term Effectiveness of Chemotherapy Containing mFOLFOX6 plus Panitumumab and 5-FU/l-LV plus Panitumumab after Primary Tumor Resection in a Case of Ascending Colon Carcinoma and Multiple Hepatic Metastases]. ( Akita, N; Gomyo, Y; Ikeno, T; Kitahama, T; Miyamoto, H; Okada, I, 2019) |
| "But it is rare in adults." | 1.51 | [Intussusception Caused by Colon Cancer in Pregnancy]. ( Jung, YJ; Kim, CL; Kim, K; Kim, TO; Ko, M; Sim, HC, 2019) |
| " Thus, the aim of this study was to examine the anticancer activity of fucosterol alone and in combination with 5-fluorouracil (5-Fu) on two human CRC cell lines (HCT116 and HT29) and compared with cytotoxicity in one normal colon fibroblast cell line (CCD-18co) in monolayer (2D)." | 1.51 | Cytotoxic activity of the seaweed compound fucosterol, alone and in combination with 5-fluorouracil, in colon cells using 2D and 3D culturing. ( Almeida, T; Lima, B; Ramos, AA; Rocha, E, 2019) |
| "Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics." | 1.51 | Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. ( Jang, H; Kim, A; Kim, H; Kim, MJ; Kim, YH; Lee, SB; Lee, SJ; Myung, JK; Park, EH; Park, JH; Park, S; Shim, S, 2019) |
| "Atypical features of Posterior reversible encephalopathy syndrome (PRES) (diffusion restriction, involvement of corpus callosum & white matter tracts along posterior limbs of internal capsule) were seen in a patient after oxaliplatin administration (FOLFOX- 4 regimen)." | 1.51 | Atypical PRES with diffusion restriction or neurotoxicity- ? part of same spectrum-after oxaliplatin (FOLFOX-4 regimen) for colonic cancer. ( Jiji, V; Prahladan, A; Ramachandran, K; Roshni, S; Sen, A; Venugopal, M, 2019) |
| " WGA-EF-NP exhibited superior anti-tumor activity and pro-apoptotic efficacy compared to the drugs and nanoparticles without WGA decoration owing to better bioavailability and longer circulation time in vivo." | 1.51 | Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles. ( Chen, J; Chen, Z; Di, L; Hu, L; Huang, J; Li, J; Qiao, H; Wang, H; Wang, R; Yang, M, 2019) |
| "A 27-year-old woman with colon cancer and liver metastasis was referred to our hospital." | 1.48 | A case of severe stenosis of hepatic veins and inferior vena cava with stomal variceal bleeding induced by oxaliplatin-based chemotherapy. ( Furuichi, Y; Itoi, T; Kasai, Y; Nakamura, I; Sugimoto, K; Takeuchi, H; Yamaguchi, H; Yoshimasu, Y, 2018) |
| "Lynch syndrome is an inherited syndrome with the development of the colorectal and various other cancers." | 1.48 | [A Case of Ascending Colon Cancer with Lynch Syndrome Who Underwent XELOX Adjuvant Chemotherapy]. ( Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Murakami, K; Murata, K; Naito, A; Nakatsuka, S; Nose, Y; Omura, Y; Sakamoto, T; Takase, K; Takeda, Y; Takeno, A; Tamura, S, 2018) |
| "Chemosensitivity of 5-Fu and MMC in colon cancer cells were tested by cell counting kit-8 (CCK-8) method." | 1.48 | Formyl peptide receptor 2 mediated chemotherapeutics drug resistance in colon cancer cells. ( Ge, YB; Peng, JM; Su, LD, 2018) |
| "non-mutated) metastatic colorectal cancer, not eligible for liver resection at baseline, from the UK National Health Service and Personal Social Services perspective." | 1.48 | Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. ( Crathorne, L; Hoyle, M; Huxley, N; Napier, M; Snowsill, T; Tikhonova, IA; Varley-Campbell, J, 2018) |
| "The in vitro cytotoxicity of EEG on colon cancer cells was determined with the CCK8 proliferation assay and the Annexin V-PE/7-AAD apoptosis assay." | 1.48 | Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer ( Chen, H; Chen, Y; Gu, Y; Hoffman, RM; Li, Y; Wang, H; Wang, W; Wu, M; Xu, M; Yang, Z; Zhu, P, 2018) |
| " Pretreatment with the pan-caspase inhibitor, z-VAD-FMK, attenuated the caspase-dependent apoptosis induced by circularly permuted tumor necrosis factor-related apoptosis-inducing ligand alone or combined with 5-fluorouracil." | 1.48 | Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. ( Liang, X; Sun, T; Yang, S; Zhao, R; Zhu, T, 2018) |
| "The effect of BGN modulation on colon cancer cells was associated with the changes in apoptosis and NF-κB pathways: BGN inhibition increased the expressions of pro-apoptosis indicators and suppressed NF-κB pathway activity while BGN overexpression had the opposite effect." | 1.48 | Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction. ( Cui, Y; Liu, B; Xing, X; Xu, T; Xu, X, 2018) |
| "5-Fluorouracil is a first-line agent in several cancer-therapy regimens." | 1.48 | Acute coronary syndrome in the oncology patient: An avoidable event? ( Félix-Oliveira, A; Madeira, S; Mendes, M; Vale, N, 2018) |
| "Colon cancer is common in the elderly, but owing to under representation in clinical trials, the benefit of standard therapies is uncertain in this age group." | 1.48 | Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. ( Aghmesheh, M; Brungs, D; Carolan, M; Clingan, P; de Souza, P; Ranson, M; Rose, J, 2018) |
| "However, esophagogastric varices are a poorly recognized outcome of oxaliplatin-based chemotherapy." | 1.48 | Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy. ( Ehira, T; Hattori, N; Ikeda, H; Itoh, F; Katayama, M; Koizumi, S; Matsumoto, N; Matsunaga, K; Matsuo, Y; Mizukami, T; Nakahara, K; Nakajima, TE; Nakano, H; Okuse, C; Otsubo, T; Sato, Y; Shigefuku, R; Suzuki, M; Suzuki, T; Tsuda, T; Watanabe, T; Yasuda, H, 2018) |
| " We report 2 patients with para-aortic lymph node metastasis treated with 4 courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab, which led to a complete response." | 1.48 | [Five-Year Survival of Two Patients with Para-Aortic Lymph Node Metastasis Treated with Four FOLFOX6and Four FOLFIRI Courses in Combination with Bevacizumab]. ( Ohara, H; Yamamoto, H, 2018) |
| "MH also influenced the anti-metastasis effects of 5-FU by decreasing migration ability, suppressing the expression of MMP-2, MMP-9 and increasing N-cadherin and E-cadherin." | 1.48 | Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. ( Afrin, S; Amici, A; Battino, M; Cianciosi, D; Forbes-Hernández, TY; Gasparrini, M; Giampieri, F; Quiles, JL, 2018) |
| "The predictive role of biomarkers in colon cancer is still being defined." | 1.48 | The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. ( Chouhan, H; Moore, JW; Sammour, T; Thomas, ML, 2018) |
| "Epichlorohydrin was employed as a crosslinker in the second crosslinking step." | 1.48 | In vitro and in vivo evaluation of colon cancer targeted epichlorohydrin crosslinked Portulaca-alginate beads. ( Asnani, GP; Kokare, CR, 2018) |
| "5-Fluorouracil has been considered as a cornerstone therapy for colorectal cancer; however, it suffers from low therapeutic response rate and severe side effects." | 1.46 | Apoptosis mediated chemosensitization of tumor cells to 5-fluorouracil on supplementation of fish oil in experimental colon carcinoma. ( Agnihotri, N; Kaur, S; Kumar, S; Rani, I; Sharma, B, 2017) |
| "It has rarely been associated with disseminated intravascular coagulation (DIC) with only 3 previously reported cases." | 1.46 | Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion. ( Ailawadhi, S; Arthurs, JR; Fischer, DL; Gannon, NA; Gibbs, M; Gupta, E; Irvin, M; Kakar, TS; Waddle, M, 2017) |
| "GRP78 expression was suppressed in LoVo colon cancer cells by utilizing small-interfering RNA (si-GRP78), and the cells were subsequently used to study the antiproliferative and anticancer effects of 5-FU treatment." | 1.46 | Enhanced Susceptibility to 5-Fluorouracil in Human Colon Cancer Cells by Silencing of GRP78. ( Han, YS; Kim, S; Lee, JH; Lee, SH; Yun, S, 2017) |
| "Two hundred thirty-one patients with colon cancers who underwent curative surgery and FOLFOX adjuvant chemotherapy between November 2005 and December 2011 were included." | 1.46 | Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy. ( Kim, YB; Noh, OK; Oh, SY; Suh, KW, 2017) |
| "Fatigue affects most cancer patients and has numerous potential causes, including cancer itself and cancer treatment." | 1.46 | Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue. ( Cullen, MJ; Dougherty, JP; Gershengorn, MC; Saligan, LN; Wolff, BS, 2017) |
| "Restoring oxygen in metastatic colon cancer through ITPP inhibits tumor spread and markedly improves animal survival; an effect that is enhanced through the application of subsequent chemotherapy." | 1.46 | The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice. ( Clavien, PA; Graf, R; Humar, B; Kachaylo, E; Kron, P; Lehn, JM; Limani, P; Linecker, M; Nicolau, C; Schneider, MA; Tschuor, C; Ungethuem, U, 2017) |
| " In combination with 5-Fu, Fx at 10 µM (in HCT116 and HT29 cells), and Ph at 300 µM (in HT29 cells) enhanced the cytotoxic effect of 5-Fu; however, no marked cytotoxicity was noted in CCD-18Co cells." | 1.46 | Anticancer effects of seaweed compounds fucoxanthin and phloroglucinol, alone and in combination with 5-fluorouracil in colon cells. ( Abreu, M; Gargiulo, D; Lopes-Costa, E; Ramos, AA; Rocha, E, 2017) |
| "5-Fluorouracil (5-FU) is an effective anticancer drug." | 1.46 | GRP78 Regulates Apoptosis, Cell Survival and Proliferation in 5-Fluorouracil-resistant SNUC5 Colon Cancer Cells. ( Lee, JH; Lee, SH; Yoon, YM, 2017) |
| "With regards to colon cancer, resistance to 5‑fluorouracil (5‑FU)‑based chemotherapy and cancer stem cells (CSCs) are considered important factors underlying therapy failure." | 1.46 | MACC1 facilitates chemoresistance and cancer stem cell‑like properties of colon cancer cells through the PI3K/AKT signaling pathway. ( Cai, H; Du, B; Feng, S; Hu, Y; Ma, W; Miao, G; Wang, J; Wang, W; Zhang, L, 2017) |
| "Pre-treatment with curcumin followed by 5-Fu may mediate autophagy turnover both in vitro and in vivo via AMPK/ULK1-dependent autophagy inhibition and AKT modulation, which may account for the increased susceptibility of the colon cancer cells/xenograft to the cytotoxicity of 5-Fu." | 1.46 | Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice. ( Chen, HF; Chen, XF; Jia, T; Lai, ZL; Sun, WQ; Wang, A; Zhang, J; Zhang, M; Zhang, P; Zhao, Z; Zhu, XM, 2017) |
| " The formulation with the lowest PCL and PVA concentration was characterized by the most optimal properties; which accounts for the desirable delayed release profile of the active drug in dissolution testing indicating an improved targeting capability and enhanced bioavailability at the action site." | 1.46 | Preparation and in vitro evaluation of 5-fluorouracil-loaded PCL nanoparticles for colon cancer treatment. ( Çalış, S; Mashal, AR; Öztürk, K; Yegin, BA, 2017) |
| " It is well known that 5-fluorouracil and capecitabine are agents that can be toxic in cases of decreased dihydropyrimidine dehydrogenase activity because this enzyme is the main limiting factor in the metabolism of both agents." | 1.46 | 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798). ( González De La Fuente, GA; González García, J; González-Perera, I; Gutiérrez-Nicolás, F; Hernández-San Gil, R; Nazco-Casariego, GJ; Pérez-Pérez, JA; Ramos-Díaz, R, 2017) |
| "Perineural invasion (PNI) in colon cancer (CC) has been associated with poorer prognosis even in stage II disease (T3-4 N0 M0)." | 1.46 | Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer. ( Baixauli, J; Beorlegui, C; Cienfuegos, JA; Hernández-Lizoáin, JL; Martínez, P; Rodríguez, J; Rosenstone, S; Sola, JJ, 2017) |
| "In this study, we used two human colon cancer cell lines, HCT116 and HT29, and evaluated the influence of miR‑302a on 5‑fluorouracil (5‑FU)‑induced cell death and viability inhibition." | 1.46 | MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. ( Chen, Y; Han, J; Hou, N; Huang, C; Jiang, T; Li, J; Liu, N; Zhao, Z, 2017) |
| "Notably, REP1 is highly expressed in colon cancer tissues and cell lines, and silencing of REP1 sensitizes colon cancer cells to serum starvation- and 5-FU-induced apoptosis." | 1.46 | REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival. ( Bae, DJ; Bae, YK; Cho, H; Chung, JY; Hibi, M; Hong, SM; Hong, SO; Kim, MG; Kim, SY; Kim, TW; Kim, YN; Lee, HJ; Oh, SJ; Rho, SB; Shim, J; Song, KH; Woo, SR, 2017) |
| "Patients with locally advanced colon cancer (LACC) have a relatively poor prognosis despite radical resection and adjuvant chemotherapy." | 1.46 | Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer. ( Huang, CJ; Huang, CM; Huang, CW; Huang, MY; Ma, CJ; Tsai, HL; Wang, JY; Yeh, Y-, 2017) |
| "Capecitabine is an oral prodrug of 5-fluorouracil and is commonly used oral chemotherapeutic drugs for advanced gastric and colorectal cancer." | 1.43 | Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. ( Achrekar, MS; Carvalho, MD; D'souza, A; Govindarajan, S; Gupta, S; Murugan, K; Ostwal, V, 2016) |
| "In nude mice bearing human colon cancer LoVo cell xenografts, chidamide alone or in combination with 5-flurouracil (5-Fu) reduced the expression of HDAC1 and HDAC2, accompanied with increased acetylation of histone H3." | 1.43 | Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. ( Chen, B; Chen, H; Liu, L; Liu, Y; Liu, Z; Qiu, S; Su, X; Zheng, Y, 2016) |
| "To evaluate the impact of the 12-gene Colon Cancer Recurrence Score Assay-a clinically validated prognosticator in stage II colon cancer after surgical resection-on adjuvant treatment decisions in T3 mismatch repair proficient (MMR-P) stage II colon cancer in clinical practice." | 1.43 | Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. ( Beny, A; Brenner, B; Chao, C; Dror, Y; Geva, R; Gluzman, A; Hubert, A; Idelevich, E; Liebermann, N; Man, S; Mishaeli, M; Purim, O; Rothney, M; Shacham-Shmueli, E; Shani, A; Shulman, K; Soussan-Gutman, L; Steiner, M; Tezcan, H, 2016) |
| "She was diagnosed with descending colon cancer with lymph node and liver metastases." | 1.43 | [A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6]. ( Ito, T; Kawamoto, K; Kawamoto, Y; Koda, Y; Ome, Y; Saga, K, 2016) |
| " Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD)." | 1.43 | Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. ( Ali, R; Assenat, E; Baracos, VE; Bianchi, L; Mollevi, C; Roberts, S; Sawyer, MB; Senesse, P, 2016) |
| "The drug 5-FU is commonly used in colon cancer treatment and was used as a reference." | 1.43 | Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells. ( Adachi, N; Aoyama, H; Fujibayashi, Y; Furukawa, T; Saga, T; Wakizaka, H; Yoshii, Y; Zhang, MR, 2016) |
| "Stem cell-like colon cancer cells (SCCs) pose a major challenge in colon cancer treatment because of their resistance to chemotherapy and radiotherapy." | 1.43 | A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer. ( Bang, SY; Heo, J; Jeong, SN; Kang, DH; Yoo, SY, 2016) |
| "DDA1 overexpression in colon cancer lines promoted cell proliferation, facilitated cell cycle progression, inhibited 5-FU-induced apoptosis, enhanced invasion, and induced the epithelial-mesenchymal transition." | 1.43 | DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling. ( Chen, J; Cui, F; Fan, J; Jiang, W; Liu, C; Liu, X; Mi, Y; Peng, Z; Qin, X; Sun, H; Tang, H; Wang, J; Wang, X; Wen, Y; Xue, Y; Yan, D; Yu, F; Yu, Y; Yue, B; Zhang, D; Zhang, M; Zhao, S; Zhou, Z, 2016) |
| "Mouse models of colon cancer have been developed and characterized." | 1.43 | Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance. ( Clipson, L; Grimes, IC; Hadac, JN; Halberg, RB; Miller, DD; Newton, MA; Schelman, WR, 2016) |
| "To (a) assess potential patient-specific factors related to adherence to mCRC chemotherapy regimens and (b) compare adherence with IV versus oral dosage forms." | 1.43 | Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer. ( Anderson, S; Seal, BS; Shermock, KM, 2016) |
| "The effect of individual dose adjustment of 5-fluorouracil (5-FU) based on pharmacokinetic monitoring on the outcome of FOLFOX for metastatic colorectal cancer was analyzed retrospectively." | 1.43 | [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ( Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2016) |
| "The mean recurrence-free survival was 13." | 1.43 | [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer]. ( Amada, E; Baba, S; Kameyama, N; Mitsuhashi, H; Miyata, R; Tomita, M, 2016) |
| "Patients with colon cancer in stage III who received adjuvant chemotherapy had a better overall survival." | 1.43 | [Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study]. ( Bellolio, F; Garrido, M; Leal, JL; Mondaca, S; Nervi, B; Padilla, O; Palma, S; Villalón, C; Zúñiga, Á, 2016) |
| " The median cumulative dosage capecitabine was lower for patients treated with CAPOX (163,744 mg/m(2), interquartile range [IQR] 83,397-202,858 mg/m(2)) than for patients treated with CapMono (189,195 mg/m(2), IQR 111,667-228,125 mg/m(2), P = 0." | 1.43 | Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients. ( Creemers, GJ; Janssen-Heijnen, ML; Lemmens, VE; Maas, HA; Pruijt, JF; Razenberg, LG; van Erning, FN, 2016) |
| "5-FU-resistant SNUC5 colon cancer cells (SNUC5/FUR cells) expressed higher levels of ER stress-related proteins than drug-sensitive SNUC5 cells." | 1.43 | Endoplasmic reticulum stress induces 5-fluorouracil resistance in human colon cancer cells. ( Boo, SJ; Fernando, PM; Han, X; Hyun, JW; Jeong, SU; Jeong, YJ; Kang, KA; Kim, JK; Na, SY; Oh, MC; Park, JE; Piao, MJ; Ryu, YS; Shilnikova, K, 2016) |
| "Mice harboring human HCT116 colon cancer xenografts were randomized to receive the control, or 4× or 12." | 1.43 | Folic Acid Supplementation Adversely Affects Chemosensitivity of Colon Cancer Cells to 5-fluorouracil. ( Croxford, R; Grin, A; Ishiguro, L; Kim, YI; Sohn, KJ; Streutker, CJ; Yang, M, 2016) |
| "We found that l-carnosine reduces colon cancer cell viability, decreases HIF-1α and multi-drug resistant protein MDR1-pg expression, and induces apoptosis." | 1.43 | l-carnosine dipeptide overcomes acquired resistance to 5-fluorouracil in HT29 human colon cancer cells via downregulation of HIF1-alpha and induction of apoptosis. ( Bevilacqua, MA; Guardia, F; Iovine, B; Irace, C, 2016) |
| "This study suggests that exposure of colon cancer cells to butyrate results in development of resistance to butyrate, which may play a role in the acquisition of chemoresistance in colon cancer." | 1.43 | Butyrate-mediated acquisition of chemoresistance by human colon cancer cells. ( Choi, HG; Jeon, CK; Kang, HR; Kim, SH; Lim, SJ, 2016) |
| "Primary cultures of colorectal cancer cells from a patient's tumors were studied using the flow cytometry and cytological methods." | 1.43 | Primary cultures of human colon cancer as a model to study cancer stem cells. ( Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A, 2016) |
| "Cycloheximide and MG132 were used to inhibit protein synthesis and degradation, respectively." | 1.43 | Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α. ( Huang, JJ; Shan, JZ; Xuan, YY; Zhang, Q, 2016) |
| "To investigate the anticancer effect of a recombinant adenovirus-mediated p53 (rAd-p53) combined with 5-fluorouracil (5-FU) in human colon cancer resistant to 5-FU in vivo and the mechanism of rAd-p53 in reversal of 5-FU resistance." | 1.43 | Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. ( Hu, JN; Wang, BS; Wu, MY; Xie, Q; Xu, J; Yang, YM; Zhang, DX; Zhang, J; Zhong, WD, 2016) |
| "No conversions or intraoperative complications occurred." | 1.43 | Robotic Right Colectomy with Modified Complete Mesocolic Excision: Long-Term Oncologic Outcomes. ( Bianchi, PP; Formisano, G; Lenti, LM; Marano, A; Priora, F; Ravazzoni, F; Spinoglio, G, 2016) |
| "There had been no evidence of recurrence for 10 years after surgery; however, peritoneal recurrence and a thyroid tumor were found using computed tomography(CT)at the 10-yearsur veillance." | 1.43 | [A Case of Stage IV Colon Cancer Relapsed 10 Years after Curative Resection with Adjuvant Chemotherapy Using Long-Term, Low-Dose Leucovorin and 5-Fluorouracil(LV/5-FU)]. ( Endo, S; Kato, H; Katsube, T; Naritaka, Y; Okayama, S; Satake, M; Shimakawa, T; Shiozawa, S; Yamada, Y; Yano, Y; Yokomizo, H; Yoshimatsu, K, 2016) |
| "Colon cancer is one of the leading causes of cancer-related death worldwide and the therapy with 5-fluorouracil (5-FU) is mainly limited due to resistance." | 1.43 | Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles. ( Budillon, A; Leone, A; Maiolino, S; Pagliara, V; Quaglia, F; Russo, A; Russo, G; Scalia, G; Tatangelo, F; Ungaro, F, 2016) |
| "Following recurrence of cancer of the sigmoid colon, the patient received a course of XELOX plus bevacizumab(Bmab)to treat peritoneal dissemination and lung metastases." | 1.43 | [A Case of Aortoesophageal Fistula Rupture Due to Descending Thoracic Aortic Dissection with Recurrent Colon Cancer during Chemotherapy Containing Bevacizumab]. ( Fujii, T; Funahashi, K; Kaneko, H; Kaneko, T; Katayanagi, T; Koda, T; Koike, J; Kurihara, A; Masuhara, H; Sawaguchi, Y; Shimada, H; Shiokawa, H; Suzuki, T; Ushigome, M; Watanabe, Y, 2016) |
| "In addition, 5-FU-resistant colon cancer cells exhibited upregulation of lactate dehydrogenase A (LDHA) expression and activity compared with parental cells." | 1.42 | Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. ( Li, X; Song, L; Zhao, H; Zhou, X, 2015) |
| "Here we report that in colon cancer PAK6 promotes tumor progression and chemoresistance both in vitro and in vivo." | 1.42 | PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy. ( Chen, J; Cui, F; Feng, X; Jiang, T; Lu, H; Peng, Z; Tang, H; Wang, J; Wang, X; Xue, Y; Yan, D; Yu, F; Yu, Y; Zhang, M; Zhao, S, 2015) |
| "In the multivariable analysis, stage II colon cancer patients with at least one G allele for ITGB3 rs4642 had higher risk of recurrence (hazard ratio (HR)=4." | 1.42 | Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. ( Benhaim, L; Bohanes, P; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; LaBonte, MJ; Lenz, C; Lenz, F; Lenz, HJ; Loupakis, F; Ning, Y; Wakatsuki, T; Yang, D; Zhang, W, 2015) |
| " The treatment effects of sequential 5-FU dosing following IrC™ are additive with no additional toxicity in contrast to previous studies where concurrent 5-FU and IrC™ treatment exacerbated 5-FU toxicity." | 1.42 | Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. ( Anantha, M; Bally, MB; Gill, N; Karim, T; Neijzen, R; Ng, SS; Strutt, D; Tai, IT; Wang, H; Waterhouse, D; Wong, MQ; Yapp, DT, 2015) |
| "Colon cancer is associated with a high incidence and a poor prognosis." | 1.42 | Fourier transform infrared microspectroscopy monitoring of 5-fluorouracil-induced apoptosis in SW620 colon cancer cells. ( Dong, L; Gao, Y; Huo, X; Sai, H; Sun, X; Wei, G; Wu, J; Xu, Y; Zhang, Y, 2015) |
| "The chemoresistance of breast and colon cancer cells against 5-FU increased on matrices prepared with cells derived from the corresponding original tissues with higher malignancy." | 1.42 | Optimization of the tissue source, malignancy, and initial substrate of tumor cell-derived matrices to increase cancer cell chemoresistance against 5-fluorouracil. ( Hoshiba, T; Tanaka, M, 2015) |
| "She was diagnosed with descending colon cancer with multiple liver metastases, and was referred to our department." | 1.42 | [Preoperative chemotherapy with modified FOLFOX + panitumumab for the treatment of descending colon cancer with multiple liver metastases - a case study]. ( Iwaya, A; Manabe, S; Yagi, Y; Yamazaki, T, 2015) |
| "Human Caco-2 colon cancer cells were treated with DMEM (control), growth media alone (LB, TSB, MRS, and M17) or EcN SNs derived from these 4 media, in the presence and absence of 5-FU." | 1.42 | Factors derived from Escherichia coli Nissle 1917, grown in different growth media, enhance cell death in a model of 5-fluorouracil-induced Caco-2 intestinal epithelial cell damage. ( Bastian, SE; Howarth, GS; Lawrence, A; Wang, H, 2015) |
| " It was designed to answer five research questions relating to safety, dosage and administration, and discontinuation from capecitabine-based adjuvant therapy." | 1.42 | Observational study of adjuvant therapy with capecitabine in colon cancer. ( Guggenberger, D; Hansen, R; Jacobs, G; Kröning, H; Schardt, C; Schmidt, P; Steffens, CC; Tschechne, B; Valdix, AR; Wohlfarth, T, 2015) |
| "Finally, using a human colon cancer xenograft murine model, we found that the combined 5-FU and 10058-F4 treatment significantly decreased tumorigenicity in nude mice compared with 5-FU or 10058-F4 treatment alone." | 1.42 | The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells. ( Enoki, T; Hamano, K; Hosoyama, T; Kugimiya, N; Li, TS; Nishimoto, A; Ueno, K, 2015) |
| "Thirteen patients with colon cancer and 7 patients with rectal cancer were enrolled after curative surgery." | 1.42 | [The present status of CapeOX as adjuvant chemotherapy for colorectal cancer]. ( Ishii, K; Kanamoto, A; Miyanaga, S; Noto, M; Takeda, T; Tani, T; Yagi, M, 2015) |
| "Overexpression of CerS6 in HT29 colon cancer cells resulted in increased apoptotic susceptibility and preferential generation of C16-ceramide, which occurred at the expense of very long chain, saturated ceramides." | 1.42 | Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner. ( Bai, A; Bielawska, A; Garrett-Mayer, E; Gencer, S; Lu, P; Ogretmen, B; Scheffel, MJ; Tirodkar, TS; Voelkel-Johnson, C, 2015) |
| "A huge ascending colon cancer measuring 10 cm in diameter and with peritoneal dissemination was diagnosed." | 1.42 | [Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer]. ( Hashiguchi, K; Kuramoto, T; Matsuyama, S; Tanaka, R, 2015) |
| "Chemoresistance of colon cancer cells to the chemotherapeutics is still a main obstacle in treatment of this malignancy." | 1.42 | MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. ( Chai, J; Dong, W; Guo, HL; Han, DL; Wang, L; Wang, S; Xie, C; Zhang, ZL, 2015) |
| "Patients with stage III colon cancer who received >70% RDI had improved 5-year OS." | 1.42 | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. ( Aspinall, SL; Boyle, DP; Calderon-Vargas, R; Carmichael, J; Chatta, G; Clifford, L; Cosgriff, S; Cruz-Diaz, L; Cunningham, FE; Depcinski, S; Fishco, S; Geraci, M; Giberti, S; Glovack, B; Good, CB; Ha, A; Heron, BB; Jean, C; Kaplan, B; Kaster, L; Keefe, S; Leone, A; Lepir, T; Lu, K; Maland, J; Molina, I; Motta, J; Nguyen, K; Passero, V; Rogers, R; Sartore, M; Sessions, J; Shields, J; Smith, D; Smith, KJ; Stone, RA; Szymanski, J; Tague, M; Tonnu-Mihara, I; Zhao, X, 2015) |
| "A total of 196 stage II and III colon cancer patients were retrospectively enrolled in prospectively collected data." | 1.42 | T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. ( An, MS; Bae, KB; Choi, CS; Hong, KH; Hwang, JW; Kang, MS; Kim, BM; Kim, JH; Kim, KH; Oh, MK; Yoo, JH, 2015) |
| "In vitro studies using human and murine colon cancer cell lines demonstrated that both types of nanocarriers significantly increased the antiproliferative effect of the encapsulated drug." | 1.42 | Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer. ( Álvarez, PJ; Áranega, A; Arias, JL; Cabeza, L; Clares, B; Melguizo, C; Ortiz, R; Prados, J; Vélez, C, 2015) |
| "First, HT-29 colon cancer cells were cultured in vitro as spheroids with a mean diameter of 100 µm." | 1.42 | Role of iron oxide core of polymeric nanoparticles in the thermosensitivity of colon cancer cell line HT-29. ( Esmaelbeygi, E; Eynali, S; Khoee, S; Khoei, S, 2015) |
| "We administered chemotherapy for colon cancer using 5-fluorouracil plus Leucovorin(5-FU/LV), after which the CPK levels gradually decreased." | 1.42 | [A case of polymyositis associated with transverse colon cancer that responded to tumor resection and chemotherapy]. ( Ito, T; Kawamoto, Y; Okabe, M; Tsukumo, Y; Uchida, Y, 2015) |
| "Colon cancer is the third most common cancer in humans which has a high mortality rate, and 5-Fluorouracil (5-FU) is one of the most widely used drugs in colon cancer therapy." | 1.42 | PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer. ( Jin, Y; Lin, D; Pei, S; Wang, H; Yang, X; Zhang, D; Zhang, H; Zhang, L; Zhang, Y; Zhou, B, 2015) |
| "We showed previously that in HT29 colon cancer cells, modulation of hypoxia-induced stress signaling affects oxaliplatin cytotoxicity." | 1.42 | Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. ( Goldstein, SR; Hierro, LC; O'Dwyer, PJ; Selvakumaran, M; Vasilevskaya, IA; Winkler, JD, 2015) |
| "The authors conclude that multiple synchronous neoplasms can be treated with individualized chemotherapeutic protocol with good efficacy and few adverse reactions." | 1.42 | [Individualized therapy of synchronous ovarian and colon cancers with lymph]. ( Bishr, AM; Deme, D; Nizar, J; Telekes, A, 2015) |
| "Stage III colon cancer is currently treated as an entity with a unified therapeutic principle." | 1.42 | A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. ( Deng, G; He, J; Ma, J; Pei, H; Shen, H; Wu, X; Zeng, S; Zhang, S; Zhang, Y, 2015) |
| " Here, we investigated whether the IMD in combination with chemotherapy could prevent cancer cachexia in colon 26 tumor-bearing mice." | 1.42 | An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice. ( Nakamura, K; Sasayama, A; Takahashi, T; Yamaji, T, 2015) |
| "Using an orthotopic colon cancer mouse model, we demonstrated that tumor-infiltrating cytotoxic T lymphocytes are FasL(+) and that FasL-mediated cancer immune surveillance is essential for colon carcinoma growth control in vivo." | 1.42 | H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. ( Bollag, WB; Choi, JH; Figueroa, M; Li, X; Liu, F; Liu, K; Lu, C; Nayak-Kapoor, A; Oberlies, NH; Paschall, AV; Pearce, C; Yang, D, 2015) |
| "Two pairs of colon cancer cell lines (HCT-116-hMLH1(Vector) (deficient MMR, dMMR) versus HCT-116-hMLH1(+) (proficient MMR, pMMR); SW480-shRNA-hMLH1 (dMMR) versus SW480-shRNA-Control (pMMR)) were established by regulating MMR status." | 1.42 | Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer. ( Kapesa, L; Liu, W; Ma, J; Shen, H; Zeng, M; Zeng, S; Zhang, Y, 2015) |
| "We examined stage III colon cancer patients ages 65+ years initiating chemotherapy between 2003 and 2008 using US population-based cancer registry data linked with Medicare claims (N = 3,660)." | 1.42 | Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis. ( Brookhart, MA; Carpenter, WR; Glynn, RJ; Mack, CD; Meyer, AM; Sandler, RS; Stürmer, T, 2015) |
| "Gossypol is a polyphenolic extract of cottonseeds." | 1.42 | Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells. ( Cao, Y; Feng, W; Hou, K; Liu, Y; Qu, J; Qu, X; Xu, L; Yang, D, 2015) |
| "288 patients presenting with stage III colon cancer and undergoing adjuvant therapies after curative surgery for more than 3-month were enrolled between January 2006 and December 2011." | 1.42 | Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70. ( Chang, PY; Chen, JH; Chen, YG; Ho, CL; Lu, CS; Wu, YY, 2015) |
| "HCT116/R, a HCT116 colon cancer cell subline carrying acquired resistance to 5-FU, showed increased expression and activation of HSP90's client proteins and transcriptional up-regulation of TYMS." | 1.42 | Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer. ( Ahn, JY; Lee, HY; Lee, JS; Min, HY, 2015) |
| "As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable." | 1.42 | Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. ( Benner, A; Bläker, H; Brenner, H; Burwinkel, B; Chang-Claude, J; Herpel, E; Hoffmeister, M; Jansen, L; Pfütze, K; Ulrich, A; Ulrich, CM; Yang, R, 2015) |
| "Colon cancer is one of the leading causes of cancer-related death worldwide, and the therapeutic application of 5-fluorouracil (5-FU) is limited due to its nonspecificity, low bioavailability, and overdose." | 1.42 | Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation. ( Huo, ZJ; Li, XC; Liu, K; Liu, P; Ma, Y; Qin, YH; Wang, SJ; Wang, ZQ, 2015) |
| "5-Fluorouracil (5FU) was chosen as reference drug and was administered intraperitoneally weekly for 7 weeks (from the 21st week of experiment) at the dose of 45 mg/kg." | 1.42 | Effects of 5-Amyno-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrol-3-one Intake on Digestive System in a Rat Model of Colon Cancer. ( Kotlyar, IP; Kuznietsova, HM; Luzhenetska, VK; Rybalchenko, VK, 2015) |
| "Here, we report that treatment of colon cancer cell with 5-FU selects for cells with mesenchymal stem-like properties that undergo a metabolic reprogramming resulting in addiction to OXPHOS to meet energy demands." | 1.42 | 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. ( Calvani, M; Caselli, A; Chiarugi, P; Cirri, P; Denise, C; Giannoni, E; Kazmi, SM; Kopetz, S; Landriscina, M; Paoli, P; Pettazzoni, P; Pia, MM; Sacco, E; Taddei, ML; Vanoni, M, 2015) |
| "Colon cancer is a frequently occurring primary malignant tumor." | 1.42 | Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma. ( Cai, S; Hu, J; Xu, Y, 2015) |
| "The optimal cutoff affecting recurrence was 276×10(9)/L." | 1.42 | [Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy]. ( Cai, Z; Guan, H; Hong, C; Liang, Z; Luo, D; Luo, P; Tan, Z; Wei, Y; Yang, Z; Zeng, Z, 2015) |
| "After disease progression, a second line based on FOLFIRI-aflibercept was started achieving an initial partial response followed by a long-lasting disease stability with a good tolerability." | 1.42 | [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]. ( Aroldi, F; Zaniboni, A, 2015) |
| "Even in cases of peritoneal recurrence of colon cancer, aggressive resection may improve the prognosis in some cases." | 1.42 | [Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report]. ( Hakamada, K; Miura, T; Nakayama, Y, 2015) |
| "5-Fluorouracil (5-FU) is a classic chemotherapeutic drug that has been widely used for colorectal cancer treatment, but colorectal cancer cells are often resistant to primary or acquired 5-FU therapy." | 1.40 | Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. ( Deng, J; Fu, JC; Lei, W; Li, JH; Xiong, JP; Zhang, L, 2014) |
| " Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity." | 1.40 | A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014) |
| "Pre-treatment with curcumin significantly enhanced the effect of 5-FU on HCT116R and HCR116+ch3R cells, in contrast to 5-FU alone as evidenced by increased disintegration of colonospheres, enhanced apoptosis and by inhibiting their growth." | 1.40 | Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. ( Buhrmann, C; Goel, A; Kraehe, P; Lueders, C; Shakibaei, M; Shayan, P, 2014) |
| "The treatment of metastatic colon cancer (mCC) utilizes either combination therapies or sequential monotherapy followed by combination therapy in subsequent lines of treatment." | 1.40 | Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer. ( Ghosh, S; Loree, JM; Mulder, KE; Spratlin, JL, 2014) |
| "Adjuvant FOLFOX4 in patients with colon cancer can have a negative effect on verbal memory." | 1.40 | Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. ( Cruzado, JA; Custodio, AB; Feliu, J; José-Moreno, G; López-Santiago, S; Martínez-Marín, V, 2014) |
| "Adjuvant treatment of colon cancer relies on fluoropyrimidine-containing regimens as the intravenous formulation, 5-FU, or its oral prodrug, CA, combined with oxaliplatin (FOLFOX and CAPOX)." | 1.40 | CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. ( Ghosh, S; Loree, JM; Mulder, KE; Spratlin, JL, 2014) |
| " This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events." | 1.40 | Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. ( Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014) |
| " In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179." | 1.40 | Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014) |
| "5-Fluorouracil (5-FU) is a widely used anticancer drug for the treatment of colorectal cancer (CRC)." | 1.40 | Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. ( Chang, WY; Hyun, JW; Kang, HK; Kang, KA; Keum, YS; Kim, KC; Park, IC; Piao, MJ; Surh, YJ, 2014) |
| "Human colon cancer xenografts propagated in NSG and NRG mice maintain structural fidelity while replacing human stromal cells with murine stromal cells." | 1.40 | NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer. ( Greiner, DL; Houghton, J; Li, H; Liu, JH; Maykel, J; Shultz, LD, 2014) |
| " In addition, the in vivo pharmacokinetic data in mouse model revealed the improved plasma concentrations of 5-FU and CUR which prolonged up to 72 h unlike the bare drugs." | 1.40 | In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. ( Anitha, A; Chennazhi, KP; Jayakumar, R; Lakshmanan, VK; Sreeranganathan, M, 2014) |
| " Moreover, the combination dosage significantly augmented the inhibition of cell cycle progression, as shown by CK19 expression." | 1.40 | Supplementation of fish oil augments efficacy and attenuates toxicity of 5-fluorouracil in 1,2-dimethylhydrazine dihydrochloride/dextran sulfate sodium-induced colon carcinogenesis. ( Agnihotri, N; Rani, I; Vaiphei, K, 2014) |
| "Neuroendocrine carcinoma is known to be extremely malignant; however, this case suggests that chemotherapy with bevacizumab may improve the prognosis of this disease." | 1.40 | [Effective chemotherapy with bevacizumab/FOLFOX4 for neuroendocrine carcinoma of the ascending colon - a case study]. ( Morimoto, D; Shibata, A; Takase, T; Tanabe, H; Tanaka, Y; Yaguchi, T, 2014) |
| "The human colon cancer cell lines SW480, Lovo and HCT116 contain 1." | 1.40 | Characterization of side population cells isolated from the colon cancer cell line SW480. ( Cheng, Y; Hu, X; Ma, L; Xiong, B; Zhang, C, 2014) |
| "Treatment of HCT-116 and Caco-2 colon cancer cells with the hypoxia mimic CoCl2 induced the formation of cells with larger cell and nuclear size (PGCCs), while the cells with normal morphology were selectively eliminated." | 1.40 | CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer. ( Aranda, E; De la Haba-Rodríguez, JR; Hernandez, V; Jimenez, C; Lopez-Pedrera, C; Lopez-Sánchez, LM; Martinez, A; Muñoz-Castañeda, JR; Peñarando, J; Rodriguez-Ariza, A; Valverde, A, 2014) |
| "To conclude, the combination of 5-FU-TCS-NPs and CRC-TCS-NPs showed enhanced anticancer effects on colon cancer cells in vitro and improved the bioavailability of the drugs in vivo." | 1.40 | Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. ( Anitha, A; Chennazhi, KP; Deepa, N; Jayakumar, R; Lakshmanan, VK, 2014) |
| "The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship." | 1.40 | Colon cancer, version 3.2014. ( Bekaii-Saab, T; Benson, AB; Chan, E; Chen, YJ; Cooper, HS; Engstrom, PF; Enzinger, PC; Fenton, MJ; Freedman-Cass, DA; Fuchs, CS; Gregory, KM; Grem, JL; Hunt, S; Kamel, A; Leong, LA; Lin, E; Messersmith, W; Mulcahy, MF; Murphy, JD; Nurkin, S; Rohren, E; Ryan, DP; Saltz, L; Sharma, S; Shibata, D; Skibber, JM; Sofocleous, CT; Stoffel, EM; Stotsky-Himelfarb, E; Venook, AP; Willett, CG, 2014) |
| "PP blocked colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC(50)), ranging from 0." | 1.40 | The impact of pyrvinium pamoate on colon cancer cell viability. ( Germer, CT; Hüttenrauch, M; Krummenast, F; Linnebacher, M; Mühling, B; Otto, C; Thalheimer, A; Uthe, FW; Wiegering, A, 2014) |
| "In the presence of PB, a lower dosage of 5-FU is required to achieve the maximum drug effect in inhibiting the growth of HT29 cells." | 1.40 | Piper betle leaf extract enhances the cytotoxicity effect of 5-fluorouracil in inhibiting the growth of HT29 and HCT116 colon cancer cells. ( Looi, ML; Mohd Yusof, YA; Ng, PL; Pin, KY; Rajab, NF; Then, SM; Wan Ngah, WZ, 2014) |
| "CPT activated NF-κB in SW480 colon cancer cells in a dose-dependent manner, but not in HCT116 cells that were either wild-type or deficient for p53." | 1.40 | Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs. ( Fadlalla, K; Gales, DN; Manne, U; Putcha, BD; Samuel, T, 2014) |
| "FuOx-resistant (chemoresistant; CR) colon cancer cells, highly enriched in CSCs, were used for this study." | 1.40 | Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. ( Banerjee, S; Dyson, G; Farhana, L; Levi, E; Maddipati, KR; Majumdar, AP; Nangia-Makker, P; Patel, A; Rajendra, SG; Vasudevan, A; Woods, J; Yu, Y, 2014) |
| "Oral capecitabine is a prodrug of 5-fluorouracil that has been used into the management of multiple cancers because of the convenience of administration and efficacy at least comparable with 5-fluorouracil." | 1.40 | Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer. ( Cleator, S; Dzaye, O; Nihoyannopoulos, P, 2014) |
| "The incidence of colon cancer has been increasing in recent years with the improvement in living standard, and becomes one of the leading causes of cancer-related death." | 1.40 | [Neoadjuvant chemotherapy for colon cancer based on evidence-based medicine]. ( Liu, Y; Yang, X, 2014) |
| "To compare XELOX and FOLFOX4 as colon cancer adjuvant chemotherapy based on MOSAIC and No." | 1.40 | Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. ( Du, ZD; He, XF; Li, Q; Tang, RL; Wen, F; Yao, K; Zhang, PF, 2014) |
| "There has been no disease recurrence 75 months after the initial surgery." | 1.40 | [Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report]. ( Kakizawa, N; Kato, T; Noda, H; Rikiyama, T; Toyama, N; Watanabe, F, 2014) |
| "Patients with stage II/III colon cancer displaying dMMR have a better prognosis than those with pMMR." | 1.40 | [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer]. ( Guo, L; Lyu, N; Qin, Q; Wang, J; Ying, J; Zhi, W; Zhou, A, 2014) |
| "Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare." | 1.40 | [A case of metastatic gastric cancer originating from transverse colon cancer]. ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014) |
| "The patient has had no recurrence of gastric cancer for 18 months after the initial operation." | 1.40 | [A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer]. ( Hanyu, T; Ichikawa, H; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nakano, M; Sakata, J; Shimada, Y; Tanaka, R; Wakai, T, 2014) |
| "Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established." | 1.40 | LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. ( Chang, WC; Chen, CW; Fan, YC; Hsu, WH; Huang, CW; Lou, YT; Lu, CY; Wang, JY; Wu, IC, 2014) |
| " Capecitabine plus oxaliplatin could be economically reasonable if full dosing occurred ≥76% of the time (base case 42%)." | 1.40 | Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers. ( Aspinall, SL; Chatta, G; Cunningham, FE; Good, CB; Passero, V; Smith, KJ; Soni, A; Zhao, X, 2014) |
| " The analogs 2a and 2b have submicromolar IC(50) values towards human HCT-116 colon cancer cells but are far less toxic to human non-malignant CRL-1790 colon cells." | 1.39 | Mitochondrial dysfunction contributes to the cytotoxicity of some 3,5-bis(benzylidene)-4-piperidone derivatives in colon HCT-116 cells. ( Bandy, B; Das, U; Dimmock, JR; Helal, M; Islam, A; Nazarali, AJ, 2013) |
| "Fifteen cancer patients (head and neck cancer (n=11), colon cancer (n=4)) were enrolled." | 1.39 | Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil. ( Hino-Shishikura, A; Horiuchi, C; Ichikawa, Y; Inoue, T; Minamimoto, R; Oka, T; Shizukuishi, K; Sugae, S; Suzuki, A; Tateishi, U, 2013) |
| "sTRAIL, in combination with conventional chemotherapeutic drug treatment in colon cancer models." | 1.39 | Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. ( Albarenque, SM; Deedigan, L; Mohr, A; Yu, R; Zwacka, RM, 2013) |
| "5-Fluorouracil (5-FU) has been a mainstay of chemotherapy for colorectal cancer, but it is still unknown whether the combining of 5-FU with novel molecular-targeting agents is effective." | 1.39 | Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. ( Sakai, T; Sowa, Y; Watanabe, M; Yogosawa, M, 2013) |
| "We examined 120 stage II colon cancer patients." | 1.39 | Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. ( Barbazza, R; Bonin, S; Donada, M; Pettirosso, D; Stanta, G, 2013) |
| "A 29-year-old woman with colon cancer and synchronous liver metastasis underwent a two-stage liver resection by the ALPPS technique because of an extremely small future liver remnant." | 1.39 | ALPPS procedure with the use of pneumoperitoneum. ( Machado, MA; Makdissi, FF; Surjan, RC, 2013) |
| "HT-29 and SW-480 colon cancer and normal CCD-18Co colon fibroblast cells were treated with curcuminoids previously analyzed by HPLC." | 1.39 | The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis. ( Angel-Morales, G; Jutooru, I; Mertens-Talcott, SU; Noratto, GD; Safe, S, 2013) |
| "Additionally, colon cancer cells resistant to 5-FU were used to assay the effects of SFRE on drug resistance." | 1.39 | Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. ( de la Cueva, A; Fornari, T; García-Risco, MR; González-Vallinas, M; Molina, S; Ramírez de Molina, A; Reglero, G; Santoyo, S; Vargas, T; Vicente, G, 2013) |
| "Transfection of miR-142-3p mimics in colon cancer cells downregulated cyclin D1 expression, induced G1 phase cell cycle arrest, and elevated the sensitivity of the cells to 5-fluorouracil." | 1.39 | MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. ( Fu, GH; Shen, WW; Zeng, Z; Zhu, WX, 2013) |
| "5-Fluorouracil (5-FU) was suspended in an ethyl acetate solution of poly D,L-lactide-co-glycolic acid (PLGA) and a vacuum drying method was applied." | 1.39 | Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors. ( Chen, Y; Sun, W; Yuan, W, 2013) |
| "p53-null colon cancer cell lines with different sets of mutations were used to validate the role of GSK3B in sustaining resistance and to characterize cell death mechanisms triggered by chemotherapy when GSK3B is silenced." | 1.39 | Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. ( Bonin, S; Donada, M; Federzoni, E; Giovannoni, R; Grassilli, E; Helin, K; Ianzano, L; Lavitrano, M; Leone, BE; Masiero, L; Narloch, R; Pisano, F; Romano, G; Stanta, G, 2013) |
| "Compared with MSI-L/MSS colon cancer, patients with MSI-H colon cancer had no significant difference in 5-year disease-free and OS (72." | 1.39 | Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. ( Kim, DY; Kim, YB; Oh, SY; Suh, KW, 2013) |
| " Simultaneous heterozygous UGT1A1 28 and UGT1A1 6 polymorphisms may produce higher exposure to SN-38 and a higher risk of adverse effects related to irinotecan." | 1.39 | Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. ( Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM, 2013) |
| "We report a case of advanced relapsed colon cancer, which had multiple liver and spleen metastasis, controlled for about two years by capecitabine therapy." | 1.39 | [A case of relapsed colon cancer successfully treated by capecitabine]. ( Hashimoto, T; Kimura, S; Toyono, M; Usuba, O; Yokoyama, M, 2013) |
| "She was diagnosed as colon cancer with hepatic metastasis." | 1.39 | [A case of metastatic colon cancer effectively treated by XELOX and IRIS]. ( Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M, 2013) |
| "A 77-year-old man with colon cancer and multiple metastases to the liver and lungs underwent resection of the primary tumor and D3 lymph node dissection." | 1.39 | [A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents]. ( Adachi, A; Nakajima, M; Uchisako, H; Uchiyama, T, 2013) |
| "Six months later, colon cancer was discovered and the patient underwent surgical procedure and chemotherapy with capecitabine thereafter." | 1.39 | Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson's disease worsened after capecitabine therapy. ( Badzek, S; Bilic, E; Golem, H; Gorsic, I; Kekez, D; Librenjak, N; Miletic, V; Plestina, S; Prejac, J, 2013) |
| "First, HCT116 human colon cancer cells were cultured with PSK and 5-fluorouracil (5-FU) or 5'-deoxy-5-fluorouridine (5'-DFUR) in the presence or absence of PBMCs, and the antiproliferative effects were compared." | 1.39 | Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers. ( Abe, H; Edamatsu, T; Fujieda, A; Fujioka, M; Mekata, E; Murata, S; Naka, S; Shimizu, T; Shiomi, H; Sonoda, H; Tani, T; Umeda, T; Wada, T; Yamamoto, H, 2013) |
| "Contrarily, patients with colon cancer stage III are routinely offered chemotherapy, but due to expected adverse effects and frailty, elderly patients are often excluded from standard protocols." | 1.39 | Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving? ( Ågesen, TH; Guren, MG; Lothe, RA; Nesbakken, A; Skotheim, RI; Sveen, A; Tveit, KM, 2013) |
| "Time to recurrence (TTR) was the primary end point of the study, Kaplan-Meier curves and log-rank tests were used to assess the association between timing of the AC and TTR." | 1.39 | Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. ( Barzi, A; Lenz, HJ; Sadeghi, S; Senagore, A; Shabihkhani, M; Thara, E; Yang, D; Yu, S, 2013) |
| "Inhibition of GHR in human colon cancer SW480 cells resulted in anti-tumor effects in nude mice." | 1.39 | siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells. ( Huang, WD; Wang, J; Yang, J; Zhang, Q; Zhou, D, 2013) |
| " The clinical efficacy and bevacizumab-related adverse reactions were observed." | 1.39 | [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. ( Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY, 2013) |
| "Furthermore pathogenesis of liver fibrosis is not well known." | 1.39 | A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer. ( Jeong, HY; Kang, DY; Kang, GH; Kim, SH; Lee, BS; Lee, ES; Lee, HY; Moon, HS; Sung, JK, 2013) |
| "Tenovin-6 induced apoptosis in all five colon cancer cell lines investigated (two cell lines with wild-type p53 and three with mutant p53) regardless of the p53 mutation status." | 1.39 | The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells. ( Endo, S; Hirai, S; Hirose, M; Hyodo, I; Saito, R; Suzuki, H; Ueno, T; Yamato, K, 2013) |
| "Human colon cancer cell lines, transfected with human chorionic gonadotropin and luciferase, were injected orthotopically into the caecal wall of severe combined immunodeficient mice, intrasplenically or subcutaneously." | 1.39 | Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. ( Francia, G; Hackl, C; Kerbel, RS; Man, S; Milsom, C; Xu, P, 2013) |
| "We describe a case of cryptogenic organizing pneumonia (COP) occurring in a 78-year-old woman after receiving 2 cycles of modified FOLFOX6 as adjuvant chemotherapy for treatment of resected nonmetastatic colon cancer." | 1.39 | Cryptogenic organizing pneumonia during adjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) for colon cancer. ( Dalvi, AG; Dretler, R; Hap, J; Shogbon, AO, 2013) |
| "However, a sub-population of colon cancer patients do not respond to 5-FU and this treatment does not provide survival benefit due to chemo resistance." | 1.39 | The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. ( Gao, H; Khan, AQ; Liang, B; Lin, P; Liu, E; Liu, S; Niu, J; Niu, W; Peng, C; Shahbaz, M; Wang, B; Wang, J, 2013) |
| "5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers." | 1.39 | 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. ( Akpinar, B; Baran, Y; Can, G; Olsson, M; Zhivotovsky, B, 2013) |
| "Patients with resected stage III colon cancer aged ≥75 years diagnosed in 1997-2004 who received adjuvant chemotherapy (N = 216) were included as well as a random sample (N = 341) of patients who only underwent surgery." | 1.39 | Treatment and complications in elderly stage III colon cancer patients in the Netherlands. ( Hoeben, KW; Janssen-Heijnen, ML; Rutten, HJ; van de Wouw, AJ; van Spronsen, DJ; van Steenbergen, LN, 2013) |
| "Among 391 patients with Stage III colon cancer, 229 patients received adjuvant oxaliplatin, fluorouracil and leucovorin chemotherapy (87 (43." | 1.39 | Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea. ( Jang, NY; Kang, SB; Kim, DW; Kim, JH; Kim, JS; Kim, JY; Kim, YJ; Lee, HS; Lee, JS; Lee, KW, 2013) |
| " The clearance (CL), central volume of distribution (V(1)), intercompartmental clearance (Q), and the peripheral volume of distribution (V(2)) were 214 mL/day, 2,830 mL, 636 mL/day, and 2,490 mL, which correspond to a disposition and elimination half-life of 1." | 1.39 | Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. ( Allison, DE; Gupta, M; Jin, D; Li, J; Visich, J; Xin, Y, 2013) |
| "We report on an 86-year-old woman with colon cancer with liver metastasis who was treated with 5-fluorouracil, folinic acid, and bevacizumab." | 1.39 | Cervical extravasation of bevacizumab. ( Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Mir, O; Perkins, G, 2013) |
| "This study in 716 colon cancer patients evaluates if a combined instead of a single marker analysis of mismatch repair (MMR) status and thymidylate synthase (TS) expression could individualize the treatment decision." | 1.39 | A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer. ( Edler, D; Hallström, M; Karlberg, M; Öhrling, K; Ragnhammar, P, 2013) |
| "Stage III colon cancer patients aged 65+ years initiating chemotherapy between 2003 and 2006 were examined using cancer registry data linked with Medicare claims." | 1.39 | Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. ( Brookhart, MA; Carpenter, WR; Glynn, RJ; Mack, CD; Meyer, AM; Sandler, RS; Stürmer, T, 2013) |
| "The purpose of this study was to investigate the anti-tumor effect and explore the mechanisms of celecoxib (a selective cyclooxygenase-2 inhibitor) combined with 5-fluorouracil (5-FU) on the treatment of human colorectal cancer in a BALB/C nude mouse subcutaneous xenograft model." | 1.39 | Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. ( Chen, WC; Guo, Q; Zhang, DQ; Zhu, JH, 2013) |
| "Exposure of colon and pancreatic cancer cells to 5-FU, CPT-11 or MTX in vitro significantly antagonizes both HSV-1 replication and lytic oncolysis." | 1.39 | Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. ( Choi, EW; Cusack, JC; Donahue, JM; Fuchs, BC; Kasuya, H; Kawasaki, H; Kulu, Y; Kuruppu, DK; Tanabe, KK, 2013) |
| "5-Fluorouracil (5-FU) has a significant antineoplastic activity and has been used for the management of various malignant neoplasms." | 1.38 | Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. ( Çağdaş, M; Çalık, AN; Çeliker, E; Güzelburç, Ö; Velibey, Y, 2012) |
| "Patients diagnosed with stage III colon cancer in 1991 to 2005 were identified from the Surveillance, Epidemiology, and End Results-Medicare database." | 1.38 | Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. ( Chan, W; Delclos, GP; Du, XL; Hu, CY, 2012) |
| "Retinal vein thrombosis is a common vascular occlusive disorder of the retina responsible for varying degrees of vision impairment." | 1.38 | Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection. ( Gilbar, P; Sorour, N, 2012) |
| " In animal models, 12 days of 5-FC administration was superior to 6 days, but dosing beyond 12 days did not further enhance efficacy." | 1.38 | Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. ( Fuchs, BC; He, X; Kuroda, T; Lanuti, M; McGinn, CM; Schmitt, A; Supko, JG; Tanabe, KK; Yamada, S, 2012) |
| "Moreover, Gli3 siRNA sensitized colon cancer cells to treatment with anti-cancer agents (5-FU and bevacizumab)." | 1.38 | Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53. ( Kang, HN; Kim, JS; Oh, SC; Yoo, YA, 2012) |
| " 5-FU-loaded biodegradable poly(ε-caprolactone) nanoparticles (PCL NPs) were combined with the cytotoxic suicide gene E (combined therapy)." | 1.38 | 5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. ( Alvarez, PJ; Aránega, A; Arias, JL; Caba, O; Luque, R; Melguizo, C; Ortiz, R; Prados, J; Ruiz, MA; Segura, A, 2012) |
| " Hospitalizations, emergency room (ER) visits, and outpatient adverse events (AEs) were measured in claims from 30 days to 9 months after patients underwent resection." | 1.38 | Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. ( Carpenter, WR; Chen, K; Freburger, J; Goldberg, RM; Li, L; Sanoff, HK; Schrag, D; Schymura, MJ; Zullig, LL, 2012) |
| "However, colon cancer stem cells remain poorly characterized." | 1.38 | A subpopulation of CD24⁺ cells in colon cancer cell lines possess stem cell characteristics. ( He, X; Ke, J; Lan, P; Lian, L; Luo, Y; Wang, H; Wang, L; Wu, X; Zou, Y, 2012) |
| "Two types of 5-FU-resistant colon cancer cells were derived from the DLD-1 and KM12C cell lines." | 1.38 | Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. ( Akaike, Y; Fukushima, M; Iima, T; Kurokawa, K; Kuwano, Y; Masuda, K; Murakami, Y; Nishida, K; Rokutan, K; Tanahashi, T; Yamamoto, Y, 2012) |
| "Capecitabine(Xeloda®)has been a global standard drug for the treatment of colon cancer since large randomized controlled trials demonstrated its efficacy and safety in treating patients suffering from the disease." | 1.38 | [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients]. ( Fukuda, M; Hanada, K; Hata, H; Ikai, I; Kubo, K; Moriyama, S; Murakami, T; Ogiso, S; Okazaki, S; Okuchi, Y; Otani, T; Sakata, S; Setoguchi, Y; Tanaka, M; Tani, M; Une, Y; Yamaguchi, T; Yamato, T; Yasui, H, 2012) |
| " In the present study, the early therapeutic response of rAd/p53, combined with 5-fluorouracil (5-FU) or with iodized oil, was observed in a human colon cancer model." | 1.38 | Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. ( Chen, MW; Gu, XF; Liang, BL; Liu, HY; Wu, YH; Xie, Q; Xu, J; Zhang, J, 2012) |
| " Under the condition of adding 5-FU at various concentrations for 24 hours, the uptake rate of (18)F-FDG was negatively correlated with 5-FU dosage (r = -0." | 1.38 | Early evaluation for treatment efficacy of 5-fluorouracil and hyperthermia on HCT-116 colon cancer cells by fluorine-18-fluorodeoxyglucose uptake. ( Chen, SJ; Deng, SM; Wang, ZX; Zhang, B, 2012) |
| "5-Fluorouracil (5-FU) is a principal drug for the treatment of colorectal cancer." | 1.38 | Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway. ( Guo, QL; Ha, J; Ke, X; Li, Z; Lu, N; Yang, HY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2012) |
| " Pharmacokinetic studies of BIIB036 in tumor-bearing mice revealed a half-life of approximately three days suggesting twice a week dosing would be necessary to maintain efficacy." | 1.38 | The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. ( Joseph, IB; Kelly, R; Michaelson, JS; Wortham, K; Yang, L; Zhang, X, 2012) |
| "Nude mouse models bearing LoVo colon cancer xenograft were randomized into vehicle control group, untreated control group, axitinib-treated group, 5-FU-treated group and combined treatment group for corresponding treatments." | 1.38 | [Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft]. ( He, B; Xie, F; Zhao, J; Zhao, T, 2012) |
| "Human colon cancer DLD-1 cells were treated with 5-FU (10 μΜ) or chloroquine (100 μΜ), or a combination of both." | 1.38 | Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. ( Choi, JH; Lee, YY; Park, BB; Won, YW; Yoon, JS, 2012) |
| "She had both advanced ascending colon cancer with multiple liver metastasis(cStage IV: cT3N1H3)and early gastric cancer(cStage 0: cTisN0M0)." | 1.38 | [The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report]. ( Asakage, M; Muto, Y; Shimoishi, K; Yamada, Y, 2012) |
| " FOLFOX4 combined with panitumumab therapy was initiated 1 month after the operation." | 1.38 | [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab]. ( Asano, T; Hattori, M; Kamiya, I; Negita, M; Takagi, D; Uemura, T, 2012) |
| "To investigate the possibility in colon cancer cells, we employed CD133 as the CSC marker, and characterized CD133 expression pattern and the biological features of the CD133 (+) and CD133 (-) subsets." | 1.38 | Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line. ( Chen, Y; Ding, J; Feng, JM; Huang, YR; Jiang, Y; Li, JX; Miao, ZH; Tong, LJ; Zhang, J, 2012) |
| "The case of an 83-year-old man with colon cancer who developed chest pain during 5-FU infusion is presented." | 1.38 | A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. ( Cho, WH; Choi, SK; Kim, SB; Kim, SM; Kwak, CH; Lee, B; Sir, JJ, 2012) |
| " Pharmacokinetics of (188)Re-liposome showed the properties of high circulation time and high bioavailability (mean residence time [MRT]=18." | 1.38 | Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. ( Chang, CH; Chang, YJ; Chen, LC; Hsu, CW; Lan, KL; Lee, TW; Ting, G, 2012) |
| " Thus, we investigated the effect of JMR-132 in combination with S-phase-specific cytotoxic agents, 5-FU, irinotecan and cisplatin on the in vitro and in vivo growth of HT-29, HCT-116 and HCT-15 human colon cancer cell lines." | 1.38 | GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. ( Block, NL; Buchholz, S; Datz, C; Hohla, F; Krishan, A; Rick, FG; Schally, AV; Seitz, S; Stadlmayr, A; Szalontay, L, 2012) |
| "The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes." | 1.38 | How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "A total of 149 patients with advanced colon cancer undergoing curative resection followed by adjuvant chemotherapy(FOLFOX6 protocol) were included." | 1.38 | [Predicting value of dynamic alteration of blood neutrophil/lymphocyte ratio on recurrence-free survival in patients with advanced colon cancer after operation and chemotherapy]. ( Cai, CN; Guan, XD; Jia, YB; Li, J; Li, PP; Xie, YY; Zhang, BM, 2012) |
| "5-Fluorouracil (5-FU) was entrapped within methacrylic-based copolymers by a solvent evaporation method." | 1.38 | Methacrylic-based nanogels for the pH-sensitive delivery of 5-fluorouracil in the colon. ( Ashwanikumar, N; Kumar, GV; Kumar, NA; Nair, SA, 2012) |
| "Capecitabine is an orally administered pro-drug of 5-fluorouracil that confers superior disease-free survival and presumably has a more favourable side-effect profile." | 1.38 | Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine? ( Chan, AO; Chan, HY; Ng, CM; Shek, CC; Tiu, SC, 2012) |
| "A total of 7642 patients with incident colon cancer were identified, of which 1041 (14%) had mCC." | 1.38 | Unsupported off-label chemotherapy in metastatic colon cancer. ( Alexander, GC; de Souza, JA; Meropol, NJ; Newcomer, LN; Perkins, M; Polite, B; Ratain, MJ, 2012) |
| "To investigate the effects of hexahydrocurcumin (HHC), and its combination with 5-fluorouracil (5-FU) on dimethylhydrazine (DMH)-induced colon cancer in rats." | 1.38 | Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. ( Chintana, PY; Srimuangwong, K; Suksamrarn, A; Tocharus, C; Tocharus, J, 2012) |
| "Human colon cancer HT-29 cells were transduced with a pLPCX expression retroviral vector containing green fluorescent protein and neomycin resistance genes." | 1.37 | A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor. ( Ding, Y; Jin, H; Sun, Y; Wang, J; Yang, Z; Zhang, S, 2011) |
| "We diagnosed the patient as a case of lung injury caused by anticancer drugs." | 1.37 | [A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer]. ( Hanatate, F; Kobayashi, K; Komaki, C, 2011) |
| "Next, we showed that nine human colon cancer cell lines established from primary tumors or metastases expressed OX1R mRNA and underwent important apoptosis on orexin-A challenge." | 1.37 | Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. ( Bedossa, P; Descatoire, V; El Firar, A; Fasseu, M; Henin, D; Laburthe, M; Lehy, T; Paradis, V; Rouyer-Fessard, C; Voisin, T; Walker, F, 2011) |
| "Pelvic schwannomas are rare; it is even more rare for a pelvic schwannoma to occur concurrently with a colon cancer." | 1.37 | Synchronous colonic adenocarcinoma and pelvic schwannoma. ( Bai, J; Kleyser-Sugrue, K; Nerenstone, SR; Welch, JP, 2011) |
| "Obesity has been associated with both the carcinogenesis and poor prognosis of colon cancer, one of the leading causes of cancer-related death." | 1.37 | Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. ( Chen, J; Hu, C; Huang, XF; Katsifis, A, 2011) |
| "Patients with dMMR colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers." | 1.37 | DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. ( Allegra, C; Foster, NR; Gallinger, S; Kim, GP; Labianca, R; Marsoni, S; Monges, G; Moore, MJ; Sargent, DJ; Sinicrope, FA; Thibodeau, SN; Yothers, G, 2011) |
| "HT29 colon cancer cells grew well in suspension culture." | 1.37 | Isolation and characterization of spheroid cells from the HT29 colon cancer cell line. ( Fan, X; Ouyang, N; Teng, H; Yao, H, 2011) |
| "We analyzed colon cancer samples for the occurrence of BARD1 splice variants, characterized novel BARD1 splice variants, and quantified the mRNA expression levels of these isoforms in primary colon cancers and their corresponding normal tissue." | 1.37 | BARD1 expression predicts outcome in colon cancer. ( Hothorn, T; Jung, B; Sporn, JC, 2011) |
| "Although colon cancer cells endogenously express Par-4, the presence or overexpression of Par-4 alone does not cause apoptosis." | 1.37 | The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU. ( Irby, RB; Kline, CL, 2011) |
| "We report a case of undifferentiated colon cancer treated with FOLFIRI therapy." | 1.37 | [A case of undifferentiated colon cancer responding to FOLFIRI therapy]. ( Fujiwara, K; Iwashita, T; Nagayoshi, Y; Nakahara, C; Yamasaki, T, 2011) |
| "A patient with colon cancer who had received an overdose of fluorouracil was successfully treated with a five-day course of oral uridine triacetate." | 1.37 | Use of uridine triacetate for the management of fluorouracil overdose. ( McEvilly, M; Popelas, C; Tremmel, B, 2011) |
| "Colon cancer is the second leading cause of cancer death worldwide." | 1.36 | Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells. ( Babaei, MH; Ghannadi Maragheh, M; Mesbah-Namin, SA; Taghikhani, M; Yavari, K, 2010) |
| "Biopsied lung tumor was diagnosed as tubular adenocarcinoma, and CK7(+)/CK20(+)/Cdx-2(-)." | 1.36 | Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report. ( Arai, M; Asakage, M; Endo, J; Furukawa, Y; Muto, Y; Nozawa, H; Oka, T; Yamada, Y, 2010) |
| "We report a resected case of ascending colon cancer with left supraclavicular and paraaortic lymph nodes and liver metastases which completely responded in terms of metastases but not the primary tumor to FOLFOX4 therapy." | 1.36 | [A case of advanced ascending colon cancer, curatively resected after complete response in left supraclavicular and paraaortic lymph nodes and liver metastases to FOLFOX4 therapy]. ( Fuji, H; Furumoto, K; Ito, D; Kogire, M; Kojima, H; Mizuno, R; Mori, T; Okuno, M; Takaya, H, 2010) |
| "Obesity is associated with an increased risk of colon cancer." | 1.36 | Obesity is an independent prognostic variable in colon cancer survivors. ( Foster, NR; O'Connell, MJ; Rankin, C; Sargent, DJ; Sinicrope, FA, 2010) |
| "Forty-eight-hour treatment of colon cancer HCT-116 and HT-29 cells with FOLFOX resulted in 60-70% survival, accompanied by a marked activation of insulin like growth factor-1 receptor (IGF-1R) and minor to moderate increase in epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER-2) as well as v-akt murine thymoma viral oncogene homolog 1 (AKT), cyclooxygenase-2 (COX-2) and cyclin-D1." | 1.36 | Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. ( Elliott, AA; Gupta, D; Majumdar, AP; Patel, BB; Sengupta, V; Yu, Y, 2010) |
| "Five colon cancer cell lines expressing a different k-ras mutational status were evaluated for: (i) EGFR-expression, (ii) susceptibility to LAK cells and (iii) cetuximab-mediated ADCC, before and after exposure to 5-flurouracil (5-FU), gemcitabine (Gem), irinotecan (Iri) alone or in multiple two/three drug combinations." | 1.36 | Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). ( Abbruzzese, A; Arcuri, FP; Caraglia, M; Carducci, A; Correale, P; Del Vecchio, MT; Loiacono, L; Marra, M; Migali, C; Misso, G; Remondo, C; Tagliaferri, P; Tassone, P, 2010) |
| " When chemotherapy with S-1 or UFT/LV started from the micrometastasis stage, not the advanced macroscopic metastasis stage, anti-LNM efficacy of S-1 was significantly higher than that of UFT/LV at the dosage in which antitumor activity of the two drugs against primary subcutaneous tumor was comparable." | 1.36 | Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV. ( Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A, 2010) |
| "We report a case of acute interstitial pneumonitis and respiratory failure occurring in a 69-year-old, previously healthy patient receiving FOLFOX regimen plus cetuximab for colon cancer." | 1.36 | Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy. ( Chang, SC; Lai, JI; Lai, YC; Lin, PC; Wang, WS, 2010) |
| "A close inspection showed progressive stomach cancer with lymph node metastasis." | 1.36 | [A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6]. ( Ishida, T; Iwasaki, T; Kanemitsu, K; Okuda, T; Tanaka, K; Toyokawa, A, 2010) |
| "Chemotherapy is the main treatment for colon cancer, while multidrug-resistance is the main reason for chemotherapy failure and tumor relapse." | 1.36 | Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines. ( Bi, F; Lang, N; Liu, M; Liu, Z; Qiu, M; Tang, QL, 2010) |
| "CASE 2: A 67-year-old male with colon cancer and liver and lung metastases was referred to our Dept." | 1.36 | [Two cases of unstable angina in patients treated with bevacizumab]. ( Okada, Y; Okura, Y; Takii, Y, 2010) |
| "RT-qPCR of FPE colon cancer tissue applied to four large independent populations has been used to develop multigene algorithms for estimating recurrence risk and benefit from FU/LV." | 1.36 | Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. ( Baehner, FL; Baker, J; Clark-Langone, KM; Cowens, JW; Lavery, I; Lopatin, M; O'Connell, MJ; Paik, S; Shak, S; Watson, D; Wolmark, N; Yothers, G, 2010) |
| "CD133-positive colon cancer stem like cells (CSLCs) are resistant to the conventional cytotoxic drug 5-fluorouracil (5-FU)." | 1.36 | 5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells. ( Deng, YH; Huang, MJ; Lin, EH; Lin, TY; Pu, XX; Xiao, J; Zhou, JM, 2010) |
| "We report two cases of colorectal cancer whose serum iron level demonstrated recurrent elevation after chemotherapy." | 1.36 | [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU]. ( Furuse, J; Hosokawa, Y; Itabashi, M; Iwamoto, N; Kase, Y; Kitagawa, N; Miyazawa, T; Motoori, S; Saisho, H, 2010) |
| "Stage III colon cancer patients receiving standard adjuvant oxaliplatin/capecitabine chemotherapy were vaccinated at the same time with keyhole limpet haemocyanin (KLH) and carcinoembryonic antigen (CEA)-peptide pulsed DCs." | 1.36 | A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. ( Aarntzen, EA; Adema, GJ; de Boer, A; de Vries, IJ; Figdor, CG; Lesterhuis, WJ; Preijers, FW; Punt, CJ; Scharenborg, NM; van de Rakt, M; van Spronsen, DJ, 2010) |
| "We report a case of high CEA advanced colon cancer, which we were able to down stage after treatment with FOLFIRI-1." | 1.36 | [A case of high CEA colon cancer responding to neoadjuvant chemotherapy with FOLFIRI]. ( Egawa, H; Kadokawa, Y; Kawabe, A; Nakajima, S; Sonoda, K; Yamamoto, T, 2010) |
| " We investigated the anti-tumor effects of CG2 (an HDACI) in combination with irinotecan, 5-FU, or oxaliplatin." | 1.36 | Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts. ( Cho, DH; Hong, YS; Jin, DH; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Na, YS; Ro, S; Ryu, MH; Yang, SJ, 2010) |
| "(51)Cr-prelabelled colon cancer cells (simulating 'circulating tumor cells', CTCs) were added to human peripheral blood and exposed to staurosporine (ST) to increase carcinoembryonic antigen (CEA) expression." | 1.36 | Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. ( Aquino, A; Balduzzi, A; Bonmassar, E; Bonmassar, L; Caporaso, P; Cappelletti, D; Cardillo, A; Concolino, F; D'Atri, S; De Vecchis, L; Formica, V; Fossile, E; Graziani, G; Greiner, JW; Prete, SP; Roselli, M; Scoppola, A; Torino, F, 2010) |
| "Goblet cell carcinoid of the large intestine is a rare neoplasm, usually located in ascending colon and rectum." | 1.36 | Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report. ( Erkasap, S; Ihtiyar, E; Karakaş, BR; Paşaoğlu, O; Yaşar, FN, 2010) |
| "To investigate the effect of Endostatin and SU6668 combined with 5-FU on the growth and metastasis of human colon cancer in vivo and its mechanism." | 1.35 | [Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice]. ( Chu, ZH; Luo, XJ; Zeng, QL; Zhou, K, 2008) |
| "The human colon cancer cell line LoVo was injected subcutaneously into the necks of five mice to generate a solid tumor." | 1.35 | A simple colostomy implantation model for evaluating colon cancer. ( Ding, Y; Jin, H; Li, VK; Liu, F; Liu, X; Ni, M; Song, Y; Yun, S; Zhou, S, 2009) |
| "In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer." | 1.35 | Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting. ( Amadori, D; Antonuzzo, L; Barone, C; Bertetto, O; Carlo Merlano, M; Di Costanzo, F; Gasperoni, S; Labianca, R; Longo, F; Luppi, G; Mansueto, G; Ravasio, R; Sobrero, A; Vinante, O, 2008) |
| "Expression of these proteins in colon cancer patients may account for differences in recurrence and survival rates." | 1.35 | Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. ( Foster, NR; O'Connell, MJ; Okumura, K; Rego, RL; Sargent, DJ; Sinicrope, FA; Windschitl, HE, 2008) |
| "The resistance of colon cancer to 5-fluorouracil (5-FU) is a critical issue, and the cause of this resistance cannot always be explained based on the known molecules." | 1.35 | Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. ( Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Kitajima, M; Kubota, T; Nishibori, H; Tsuruta, M, 2008) |
| "We reported a case of super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy." | 1.35 | [Super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy--report of a case]. ( Fujita, S; Ishida, H; Kabuto, T; Nakaguchi, K; Wada, A; Watanabe, Y, 2008) |
| "A 62-year-old male presents with colon cancer that has metastasized to both lobes of the liver." | 1.35 | Sequential or combination chemotherapy for a patient with mCRC? ( Arnold, D, 2008) |
| "This study aimed to develop an efficient and safe strategy to introduce suicide genes into colon cancer cells." | 1.35 | Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. ( Chen, Y; Chen, YH; Liu, T; Peng, J; Xu, M; Yu, S; Yuan, J; Zhang, G; Zhang, X, 2009) |
| "The data set assembled by the Adjuvant Colon Cancer Endpoints Group, a collection of individual patient data from 18 trials and more than 20,800 patients testing fluorouracil-based adjuvant therapy in patients with stage II or III colon cancer, was analyzed." | 1.35 | Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. ( Andre, T; Buyse, M; de Gramont, A; Francini, G; Goldberg, R; Green, E; Grothey, A; Haller, D; Labianca, R; O'Callaghan, C; O'Connell, MJ; Sargent, D; Seitz, JF; Sobrero, A; Yothers, G; Zheng, Y, 2009) |
| "Twenty-five patients diagnosed with colon cancer at an initial, intermediate and late phase submitted to specifically devised therapy were assessed." | 1.35 | Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. ( Busamia, BE; Campos, ML; Dubersarsky, C; Finkelberg, AB; Jarchum, G; Lavarda, M; Linares, JA; Mazzeo, MA, 2009) |
| "A local recurrence in the right lateral abdominal wall was confirmed by PET-CT examination." | 1.35 | [A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)]. ( Arai, H; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Nishi, Y; Sasajima, K; Sugiura, A; Suzuki, S; Tajiri, T; Wakabayashi, H; Yanagi, K; Yokoyama, T, 2009) |
| "The expression profiles of human colon cancer cell line DLD-1, its 5-FU-resistant subclone DLD-1/FU and a further 21 types of colon cancer cell lines were compared to identify the novel genes defining the sensitivity to 5-FU and to estimate which population of genes is responsible for 5-FU sensitivity." | 1.35 | Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. ( Ando, T; Fujibuchi, W; Ishida, K; Kaneko, N; Karasawa, H; Kinouchi, M; Miura, K; Murata, Y; Okabe, M; Sasaki, H; Sasaki, I; Shibata, C; Takami, K; Yamamura, A, 2009) |
| "KM12SM and HCT116 colon cancer cells were exposed to 5-FU and/or SN-38 in various conditions." | 1.35 | Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. ( Matono, K; Ogata, Y; Shirouzu, K; Torigoe, S, 2009) |
| "Treatment of p53 mutant colon cancer cells with 5-FU led to an elongated G1 in a Mirk-dependent manner, as G1 was shortened by ectopic overexpression of cyclin D1 mutated at the Mirk phosphorylation site (T288A), but not by wild-type cyclin D1." | 1.35 | Mirk regulates the exit of colon cancer cells from quiescence. ( Ewton, DZ; Friedman, E; Hu, J; Jin, K; Park, S, 2009) |
| "The outcome was colon cancer-specific death during the follow-up period." | 1.35 | Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. ( Choti, MA; Davidoff, A; Gardner, J; Mullins, CD; Onukwugha, E; Rapp, T; Seal, B; Zuckerman, IH, 2009) |
| "A 77-year-old female with metastatic colon cancer presented with vomiting and diarrhea." | 1.35 | Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. ( Gunderson, HD; Leung, N; Shaikh, A; Wiisanen, ME, 2009) |
| "In addition, after human colon cancer cell lines were treated with Survivin siRNA and/or 5-fluorouracil, MTT assay and flow cytometry were used to analyze cell proliferation and apoptosis." | 1.35 | Enhanced chemotherapy sensitivity of human colon cancer cells to 5-fluorouracil by siRNA recombinant expression vector targeting survivin gene. ( Cai, CX; Cai, M; Tao, KX; Wang, GB, 2009) |
| "Thirty-three patients with rectal cancer underwent preoperative CRT." | 1.35 | Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. ( Ioue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "Capecitabine was also projected to increase the number of QALYs compared with FU/LV." | 1.35 | Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. ( Fukuda, T; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Tsutani, K, 2009) |
| "For patients with T3N0M0 colon cancer without known risk factors, the necessity of chemotherapy has no definite consensus." | 1.35 | The necessity of chemotherapy in T3N0M0 colon cancer without risk factors. ( Cho, YB; Chun, HK; Kim, HC; Lee, WY; Yun, HR; Yun, SH, 2009) |
| "Prognosis of stage II colorectal cancer varies." | 1.35 | [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy]. ( Ding, PR; Li, LR; Lin, JZ; Pan, ZZ; Peng, ZH; Wan, DS; Wu, XJ; Zhou, ZG, 2009) |
| "Twenty-two specimens of colorectal cancer were collected." | 1.35 | [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues]. ( Chen, G; Fu, LW; Liang, YJ; Qiu, HB; Yuan, SQ; Zhang, LY; Zhou, ZW, 2009) |
| "Many studies have shown that colon cancer is an estrogen-dependent carcinoma." | 1.35 | MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells. ( Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Zhang, LY, 2009) |
| "Once interstitial pneumonia has occurred, cessation of the regimen is mandatory, and high-dose corticosteroid treatment is commonly given to rescue patients from this potentially lethal complication." | 1.35 | Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). ( Hatakeyama, K; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakai, T, 2009) |
| "We report a case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor." | 1.35 | [A case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor]. ( Hazama, S; Nakatsu, H; Oka, M; Tokuhisa, Y; Tomochika, S; Yoshida, S; Yoshino, S, 2009) |
| "A 45-year-old male patient with right colonic cancer, of which clinical finding was SIM1 (No." | 1.35 | [A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy]. ( Inoue, S; Nasu, K; Noda, K; Umekita, N, 2009) |
| "We report a case of transverse colon cancer with gastric regional lymph node metastasis." | 1.35 | [Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report]. ( Hazama, S; Nakatsu, H; Oka, M; Sakamoto, K; Tomochika, S; Yoshino, S, 2009) |
| "The standard chemotherapy regimen for esophageal cancer is cisplatin and 5-fluorouracil (5-FU)." | 1.35 | [A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy]. ( Oka, M; Takeda, S; Tsutsui, M; Watanabe, Y; Yoshino, S, 2009) |
| "Gastrointestinal perforation is a known risk factor of unknown etiology associated with the use of bevacizumab." | 1.35 | [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. ( Abbrederis, K; Kremer, M; Schuhmacher, C, 2008) |
| "The hydroxyproline levels were higher in the IGF-I and the IGF-I +5-FU groups as a result of the stimulating act of IGF-I." | 1.35 | Effect of IGF-I on healing of colonic anastomoses in rats under 5-FU treatment. ( Betsis, D; Demetriades, H; Kanellos, I; Koliakos, G; Lambrou, I; Pramateftakis, MG; Zacharakis, E; Zaraboukas, T, 2008) |
| "Significant prognostic factors of recurrence in multivariate analysis were: male sex (odds ratio, OR=3." | 1.35 | Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. ( Azuara, D; Biondo, S; Capella, G; de Oca, J; Hotter, G; Martí-Ragué, J; Moreno, V; Navarro, M; Osorio, A; Rafecas, A; Sanchez-Santos, R; Sola, A, 2008) |
| "We analyzed primary breast and colon cancers for p53 mutations and FAK expression, and showed that FAK expression was increased in tumors containing mutations of p53 compared to tumors with wild type p53." | 1.35 | p53 regulates FAK expression in human tumor cells. ( Campbell-Thompson, M; Cance, WG; Finch, R; Golubovskaya, VM; Kweh, F; Massoll, NA; Wallace, MR, 2008) |
| "A review of patients with stage III colon cancer over a 7-year period at Western Hospital using a prospective, comprehensive colorectal database was carried out." | 1.35 | Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer. ( Chapman, M; Faragher, I; Gibbs, P; Handolias, D; Johns, J; McLaughlin, S, 2008) |
| "The X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy) compared traditional bolus 5-FU/LV (as per the Mayo Clinic regimen) with capecitabine, in the adjuvant treatment of 1987 stage III colon cancer patients." | 1.35 | Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. ( Cassidy, J; Glen, H, 2008) |
| " The pharmacokinetic parameters of 5-FU/PEG-PBLG nanoparticles in rabbit plasma were determined by measuring the 5-FUby high-performance liquid chromatography (HPLC)." | 1.35 | Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. ( Guan, Z; Jiang, W; Li, S; Wang, A, 2008) |
| " A long-term dosing study is required to ascertain the therapeutic benefits." | 1.35 | In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil. ( Ali, M; Charoo, NA; Khar, RK; Kohli, K; Mohammed, NN; Rahman, Z; Repka, MA; Shamsher, AA; Tauseef, M; Zhang, SQ, 2008) |
| "Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)." | 1.35 | Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008) |
| "Tezacitabine is a nucleoside analogue characterized by a dual mechanism of action." | 1.34 | Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts. ( Aardalen, K; Doyle, L; Hibner, B; Jekic-McMullen, D; Moler, E; Rendahl, K; Salangsang, F; Shao, Y; Taverna, P, 2007) |
| "The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies." | 1.34 | The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. ( Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007) |
| "19 out of 29 patients were colon cancer, and the other 10 were rectal cancer." | 1.34 | [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. ( Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "Patients aged > or = 70 years with colon cancer benefit from chemotherapy, with no major added toxicities compared with a younger population." | 1.34 | Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. ( Fakih, MG; Reddy, N; Yu, J, 2007) |
| "We developed a recombinant defective adenovirus with an insert of gene encoding extracellular domain of mouse Flt3L (Ad-mFlt3L) under control of cytomegalovirus promoter to investigate the biological efficacy of Flt3L in combination with chemotherapeutical drug, 5-FU, in eliciting an effective anti-cancer immunity in mouse hepatoma and colon cancer model systems." | 1.34 | Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. ( Dai, J; Fan, X; Guo, Y; Hou, S; Kou, G; Li, B; Li, J; Lin, B; Ma, J; Qian, W; Wang, H; Wu, M; Zhang, D; Zhao, J, 2007) |
| "HT-29 and SNU-C4 human colon cancer cell lines were treated with 5-FU and their relative chemoresistance, and Hsp70 were determined." | 1.34 | Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. ( Correa, LP; da Rocha, AB; Grivicich, I; Henriques, JA; Jotz, GP; Regner, A; Schwartsmann, G; Zanoni, C, 2007) |
| "Human colon cancer HT-29 cells were cultured in vitro and treated with fluorouracil and/or rosiglitazone." | 1.34 | Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. ( Cao, JG; Dong, L; Liu, HQ; Qin, Y; Sun, L; Tang, XQ; Xia, H; Zhang, YQ, 2007) |
| "Two human colon cancer cell lines (HCT-15 and HT-29) were treated with 5-FU and celecoxib, alone and in combination." | 1.34 | Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. ( Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC, 2007) |
| "However, severe hyperbilirubinemia (grade 3/4) has not been previously reported in association with this chemotherapeutic agent." | 1.34 | Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. ( Fakih, MG; Gupta, B; LeVea, C; Litwin, A, 2007) |
| "Human colon cancer RKO cells were used as our model system." | 1.34 | Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. ( Chu, E; Ju, J; Kudo, K; Schmitz, JC; Song, B, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| " We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP." | 1.34 | [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. ( Chisato, N; Ebisawa, Y; Kono, T; Mamiya, K; Mamiya, N; Satomi, M, 2007) |
| "Colon cancer is c-kit positive and responsive to the specific tyrosine kinase inhibitor imatinib." | 1.34 | Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. ( Chalkiadakis, G; Kanakis, I; Karamanos, NK; Kletsas, D; Mavroudis, D; Roussidis, AE; Stahtea, XN; Tzanakakis, GN, 2007) |
| "In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice." | 1.34 | Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007) |
| "Thirty-nine patients with colorectal cancer, who received m-FOLFOX6 in our institution, were studied." | 1.34 | [Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients]. ( Fukunaga, S; Hirakawa, K; Inoue, T; Kaizaki, R; Maeda, K; Nakano, T; Noda, E; Shinto, O; Wada, K; Young Kim, W, 2007) |
| "In vitro, human colon cancer cell lines were treated with anti-CEA MAb IgG1, hMN-14 (labetuzumab), to assess direct effects on proliferation, as well as antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC)." | 1.33 | Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. ( Blumenthal, RD; Goldenberg, DM; Hansen, HJ; Hayes, MK; Horak, ID; Osorio, L, 2005) |
| "5-Fluorouracil (5-FU) and capecitabine alone and in combination with irinotecan/oxaliplatin are clinically active in the treatment of colorectal and other solid tumors." | 1.33 | Synergistic antitumor activity of capecitabine in combination with irinotecan. ( Cao, S; Durrani, FA; Rustum, YM, 2005) |
| " In the present study, the antitumour activity of XR5944 was investigated in combination with 5-fluorouracil (5-FU) or irinotecan in human colon carcinoma cell lines and xenografts." | 1.33 | Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. ( Brown, JL; Charlton, PA; Freathy, C; Harris, SM; Mistry, P, 2005) |
| " TFT is a good substrate for thymidine phosphorylase (TP), and the combination of TFT and a TP inhibitor (TPI), called TAS-102, has been developed to enhance the bioavailability of TFT in vivo, and is currently being studied in a phase I study." | 1.33 | Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. ( Comijn, EM; de Bruin, M; Fukushima, M; Peters, GJ; Temmink, OH, 2005) |
| " This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events." | 1.33 | [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. ( Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005) |
| " After three cycles of chemotherapy over a 10-week period, the patient's dosage requirements returned to her baseline level (before treatment with 5-fluorouracil and leucovorin had started)." | 1.33 | Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy. ( Davis, DA; Fugate, SE, 2005) |
| "Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest." | 1.33 | Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. ( Augenlicht, L; Huang, J; Klampfer, L; Sasazuki, T; Shirasawa, S; Swaby, LA, 2005) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "Fifty-one patients with postoperative colon cancer (mean 61." | 1.33 | Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. ( Hayakawa, K; Miyake, K; Morimoto, T; Mukaihara, S; Nishino, M, 2005) |
| "C22-20, a clonal subline, derived from colon cancer HT-29 line, selected for low expression of CEA, was used in our experimental model." | 1.33 | Combined effects of protein kinase inhibitors and 5-fluorouracil on CEA expression in human colon cancer cells. ( Aquino, A; Baier, S; Bonmassar, E; Correale, PP; De Vecchis, L; Prete, SP; Rossi, L; Tamburrelli, G; Turriziani, M, 2005) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 1.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "Human colon cancer cells were injected subcutaneous in nude mice." | 1.33 | Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. ( El-Salhy, M; Tjomsland, V, 2005) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "A human colon cancer cell line (S1) was treated with various doses of oxaliplatin, 5FU, radiation, and combinations thereof." | 1.33 | In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. ( Johnsson, A; Kjellén, E; Kjellström, J, 2005) |
| "A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt." | 1.33 | [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005) |
| "When curcumin and 5-FU were used concurrently, synergistic inhibition of growth was quantitatively demonstrated." | 1.33 | Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. ( Du, B; Jiang, L; Xia, Q; Zhong, L, 2006) |
| "Patients with bilobar colorectal cancer metastases to the liver present a unique problem in terms of resection." | 1.33 | Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved. ( Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL, 2006) |
| "The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history." | 1.33 | 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| "Progressive respiratory failure developed in a 68 year-old female who was treated with single-agent oxaliplatin for colorectal cancer." | 1.33 | Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. ( Colomer, R; Fabregat, MB; Merino, BQ; Puig, J; Soy, E; Yagüe, XH, 2005) |
| " Furthermore, the efficacy of immunotherapy combined with either 5-fluorouracil or irinotecan was similar to that of immunotherapy alone." | 1.33 | Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. ( Beck, S; Bourquin, C; Endres, S; Hartmann, G; Schreiber, S, 2006) |
| "Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow." | 1.33 | Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. ( Aster, RH; Blank, J; Curtis, BR; Kaliszewski, J; Marques, MB; McFarland, JG; Nabelle, L; Saif, MW, 2006) |
| "Treatment with uridine alone did not protect from FUra toxicity at the dose of 200 mg/kg as all mice died." | 1.33 | Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor. ( Al Safarjalani, ON; el Kouni, MH; Naguib, FN; Rais, R; Schinazi, RF; Shi, J, 2006) |
| "Human colon cancer cell lines (HT-29, Caco-2, and DLD-1) were incubated with 5-FU and with 5-FU combined with cisplatin, camptothecin, paclitaxel, mitomycin C, interferon, or TNF-related apoptosis-inducing ligand." | 1.33 | Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. ( Matsui, H; Matsuzaki, Y; Miyazaki, K; Nakahara, A; Sato, D; Shibahara, T; Suzuki, H; Uchida, K; Yanaka, A, 2006) |
| "(1) The standard treatment for colon cancer is surgical excision, but without additional treatment nearly 50% of surgically treated patients die from relapse and metastatic disease progression." | 1.33 | Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases. ( , 2006) |
| "The human colon cancer LoVo cells were transfected by liposome with pU6-EGFR-shRNA-1 and pU6-EGFR-shRNA-2 expressive vectors which were established by p Genesil-1 plasmid and EGFR short hairpin RNA (shRNA) synthesized in vitro, then were selected for 4 weeks by using G418." | 1.33 | [Double sites short hairpin RNAs targeting epidermal growth factor receptor to promote colon cancer cells apoptosis and enhance 5-fluorouracil chemotherapy effect]. ( Chen, DD; Tao, KX; Tian, Y; Wang, GB; Wu, XB; Zhang, JH, 2006) |
| "Resistant HCT-8 colon cancer cell lines (HCT-8/FUI/15R and HCT-8/FUB/2R) were selected from parental sensitive HCT-8 cells by long-term and short-term exposure schedules, respectively." | 1.33 | Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules. ( Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E, 2005) |
| "Coculture assays of colon cancer cells and Jurkat cells (Fas-sensitive cells) were performed to observe the counterattack of colon cancer cells to lymphocytes." | 1.33 | Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. ( Cui, Y; Li, YQ; Liu, JY; Qin, CY; Wang, HB; Xu, HW; Yang, CM; Zhang, AZ; Zhu, Q, 2006) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| "The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin." | 1.33 | Is acute dyspnea related to oxaliplatin administration? ( Monfardini, S; Pasetto, LM, 2006) |
| "HCT116 colon cancer cells were treated with docetaxel, flavopiridol, and 5-FU in several different administrative schedules in vitro, either sequentially or simultaneously." | 1.33 | Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. ( Becerra, CR; Frenkel, EP; Fu, YC; Guo, J; Tripathy, D; Verma, UN; Zhou, AW, 2006) |
| " We present a colon cancer patient with the UGT1A1 polymorphism (UGT1A1 *28) as a known high risk for irinotecan, who was treated with a combination of doxifluridine and irinotecan for peritoneal dissemination resulting in stable disease for 2 years without adverse reactions, although the patient initially developed severe adverse effects to the combination of the protracted venous infusion of 5-FU and irinotecan." | 1.33 | Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report. ( Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Nakatani, K; Nobori, T; Ojima, E; Toiyama, Y; Watanabe, H, 2006) |
| " NV1020 is currently under investigation in a clinical phase I/II trial as an agent for the treatment of colon cancer liver metastases, in combination with conventional chemotherapeutic agents such as 5-fluorouracil (5-FU), SN38 (the active metabolite of irinotecan), and oxaliplatin." | 1.33 | Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. ( Breidenstein, C; Gungor, D; Gutermann, A; Lechmann, M; Mayer, E; Moebius, U; Muench, M; Suehnel, J; von Dehn-Rothfelser, K; Weber, M, 2006) |
| "Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy." | 1.32 | Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. ( Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC, 2003) |
| "We present a case of colon cancer with idiopathic leukopenia who tolerated chemotherapy without worsening of leukopenia." | 1.32 | Adjuvant therapy of colon cancer in idiopathic leukopenia. ( Mehdi, SA; Pervez, H; Potti, A, 2003) |
| "Levamisole has no direct cytotoxic effect and no additive or synergistic cytotoxic effect when combined with 5-FU on two colon cancer cell lines." | 1.32 | Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole. ( Eckert, GJ; Grieshop, NA; Loehrer, PJ; Sidner, RA; Wiebke, EA, 2003) |
| "The treatment of colon cancer has been aimed by approaches of oral drug administration." | 1.32 | Microsphere design for the colonic delivery of 5-fluorouracil. ( Kawashima, Y; Lamprecht, A; Takeuchi, H; Yamamoto, H, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation." | 1.32 | [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. ( Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003) |
| "Etodolac did not increase the inhibitory effect of 5-FU on cell proliferation." | 1.32 | Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. ( Hirakawa, K; Matsunaga, N; Nishiguchi, Y; Nishino, H; Ohira, M; Seki, S; Tachimori, A; Yamada, N, 2004) |
| " FO was tested alone and in combination with the anticancer drug 5-fluorouracil (5-FU)." | 1.32 | Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. ( Jordan, A; Stein, J, 2003) |
| "Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments." | 1.32 | Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003) |
| " The parameters of the pharmacodynamic model are related to the growth characteristics of the tumor, to the drug potency, and to the kinetics of the tumor cell death." | 1.32 | Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. ( Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M, 2004) |
| "Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI)." | 1.32 | Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. ( Cats, A; de Vos tot Nederveen Cappel, WH; Gelderblom, H; Griffioen, G; Kleibeuker, JH; Menko, FH; Meulenbeld, HJ; Morreau, H; Nagengast, FM; Vasen, HF, 2004) |
| "Under a diagnosis of advanced ileocecal colon cancer with metastases to Virchow's and the paraaortic lymph nodes, ileocecal resection was performed." | 1.32 | [A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy]. ( Kathou, T; Maruyama, H; Mio, H; Sekiya, M; Yamada, T, 2004) |
| "A 58-year-old man who had colon cancer with liver and multiple lung metastases underwent ileocecal resection on May 10, 2002." | 1.32 | [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11]. ( Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T, 2004) |
| " He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11." | 1.32 | [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004) |
| "We subjected HCT116 colon cancer cells to two different 5-FU treatment protocols in an attempt to generate resistant derivatives: one that simulated the clinical bolus regimens using clinically-achievable 5-FU levels, the other that utilized serial passage in the presence of increasing 5-FU concentrations (continuous exposure)." | 1.32 | Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. ( De Angelis, PM; Haug, T; Kravik, KL; Reichelt, WH; Tunheim, SH, 2004) |
| "Human colon cancer cells were implanted s." | 1.32 | Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer. ( El-Salhy, M, 2004) |
| "The mechanism of NS-398 against colon cancer may be independent upon the expression levels of COX-2 mRNA and PGE2 of colon cancer." | 1.32 | [Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study]. ( Cui, ZR; Liang, B; Wang, S; Ye, YJ; Zhang, H; Zhang, YC, 2004) |
| "We report a patient with metastatic colon cancer who developed a hypersensitivity reaction to oxaliplatin during the sixth cycle of combination chemotherapy with oxaliplatin, high-dose 5-fluorouracil and leucovorin." | 1.32 | Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. ( Chang, MC; Chang, YF; Hsieh, RK; Huang, MJ; Lim, KH; Lin, HC; Lin, J; Su, YW, 2004) |
| "We prepared a colon cancer-bearing Yoshida sarcoma rat model to examine the dose-response relationship of antitumor activity of intracolonically or orally administered 5-fluorouracil (5-FU; 45, 30, 20, 13, and 8 mg/kg)." | 1.32 | A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model. ( Fujimura, A; Goto, T; Kobayashi, E; Tomizawa, N, 2004) |
| "5-Fluorouracil (5-FU) has been the mainstay treatment for colorectal cancer for the past few decades." | 1.32 | Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. ( Chang, HJ; Hong, SH; Jeon, E; Park, JG; Shin, YK; Yoo, BC, 2004) |
| "SW48 colon cancer cells were used for all experiments." | 1.32 | Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. ( Brank, A; Camp, ER; Hochwald, SN; Li, J; MacKay, SL; Moldawer, LL; Voboril, R; Weberova, J; Wessels, F, 2004) |
| " Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition." | 1.32 | A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. ( Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004) |
| "Capecitabine was started." | 1.32 | Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis. ( Aksu, G; Fayda, M; Kapran, Y; Sakar, B, 2003) |
| "We investigated on colon cancer cells the effect of geraniol on thymidylate synthase and thymidine kinase expression, two enzymes related to 5-fluorouracil cytotoxicity." | 1.32 | Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts. ( Bradaia, A; Bras-Gonçalves, R; Carnesecchi, S; Gossé, F; Poupon, MF; Raul, F; Zeisel, M, 2004) |
| "After surgical resection of colon cancer, he suffered a multiple liver metastasis." | 1.32 | [A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery]. ( Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T, 2004) |
| "We report a case of recurrent colon cancer resistant to 5-FU, whose QOL and PS has been well maintained with low-dose CPT-11/CDDP administered on an outpatient basis for more than 28 months." | 1.32 | [A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis]. ( Fukuhara, A; Kikuchi, S; Murayama, M; Nakamura, E; Nishimoto, Y; Nozaki, H; Shouda, S; Watanabe, Y; Yagyu, T, 2004) |
| "To estimate patterns of colon cancer presentation, diagnosis, and treatment according to history of dementia using National Cancer Institute (NCI) Surveillance, Epidemiology, and End-Result (SEER) Medicare data." | 1.32 | Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. ( Gupta, SK; Lamont, EB, 2004) |
| "Human HCT116 colon cancer cells were stably transfected with the sense or antisense FPGS cDNA or blank (control)." | 1.32 | Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Moskovitz, DN; Novakovic, P; Smirnakis, F; Sohn, KJ; Yates, Z, 2004) |
| "30 colorectal cancer patients were enrolled into the study to receive adjuvant chemotherapy 2 weeks after cured resection." | 1.32 | [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients]. ( Chen, G; Li, S; Liao, H; Pan, ZZ; Wan, DS; Wang, GQ; Zhou, ZW, 2004) |
| "In a panel of 18 colon cancer cell lines we found that the thymidylate synthase (TS) genotype was related to TS enzyme activity, but not to TS protein and mRNA levels." | 1.32 | Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. ( Beumer, IJ; Marsh, S; Mauritz, R; McLeod, HL; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2004) |
| "Gastrointestinal carcinoid tumors are often associated with other tumors, particularly colon adenocarcinomas; but the association between carcinoid tumors and hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has not yet been explored." | 1.32 | An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. ( Ducreux, M; Duvillard, P; Elias, D; Grandjouan, S; Miquel, C; Praz, F; Sabourin, JC; Viguier, J, 2004) |
| "5-fluorouracil (5-FU) is an important antineoplastic agent that has proven to be effective in the treatment of colorectal cancer." | 1.31 | Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells. ( Fukushima, M; Kanai, M; Kawai, Y; Obama, K; Takabayashi, A, 2002) |
| " Therefore, we evaluated the anti-proliferative potential of MTA combined with drugs known to exert therapeutic activity against colon cancer, including 5-fluorouracil, oxaliplatin, and SN38, the active metabolite of irinotecan." | 1.31 | Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. ( Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C, 2002) |
| "p53 wild- and mutant-type gastric and colon cancer cell lines were treated by 5FU alone, TRAIL alone, and a combination of 5FU and TRAIL, and cell viability after each treatment was determined by MTT assay." | 1.31 | Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. ( Kaminishi, M; Kusada, O; Mochizuki, Y; Shimoyama, S, 2002) |
| "These results suggest that colon cancer cells with microsatellite instability are more sensitive to 5-FU, whereas more resistant to CDDP." | 1.31 | Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. ( Chen, XX; Huang, Q; Lai, MD; Zhang, YL, 2002) |
| " We examined the response of three human colon tumors to TRAIL alone and in combination with chemotherapy, using SCID mice engrafted with intact patient surgical specimens." | 1.31 | Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. ( Hylander, BL; Naka, T; Repasky, EA; Rustum, YM; Sugamura, K; Widmer, MB, 2002) |
| "Coronary artery spasm has been postulated to be involved in the mechanism of this incident Patients may present with angina, myocardial infarction, arrhythmias and/or even sudden death." | 1.31 | A case of coronary spasm induced by 5-fluorouracil. ( Celik, S; Gorgulu, S; Tezel, T, 2002) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| "During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver." | 1.31 | Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. ( Bolton, M; Copur, S; Frankforter, S; Fruehling, RM; Ledakis, P; Mleczko, KL; Muhvic, J; Norvell, M; Novinski, D; VanWie, E, 2001) |
| " Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co." | 1.31 | [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. ( Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002) |
| "Human colon cancer LoVo cells were treated in both a dose- and time-dependent manner using clinically relevant concentrations of and exposure to 5-FU and/or SN-38." | 1.31 | Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. ( Azzariti, A; Church, SW; Colucci, G; Johnston, PG; Lacalamita, R; Paradiso, A; Tommasi, S; Xu, JM, 2002) |
| " This study was designed to investigate the effects of angiogenesis inhibitor TNP-470 in combination with 5-fluorouracil (5-FU) on the growth of human colon cancer cell line, LOVO, in vitro and in vivo." | 1.31 | [Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer]. ( Fan, YF; Huang, ZH; Nie, J, 2002) |
| "5-Fluorouracil (5-FU) is a drug of standard use in chemotherapy of colon carcinoma." | 1.31 | Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil. ( Cordel, S; Goupille, C; Hallouin, F; Le Pendu, J; Meflah, K, 2000) |
| "We investigated the effects of 2'-deoxyinosine (d-Ino), a modulator yielding thymidine phosphorylase activity, on cellular pharmacology of 5-fluorouracil (FUra) in various human colorectal cell lines and its antitumoral activity when combined with FUra in human xenografts." | 1.31 | Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. ( Aubert, C; Catalin, J; Ciccolini, J; Cuq, P; Evrard, A; Formento, P; Milano, G; Peillard, L; Pelegrin, A, 2000) |
| "A nationwide questionnaire survey was carried out on low-dose cisplatin-5-FU therapy for solid malignant tumors (mostly stomach and colon cancer) regarding its antitumor as well as adverse effects." | 1.31 | [Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects]. ( Hirata, K; Nakazato, H; Nishiyama, M; Saji, S; Sowa, M; Toge, T; Yamamitsu, S, 2000) |
| "Treatment of a patient with carcinoid metastases in the liver is discussed." | 1.31 | Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles. ( Adamyan, A; Gumargalieva, K; Guseinov, E; Horák, D; Kokov, L; Skuba, N; Tchjao, A; Titova, M; Trostenyuk, N; Tsvirkun, V; Vishnevskii, V, 2000) |
| "In the present study we adapted 4 colon cancer (C26-A, C26-10, C26-G and WiDr) and 3 squamous cell carcinoma of the head and neck (HNSCC) cell lines (11B, 14C and 22B) to culture medium with low folate (LF) levels (2." | 1.31 | Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. ( Backus, HH; Jansen, G; Molders, N; Padrón, JM; Peters, GJ; Pinedo, HM; van Der Wilt, CL; van Groeningen, CJ; Wouters, D, 2000) |
| "We encountered a case of unresectable colon cancer that disappeared following pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)]. ( Asahara, T; Nakahara, H; Nakahara, M; Okajima, M; Yano, M, 2000) |
| "SW 480 colon cancer cells were cultured to semiconfluent conditions with dose titrations performed for 5-FU to determine that the IC(50) (inhibitory concentration of 50% of the cells) was 0." | 1.31 | Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. ( Beech, DJ; Madan, AK; Pang, Y; Perer, ES; Romeguera, K; Shurin, A; Zakris, E, 2000) |
| "The oestrogen receptor positive breast cancer cell lines (MCF-7, T47D) demonstrated an increased level of HSP 27 and 70 expression compared with oestrogen receptor negative cell lines (BT20, HBL100)." | 1.31 | Heat shock protein expression in human tumours grown in severe combined immunodeficient mice. ( Katoh, M; Koninkx, J; Schumacher, U, 2000) |
| "For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival." | 1.31 | [Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers]. ( Hirakawa, K; Nishino, H; Ohira, M; Shimizu, S; Tamamori, Y; Tanaka, H; Yamada, N, 2000) |
| "5-Fluorouracil (5-FU) has been used as a chemotherapeutic drug for colorectal cancer." | 1.31 | Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. ( Fuji, H; Hamada, H; Hirao, T; Koyama, F; Nakano, H; Sawada, H; Ueno, M, 2000) |
| "A total of 18 patients (13: colon cancer, 5: gastric cancer) with multiple liver metastases (H3) underwent hepatic arterial infusion chemotherapy (HAI) using an implanted arterial port with portable syringe pumps in our outpatient clinic." | 1.31 | [Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases]. ( Fukunaga, M; Goda, F; Maeba, T; Maeta, H; Mihara, T; Mori, S; Ohkawa, M; Okada, H; Okano, K; Senda, S; Uchida, Y; Usuki, H; Wakabayashi, H, 2000) |
| "Two human colon cancer cell lines were used (WIDR and SW620 both p53 mutated)." | 1.31 | Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. ( Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Milano, G; Rostagno, P, 2001) |
| "Raltitrexed (Tomudex) is a novel thymidylate synthase inhibitor with significant activity against advanced colorectal cancer." | 1.31 | Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro. ( Akutsu, M; Furukawa, Y; Kano, Y; Suzuki, K; Tsunoda, S; Yazawa, Y, 2000) |
| "The adjuvant treatment of colon cancer is now accepted as an effective therapy following surgical resection of the primary tumor in patients at high risk for relapse." | 1.31 | North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer. ( O'Connell, MJ, 2001) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate that is preferentially converted to 5-fluorouracil in tumors relative to normal tissue." | 1.31 | 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer. ( Seitz, JF, 2001) |
| "In node-positive colon cancer, we assessed the S-phase fraction (SPF) index, the vascular endothelial growth factor (VEGF) expression and the TS levels." | 1.31 | Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. ( Baldelli, AM; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Graziano, F; Grianti, C; Muretto, P; Rossi, C; Staccioli, MP; Valentini, M, 2001) |
| "Human colon cancer cells (KM12SM) were injected into the cecal wall of the nude rats." | 1.31 | [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. ( Akagi, Y; Kobayashi, H; Matono, K; Miyagi, Y; Nakagawa, M; Nozoe, Y; Ogata, Y; Sasatomi, T; Shirouzu, K, 2001) |
| "Therefore, two human colon cancer cell lines, WiDr and Lovo, with a different clonogenic origin, were treated with equitoxic concentrations of 5-FU, AG337, and MTA to determine the induction of DNA damage, cell cycle arrest, downstream protein expression, and cell death." | 1.31 | Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. ( Backus, HH; Jansen, G; Kuiper, CM; Peters, GJ; Pinedo, HM; van Groeningen, CJ; Wouters, D, 2000) |
| "Human MLH1(-) and MMR-deficient HCT116 colon cancer cells were 18-fold more resistant to 7." | 1.31 | Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. ( Boothman, DA; Hwang, HS; Kinsella, TJ; Meyers, M; Wagner, MW, 2001) |
| "Leser-Trélat-syndrome is characterized as the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease." | 1.31 | [Clinical and histopathological characteristics of early Leser-Trélat syndrome]. ( Barth, G; Basten, O; Rompel, R; Rüschoff, J, 2001) |
| "Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU." | 1.31 | Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001) |
| " This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues." | 1.31 | Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001) |
| "In vitro, AdCDUPRT infection of colon cancer cells resulted in a marked increase in sensitisation to 5-FU, compared with AdCD-infected or uninfected cells." | 1.31 | In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. ( Anderson, D; Burton, A; Chen, MJ; Chung-Faye, GA; Green, NK; Kerr, DJ; Mautner, V; Searle, PF, 2001) |
| "The phenytoin dosage was decreased and the symptoms resolved." | 1.31 | Phenytoin and fluorouracil interaction. ( Brodribb, TR; Gilbar, PJ, 2001) |
| " A physiologically based pharmacokinetic (PBPK) model integrating the activation process of capecitabine to 5-FU and 5-FU elimination was constructed to describe the concentration/time profiles of capecitabine and its three metabolites, including 5-FU, in blood and organs." | 1.31 | Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue b ( Horii, I; Ishikawa, T; Ishitsuka, H; Kato, Y; Sugiyama, Y; Tsukamoto, Y; Ura, M, 2001) |
| " Because no data are available for patients with severe renal failure, the pharmacokinetic parameters of 5-FU and its catabolites were determined for a patient with colorectal carcinoma and end-stage renal disease on maintenance hemodialysis therapy." | 1.31 | Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ( Bommer, J; Göggelmann, C; Hull, WE; Rengelshausen, J; Schwenger, V; Walter-Sack, I, 2002) |
| "Some degree of aneuploidy was detected in all primary carcinomas." | 1.31 | Markers of drug resistance in relapsing colon cancer. ( Davaris, PS; Kavantzas, NG; Lazaris, AC; Tsavaris, NV; Zorzos, HS, 2002) |
| "Since 1981, 100 colon cancer patients have been treated with combination therapy including surgical resection, chemotherapy, and external plus intraoperative radiotherapy." | 1.31 | The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. ( Devine, RM; Donohue, JH; Gunderson, LL; Haddock, MG; Larson, DR; Nagorney, DM; Nelson, H; O'Connell, MJ; Rubin, J; Taylor, WE, 2002) |
| "A pair of colon cancer cell lines that differ only in their p53 status (RKO with wild-type p53 and RKOp53 with deficient p53) was tested." | 1.31 | Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status. ( Cerna, C; Davidson, KK; Heise, C; Izbicka, E; Kirn, D; Lawrence, RA; Petit, T; Von Hoff, DD, 2002) |
| "Human colon cancer cell lines LS174T and LiM6 were plated on plastic, on hepatocyte-derived ECM or on stromal ECM and in the presence of the antimetabolite 5-fluorouracil (5-FU)." | 1.31 | Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. ( Brill, S; Halpern, Z; Khaikin, M; Kouniavsky, G; Papa, M; Zippel, D; Zvibel, I, 2002) |
| "Differentiation of human colonic cancer cells at confluency has been correlated to their increased resistance to chemotherapeutic agents." | 1.31 | Geraniol, a component of plant essential oils, sensitizes human colonic cancer cells to 5-Fluorouracil treatment. ( Carnesecchi, S; Exinger, F; Gosse, F; Langley, K; Raul, F, 2002) |
| "To the best of our knowledge no anaphylactic reaction secondary to folinic acid (FA) administration has ever been reported before." | 1.31 | Anaphylactic shock secondary to intravenous administration of folinic acid: a first report. ( Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E, 2002) |
| "A 59-year-old man with colon cancer was diagnosed as having a local recurrence of the disease, forming a huge intra pelvic tumor, accompanied by pulmonary metastasis 16 months after hemicolectomy." | 1.30 | [A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin]. ( Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Tabata, H; Takasaki, S, 1997) |
| "For locally advanced primary colorectal cancer, our institution has combined intraoperative electron irradiation (IOERT) with external beam irradiation (EBRT) +/- 5-fluorouracil (5-FU) and surgical resection." | 1.30 | Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1997) |
| "5-Fluorouracil was administered at an initial daily dose of 125 mg/m2, with dose escalation planned in 25-mg increments, depending on patient tolerance." | 1.30 | Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer. ( Burch, PA; Garton, GR; Kugler, JW; Martenson, JA; Pitot, HC; Santala, RG; Schroeder, G; Stella, PJ; Swaminathan, R; Wright, K, 1997) |
| "We studied IFN modulation in three colon cancer cell lines (SW948, WiDr, human; C26-10, murine) and the sublines WiDr/F and C26-10/F, which were adapted to low folate levels." | 1.30 | Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. ( Aherne, GW; Noordhuis, P; Peters, GJ; Smid, K; van der Wilt, CL, 1997) |
| "In patients with stage III colon cancer, adjuvant chemotherapy with fluorouracil and levamisole has been shown to produce a 40 percent reduction in the recurrence rate at a median follow-up of 6." | 1.30 | Adjuvant therapy for colon and rectal cancer. ( Ratkin, GA, 1997) |
| "Cranial dystonia is usually idiopathic but may be caused by trauma or medications." | 1.30 | Focal dystonia after chemotherapy: a case series. ( Brashear, A; Siemers, E, 1997) |
| " This study investigates the cytotoxic effects of oxaliplatin in combination with 5-FU and AG337 in cultured human colon (HT29, CaCo2), breast (MCF-7, MDA-MB-231) and ovarian (2008) cancer cell lines, and their derived counterparts selected for their resistance to 5-FU (HT29-5-FU), doxorubicin (MCF-7mdr) or cisplatin (2008C13)." | 1.30 | Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. ( Allain, P; Buquet-Fagot, C; Cvitkovic, E; Djelloul, S; Gespach, C; Louvet, C; Mester, J; Raymond, E, 1997) |
| "5-Fluorouracil, 2600 mg/m2, was administered concurrently with 100 mg/m2 leucovorin over 24 hours of continuous intravenous infusion." | 1.30 | Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience. ( Chen, PM; Chen, WS; Chiou, TJ; Fan, FS; Hsieh, RK; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, WS; Yen, CC, 1998) |
| "Fifty-five colorectal cancer patients who had continuous intraportal chemotherapy between 1990 and 1993 (treated group) and 130 colorectal cancer patients who did not have portal chemotherapy between 1982 and 1993 (untreated group) were studied to clarify the effects of continuous intraportal chemotherapy on the prognosis." | 1.30 | [Continuous intraportal chemotherapy for prevention of metachronous hepatic metastasis in colorectal cancer]. ( Adachi, W; Amano, J; Kajikawa, S; Koide, N; Koike, S; Kuroda, T; Mihara, M; Nakata, S; Watanabe, H; Yazawa, K, 1998) |
| "Twenty-nine patients with advanced colorectal cancer were divided into four groups, 3 days, 5 days, 7 days, and 10 days." | 1.30 | [Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern]. ( Kaibara, N; Kurayoshi, K; Makino, M; Taniguchi, T; Yamane, N, 1998) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "A human colon cancer cell line, HCT-15, was found to proliferate in human sera." | 1.30 | [Serum factors in cancer patients affecting the antitumor effect of 5-fluorouracil]. ( Kojima, T; Miwa, M; Naruse, T, 1998) |
| "Using five human colon cancer cell lines, we found that equitoxic (IC50) doses of 5-FU induced apoptosis in both wild-type p53 and mutant p53 cells." | 1.30 | 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. ( Fu, CG; Fujii, S; Muto, T; Nagawa, H; Nita, ME; Sasaki, S; Takenoue, T; Tominaga, O; Tsuno, N; Tsuruo, T, 1998) |
| "Treatment of two human colon cancer cell lines (HT-29 and WiDr) with 5-FU + gamma-IFN resulted in an increase of CEA expression higher than that obtainable with both agents alone, although no synergistic effects were obtained." | 1.30 | Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. ( Aquino, A; Bonmassar, E; De Filippi, R; De Vecchis, L; Giuliani, A; Graziani, G; Greiner, JW; Masci, G; Prete, SP; Turriziani, M, 1998) |
| "Forty-four advanced colorectal cancer patients (15 women and 29 men; median age 63, range, 27-78 years) receiving a standard FU-folinic acid protocol were included." | 1.30 | Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. ( Chazal, M; Cheradame, S; Cure, H; Etienne, MC; Formento, JL; Formento, P; François, E; Francoual, M; Letoublon, C; Milano, G; Mousseau, M; Pezet, D; Richelme, H; Seitz, JF, 1997) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 1.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Nineteen patients (16 with colon cancer and 3 with breast cancer) who were treated with systemic 5-FU with complaints of tearing were studied retrospectively." | 1.30 | The treatment of punctal and canalicular stenosis in patients on systemic 5-FU. ( Fezza, JP; Klippenstein, KA; Wesley, RE, 1999) |
| "Advanced gastric, colon and esophageal cancers (n = 21) were treated with 5-FU (250 mg) modulated by CDDP (5 mg)." | 1.30 | [Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis]. ( Hisano, H; Kida, H; Nomura, M; Shibasaki, S; Shinkai, K; Yano, H, 1999) |
| "An 80-year-old woman with metastatic bone cancer from ascending colon showed a remarkable response to combination therapy of 5-FU and radiation." | 1.30 | [Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report]. ( Masuda, M; Nakamura, N; Nakanishi, K; Okamoto, E; Satoh, M; Takeuchi, T; Tanihata, H; Terada, M; Ueno, Y; Yoshikawa, H, 1999) |
| " In this study, the potential application of MGI-114 in the treatment of colon cancer was further explored by evaluating the activity of MGI-114 in combination with irinotecan (CPT-11) and 5-fluorouracil (5FU)." | 1.30 | Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. ( Britten, CD; Eckhardt, SG; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S, 1999) |
| "In a panel of 13 nonselected human colon cancer cell lines, we evaluated the role of TS levels in sensitivity to 5-fluorouracil (5FU) and four folate-based TS inhibitors that have been introduced recently into the clinic: ZD1694 (Tomudex, Raltitrexed, TDX), GW1843U89 (GW), LY231514 (LY), and AG337 (Thymitaq, AG)." | 1.30 | Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. ( Jansen, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Schoenmakers, PS; Smid, K; Telleman, F; van der Wilt, CL; van Hensbergen, Y; van Laar, JA; van Triest, B, 1999) |
| "HT29 human colon cancer cells transduced with yCD (HT29/yCD) were significantly more sensitive to 5-FC in vitro than HT29 cells transduced with bCD (HT29/bCD)." | 1.30 | Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. ( Bershad, E; Dev, I; Kievit, E; Lawrence, TS; Ng, E; Rehemtulla, A; Sethna, P, 1999) |
| "A total of 51 stage III colon cancer patients were identified through our tumor registry." | 1.30 | MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy. ( Bell, T; Jones, D; Monk, JS; Toman, J; Wisotzkey, JD, 1999) |
| "Lovastatin treatment resulted in decreased expression of the antiapoptotic protein bcl-2 and increased the expression of the proapoptotic protein bax." | 1.30 | Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. ( Agarwal, B; Bhendwal, S; Halmos, B; Holt, PR; Moss, SF; Ramey, WG, 1999) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "Mice bearing human colon cancer were treated with a combination of 4." | 1.30 | Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts. ( Aburano, T; Hiramatsu, T; Kinuya, S; Konishi, S; Michigishi, T; Shuke, N; Takayama, T; Tega, H; Tonami, N; Watanabe, N; Yokoyama, K, 1999) |
| "To determine the maximum-tolerated dose (MTD) and recommended dose of irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a biweekly LV5FU2 regimen and increasing doses of CPT-11, and to assess the efficacy of this combination in pretreated patients with colorectal cancer (CRC)." | 1.30 | Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ( Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M, 1999) |
| " Pharmacokinetic studies revealed that 1 h after 400 mg/kg EtdUrd administration - i." | 1.30 | 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. ( Erdélyi-Tóth, V; Jeney, A; Katona, C; Kovács, P; Kralovánszky, J; Noordhuis, P; Otvös, L; Pandi, E; Peters, GJ; Van der Wilt, CL, 1999) |
| "At the current time, patients with colon cancer of Dukes stage C should be offered adjuvant chemotherapy with 5-FU/levamisole outside of clinical studies." | 1.29 | [Adjuvant treatment of colonic carcinoma]. ( Herrmann, R; Rochlitz, CF, 1995) |
| "All 1992 phase II colorectal cancer abstracts from the 1992 Proceedings of the American Society of Clinical Oncology were reviewed and analyzed for descriptive and quantitative data and conclusions." | 1.29 | The style of early clinical research reporting: what are we saying and how do we say it? ( Gedney, C; Weissman, DE, 1993) |
| "5-Fluorouracil was given as a continuous infusion during therapy." | 1.29 | Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy in advanced colon cancer. ( Ben-Josef, E; Court, WS, 1995) |
| "CAV is cytotoxic to MIA PaCa-2 human pancreatic cancer cells." | 1.29 | Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies. ( Ang, CY; Crooks, PA; Desai, PB; John, WJ; Rosenthal, GA; Swaffar, DS; Thomas, DA, 1995) |
| "Three gastric, three colon and three breast cancer patients were administered 300 mg/m2 FUra continuously for 10 h per day from 2100 h to 0700 h for more than 20 consecutive days." | 1.29 | Serum concentrations of 5-fluorouracil achieved with nocturnal constant-rate infusion in patients with disseminated cancer. ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1995) |
| "5-Fluorouracil (5-FU) is an effective antitumor agent used in treating various cancers." | 1.29 | 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. ( Chang, CN; Chang, CP; Chen, HX; Cheng, YC; Guo, X; Lerner-Tung, M; Lin, TS; Pizzorno, G; Zhu, JL, 1995) |
| "We examined the importance of dosing interval between leucovorin (LCV) and 5-fluorouracil (5-FU) on intracellular thymidylate synthase (TS) ternary complex, free TS and total TS protein levels in human MCF-7 breast and NCI H630 colon cancer cell lines." | 1.29 | The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. ( Allegra, CJ; Drake, JC; Johnston, PG; Voeller, DM, 1995) |
| "The other five patients with advanced stomach cancer who could not have so good nutrition were receiving home parental nutrition (HPN, 1,200 kcal/day) and continuous or intermittent 5-FU infusion (250-500 mg/body/day) using Lentinan at the same time." | 1.29 | [Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer]. ( Chibai, M; Inomata, Y; Isshi, K; Nakamura, Y; Sakuyama, T; Shimono, S; Tadaoka, N; Takahashi, N; Takamura, S; Yamada, T, 1994) |
| "51 patients with metastatic colorectal cancer (stage Dukes D) were treated with intravenous (i." | 1.29 | Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum. ( Dünser, E; Essl, R; Fritz, E; Mascher, H; Micksche, M; Sagaster, P; Teich, G; Umek, H; Wasilewski, M, 1994) |
| " Because of the potential severity of this interaction, close monitoring of INR and warfarin dosage adjustment is recommended in patients receiving warfarin along with levamisole and 5-FU." | 1.29 | Possible drug interaction between warfarin and combination of levamisole and fluorouracil. ( Israel, MK; Scarfe, MA, 1994) |
| "A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring." | 1.29 | An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. ( Fleming, TR; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tangen, C, 1993) |
| "Cavitation has been shown to hinder colon cancer cell proliferation in vitro." | 1.29 | Increased chemocytotoxicity to colon cancer cells by shock wave-induced cavitation. ( Beaumatin, J; Cathignol, D; Chapelon, JY; Luccioni, C; Pansu, D; Ponchon, T; Prat, F; Sibille, A, 1994) |
| "Survival for carcinoids of the colon was significantly lower compared with carcinoids of the rectum or appendix, and with colon adenocarcinomas." | 1.29 | Colon carcinoid tumors. A population-based study. ( Berkel, H; Jenkins, H; Jewell, L; Spread, C; Yakimets, W, 1994) |
| "A 58-year-old woman with colon cancer, who had received oral 5-FU over 17 months after right hemicolectomy, was diagnosed as having a recurrence of the disease with multiple pulmonary metastasis." | 1.29 | [A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a]. ( Hirata, Y; Ichiki, Y; Kanaya, S; Nakamura, M; Nakano, S; Niho, Y, 1993) |
| " 5-FU oral bioavailability was approximately 100% in rats pretreated with 5-EU." | 1.29 | 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. ( Baccanari, DP; Davis, ST; Knick, VC; Spector, T, 1993) |
| " Cavitation was produced by various SW regimens (250 to 750SW) combined with bubbles (air/gelatin emulsion) infused through an IP catheter." | 1.29 | In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat. ( Cathignol, D; Chapelon, JY; el Fadil, FA; Ponchon, T; Prat, F; Theillère, Y, 1993) |
| " The appropriate dosage of six well-known antitumor drugs [mitomycin C (MMC), cyclophosphamide (CPA), nimustine hydrochloride 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cis-platinum (II) diaminodichloride (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)] in human tumor-bearing nude mice was determined based on the maximum tolerance dose of the drug." | 1.29 | A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors. ( Abe, O; Hattori, T; Imaizumi, M; Kitano, M; Kondo, T; Taguchi, T; Wakui, A, 1993) |
| "Effects of 5-fluorouracil (5-FU) and UFT on an experimental liver metastasis model were compared at equi-effective dosage levels against subcutaneous tumor of mouse colon 26." | 1.29 | Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells. ( Kosaki, G; Kurihara, M; Tominaga, T; Yoshida, Y, 1993) |
| "Sixteen patients with breast cancer were administered epi-adriamycin (Epi-ADM) singly or in a combination of 5-FU and mitomycin C through both subclavicular artery and internal thoracic artery." | 1.29 | [Complications of intra-arterial chemo-infusion using implantable vascular access system]. ( Kikkawa, N; Takatsuka, Y; Tamaki, Y, 1993) |
| "Forty gastric cancer patients and 29 colorectal cancer patients were treated by subselective intraarterial infusion chemotherapy." | 1.29 | [Evaluation of subselective intraarterial infusion chemotherapy in far advanced gastric and colorectal cancer]. ( Fujimoto, T; Kitada, M; Murotani, M; Okumura, Y; Saito, M; Shibata, T; Takada, T; Takami, M; Tsukahara, Y; Watanabe, Y, 1993) |
| "To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients." | 1.29 | A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993) |
| "Tegafur or UFT was administrated orally to patients with gastric or colorectal cancers after surgery for at least a year." | 1.29 | [Evaluation of long-term administration of oral anti-cancer agent]. ( Sakakibara, N; Watanabe, H, 1993) |
| "Two patients (breast and colorectal cancer) achieved a partial remission; two additional cases showed a > 50% decrease in tumor marker levels." | 1.29 | 5-fluorouracil by protracted subcutaneous infusion. A pilot study. ( Alghisi, A; Marini, G; Meriggi, F; Zaniboni, A, 1995) |
| "Peritoneal carcinomatosis has been regarded as a uniformly lethal clinical entity with no specific plan for management." | 1.29 | Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. ( Sugarbaker, PH, 1996) |
| "Distant metastases occurred in 66 patients (54 percent); five-year rate was 72 percent." | 1.29 | Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1996) |
| "Irinotecan and etoposide were combined using the (d x 5)2 i." | 1.29 | Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996) |
| "Thirty-four patients with metastatic colon cancer were treated with 5 fluorouracil and folinic acid." | 1.29 | [Clinical importance of the determination of the hydrophobic forms of serum carcinoembryonic antigen (CEA) in metastatic cancer of the colon]. ( Giovannini, M; Reggio, H; Sauvan, R; Seigner, C, 1995) |
| "The chemosensitivity of various head and neck cancers was investigated with the 5-day rapid thymidine incorporation assay in soft agar culture." | 1.28 | Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application. ( Fujieda, S; Ohtsubo, T; Saito, H; Tanigawa, N, 1992) |
| "Levamisole is an effective antihelminthic drug with immunomodulatory and anticancer activities in model systems." | 1.28 | Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. ( Kovach, JS; Schaid, DJ; Svingen, PA, 1992) |
| " injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg." | 1.28 | Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992) |
| "Hypertriglyceridemia was maintained within acceptable levels, without adjusting the treatment plan, by an appropriate diet and gemfibrosil administration." | 1.28 | Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. ( Berruti, A; Dogliotti, L; Gorzegno, G; Tampellini, M; Vitetta, G, 1992) |
| "5-fluorouracil (5-FU) was infused continuously through an Infuse-A-Port; 360 mg/m2/day for one week after operation, and 180 mg/m2/day for the following three weeks." | 1.28 | [Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer]. ( Kubota, Y; Masaki, T; Ooya, M; Sakaguchi, M; Sameshima, S; Sawada, T; Shinozaki, M; Tsuno, N; Uchiyama, M; Watanabe, T, 1992) |
| "Pretreatment with Brequinar 4 and 24 h prior to administration of [3H]fluorouracil significantly increased incorporation of the fluoropyrimidine into Colon 38 tumor RNA, while minimal effects were seen in normal tissues of C57/BL6 mice." | 1.28 | Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools. ( Handschumacher, RE; Lentz, SK; Pizzorno, G; Wiegand, RA, 1992) |
| "Determined by clonogenic assay in human colon cancer HT-29 cells, the cell survivals for AZT, 10 microM, dipyridamole, 5 microM, and methotrexate (MTX), 0." | 1.28 | Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. ( Taniki, T; Weber, G; Zhen, YS, 1992) |
| " At a tolerable dosage level, bleomycin A6 exerted remarkable growth inhibition on human colon cancer HT-29 and cecum cancer Hce-8693 xenografts (approximately 90% inhibition)." | 1.28 | [Inhibitory effect of bleomycin A6 on human colon cancer xenografts in nude mice]. ( Deng, Y, 1990) |
| " When 50 U/ml IFN-gamma were combined with 5-FU or FUdR, the antiproliferative effects were synergistic in those cell lines with sensitivity to IFN-gamma as a single agent, but not in the IFN-gamma-insensitive cell lines." | 1.28 | The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. ( Boven, E; Haisma, HJ; Maas, IW; Pinedo, HM; Schlüper, HM, 1991) |
| "Presence of hepatomegaly emerged as the more significant (P = 0." | 1.28 | Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. ( Ducreux, M; Elias, D; Lasser, PH; Lumbroso, J; Pignon, JP; Rougier, P; Ruffie, P; Tigaud, JM, 1991) |
| "Eighty-three rats with isolated colon cancer underwent total colectomy; 40 of these rats with no metastases were randomized into two groups: surgery alone or surgery plus 5-FU (5 mg/kg body weight/day) for 5 days after surgery." | 1.28 | Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. ( Ballet, F; Delelo, R; Herve, JP; Nordlinger, B; Panis, Y; Puts, JP, 1991) |
| "The evidence of enhanced response of breast tumors to emoxyl obtained during the histologic examination of xenografts is in good agreement with measurements of tumor fragment weight." | 1.28 | Subrenal capsule assay of human tumor chemosensitivity. ( Diatchkovskaya, RF; Ganieva, LKh; Konovalova, NP; Lapshin, IM; Shapiro, AB; Volkova, LM, 1991) |
| "(3) In hepatic metastasis of breast cancer, arterial infusion therapy was more effective, and the survival period was prolonged significantly." | 1.28 | [Loco-regional cancer therapy for hepatic metastasis]. ( Aogi, K; Jinushi, K; Sawamura, A; Toge, T, 1991) |
| "Only two of them bore colonic cancer." | 1.28 | Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases. ( Fujita, S; Kusunoki, M; Sakanoue, Y; Shoji, Y; Utsunomiya, J; Yamamura, T; Yanagi, H, 1991) |
| "A new human colon cancer cell line (020588) has been derived by means of a combined in vitro matrix-in vivo xenograft technique." | 1.28 | A human colon cancer cell line established from collagen matrix cultures transplanted into nude mice. ( Agrez, MV; Chua, FK; Fagan, K; Ferguson, NW; Heath, JW, 1991) |
| "Pericarditis and cardiac arrhythmias developed, but the patient did not have cardiac tamponade." | 1.28 | Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter. ( Cathcart-Rake, WF; Mowery, WE, 1991) |
| "Because many patients with colon cancer will suffer a relapse we recommend that they be offered the opportunity to participate in clinical trials of adjuvant therapy." | 1.28 | Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication. ( Eisenhauer, E; Erlichman, C; Germond, C; Kerr, I; Levine, M; Lofters, W; Maroun, J; Rayner, HL; Skillings, JR; Yoshida, S, 1991) |
| "A case of iatrogenic sclerosing cholangitis secondary to hepatic intra-arterial 5-fluorouracil (5FU) and Mitomycin C (MMC) chemotherapy is described." | 1.28 | Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy. ( Fukuzumi, S; Makuuchi, M; Moriya, Y; Terui, S, 1990) |
| "5-FU concentration in liver cancer lesion was 0." | 1.28 | [Tissue UFT distribution and histological changes following UFT administration in metastatic liver cancer cases]. ( Amemiya, A; Emoto, T; Fujii, M; Han, N; Itou, A; Iwasaki, T; Tsujimura, T; Yoshikawa, K, 1990) |
| "In case of breast cancer, it was 10 times higher than normal tissue." | 1.28 | [A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon]. ( Adachi, I; Douden, K; Hayashi, H; Hikishima, H; Iwa, T; Munemoto, Y; Okada, Y; Omura, K; Watanabe, Y, 1990) |
| "Two patients had primary hepatocellular cancer (HCC)." | 1.28 | Repeated dearterialization of hepatic tumors with an implantable occluder. ( Bengmark, S; Ekberg, H; Jeppsson, B; Lundstedt, C; Persson, BG; Tranberg, KG, 1990) |
| "Patients with colon cancer involving regional lymph nodes (stage C disease) have a 5-year survival rate of only 30% to 40%, and the majority die of recurrent disease." | 1.28 | New findings in treatment of colon cancer. ( Joseph, RR; Treat, J, 1990) |
| " The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0." | 1.28 | Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ( Albright, MJ; Atkinson, D; Barker, PB; el-Tahtawy, A; King, M; Ong, R; Presant, CA; Ring, R; Servis, KL; Wolf, W, 1990) |
| " Experimental studies suggest that this adverse effect could be due to myocardial accumulation of 5-FU leading to depletion of high energy phosphate compounds." | 1.28 | Acute myocardiotoxicity during 5-fluorouracil therapy. ( Escudier, B; Leclercq, B; Misset, B; Nitenberg, G; Rivara, D; Rougier, P, 1990) |
| "Azidothymidine (10 microM) was synergistically cytotoxic with 5-fluorouracil (0." | 1.28 | Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. ( Ichikawa, S; Nagai, M; Natsumeda, Y; Weber, G, 1990) |
| "In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases)." | 1.28 | [Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT]. ( Hosoi, H; Kitagawa, M; Sinmyo, K; Susaki, H; Suwa, H; Yamaguchi, K, 1989) |
| "Tegafur (FT) is a masked compound of 5-fluorouracil (5-FU) and supposed to be activated in the liver." | 1.28 | [Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction]. ( Imai, S; Nio, Y; Ohgaki, K; Shiraishi, T; Tobe, T, 1989) |
| "Twelve patients with advanced colorectal cancer were subjected to alternating cycles of treatment with low immunomodulating doses of recombinant alpha-interferon (alpha IFN) + 5-fluorouracil (5FU) or with 5FU alone." | 1.28 | Immunochemotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. 1. Toxicological studies. ( Bonmassar, E; Bonmassar, G; Cucchiara, G; De Vecchis, L; Lagomarsino Caprino, M; Nunziata, C; Picconi, A; Ricci, F, 1989) |
| " We studied whether Lev was directly toxic to three human colorectal carcinoma cell lines (HCT 116, SNU-C4, and NCI-H630)." | 1.28 | Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. ( Allegra, CJ; Grem, JL, 1989) |
| "Overall median survival was 352 days in colon cancer and 449 days in gastric cancer." | 1.28 | [A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. ( Arai, Y; Endo, T; Kido, C; Miyake, Y; Sakamoto, K, 1989) |
| "Clinically, 5-formyltetrahydrofolate (leucovorin, folinic acid, LV) in combination with 5-fluorouracil (5-FU) has been used at various doses, schedules, and routes of administration with therapeutic benefit to patients with advanced colorectal carcinoma and breast carcinoma." | 1.28 | Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. ( Rustum, YM, 1989) |
| " With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor." | 1.27 | 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. ( Armstrong, RD; Cadman, E, 1983) |
| "Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment." | 1.27 | Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983) |
| "One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks." | 1.27 | [Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984) |
| " In bioavailability studies of CF p." | 1.27 | Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Campbell, J; Creaven, PJ; Herrera, L; Madajewicz, S; Mittelman, A; Perry, A; Petrelli, N; Rustum, YM, 1984) |
| " Isolated hyperthermic liver perfusion at 40 degrees C with an average dosage of 1000 mg 5-FU was performed in 32 patients with liver metastases (29 colorectal carcinomas, 2 carcinoids, 1 primary hepatoma)." | 1.27 | [Isolated liver perfusion in advanced metastases of colorectal cancers]. ( Aigner, KR; Link, KH; Schoch, P; Schwemmle, K; Tonn, JC; Walther, H, 1984) |
| "CR was observed in one case of breast cancer, and PR in 29 cases." | 1.27 | [Cooperative phase II study of spansule tegafur (SF-SP)]. ( Taguchi, T, 1984) |
| "We studied 161 gastric cancer patients with P0, H(+) and 51 colorectal cancer patients with P0, H(+) from among cancer patients of the digestive organs and obtained the following conclusions." | 1.27 | [Basic and clinical studies on metastatic cancer--with special reference of multidisciplinary treatment of gastric and colorectal cancer patients with hepatic metastasis]. ( Hanaoka, A; Isono, K; Kimura, M; Koide, Y; Okuyama, K; Onoda, S; Ryu, M; Satoh, H; Tohnosu, N; Yamamoto, Y, 1983) |
| "To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0." | 1.27 | [Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer]. ( Hirooka, Y; Kanayama, H; Koga, S; Maeta, M; Murakami, A; Oda, M; Osaki, Y, 1984) |
| "We report 19 patients with metastatic colon cancer whose bulk disease was limited to the liver, but was not amenable to surgical resection." | 1.27 | Hepatic artery ligation and portal vein infusion for liver metastases from colon cancer. ( Courter, S; Guy, JF; Guy, JT; Laufman, LR; Nims, TA, 1984) |
| "Spontaneous metastasis of highly metastatic variants, B16 melanoma BL-6 and colon adenocarcinoma 26 NL-22, was examined." | 1.27 | Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis. ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "Exponentially growing cells of human cancer lines have been utilized to investigate the cytotoxic activity of antineoplastic agents." | 1.27 | The use of human cancer cell lines as a primary screening system for antineoplastic compounds. ( Baguley, BC; Finlay, GJ, 1984) |
| "Eighty Wistar rats received a colon cancer producing regimen on DMH (40 mg/kg body weight/week, subcutaneously for 10 weeks)." | 1.27 | Combination chemotherapy with 5-fluorouracil (5FU) and 1,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) prolongs survival of rats with dimethylhydrazine-induced colon cancer. ( Clark, CG; Cruse, JP; Danzi, M; Lewin, MR, 1983) |
| "Two cohorts of rats, 240 with colon cancer and 150 controls, were assessed clinically and immunologically for their response to tumour and its management which was either by surgical excision alone or by surgical excision combined with either adjuvant chemotherapy or immunotherapy." | 1.27 | Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model. ( House, AK; Maley, MA, 1983) |
| "Of 29 evaluable patients with breast cancer (six of whom had received prior chemotherapy), one achieved a complete response and five achieved a partial response (total response rate, 21%)." | 1.27 | Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study. ( Calman, KC; Crossling, F; Ferguson, C; George, WD; Habeshaw, T; Hutcheon, A; Kaye, SB; McArdle, C; Sangster, G; Smith, D, 1984) |
| " Paradoxical dose-response relationships for cytostatic agents or radiation in vitro point to artifacts." | 1.27 | Chemosensitivity testing of human neoplasms using the soft agar colony assay. ( Flentje, D; Schlag, P, 1984) |
| "Tumor metastasis was examined after iv inoculation of highly metastatic variants of mouse tumors." | 1.27 | Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. ( Hori, K; Kawabata, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "5-Fluorouracil was administered intraperitoneally in maximally tolerated doses from week 26 onwards and failed to influence significantly the development of either benign or malignant tumours." | 1.27 | Chemotherapy of chemically-induced colorectal tumours. ( Gilbert, JM; Kark, AE; Slavin, G; Thompson, EM, 1983) |
| "However, against colo-rectal and stomach cancer, the response rate was only 25% (2/8) and 28." | 1.27 | [Chemotherapy and total body hyperthermia]. ( Kato, N; Yamanaka, N, 1985) |
| "Pseudomyxoma peritonei is an unusual malignancy arising from the goblet cells of the large bowel or appendix." | 1.27 | Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. ( Kern, K; Lack, E; Sugarbaker, PH, 1987) |
| "The chemosensitivity of human colorectal cancer was studied in relation to the biological features of the tumor using a human tumor/nude mouse in-vivo system." | 1.27 | Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice. ( Yamada, K, 1987) |
| " In 10 of these tumors, comparative dose-response curves were obtained." | 1.27 | Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA). ( Flentje, D; Flentje, M; Schlag, P, 1986) |
| " Furthermore the differing levels of 5-FU metabolites in normal and malignant tissue could not be correlated with the pharmacokinetic parameters studied." | 1.27 | The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. ( Chisholm, EM; Finan, PJ; Giles, GR; Woodhouse, L, 1987) |
| "All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls." | 1.27 | Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985) |
| "Effect of this treatment on the pain could be evaluated in 16 patients." | 1.27 | Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985) |
| "The mitomycin C and BCNU were alternated monthly at the start of each FUDR cycle." | 1.27 | Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. ( Cohen, AM; Higgins, J; Schaeffer, N, 1986) |
| "Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea." | 1.27 | The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986) |
| " However, increase in tegafur dosage volume did not correlate with 5-FU levels." | 1.27 | [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur]. ( Arima, S; Futami, K; Kinashi, M; Shigeta, M; Shimura, H, 1986) |
| "Five-fluorouracil was measured by GC-MF method and FT-207 was also done by HPLC method." | 1.27 | [The effect of tegafur suppository and glutathione in patients with gastric and colonic cancer with special reference to the histopathological anticancer effect]. ( Fukuzumi, N; Ikeda, Y; Kaga, F; Kitajima, M; Kiuchi, T; Okada, N, 1987) |
| "The sensitivity of human colorectal cancer to 5-fluorouracil (5-FU) and its derivatives: 1-(tetrahydro-2-furyl)-5-FU (tegafur) and 1-hexylcarbamoyl-5-FU (HCFU) was determined by in vitro succinate dehydrogenase inhibition (SDI) test and in vivo subrenal capsule (SRC) assay." | 1.27 | [Human colorectal carcinoma is more sensitive to HCFU than 5-FU and tegafur in in vitro and in vivo drug sensitivity tests]. ( Anai, H; Fukuchi, K; Kusumoto, H; Kusumoto, T; Maehara, Y; Miyamoto, K; Sugimachi, K, 1988) |
| "Since colorectal cancer tissues are resistant to various antitumor drugs, the chemosensitivity test of HCFU should aid in determining the effects of a particular drug for an individual patient." | 1.27 | Colorectal carcinoma in vitro is more sensitive to 1-hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, Adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil. ( Anai, H; Kusumoto, H; Kusumoto, T; Maehara, Y; Sugimachi, K, 1988) |
| "Fifteen patients with stomach cancer and colorectal cancer were orally administered 600 mg of UFT before operation and the concentration of tegafur, 5-fluorouracil (5-FU) and uracil in the tissues and serum were measured by chemical assay." | 1.27 | [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT]. ( Kikuchi, K; Kunii, Y; Mori, Y; Nitta, A; Saitou, T; Takahashi, N, 1988) |
| "Excisions of metastatic liver cancer were performed in 23 pts and 15 pts had nonresectable metastatic liver cancer." | 1.27 | [Results of intra-arterial infusion chemotherapy in colorectal cancer patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1988) |
| "Flavone acetic acid (FAA) is a compound with proven activity against various transplantable colon cancers in mice." | 1.27 | Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512). ( D'Incalci, M; Damia, G; Manzotti, C; Pratesi, G, 1988) |
| "Fluorodeoxyuridylate (FdUMP) was assayed by isotope dilution of [3H]FdUMP binding to bacterial TS; free and total TS was determined by [3H]FdUMP binding; and deoxyuridylate (dUMP) was assayed by conversion to [14C]thymidylate." | 1.27 | Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. ( Berne, M; Bernstein, L; Frösing, R; Gustavsson, BG; Hayes, AA; Spears, CP, 1988) |
| "Twenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5 IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days." | 1.27 | High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. ( Bartolucci, R; Brugia, M; Buzzi, F; Di Costanzo, F; Padalino, D, 1988) |
| "However, it is unfortunate that colorectal cancer screening in young patients is difficult because of the low rates of precancerous states (4%)." | 1.27 | Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. ( Astre, C; Domergue, J; Ismail, M; Joyeux, H; Pujol, H; Saint-Aubert, B; Solassol, C, 1988) |
| " Fifty-one rats with hepatic tumors of colonic origin were randomly assigned to one of three dosage groups (20, 40, or 80 mg/kg) receiving 5-FU by ILP, hepatic artery infusion (HAI), or jugular vein infusion (JVI)." | 1.27 | In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. ( Bell, AV; de Brauw, LM; de Bruijn, EA; Hermans, J; Tjaden, UR; van de Velde, CJ; Zwaveling, A, 1988) |
| " There have been a number of reports relating the plasma levels of cytotoxic agents with pharmacodynamic parameters." | 1.27 | Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. ( Goldberg, JA; Kerr, DJ; McArdle, CS; McKillop, JH; Willmott, N, 1988) |
| "In analysing the anticancer effects of TBHT according to cancer site, a high efficacy was observed in patients with their main tumor in the lung, liver and lymph nodes." | 1.27 | [Clinical results and problems of total-body thermochemotherapy]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T, 1988) |
| "In patients with colorectal cancer metastatic to the liver, partial response (PR) rates in Regimens I and II were 38% and 62%, respectively." | 1.27 | Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers. ( Hamazoe, R; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawada, T; Shimizu, N, 1988) |
| "32 cases of colon cancer were given I/V 5-fluorouracil for at least one year." | 1.27 | Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital. ( Chia, KB; Chua, EJ; Khor, TH; Sethi, VK; Tan, BC; Tan, TM, 1987) |
| "Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d." | 1.27 | High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986) |
| "Colorectal cancer is one of the most resistant tumors to chemotherapy." | 1.27 | [Chemotherapy of advanced and recurrent colorectal cancer]. ( Tominaga, T, 1986) |
| "In summary, in this phase II study on gastric cancer, although the response was limited with A, the relatively high response rate of 40." | 1.27 | [Biochemical modulation with sequential methotrexate (MTX)-5-fluorouracil (5-FU) treatment]. ( Murakami, M; Ota, K, 1987) |
| "We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days." | 1.27 | High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. ( Astone, A; Barone, C; Cassano, A; Cavallaro, A; Garufi, C; Grieco, A; Netri, G; Noviello, MR; Ricevuto, E; Rossi, S, 1987) |
| "In the colorectal cancer group, the response rate for Regimen A was 28." | 1.27 | [Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group]. ( Akazawa, S; Futatsuki, K; Kanamaru, R; Miyazaki, T; Murakami, M; Niitsu, Y; Ota, K; Sakai, Y; Wakui, A; Yokoyama, M, 1987) |
| "4 of the 23 completed cases with stomach cancer were judged as PR, and the response rate was 19." | 1.27 | [Phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Group]. ( Furue, H; Nakatsu, T; Takahashi, H, 1987) |
| "Patients with metastatic colorectal cancer confined to the liver received fluorodeoxyuridine (FUdR) through the hepatic artery or through the portal vein." | 1.27 | Tumor and liver drug uptake following hepatic artery and portal vein infusion. ( Daly, JM; Kemeny, N; Ridge, JA; Sigurdson, ER, 1987) |
| "Eleven non-resectable cancer patients have been successfully treated by means of a one-shot and continuous intra-arterial infusion chemotherapy, utilizing an implantable vascular access device (Catheter Access) connected to a continuous infusion pump (Nipro portable syringe infusion pump) via a non-corning needle (Nipro coreless needle set)." | 1.27 | [Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump]. ( Agishi, T; Fuchinoue, S; Honda, H; Nakagawa, Y; Nakazawa, H; Ohta, K; Takahashi, K; Teraoka, S, 1987) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| " While the in vitro studies failed to reveal any synergism between 5-FU and MND, pharmacokinetic evaluation revealed that 5-FU clearance was significantly reduced (26." | 1.27 | 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. ( Ayoub, J; Bardakji, Z; Besner, JG; Jolivet, J; Langelier, Y, 1986) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 1.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "Five patients with colorectal cancer and unresectable synchronous liver metastases have survived for over five years at this writing." | 1.27 | Long-term survivors of colorectal cancer with unresectable hepatic metastases. ( Fujimoto, S; Higuchi, M; Kitsukawa, Y; Miyazaki, M; Okui, K, 1985) |
| "A 61-year-old man with double colon cancers and a solitary hepatic metastasis underwent right hemicolectomy and catheterization of the proper hepatic artery in April 1979." | 1.27 | [A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy]. ( Itoh, J; Koyama, K; Masuda, T; Narisawa, T, 1985) |
| "Multimodality therapy for colorectal cancer is composed of surgery, chemotherapy and irradiation; and hyperthermia joins them recently." | 1.27 | [Multimodality therapy of colorectal cancer]. ( Fujimoto, S; Miyazaki, M; Okui, K, 1985) |
| "5-Fluorouracil treatments resulted in a dose-dependent inhibition of tumor growth under the two examined schedules (five daily doses and three doses every 4 days) when administered either i." | 1.27 | 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. ( Frei, E; Goldin, A; Mantel, N; VanWinkle, TJ; Zimmerman, RJ, 1986) |
| " 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule." | 1.27 | Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer. ( Ahmann, FR; Garewal, H; Greenberg, BR, 1986) |
| "Thirty-six patients with advanced colorectal cancer whose disease progressed during treatment with 5-fluorouracil (5-FU) chemotherapy were treated with methyl-CCNU and methotrexate." | 1.27 | Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy. ( Bazos, MJ; Evans, WK; Myers, R; Shepherd, FA; Zorzitto, ML, 1986) |
| "The Southwest Oncology Group conducted a pilot study in patients who had had total clinical resection of cancer of the colon and had a high risk of recurrence (Duke's C); the purpose of the study was to determine the toxic effects of intra-arterial chemotherapy combined with hepatic radiotherapy, in anticipation of their potential use in an adjuvant groupwide protocol." | 1.27 | Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study. ( Boyer, C; Janaki, L; McCracken, JD; Oishi, N; Weatherall, TJ, 1985) |
| "In group A for gastric cancer and in group C for colon cancer, the histological response was stronger at the edge of the cancer than at its surface." | 1.27 | [Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer]. ( Hashizume, Y; Hirano, M; Iwa, T; Kawaura, Y; Ohmura, K; Sakatoku, M; Takayama, K; Yamada, T, 1985) |
| " In pharmacokinetic studies in five patients, both schedules produced prolonged plasma beta-half-lives of 5-FU (96-189 minutes)." | 1.27 | Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma. ( Chun, H; Kemeny, N; Lynch, G; Martin, D; Young, C, 1985) |
| "Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses." | 1.27 | A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. ( Ford, J; Margolese, R; Panasci, L, 1985) |
| "Allopurinol has been shown to decrease the gastro-intestinal and bone marrow toxicity of 5-fluorouracil." | 1.27 | Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. ( Clark, PI; Slevin, ML, 1985) |
| "Treatment of colorectal cancer beyond surgical resection has had only minimal success in the past." | 1.27 | Colorectal cancer: speculations on the role of intraperitoneal therapy. ( Muggia, FM, 1985) |
| "Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy." | 1.26 | Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. ( Goldenberg, DM; Nelson, MO; Pant, KD; Shochat, D, 1982) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma." | 1.26 | Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982) |
| "A retrospective study of 37 colorectal cancer patients with synchronous liver metastases was made." | 1.26 | Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer. ( Fujimoto, S; Kitsukawa, Y; Miyazaki, M; Okui, K, 1981) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| " Further evaluation of vindesine will require dosage modification." | 1.26 | Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea. ( Bedikian, AY; Bennetts, RW; Bodey, GP; Karlin, DA; Stroehlein, JR; Valdivieso, M, 1982) |
| "Twenty-seven patients with liver metastasis from colorectal cancer were treated with intrahepatic arterial chemotherapy and external radiotherapy consisting of 5-fluorouracil (5-FU) (10 mg/kg/day for 8 days), adriamycin (5 mg/m2/day for 7 days) and methotrexate (MTX) (240 mg/m2/X1), combined with 2,100 rads of whole liver irradiation." | 1.26 | Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate. ( Friedman, MA; Phillips, TL; Resser, KJ; Volberding, PA, 1982) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | 1.26 | Chemotherapy for gastrointestinal malignancy. ( Balint, JA; Van der Veer, LD, 1980) |
| "Tobramycin excretion was 8." | 1.26 | Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. ( Levin, MJ; Mayer, RJ; Siber, GR, 1980) |
| "The role of chemotherapy in colorectal cancer is still not precisely defined." | 1.26 | [Incurable colorectal cancer. Possibilities and limits of differentiated therapy (author's transl)]. ( Rauchenberger, B; Winkler, R, 1977) |
| "A group of 24 patients with colorectal cancer and another group of 28 patients with 13 different primaries were treated." | 1.26 | Treatment of hepatic metastases by percutaneous hepatic arterial infusion. ( Minton, JP; Petrek, JA, 1979) |
| "Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2." | 1.26 | Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study. ( Buroker, T; Groppe, C; Guy, G; Heilbrun, L; Hoogstraten, B; McCracken, J; Padilla, F; Quagliana, J; Vaitkevicius, VK, 1979) |
| "Fifty-two patients with advanced colorectal cancer were treated with a combination of 5-Fluorouracil (FU) plus methyl-1,3-cis (2-chlorethyl)-1-nitrosourea (MeCCNU)." | 1.26 | Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer. ( Frei, E; Lokich, JJ; Mayer, RJ; Skarin, AT, 1977) |
| "The therapy of cancer of the colon still remains unsatisfactory: the rate of remissions could be increased, but survival remains unaltered." | 1.26 | [Current state of therapy for gastrointestinal tumors]. ( Hartmann, D; Obrecht, JP, 1978) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| "Metastases were from colon cancer in 13 and from other primary cancers in 6." | 1.25 | Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: clinical and pathophysiological results. ( Hallauer, WC; Morton, DL; Mosher, MB; Passaro, E; Rangel, D; Silverstein, MJ; Sparks, FC, 1975) |
| "The roles of lysosomal enzymes in colorectal cancer are discussed." | 1.25 | Arylsulfatse B in colorectal cancer. ( Krementz, ET; Meeker, W; Morgan, LR; Samuels, MS; Thomas, W, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 871 (23.91) | 18.7374 |
| 1990's | 636 (17.46) | 18.2507 |
| 2000's | 828 (22.73) | 29.6817 |
| 2010's | 947 (26.00) | 24.3611 |
| 2020's | 361 (9.91) | 2.80 |
| Authors | Studies |
|---|---|
| Rewcastle, GW | 1 |
| Atwell, GJ | 1 |
| Baguley, BC | 2 |
| Calveley, SB | 1 |
| Denny, WA | 1 |
| Tezuka, Y | 4 |
| Gewali, MB | 1 |
| Ali, MS | 1 |
| Banskota, AH | 4 |
| Kadota, S | 4 |
| Tran, QL | 1 |
| Tran, QK | 1 |
| Saiki, I | 2 |
| Usia, T | 2 |
| Midorikawa, K | 1 |
| Matsushige, K | 1 |
| Kouda, K | 1 |
| Nguyen, NT | 1 |
| Otrubova, K | 1 |
| McGuire, KL | 1 |
| McAlpine, SR | 1 |
| Tangeda, SJ | 1 |
| Garlapati, A | 1 |
| Reddy, DM | 1 |
| Qazi, NA | 1 |
| Sawant, SD | 1 |
| Bandey, AH | 1 |
| Srinivas, J | 1 |
| Shankar, M | 1 |
| Singh, SK | 1 |
| Verma, M | 1 |
| Chashoo, G | 1 |
| Saxena, A | 1 |
| Mondhe, D | 1 |
| Saxena, AK | 1 |
| Sethi, VK | 2 |
| Taneja, SC | 1 |
| Qazi, GN | 1 |
| Sampath Kumar, HM | 1 |
| Liu, W | 8 |
| Zhou, J | 4 |
| Zhang, T | 3 |
| Zhu, H | 8 |
| Qian, H | 1 |
| Zhang, H | 11 |
| Huang, W | 3 |
| Gust, R | 1 |
| Helal, M | 1 |
| Das, U | 3 |
| Bandy, B | 2 |
| Islam, A | 1 |
| Nazarali, AJ | 1 |
| Dimmock, JR | 3 |
| Das, S | 2 |
| Michel, D | 1 |
| Gorecki, DK | 1 |
| Mansoor, TA | 1 |
| Borralho, PM | 5 |
| Luo, X | 3 |
| Mulhovo, S | 3 |
| Rodrigues, CM | 5 |
| Ferreira, MJ | 2 |
| Ai, Y | 1 |
| Kang, F | 1 |
| Huang, Z | 4 |
| Xue, X | 1 |
| Lai, Y | 2 |
| Peng, S | 1 |
| Tian, J | 2 |
| Zhang, Y | 16 |
| Wang, F | 4 |
| Yang, Z | 7 |
| Liu, Y | 19 |
| Ma, L | 2 |
| Wu, Y | 9 |
| He, L | 1 |
| Shao, M | 1 |
| Yu, K | 1 |
| Wu, W | 1 |
| Pu, Y | 1 |
| Nie, C | 1 |
| Chen, L | 5 |
| Paterna, A | 2 |
| Gomes, SE | 3 |
| Weidner, C | 1 |
| Rousseau, M | 1 |
| Micikas, RJ | 1 |
| Fischer, C | 1 |
| Plauth, A | 1 |
| Wowro, SJ | 1 |
| Siems, K | 1 |
| Hetterling, G | 1 |
| Kliem, M | 1 |
| Schroeder, FC | 1 |
| Sauer, S | 1 |
| Ferreira, MU | 1 |
| Kim, JW | 2 |
| Kim, HP | 1 |
| Sung, SH | 1 |
| Addala, E | 1 |
| Rafiei, H | 1 |
| Karki, SS | 1 |
| Haque, MA | 1 |
| Sailo, BL | 1 |
| Padmavathi, G | 1 |
| Kunnumakkara, AB | 2 |
| Jana, CK | 1 |
| Zou, Y | 3 |
| Hu, Y | 4 |
| Ge, S | 1 |
| Zheng, Y | 7 |
| Li, Y | 14 |
| Guo, W | 4 |
| Xu, Q | 3 |
| Witkowska, M | 1 |
| Maciejewska, N | 1 |
| Ryczkowska, M | 1 |
| Olszewski, M | 1 |
| Bagiński, M | 1 |
| Makowiec, S | 1 |
| Hu, X | 9 |
| Li, J | 26 |
| Yu, Q | 2 |
| Wang, Y | 22 |
| Li, X | 10 |
| Long, L | 1 |
| Jiang, W | 4 |
| Wang, Z | 9 |
| Gao, J | 4 |
| Logan, KA | 1 |
| Nesbitt, H | 1 |
| Callan, B | 1 |
| McKaig, T | 1 |
| Taylor, M | 2 |
| Love, M | 1 |
| McHale, AP | 1 |
| Griffith, DM | 1 |
| Callan, JF | 1 |
| Yin, J | 2 |
| Salem, ME | 3 |
| Dixon, JG | 2 |
| Jin, Z | 1 |
| Cohen, R | 3 |
| DeGramont, A | 2 |
| Van Cutsem, E | 23 |
| Taieb, J | 32 |
| Alberts, SR | 21 |
| Wolmark, N | 33 |
| Schmoll, HJ | 14 |
| Saltz, LB | 14 |
| George, TJ | 6 |
| Goldberg, RRM | 1 |
| Kerr, R | 6 |
| Lonardi, S | 17 |
| Yoshino, T | 23 |
| Yothers, G | 33 |
| Grothey, A | 24 |
| Andre, T | 35 |
| Shi, Q | 22 |
| Boyle, JM | 1 |
| Kuryba, A | 1 |
| Cowling, TE | 1 |
| van der Meulen, J | 2 |
| Fearnhead, NS | 1 |
| Walker, K | 1 |
| Braun, MS | 2 |
| Aggarwal, A | 1 |
| Cui, Z | 2 |
| Wang, Q | 3 |
| Deng, MH | 1 |
| Han, QL | 1 |
| Hou, XY | 1 |
| Zhang, P | 2 |
| Du, HZ | 1 |
| Gao, YQ | 1 |
| Sun, RQ | 1 |
| Qin, SY | 1 |
| Tian, Y | 4 |
| Zhang, YX | 1 |
| Chu, WH | 1 |
| Zhang, ZJ | 2 |
| Xu, FG | 1 |
| Gao, S | 1 |
| Soares, F | 1 |
| Wang, S | 5 |
| Wong, CC | 1 |
| Chen, H | 5 |
| Go, MYY | 1 |
| Ahmed, M | 1 |
| Zeng, Y | 1 |
| O'Brien, CA | 1 |
| Sung, JJY | 1 |
| He, HH | 1 |
| Yu, J | 6 |
| Dung, DTM | 1 |
| Park, EJ | 3 |
| Anh, DT | 1 |
| Hai, PT | 1 |
| Huy, LD | 1 |
| Jun, HW | 1 |
| Kwon, JH | 2 |
| Young Ji, A | 1 |
| Kang, JS | 1 |
| Tung, TT | 1 |
| Dung, PTP | 1 |
| Han, SB | 1 |
| Nam, NH | 1 |
| Arai, H | 4 |
| Xiao, Y | 2 |
| Millstein, J | 3 |
| Wang, J | 26 |
| Battaglin, F | 3 |
| Kawanishi, N | 3 |
| Jayachandran, P | 3 |
| Soni, S | 3 |
| Zhang, W | 17 |
| Mancao, C | 3 |
| Salhia, B | 1 |
| Mumenthaler, SM | 1 |
| Parikh, AR | 1 |
| Lenz, HJ | 20 |
| Rosati, G | 7 |
| Corsi, D | 3 |
| Avallone, A | 3 |
| Brugnatelli, S | 1 |
| Dell'Aquila, E | 2 |
| Cinausero, M | 1 |
| Aprile, G | 2 |
| Cicero, G | 2 |
| Carlomagno, C | 3 |
| Colombo, A | 2 |
| Rapisardi, S | 2 |
| Pinto, C | 3 |
| Reggiardo, G | 1 |
| Bilancia, D | 3 |
| Duarte, D | 4 |
| Vale, N | 5 |
| Li, S | 8 |
| Xu, Z | 2 |
| Alrobaian, M | 1 |
| Afzal, O | 1 |
| Kazmi, I | 1 |
| Almalki, WH | 1 |
| Altamimi, ASA | 1 |
| Al-Abbasi, FA | 1 |
| Alharbi, KS | 1 |
| Altowayan, WM | 1 |
| Singh, T | 1 |
| Akhter, MH | 1 |
| Gupta, M | 2 |
| Rahman, M | 3 |
| Beg, S | 1 |
| Oneda, E | 2 |
| Zaniboni, A | 18 |
| Liu, S | 3 |
| Wu, J | 6 |
| Sun, Z | 3 |
| Lee, M | 6 |
| Yang, C | 4 |
| Park, S | 3 |
| Song, G | 1 |
| Lim, W | 1 |
| Peng, Y | 2 |
| Qiu, L | 1 |
| Cianciosi, D | 3 |
| Forbes-Hernández, TY | 2 |
| Regolo, L | 1 |
| Alvarez-Suarez, JM | 2 |
| Quinzi, D | 1 |
| Sargenti, A | 1 |
| Bai, W | 2 |
| Tian, L | 1 |
| Giampieri, F | 3 |
| Battino, M | 3 |
| Lee, J | 6 |
| Koom, WS | 2 |
| Byun, HK | 1 |
| Yang, G | 3 |
| Kim, MS | 2 |
| Ahn, JB | 8 |
| Beom, SH | 4 |
| Kim, HS | 3 |
| Shin, SJ | 6 |
| Kim, K | 4 |
| Chang, JS | 1 |
| Pumpalova, Y | 2 |
| Rogers, AM | 2 |
| Tan, SX | 2 |
| Herbst, CL | 2 |
| Ruff, P | 2 |
| Neugut, AI | 5 |
| Hur, C | 2 |
| Baxter, NN | 3 |
| Kennedy, EB | 1 |
| Bergsland, E | 1 |
| Berlin, J | 1 |
| Gill, S | 14 |
| Gold, PJ | 1 |
| Hantel, A | 5 |
| Jones, L | 1 |
| Lieu, C | 1 |
| Mahmoud, N | 1 |
| Morris, AM | 1 |
| Ruiz-Garcia, E | 1 |
| You, YN | 2 |
| Meyerhardt, JA | 13 |
| Meirovitz, A | 2 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 2 |
| Nixon, AB | 2 |
| Sibley, AB | 1 |
| Hatch, AJ | 1 |
| Jiang, C | 2 |
| Mulkey, F | 1 |
| Starr, MD | 1 |
| Brady, JC | 1 |
| Niedzwiecki, D | 12 |
| Venook, AP | 7 |
| Baez-Diaz, L | 1 |
| O'Neil, BH | 3 |
| Innocenti, F | 3 |
| O'Reilly, EM | 3 |
| Owzar, K | 1 |
| Hurwitz, HI | 2 |
| Jafari, MD | 1 |
| Carmichael, JC | 1 |
| Dayyani, F | 1 |
| McKinney, C | 1 |
| Wenzel, L | 1 |
| Zell, JA | 1 |
| Pigazzi, A | 1 |
| Rong, X | 2 |
| Liu, H | 4 |
| Yu, H | 2 |
| Zhao, J | 5 |
| Fernández Montes, A | 1 |
| Élez, E | 3 |
| Vivancos, A | 1 |
| Martínez, N | 1 |
| González, P | 1 |
| Covela, M | 1 |
| de la Cámara, J | 2 |
| Cousillas, A | 1 |
| Méndez, JC | 2 |
| Graña, B | 2 |
| Aranda, E | 7 |
| Arbag, HC | 1 |
| Sumbul, HE | 1 |
| Buyuksimsek, M | 1 |
| Ogul, A | 1 |
| Yetisir, AE | 1 |
| Koseci, T | 1 |
| Bozkurt Duman, B | 1 |
| Tohumcuoglu, M | 1 |
| Kesen, O | 1 |
| Cil, T | 1 |
| Nagahisa, S | 1 |
| Watanabe, M | 8 |
| Minagi, H | 1 |
| Ogawa, T | 2 |
| Araki, H | 2 |
| Kimura, Y | 1 |
| Taniguchi, F | 1 |
| Arata, T | 1 |
| Katsuda, K | 1 |
| Tanakaya, K | 4 |
| Aoki, H | 1 |
| Shibahara, H | 1 |
| Shiroiwa, T | 2 |
| Ishiguro, M | 4 |
| Nakamura, M | 10 |
| Hasegawa, J | 7 |
| Yamaguchi, S | 7 |
| Masuda, Y | 1 |
| Sakamoto, J | 15 |
| Tomita, N | 4 |
| Fukuda, T | 2 |
| Pfab, C | 1 |
| Abgaryan, A | 1 |
| Danzer, B | 1 |
| Mourtada, F | 1 |
| Ali, W | 1 |
| Gessner, A | 1 |
| El-Najjar, N | 1 |
| McCleary, NJ | 3 |
| Zhang, S | 12 |
| Ma, C | 4 |
| Ou, FS | 3 |
| Bainter, TM | 1 |
| Polite, BN | 1 |
| Hochster, HS | 1 |
| Atkins, JN | 6 |
| Goldberg, RM | 41 |
| Ng, K | 4 |
| Mayer, RJ | 18 |
| Blanke, CD | 4 |
| Fuchs, CS | 10 |
| Takii, Y | 4 |
| Mizusawa, J | 3 |
| Kanemitsu, Y | 3 |
| Komori, K | 1 |
| Shiozawa, M | 8 |
| Ohue, M | 2 |
| Ikeda, S | 1 |
| Takiguchi, N | 1 |
| Kobatake, T | 1 |
| Ike, H | 2 |
| Sato, T | 6 |
| Ota, M | 3 |
| Masaki, T | 4 |
| Hamaguchi, T | 7 |
| Shida, D | 2 |
| Katayama, H | 1 |
| Shimada, Y | 13 |
| Fukuda, H | 5 |
| Niu, H | 1 |
| Zhao, M | 3 |
| Huang, J | 6 |
| Si, Y | 1 |
| Cheng, S | 1 |
| Ding, W | 1 |
| Atci, MM | 1 |
| Akagunduz, B | 1 |
| Demir, M | 1 |
| Arikan, R | 1 |
| Ay, S | 1 |
| Ozer, M | 1 |
| Ayhan, M | 1 |
| Cil, I | 1 |
| Demir, N | 2 |
| Ozyurt, N | 1 |
| Karakaya, G | 1 |
| Cevik, GT | 1 |
| Onder, AH | 1 |
| Selvi, O | 1 |
| Sakin, A | 3 |
| Tsai, HL | 5 |
| Chen, YC | 3 |
| Yin, TC | 2 |
| Su, WC | 1 |
| Chen, PJ | 1 |
| Chang, TK | 1 |
| Li, CC | 1 |
| Huang, CW | 5 |
| Wang, JY | 9 |
| Samoon, Z | 1 |
| Naher, SK | 1 |
| Sjoquist, KM | 1 |
| Zalcberg, J | 3 |
| Cha, Y | 1 |
| Xiong, H | 1 |
| Yuan, X | 1 |
| Murray, NP | 1 |
| Villalon, R | 1 |
| Hartmann, D | 2 |
| Rodriguez, PM | 1 |
| Aedo, S | 1 |
| Alarid-Escudero, F | 1 |
| Schrag, D | 4 |
| Kuntz, KM | 1 |
| Ge, P | 1 |
| Reyila, A | 1 |
| Li, XY | 1 |
| Liu, SY | 1 |
| Jiang, YX | 1 |
| Yang, YJ | 1 |
| Li, XL | 1 |
| Bian, Y | 1 |
| Jo, H | 1 |
| Lee, MS | 1 |
| Lee, YP | 1 |
| Kim, H | 7 |
| Hong, JY | 1 |
| Park, SH | 2 |
| Park, JO | 4 |
| Park, YS | 9 |
| Lim, HY | 2 |
| Kang, WK | 5 |
| Kim, ST | 3 |
| Tang, J | 1 |
| Du, Y | 1 |
| Bai, F | 1 |
| Yang, L | 6 |
| Jin, X | 3 |
| Wang, T | 4 |
| Alkis, ME | 1 |
| Akdag, MZ | 1 |
| Kandemir, SI | 1 |
| Booth, L | 1 |
| West, C | 3 |
| Von Hoff, D | 1 |
| Dent, P | 1 |
| Liang, YH | 1 |
| Liang, JT | 3 |
| Lin, BR | 1 |
| Hung, JS | 1 |
| Lai, SL | 1 |
| Chen, TC | 2 |
| Tsai, JH | 1 |
| Cheng, YM | 1 |
| Tsao, TH | 1 |
| Hsu, WL | 1 |
| Chen, KH | 1 |
| Yeh, KH | 3 |
| Pan, SL | 1 |
| Deng, YY | 1 |
| Fu, J | 3 |
| Zhang, YH | 1 |
| Qin, XJ | 1 |
| Matsubara, Y | 1 |
| Masuishi, T | 2 |
| Ogata, T | 1 |
| Nakazawa, T | 2 |
| Kato, K | 3 |
| Nozawa, K | 1 |
| Narita, Y | 1 |
| Honda, K | 3 |
| Bando, H | 4 |
| Taniguchi, H | 6 |
| Kadowaki, S | 1 |
| Ando, M | 5 |
| Tajika, M | 2 |
| Muro, K | 8 |
| Sabry, NM | 1 |
| Naguib, TM | 1 |
| Kabel, AM | 1 |
| Khafagy, ES | 1 |
| Arab, HH | 1 |
| Almorsy, WA | 1 |
| Punt, CJA | 4 |
| Kwakman, JJM | 1 |
| Mol, L | 2 |
| Kim, JG | 2 |
| Baik, SH | 2 |
| Shin, SH | 2 |
| Park, I | 1 |
| Lee, MA | 1 |
| Lee, S | 4 |
| Jeon, SY | 1 |
| Han, SW | 5 |
| Kang, MH | 1 |
| Oh, J | 2 |
| Kim, JS | 6 |
| Kim, JY | 6 |
| Ahn, MS | 1 |
| Zang, DY | 3 |
| Bae, BN | 1 |
| Jo, HJ | 1 |
| Kim, HK | 2 |
| Kim, JH | 11 |
| Yoon, JA | 1 |
| Kim, DH | 2 |
| Bello Crespo, M | 1 |
| Trujillano Ruiz, A | 1 |
| Gajete Pablos, MA | 1 |
| Roa García, DM | 1 |
| Gioseffi, HA | 1 |
| Satake, H | 4 |
| Kagawa, Y | 5 |
| Shinozaki, E | 4 |
| Tanizawa, Y | 1 |
| Jin, L | 1 |
| Cai, Z | 2 |
| Makiyama, A | 6 |
| Hegazy, SK | 1 |
| El-Azab, GA | 1 |
| Zakaria, F | 1 |
| Mostafa, MF | 1 |
| El-Ghoneimy, RA | 1 |
| Wu, H | 3 |
| Du, J | 1 |
| Li, C | 5 |
| Li, H | 8 |
| Guo, H | 2 |
| Li, Z | 8 |
| Ii, Y | 1 |
| Irie, T | 3 |
| Kobari, A | 1 |
| Kawaguchi, M | 3 |
| Momose, H | 1 |
| Tsukamoto, R | 1 |
| Kawai, M | 3 |
| Sugimoto, K | 5 |
| Kojima, Y | 3 |
| Arakawa, A | 1 |
| Terao, Y | 1 |
| Tomiki, Y | 3 |
| Sakamoto, K | 8 |
| Karthika, C | 2 |
| Sureshkumar, R | 2 |
| Sajini, DV | 1 |
| Ashraf, GM | 1 |
| Rahman, MH | 1 |
| Bess, SN | 1 |
| Greening, GJ | 1 |
| Rajaram, N | 1 |
| Muldoon, TJ | 1 |
| Moriwaki, T | 3 |
| Nishina, T | 4 |
| Sakai, Y | 3 |
| Yamamoto, Y | 10 |
| Shimada, M | 1 |
| Ishida, H | 12 |
| Amagai, K | 1 |
| Sato, M | 3 |
| Endo, S | 5 |
| Negoro, Y | 2 |
| Kuramochi, H | 1 |
| Denda, T | 6 |
| Hatachi, Y | 1 |
| Ikezawa, K | 1 |
| Nakajima, G | 2 |
| Bando, Y | 1 |
| Tsuji, A | 3 |
| Morimoto, M | 2 |
| Kobayashi, K | 6 |
| Hyodo, I | 9 |
| Tominaga, T | 7 |
| Nonaka, T | 1 |
| Oyama, S | 1 |
| Shiraishi, T | 2 |
| Takeshita, H | 1 |
| Hisanaga, M | 1 |
| Fukuoka, H | 1 |
| Fukuda, A | 3 |
| Sumida, Y | 1 |
| Hashimoto, S | 1 |
| To, K | 1 |
| Tanaka, K | 9 |
| Sawai, T | 2 |
| Nagayasu, T | 1 |
| van Dijk, E | 1 |
| van Werkhoven, E | 1 |
| Asher, R | 1 |
| Mooi, JK | 1 |
| Espinoza, D | 1 |
| van Essen, HF | 1 |
| van Tinteren, H | 2 |
| van Grieken, NCT | 1 |
| Tebbutt, NC | 4 |
| Ylstra, B | 1 |
| Zhao, Q | 4 |
| Long, Y | 1 |
| Cheng, W | 2 |
| Huang, Y | 7 |
| Guo, X | 5 |
| Li, G | 4 |
| Gong, K | 1 |
| Zhang, J | 11 |
| Oki, E | 8 |
| Misumi, T | 5 |
| Kotaka, M | 8 |
| Manaka, D | 7 |
| Eto, T | 3 |
| Takagane, A | 5 |
| Kato, T | 22 |
| Munemoto, Y | 9 |
| Nakamura, F | 1 |
| Sakamoto, Y | 2 |
| Nishi, M | 1 |
| Horiuchi, T | 1 |
| Yamagishi, H | 2 |
| Mizushima, T | 7 |
| Ohtsu, A | 10 |
| Mori, M | 8 |
| Ji, H | 1 |
| Zhang, K | 2 |
| Pan, G | 2 |
| Cui, H | 1 |
| Zhou, R | 3 |
| Xie, F | 2 |
| Liu, K | 5 |
| Zhou, X | 3 |
| Chen, X | 7 |
| Chen, J | 15 |
| Xi, S | 2 |
| Kiweler, N | 1 |
| Schwarz, H | 1 |
| Nguyen, A | 1 |
| Matschos, S | 1 |
| Mullins, C | 1 |
| Piée-Staffa, A | 1 |
| Brachetti, C | 1 |
| Roos, WP | 1 |
| Schneider, G | 1 |
| Linnebacher, M | 2 |
| Brenner, W | 1 |
| Krämer, OH | 1 |
| Fischer, LE | 1 |
| Stintzing, S | 14 |
| von Weikersthal, LF | 4 |
| Modest, DP | 10 |
| Decker, T | 3 |
| Kiani, A | 2 |
| Kaiser, F | 4 |
| Al-Batran, SE | 1 |
| Heintges, T | 2 |
| Lerchenmüller, C | 1 |
| Kahl, C | 3 |
| Seipelt, G | 1 |
| Kullmann, F | 2 |
| Stauch, M | 3 |
| Scheithauer, W | 13 |
| Giessen-Jung, C | 1 |
| Uhlig, J | 1 |
| Peuser, B | 1 |
| Denzlinger, C | 2 |
| Stahler, A | 8 |
| Weiss, L | 1 |
| Heinrich, K | 5 |
| Held, S | 7 |
| Jung, A | 2 |
| Kirchner, T | 3 |
| Heinemann, V | 13 |
| Tie, J | 1 |
| Cohen, JD | 1 |
| Lahouel, K | 1 |
| Lo, SN | 1 |
| Kosmider, S | 1 |
| Wong, R | 1 |
| Shapiro, J | 1 |
| Harris, S | 1 |
| Khattak, A | 1 |
| Burge, M | 1 |
| Harris, M | 1 |
| Lynam, J | 1 |
| Nott, L | 1 |
| Day, F | 1 |
| Hayes, T | 1 |
| McLachlan, SA | 1 |
| Lee, B | 2 |
| Ptak, J | 1 |
| Silliman, N | 1 |
| Dobbyn, L | 1 |
| Popoli, M | 1 |
| Hruban, R | 1 |
| Lennon, AM | 1 |
| Papadopoulos, N | 1 |
| Kinzler, KW | 2 |
| Vogelstein, B | 2 |
| Tomasetti, C | 1 |
| Gibbs, P | 2 |
| Martínez-Lago, N | 1 |
| Cameselle García, S | 1 |
| Alonso de Castro, B | 1 |
| Gómez-Randulfe Rodríguez, MI | 1 |
| Carmona Campos, M | 1 |
| González Villarroel, P | 1 |
| Salgado Fernández, M | 1 |
| De la Cámara Gómez, JC | 1 |
| Romero Reinoso, C | 1 |
| Cousillas Castiñeiras, A | 1 |
| Méndez Méndez, JC | 1 |
| Vidal Insua, Y | 1 |
| Fernández-Montes, A | 1 |
| Moretto, R | 4 |
| Elliott, A | 1 |
| Rossini, D | 5 |
| Intini, R | 1 |
| Conca, V | 3 |
| Pietrantonio, F | 10 |
| Sartore-Bianchi, A | 2 |
| Antoniotti, C | 4 |
| Rasola, C | 1 |
| Scartozzi, M | 3 |
| Salati, M | 1 |
| Pella, N | 4 |
| Calegari, MA | 1 |
| Carullo, M | 3 |
| Corti, F | 1 |
| Mauri, G | 1 |
| Fassan, M | 2 |
| Masi, G | 3 |
| Brodskiy, P | 1 |
| Shields, A | 2 |
| Korn, M | 1 |
| Cremolini, C | 10 |
| Brooks, GA | 1 |
| Tapp, S | 1 |
| Daly, AT | 1 |
| Busam, JA | 1 |
| Tosteson, ANA | 1 |
| Brown, JC | 2 |
| Cespedes Feliciano, EM | 1 |
| Cheng, E | 1 |
| Caan, BJ | 1 |
| Monji, H | 1 |
| Zand, H | 2 |
| Ghorbani, A | 2 |
| Pourvali, K | 2 |
| Wei, X | 1 |
| Chen, G | 5 |
| Teng, Z | 1 |
| Sun, X | 2 |
| Guo, Y | 4 |
| Zhang, M | 9 |
| Xu, M | 3 |
| Yang, Y | 5 |
| Zhou, YW | 1 |
| Long, YX | 1 |
| Liu, X | 5 |
| Liu, JY | 3 |
| Qiu, M | 2 |
| Watanabe, J | 4 |
| Maeda, H | 4 |
| Nagasaka, T | 1 |
| Yokota, M | 2 |
| Hirata, K | 6 |
| Akazawa, N | 2 |
| Yamada, T | 10 |
| Ando, T | 3 |
| Mishima, H | 4 |
| Oba, K | 5 |
| Nagata, N | 3 |
| Akkın, S | 1 |
| Varan, G | 1 |
| Aksüt, D | 1 |
| Malanga, M | 1 |
| Ercan, A | 1 |
| Şen, M | 1 |
| Bilensoy, E | 1 |
| Demeckova, V | 1 |
| Mudronova, D | 1 |
| Gancarcikova, S | 1 |
| Kubatka, P | 1 |
| Kajo, K | 1 |
| Kassayova, M | 1 |
| Bojkova, B | 1 |
| Adamkov, M | 1 |
| Solár, P | 1 |
| Loupakis, F | 3 |
| Liu, T | 3 |
| Falcone, A | 8 |
| Shen, L | 4 |
| Porretto, CM | 1 |
| Aparicio, J | 2 |
| Virgili Manrique, AC | 1 |
| Capdevila, J | 1 |
| Muñoz Boza, F | 1 |
| Galván, P | 1 |
| Richart, P | 1 |
| Oliveres, H | 1 |
| Páez, D | 3 |
| Hernando, J | 1 |
| Serrano, S | 1 |
| Vera, R | 2 |
| Hernandez-Yagüe, X | 1 |
| Gallego, RÁ | 1 |
| Riesco-Martinez, MC | 2 |
| García de Albeniz, X | 1 |
| Maurel, J | 2 |
| Kim, SY | 6 |
| Yun, SH | 4 |
| Kim, HC | 3 |
| Lee, WY | 5 |
| Kim, TW | 9 |
| Hong, YS | 5 |
| Lim, SB | 2 |
| Baek, JY | 1 |
| Oh, JH | 2 |
| Kim, SG | 1 |
| Kang, SY | 1 |
| Sym, SJ | 1 |
| Kim, YH | 5 |
| Choi, IS | 1 |
| Kang, JH | 2 |
| Kim, MJ | 5 |
| Ak Aksoy, S | 1 |
| Tunca, B | 1 |
| Erçelik, M | 1 |
| Tezcan, G | 1 |
| Ozturk, E | 1 |
| Cecener, G | 1 |
| Ugras, N | 1 |
| Yilmazlar, T | 1 |
| Yerci, O | 1 |
| Chrabaszcz, S | 1 |
| Rajeev, R | 1 |
| Witmer, HDD | 1 |
| Dhiman, A | 1 |
| Klooster, B | 1 |
| Gamblin, TC | 1 |
| Banerjee, A | 1 |
| Johnston, FM | 1 |
| Turaga, KK | 1 |
| Ito, T | 7 |
| Takashima, A | 6 |
| Yamazaki, K | 10 |
| Yukami, H | 1 |
| Uetake, H | 4 |
| Tsuda, M | 1 |
| Suto, T | 1 |
| Sugimoto, N | 2 |
| Ojima, H | 2 |
| Yasui, H | 4 |
| Esaki, T | 5 |
| Goto, M | 3 |
| Saruta, M | 1 |
| Otsu, S | 3 |
| Shinozaki, K | 6 |
| Fujiwara, T | 3 |
| Tamura, T | 6 |
| Baba, E | 1 |
| Ueno, H | 1 |
| Nagashima, K | 2 |
| Ou, K | 1 |
| Ma, X | 2 |
| Gao, L | 6 |
| Cao, W | 2 |
| Zhang, B | 3 |
| Strickler, JH | 1 |
| Cubillo, A | 1 |
| Matrana, M | 1 |
| Kozloff, M | 1 |
| Lowe, T | 1 |
| Blaney, M | 1 |
| Sahtout, M | 1 |
| Naumovski, L | 1 |
| Wainberg, ZA | 1 |
| He, MM | 1 |
| Xiao, J | 3 |
| Zhang, YQ | 2 |
| Yuan, XL | 1 |
| Fang, WJ | 1 |
| Wang, W | 11 |
| Hu, XH | 1 |
| Ma, ZG | 1 |
| Yao, YC | 1 |
| Zhuang, ZX | 1 |
| Zhou, FX | 1 |
| Ying, JE | 1 |
| Yuan, Y | 3 |
| Zou, QF | 1 |
| Guo, ZQ | 1 |
| Wu, XY | 1 |
| Jin, Y | 4 |
| Mai, ZJ | 1 |
| Wang, ZQ | 4 |
| Qiu, H | 1 |
| Shi, SM | 1 |
| Chen, SZ | 1 |
| Luo, HY | 2 |
| Zhang, DS | 2 |
| Wang, FH | 3 |
| Li, YH | 5 |
| Xu, RH | 6 |
| Teufel, A | 2 |
| Li, M | 2 |
| Gerken, M | 2 |
| Ebert, MP | 1 |
| Schlitt, HJ | 2 |
| Evert, M | 1 |
| Herr, W | 1 |
| Klinkhammer-Schalke, M | 3 |
| Fischer von Weikersthal, L | 3 |
| Graeven, U | 7 |
| Schwaner, I | 2 |
| Schenk, M | 1 |
| Kurreck, A | 7 |
| Gießen-Jung, C | 1 |
| Neumann, J | 1 |
| Zhang, Z | 9 |
| Wang, X | 19 |
| Zhou, D | 2 |
| Zheng, G | 1 |
| Gu, J | 2 |
| Hofmann, FO | 1 |
| D'Anastasi, M | 1 |
| Gesenhues, AB | 1 |
| Hesse, N | 1 |
| Moehler, M | 3 |
| Link, H | 1 |
| Holch, JW | 1 |
| Zhu, Z | 4 |
| Hou, Q | 1 |
| Wang, B | 5 |
| Liu, L | 5 |
| Gong, W | 1 |
| Chai, J | 2 |
| Jia, Y | 1 |
| Ciardiello, D | 3 |
| Chiarazzo, C | 1 |
| Famiglietti, V | 2 |
| Damato, A | 1 |
| Zampino, MG | 6 |
| Castellano, G | 1 |
| Gervaso, L | 1 |
| Bordonaro, R | 1 |
| Zichi, C | 1 |
| De Vita, F | 4 |
| Di Maio, M | 1 |
| Parisi, A | 1 |
| Giampieri, R | 1 |
| Berardi, R | 1 |
| Lavacchi, D | 1 |
| Antonuzzo, L | 3 |
| Tamburini, E | 5 |
| Maiorano, BA | 1 |
| Parrella, P | 1 |
| Latiano, TP | 2 |
| Normanno, N | 2 |
| De Stefano, A | 3 |
| Martini, G | 2 |
| Napolitano, S | 3 |
| Troiani, T | 3 |
| Martinelli, E | 3 |
| Ciardiello, F | 6 |
| Maiello, E | 6 |
| Gathirua-Mwangi, W | 1 |
| Yang, T | 1 |
| Khan, T | 1 |
| Afable, M | 1 |
| Sousa-Squiavinato, ACM | 1 |
| Arregui Ramos, DA | 1 |
| Wagner, MS | 1 |
| Tessmann, JW | 1 |
| de-Freitas-Junior, JCM | 1 |
| Morgado-Díaz, JA | 1 |
| Miao, LI | 1 |
| Jialu, Z | 1 |
| Shuangshuang, W | 1 |
| Lei, C | 1 |
| Xiao, P | 1 |
| Jinfang, C | 1 |
| Hongmei, AN | 1 |
| Bing, HU | 1 |
| Liu, Z | 10 |
| Wang, D | 4 |
| Cao, Q | 1 |
| Zhou, B | 2 |
| Mai, Z | 1 |
| Ye, Y | 1 |
| Song, Y | 2 |
| Yang, X | 8 |
| Xia, W | 1 |
| Qiu, X | 1 |
| Aparicio, T | 3 |
| Bouché, O | 10 |
| Etienne, PL | 1 |
| Barbier, E | 3 |
| Mineur, L | 5 |
| Desgrippes, R | 1 |
| Guérin-Meyer, V | 3 |
| Hocine, F | 1 |
| Martin, J | 1 |
| Le Brun-Ly, V | 1 |
| Cretin, J | 1 |
| Desramé, J | 3 |
| Rinaldi, Y | 1 |
| Cany, L | 1 |
| Falandry, C | 1 |
| Lefevre, LB | 1 |
| Marous, M | 1 |
| Terrebonne, E | 1 |
| Mosser, L | 1 |
| Turpin, J | 1 |
| Turpin, A | 2 |
| Bauguion, L | 1 |
| Reichling, C | 1 |
| Van den Eynde, M | 2 |
| Carola, E | 3 |
| Hiret, S | 1 |
| Robles, J | 1 |
| Pintado-Berninches, L | 1 |
| Boukich, I | 1 |
| Escudero, B | 1 |
| de Los Rios, V | 1 |
| Bartolomé, RA | 1 |
| Jaén, M | 1 |
| Martín-Regalado, Á | 1 |
| Fernandez-Aceñero, MJ | 1 |
| Imbaud, JI | 1 |
| Casal, JI | 1 |
| Monzer, A | 1 |
| Wakimian, K | 1 |
| Ballout, F | 1 |
| Al Bitar, S | 1 |
| Yehya, A | 1 |
| Kanso, M | 1 |
| Saheb, N | 1 |
| Tawil, A | 1 |
| Doughan, S | 1 |
| Hussein, M | 1 |
| Mukherji, D | 1 |
| Faraj, W | 1 |
| Gali-Muhtasib, H | 1 |
| Abou-Kheir, W | 1 |
| Kibudde, S | 1 |
| Begg, W | 1 |
| Khan, S | 1 |
| Madni, A | 1 |
| Shah, H | 1 |
| Jan, N | 1 |
| Shafiq, A | 1 |
| Basit, A | 1 |
| Rai, N | 1 |
| Ali, A | 1 |
| Khan, MM | 1 |
| Čižauskaitė, A | 1 |
| Šimčikas, D | 1 |
| Schultze, D | 1 |
| Kallifatidis, G | 1 |
| Bruns, H | 1 |
| Čekauskas, A | 1 |
| Herr, I | 1 |
| Baušys, A | 1 |
| Strupas, K | 1 |
| Schemmer, P | 1 |
| Kroupová, J | 1 |
| Hanuš, J | 1 |
| Štěpánek, F | 1 |
| Jones, E | 1 |
| Duan, Z | 1 |
| Nguyen, TT | 1 |
| Giordano, SH | 1 |
| Zhao, H | 6 |
| Nair, VA | 2 |
| Malhab, LJB | 1 |
| Abdel-Rahman, WM | 2 |
| Sochacka-Ćwikła, A | 1 |
| Mączyński, M | 1 |
| Czyżnikowska, Ż | 2 |
| Wiatrak, B | 2 |
| Jęśkowiak, I | 1 |
| Czerski, A | 1 |
| Regiec, A | 1 |
| Ko, HM | 1 |
| Jee, W | 2 |
| Park, DI | 1 |
| Kim, KI | 2 |
| Jung, JH | 2 |
| Jang, HJ | 2 |
| Ciszewski, WM | 1 |
| Włodarczyk, J | 1 |
| Chmielewska-Kassassir, M | 1 |
| Fichna, J | 1 |
| Wozniak, LA | 1 |
| Sobierajska, K | 1 |
| Sahin, IH | 2 |
| Lin, Y | 2 |
| Lucas, PC | 1 |
| Deming, D | 1 |
| Kopetz, S | 4 |
| Lieu, CH | 1 |
| Dasari, A | 1 |
| Khatib, AW | 1 |
| Selub, SM | 1 |
| Uryvaey, A | 1 |
| Baranseh, J | 1 |
| Shai, A | 1 |
| Nunes, M | 1 |
| Ricardo, S | 1 |
| Kemeny, MM | 2 |
| Zhao, F | 3 |
| Forastiere, AA | 1 |
| Catalano, P | 1 |
| Hamilton, SR | 6 |
| Miedema, BW | 1 |
| Dawson, NA | 1 |
| Weiner, LM | 2 |
| Smith, BD | 1 |
| Mason, BA | 1 |
| Graziano, SL | 1 |
| Gilman, PB | 1 |
| Pinto, HA | 1 |
| Whitehead, RP | 1 |
| O'Dwyer, PJ | 4 |
| Benson, AB | 14 |
| Gallois, C | 3 |
| Meyers, JP | 4 |
| Iveson, T | 6 |
| de Gramont, A | 28 |
| Sobrero, AF | 6 |
| Haller, DG | 29 |
| Shields, AF | 5 |
| Kelly, C | 1 |
| Boukovinas, I | 4 |
| Labianca, R | 30 |
| Sinicrope, FA | 26 |
| Souglakos, I | 2 |
| Papamichael, D | 3 |
| Terazawa, T | 1 |
| Yamane, S | 1 |
| Kazama, H | 1 |
| Kanesada, K | 1 |
| Tsunedomi, R | 1 |
| Hazama, S | 3 |
| Ogihara, H | 1 |
| Hamamoto, Y | 1 |
| Shindo, Y | 2 |
| Matsui, H | 2 |
| Tokumitsu, Y | 1 |
| Yoshida, S | 6 |
| Iida, M | 1 |
| Suzuki, N | 2 |
| Takeda, S | 4 |
| Ioka, T | 1 |
| Nagano, H | 1 |
| Jurczyk, M | 1 |
| Midro, A | 1 |
| Król, M | 1 |
| Olesiak, W | 1 |
| Stąpor, D | 1 |
| Gil, A | 2 |
| Gil, K | 1 |
| Breadner, D | 1 |
| Loree, JM | 5 |
| Cheung, WY | 8 |
| Gipson, M | 1 |
| Lakkunarajah, S | 1 |
| Mulder, KE | 5 |
| Spartlin, JL | 1 |
| Kong, S | 1 |
| Ding, PQ | 1 |
| Welch, SA | 1 |
| Fulgenzi, CAM | 1 |
| Passardi, A | 3 |
| Vetere, G | 1 |
| Citarella, F | 1 |
| Spagnoletti, A | 1 |
| Marmorino, F | 1 |
| Borelli, B | 1 |
| Allegrini, G | 1 |
| Nappo, F | 1 |
| Santini, D | 5 |
| Li, L | 3 |
| Zeng, D | 1 |
| Sun, H | 2 |
| Wang, L | 12 |
| Shi, M | 3 |
| Bin, J | 1 |
| Liao, Y | 1 |
| Liao, W | 1 |
| Zhang, C | 9 |
| Zhan, Y | 2 |
| Ni, K | 2 |
| Xin, R | 2 |
| Han, Q | 5 |
| Ping, H | 2 |
| Zhao, X | 5 |
| Yan, S | 2 |
| Sun, J | 2 |
| Zhang, Q | 5 |
| Wang, G | 12 |
| Zhang, X | 10 |
| Almasan, A | 3 |
| Gurkan-Cavusoglu, E | 3 |
| Sommerhäuser, G | 6 |
| Beck, A | 3 |
| Fehrenbach, U | 3 |
| Karthaus, M | 6 |
| Fruehauf, S | 5 |
| Mueller, L | 4 |
| Koenig, AO | 3 |
| V Weikersthal, LF | 3 |
| Goekkurt, E | 5 |
| Haas, S | 4 |
| Alig, AHS | 5 |
| Kasper, S | 4 |
| Trarbach, T | 7 |
| Mahbub, AA | 3 |
| Liu, HH | 3 |
| Lee, CH | 4 |
| Hsieh, YC | 4 |
| Zheng, JH | 3 |
| Liu, YR | 4 |
| Chang, CH | 6 |
| Cho, EC | 4 |
| Li, R | 4 |
| Qin, J | 3 |
| Lv, F | 3 |
| Guo, J | 5 |
| Ishitobi, K | 4 |
| Kotani, H | 5 |
| Iida, Y | 5 |
| Taniura, T | 4 |
| Notsu, Y | 3 |
| Tajima, Y | 6 |
| Harada, M | 4 |
| Okamoto, W | 2 |
| Sakai, K | 2 |
| Shitara, K | 5 |
| Izawa, N | 2 |
| Nakano, Y | 3 |
| Hara, H | 2 |
| Miura, Y | 2 |
| Boku, N | 5 |
| Hironaka, S | 3 |
| Nishio, K | 2 |
| Shah, MA | 3 |
| Tabernero, J | 22 |
| Cervantes, A | 6 |
| Oh, SC | 3 |
| Yamaguchi, K | 8 |
| Fakih, M | 3 |
| Wu, C | 3 |
| Chiu, VK | 2 |
| Tomasek, J | 2 |
| Bendell, J | 2 |
| Fontaine, M | 2 |
| Hitron, M | 2 |
| Xu, B | 3 |
| Kang, C | 2 |
| Ju, S | 3 |
| Kim, J | 4 |
| Jung, Y | 2 |
| Erol, C | 2 |
| Sendur Mehmet, AN | 2 |
| Bilgetekin, I | 2 |
| Garbioglu, DB | 2 |
| Hamdard, J | 2 |
| Akbas, S | 2 |
| Hizal, M | 2 |
| Arslan, C | 2 |
| Sevinc, A | 3 |
| Kucukarda, A | 2 |
| Erdem, D | 2 |
| Kahraman, S | 2 |
| Cakir, E | 2 |
| Demirkiran, A | 2 |
| On, S | 2 |
| Dogan, I | 2 |
| Erdogan, AP | 2 |
| Koca, S | 2 |
| Kubilay, P | 2 |
| Eren, OO | 2 |
| Cilbir, E | 2 |
| Celik, E | 2 |
| Araz, M | 4 |
| Ozyukseler, DT | 2 |
| Yildirim, ME | 2 |
| Bahceci, A | 3 |
| Taskaynatan, H | 2 |
| Oyman, A | 2 |
| Deniz, GI | 2 |
| Menekse, S | 3 |
| Kut, E | 2 |
| Gulmez, A | 2 |
| Nayir, E | 2 |
| Acar, R | 2 |
| Sen, E | 2 |
| Inal, A | 2 |
| Turhal, S | 2 |
| Kaya, AO | 2 |
| Paydas, S | 3 |
| Tastekin, D | 2 |
| Hacibekiroglu, I | 3 |
| Cincin, I | 2 |
| Bilici, A | 3 |
| Mandel, NM | 2 |
| Dede, DS | 2 |
| Akinci, MB | 2 |
| Oksuzoglu, B | 3 |
| Uncu, D | 2 |
| Yalcin, B | 2 |
| Artac, M | 3 |
| Williams, CJ | 2 |
| Fish, R | 2 |
| Akerman, L | 2 |
| West, N | 2 |
| Tolan, D | 2 |
| Quyn, AJ | 2 |
| Seligmann, JF | 2 |
| Chen, W | 8 |
| Chen, Y | 13 |
| Hui, T | 1 |
| Bouvet, M | 3 |
| Hoffman, RM | 10 |
| Park, JH | 5 |
| Liu, J | 5 |
| Imanirad, I | 1 |
| Felder, SI | 1 |
| Kim, RD | 2 |
| Xie, H | 3 |
| Shekh, R | 1 |
| Ahmad, A | 1 |
| Tiwari, RK | 1 |
| Saeed, M | 1 |
| Shukla, R | 1 |
| Al-Thubiani, WS | 1 |
| Ansari, IA | 1 |
| Ashfaque, M | 1 |
| Bajpai, P | 1 |
| Toledano-Fonseca, M | 1 |
| Gómez-España, MA | 1 |
| Grávalos, C | 1 |
| García-Alfonso, P | 2 |
| Rodríguez, R | 1 |
| Losa, F | 1 |
| Alés Díaz, I | 1 |
| Valladares-Ayerbes, M | 2 |
| García-Ortiz, MV | 2 |
| Polo, E | 1 |
| Salgado, M | 3 |
| Rivera, F | 4 |
| Safont, MJ | 2 |
| Salud, A | 2 |
| Ruiz-Casado, A | 1 |
| Tabernero, JM | 1 |
| Riesco, MC | 1 |
| Rodríguez-Ariza, A | 2 |
| Platt, JR | 1 |
| Williams, CJM | 1 |
| Craig, Z | 1 |
| Cairns, DA | 1 |
| Glasbey, JC | 1 |
| Morton, D | 1 |
| Seligmann, J | 1 |
| Janssens, K | 1 |
| Vanhoutte, G | 1 |
| Lybaert, W | 1 |
| Demey, W | 1 |
| Decaestecker, J | 1 |
| Hendrickx, K | 1 |
| Rezaei Kalantari, H | 1 |
| Zwaenepoel, K | 1 |
| Pauwels, P | 1 |
| Fransen, E | 1 |
| Op de Beeck, K | 1 |
| Van Camp, G | 1 |
| Rolfo, C | 1 |
| Peeters, M | 3 |
| Tong, J | 3 |
| Tan, X | 2 |
| Hao, S | 1 |
| Ermine, K | 1 |
| Lu, X | 1 |
| Jha, A | 1 |
| Zhang, L | 16 |
| Raga, MG | 1 |
| Pérez, IP | 1 |
| Veiga, RC | 1 |
| Sosa, MM | 1 |
| Aguilera, MJS | 1 |
| Rodríguez, PL | 1 |
| Bonastre, MTT | 1 |
| Urtasun, JA | 1 |
| Abad, LP | 1 |
| Hernández, IB | 1 |
| Suda, K | 1 |
| Chiku, T | 1 |
| Fukuyama, M | 1 |
| Shinoda, K | 1 |
| Hashiba, H | 1 |
| Sano, W | 1 |
| Ando, K | 2 |
| Kocak, MZ | 1 |
| Er, M | 1 |
| Ugrakli, M | 1 |
| Hendem, E | 1 |
| Eryilmaz, MK | 1 |
| Germani, MM | 2 |
| Giordano, M | 2 |
| Proietti, A | 1 |
| Niccoli, C | 1 |
| Fanotto, V | 1 |
| Di Donato, S | 2 |
| Prisciandaro, M | 2 |
| Bergamo, F | 6 |
| Fontanini, G | 1 |
| Ugolini, C | 1 |
| Mafi, A | 1 |
| Rezaee, M | 1 |
| Hedayati, N | 1 |
| Hogan, SD | 1 |
| Reiter, RJ | 1 |
| Aarabi, MH | 1 |
| Asemi, Z | 2 |
| Chen, Q | 3 |
| Song, H | 2 |
| Xing, W | 1 |
| Jin, S | 1 |
| Song, X | 1 |
| Yang, H | 3 |
| Zhao, W | 3 |
| Katsumata, K | 3 |
| Naito, M | 1 |
| Hisatsune, Y | 1 |
| Amano, Y | 1 |
| Usui, S | 1 |
| Kikuchi, Y | 3 |
| Negishi, H | 1 |
| Oshima, R | 1 |
| Kokuba, Y | 1 |
| Furuhata, T | 2 |
| Otsubo, T | 2 |
| Kawamoto, S | 2 |
| Yamamoto, K | 7 |
| Atarashi, M | 1 |
| Terashima, T | 1 |
| Kurogi, N | 1 |
| Gong, G | 1 |
| Ganesan, K | 1 |
| Xiong, Q | 1 |
| Tsim, KWK | 1 |
| Batibay, GS | 1 |
| Keser Karaoglan, G | 1 |
| Gumrukcu Kose, G | 1 |
| Ozcelik Kazancioglu, E | 1 |
| Metin, E | 1 |
| Danisman Kalindemirtas, F | 1 |
| Erdem Kuruca, S | 1 |
| Arsu, N | 1 |
| Hemachudha, P | 1 |
| Rattanawong, W | 1 |
| Pongpitakmetha, T | 1 |
| Phuenpathom, W | 1 |
| Moreno-Londoño, AP | 1 |
| Castañeda-Patlán, MC | 1 |
| Sarabia-Sánchez, MA | 1 |
| Macías-Silva, M | 1 |
| Robles-Flores, M | 1 |
| La Rocca, A | 1 |
| De Gregorio, V | 1 |
| Lagreca, E | 1 |
| Vecchione, R | 1 |
| Netti, PA | 1 |
| Imparato, G | 1 |
| Maughan, T | 1 |
| McDermott, R | 1 |
| Bodoky, G | 4 |
| Osterlund, P | 3 |
| Teske, AJ | 1 |
| Pfeiffer, P | 2 |
| Pooresmaeil, M | 1 |
| Namazi, H | 1 |
| Yu, Z | 1 |
| Chan, S | 1 |
| Sun, R | 1 |
| Wang, M | 3 |
| Zuo, X | 1 |
| Boccaccino, A | 2 |
| Seitz, R | 1 |
| Catteau, A | 2 |
| Salvatore, L | 1 |
| McGregor, K | 1 |
| Leonetti, S | 1 |
| Morano, F | 3 |
| Papiani, G | 1 |
| Bensi, M | 1 |
| Murgioni, S | 1 |
| Ross, DT | 1 |
| Boquet, I | 1 |
| Nielsen, TJ | 1 |
| Galon, J | 2 |
| Varga, MG | 1 |
| Schweitzer, BL | 1 |
| Kang, S | 2 |
| Lee, MW | 2 |
| Song, IC | 1 |
| Lee, HJ | 6 |
| Yun, HJ | 1 |
| Jo, DY | 1 |
| Lee, KH | 4 |
| Ryu, H | 1 |
| Li, E | 1 |
| Shen, G | 3 |
| Dong, Q | 1 |
| Ren, D | 1 |
| Zhao, Y | 2 |
| Ma, J | 4 |
| Xie, Q | 4 |
| Aoyama, T | 2 |
| Honda, M | 2 |
| Muto, M | 2 |
| Mayanagi, S | 2 |
| Kanda, M | 2 |
| Kashiwabara, K | 2 |
| Yoshikawa, T | 5 |
| Woods, M | 1 |
| Lee, HM | 1 |
| De Falco, V | 2 |
| Della Corte, CM | 1 |
| Anderson, A | 1 |
| Fowlkes, NW | 1 |
| Villareal, OE | 1 |
| Sorokin, A | 1 |
| Kanikarla, P | 1 |
| Coker, O | 1 |
| Morris, V | 1 |
| Altucci, L | 1 |
| Ohori, H | 2 |
| Yuasa, Y | 2 |
| Miwa, K | 2 |
| Naitoh, T | 1 |
| Komatsu, Y | 4 |
| Hihara, M | 1 |
| Soeda, J | 1 |
| Akagi, K | 1 |
| Ochiai, A | 1 |
| Tsuchihara, K | 1 |
| Kauffels, A | 1 |
| Nowack, H | 1 |
| Bohnenberger, H | 1 |
| Spitzner, M | 2 |
| Sprenger, T | 1 |
| Ghadimi, M | 1 |
| Sperling, J | 1 |
| Falcão, SI | 1 |
| Diallo, M | 1 |
| Santos, J | 1 |
| Ribeiro, E | 1 |
| Vilas-Boas, M | 1 |
| Park, SM | 1 |
| Park, YR | 1 |
| Na, YC | 1 |
| He, S | 2 |
| Wen, F | 3 |
| Lu, L | 1 |
| Xu, L | 7 |
| Wu, S | 4 |
| Babaei, Z | 1 |
| Namavari, G | 1 |
| Khademi, F | 1 |
| Koohpeyma, F | 1 |
| Rashidi, M | 1 |
| Shafiee, SM | 1 |
| Zal, F | 1 |
| Seghatoleslam, A | 1 |
| Liu, G | 6 |
| Wang, H | 16 |
| Ran, R | 1 |
| Mao, C | 1 |
| Ji, D | 1 |
| Ding, Y | 4 |
| Song, W | 1 |
| Song, L | 2 |
| Feng, X | 3 |
| Cao, J | 1 |
| Xu, N | 2 |
| Hou, Y | 1 |
| Zheng, X | 4 |
| Sun, Y | 4 |
| Yi, X | 1 |
| Wu, Z | 1 |
| Lin, JM | 1 |
| Huebner, K | 1 |
| Hampel, C | 1 |
| Erlenbach-Wuensch, K | 1 |
| Selvamani, SB | 1 |
| Shukla, V | 1 |
| Geppert, CI | 1 |
| Hartmann, A | 2 |
| Mahadevan, V | 1 |
| Schneider-Stock, R | 1 |
| Thakur, A | 1 |
| Chorawala, MR | 1 |
| Patel, RS | 1 |
| Lei, Y | 1 |
| Tian, X | 2 |
| Wei, J | 2 |
| Dote, S | 1 |
| Shiwaku, E | 1 |
| Kohno, E | 1 |
| Fujii, R | 1 |
| Mashimo, K | 1 |
| Morimoto, N | 1 |
| Yoshino, M | 3 |
| Odaira, N | 1 |
| Ikesue, H | 1 |
| Hirabatake, M | 1 |
| Takahashi, K | 14 |
| Takahashi, M | 12 |
| Takagi, M | 3 |
| Nishiuma, S | 1 |
| Ito, K | 7 |
| Shimato, A | 1 |
| Itakura, S | 1 |
| Takahashi, Y | 3 |
| Shigemori, M | 1 |
| Watanabe, H | 8 |
| Hayasaka, D | 1 |
| Nakao, M | 1 |
| Tasaka, M | 1 |
| Goto, E | 1 |
| Kataoka, N | 1 |
| Yokomizo, A | 1 |
| Kobayashi, A | 1 |
| Nakata, Y | 1 |
| Miyake, M | 3 |
| Hayashi, Y | 5 |
| Hirata, T | 3 |
| Azuma, K | 2 |
| Makihara, K | 1 |
| Fukui, R | 1 |
| Tokutome, A | 1 |
| Yagisawa, K | 1 |
| Honda, S | 3 |
| Meguro, Y | 1 |
| Suzuki, S | 5 |
| Yamaguchi, D | 1 |
| Miyata, H | 1 |
| Kobayashi, Y | 2 |
| Raimondi, A | 2 |
| Tomasello, G | 1 |
| Niger, M | 2 |
| Daniel, F | 1 |
| Bustreo, S | 1 |
| Procaccio, L | 1 |
| Clavarezza, M | 1 |
| Cupini, S | 1 |
| Libertini, M | 1 |
| Palermo, F | 2 |
| Bardania, H | 1 |
| Jafari, F | 1 |
| Baneshi, M | 1 |
| Mahmoudi, R | 1 |
| Ardakani, MT | 1 |
| Safari, F | 1 |
| Barmak, MJ | 1 |
| Xu, Y | 11 |
| Tang, Q | 2 |
| Ding, N | 1 |
| Luo, H | 1 |
| Bhatt, K | 1 |
| Tougeron, D | 4 |
| Eucker, J | 1 |
| Pihusch, R | 1 |
| Müller, C | 1 |
| Burkart, C | 1 |
| Reinacher-Schick, A | 2 |
| Kasper-Virchow, S | 1 |
| Krammer-Steiner, B | 1 |
| Prager, GW | 1 |
| Meng, L | 1 |
| Thapa, R | 1 |
| Delgado, MG | 1 |
| Gomez, MF | 1 |
| Ji, R | 2 |
| Knepper, TC | 1 |
| Hubbard, JM | 1 |
| Permuth, JB | 1 |
| Laber, DA | 1 |
| Fukuda, K | 2 |
| Osumi, H | 1 |
| Yoshino, K | 1 |
| Nakayama, I | 1 |
| Fukuoka, S | 1 |
| Ogura, M | 2 |
| Wakatsuki, T | 4 |
| Ooki, A | 1 |
| Takahari, D | 4 |
| Chin, K | 1 |
| Armas Diaz, Y | 1 |
| Zhang, D | 6 |
| Martínez López, NM | 1 |
| Briones Urbano, M | 1 |
| Quiles, JL | 2 |
| Amici, A | 2 |
| Lin, D | 2 |
| Zheng, J | 1 |
| Xia, H | 2 |
| Huang, L | 1 |
| Zeng, C | 1 |
| König, AO | 2 |
| Caca, K | 1 |
| Kretzschmar, A | 1 |
| Nichetti, F | 2 |
| Wasan, HS | 1 |
| Randon, G | 1 |
| Meade, AM | 1 |
| Díaz-Rubio, E | 4 |
| Fisher, D | 1 |
| Ballhausen, A | 1 |
| Müller, L | 1 |
| Meyer-Knees, JW | 1 |
| Chang, W | 2 |
| Lin, Q | 1 |
| Lv, Y | 3 |
| Tang, W | 1 |
| Xu, J | 10 |
| Fang, X | 1 |
| Zhong, C | 1 |
| Weng, S | 1 |
| Hu, H | 2 |
| Xiao, Q | 2 |
| Sun, L | 3 |
| Xu, D | 1 |
| Liao, X | 2 |
| Dong, C | 1 |
| Ding, K | 2 |
| Zhang, JT | 1 |
| Liu, P | 2 |
| Wang, WL | 1 |
| Xie, XX | 1 |
| He, TH | 1 |
| Cui, YR | 1 |
| Kocyigit, A | 1 |
| Guler, EM | 1 |
| Durmus, E | 1 |
| Yenigun, VB | 1 |
| Kanimdan, E | 1 |
| Ozman, Z | 1 |
| Yasar, O | 1 |
| Goren, AC | 1 |
| Hekimoglu, ER | 1 |
| Oruc, HH | 1 |
| Aydogdu, G | 1 |
| Sue-Chue-Lam, C | 2 |
| Brezden-Masley, C | 2 |
| Sutradhar, R | 2 |
| Yu, AYX | 2 |
| Strzelecka, M | 1 |
| Jawień, P | 1 |
| Świątek, P | 1 |
| Chen, F | 1 |
| Gou, S | 1 |
| Tang, Z | 1 |
| Wang, R | 4 |
| Liu, B | 3 |
| Walden, DJ | 1 |
| Larson, JJ | 1 |
| Griswold, CR | 1 |
| Ueberroth, BE | 1 |
| Patel, B | 1 |
| Draper, A | 1 |
| Raman, P | 1 |
| Alese, OB | 1 |
| Sonbol, MB | 1 |
| Bekaii-Saab, TS | 1 |
| Wu, CS | 1 |
| Ahn, DH | 1 |
| Putri, S | 1 |
| Saldi, SRF | 1 |
| Khoe, LC | 1 |
| Setiawan, E | 1 |
| Megraini, A | 1 |
| Santatiwongchai, B | 1 |
| Nugraha, RR | 1 |
| Permanasari, VY | 1 |
| Nadjib, M | 1 |
| Sastroasmoro, S | 1 |
| Armansyah, A | 1 |
| Hashimoto, T | 9 |
| Kataoka, T | 3 |
| Tsukamoto, S | 2 |
| Yuki, S | 1 |
| Sunakawa, Y | 3 |
| Takahashi, N | 4 |
| Kawakami, H | 1 |
| Matsuhashi, N | 4 |
| Asano, C | 1 |
| Abe, Y | 1 |
| Nomura, S | 2 |
| Raunkilde, L | 1 |
| Hansen, TF | 1 |
| Havelund, BM | 1 |
| Thomsen, CB | 1 |
| Rafaelsen, SR | 1 |
| Lindebjerg, J | 1 |
| Jensen, LH | 1 |
| Chi, XJ | 1 |
| Song, YB | 1 |
| Liu, DH | 1 |
| Wei, LQ | 1 |
| Zhao, AR | 1 |
| An, X | 2 |
| Feng, ZZ | 1 |
| Lan, XH | 1 |
| Lv, YM | 1 |
| Li, HJ | 1 |
| Lan, D | 1 |
| He, HM | 1 |
| Flynn, JR | 1 |
| Curry, M | 1 |
| Zhao, B | 1 |
| Dercle, L | 1 |
| Fojo, AT | 1 |
| Connors, DE | 1 |
| Schwartz, LH | 1 |
| Gönen, M | 1 |
| Moskowitz, CS | 1 |
| Binabaj, MM | 1 |
| Asgharzadeh, F | 2 |
| Rahmani, F | 1 |
| Al-Asady, AM | 1 |
| Hashemzehi, M | 1 |
| Soleimani, A | 1 |
| Avan, A | 2 |
| Mehraban, S | 1 |
| Ghorbani, E | 1 |
| Ryzhikov, M | 1 |
| Khazaei, M | 2 |
| Hassanian, SM | 2 |
| Cartwright, BM | 1 |
| Corso, JN | 1 |
| Lightner, J | 1 |
| Whitted, C | 1 |
| Torrenegra, RD | 1 |
| Krishnan, K | 1 |
| Palau, VE | 1 |
| Liu, F | 3 |
| Nian, J | 1 |
| Maruyama, S | 4 |
| Piringer, G | 1 |
| Thaler, J | 5 |
| Anchisi, S | 1 |
| Geffriaud-Ricouard, C | 1 |
| Gueldner, M | 1 |
| Scholten, F | 1 |
| Derigs, HG | 1 |
| Bohanes, P | 3 |
| Grünberger, B | 1 |
| Schwarz, L | 1 |
| von Moos, R | 2 |
| Hofheinz, RD | 1 |
| Wang, YN | 1 |
| Gui, MB | 1 |
| Qu, LP | 1 |
| Zou, M | 1 |
| Gao, F | 1 |
| Ghelardi, F | 1 |
| De Grandis, MC | 1 |
| Barsotti, G | 1 |
| Formica, V | 4 |
| Frassineti, GL | 3 |
| Boscolo, G | 1 |
| Cinieri, S | 3 |
| Ambrosini, M | 1 |
| Piva, VM | 1 |
| Tian, M | 1 |
| Dong, W | 2 |
| Jiang, T | 4 |
| Zeng, J | 2 |
| Jiang, X | 1 |
| Yin, Z | 1 |
| Ozawa, S | 4 |
| Ruzzo, A | 2 |
| Graziano, F | 3 |
| Galli, F | 10 |
| Rulli, E | 5 |
| Ronzoni, M | 6 |
| Massidda, B | 4 |
| Zagonel, V | 4 |
| Mucciarini, C | 2 |
| Ionta, MT | 2 |
| Bagaloni, I | 1 |
| Veltri, E | 2 |
| Sozzi, P | 2 |
| Barni, S | 8 |
| Ricci, V | 2 |
| Foltran, L | 2 |
| Nicolini, M | 3 |
| Biondi, E | 2 |
| Bramati, A | 2 |
| Turci, D | 3 |
| Lazzarelli, S | 2 |
| Verusio, C | 2 |
| Sobrero, A | 19 |
| Frontini, L | 2 |
| Magnani, M | 2 |
| Cha, YJ | 1 |
| Lee, KY | 5 |
| Kang, J | 1 |
| Song, Q | 1 |
| Jia, J | 2 |
| Niu, X | 1 |
| Zheng, C | 1 |
| Higuchi, T | 4 |
| Sugisawa, N | 2 |
| Yamamoto, J | 2 |
| Singh, SR | 3 |
| Clary, B | 2 |
| Jongeneel, G | 1 |
| Klausch, T | 1 |
| van Erning, FN | 3 |
| Vink, GR | 1 |
| Koopman, M | 2 |
| Greuter, MJE | 1 |
| Coupé, VMH | 1 |
| Pranzini, E | 1 |
| Leo, A | 1 |
| Rapizzi, E | 1 |
| Ramazzotti, M | 1 |
| Magherini, F | 1 |
| Giovannelli, L | 1 |
| Caselli, A | 2 |
| Cirri, P | 2 |
| Taddei, ML | 2 |
| Paoli, P | 2 |
| Qian, Y | 1 |
| Wu, X | 12 |
| Yokoyama, Y | 4 |
| Okuzaki, D | 1 |
| Taguchi, M | 1 |
| Hirose, H | 1 |
| Hata, T | 2 |
| Inoue, A | 1 |
| Hiraki, M | 1 |
| Ohtsuka, M | 2 |
| Takahashi, H | 4 |
| Haraguchi, N | 1 |
| Tanaka, S | 9 |
| Yamamoto, H | 9 |
| Yamanaka, T | 4 |
| Takeuchi, S | 2 |
| Gamoh, M | 2 |
| Saji, S | 11 |
| Maehara, Y | 8 |
| Lavitrano, M | 2 |
| Ianzano, L | 2 |
| Bonomo, S | 1 |
| Cialdella, A | 1 |
| Cerrito, MG | 1 |
| Pisano, F | 2 |
| Missaglia, C | 1 |
| Giovannoni, R | 2 |
| Romano, G | 2 |
| McLean, CM | 1 |
| Voest, EE | 1 |
| D'Amato, F | 1 |
| Noli, B | 1 |
| Ferri, GL | 1 |
| Agostini, M | 1 |
| Pucciarelli, S | 1 |
| Helin, K | 2 |
| Leone, BE | 2 |
| Canzonieri, V | 1 |
| Grassilli, E | 2 |
| Kudo, T | 2 |
| Ura, T | 1 |
| Fujii, H | 1 |
| Kajiwara, T | 1 |
| Nakajima, TE | 2 |
| Takahashi, S | 4 |
| Nagashima, F | 2 |
| Itabashi, M | 2 |
| Sasaki, T | 5 |
| Chiron, M | 1 |
| Chen, S | 3 |
| Yue, T | 2 |
| Zhu, J | 3 |
| Bu, D | 2 |
| Pan, Y | 3 |
| Wang, P | 3 |
| Touyama, T | 4 |
| Matsui, T | 5 |
| Ishigure, K | 3 |
| Inoue, K | 4 |
| Ishikawa, H | 6 |
| Ogata, Y | 7 |
| Goto, K | 2 |
| Roychoudhury, S | 1 |
| Biswas, P | 1 |
| Mohapatra, B | 1 |
| Ray, S | 1 |
| Dowlatshahi, K | 1 |
| Band, V | 1 |
| Talmon, G | 1 |
| Bhakat, KK | 1 |
| Bazzaz, R | 1 |
| Bijanpour, H | 1 |
| Pirouzpanah, SMB | 1 |
| Yaghmaei, P | 1 |
| Rashtchizadeh, N | 1 |
| Park, H | 1 |
| Jung, M | 2 |
| Min, J | 1 |
| Lee, CK | 2 |
| Jeon, JY | 1 |
| Ishikawa, K | 4 |
| Kawano, Y | 1 |
| Arihara, Y | 1 |
| Kubo, T | 1 |
| Takada, K | 2 |
| Murase, K | 2 |
| Miyanishi, K | 2 |
| Kobune, M | 1 |
| Kato, J | 6 |
| Handali, S | 3 |
| Moghimipour, E | 3 |
| Rezaei, M | 3 |
| Ramezani, Z | 2 |
| Dorkoosh, FA | 3 |
| Burocziova, M | 1 |
| Burdova, K | 1 |
| Martinikova, AS | 1 |
| Kasparek, P | 1 |
| Kleiblova, P | 1 |
| Danielsen, SA | 1 |
| Borecka, M | 1 |
| Jenikova, G | 1 |
| Janečková, L | 1 |
| Pavel, J | 1 |
| Zemankova, P | 1 |
| Schneiderova, M | 1 |
| Schwarzova, L | 1 |
| Ticha, I | 1 |
| Sun, XF | 1 |
| Jiraskova, K | 1 |
| Liska, V | 1 |
| Vodickova, L | 1 |
| Vodicka, P | 2 |
| Sedlacek, R | 1 |
| Kleibl, Z | 1 |
| Lothe, RA | 2 |
| Korinek, V | 1 |
| Macurek, L | 1 |
| Fang, W | 1 |
| Cai, X | 2 |
| Gu, Y | 3 |
| Genovese, S | 2 |
| Epifano, F | 2 |
| Preziuso, F | 1 |
| Slater, J | 1 |
| Nangia-Makker, P | 3 |
| Majumdar, APN | 1 |
| Fiorito, S | 1 |
| Tan, Y | 1 |
| Yoon, SN | 1 |
| Alwers, E | 1 |
| Jansen, L | 2 |
| Bläker, H | 2 |
| Kloor, M | 2 |
| Tagscherer, KE | 2 |
| Roth, W | 3 |
| Boakye, D | 1 |
| Herpel, E | 2 |
| Grüllich, C | 1 |
| Chang-Claude, J | 2 |
| Brenner, H | 2 |
| Hoffmeister, M | 2 |
| Abdel Raouf, SM | 1 |
| Ibrahim, TR | 1 |
| Abdelaziz, LA | 2 |
| Farid, MI | 1 |
| Mohamed, SY | 1 |
| Socca, EAR | 1 |
| Reis, SK | 1 |
| Genaro, SC | 1 |
| Leite, SK | 1 |
| Reis, IB | 1 |
| Bockëlmann, PK | 1 |
| Durán, N | 1 |
| Fávaro, WJ | 1 |
| Jimi, S | 1 |
| Oohata, Y | 1 |
| Takahata, S | 1 |
| Kamei, T | 1 |
| Gu, XY | 1 |
| Jiang, Y | 3 |
| Li, MQ | 1 |
| Han, P | 2 |
| Liu, YL | 1 |
| Cui, BB | 1 |
| Öz, A | 1 |
| Server, S | 1 |
| Koyuncu Sökmen, B | 1 |
| Namal, E | 1 |
| İnan, N | 1 |
| Balcı, NC | 1 |
| Liang, G | 1 |
| Zhu, Y | 5 |
| Ali, DJ | 1 |
| Tian, T | 1 |
| Xu, H | 1 |
| Si, K | 1 |
| Sun, B | 1 |
| Chen, B | 2 |
| Xiao, Z | 1 |
| Allison, JD | 1 |
| Tanavin, T | 1 |
| Birnbaum, G | 1 |
| Khalid, U | 1 |
| Hadad, SE | 1 |
| Hazmi, BA | 1 |
| Alhebshi, A | 1 |
| Aldahlawi, AM | 1 |
| Bassam, RA | 1 |
| Cantore, M | 3 |
| Banzi, M | 7 |
| Mattioli, R | 2 |
| Cardellino, GG | 1 |
| Di Bartolomeo, M | 5 |
| Tamberi, S | 1 |
| Marchetti, P | 6 |
| Rimassa, L | 4 |
| Bochicchio, AM | 2 |
| Artioli, F | 1 |
| Bregni, G | 1 |
| Vernerey, D | 6 |
| Im, SA | 4 |
| Buzzoni, R | 2 |
| Reingold, S | 1 |
| McKendrick, J | 5 |
| Ravit, G | 1 |
| Fountzilas, G | 5 |
| Yong, WP | 1 |
| Isaacs, R | 1 |
| Creemers, GJ | 2 |
| Rakez, M | 3 |
| Cunningham, D | 7 |
| Schaefer, JK | 1 |
| Ramnath, N | 1 |
| Han, JG | 1 |
| Wang, ZJ | 1 |
| Zeng, WG | 1 |
| Wang, YB | 1 |
| Wei, GH | 1 |
| Zhai, ZW | 1 |
| Zhao, BC | 1 |
| Yi, BQ | 1 |
| Xie, ZY | 1 |
| Wang, FF | 1 |
| Xiao, ZH | 1 |
| Liu, SF | 1 |
| Tang, SL | 1 |
| Lai, YL | 1 |
| Gao, Q | 2 |
| Li, XX | 1 |
| Xu, YM | 1 |
| Zhang, JZ | 1 |
| Rong, SD | 1 |
| Qin, YQ | 1 |
| Fang, J | 1 |
| Lu, C | 3 |
| Klement, JD | 1 |
| Yang, D | 11 |
| Albers, T | 1 |
| Lebedyeva, IO | 1 |
| Waller, JL | 1 |
| Chen, CH | 1 |
| Yang, PM | 1 |
| Pederson, LD | 1 |
| Marshall, JL | 3 |
| Kerr, RS | 1 |
| Bridgewater, J | 8 |
| Xu, G | 2 |
| Zhu, D | 2 |
| Petito, LC | 1 |
| García-Albéniz, X | 1 |
| Logan, RW | 1 |
| Howlader, N | 1 |
| Mariotto, AB | 1 |
| Dahabreh, IJ | 1 |
| Hernán, MA | 1 |
| Nemoto, T | 1 |
| Isohata, N | 1 |
| Takayanagi, D | 1 |
| Nemoto, D | 1 |
| Aizawa, M | 1 |
| Utano, K | 1 |
| Togashi, K | 1 |
| Oshibe, I | 1 |
| Soeta, N | 1 |
| Saito, T | 3 |
| Yu, IS | 1 |
| Pereira, AAL | 1 |
| Korphaisarn, K | 1 |
| Marshall, J | 2 |
| Segelov, E | 2 |
| O'Callaghan, C | 2 |
| Lim, HJ | 4 |
| Wu, XX | 1 |
| Huang, XL | 1 |
| Lin, XR | 1 |
| Li, YL | 1 |
| Chen, YH | 2 |
| Huang, ZM | 1 |
| Yao, Y | 2 |
| Li, N | 2 |
| Frydenberg, H | 1 |
| Harsem, NK | 1 |
| Ofigsbø, Å | 1 |
| Skoglund, H | 1 |
| Brændengen, M | 1 |
| Kaasa, S | 1 |
| Guren, MG | 2 |
| Buhrmann, C | 3 |
| Popper, B | 1 |
| Majeed, M | 1 |
| Aggarwal, BB | 1 |
| Shakibaei, M | 3 |
| Mendoza-Rodríguez, MG | 1 |
| Sánchez-Barrera, CÁ | 1 |
| Callejas, BE | 1 |
| García-Castillo, V | 1 |
| Beristain-Terrazas, DL | 1 |
| Delgado-Buenrostro, NL | 1 |
| Chirino, YI | 1 |
| León-Cabrera, SA | 1 |
| Rodríguez-Sosa, M | 1 |
| Gutierrez-Cirlos, EB | 1 |
| Pérez-Plasencia, C | 1 |
| Vaca-Paniagua, F | 1 |
| Meraz-Ríos, MA | 1 |
| Terrazas, LI | 1 |
| Rajan, SAP | 1 |
| Skardal, A | 3 |
| Hall, AR | 1 |
| Pagès, F | 1 |
| Henriques, J | 2 |
| Borg, C | 1 |
| Marliot, F | 1 |
| Ben Jannet, R | 1 |
| Louvet, C | 14 |
| Bennouna, J | 4 |
| Faroux, R | 4 |
| Kirilovsky, A | 1 |
| Duval, A | 3 |
| Laurent-Puig, P | 9 |
| Svrcek, M | 1 |
| Hermitte, F | 1 |
| Emile, JF | 9 |
| Perez-Ortiz, JM | 1 |
| Galan-Moya, EM | 1 |
| de la Cruz-Morcillo, MA | 1 |
| Rodriguez, JF | 1 |
| Gracia, I | 1 |
| Garcia, MT | 1 |
| Redondo-Calvo, FJ | 1 |
| Wu, P | 1 |
| Zhou, Q | 2 |
| Zhuang, Y | 1 |
| Bao, J | 1 |
| Blangero, Y | 1 |
| Rabilloud, M | 1 |
| Le Malicot, K | 9 |
| Lepage, C | 12 |
| Ecochard, R | 1 |
| Subtil, F | 2 |
| Shibata, K | 2 |
| Machiki, Y | 1 |
| Hiromatsu, T | 1 |
| Takara, D | 1 |
| Idetsu, A | 1 |
| Ohara, N | 1 |
| Naito, A | 2 |
| Kawai, K | 4 |
| Takeno, A | 2 |
| Takeda, Y | 2 |
| Suzuki, Y | 3 |
| Imasato, M | 1 |
| Fujie, Y | 1 |
| Nakaba, H | 1 |
| Akamatsu, H | 1 |
| Murata, K | 6 |
| Woźniak, M | 1 |
| Makuch, S | 1 |
| Winograd, K | 1 |
| Wiśniewski, J | 1 |
| Ziółkowski, P | 1 |
| Agrawal, S | 2 |
| Benhaim, L | 4 |
| Laurent Puig, P | 2 |
| Geillon, F | 1 |
| Manfredi, S | 1 |
| Chauvenet, M | 1 |
| Taly, V | 1 |
| Owen, D | 1 |
| Lukovic, J | 1 |
| Hosni, A | 1 |
| Crane, CH | 1 |
| Hong, TS | 1 |
| Dawson, LA | 1 |
| Velec, M | 1 |
| Lawrence, TS | 7 |
| Janardhanam, LSL | 1 |
| Indukuri, VV | 1 |
| Verma, P | 1 |
| Dusane, AC | 1 |
| Venuganti, VVK | 1 |
| Cao, C | 1 |
| Parikh, P | 1 |
| Moezardalan, K | 1 |
| Anantharaman, A | 1 |
| Azarm, A | 1 |
| Lai, J | 1 |
| Hanna, DL | 2 |
| Hanaka, J | 1 |
| Goya, T | 1 |
| Ishimoto, K | 3 |
| Minami, A | 1 |
| Minami, K | 3 |
| Ueda, N | 1 |
| Tsujiuchi, T | 4 |
| Gomez, D | 1 |
| Calderón, C | 1 |
| Carmona-Bayonas, A | 1 |
| Cacho Lavin, D | 1 |
| Muñoz, MM | 1 |
| Martinez Cabañez, R | 1 |
| Jimenez-Fonseca, P | 1 |
| Shi, J | 5 |
| Ma, Z | 1 |
| Pan, H | 2 |
| Chu, Y | 1 |
| Groehs, RV | 1 |
| Negrao, MV | 1 |
| Hajjar, LA | 1 |
| Jordão, CP | 1 |
| Carvalho, BP | 1 |
| Toschi-Dias, E | 1 |
| Andrade, AC | 1 |
| Hodas, FP | 1 |
| Alves, MJNN | 1 |
| Sarmento, AO | 1 |
| Testa, L | 1 |
| Hoff, PMG | 1 |
| Negrao, CE | 1 |
| Filho, RK | 1 |
| Ohta, R | 1 |
| Hara, K | 3 |
| Iwai, T | 2 |
| Ishibashi, K | 8 |
| Yoshimatsu, K | 9 |
| Kosugi, C | 2 |
| Tsubaki, M | 6 |
| Nakajima, H | 3 |
| Oya, M | 4 |
| Yoshida, H | 4 |
| Koda, K | 4 |
| Gallego, J | 2 |
| González, E | 1 |
| Vaghari-Tabari, M | 1 |
| Majidinia, M | 1 |
| Moein, S | 1 |
| Qujeq, D | 1 |
| Alemi, F | 1 |
| Mohamadzadeh, R | 1 |
| Targhazeh, N | 1 |
| Safa, A | 1 |
| Yousefi, B | 1 |
| Ramadan, RA | 1 |
| Moghazy, TF | 1 |
| Hafez, R | 1 |
| Morsi, H | 1 |
| Samir, M | 1 |
| Shamesya, M | 1 |
| Wagner, AD | 1 |
| Allegra, CJ | 32 |
| VanCutsem, E | 1 |
| O'Connell, MJ | 44 |
| Twelves, C | 9 |
| Francini, E | 3 |
| Seitz, JF | 20 |
| Marsoni, S | 9 |
| Park, SR | 1 |
| Namkoong, S | 1 |
| Friesen, L | 1 |
| Cho, CS | 2 |
| Zhang, ZZ | 1 |
| Yoon, E | 1 |
| Kim, CH | 2 |
| Kwak, H | 1 |
| Kang, HM | 1 |
| Lee, JH | 8 |
| Lu, Y | 2 |
| Zhang, R | 3 |
| Yao, Q | 1 |
| Knapen, DG | 1 |
| Cherny, NI | 1 |
| Zygoura, P | 1 |
| Latino, NJ | 1 |
| Douillard, JY | 6 |
| Dafni, U | 2 |
| de Vries, EGE | 1 |
| de Groot, DJ | 1 |
| Ishibe, A | 1 |
| Suwa, Y | 1 |
| Nakagawa, K | 5 |
| Suwa, H | 2 |
| Endo, I | 2 |
| Hong, S | 1 |
| Cai, W | 1 |
| Mi, X | 1 |
| Lin, Z | 1 |
| Saito, Y | 2 |
| Tsuji, Y | 5 |
| Harihara, Y | 1 |
| Kurihara, N | 1 |
| Kusakawa, G | 1 |
| Sakai, T | 3 |
| Uchida, Y | 4 |
| Takamoto, M | 1 |
| Kimoto, S | 1 |
| Woo, IT | 1 |
| Park, JS | 1 |
| Kang, BW | 2 |
| Park, SY | 1 |
| Kim, HJ | 4 |
| Choi, GS | 2 |
| Gwang Kim, J | 1 |
| Baik, H | 3 |
| Bae, KB | 4 |
| Golbaz, R | 1 |
| Khoei, S | 4 |
| Khoee, S | 4 |
| Shirvalilou, S | 1 |
| Safa, M | 1 |
| Mahdavi, SR | 1 |
| Karimi, MR | 1 |
| Go, G | 1 |
| Yun, CW | 2 |
| Yoon, YM | 2 |
| Lim, JH | 1 |
| Lee, SH | 8 |
| Bajic, D | 1 |
| Chester, K | 1 |
| Neri, D | 1 |
| Lund, JL | 3 |
| Webster-Clark, MA | 1 |
| Hinton, SP | 1 |
| Shmuel, S | 1 |
| Stürmer, T | 7 |
| Sanoff, HK | 7 |
| Wei, GY | 1 |
| Zhang, RP | 1 |
| Wang, SM | 1 |
| Du, GH | 1 |
| Tian, R | 1 |
| Shang, K | 1 |
| Dong, X | 2 |
| Cao, B | 1 |
| Chibaudel, B | 4 |
| Brenner, B | 2 |
| Martinez-Villacampa, M | 1 |
| Gallego-Plazas, J | 1 |
| Shim, K | 1 |
| Jonker, D | 1 |
| Banzi, C | 1 |
| Dewdney, A | 1 |
| Dejthevaporn, T | 1 |
| Bloemendal, HJ | 1 |
| Roth, A | 4 |
| Hoff, PM | 2 |
| McGillivray, E | 1 |
| Farma, J | 1 |
| Savage, M | 1 |
| Hall, MJ | 1 |
| Luo, B | 1 |
| Jain, R | 1 |
| Shiomi, A | 1 |
| Rikiyama, T | 2 |
| Fukunaga, M | 5 |
| Ueki, T | 2 |
| Shinkai, H | 2 |
| Tanida, N | 1 |
| Sunami, E | 4 |
| Kanto, S | 1 |
| Takeji, S | 1 |
| Okamura, M | 1 |
| Sakikubo, M | 1 |
| Tatsumi, K | 3 |
| Yasuda, S | 3 |
| Kawabe, A | 2 |
| Othman, MH | 1 |
| Zayed, GM | 1 |
| Ali, UF | 1 |
| Abdellatif, AAH | 1 |
| Beypinar, I | 1 |
| Demir, H | 1 |
| Baykara, M | 1 |
| Aykan, NF | 1 |
| Rawlley, B | 1 |
| Diab, O | 1 |
| Al-Rajabi, R | 1 |
| Carroll, E | 1 |
| Melancon, T | 1 |
| Kasi, A | 1 |
| Labadie, JD | 1 |
| Hua, X | 1 |
| Harrison, TA | 1 |
| Banbury, BL | 1 |
| Huyghe, JR | 1 |
| Sun, W | 4 |
| Penney, KL | 1 |
| Phipps, AI | 2 |
| Cohen, SA | 1 |
| Peters, U | 1 |
| Chan, AT | 3 |
| Newcomb, PA | 2 |
| Hu, K | 1 |
| Miyake, K | 3 |
| Kiyuna, T | 1 |
| Oshiro, H | 1 |
| Wangsiricharoen, S | 1 |
| Kawaguchi, K | 1 |
| Razmjooei, S | 1 |
| Chawla, SP | 1 |
| Kong, Y | 1 |
| Hong, L | 1 |
| Xu, X | 2 |
| Meyerhardt, J | 2 |
| Saunders, M | 4 |
| Meyers, J | 2 |
| Harkin, A | 2 |
| Torri, V | 7 |
| Georgoulias, V | 3 |
| Ouali, K | 1 |
| Neuzillet, C | 1 |
| Rousseau, B | 1 |
| Garcia-Larnicol, ML | 1 |
| Tournigand, C | 7 |
| Samalin, E | 1 |
| Castro, MP | 1 |
| Afshar, M | 1 |
| Williams, C | 2 |
| Turcat, T | 1 |
| Parker, D | 1 |
| Gordon, E | 1 |
| Zambelli, J | 1 |
| McDonald, A | 1 |
| Suh, C | 1 |
| Baylon, S | 1 |
| Biskup, S | 1 |
| Fiskum, J | 1 |
| Goldberg, R | 2 |
| Alberts, S | 3 |
| Allegra, C | 4 |
| O'Connell, M | 2 |
| Haller, D | 4 |
| Erlichman, C | 7 |
| Tamilselvi, S | 1 |
| Kavitha, R | 1 |
| Usharani, M | 1 |
| Mumjitha, M | 1 |
| Mohanapriya, S | 2 |
| Kulthanachairojana, N | 1 |
| Chansriwong, P | 1 |
| Thokanit, NS | 1 |
| Sirilerttrakul, S | 1 |
| Wannakansophon, N | 1 |
| Taychakhoonavudh, S | 1 |
| Rani, I | 3 |
| Kumar, S | 2 |
| Sharma, B | 2 |
| Prasad, R | 1 |
| Kaur, S | 2 |
| Sharma, P | 1 |
| Agnihotri, N | 3 |
| Dupertuis, YM | 2 |
| Boulens, N | 1 |
| Angibaud, E | 1 |
| Briod, AS | 1 |
| Viglione, A | 1 |
| Allémann, E | 1 |
| Delie, F | 1 |
| Pichard, C | 2 |
| Ghatak, S | 1 |
| Hascall, VC | 1 |
| Markwald, RR | 1 |
| Misra, S | 2 |
| Hasegawa, K | 1 |
| Otomo, M | 1 |
| Takatsuno, Y | 1 |
| Maejima, K | 1 |
| Kaneko, J | 1 |
| Maejima, S | 1 |
| Isogai, J | 1 |
| Montrose, DC | 1 |
| Saha, S | 2 |
| Foronda, M | 1 |
| McNally, EM | 1 |
| Zhou, XK | 1 |
| Ha, T | 1 |
| Krumsiek, J | 1 |
| Buyukozkan, M | 1 |
| Verma, A | 2 |
| Elemento, O | 1 |
| Yantiss, RK | 1 |
| Gross, SS | 1 |
| Galluzzi, L | 1 |
| Dow, LE | 1 |
| Dannenberg, AJ | 1 |
| Mulens-Arias, V | 1 |
| Nicolás-Boluda, A | 1 |
| Pinto, A | 1 |
| Balfourier, A | 1 |
| Carn, F | 1 |
| Silva, AKA | 1 |
| Pocard, M | 3 |
| Gazeau, F | 1 |
| Mahdi, WA | 1 |
| Hussain, A | 1 |
| Ramzan, M | 1 |
| Faruk, A | 1 |
| Bukhari, SI | 1 |
| Dev, A | 1 |
| Shimizu, H | 2 |
| Kuriu, Y | 1 |
| Arita, T | 1 |
| Kiuchi, J | 1 |
| Konishi, H | 2 |
| Morimura, R | 1 |
| Shiozaki, A | 1 |
| Ikoma, H | 1 |
| Kubota, T | 17 |
| Fujiwara, H | 3 |
| Okamoto, K | 3 |
| Otsuji, E | 3 |
| Quinonero, F | 1 |
| Cepero, A | 1 |
| Urbano, D | 1 |
| Munoz-Gamez, JA | 1 |
| Martin-Guerrero, SM | 1 |
| Martin-Oliva, D | 1 |
| Prados, J | 5 |
| Melguizo, C | 7 |
| Ortiz, R | 5 |
| Karoui, M | 4 |
| Piessen, G | 2 |
| Legoux, JL | 2 |
| De Chaisemartin, C | 2 |
| Lecaille, C | 3 |
| Ammarguellat, H | 2 |
| Brunetti, F | 2 |
| Prudhomme, M | 2 |
| Regimbeau, JM | 2 |
| Glehen, O | 2 |
| Lievre, A | 2 |
| Portier, G | 2 |
| Hartwig, J | 2 |
| Goujon, G | 2 |
| Romain, B | 2 |
| Takeshita, E | 1 |
| Oda, N | 2 |
| Sato, Y | 11 |
| Momma, T | 3 |
| Maekawa, H | 2 |
| Kobayashi, M | 9 |
| Lin, SM | 2 |
| Wang, XJ | 1 |
| Huang, SH | 1 |
| Xu, ZB | 1 |
| Lu, XR | 1 |
| Xu, DB | 1 |
| Chi, P | 1 |
| Xiao, WW | 1 |
| Xie, WH | 1 |
| Cai, PQ | 1 |
| Wang, QX | 2 |
| Chang, H | 1 |
| Chen, BQ | 1 |
| Zhou, WH | 1 |
| Zeng, ZF | 1 |
| Wu, XJ | 4 |
| Liu, Q | 3 |
| Li, LR | 4 |
| Gao, YH | 1 |
| Wang, XY | 1 |
| Yao, QH | 1 |
| Chen, YB | 1 |
| Suetsugu, T | 1 |
| Mori, R | 1 |
| Futamura, M | 1 |
| Fukada, M | 1 |
| Tanaka, H | 5 |
| Yasufuku, I | 1 |
| Iwata, Y | 1 |
| Imai, T | 1 |
| Imai, H | 1 |
| Tanaka, Y | 11 |
| Okumura, N | 1 |
| Takahashi, T | 15 |
| Yoshida, K | 3 |
| Morii, Y | 1 |
| Takeda, T | 3 |
| Otubo, R | 1 |
| Seki, S | 2 |
| Yamatomo, Y | 1 |
| Imano, M | 1 |
| Satou, T | 1 |
| Shimomura, K | 2 |
| Nishida, S | 1 |
| Zhao, K | 1 |
| Cheng, X | 3 |
| Ye, Z | 1 |
| Peng, W | 1 |
| Xing, C | 1 |
| Webster-Clark, M | 1 |
| Keil, AP | 1 |
| Westreich, D | 1 |
| Pasini, F | 3 |
| Bozzarelli, S | 2 |
| Garattini, SK | 1 |
| Ferrari, D | 4 |
| Montesarchio, V | 1 |
| Mambrini, A | 1 |
| Ciuffreda, L | 3 |
| Pusceddu, V | 1 |
| Bidoli, P | 2 |
| Amoroso, D | 1 |
| Frassineti, L | 2 |
| Pastorino, A | 1 |
| Margalit, O | 2 |
| Boursi, B | 2 |
| Thierry, A | 1 |
| Shacham-Shmueli, E | 4 |
| Asada, Y | 3 |
| Tsuruta, M | 3 |
| Okabayashi, K | 2 |
| Shigeta, K | 2 |
| Ishida, T | 4 |
| Shimada, T | 2 |
| Suzumura, H | 2 |
| Koishikawa, K | 2 |
| Akimoto, S | 2 |
| Hasegawa, H | 6 |
| Kitagawa, Y | 4 |
| Fan, L | 1 |
| Tan, B | 1 |
| Li, B | 4 |
| Yu, B | 2 |
| Xi, J | 1 |
| Waghela, BN | 1 |
| Vaidya, FU | 1 |
| Pathak, C | 2 |
| Ghobashy, MM | 1 |
| Elbarbary, AM | 1 |
| Hegazy, DE | 1 |
| Mas, L | 1 |
| Bachet, JB | 3 |
| Jooste, V | 1 |
| Bouvier, AM | 2 |
| Guo, S | 1 |
| de Castro E Gloria, H | 1 |
| Jesuíno Nogueira, L | 1 |
| Bencke Grudzinski, P | 1 |
| da Costa Ghignatti, PV | 1 |
| Guecheva, TN | 1 |
| Motta Leguisamo, N | 1 |
| Saffi, J | 1 |
| Abulizi, A | 1 |
| Hu, L | 2 |
| Ma, A | 1 |
| Shao, FY | 1 |
| Zhu, HZ | 1 |
| Shao, GY | 1 |
| Ran, JH | 1 |
| Zhou, H | 1 |
| Lin, DM | 1 |
| Wang, LF | 1 |
| Yang, BX | 1 |
| Kelm, M | 1 |
| Schollbach, J | 1 |
| Anger, F | 1 |
| Wiegering, A | 2 |
| Klein, I | 1 |
| Germer, CT | 2 |
| Schlegel, N | 1 |
| Kunzmann, V | 1 |
| Löb, S | 1 |
| Gosavi, R | 1 |
| Chia, C | 1 |
| Michael, M | 4 |
| Heriot, AG | 1 |
| Warrier, SK | 1 |
| Kong, JC | 1 |
| Chen, PH | 1 |
| Wu, YY | 3 |
| Chung, CH | 1 |
| Chen, YG | 3 |
| Huang, TC | 1 |
| Yeh, RH | 1 |
| Chang, PY | 2 |
| Dai, MS | 1 |
| Lai, SW | 1 |
| Ho, CL | 4 |
| Chen, JH | 3 |
| Hu, JM | 1 |
| Yang, SS | 1 |
| Chien, WC | 1 |
| Abdel-Rahman, O | 1 |
| Tang, PA | 1 |
| Koski, S | 1 |
| Milczarek, M | 3 |
| Pogorzelska, A | 1 |
| Wiktorska, K | 1 |
| Voron, T | 1 |
| Lo Dico, R | 1 |
| Malicot, KL | 1 |
| Espin, E | 1 |
| Cianchi, F | 1 |
| Jürgen, W | 1 |
| Buggenhout, A | 1 |
| Bruzzi, M | 1 |
| Denimal, F | 1 |
| Cazelles, A | 1 |
| Douard, R | 1 |
| Ramos-Esquivel, A | 1 |
| Chinchilla-Monge, R | 1 |
| Abbas, J | 1 |
| Valle, M | 1 |
| Yaghoubi, A | 1 |
| Movaqar, A | 1 |
| Ghazvini, K | 1 |
| Soleimanpour, S | 1 |
| Blinman, P | 1 |
| Martin, A | 1 |
| Jefford, M | 1 |
| Goldstein, D | 4 |
| Boadle, D | 1 |
| Morris, M | 4 |
| Tebbutt, N | 1 |
| Aiken, C | 1 |
| Haydon, A | 2 |
| Stockler, MR | 1 |
| Cervena, K | 1 |
| Pardini, B | 1 |
| Urbanova, M | 1 |
| Vodenkova, S | 1 |
| Eva, P | 1 |
| Veskrnova, V | 1 |
| Levy, M | 1 |
| Buchler, T | 1 |
| Mokrejs, M | 1 |
| Naccarati, A | 1 |
| Vymetalkova, V | 1 |
| Robling, KR | 1 |
| Abada, PB | 1 |
| Hozak, RR | 1 |
| Siegel, R | 1 |
| Fill, JA | 1 |
| Wijayawardana, S | 1 |
| Walgren, RA | 1 |
| Giles, B | 1 |
| Jones, A | 1 |
| Pitts, KR | 1 |
| Drove, N | 1 |
| Ekremoglu, O | 1 |
| Koc, A | 1 |
| Taha, HF | 1 |
| Harb, OA | 1 |
| Gertallah, LM | 1 |
| Al-Taie, A | 1 |
| Koseoglu, A | 1 |
| Cardoso, A | 1 |
| Guimarães, PPG | 1 |
| Viana, CTR | 1 |
| Pereira, L | 1 |
| Gontijo, SML | 1 |
| Campos, PP | 1 |
| Andrade, SP | 1 |
| Santos, RAS | 1 |
| Sinisterra, RD | 1 |
| Hanna, C | 1 |
| Iveson, P | 1 |
| Levasseur, A | 1 |
| Park, J | 1 |
| Kang, SH | 1 |
| Seo, SH | 2 |
| Kim, KH | 8 |
| Oh, MK | 3 |
| Lee, HS | 2 |
| An, MS | 3 |
| Dong, H | 1 |
| Borderwala, K | 1 |
| Rathod, S | 1 |
| Yadav, S | 1 |
| Vyas, B | 1 |
| Shah, P | 1 |
| Schürmann, L | 1 |
| Schumacher, L | 1 |
| Roquette, K | 1 |
| Brozovic, A | 1 |
| Fritz, G | 1 |
| Cai, P | 1 |
| Yang, J | 3 |
| Kanai, M | 3 |
| Kawaguchi, T | 2 |
| Matsumoto, S | 6 |
| Matsuda, F | 2 |
| Bayir Garbioglu, D | 1 |
| Ozel, C | 1 |
| Avci, H | 1 |
| Dincer, M | 2 |
| Huang, WY | 1 |
| Lee, CC | 1 |
| Hsiao, CW | 1 |
| Wu, CC | 2 |
| Jao, SW | 1 |
| Yang, JF | 1 |
| Lo, CH | 1 |
| Shi, Y | 2 |
| Dai, G | 1 |
| Guren, TK | 1 |
| Thomsen, M | 1 |
| Kure, EH | 1 |
| Sorbye, H | 1 |
| Glimelius, B | 7 |
| Sigurdsson, F | 1 |
| Lothe, IMB | 1 |
| Dalsgaard, AM | 1 |
| Skovlund, E | 1 |
| Christoffersen, T | 1 |
| Tveit, KM | 5 |
| Matsuda, K | 3 |
| Namiki, T | 1 |
| Ueno, M | 4 |
| Hanafusa, T | 1 |
| Yokozeki, H | 1 |
| Waddle, M | 1 |
| Irvin, M | 1 |
| Gupta, E | 1 |
| Gibbs, M | 1 |
| Kakar, TS | 1 |
| Gannon, NA | 1 |
| Arthurs, JR | 1 |
| Fischer, DL | 1 |
| Ailawadhi, S | 1 |
| Przybyła, T | 1 |
| Sakowicz-Burkiewicz, M | 3 |
| Maciejewska, I | 3 |
| Bielarczyk, H | 2 |
| Pawełczyk, T | 1 |
| Shiozaki, H | 1 |
| Lee, JE | 2 |
| Passot, G | 1 |
| Goumard, C | 1 |
| Okuno, M | 2 |
| Aloia, TA | 1 |
| Eng, C | 2 |
| Chang, G | 1 |
| Vauthey, JN | 3 |
| Conrad, C | 1 |
| Bash-Imam, Z | 1 |
| Thérizols, G | 1 |
| Vincent, A | 1 |
| Lafôrets, F | 1 |
| Polay Espinoza, M | 1 |
| Pion, N | 1 |
| Macari, F | 1 |
| Pannequin, J | 1 |
| David, A | 3 |
| Saurin, JC | 1 |
| Mertani, HC | 1 |
| Textoris, J | 1 |
| Auboeuf, D | 1 |
| Catez, F | 1 |
| Dalla Venezia, N | 1 |
| Dutertre, M | 1 |
| Marcel, V | 1 |
| Diaz, JJ | 1 |
| Sato, N | 4 |
| Fuyuno, S | 1 |
| Hatada, T | 2 |
| Furuhashi, T | 1 |
| Abe, T | 3 |
| Yun, S | 2 |
| Han, YS | 2 |
| Kim, S | 2 |
| Dai, F | 1 |
| Chen, D | 2 |
| De Almeida, CV | 1 |
| Zamame, JA | 1 |
| Romagnoli, GG | 1 |
| Rodrigues, CP | 1 |
| Magalhães, MB | 1 |
| Amedei, A | 1 |
| Kaneno, R | 1 |
| Devarasetty, M | 2 |
| Wang, E | 1 |
| Soker, S | 2 |
| Al-Khayyal, NA | 1 |
| Aravind, SR | 1 |
| Saber-Ayad, M | 1 |
| Martínez-Pérez, J | 1 |
| Lopez-Calderero, I | 1 |
| Saez, C | 1 |
| Benavent, M | 1 |
| Limon, ML | 1 |
| Gonzalez-Exposito, R | 1 |
| Soldevilla, B | 1 |
| Salamanca, J | 1 |
| Carnero, A | 1 |
| Garcia-Carbonero, R | 2 |
| Zhao, C | 3 |
| Huang, X | 2 |
| Zhan, F | 1 |
| Yan, F | 2 |
| Julié, C | 3 |
| Mini, E | 10 |
| Folprecht, G | 7 |
| Van Laethem, JL | 8 |
| Dimet, S | 1 |
| Boulagnon-Rombi, C | 1 |
| Allard, MA | 1 |
| Penault-Llorca, F | 2 |
| Rosanova, M | 1 |
| Malapelle, U | 1 |
| Martini, M | 1 |
| De Falco, S | 1 |
| Attademo, L | 1 |
| Fiore, G | 1 |
| Cenci, T | 1 |
| Bellevicine, C | 1 |
| De Placido, S | 2 |
| Troncone, G | 1 |
| Atrián-Blasco, E | 1 |
| Gascón, S | 1 |
| Rodrı Guez-Yoldi, MJ | 1 |
| Laguna, M | 1 |
| Cerrada, E | 1 |
| Lee, SM | 2 |
| Hong, KH | 2 |
| Ejaz, A | 1 |
| Casadaban, L | 1 |
| Maker, AV | 1 |
| Patras, L | 1 |
| Sylvester, B | 1 |
| Luput, L | 1 |
| Sesarman, A | 1 |
| Licarete, E | 1 |
| Porfire, A | 1 |
| Muntean, D | 1 |
| Drotar, DM | 1 |
| Rusu, AD | 1 |
| Nagy, AL | 1 |
| Catoi, C | 1 |
| Tomuta, I | 1 |
| Vlase, L | 2 |
| Banciu, M | 1 |
| Achim, M | 1 |
| Noh, OK | 1 |
| Oh, SY | 2 |
| Kim, YB | 3 |
| Suh, KW | 2 |
| Nguyen, MT | 1 |
| Stoianovici, R | 1 |
| Brunetti, L | 1 |
| Sha, A | 2 |
| Abadi, S | 2 |
| Dougherty, JP | 1 |
| Wolff, BS | 1 |
| Cullen, MJ | 1 |
| Saligan, LN | 1 |
| Gershengorn, MC | 1 |
| Guo, YX | 1 |
| Xu, YH | 1 |
| Zheng, GH | 1 |
| Jin, XQ | 1 |
| Pretel, E | 1 |
| Arias, JL | 5 |
| Cabeza, L | 3 |
| Mallandrich, M | 1 |
| Suñer, J | 1 |
| Clares, B | 3 |
| Limani, P | 2 |
| Linecker, M | 2 |
| Schneider, MA | 1 |
| Kron, P | 2 |
| Tschuor, C | 2 |
| Kachaylo, E | 2 |
| Ungethuem, U | 2 |
| Nicolau, C | 2 |
| Lehn, JM | 2 |
| Graf, R | 2 |
| Humar, B | 2 |
| Clavien, PA | 2 |
| Wang, YR | 1 |
| Dai, GH | 1 |
| Jia, TT | 1 |
| Huang, QX | 1 |
| Qiu, YY | 1 |
| Yin, PH | 1 |
| Lopes-Costa, E | 1 |
| Abreu, M | 1 |
| Gargiulo, D | 1 |
| Rocha, E | 2 |
| Ramos, AA | 2 |
| Sellick, MJ | 1 |
| Michaud, M | 1 |
| Wong, S | 3 |
| Candler, D | 1 |
| Watanabe, SM | 1 |
| Iqbal, A | 1 |
| Han, J | 3 |
| Tang, K | 1 |
| Guo, B | 2 |
| Hou, N | 5 |
| Huang, C | 4 |
| Hosseinifar, T | 1 |
| Sheybani, S | 1 |
| Abdouss, M | 1 |
| Hassani Najafabadi, SA | 1 |
| Shafiee Ardestani, M | 1 |
| Ikemura, M | 1 |
| Hashida, T | 1 |
| Zaanan, A | 7 |
| Smyrk, TC | 6 |
| Zawadi, A | 1 |
| Sargent, DJ | 36 |
| Cai, H | 1 |
| Du, B | 2 |
| Ma, W | 4 |
| Feng, S | 1 |
| Miao, G | 1 |
| Leelakanok, N | 1 |
| Geary, SM | 1 |
| Salem, AK | 1 |
| Mizandari, M | 1 |
| Paksashvili, N | 1 |
| Kikodze, N | 1 |
| Azrumelashvili, T | 1 |
| Pantsulaia, I | 1 |
| Shanava, K | 1 |
| Janikashvili, N | 1 |
| Chikovani, T | 1 |
| Ungari, AQ | 1 |
| Pereira, LRL | 1 |
| Nunes, AA | 1 |
| Peria, FM | 1 |
| Was, H | 1 |
| Czarnecka, J | 1 |
| Kominek, A | 1 |
| Barszcz, K | 1 |
| Bernas, T | 1 |
| Piwocka, K | 1 |
| Kaminska, B | 1 |
| Kim, M | 1 |
| Fisher, DT | 1 |
| Powers, CA | 1 |
| Gabriel, EM | 1 |
| Korman, AM | 1 |
| Sexton, S | 1 |
| Gudkov, AV | 2 |
| Skitzki, JJ | 1 |
| Kim, C | 2 |
| Hong, Y | 1 |
| Lee, H | 2 |
| Kang, H | 1 |
| Lee, EK | 2 |
| Izdebska, M | 1 |
| Gagat, M | 1 |
| Grzanka, A | 1 |
| Ji, WB | 1 |
| Hong, KD | 1 |
| Joung, SY | 1 |
| Um, JW | 1 |
| Min, BW | 1 |
| Zhang, YM | 1 |
| Zhang, YG | 1 |
| Zhu, RW | 1 |
| Morales-Ruiz, T | 1 |
| Devesa-Guerra, I | 1 |
| Raya-Ruiz, L | 1 |
| Tejedor, JR | 1 |
| Bayón, GF | 1 |
| Sierra, MI | 1 |
| Fraga, MF | 1 |
| Ariza, RR | 1 |
| Roldán-Arjona, T | 1 |
| Kim, SR | 3 |
| Song, N | 2 |
| Gavin, PG | 2 |
| Paik, S | 5 |
| Pogue-Geile, KL | 3 |
| Castro-Rojas, CA | 1 |
| Esparza-Mota, AR | 1 |
| Hernandez-Cabrera, F | 1 |
| Romero-Diaz, VJ | 1 |
| Gonzalez-Guerrero, JF | 1 |
| Maldonado-Garza, H | 1 |
| Garcia-Gonzalez, IS | 1 |
| Buenaventura-Cisneros, S | 1 |
| Sanchez-Lopez, JY | 1 |
| Ortiz-Lopez, R | 1 |
| Camacho-Morales, A | 1 |
| Barboza-Quintana, O | 1 |
| Rojas-Martinez, A | 1 |
| Ebadi, M | 1 |
| Field, CJ | 2 |
| Lehner, R | 1 |
| Mazurak, VC | 1 |
| Lai, ZL | 1 |
| Chen, HF | 1 |
| Wang, A | 2 |
| Jia, T | 1 |
| Sun, WQ | 1 |
| Zhu, XM | 1 |
| Chen, XF | 1 |
| Zhao, Z | 2 |
| Kouchak, M | 1 |
| Amini, M | 1 |
| Angali, KA | 1 |
| Trivedi, ND | 1 |
| Hernández-Aragüés, I | 1 |
| Baniandrés-Rodríguez, O | 1 |
| Vilas-Boas, PT | 1 |
| Conde-Montero, E | 1 |
| Suárez-Fernández, R | 1 |
| Yamaguchi, H | 5 |
| Furuichi, Y | 2 |
| Kasai, Y | 3 |
| Takeuchi, H | 3 |
| Yoshimasu, Y | 1 |
| Nakamura, I | 2 |
| Itoi, T | 1 |
| Kong, D | 1 |
| Chu, X | 1 |
| Takase, K | 1 |
| Nose, Y | 1 |
| Sakamoto, T | 2 |
| Murakami, K | 2 |
| Katsura, Y | 1 |
| Omura, Y | 1 |
| Nakatsuka, S | 1 |
| Tamura, S | 1 |
| Su, LD | 1 |
| Peng, JM | 1 |
| Ge, YB | 1 |
| Fukushima, K | 4 |
| Otagaki, S | 2 |
| Fukushima, N | 3 |
| Honoki, K | 3 |
| Kato, M | 3 |
| Murata, A | 1 |
| Nishikawa, S | 1 |
| Tsutsumi, S | 3 |
| Yokoyama, H | 1 |
| Morita, T | 1 |
| Zhou, Z | 2 |
| Parise, RA | 1 |
| Chu, E | 13 |
| Schmitz, JC | 3 |
| Jiang, H | 1 |
| Shi, X | 2 |
| Yu, X | 2 |
| He, X | 5 |
| An, Y | 1 |
| Lu, H | 3 |
| Zykova, T | 1 |
| Zhu, F | 2 |
| Lim, DY | 1 |
| Yao, K | 2 |
| Roh, E | 1 |
| Yoon, SP | 1 |
| Kim, HG | 3 |
| Wen, W | 1 |
| Nadas, J | 1 |
| Bode, AM | 2 |
| Dong, Z | 3 |
| Kato, R | 3 |
| Kato, H | 5 |
| Narushima, K | 1 |
| Shuto, K | 1 |
| Soleimani, M | 1 |
| Kennecke, HF | 4 |
| Ho, MY | 2 |
| Spratlin, JL | 4 |
| Baba, T | 2 |
| Kokuryo, T | 1 |
| Yamaguchi, J | 1 |
| Uehara, K | 1 |
| Ebata, T | 2 |
| Nagino, M | 1 |
| Tikhonova, IA | 1 |
| Huxley, N | 1 |
| Snowsill, T | 1 |
| Crathorne, L | 1 |
| Varley-Campbell, J | 1 |
| Napier, M | 1 |
| Hoyle, M | 1 |
| Crawford, N | 1 |
| Salvucci, M | 1 |
| Hellwig, CT | 1 |
| Lincoln, FA | 1 |
| Mooney, RE | 1 |
| O'Connor, CL | 1 |
| Prehn, JH | 1 |
| Longley, DB | 2 |
| Rehm, M | 1 |
| Gouveia, HS | 1 |
| Lopes, SO | 1 |
| Faria, AL | 1 |
| Hamada, C | 5 |
| Sadahiro, S | 6 |
| Raj, V | 1 |
| Bhadauria, AS | 1 |
| Singh, AK | 1 |
| Kumar, U | 1 |
| Rai, A | 1 |
| Keshari, AK | 1 |
| Kumar, P | 1 |
| Kumar, D | 1 |
| Maity, B | 1 |
| Nath, S | 1 |
| Prakash, A | 1 |
| Ansari, KM | 1 |
| Jat, JL | 1 |
| Paul, J | 2 |
| Souglakos, J | 2 |
| Renfro, LA | 3 |
| Watanabe, T | 15 |
| Zhu, P | 2 |
| Wu, M | 4 |
| Fratte, S | 2 |
| Hug de Larauze, M | 1 |
| Paget-Bailly, S | 1 |
| Bez, J | 1 |
| Dauba, J | 1 |
| Lepere, C | 1 |
| Dupuis, O | 1 |
| Becouarn, Y | 5 |
| Mabro, M | 1 |
| Egreteau, J | 1 |
| Deplanque, G | 1 |
| Ychou, M | 6 |
| Galais, MP | 1 |
| Ghiringhelli, F | 1 |
| Dourthe, LM | 1 |
| Khalil, A | 1 |
| Bonnetain, F | 5 |
| Baretti, M | 1 |
| Personeni, N | 1 |
| Giordano, L | 1 |
| Tronconi, MC | 2 |
| Pressiani, T | 1 |
| Santoro, A | 2 |
| Tokuyama, S | 1 |
| Konishi, K | 1 |
| Yukimoto, R | 1 |
| Okamoto, A | 1 |
| Saito, A | 2 |
| Okada, K | 4 |
| Ota, H | 1 |
| Yokoyama, S | 2 |
| Miki, H | 1 |
| Greally, M | 1 |
| Pilson, K | 1 |
| Linehan, A | 1 |
| O'Keane, C | 1 |
| Shields, CJ | 1 |
| Conneely, JB | 1 |
| McCaffrey, JA | 2 |
| Sun, T | 1 |
| Zhu, T | 1 |
| Liang, X | 1 |
| Yang, S | 5 |
| Zhao, R | 2 |
| Mamtani, R | 1 |
| Yang, YX | 1 |
| Reiss, KA | 1 |
| Golan, T | 1 |
| Halpern, N | 1 |
| Aderka, D | 1 |
| Giantonio, B | 1 |
| Song, K | 2 |
| Zhang, N | 4 |
| Wang, K | 3 |
| Chang, Z | 1 |
| Moreno Vera, S | 1 |
| Kang, KA | 4 |
| Ryu, YS | 3 |
| Piao, MJ | 4 |
| Shilnikova, K | 2 |
| Kang, HK | 4 |
| Yi, JM | 1 |
| Boulanger, M | 1 |
| Paolillo, R | 1 |
| Bossis, G | 1 |
| Yoon, SY | 1 |
| Kim, SB | 2 |
| Hyun, JW | 5 |
| Attoub, S | 1 |
| Arafat, K | 1 |
| Khalaf, T | 1 |
| Sulaiman, S | 1 |
| Iratni, R | 1 |
| Abd-Rabou, AA | 1 |
| Shalby, AB | 1 |
| Ahmed, HH | 1 |
| Onishi, Y | 2 |
| Zunder, SM | 1 |
| van Pelt, GW | 1 |
| Gelderblom, HJ | 1 |
| Putter, H | 1 |
| Tollenaar, RA | 1 |
| Mesker, WE | 1 |
| Wang, C | 3 |
| Cao, L | 2 |
| Xu, T | 1 |
| Cui, Y | 2 |
| Xing, X | 1 |
| Zhou, S | 2 |
| Ji, Z | 1 |
| Mu, R | 1 |
| Félix-Oliveira, A | 1 |
| Madeira, S | 1 |
| Mendes, M | 1 |
| Fernández, LP | 1 |
| Sánchez-Martínez, R | 2 |
| Vargas, T | 3 |
| Herranz, J | 1 |
| Martín-Hernández, R | 2 |
| Mendiola, M | 1 |
| Hardisson, D | 1 |
| Reglero, G | 3 |
| Feliu, J | 3 |
| Redondo, A | 1 |
| Ramírez de Molina, A | 3 |
| Machover, D | 7 |
| Goldschmidt, E | 6 |
| Mollicone, R | 1 |
| Haghighi-Rad, F | 1 |
| Desterke, C | 1 |
| Gaston-Mathé, Y | 1 |
| Saffroy, R | 1 |
| Boucheix, C | 1 |
| Dairou, J | 1 |
| Brungs, D | 1 |
| Aghmesheh, M | 1 |
| de Souza, P | 2 |
| Carolan, M | 1 |
| Clingan, P | 4 |
| Rose, J | 1 |
| Ranson, M | 1 |
| Le Corre, D | 1 |
| Mulot, C | 2 |
| Shigefuku, R | 1 |
| Mizukami, T | 1 |
| Matsunaga, K | 2 |
| Hattori, N | 1 |
| Ehira, T | 1 |
| Suzuki, T | 11 |
| Nakano, H | 4 |
| Matsuo, Y | 1 |
| Nakahara, K | 1 |
| Ikeda, H | 2 |
| Matsumoto, N | 3 |
| Tsuda, T | 2 |
| Katayama, M | 1 |
| Koizumi, S | 1 |
| Okuse, C | 1 |
| Suzuki, M | 3 |
| Yasuda, H | 1 |
| Itoh, F | 1 |
| Han, L | 1 |
| Mu, S | 1 |
| Yin, X | 2 |
| Liang, S | 1 |
| Fang, H | 1 |
| Chang, J | 1 |
| Bhasin, SS | 1 |
| Bielenberg, DR | 1 |
| Sukhatme, VP | 1 |
| Bhasin, M | 1 |
| Huang, S | 3 |
| Kieran, MW | 1 |
| Panigrahy, D | 1 |
| Xi, C | 1 |
| Ye, H | 2 |
| Gong, Z | 1 |
| Ahmed, F | 1 |
| Kumari, S | 1 |
| Kondapi, AK | 1 |
| Ohara, H | 1 |
| Afrin, S | 1 |
| Gasparrini, M | 1 |
| Brachtendorf, S | 1 |
| Wanger, RA | 1 |
| Birod, K | 1 |
| Thomas, D | 1 |
| Trautmann, S | 1 |
| Wegner, MS | 1 |
| Fuhrmann, DC | 1 |
| Brüne, B | 1 |
| Geisslinger, G | 1 |
| Grösch, S | 1 |
| Carriere, PP | 1 |
| Kapur, N | 1 |
| Mir, H | 1 |
| Ward, AB | 1 |
| Singh, S | 1 |
| Jeong, D | 1 |
| Kwon, HY | 1 |
| Baek, MJ | 1 |
| Yao, X | 1 |
| Ni, P | 1 |
| Cheng, L | 1 |
| Ni, S | 1 |
| Li, Q | 4 |
| Zhou, K | 2 |
| Zhou, F | 1 |
| Lee, JJ | 2 |
| Saremy, S | 1 |
| Zeynali-Moghaddam, S | 1 |
| Mohammadian, M | 1 |
| Kheradmand, F | 1 |
| Fathi-Azarbayjani, A | 1 |
| Rasmi, Y | 1 |
| Esna-Ashari, O | 1 |
| Malekinejad, H | 1 |
| Lambert, P | 1 |
| Bremhorst, V | 1 |
| Satake, M | 3 |
| Ito, Y | 5 |
| Imaizumi, R | 1 |
| Sano, M | 3 |
| Kodera, A | 1 |
| Miyano, Y | 1 |
| Koike, T | 1 |
| Yamada, Y | 13 |
| Okayama, S | 2 |
| Yokomizo, H | 5 |
| Usui, T | 1 |
| Shiozawa, S | 3 |
| Shimakawa, T | 3 |
| Katsube, T | 3 |
| Naritaka, Y | 3 |
| Suehiro, Y | 1 |
| Takemoto, Y | 1 |
| Nishimoto, A | 2 |
| Ueno, K | 5 |
| Shirasawa, B | 1 |
| Tanaka, T | 6 |
| Kugimiya, N | 2 |
| Suga, A | 1 |
| Harada, E | 1 |
| Hamano, K | 3 |
| Chouhan, H | 1 |
| Sammour, T | 1 |
| Thomas, ML | 1 |
| Moore, JW | 1 |
| Druzhkova, I | 1 |
| Ignatova, N | 1 |
| Prodanets, N | 1 |
| Kiselev, N | 1 |
| Zhukov, I | 1 |
| Shirmanova, M | 1 |
| Zagainov, V | 1 |
| Zagaynova, E | 1 |
| Yoshino, Y | 1 |
| Tamura, A | 1 |
| Kagami, S | 1 |
| Funahashi, K | 3 |
| Chong, Y | 1 |
| Dai, X | 1 |
| Fang, G | 1 |
| Wu, R | 1 |
| Zhao, L | 4 |
| Chen, C | 1 |
| Chai, Z | 1 |
| Ge, C | 1 |
| Patel, S | 2 |
| Waghela, B | 1 |
| Shah, K | 1 |
| Vaidya, F | 1 |
| Mirza, S | 1 |
| Rawal, R | 1 |
| Shakery, A | 1 |
| Fereidani, SS | 1 |
| Imanishi, M | 1 |
| Sugaya, A | 1 |
| Hirose, M | 2 |
| Natori, Y | 1 |
| Yamato, K | 2 |
| Senda, N | 1 |
| Miyagaki, T | 1 |
| Oka, T | 8 |
| Nonogaki, A | 1 |
| Yoshizaki, A | 1 |
| Shibata, S | 1 |
| Sato, S | 3 |
| da Silva Sousa, AC | 1 |
| Guedes Pereira, RVA | 1 |
| Menezes, NMBVN | 1 |
| Furtado, AMC | 1 |
| Baptista, AM | 1 |
| Gao, D | 1 |
| Miskimins, K | 1 |
| Qian, SY | 3 |
| Jang, HY | 1 |
| Kim, WD | 1 |
| Hwang, JJ | 1 |
| Lee, SJ | 6 |
| Moon, DH | 2 |
| Vernieri, C | 1 |
| Ferrari, L | 1 |
| Iaffaioli, RV | 1 |
| Damiani, A | 1 |
| Labianca, RF | 1 |
| Pavesi, L | 1 |
| Buonadonna, A | 1 |
| Ferrario, S | 1 |
| Re, GL | 1 |
| Adamo, V | 1 |
| Clerico, M | 1 |
| Giordani, P | 2 |
| Leonardi, F | 1 |
| Ciarlo, A | 1 |
| Cavanna, L | 1 |
| Gori, S | 1 |
| Faedi, M | 1 |
| Aglietta, M | 2 |
| Antista, M | 1 |
| Dotti, KF | 1 |
| Song, M | 2 |
| Zemla, TJ | 1 |
| Hull, MA | 1 |
| Limburg, PJ | 2 |
| Giovannucci, EL | 2 |
| Van Blarigan, EL | 1 |
| Riahi-Chebbi, I | 1 |
| Souid, S | 1 |
| Othman, H | 1 |
| Haoues, M | 1 |
| Karoui, H | 1 |
| Morel, A | 2 |
| Srairi-Abid, N | 1 |
| Essafi, M | 1 |
| Essafi-Benkhadir, K | 1 |
| Park, JW | 2 |
| Cho, S | 1 |
| Kwon, YH | 1 |
| Ryoo, SB | 1 |
| Jeong, SY | 5 |
| Park, KJ | 3 |
| Wang, YJ | 1 |
| Fletcher, R | 1 |
| Schoen, RE | 1 |
| Asnani, GP | 1 |
| Kokare, CR | 1 |
| Kumar, V | 1 |
| Kumar, B | 1 |
| Deeba, F | 1 |
| Bano, S | 1 |
| Kulshreshtha, A | 1 |
| Gopinath, P | 2 |
| Negi, YS | 2 |
| Aoto, K | 1 |
| Inoue, N | 2 |
| Kono, K | 1 |
| Matsui, S | 1 |
| Kajiyama, D | 1 |
| Ohira, K | 1 |
| Amagasa, H | 1 |
| Noguchi, T | 5 |
| Sugita, H | 2 |
| Ganno, H | 2 |
| Imai, K | 1 |
| Ami, K | 2 |
| Hotta, S | 2 |
| Kameyama, H | 4 |
| Yamada, S | 2 |
| Nakano, M | 6 |
| Ichikawa, H | 2 |
| Hanyu, T | 3 |
| Takizawa, K | 4 |
| Nagahashi, M | 1 |
| Sakata, J | 7 |
| Kobayashi, T | 8 |
| Wakai, T | 8 |
| Mayer, SE | 1 |
| Tan, HJ | 1 |
| Peacock Hinton, S | 1 |
| Hester, LL | 1 |
| Faurot, KR | 1 |
| Jonsson Funk, M | 1 |
| Richardson, R | 1 |
| Talebloo, N | 1 |
| Mukherjee, P | 1 |
| Moore, A | 1 |
| Sougiannis, AT | 1 |
| VanderVeen, BN | 1 |
| Enos, RT | 1 |
| Velazquez, KT | 1 |
| Bader, JE | 1 |
| Carson, M | 1 |
| Chatzistamou, I | 1 |
| Walla, M | 1 |
| Pena, MM | 1 |
| Kubinak, JL | 1 |
| Nagarkatti, M | 1 |
| Carson, JA | 2 |
| Murphy, EA | 1 |
| Shi, Z | 1 |
| Yuan, M | 1 |
| Lv, W | 1 |
| Feng, T | 1 |
| Bai, R | 1 |
| Zhong, H | 1 |
| Lin, A | 1 |
| Raab, GT | 1 |
| Hillyer, GC | 1 |
| Keller, D | 1 |
| O'Neil, DS | 1 |
| Accordino, MK | 1 |
| Kiran, RP | 1 |
| Wright, J | 1 |
| Hershman, DL | 2 |
| Conev, NV | 1 |
| Dimitrova, EG | 1 |
| Bogdanova, MK | 1 |
| Kashlov, YK | 1 |
| Chaushev, BG | 1 |
| Radanova, MA | 1 |
| Petrov, DP | 1 |
| Georgiev, KD | 1 |
| Bachvarov, CH | 1 |
| Todorov, GN | 1 |
| Kalchev, KP | 1 |
| Popov, HB | 1 |
| Manev, RR | 1 |
| Donev, IS | 1 |
| Bao, Y | 1 |
| Yang, GK | 1 |
| Wan, J | 2 |
| Du, LJ | 1 |
| Ma, ZH | 1 |
| Rothé, F | 1 |
| Maetens, M | 2 |
| Rouas, G | 1 |
| Paesmans, M | 3 |
| Vergauwe, P | 1 |
| Deboever, G | 1 |
| Bareche, Y | 1 |
| Vandeputte, C | 2 |
| Ignatiadis, M | 1 |
| Hendlisz, A | 5 |
| Oshiro, M | 1 |
| Ooki, S | 1 |
| Matsunami, T | 1 |
| Yokoyama, M | 6 |
| Tajmohammadi, I | 1 |
| Mohammadian, J | 1 |
| Sabzichi, M | 1 |
| Mahmuodi, S | 1 |
| Ramezani, M | 1 |
| Aghajani, M | 1 |
| Ramezani, F | 1 |
| Bu, Z | 1 |
| Lai, H | 1 |
| Qin, Y | 3 |
| Xiao, M | 1 |
| Cheng, C | 3 |
| Lee, SW | 1 |
| Deng, SP | 1 |
| Guo, Z | 1 |
| Yu, W | 2 |
| Qiao, W | 1 |
| Parikh, DA | 1 |
| Lin, AY | 1 |
| Moon, JR | 1 |
| Oh, SJ | 3 |
| Chi, SG | 1 |
| Degirmencioglu, S | 1 |
| Tanrıverdi, O | 3 |
| Demiray, AG | 1 |
| Senol, H | 1 |
| Dogu, GG | 1 |
| Yaren, A | 1 |
| Boyne, DJ | 1 |
| Cuthbert, CA | 1 |
| O'Sullivan, DE | 1 |
| Sajobi, TT | 1 |
| Hilsden, RJ | 1 |
| Friedenreich, CM | 1 |
| Brenner, DR | 1 |
| Domenico, C | 1 |
| Antonella, I | 1 |
| Benedetto, C | 1 |
| Luigi, S | 1 |
| Antonio, C | 1 |
| Lidia, C | 1 |
| Giuseppe, S | 1 |
| Gallelli, L | 1 |
| Natalicchio, MI | 1 |
| Coppola, N | 1 |
| Conzo, G | 1 |
| Zanaletti, N | 1 |
| Vitale, P | 1 |
| Giunta, EF | 1 |
| Vietri, MT | 1 |
| Vitiello, PP | 1 |
| Marinaccio, A | 1 |
| Bedoui, S | 1 |
| Dallel, M | 1 |
| Barbirou, M | 1 |
| Stayoussef, M | 1 |
| Mokrani, A | 1 |
| Mezlini, A | 1 |
| Bouhaouala, B | 1 |
| Almawi, WY | 1 |
| Yacoubi-Loueslati, B | 1 |
| Orlandi, P | 1 |
| Gentile, D | 1 |
| Banchi, M | 1 |
| Cucchiara, F | 1 |
| Di Desidero, T | 1 |
| Bocci, G | 2 |
| Kitahama, T | 1 |
| Gomyo, Y | 1 |
| Okada, I | 1 |
| Akita, N | 1 |
| Ikeno, T | 1 |
| Miyamoto, H | 2 |
| Qin, C | 2 |
| Shen, Y | 2 |
| Qu, H | 2 |
| Qu, B | 1 |
| Callebout, E | 1 |
| Ribeiro, SM | 1 |
| Laurent, S | 1 |
| De Man, M | 1 |
| Ferdinande, L | 1 |
| Claes, KBM | 1 |
| Geboes, KP | 1 |
| Kadakia, KC | 1 |
| Worrilow, WM | 1 |
| Coley, H | 1 |
| Kakolyris, S | 1 |
| Xynogalos, S | 1 |
| Ziras, N | 2 |
| Athanasiadis, A | 1 |
| Androulakis, N | 1 |
| Christopoulou, A | 1 |
| Vaslamatzis, M | 1 |
| Ardavanis, A | 1 |
| Emmanouilides, C | 1 |
| Bompolaki, I | 1 |
| Kourousis, C | 1 |
| Makrantonakis, P | 1 |
| Christofyllakis, C | 1 |
| Athanasiadis, E | 1 |
| Kentepozidis, N | 1 |
| Karampeazis, A | 1 |
| Katopodi, U | 1 |
| Anagnosopoulos, A | 1 |
| Papadopoulos, G | 1 |
| Prinarakis, E | 1 |
| Kalisperi, A | 1 |
| Mavroudis, D | 2 |
| Ko, M | 1 |
| Sim, HC | 1 |
| Kim, CL | 1 |
| Jung, YJ | 1 |
| Kim, TO | 1 |
| Almeida, T | 1 |
| Lima, B | 1 |
| Ambrož, M | 1 |
| Šmatová, M | 1 |
| Šadibolová, M | 1 |
| Pospíšilová, E | 1 |
| Hadravská, P | 1 |
| Kašparová, M | 1 |
| Skarková, VH | 1 |
| Králová, V | 1 |
| Skálová, L | 1 |
| Pederson, L | 1 |
| Park, EH | 1 |
| Kim, A | 1 |
| Lee, SB | 1 |
| Shim, S | 1 |
| Jang, H | 1 |
| Myung, JK | 1 |
| Mezheyeuski, A | 1 |
| Hrynchyk, I | 1 |
| Herrera, M | 1 |
| Karlberg, M | 2 |
| Osterman, E | 1 |
| Ragnhammar, P | 3 |
| Edler, D | 3 |
| Portyanko, A | 1 |
| Ponten, F | 1 |
| Sjöblom, T | 1 |
| Östman, A | 1 |
| Sen, A | 1 |
| Jiji, V | 1 |
| Roshni, S | 1 |
| Prahladan, A | 1 |
| Venugopal, M | 1 |
| Ramachandran, K | 1 |
| Karan, S | 1 |
| Choudhury, H | 1 |
| Chakra, BK | 1 |
| Chatterjee, TK | 1 |
| Rullier, A | 2 |
| Yang, M | 3 |
| Qiao, H | 1 |
| Chen, Z | 2 |
| Di, L | 1 |
| Condello, M | 1 |
| Pellegrini, E | 1 |
| Spugnini, EP | 1 |
| Baldi, A | 2 |
| Amadio, B | 1 |
| Vincenzi, B | 2 |
| Occhionero, G | 1 |
| Delfine, S | 1 |
| Mastrodonato, F | 1 |
| Meschini, S | 1 |
| Hamada, T | 1 |
| Taniguchi, E | 1 |
| Ohta, K | 2 |
| Yoshikawa, M | 1 |
| Yamagami, Y | 1 |
| Ohashi, S | 1 |
| Hino-Shishikura, A | 1 |
| Suzuki, A | 4 |
| Minamimoto, R | 2 |
| Shizukuishi, K | 1 |
| Tateishi, U | 1 |
| Sugae, S | 2 |
| Ichikawa, Y | 2 |
| Horiuchi, C | 1 |
| Inoue, T | 7 |
| Aketa, H | 1 |
| Tatsumi, T | 1 |
| Kohga, K | 1 |
| Tsunematsu, H | 1 |
| Aono, S | 1 |
| Shimizu, S | 2 |
| Kodama, T | 1 |
| Nawa, T | 1 |
| Shigekawa, M | 1 |
| Hikita, H | 1 |
| Sakamori, R | 1 |
| Hosui, A | 1 |
| Miyagi, T | 1 |
| Hiramatsu, N | 1 |
| Kanto, T | 1 |
| Hayashi, N | 2 |
| Takehara, T | 4 |
| Lu, CY | 3 |
| Uen, YH | 1 |
| Hu, HM | 1 |
| Chen, CW | 2 |
| Cheng, TL | 1 |
| Lin, SR | 1 |
| Yu, R | 1 |
| Deedigan, L | 1 |
| Albarenque, SM | 1 |
| Mohr, A | 1 |
| Zwacka, RM | 1 |
| Sowa, Y | 1 |
| Yogosawa, M | 1 |
| Donada, M | 3 |
| Bonin, S | 4 |
| Barbazza, R | 1 |
| Pettirosso, D | 1 |
| Stanta, G | 3 |
| Kitowska, A | 1 |
| Grden, M | 1 |
| Szutowicz, A | 1 |
| Pawelczyk, T | 2 |
| Machado, MA | 1 |
| Makdissi, FF | 1 |
| Surjan, RC | 1 |
| Noratto, GD | 1 |
| Jutooru, I | 1 |
| Safe, S | 1 |
| Angel-Morales, G | 1 |
| Mertens-Talcott, SU | 1 |
| Marin-Vicente, C | 1 |
| Lyutvinskiy, Y | 1 |
| Romans Fuertes, P | 1 |
| Zubarev, RA | 1 |
| Visa, N | 1 |
| Li, P | 2 |
| Fang, YJ | 3 |
| Li, F | 1 |
| Ou, QJ | 1 |
| Ma, G | 1 |
| Biedma-Ortiz, RA | 1 |
| Sáez-Fernández, E | 1 |
| Prados, JC | 3 |
| Wei, YQ | 1 |
| Deng, HX | 1 |
| Matsuda, C | 1 |
| Tamagawa, H | 1 |
| Nishikawa, K | 1 |
| Deguchi, T | 1 |
| Kawata, J | 1 |
| Iwase, K | 2 |
| Fukui, A | 1 |
| Nezu, R | 1 |
| Kuznietsova, HM | 2 |
| Ogloblya, OV | 1 |
| Rybalchenko, VK | 2 |
| Glavas-Dodov, M | 1 |
| Steffansen, B | 1 |
| Crcarevska, MS | 2 |
| Geskovski, N | 2 |
| Dimchevska, S | 1 |
| Kuzmanovska, S | 1 |
| Goracinova, K | 2 |
| Nelson, GD | 4 |
| Allen, JE | 2 |
| Gallant, JN | 1 |
| Dicker, DT | 3 |
| Amin, S | 1 |
| Irby, RB | 3 |
| Sharma, AK | 1 |
| El-Deiry, WS | 4 |
| González-Vallinas, M | 2 |
| Molina, S | 2 |
| Vicente, G | 1 |
| de la Cueva, A | 1 |
| Santoyo, S | 1 |
| García-Risco, MR | 1 |
| Fornari, T | 1 |
| Absenger, G | 2 |
| Szkandera, J | 3 |
| Labonte, MJ | 5 |
| Pichler, M | 3 |
| Stotz, M | 3 |
| Samonigg, H | 5 |
| Renner, W | 2 |
| Gerger, A | 7 |
| Kiel, K | 1 |
| Engstrom, PF | 7 |
| Diasio, RB | 6 |
| Köhne, CH | 4 |
| Bedenne, L | 7 |
| Carrato, A | 3 |
| Popov, I | 2 |
| Gaspà, L | 1 |
| Valladares, M | 1 |
| Rougier, P | 14 |
| Gog, C | 1 |
| Reichardt, P | 1 |
| Wils, J | 8 |
| Pignatti, F | 1 |
| Biertz, F | 1 |
| Magnani, E | 1 |
| Farnetti, E | 1 |
| Nicoli, D | 1 |
| Casali, B | 1 |
| Savoldi, L | 1 |
| Focaccetti, C | 1 |
| Boni, C | 5 |
| Albini, A | 1 |
| Golfinopoulos, V | 1 |
| Deleporte, A | 1 |
| Mansy, HE | 1 |
| Garcia, C | 1 |
| Annemans, L | 1 |
| Borbath, I | 1 |
| Dresse, D | 1 |
| Houbiers, G | 1 |
| Fried, M | 1 |
| Awada, A | 2 |
| Piccart, M | 2 |
| Laethem, JL | 1 |
| Flamen, P | 1 |
| Bondar', GV | 1 |
| Basheev, VKh | 1 |
| Zolotukhin, SÉ | 1 |
| Sovpel', IV | 1 |
| Sovpel', OV | 1 |
| Shen, WW | 1 |
| Zeng, Z | 2 |
| Zhu, WX | 1 |
| Fu, GH | 1 |
| Yuan, W | 1 |
| Mehta, S | 1 |
| Singh, G | 3 |
| Paul, BS | 1 |
| Mazzeo, MA | 2 |
| Linares, JA | 2 |
| López, MM | 1 |
| Bachmeier, E | 1 |
| Wietz, FM | 1 |
| Galván, V | 1 |
| Valentinuzzi, MC | 1 |
| Riveros, JA | 1 |
| Finkelberg, A | 1 |
| Singh, N | 3 |
| Chakrabarty, S | 5 |
| Park, JM | 2 |
| Narloch, R | 1 |
| Federzoni, E | 1 |
| Masiero, L | 1 |
| El Bouzidi, L | 1 |
| Mahiou-Leddet, V | 1 |
| Bun, SS | 2 |
| Larhsini, M | 1 |
| Abbad, A | 1 |
| Markouk, M | 1 |
| Fathi, M | 1 |
| Boudon, M | 1 |
| Ollivier, E | 1 |
| Bekkouche, K | 1 |
| Kim, DY | 3 |
| Deng, S | 1 |
| Hu, B | 1 |
| An, HM | 1 |
| Du, Q | 1 |
| Shen, KP | 1 |
| Shi, XF | 1 |
| Wei, MM | 1 |
| Todaro, M | 2 |
| Orlando, V | 1 |
| Caccamo, N | 1 |
| Meraviglia, S | 1 |
| Stassi, G | 2 |
| Dieli, F | 1 |
| Psurski, M | 1 |
| Kutner, A | 4 |
| Wietrzyk, J | 2 |
| Cassidy, J | 12 |
| Kerr, DJ | 6 |
| Weirauch, U | 1 |
| Beckmann, N | 1 |
| Thomas, M | 1 |
| Grünweller, A | 1 |
| Huber, K | 1 |
| Bracher, F | 1 |
| Hartmann, RK | 1 |
| Aigner, A | 1 |
| Kaniwa, N | 2 |
| Sai, K | 2 |
| Shirao, K | 6 |
| Matsumura, Y | 3 |
| Takahashi, A | 1 |
| Odaka, Y | 1 |
| Okuyama, M | 2 |
| Sawada, J | 1 |
| Sakamoto, H | 3 |
| Yoshida, T | 5 |
| Benhanim, L | 1 |
| Kahn, M | 3 |
| Lenz, F | 2 |
| Lenz, C | 2 |
| Ning, Y | 5 |
| Xu, JM | 5 |
| Ge, FJ | 2 |
| Lin, L | 2 |
| Liu, ZY | 1 |
| Sharma, MR | 1 |
| Golubovskaya, VM | 2 |
| Ho, B | 1 |
| Zheng, M | 1 |
| Magis, A | 1 |
| Ostrov, D | 1 |
| Morrison, C | 1 |
| Cance, WG | 2 |
| Kimura, S | 1 |
| Usuba, O | 1 |
| Toyono, M | 1 |
| Furuyama, H | 1 |
| Fuji, H | 3 |
| Okumura, S | 1 |
| Nishigori, T | 1 |
| Kadokawa, Y | 2 |
| Kondo, M | 2 |
| Machimoto, T | 1 |
| Asao, Y | 1 |
| Yoshimura, T | 1 |
| Nishizawa, T | 1 |
| Kinoshita, S | 1 |
| Sakuno, T | 1 |
| Fujiyama, Y | 1 |
| Kikuchi, M | 1 |
| Kaneko, H | 3 |
| Suzuki, H | 5 |
| Leone, F | 2 |
| Artale, S | 1 |
| Marino, D | 1 |
| Cagnazzo, C | 1 |
| Cascinu, S | 5 |
| Fornarini, G | 1 |
| Tampellini, M | 2 |
| Di Fabio, F | 1 |
| De Carlis, L | 1 |
| Pugliese, R | 1 |
| Capussotti, L | 1 |
| Gioeni, L | 1 |
| Siena, S | 1 |
| Kim, SH | 4 |
| Kim, TI | 3 |
| Kang, DR | 1 |
| Hur, H | 1 |
| Min, BS | 3 |
| Kim, NK | 5 |
| Chung, HC | 2 |
| Roh, JK | 2 |
| Rosa, A | 2 |
| Scano, P | 1 |
| Atzeri, A | 2 |
| Deiana, M | 1 |
| Falchi, AM | 1 |
| Sawai, K | 2 |
| Goi, T | 3 |
| Koneri, K | 2 |
| Katayama, K | 2 |
| Yamaguchi, A | 3 |
| Bot, BM | 1 |
| Benedetti, JK | 4 |
| Nakajima, M | 2 |
| Uchiyama, T | 1 |
| Adachi, A | 1 |
| Uchisako, H | 1 |
| Mahoney, MR | 6 |
| Thibodeau, SN | 8 |
| Warren, RS | 4 |
| Bertagnolli, MM | 7 |
| Badzek, S | 1 |
| Miletic, V | 1 |
| Prejac, J | 1 |
| Gorsic, I | 1 |
| Golem, H | 1 |
| Bilic, E | 1 |
| Kekez, D | 1 |
| Librenjak, N | 1 |
| Plestina, S | 1 |
| Kim, SE | 1 |
| Cole, PD | 1 |
| Cho, RC | 1 |
| Ly, A | 1 |
| Ishiguro, L | 2 |
| Sohn, KJ | 4 |
| Croxford, R | 4 |
| Kamen, BA | 1 |
| Kim, YI | 4 |
| Das, R | 2 |
| Bhattacharya, K | 1 |
| Sarkar, S | 1 |
| Samanta, SK | 1 |
| Pal, BC | 1 |
| Mandal, C | 1 |
| Nordlinger, B | 5 |
| Beretta, GD | 2 |
| Mosconi, S | 3 |
| Mandalà, M | 1 |
| Arnold, D | 5 |
| Chao, D | 1 |
| Chen, WC | 2 |
| Thirkill, CE | 1 |
| Lee, AG | 1 |
| Dinicola, S | 3 |
| Morini, V | 1 |
| Coluccia, P | 4 |
| Proietti, S | 4 |
| D'Anselmi, F | 3 |
| Pasqualato, A | 3 |
| Masiello, MG | 2 |
| Palombo, A | 3 |
| De Toma, G | 1 |
| Bizzarri, M | 4 |
| Cucina, A | 4 |
| Nomura, Y | 1 |
| Kawaraguchi, Y | 1 |
| Sugimoto, H | 1 |
| Furuya, H | 1 |
| Mekata, E | 1 |
| Murata, S | 1 |
| Sonoda, H | 1 |
| Shimizu, T | 5 |
| Umeda, T | 1 |
| Shiomi, H | 1 |
| Naka, S | 1 |
| Abe, H | 2 |
| Edamatsu, T | 1 |
| Fujieda, A | 1 |
| Fujioka, M | 1 |
| Wada, T | 2 |
| Tani, T | 3 |
| Sveen, A | 1 |
| Nesbakken, A | 1 |
| Ågesen, TH | 1 |
| Skotheim, RI | 1 |
| Winder, T | 3 |
| Volz, N | 1 |
| Stremitzer, S | 2 |
| El-Khoueiry, R | 3 |
| Ikehata, M | 1 |
| Ogawa, M | 5 |
| Ueda, K | 1 |
| Iwakawa, S | 1 |
| Yu, M | 2 |
| Tong, X | 1 |
| Qi, B | 1 |
| Dong, S | 1 |
| Tang, N | 1 |
| Yu, S | 2 |
| Shabihkhani, M | 1 |
| Thara, E | 1 |
| Senagore, A | 1 |
| Sadeghi, S | 1 |
| Barzi, A | 2 |
| Murai, A | 1 |
| Lopatin, M | 2 |
| Clark-Langone, KM | 2 |
| Millward, C | 1 |
| Sharif, S | 6 |
| Shak, S | 2 |
| Ahn, JY | 2 |
| Min, HY | 2 |
| Jeong, JH | 1 |
| Byun, Y | 1 |
| Lee, HY | 4 |
| Ogino, S | 4 |
| Imamura, Y | 1 |
| Yamauchi, M | 4 |
| Whittom, R | 3 |
| Mowat, RB | 1 |
| Spiegelman, D | 2 |
| Kubo, H | 1 |
| Nakasuga, C | 1 |
| Tada, K | 1 |
| Miyahara, M | 1 |
| Toshima, T | 1 |
| Kodera, M | 1 |
| Yamashita, Y | 2 |
| Oishi, M | 1 |
| Seshimo, K | 1 |
| Yamamura, M | 1 |
| Mizuno, K | 1 |
| Shang, J | 1 |
| Yang, F | 2 |
| Xue, G | 1 |
| Mei, Q | 1 |
| Sun, S | 1 |
| Zhang, JM | 2 |
| Wang, QW | 1 |
| Ye, DJ | 1 |
| Das, D | 3 |
| Preet, R | 2 |
| Mohapatra, P | 2 |
| Satapathy, SR | 3 |
| Kundu, CN | 3 |
| Deng, J | 2 |
| Lei, W | 2 |
| Fu, JC | 1 |
| Li, JH | 1 |
| Xiong, JP | 2 |
| Ma, YS | 1 |
| Yang, IP | 1 |
| Juo, SH | 1 |
| Loprinzi, CL | 3 |
| Qin, R | 2 |
| Dakhil, SR | 4 |
| Fehrenbacher, L | 6 |
| Flynn, KA | 1 |
| Atherton, P | 1 |
| Seisler, D | 1 |
| Qamar, R | 1 |
| Lewis, GC | 1 |
| Huang, WD | 1 |
| Bank, PC | 1 |
| Guchelaar, HJ | 1 |
| Swen, JJ | 1 |
| Liu, TS | 2 |
| Yu, YY | 1 |
| Zhou, YH | 1 |
| Zhuang, RY | 1 |
| Cui, YH | 1 |
| Senfter, D | 2 |
| Huttary, N | 2 |
| Krupitza, G | 6 |
| Dolznig, H | 2 |
| Mader, RM | 15 |
| Touil, Y | 1 |
| Igoudjil, W | 1 |
| Corvaisier, M | 2 |
| Dessein, AF | 2 |
| Vandomme, J | 1 |
| Monté, D | 3 |
| Stechly, L | 2 |
| Skrypek, N | 2 |
| Langlois, C | 1 |
| Grard, G | 2 |
| Millet, G | 2 |
| Leteurtre, E | 4 |
| Dumont, P | 6 |
| Truant, S | 4 |
| Pruvot, FR | 3 |
| Hebbar, M | 4 |
| Fan, F | 1 |
| Ellis, LM | 2 |
| Formstecher, P | 2 |
| Van Seuningen, I | 3 |
| Gespach, C | 7 |
| Polakowska, R | 1 |
| Huet, G | 4 |
| Yoo, BC | 6 |
| Kim, WK | 2 |
| Hong, JP | 2 |
| Song, EY | 1 |
| Lee, JY | 2 |
| Cho, JY | 2 |
| Ku, JL | 3 |
| Kang, GH | 4 |
| Moon, HS | 1 |
| Lee, ES | 2 |
| Sung, JK | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Kang, DY | 1 |
| Arminger, F | 1 |
| Schaberl-Moser, R | 4 |
| Stojakovic, T | 1 |
| Saif, MW | 7 |
| Lee, AM | 3 |
| Offer, SM | 1 |
| McConnell, K | 1 |
| Relias, V | 1 |
| Kadota, T | 1 |
| Osuga, T | 1 |
| Ogawa, H | 3 |
| Kitami, M | 1 |
| Ishimura, M | 1 |
| Shigaki, Y | 1 |
| Nakajima, E | 1 |
| Nakata, S | 2 |
| Kadota, C | 1 |
| Hirano, S | 2 |
| Ikura, Y | 1 |
| Iwai, Y | 1 |
| Ueno, N | 2 |
| Koda, T | 2 |
| Koike, J | 2 |
| Ushigome, M | 2 |
| Shiokawa, H | 2 |
| Kurihara, A | 2 |
| Nagashima, Y | 1 |
| Shimada, H | 4 |
| Ojima, E | 4 |
| Nakano, T | 2 |
| Kanamoto, A | 2 |
| Sasaki, S | 2 |
| Murayama, M | 3 |
| Kohno, T | 1 |
| Miyazawa, M | 1 |
| Shimazaki, A | 1 |
| Miyaki, A | 1 |
| Usuda, A | 1 |
| Asaka, S | 1 |
| Mishra, RK | 1 |
| Ramasamy, K | 1 |
| Ahmad, NA | 1 |
| Eshak, Z | 1 |
| Majeed, AB | 1 |
| Kraehe, P | 2 |
| Shayan, P | 2 |
| Lueders, C | 2 |
| Goel, A | 2 |
| Fu, Y | 1 |
| Peng, C | 2 |
| Li, W | 2 |
| Ghosh, S | 3 |
| Okazaki, S | 2 |
| Sugawara, K | 1 |
| Hashizume, E | 1 |
| Abe, M | 2 |
| Hagiwara, M | 1 |
| Aiso, T | 1 |
| Shirahata, Y | 1 |
| Chin, M | 1 |
| Kuriya, Y | 1 |
| Yamanashi, T | 1 |
| Nishi, T | 1 |
| Yamamoto, T | 6 |
| Toriumi, F | 1 |
| Koshida, Y | 1 |
| Mukai, K | 1 |
| Shimoyama, Y | 1 |
| Gao, W | 1 |
| Zeng, F | 1 |
| Kong, LX | 1 |
| Akao, Y | 1 |
| Khoo, F | 1 |
| Kumazaki, M | 1 |
| Shinohara, H | 1 |
| Miki, K | 1 |
| Yamada, N | 4 |
| Depani, BP | 1 |
| Naik, AA | 1 |
| Nair, HA | 1 |
| Hu, DL | 1 |
| Guo, XD | 1 |
| Sun, ZN | 1 |
| Zhao, YM | 1 |
| Yu, Y | 10 |
| Vasudevan, A | 2 |
| Farhana, L | 2 |
| Rajendra, SG | 2 |
| Levi, E | 2 |
| Majumdar, AP | 5 |
| Mirtsching, BC | 1 |
| George, JN | 1 |
| Aster, RH | 2 |
| Curtis, BR | 2 |
| Hong, IK | 1 |
| Chung, JH | 1 |
| Ryu, JS | 1 |
| Ueno, T | 1 |
| Saito, R | 1 |
| Hirai, S | 1 |
| Nair, SG | 3 |
| Chan, E | 4 |
| Kahlenberg, MS | 3 |
| Quesenberry, JT | 2 |
| Webb, TA | 2 |
| Farr, GH | 2 |
| Pockaj, BA | 2 |
| Berenberg, JL | 3 |
| Mooney, M | 2 |
| Van Loon, K | 1 |
| Cruzado, JA | 1 |
| López-Santiago, S | 1 |
| Martínez-Marín, V | 1 |
| José-Moreno, G | 1 |
| Custodio, AB | 1 |
| Kojouharov, BM | 1 |
| Brackett, CM | 1 |
| Veith, JM | 1 |
| Johnson, CP | 1 |
| Gitlin, II | 1 |
| Toshkov, IA | 1 |
| Gleiberman, AS | 1 |
| Burdelya, LG | 1 |
| Kim, SC | 1 |
| Yeo, HY | 1 |
| Yang, SY | 3 |
| Ni, J | 1 |
| Zhou, Y | 2 |
| Liu, D | 1 |
| Sun, XJ | 1 |
| Du, JK | 1 |
| Huo, XW | 1 |
| Zheng, JB | 1 |
| Zhang, SY | 1 |
| Zhang, YF | 2 |
| Xu, YZ | 1 |
| Wu, JG | 1 |
| Hamza, S | 1 |
| Rollot, F | 1 |
| Faivre, J | 1 |
| Lu, B | 2 |
| Ma, ZJ | 1 |
| van Laarhoven, HW | 2 |
| Henselmans, I | 1 |
| de Haes, JH | 1 |
| Yoon, HH | 1 |
| Bose, A | 1 |
| Elyagoby, A | 1 |
| Wong, TW | 1 |
| Zhang, E | 1 |
| Huo, BL | 1 |
| Wang, YH | 4 |
| Cui, SX | 1 |
| Zhang, HL | 2 |
| Xu, WF | 1 |
| Qu, XJ | 2 |
| Sui, X | 1 |
| Kong, N | 1 |
| Fang, Y | 2 |
| Li, D | 1 |
| Jin, W | 1 |
| Lou, F | 1 |
| Gong, L | 1 |
| Han, W | 3 |
| Yang, GD | 1 |
| Lin, XC | 1 |
| Wang, CH | 1 |
| Lou, WJ | 1 |
| Wang, XB | 1 |
| Kim, KC | 1 |
| Chang, WY | 2 |
| Park, IC | 1 |
| Keum, YS | 2 |
| Surh, YJ | 1 |
| Shi, H | 1 |
| Jiang, J | 1 |
| Ji, J | 2 |
| Cai, Q | 1 |
| Tang, L | 1 |
| Dong, J | 1 |
| Jiang, G | 1 |
| Maykel, J | 1 |
| Liu, JH | 5 |
| Shultz, LD | 1 |
| Greiner, DL | 1 |
| Houghton, J | 1 |
| Anitha, A | 2 |
| Sreeranganathan, M | 1 |
| Chennazhi, KP | 2 |
| Lakshmanan, VK | 2 |
| Jayakumar, R | 2 |
| Scarabelli, L | 1 |
| Giovanardi, F | 1 |
| Gervasi, E | 1 |
| Prati, G | 1 |
| Pezzuolo, D | 1 |
| Scaltriti, L | 1 |
| Shiovitz, S | 1 |
| Nam, E | 1 |
| Foster, NR | 10 |
| Dzieciatkowski, S | 1 |
| Luo, Y | 2 |
| Lao, VV | 2 |
| Monnat, RJ | 2 |
| Emond, MJ | 1 |
| Maizels, N | 2 |
| Venook, A | 2 |
| Grady, WM | 1 |
| Tashiro, J | 1 |
| Ishii, T | 2 |
| Kondo, H | 2 |
| Morita, Y | 1 |
| Koyama, I | 2 |
| Lee, DW | 1 |
| Kim, KJ | 2 |
| Rhee, YY | 2 |
| Bae, JM | 1 |
| Cho, NY | 2 |
| Kim, TY | 4 |
| Oh, DY | 2 |
| Bang, YJ | 2 |
| Park, JG | 6 |
| Huang, R | 1 |
| You, Q | 1 |
| Jiang, Z | 2 |
| Yu, L | 1 |
| Muhammad, S | 1 |
| He, J | 2 |
| Xie, G | 1 |
| Huang, H | 1 |
| Wang, N | 1 |
| Liang, H | 1 |
| Cheah, KY | 1 |
| Howarth, GS | 2 |
| Bindon, KA | 1 |
| Kennedy, JA | 1 |
| Bastian, SE | 2 |
| Shakeri-Zadeh, A | 2 |
| Shiran, MB | 2 |
| Sharifi, AM | 2 |
| Ghaznavi, H | 1 |
| Vaiphei, K | 1 |
| Tanabe, H | 3 |
| Takase, T | 1 |
| Morimoto, D | 1 |
| Shibata, A | 1 |
| Yaguchi, T | 1 |
| Filip-Psurska, B | 1 |
| Swiętnicki, W | 1 |
| Lairson, DR | 2 |
| Parikh, RC | 1 |
| Cormier, JN | 1 |
| Chan, W | 4 |
| Du, XL | 4 |
| Umemori, Y | 1 |
| Kuribayashi, K | 2 |
| Nirasawa, S | 1 |
| Kondoh, T | 1 |
| Tanaka, M | 6 |
| Kobayashi, D | 1 |
| Watanabe, N | 3 |
| Xiong, B | 1 |
| Cheng, Y | 1 |
| Ting, DT | 1 |
| Ryan, DP | 3 |
| Petersen, LN | 2 |
| Blons, H | 2 |
| Collette, L | 3 |
| Salazar, R | 3 |
| Lopez-Sánchez, LM | 1 |
| Jimenez, C | 1 |
| Valverde, A | 1 |
| Hernandez, V | 1 |
| Peñarando, J | 1 |
| Martinez, A | 1 |
| Lopez-Pedrera, C | 1 |
| Muñoz-Castañeda, JR | 1 |
| De la Haba-Rodríguez, JR | 1 |
| Deepa, N | 1 |
| Niwa, K | 2 |
| Ishiyama, S | 2 |
| Komiyama, H | 2 |
| Yaginuma, Y | 2 |
| Okuzawa, A | 2 |
| Yamamura, Y | 1 |
| Tsuchikawa, T | 1 |
| Miyauchi, K | 1 |
| Wada, M | 2 |
| Kuwatani, T | 1 |
| Kyogoku, N | 1 |
| Kuroda, A | 1 |
| Maki, T | 1 |
| Shichinohe, T | 1 |
| Bekaii-Saab, T | 2 |
| Chen, YJ | 1 |
| Cooper, HS | 1 |
| Enzinger, PC | 1 |
| Fenton, MJ | 1 |
| Grem, JL | 21 |
| Hunt, S | 1 |
| Kamel, A | 1 |
| Leong, LA | 1 |
| Lin, E | 1 |
| Messersmith, W | 1 |
| Mulcahy, MF | 4 |
| Murphy, JD | 1 |
| Nurkin, S | 1 |
| Rohren, E | 1 |
| Saltz, L | 3 |
| Sharma, S | 1 |
| Shibata, D | 1 |
| Skibber, JM | 1 |
| Sofocleous, CT | 1 |
| Stoffel, EM | 1 |
| Stotsky-Himelfarb, E | 1 |
| Willett, CG | 3 |
| Gregory, KM | 1 |
| Freedman-Cass, DA | 1 |
| Qian, L | 1 |
| Zhu, S | 1 |
| Guan, W | 1 |
| Oshima, N | 1 |
| Nagayama, S | 2 |
| Kawada, K | 1 |
| Hasegawa, S | 2 |
| Okabe, H | 4 |
| Aoi, T | 1 |
| Smoragiewicz, M | 1 |
| Javaheri, KR | 1 |
| Yin, Y | 1 |
| Uthe, FW | 1 |
| Hüttenrauch, M | 1 |
| Mühling, B | 1 |
| Krummenast, F | 1 |
| Thalheimer, A | 1 |
| Otto, C | 1 |
| Kim, W | 1 |
| Yoon, SK | 1 |
| Kuh, HJ | 1 |
| Nam, SW | 1 |
| Goh, TB | 1 |
| Koh, RY | 1 |
| Mordi, MN | 1 |
| Mansor, SM | 1 |
| Battisti, S | 1 |
| Guida, FM | 1 |
| Pagliara, E | 1 |
| Tonini, G | 3 |
| Zobel, BB | 1 |
| Kim, CA | 1 |
| Armstrong, DE | 1 |
| Ng, PL | 1 |
| Rajab, NF | 1 |
| Then, SM | 1 |
| Mohd Yusof, YA | 1 |
| Wan Ngah, WZ | 1 |
| Pin, KY | 1 |
| Looi, ML | 1 |
| Wang, ZH | 1 |
| Ruan, SQ | 1 |
| Hu, YT | 1 |
| Hu, LF | 1 |
| Chen, HY | 1 |
| Zheng, S | 1 |
| Zhang, SZ | 3 |
| Ding, KF | 1 |
| Cottone, L | 1 |
| Capobianco, A | 1 |
| Gualteroni, C | 1 |
| Perrotta, C | 1 |
| Bianchi, ME | 1 |
| Rovere-Querini, P | 1 |
| Manfredi, AA | 1 |
| Qi, J | 1 |
| Wu, E | 1 |
| Samuel, T | 1 |
| Fadlalla, K | 1 |
| Gales, DN | 1 |
| Putcha, BD | 1 |
| Manne, U | 1 |
| Bellamkonda, K | 1 |
| Sime, W | 1 |
| Sjölander, A | 1 |
| Jung, HW | 1 |
| Kim, SW | 1 |
| Yang, HK | 1 |
| Lee, JW | 1 |
| Lee, KW | 4 |
| Kim, DW | 3 |
| Kang, SB | 3 |
| Zhang, JX | 1 |
| Yang, ZR | 1 |
| Wu, DD | 1 |
| Song, J | 2 |
| Guo, XF | 1 |
| Dong, WG | 1 |
| Reitkopf-Brodutch, S | 1 |
| Confino, H | 1 |
| Schmidt, M | 1 |
| Cooks, T | 1 |
| Efrati, M | 1 |
| Arazi, L | 1 |
| Rath-Wolfson, L | 1 |
| Marshak, G | 1 |
| Kelson, I | 1 |
| Keisari, Y | 2 |
| Banerjee, S | 1 |
| Woods, J | 1 |
| Patel, A | 1 |
| Dyson, G | 1 |
| Maddipati, KR | 1 |
| Cheng, AL | 3 |
| Vaid, AK | 1 |
| Ma, BB | 1 |
| Teh, C | 1 |
| Bello, M | 1 |
| Charoentum, C | 1 |
| Chen, LT | 2 |
| de Lima Lopes, G | 1 |
| Ho, GF | 1 |
| Kong, HL | 1 |
| Lam, KO | 1 |
| Sriuranpong, V | 1 |
| Sudoyo, AW | 1 |
| Shaw, M | 1 |
| Wang, XT | 1 |
| Dan, X | 1 |
| Sun, LL | 1 |
| Hestetun, KE | 1 |
| Brydøy, M | 1 |
| Myklebust, MP | 1 |
| Dahl, O | 6 |
| Zhao, S | 3 |
| Tang, H | 3 |
| Cui, F | 3 |
| Liu, C | 3 |
| Guo, F | 2 |
| Xue, Y | 3 |
| Peng, Z | 3 |
| Yan, D | 3 |
| Dzaye, O | 1 |
| Cleator, S | 1 |
| Nihoyannopoulos, P | 1 |
| Noguchi, Y | 1 |
| Tsurushima, M | 1 |
| Kawara, H | 1 |
| Mitani, T | 1 |
| Tokuyama, Y | 1 |
| Uchiyama, K | 1 |
| Shimizu, Y | 1 |
| Cho, KP | 1 |
| Lee, JS | 5 |
| Seong, JS | 1 |
| Woo, YM | 1 |
| Cho, YJ | 1 |
| Jeong, BJ | 1 |
| Sohn, JH | 1 |
| Kim, SJ | 1 |
| Schaeffer, DF | 1 |
| Yoshida, EM | 1 |
| Fongue, J | 1 |
| Meunier, B | 1 |
| Lardet, D | 1 |
| Dicostanzo, MP | 1 |
| Rouby, F | 1 |
| Terrier, JP | 1 |
| Harlé, JR | 1 |
| Richard, MA | 1 |
| Chiche, L | 1 |
| Nørgård-Petersen, L | 1 |
| Zawadi, MA | 1 |
| Hedbrant, A | 1 |
| Erlandsson, A | 1 |
| Delbro, D | 1 |
| Wijkander, J | 1 |
| Pavelitz, T | 1 |
| Renfro, L | 1 |
| Caracol, A | 1 |
| Welsch, P | 1 |
| Grady, WB | 1 |
| Rabinovitch, PS | 1 |
| Emond, M | 1 |
| Akasaka, T | 1 |
| Tsujii, M | 2 |
| Kondo, J | 1 |
| Ying, J | 2 |
| Yamamoto, S | 3 |
| Tsujii, Y | 2 |
| Maekawa, A | 2 |
| Fujinaga, T | 2 |
| Shiraishi, E | 1 |
| Hiyama, S | 2 |
| Shinzaki, S | 3 |
| Watabe, K | 1 |
| Nishida, T | 3 |
| Iijima, H | 4 |
| Lerdkiattikorn, P | 1 |
| Chaikledkaew, U | 1 |
| Lausoontornsiri, W | 1 |
| Chindavijak, S | 1 |
| Khuhaprema, T | 1 |
| Tantai, N | 1 |
| Teerawattananon, Y | 1 |
| Shimoyama, R | 1 |
| Ban, T | 1 |
| Isogai, N | 1 |
| Ikegaya, Y | 1 |
| Kawachi, J | 1 |
| Ogino, H | 1 |
| Watanabe, K | 2 |
| Wettergren, Y | 1 |
| Taflin, H | 1 |
| Odin, E | 2 |
| Kodeda, K | 1 |
| Derwinger, K | 1 |
| Klingbiel, D | 2 |
| Saridaki, Z | 1 |
| Roth, AD | 3 |
| Bosman, FT | 2 |
| Delorenzi, M | 3 |
| Tejpar, S | 4 |
| Giacomini, E | 1 |
| Floriani, I | 1 |
| Pavey, E | 1 |
| Miyazaki, S | 2 |
| Miyoshi, N | 1 |
| Uemura, M | 1 |
| Nishimura, J | 1 |
| Takemasa, I | 2 |
| Konno, M | 1 |
| Doki, Y | 1 |
| Ishii, H | 1 |
| Yu, F | 4 |
| Sato, K | 3 |
| Chan, JA | 1 |
| Schaefer, PL | 1 |
| Malkhasyan, K | 1 |
| Halene, S | 1 |
| Lacy, J | 1 |
| Wan, LY | 1 |
| Xiang, XJ | 2 |
| Feng, M | 2 |
| Cartwright, T | 2 |
| McKenna, E | 1 |
| Saif, M | 1 |
| Siddharth, S | 2 |
| Tamir, T | 1 |
| Jain, V | 1 |
| Bharatam, PV | 1 |
| Wyatt, MD | 1 |
| Peixoto, RD | 2 |
| Kumar, A | 2 |
| Speers, C | 3 |
| Renouf, D | 1 |
| Melosky, B | 1 |
| Rowe, J | 1 |
| Cen, P | 1 |
| El-Khoueiry, A | 3 |
| Neijzen, R | 1 |
| Wong, MQ | 1 |
| Gill, N | 1 |
| Karim, T | 1 |
| Anantha, M | 1 |
| Strutt, D | 1 |
| Waterhouse, D | 1 |
| Bally, MB | 1 |
| Tai, IT | 3 |
| Ng, SS | 1 |
| Yapp, DT | 1 |
| Gao, Y | 2 |
| Huo, X | 1 |
| Dong, L | 2 |
| Sai, H | 1 |
| Wei, G | 1 |
| Kim, MK | 1 |
| Di Caro, G | 1 |
| Wong, J | 1 |
| Shalapour, S | 1 |
| Zhong, Z | 2 |
| Sanchez-Lopez, E | 1 |
| Wu, LW | 1 |
| Taniguchi, K | 1 |
| Feng, Y | 3 |
| Fearon, E | 1 |
| Grivennikov, SI | 1 |
| Karin, M | 1 |
| Ni, L | 1 |
| Song, T | 1 |
| Trivedi, H | 1 |
| Chamarthy, U | 1 |
| Dicarlo, L | 1 |
| Herman, J | 1 |
| Srkalovic, G | 1 |
| Du, ZD | 1 |
| He, XF | 1 |
| Zhang, PF | 1 |
| Tang, RL | 1 |
| Liang, B | 3 |
| Shahbaz, M | 2 |
| Gao, H | 3 |
| Fang, R | 1 |
| Niu, Z | 1 |
| Sun, Q | 1 |
| Niu, W | 3 |
| Liu, E | 2 |
| Niu, J | 2 |
| Duran, AO | 1 |
| Karaca, H | 1 |
| Besiroglu, M | 1 |
| Bayoglu, IV | 2 |
| Yapici, HS | 1 |
| Yazilitas, D | 1 |
| Uysal, M | 1 |
| Aksoy, A | 1 |
| Arpaci, E | 1 |
| Inanc, M | 1 |
| Dane, F | 1 |
| Ozkan, M | 2 |
| Leshem, Y | 1 |
| Fennig, S | 1 |
| Talianski, E | 1 |
| Greenberg, G | 1 |
| Wolf, I | 1 |
| Damnjanovic, I | 1 |
| Kocic, G | 1 |
| Najman, S | 1 |
| Stojanovic, S | 1 |
| Stojanovic, D | 1 |
| Veljkovic, A | 1 |
| Conic, I | 1 |
| Langerholc, T | 1 |
| Pesic, S | 1 |
| Hoshiba, T | 1 |
| Desurmont, T | 1 |
| Duhamel, A | 1 |
| Jonckheere, N | 2 |
| Gosset, P | 1 |
| Duchene, B | 1 |
| Ramdane, N | 1 |
| Noda, H | 1 |
| Watanabe, F | 1 |
| Kakizawa, N | 1 |
| Toyama, N | 1 |
| Yagi, Y | 2 |
| Yamazaki, T | 2 |
| Iwaya, A | 1 |
| Manabe, S | 1 |
| Qin, Q | 1 |
| Lyu, N | 1 |
| Guo, L | 1 |
| Zhi, W | 1 |
| Zhou, A | 1 |
| Lawrence, A | 1 |
| Wang, CZ | 1 |
| Wan, JY | 1 |
| Zhang, CF | 1 |
| Anderson, S | 2 |
| Yu, C | 1 |
| He, TC | 1 |
| Qi, LW | 1 |
| Yuan, CS | 1 |
| Nieddu, M | 1 |
| Piras, A | 1 |
| Putzu, D | 1 |
| Rescigno, A | 1 |
| Steffens, CC | 1 |
| Tschechne, B | 1 |
| Schardt, C | 1 |
| Jacobs, G | 1 |
| Valdix, AR | 1 |
| Schmidt, P | 1 |
| Hansen, R | 2 |
| Kröning, H | 2 |
| Wohlfarth, T | 1 |
| Guggenberger, D | 1 |
| Herzog, S | 1 |
| Stiegelbauer, V | 1 |
| Asslaber, M | 1 |
| Lax, S | 1 |
| Leitner, G | 1 |
| Berghold, A | 1 |
| Hosoyama, T | 1 |
| Enoki, T | 1 |
| Li, TS | 1 |
| Yonemitsu, K | 1 |
| Maeno, H | 1 |
| Okubo, S | 1 |
| Hosaka, S | 2 |
| Umemoto, S | 1 |
| Ohara, C | 1 |
| Kuji, M | 1 |
| Masuko, H | 1 |
| Yamagami, H | 1 |
| Tanioka, T | 1 |
| Ishizu, H | 1 |
| Hashimoto, Y | 2 |
| Hosoi, M | 1 |
| Nogami, H | 1 |
| Ishikawa, T | 9 |
| Minagawa, M | 2 |
| Kosugi, S | 2 |
| Koyama, Y | 8 |
| Nushijima, Y | 1 |
| Nakano, K | 2 |
| Nakaguchi, K | 5 |
| Kan, K | 1 |
| Maruyama, H | 3 |
| Doi, S | 1 |
| Okamura, S | 2 |
| Tanaka, R | 2 |
| Qiu, T | 1 |
| Xiang, X | 1 |
| Hao, C | 2 |
| Xiong, J | 1 |
| Sánchez, J | 1 |
| Martínez-Romero, J | 1 |
| Gómez de Cedrón, M | 1 |
| Dávalos, A | 1 |
| Calani, L | 1 |
| Del Rio, D | 1 |
| González-Sarrías, A | 2 |
| Espín, JC | 2 |
| Tomás-Barberán, FA | 2 |
| Maione, F | 1 |
| Oliaro-Bosso, S | 1 |
| Meda, C | 1 |
| Di Nicolantonio, F | 1 |
| Bussolino, F | 1 |
| Balliano, G | 1 |
| Viola, F | 1 |
| Giraudo, E | 1 |
| Gonella, S | 1 |
| Gonella, F | 1 |
| Rodman, C | 1 |
| Atala, A | 1 |
| Kim, EJ | 1 |
| Kang, JI | 1 |
| Kwak, JW | 1 |
| Jeon, CH | 1 |
| Tung, NH | 1 |
| Choi, CH | 2 |
| Koh, YS | 1 |
| Yoo, ES | 1 |
| Ishii, K | 1 |
| Miyanaga, S | 1 |
| Noto, M | 1 |
| Yagi, M | 1 |
| Hassan, AS | 1 |
| Naicker, M | 1 |
| Yusof, KH | 1 |
| Wan Ishak, WZ | 1 |
| Kucukzeybek, Y | 1 |
| Dirican, A | 1 |
| Demir, L | 1 |
| Yildirim, S | 1 |
| Akyol, M | 1 |
| Yildiz, Y | 1 |
| Alacacioglu, A | 1 |
| Varol, U | 1 |
| Salman, T | 1 |
| Yildiz, I | 1 |
| Can, H | 1 |
| Tarhan, MO | 1 |
| Holzner, S | 1 |
| Kalipciyan, M | 6 |
| Staribacher, A | 2 |
| Walzl, A | 1 |
| Krieger, S | 1 |
| Brenner, S | 1 |
| Jäger, W | 1 |
| Tirodkar, TS | 1 |
| Lu, P | 1 |
| Bai, A | 1 |
| Scheffel, MJ | 1 |
| Gencer, S | 1 |
| Garrett-Mayer, E | 1 |
| Bielawska, A | 1 |
| Ogretmen, B | 1 |
| Voelkel-Johnson, C | 1 |
| Matsuyama, S | 1 |
| Kuramoto, T | 2 |
| Hashiguchi, K | 1 |
| Tomé-Carneiro, J | 1 |
| Bellesia, A | 1 |
| Xie, C | 1 |
| Han, DL | 1 |
| Guo, HL | 1 |
| Zhang, ZL | 1 |
| Aspinall, SL | 2 |
| Good, CB | 2 |
| Cunningham, FE | 2 |
| Heron, BB | 1 |
| Geraci, M | 1 |
| Passero, V | 2 |
| Stone, RA | 1 |
| Smith, KJ | 2 |
| Rogers, R | 1 |
| Shields, J | 1 |
| Sartore, M | 1 |
| Boyle, DP | 1 |
| Giberti, S | 1 |
| Szymanski, J | 1 |
| Smith, D | 2 |
| Ha, A | 1 |
| Sessions, J | 1 |
| Depcinski, S | 1 |
| Fishco, S | 1 |
| Molina, I | 1 |
| Lepir, T | 1 |
| Jean, C | 1 |
| Cruz-Diaz, L | 1 |
| Motta, J | 1 |
| Calderon-Vargas, R | 1 |
| Maland, J | 1 |
| Keefe, S | 1 |
| Tague, M | 1 |
| Leone, A | 2 |
| Glovack, B | 1 |
| Kaplan, B | 1 |
| Cosgriff, S | 1 |
| Kaster, L | 1 |
| Tonnu-Mihara, I | 1 |
| Nguyen, K | 1 |
| Carmichael, J | 1 |
| Clifford, L | 1 |
| Lu, K | 2 |
| Chatta, G | 2 |
| Yoo, JH | 1 |
| Choi, CS | 1 |
| Hwang, JW | 1 |
| Kim, BM | 1 |
| Kang, MS | 1 |
| Álvarez, PJ | 3 |
| Vélez, C | 1 |
| Áranega, A | 4 |
| Lou, YT | 1 |
| Fan, YC | 1 |
| Chang, WC | 1 |
| Wu, IC | 1 |
| Hsu, WH | 1 |
| Iskandar, MZ | 1 |
| Quasem, W | 1 |
| El-Omar, M | 1 |
| Esmaelbeygi, E | 1 |
| Eynali, S | 1 |
| Okabe, M | 2 |
| Kawamoto, Y | 2 |
| Tsukumo, Y | 1 |
| Pei, S | 1 |
| Gariboldi, MB | 2 |
| Taiana, E | 1 |
| Bonzi, MC | 1 |
| Craparotta, I | 1 |
| Giovannardi, S | 1 |
| Mancini, M | 1 |
| Monti, E | 2 |
| Hartl, J | 1 |
| Itzel, T | 1 |
| Fichtner-Feigl, S | 1 |
| Stroszczynski, C | 1 |
| Hofstädter, F | 2 |
| Lee, MR | 1 |
| Ji, SY | 1 |
| Mia-Jan, K | 1 |
| Cho, MY | 1 |
| Vasilevskaya, IA | 1 |
| Selvakumaran, M | 1 |
| Hierro, LC | 1 |
| Goldstein, SR | 1 |
| Winkler, JD | 1 |
| Deme, D | 1 |
| Bishr, AM | 1 |
| Nizar, J | 1 |
| Telekes, A | 1 |
| Florit-Sureda, M | 1 |
| Conde-Estévez, D | 1 |
| Vidal, J | 1 |
| Montagut, C | 1 |
| Deng, G | 1 |
| Pei, H | 1 |
| Shen, H | 2 |
| Zeng, S | 2 |
| Nayak, A | 1 |
| Renouf, DJ | 2 |
| Speers, CH | 1 |
| Nakamura, K | 1 |
| Sasayama, A | 1 |
| Yamaji, T | 1 |
| Paschall, AV | 1 |
| Choi, JH | 2 |
| Figueroa, M | 1 |
| Oberlies, NH | 1 |
| Pearce, C | 1 |
| Bollag, WB | 1 |
| Nayak-Kapoor, A | 1 |
| Kapesa, L | 1 |
| Zeng, M | 1 |
| Luciani, A | 1 |
| Auriault, ML | 1 |
| Sarran, A | 1 |
| Monges, G | 3 |
| Trillaud, H | 1 |
| Leroy, K | 1 |
| Sobhani, I | 1 |
| Bardier, A | 1 |
| Moreau, M | 1 |
| Brindel, I | 1 |
| Vargas, A | 1 |
| Montironi, C | 1 |
| Buxó, E | 1 |
| Abdullah, A | 2 |
| Sane, S | 2 |
| Branick, KA | 1 |
| Freeling, JL | 1 |
| Rezvani, K | 2 |
| Bibeau, F | 2 |
| Planutis, AK | 1 |
| Holcombe, RF | 3 |
| Planoutene, MV | 1 |
| Planoutis, KS | 1 |
| Mack, CD | 3 |
| Brookhart, MA | 2 |
| Glynn, RJ | 2 |
| Meyer, AM | 4 |
| Carpenter, WR | 5 |
| Sandler, RS | 2 |
| Refaat, B | 2 |
| El-Shemi, AG | 2 |
| Kensara, OA | 2 |
| Mohamed, AM | 2 |
| Idris, S | 2 |
| Ahmad, J | 2 |
| Khojah, A | 1 |
| Qu, J | 1 |
| Qu, X | 1 |
| Cao, Y | 1 |
| Hou, K | 1 |
| Feng, W | 1 |
| Park, MI | 2 |
| Rouhollahi, E | 1 |
| Moghadamtousi, SZ | 1 |
| Al-Henhena, N | 1 |
| Kunasegaran, T | 1 |
| Hasanpourghadi, M | 1 |
| Looi, CY | 1 |
| Abd Malek, SN | 1 |
| Awang, K | 1 |
| Abdulla, MA | 1 |
| Mohamed, Z | 1 |
| Pachman, DR | 1 |
| Seisler, DK | 1 |
| Smith, EM | 1 |
| Beutler, AS | 1 |
| Ta, LE | 1 |
| Lafky, JM | 1 |
| Wagner-Johnston, ND | 1 |
| Ruddy, KJ | 1 |
| Dakhil, S | 1 |
| Staff, NP | 1 |
| Lu, CL | 1 |
| Yao, HJ | 1 |
| Luo, KL | 1 |
| Li, JM | 1 |
| Wu, T | 1 |
| Wu, GZ | 1 |
| Liao, MY | 1 |
| Lai, JK | 1 |
| Kuo, MY | 1 |
| Lu, RM | 1 |
| Lin, CW | 1 |
| Cheng, PC | 1 |
| Liang, KH | 1 |
| Wu, HC | 1 |
| Maroun, J | 9 |
| de Braud, F | 3 |
| Price, T | 3 |
| Hill, M | 4 |
| Hoersch, S | 1 |
| Rittweger, K | 2 |
| Sebio, A | 1 |
| Matsusaka, S | 2 |
| Yamauchi, S | 2 |
| Fujimoto, Y | 2 |
| Lu, CS | 1 |
| Mayer, B | 1 |
| Sander, S | 3 |
| Paschke, S | 1 |
| Henne-Bruns, D | 3 |
| Link, KH | 11 |
| Kornmann, M | 7 |
| Wu, L | 1 |
| Peng, R | 1 |
| Gong, S | 1 |
| Zou, F | 1 |
| Kandioler, D | 1 |
| Mittlböck, M | 2 |
| Kappel, S | 1 |
| Puhalla, H | 1 |
| Herbst, F | 2 |
| Langner, C | 1 |
| Wolf, B | 1 |
| Tschmelitsch, J | 3 |
| Schippinger, W | 3 |
| Steger, G | 3 |
| Hofbauer, F | 3 |
| Gnant, M | 3 |
| Teleky, B | 1 |
| Kührer, I | 1 |
| Pfütze, K | 1 |
| Benner, A | 2 |
| Yang, R | 1 |
| Ulrich, A | 1 |
| Ulrich, CM | 1 |
| Burwinkel, B | 1 |
| Wei, Y | 4 |
| Ren, L | 1 |
| Zhong, Y | 1 |
| Ye, L | 1 |
| Zhao, N | 2 |
| Qin, X | 2 |
| Zalcberg, JR | 2 |
| El-Serafi, M | 2 |
| Buzaid, A | 1 |
| Ghosn, M | 2 |
| Tolba, MF | 1 |
| Abdel-Rahman, SZ | 1 |
| Wang, SJ | 1 |
| Qin, YH | 1 |
| Ma, Y | 1 |
| Li, XC | 1 |
| Huo, ZJ | 1 |
| Lee, IH | 1 |
| Byeon, SW | 1 |
| Huo, SM | 1 |
| Yoon, SB | 1 |
| Roh, SY | 1 |
| He, C | 1 |
| Fang, FQ | 1 |
| Guo, HS | 1 |
| Ban, LY | 1 |
| Liu, JW | 1 |
| Yu, PY | 1 |
| Luzhenetska, VK | 1 |
| Kotlyar, IP | 1 |
| Kotlarz, A | 2 |
| Przybyszewska, M | 2 |
| Swoboda, P | 2 |
| Miłoszewska, J | 2 |
| Grygorowicz, MA | 2 |
| Markowicz, S | 2 |
| Ko, JJ | 1 |
| Woods, R | 2 |
| Matsuda, S | 1 |
| Koketsu, H | 1 |
| Hayakawa, M | 1 |
| Oliver Metzig, M | 1 |
| Fuchs, D | 1 |
| Gröne, HJ | 1 |
| Schirmacher, P | 1 |
| Chang, AY | 2 |
| Ruan, JY | 1 |
| Denise, C | 1 |
| Calvani, M | 1 |
| Giannoni, E | 1 |
| Kazmi, SM | 1 |
| Pia, MM | 1 |
| Pettazzoni, P | 1 |
| Sacco, E | 1 |
| Vanoni, M | 1 |
| Landriscina, M | 1 |
| Chiarugi, P | 1 |
| Tijeras-Raballand, A | 1 |
| Scriva, A | 1 |
| Hickish, T | 4 |
| Maartense, E | 1 |
| Shmueli, E | 1 |
| Carlsson, GU | 1 |
| Landolfi, S | 1 |
| Demetter, P | 1 |
| Colote, S | 1 |
| Fléjou, JF | 3 |
| Kim, WI | 1 |
| Kim, JM | 1 |
| Kim, GW | 1 |
| Mun, JH | 1 |
| Kim, BS | 2 |
| Kim, MB | 1 |
| Ko, HC | 1 |
| Cutler, MJ | 1 |
| Lowthers, EL | 1 |
| Richard, CL | 1 |
| Hajducek, DM | 1 |
| Spagnuolo, PA | 1 |
| Blay, J | 1 |
| Oh, SK | 1 |
| Kim, HW | 1 |
| Kang, DH | 2 |
| Choi, CW | 1 |
| Choi, YY | 1 |
| Lim, HK | 1 |
| Goo, JJ | 1 |
| Choi, SY | 1 |
| Yuan, H | 1 |
| Zheng, B | 1 |
| Tu, S | 1 |
| Öztürk, K | 1 |
| Mashal, AR | 1 |
| Yegin, BA | 1 |
| Çalış, S | 2 |
| Hu, J | 3 |
| Cai, S | 2 |
| Soni, A | 1 |
| Nelson, ME | 1 |
| Chauhan, SC | 1 |
| Newton, SS | 1 |
| Polite, B | 2 |
| Jain, A | 2 |
| Jain, SK | 2 |
| He, Y | 2 |
| Yang, W | 2 |
| Shan, M | 1 |
| Weng, M | 2 |
| Wu, D | 1 |
| Cui, B | 1 |
| Vargo, CA | 1 |
| Blazer, M | 1 |
| Reardon, J | 1 |
| Gulati, M | 1 |
| Liang, Z | 1 |
| Hong, C | 1 |
| Luo, D | 1 |
| Guan, H | 1 |
| Luo, P | 1 |
| Tan, Z | 1 |
| Murugan, K | 1 |
| Ostwal, V | 1 |
| Carvalho, MD | 1 |
| D'souza, A | 1 |
| Achrekar, MS | 1 |
| Govindarajan, S | 1 |
| Gupta, S | 1 |
| Canipari, R | 1 |
| Catizone, A | 1 |
| Ricci, G | 1 |
| Harrath, AH | 1 |
| Alwasel, SH | 1 |
| Lv, L | 1 |
| Liu, HG | 2 |
| Dong, SY | 1 |
| Guo, GL | 2 |
| Pan, YF | 1 |
| Zhang, XH | 1 |
| Francois, E | 2 |
| Cristol-Dalstein, L | 1 |
| Maillard, E | 1 |
| Paillaud, E | 1 |
| Retornaz, F | 1 |
| Qiu, S | 1 |
| Su, X | 1 |
| Aroldi, F | 1 |
| Geva, R | 1 |
| Rothney, M | 1 |
| Beny, A | 1 |
| Dror, Y | 1 |
| Steiner, M | 1 |
| Hubert, A | 1 |
| Idelevich, E | 1 |
| Gluzman, A | 1 |
| Purim, O | 1 |
| Shulman, K | 1 |
| Mishaeli, M | 1 |
| Man, S | 3 |
| Soussan-Gutman, L | 1 |
| Tezcan, H | 1 |
| Chao, C | 1 |
| Shani, A | 1 |
| Liebermann, N | 1 |
| Sugihara, K | 6 |
| Nakayama, Y | 2 |
| Miura, T | 6 |
| Hakamada, K | 1 |
| Nishimura, Y | 1 |
| Nishizawa, Y | 1 |
| Mori, Y | 2 |
| Takano, M | 1 |
| Takenoya, T | 1 |
| Asayama, M | 1 |
| Kawashima, Y | 2 |
| Masuda, T | 5 |
| Nagai, K | 4 |
| Sanada, K | 1 |
| Ome, Y | 1 |
| Koda, Y | 1 |
| Saga, K | 1 |
| Kawamoto, K | 1 |
| Kakuta, S | 1 |
| Takayama, W | 2 |
| Kou, T | 1 |
| Satou, M | 1 |
| Sugaya, M | 1 |
| Yeh, YS | 1 |
| Wang, JH | 2 |
| Lin, YW | 1 |
| Tang, HC | 1 |
| Sung, YC | 1 |
| Ali, R | 1 |
| Baracos, VE | 2 |
| Sawyer, MB | 2 |
| Bianchi, L | 1 |
| Roberts, S | 1 |
| Assenat, E | 1 |
| Mollevi, C | 2 |
| Senesse, P | 1 |
| Luo, F | 1 |
| Zhong, X | 1 |
| Yoshii, Y | 1 |
| Furukawa, T | 9 |
| Aoyama, H | 3 |
| Adachi, N | 1 |
| Zhang, MR | 1 |
| Wakizaka, H | 1 |
| Fujibayashi, Y | 1 |
| Saga, T | 1 |
| Sheng, D | 1 |
| Hou, J | 1 |
| Zhu, B | 1 |
| Han, Z | 1 |
| Wei, L | 1 |
| Yoo, SY | 1 |
| Bang, SY | 1 |
| Jeong, SN | 1 |
| Heo, J | 1 |
| Fan, J | 1 |
| Wen, Y | 1 |
| Yue, B | 1 |
| Mi, Y | 1 |
| Hadac, JN | 1 |
| Miller, DD | 1 |
| Grimes, IC | 1 |
| Clipson, L | 1 |
| Newton, MA | 1 |
| Schelman, WR | 1 |
| Halberg, RB | 1 |
| Seal, BS | 1 |
| Shermock, KM | 1 |
| Galateanu, B | 1 |
| Hudita, A | 1 |
| Negrei, C | 1 |
| Ion, RM | 1 |
| Costache, M | 1 |
| Stan, M | 1 |
| Nikitovic, D | 1 |
| Hayes, AW | 1 |
| Spandidos, DA | 1 |
| Tsatsakis, AM | 1 |
| Ginghina, O | 1 |
| Wen, X | 1 |
| Song, YS | 1 |
| Lee, TH | 1 |
| Muneoka, K | 4 |
| Shirai, Y | 4 |
| Sasaki, M | 2 |
| Kanda, J | 1 |
| Wakabayashi, H | 3 |
| Miyata, R | 1 |
| Kameyama, N | 1 |
| Tomita, M | 5 |
| Mitsuhashi, H | 1 |
| Baba, S | 1 |
| Amada, E | 1 |
| Körber, MI | 2 |
| Ratzenböck, I | 1 |
| Mondaca, S | 1 |
| Villalón, C | 1 |
| Leal, JL | 1 |
| Zúñiga, Á | 1 |
| Bellolio, F | 1 |
| Padilla, O | 1 |
| Palma, S | 1 |
| Garrido, M | 1 |
| Nervi, B | 1 |
| Zhao, P | 2 |
| Yan, C | 1 |
| González-Perera, I | 1 |
| Gutiérrez-Nicolás, F | 1 |
| Nazco-Casariego, GJ | 1 |
| Ramos-Díaz, R | 1 |
| Hernández-San Gil, R | 1 |
| Pérez-Pérez, JA | 1 |
| González García, J | 1 |
| González De La Fuente, GA | 1 |
| Razenberg, LG | 1 |
| Lemmens, VE | 4 |
| Pruijt, JF | 1 |
| Maas, HA | 1 |
| Janssen-Heijnen, ML | 2 |
| Bleiberg, H | 10 |
| Pereira, DM | 1 |
| Simões, AE | 1 |
| Castro, RE | 1 |
| Carvalho, T | 1 |
| Kim, JK | 1 |
| Han, X | 1 |
| Fernando, PM | 1 |
| Oh, MC | 1 |
| Park, JE | 2 |
| Boo, SJ | 1 |
| Na, SY | 1 |
| Jeong, YJ | 1 |
| Jeong, SU | 1 |
| Vissers, PA | 1 |
| Punt, CJ | 6 |
| Sainakham, M | 1 |
| Manosroi, A | 1 |
| Manosroi, W | 1 |
| Manosroi, J | 1 |
| Buhl, IK | 1 |
| Gerster, S | 1 |
| Jensen, T | 1 |
| Jensen, PB | 1 |
| Bosman, F | 2 |
| Brunner, N | 3 |
| Hansen, A | 1 |
| Knudsen, S | 1 |
| Streutker, CJ | 1 |
| Grin, A | 1 |
| Iovine, B | 1 |
| Guardia, F | 1 |
| Irace, C | 1 |
| Bevilacqua, MA | 1 |
| Johnson, NL | 1 |
| Lipchik, C | 1 |
| Petrelli, NJ | 17 |
| Kubicka, S | 2 |
| Kang, HR | 1 |
| Choi, HG | 1 |
| Jeon, CK | 1 |
| Lim, SJ | 2 |
| Alyami, MS | 1 |
| Lundberg, PW | 1 |
| Cotte, EG | 1 |
| Glehen, OJ | 1 |
| Gögenur, M | 1 |
| Gögenur, I | 1 |
| Ciccolini, J | 5 |
| Milano, G | 13 |
| Boige, V | 2 |
| Vincent, M | 4 |
| Lewis, C | 1 |
| Xun, P | 1 |
| He, K | 2 |
| Neska, J | 1 |
| Bolla, NR | 1 |
| Kalaitzakis, E | 1 |
| Havre, RF | 1 |
| Willemoe, GL | 1 |
| Meisner, S | 1 |
| Chung, YH | 1 |
| Kim, D | 1 |
| Pagliara, V | 2 |
| Saide, A | 1 |
| Mitidieri, E | 1 |
| d'Emmanuele di Villa Bianca, R | 1 |
| Sorrentino, R | 1 |
| Russo, G | 2 |
| Russo, A | 5 |
| Koshkin, S | 1 |
| Danilova, A | 1 |
| Raskin, G | 1 |
| Petrov, N | 1 |
| Bajenova, O | 1 |
| O'Brien, SJ | 1 |
| Tomilin, A | 1 |
| Tolkunova, E | 1 |
| Przybyla, T | 1 |
| Wesserling, M | 1 |
| Schlegel, A | 1 |
| Jang, JH | 1 |
| Georgiopoulou, S | 1 |
| Arredondo, J | 2 |
| Baixauli, J | 3 |
| Pastor, C | 2 |
| Chopitea, A | 2 |
| Sola, JJ | 2 |
| González, I | 2 |
| A-Cienfuegos, J | 1 |
| Martínez, P | 2 |
| Rodriguez, J | 3 |
| Hernández-Lizoain, JL | 3 |
| Fujiya, M | 1 |
| Moriichi, K | 1 |
| Sasajima, J | 1 |
| Ikuta, K | 1 |
| Akutsu, H | 1 |
| Kohgo, Y | 1 |
| Hakata, S | 1 |
| Terashima, J | 1 |
| Gamou, T | 1 |
| Habano, W | 1 |
| Bauzone, M | 1 |
| Corfiotti, F | 1 |
| Renaud, F | 1 |
| El Amrani, M | 1 |
| Massida, B | 1 |
| Shan, JZ | 1 |
| Xuan, YY | 1 |
| Huang, JJ | 1 |
| Wu, MY | 1 |
| Zhang, DX | 1 |
| Yang, YM | 1 |
| Wang, BS | 1 |
| Zhong, WD | 1 |
| Hu, JN | 1 |
| Cienfuegos, JA | 1 |
| Beorlegui, C | 1 |
| Rosenstone, S | 1 |
| Deng, Z | 1 |
| Zhou, C | 2 |
| Kim, CG | 1 |
| Heo, SJ | 1 |
| Kim, YJ | 3 |
| Roh, YH | 1 |
| Ma, BG | 1 |
| Spinoglio, G | 1 |
| Marano, A | 1 |
| Bianchi, PP | 1 |
| Priora, F | 1 |
| Lenti, LM | 1 |
| Ravazzoni, F | 1 |
| Formisano, G | 3 |
| Jaferian, S | 1 |
| Negahdari, B | 1 |
| Eatemadi, A | 1 |
| Yano, Y | 1 |
| Chen, M | 2 |
| Ning, N | 1 |
| Redpath, RJ | 1 |
| Zhang, F | 1 |
| Xue, M | 1 |
| Chung, DC | 1 |
| Iseki, Y | 1 |
| Shibutani, M | 1 |
| Maeda, K | 5 |
| Nagahara, H | 1 |
| Fukuoka, T | 2 |
| Ikeya, T | 1 |
| Matsutani, S | 1 |
| Kimura, K | 3 |
| Toyokawa, T | 1 |
| Amano, R | 1 |
| Muguruma, K | 1 |
| Hirakawa, K | 6 |
| Ohira, M | 3 |
| Bezborodova, OA | 1 |
| Nemtsova, ER | 1 |
| Gevorkov, AR | 1 |
| Boyko, AV | 1 |
| Venediktova, JB | 1 |
| Alekseenko, IV | 1 |
| Kostina, MB | 1 |
| Monastyrskaya, GS | 1 |
| Sverdlov, ED | 1 |
| Khmelevskiy, EV | 1 |
| Yakubovskaya, RI | 1 |
| Hasson, RM | 1 |
| Ye, C | 1 |
| Redston, M | 2 |
| Compton, CC | 2 |
| Colacchio, TA | 1 |
| Li, DD | 1 |
| Xie, B | 2 |
| Li, JJ | 2 |
| Wen, XZ | 1 |
| Zhu, SG | 1 |
| Zhang, XS | 1 |
| Peng, RQ | 1 |
| El-Hammadi, MM | 1 |
| Delgado, ÁV | 1 |
| Maiolino, S | 1 |
| Ungaro, F | 1 |
| Tatangelo, F | 1 |
| Scalia, G | 1 |
| Budillon, A | 1 |
| Quaglia, F | 1 |
| Cai, Y | 1 |
| Wei, W | 1 |
| Yin, C | 2 |
| Hao, Z | 1 |
| Shen, C | 1 |
| Onozawa, H | 1 |
| Saito, M | 3 |
| Saito, K | 2 |
| Kanke, Y | 1 |
| Watanabe, Y | 10 |
| Hayase, S | 1 |
| Sakamoto, W | 1 |
| Ishigame, T | 1 |
| Ohki, S | 2 |
| Takenoshita, S | 3 |
| Liu, N | 1 |
| Kim, JE | 1 |
| Kim, KP | 1 |
| Park, IJ | 1 |
| Kim, CW | 1 |
| Yoon, YS | 1 |
| Yu, CS | 1 |
| Kim, JC | 2 |
| Xiao, X | 1 |
| Hao, J | 1 |
| Xiao, B | 1 |
| Xiong, S | 1 |
| Deng, W | 1 |
| Fu, Q | 1 |
| Cheng, J | 2 |
| Luo, S | 1 |
| Xie, J | 2 |
| Ihemelandu, C | 1 |
| Sugarbaker, PH | 12 |
| Spencer, NJ | 1 |
| Liu, M | 3 |
| Du, K | 1 |
| Peng, L | 1 |
| Lv, Z | 1 |
| You, W | 1 |
| Xiong, Y | 1 |
| Fu, Z | 1 |
| Kumar, SU | 1 |
| Inui, K | 2 |
| Node, Y | 1 |
| Yao, Z | 1 |
| Balogoun, R | 1 |
| Levaché, CB | 1 |
| Saban-Roche, L | 1 |
| Perkins, G | 2 |
| Luc Van Laethem, J | 1 |
| Yeh, CC | 1 |
| Lai, CY | 1 |
| Chang, SN | 1 |
| Hsieh, LL | 1 |
| Tang, R | 3 |
| Sung, FC | 1 |
| Lin, YK | 1 |
| Song, KH | 1 |
| Woo, SR | 1 |
| Chung, JY | 1 |
| Hong, SO | 1 |
| Shim, J | 1 |
| Kim, YN | 1 |
| Rho, SB | 1 |
| Hong, SM | 1 |
| Cho, H | 1 |
| Hibi, M | 1 |
| Bae, DJ | 1 |
| Kim, MG | 1 |
| Bae, YK | 1 |
| Jouvin, I | 1 |
| Najah, H | 1 |
| Pimpie, C | 1 |
| Canet Jourdan, C | 1 |
| Kaci, R | 1 |
| Mirshahi, M | 1 |
| Eveno, C | 1 |
| Park, BS | 1 |
| Masuhara, H | 1 |
| Kaneko, T | 1 |
| Sawaguchi, Y | 2 |
| Katayanagi, T | 1 |
| Fujii, T | 2 |
| Uno, H | 1 |
| Shida, T | 1 |
| Ogasawara, T | 2 |
| Takahara, Y | 1 |
| Komatu, T | 1 |
| Oyamatsu, M | 1 |
| Iwaki, T | 1 |
| Yoshii, S | 1 |
| Sakatani, A | 1 |
| Huang, CM | 1 |
| Huang, MY | 1 |
| Ma, CJ | 1 |
| Yeh, Y- | 1 |
| Huang, CJ | 2 |
| Heyne, K | 1 |
| Schmitt, K | 1 |
| Mueller, D | 1 |
| Armbruester, V | 1 |
| Mestres, P | 1 |
| Roemer, K | 2 |
| Lurje, G | 2 |
| Schultheis, AM | 1 |
| Groshen, S | 3 |
| Hendifar, AE | 1 |
| Husain, H | 1 |
| Gordon, MA | 2 |
| Chang, HM | 2 |
| Jirillo, A | 1 |
| Stefani, M | 1 |
| Vascon, F | 1 |
| Prete, SP | 8 |
| Turriziani, M | 5 |
| Massara, MC | 1 |
| De Rossi, A | 1 |
| Correale, P | 11 |
| De Vecchis, L | 9 |
| Torino, F | 3 |
| Bonmassar, L | 3 |
| Aquino, A | 11 |
| Zhao, HY | 3 |
| Ooyama, A | 3 |
| Yamamoto, M | 5 |
| Ikeda, R | 2 |
| Haraguchi, M | 2 |
| Tabata, S | 2 |
| Che, XF | 2 |
| Iwashita, K | 1 |
| Fukushima, M | 15 |
| Nakagawa, M | 4 |
| Ono, M | 3 |
| Kuwano, M | 3 |
| Akiyama, S | 7 |
| Tagliaferri, P | 3 |
| Fioravanti, A | 3 |
| Del Vecchio, MT | 6 |
| Remondo, C | 3 |
| Montagnani, F | 3 |
| Rotundo, MS | 2 |
| Ginanneschi, C | 2 |
| Martellucci, I | 1 |
| Cusi, MG | 6 |
| Tassone, P | 3 |
| Francini, G | 13 |
| Pruefer, FG | 1 |
| Lizarraga, F | 1 |
| Maldonado, V | 1 |
| Melendez-Zajgla, J | 1 |
| Varani, J | 1 |
| Mano, MS | 1 |
| Duhoux, F | 1 |
| Gustafsson, SB | 1 |
| Lindgren, T | 1 |
| Jonsson, M | 1 |
| Jacobsson, SO | 1 |
| Sakai, A | 1 |
| Fushitani, H | 1 |
| Ogata, A | 1 |
| Miyamoto, A | 2 |
| Wada, A | 2 |
| Tanigawa, N | 3 |
| Zeng, QL | 1 |
| Chu, ZH | 1 |
| Luo, XJ | 1 |
| Diao, C | 1 |
| Cheng, RC | 1 |
| Wei, XP | 1 |
| Su, YJ | 1 |
| Liu, QY | 1 |
| Xu, JB | 1 |
| Gosens, MJ | 3 |
| Moerland, E | 3 |
| Lemmens, VP | 1 |
| Rutten, HT | 1 |
| Tan-Go, I | 1 |
| van den Brule, AJ | 4 |
| Kerr, D | 1 |
| Raffaele Bianco, A | 1 |
| Paillot, B | 1 |
| Sanches, E | 1 |
| Welch, J | 1 |
| Praet, M | 1 |
| MacLachlan, TK | 1 |
| Comella, P | 2 |
| Filippelli, G | 3 |
| Farris, A | 2 |
| Natale, D | 1 |
| Barberis, G | 1 |
| Maiorino, L | 1 |
| Palmeri, S | 5 |
| Cannone, M | 1 |
| Condemi, G | 1 |
| Zhang, XD | 1 |
| Bai, Y | 1 |
| Chu, YP | 1 |
| Liu, DQ | 1 |
| Jin, ML | 1 |
| Trojan, J | 1 |
| Lubomierski, N | 1 |
| Lehnert, T | 2 |
| Engels, K | 1 |
| Zeuzem, S | 1 |
| Bechstein, WO | 1 |
| Peng, QP | 1 |
| Zhou, JM | 2 |
| Pan, F | 2 |
| Zhong, DP | 1 |
| Liang, HJ | 2 |
| Jin, H | 2 |
| Li, VK | 1 |
| Ni, M | 1 |
| Di Costanzo, F | 7 |
| Ravasio, R | 1 |
| Bertetto, O | 2 |
| Vinante, O | 1 |
| Luppi, G | 4 |
| Amadori, D | 5 |
| Barone, C | 4 |
| Carlo Merlano, M | 1 |
| Longo, F | 1 |
| Mansueto, G | 1 |
| Gasperoni, S | 2 |
| Weihrauch, MR | 1 |
| Stippel, D | 1 |
| Fries, JW | 1 |
| Bovenschulte, H | 1 |
| Coutelle, O | 1 |
| Hacker, U | 1 |
| Rego, RL | 3 |
| Okumura, K | 1 |
| Windschitl, HE | 3 |
| Lopa, S | 3 |
| Nishibori, H | 3 |
| Ishii, Y | 2 |
| Endo, T | 6 |
| Kitajima, M | 6 |
| Bernhaus, A | 1 |
| Fritzer-Szekeres, M | 3 |
| Grusch, M | 2 |
| Saiko, P | 2 |
| Venkateswarlu, S | 1 |
| Trimurtulu, G | 1 |
| Jaeger, W | 2 |
| Szekeres, T | 3 |
| Huh, JW | 1 |
| Park, YA | 1 |
| Jung, EJ | 1 |
| Kwon, JE | 1 |
| Sohn, SK | 2 |
| Jurado, JM | 1 |
| Pajares, B | 1 |
| Olmos, D | 1 |
| Sevilla, I | 1 |
| Alba, E | 2 |
| Shouji, D | 1 |
| Watanabe, C | 1 |
| Suenaga, M | 2 |
| Matsuda, M | 2 |
| Kuboki, K | 1 |
| Ichimura, T | 1 |
| Keisho, C | 1 |
| Mizunuma, N | 2 |
| Hatake, K | 2 |
| Fujita, S | 4 |
| Kabuto, T | 2 |
| Chaput, U | 1 |
| Coriat, R | 2 |
| Terris, B | 1 |
| Brezault, C | 2 |
| Chaussade, S | 2 |
| Okita, NT | 1 |
| Honda, T | 1 |
| Hirashima, Y | 1 |
| Matsubara, J | 1 |
| Shimoda, T | 1 |
| Motylewska, E | 1 |
| Mełeń-Mucha, G | 2 |
| Hill, SE | 1 |
| Phillips, R | 2 |
| Francis, N | 1 |
| Agnew, K | 1 |
| Iacopetta, B | 6 |
| Kawakami, K | 3 |
| D'Incalci, M | 3 |
| Gavin, EJ | 1 |
| Song, B | 3 |
| Xi, Y | 3 |
| Ju, J | 4 |
| Faried, A | 2 |
| Takeuchi, T | 5 |
| Kuwano, H | 3 |
| Zhang, G | 2 |
| Peng, J | 1 |
| Yuan, J | 1 |
| Sargent, D | 2 |
| Buyse, M | 9 |
| Green, E | 1 |
| Ersoy, E | 1 |
| Akbulut, H | 2 |
| Moray, G | 1 |
| Hong, SH | 3 |
| Shin, YK | 4 |
| Jang, SG | 1 |
| Kim, IJ | 1 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Larsen, ME | 1 |
| Rowntree, J | 1 |
| Young, AM | 1 |
| Pearson, S | 1 |
| Smith, J | 1 |
| Gibson, OJ | 1 |
| Weaver, A | 1 |
| Tarassenko, L | 1 |
| Yri, OE | 1 |
| Vig, J | 1 |
| Hegstad, E | 1 |
| Hovde, O | 1 |
| Pignon, I | 1 |
| Jynge, P | 1 |
| Ravizza, R | 1 |
| Molteni, R | 1 |
| Marras, E | 1 |
| Perletti, G | 1 |
| Jain, AK | 1 |
| Motil, KJ | 1 |
| Olutoye, OO | 1 |
| Cope-Yokoyama, S | 1 |
| Egler, RA | 1 |
| Tatevian, N | 1 |
| Raoul, JL | 2 |
| Gourgou-Bourgade, S | 1 |
| Bugat, R | 2 |
| Viret, F | 1 |
| Gamelin, E | 9 |
| Ducreux, M | 9 |
| Conroy, T | 3 |
| Kramar, A | 1 |
| Schmidt, WM | 5 |
| Steger, GG | 11 |
| Cerny, J | 1 |
| Hassan, A | 1 |
| Smith, C | 1 |
| Piperdi, B | 1 |
| The, A | 1 |
| Ledbetter, L | 2 |
| Demirci, U | 1 |
| Büyükberber, S | 2 |
| Yilmaz, G | 1 |
| Oztürk, B | 1 |
| Akyürek, N | 1 |
| Yildiz, R | 1 |
| Tonyali, O | 1 |
| Coşkun, U | 2 |
| Benekli, M | 2 |
| Campos, ML | 1 |
| Busamia, BE | 1 |
| Dubersarsky, C | 1 |
| Lavarda, M | 1 |
| Jarchum, G | 1 |
| Finkelberg, AB | 1 |
| Fluge, Ø | 1 |
| Carlsen, E | 1 |
| Wiig, JN | 1 |
| Myrvold, HE | 1 |
| Vonen, B | 1 |
| Podhorny, N | 1 |
| Bjerkeset, O | 1 |
| Eide, TJ | 1 |
| Halvorsen, TB | 1 |
| Xue, H | 1 |
| Le Roy, S | 1 |
| Dieleman, LA | 1 |
| Shimamura, T | 1 |
| Sato, R | 1 |
| Sasaki, K | 7 |
| Cho, N | 1 |
| Hahn, HP | 1 |
| Hall, M | 1 |
| Damas, B | 1 |
| Jewell, SD | 1 |
| Matsutani, T | 1 |
| Sasajima, K | 1 |
| Matsushita, A | 1 |
| Matsuda, A | 2 |
| Miyamoto, M | 1 |
| Yokoyama, T | 1 |
| Sugiura, A | 1 |
| Yanagi, K | 1 |
| Nishi, Y | 1 |
| Tajiri, T | 2 |
| Karasawa, H | 1 |
| Miura, K | 2 |
| Fujibuchi, W | 1 |
| Ishida, K | 2 |
| Kaneko, N | 1 |
| Kinouchi, M | 1 |
| Murata, Y | 1 |
| Sasaki, H | 1 |
| Takami, K | 1 |
| Yamamura, A | 1 |
| Shibata, C | 1 |
| Sasaki, I | 1 |
| Lee, YJ | 2 |
| Jeong, KC | 1 |
| Kang, JG | 1 |
| Kim, YT | 1 |
| Colin, D | 1 |
| Gimazane, A | 1 |
| Lizard, G | 1 |
| Izard, JC | 1 |
| Solary, E | 1 |
| Latruffe, N | 1 |
| Delmas, D | 1 |
| Cafferata, EG | 1 |
| Macció, DR | 1 |
| Lopez, MV | 1 |
| Viale, DL | 1 |
| Carbone, C | 1 |
| Mazzolini, G | 1 |
| Podhajcer, OL | 1 |
| Burz, C | 1 |
| Berindan-Neagoe, IB | 1 |
| Balacescu, O | 1 |
| Tanaselia, C | 1 |
| Ursu, M | 1 |
| Gog, A | 1 |
| Chintoanu, M | 1 |
| Balacescu, L | 1 |
| Leucuta, SE | 1 |
| Irimie, A | 1 |
| Cristea, V | 1 |
| Dalzell, JR | 1 |
| Samuel, LM | 1 |
| Murphy, KC | 1 |
| Zhou, LY | 1 |
| Shan, ZZ | 1 |
| You, JL | 1 |
| Colangelo, LH | 7 |
| Lopa, SH | 3 |
| Seay, TE | 6 |
| O'Reilly, S | 2 |
| Chu, L | 2 |
| Azar, CA | 2 |
| Salepci, T | 1 |
| Seker, M | 1 |
| Uyarel, H | 1 |
| Gumus, M | 1 |
| Ustaalioğlu, BB | 1 |
| Oztürk, A | 1 |
| Sonmez, B | 1 |
| Orcun, A | 1 |
| Ozates, M | 1 |
| Irmak, R | 1 |
| Yaylaci, M | 1 |
| Kabra, N | 1 |
| Yeatman, T | 1 |
| Coppola, D | 1 |
| Vickers, MM | 1 |
| Easaw, JC | 1 |
| Pena Alvarez, C | 1 |
| Suh Oh, HJ | 1 |
| Sáenz de Miera Rodríguez, A | 1 |
| García Arroyo, FR | 1 |
| Covela Rúa, M | 1 |
| Salgado Boquete, L | 1 |
| López Clemente, PM | 1 |
| Constenla Figueiras, M | 1 |
| Topham, C | 4 |
| Greil, R | 2 |
| Cisar, L | 2 |
| Khayat, D | 1 |
| Bokemeyer, C | 2 |
| Navarro, M | 3 |
| Bonetti, A | 1 |
| Teraishi, F | 3 |
| Nakamoto, M | 1 |
| Chikuba, A | 1 |
| Nezu, M | 1 |
| Shimamura, H | 2 |
| Matsuda, T | 2 |
| Takiue, T | 1 |
| Chikuba, H | 1 |
| Chen, YY | 1 |
| Wang, ZX | 2 |
| Chang, PA | 1 |
| Bian, ZH | 1 |
| Zou, L | 1 |
| He, JM | 1 |
| Akhdar, H | 1 |
| Loyer, P | 1 |
| Rauch, C | 1 |
| Corlu, A | 1 |
| Guillouzo, A | 1 |
| Morel, F | 1 |
| Degirmenci, M | 1 |
| Karaca, B | 2 |
| Gorumlu, G | 1 |
| Durusoy, R | 1 |
| Demir Piskin, G | 1 |
| Bozkurt, MT | 1 |
| Cirak, Y | 1 |
| Tunali, D | 1 |
| Karabulut, B | 1 |
| Sanli, UA | 1 |
| Uslu, R | 1 |
| Torigoe, S | 1 |
| Matono, K | 3 |
| Shirouzu, K | 5 |
| Jin, K | 2 |
| Ewton, DZ | 1 |
| Friedman, E | 1 |
| Zuckerman, IH | 2 |
| Rapp, T | 2 |
| Onukwugha, E | 4 |
| Davidoff, A | 1 |
| Choti, MA | 2 |
| Gardner, J | 1 |
| Seal, B | 1 |
| Mullins, CD | 4 |
| Ulusakarya, A | 1 |
| Haydar, M | 1 |
| Habert, H | 1 |
| Castagne, V | 1 |
| Gumus, Y | 1 |
| Delmas-Marsalet, B | 1 |
| Glavas Dodov, M | 1 |
| Petrovska, V | 1 |
| Chang, HJ | 5 |
| Jung, KH | 1 |
| Shaikh, A | 1 |
| Wiisanen, ME | 1 |
| Gunderson, HD | 1 |
| Leung, N | 1 |
| Farina, A | 1 |
| Malafronte, C | 1 |
| Valsecchi, MA | 1 |
| Achilli, F | 1 |
| Lee, SC | 3 |
| Chan, JY | 3 |
| Pervaiz, S | 2 |
| Cai, M | 1 |
| Wang, GB | 2 |
| Tao, KX | 2 |
| Cai, CX | 1 |
| Toyokawa, A | 2 |
| Nakajima, T | 2 |
| Yamashita, H | 3 |
| Gon, H | 1 |
| Kanemitsu, K | 3 |
| Tsukamoto, T | 1 |
| Hamabe, Y | 1 |
| Segal, NH | 1 |
| Cennamo, V | 1 |
| Fuccio, L | 1 |
| Mutri, V | 1 |
| Minardi, ME | 1 |
| Eusebi, LH | 1 |
| Ceroni, L | 1 |
| Laterza, L | 1 |
| Ansaloni, L | 1 |
| Pinna, AD | 1 |
| Salfi, N | 1 |
| Martoni, AA | 1 |
| Bazzoli, F | 2 |
| Sharief, U | 1 |
| Perry, DJ | 2 |
| Grenader, T | 1 |
| Goldberg, A | 1 |
| Gabizon, A | 1 |
| Yassin, AE | 2 |
| Alsarra, IA | 2 |
| Alanazi, FK | 1 |
| Al-Mohizea, AM | 1 |
| Al-Robayan, AA | 1 |
| Al-Obeed, OA | 1 |
| Saigusa, S | 1 |
| Toiyama, Y | 6 |
| Yokoe, T | 1 |
| Okugawa, Y | 1 |
| Ioue, Y | 1 |
| Miki, C | 7 |
| Kusunoki, M | 8 |
| Malavasi, N | 1 |
| Ponti, G | 1 |
| Depenni, R | 1 |
| Bertolini, F | 1 |
| Zironi, S | 1 |
| Conte, PF | 1 |
| Xiong, HY | 1 |
| Guo, XL | 1 |
| Bu, XX | 1 |
| Zhang, SS | 1 |
| Ma, NN | 1 |
| Song, JR | 1 |
| Hu, F | 1 |
| Tao, SF | 1 |
| Sun, K | 1 |
| Wu, MC | 1 |
| Wei, LX | 1 |
| Tan, BK | 1 |
| Shimozuma, K | 3 |
| Ohashi, Y | 8 |
| Tsutani, K | 1 |
| Yavari, K | 1 |
| Taghikhani, M | 1 |
| Ghannadi Maragheh, M | 1 |
| Mesbah-Namin, SA | 1 |
| Babaei, MH | 1 |
| Yan, P | 2 |
| Fiocca, R | 2 |
| Kennedy, RD | 1 |
| Dietrich, D | 1 |
| Salvage, AV | 1 |
| Quinn, B | 1 |
| Yun, HR | 1 |
| Cho, YB | 2 |
| Chun, HK | 4 |
| Zhou, ZG | 1 |
| Pan, ZZ | 4 |
| Wan, DS | 6 |
| Ding, PR | 2 |
| Lin, JZ | 1 |
| Peng, ZH | 2 |
| Feng, F | 2 |
| Jiang, WQ | 3 |
| He, YJ | 5 |
| Yuan, SQ | 1 |
| Zhou, ZW | 4 |
| Liang, YJ | 1 |
| Fu, LW | 1 |
| Qiu, HB | 1 |
| Zhang, LY | 2 |
| Kline, CL | 2 |
| Shanmugavelandy, SS | 1 |
| Kester, M | 1 |
| Kudo, K | 2 |
| Bruheim, S | 1 |
| Botchkina, GI | 1 |
| Gavin, E | 1 |
| Wan, Y | 1 |
| Formentini, A | 4 |
| Fodstad, O | 2 |
| Kakar, M | 1 |
| Seierstad, T | 1 |
| Røe, K | 1 |
| Olsen, DR | 1 |
| Tenma, K | 1 |
| Hibino, M | 1 |
| Sasaki, Y | 2 |
| Kitamura, T | 1 |
| Nagy, Z | 1 |
| Turcsik, V | 1 |
| Blaskó, G | 1 |
| Pandey, S | 1 |
| Goessl, E | 1 |
| Brown, J | 1 |
| Armesilla, AL | 2 |
| Darling, JL | 2 |
| Lu, ZH | 2 |
| Davidoff, AJ | 1 |
| Hanna, N | 3 |
| Pandya, N | 2 |
| Bijnsdorp, IV | 1 |
| Peters, GJ | 53 |
| Temmink, OH | 3 |
| Kruyt, FA | 2 |
| Cuilliere-Dartigues, P | 2 |
| Guilloux, A | 1 |
| Parc, Y | 1 |
| Tiret, E | 1 |
| Dumont, S | 1 |
| Gayet, B | 1 |
| Validire, P | 2 |
| Praz, F | 3 |
| Palomares, T | 2 |
| Caramés, M | 2 |
| García-Alonso, I | 2 |
| Alonso-Varona, A | 2 |
| Hatakeyama, K | 3 |
| Arts, J | 1 |
| King, P | 1 |
| Mariën, A | 1 |
| Floren, W | 1 |
| Beliën, A | 1 |
| Janssen, L | 1 |
| Pilatte, I | 1 |
| Roux, B | 1 |
| Decrane, L | 1 |
| Gilissen, R | 1 |
| Hickson, I | 1 |
| Vreys, V | 1 |
| Cox, E | 1 |
| Bol, K | 1 |
| Talloen, W | 1 |
| Goris, I | 1 |
| Andries, L | 1 |
| Du Jardin, M | 1 |
| Janicot, M | 1 |
| Page, M | 1 |
| van Emelen, K | 1 |
| Angibaud, P | 1 |
| Benomar, S | 1 |
| Boutayeb, S | 1 |
| Benzekri, L | 1 |
| Senouci, K | 1 |
| Errihani, H | 1 |
| Hassam, B | 1 |
| Zhang, XM | 1 |
| Tavaluc, RT | 1 |
| Hart, LS | 2 |
| Nozawa, H | 1 |
| Muto, Y | 2 |
| Endo, J | 1 |
| Asakage, M | 2 |
| Furukawa, Y | 2 |
| Arai, M | 1 |
| Yin, B | 1 |
| Hao, W | 1 |
| Ju, W | 1 |
| Bai, C | 1 |
| Kobashikawa, K | 1 |
| Tamura, J | 1 |
| Takaki, R | 1 |
| Ohshiro, M | 1 |
| Matayoshi, R | 1 |
| Kinjyo, F | 1 |
| Fujita, J | 1 |
| Le, M | 2 |
| Windschitl, H | 3 |
| Takiuchi, H | 2 |
| Garg, R | 1 |
| Angus, E | 1 |
| Fincher, S | 1 |
| Lee, C | 1 |
| Uña, E | 1 |
| Chang, DK | 1 |
| Rhee, PL | 1 |
| Kim, DS | 1 |
| Yun, H | 1 |
| Minagawa, R | 1 |
| Hamatsu, T | 1 |
| Honbou, T | 1 |
| Ushijima, C | 1 |
| Ikebe, M | 1 |
| Kitamura, M | 1 |
| Miura, N | 1 |
| Tomochika, S | 2 |
| Nakatsu, H | 2 |
| Tokuhisa, Y | 1 |
| Yoshino, S | 3 |
| Oka, M | 3 |
| Noda, K | 1 |
| Umekita, N | 3 |
| Nasu, K | 1 |
| Inoue, S | 1 |
| Miki, Y | 1 |
| Ikenaga, M | 1 |
| Tsujie, M | 2 |
| Yasui, M | 1 |
| Miyazaki, M | 5 |
| Hirao, M | 1 |
| Fujitani, K | 1 |
| Nakamori, S | 2 |
| Tsujinaka, T | 1 |
| Nishimura, T | 2 |
| Maeda, Y | 4 |
| Okada, T | 1 |
| Sakata, K | 2 |
| Setoguchi, M | 1 |
| Kawasaki, N | 2 |
| Tsutsui, M | 1 |
| Son, HS | 1 |
| Lee, WS | 2 |
| Choi, SH | 1 |
| Wilkinson, NW | 1 |
| Costantino, JP | 2 |
| Kim, NS | 1 |
| Park, JY | 1 |
| Chae, YS | 1 |
| Moon, JH | 1 |
| Ryoo, HM | 1 |
| Bae, SH | 1 |
| Jun, SH | 1 |
| Hirai, H | 1 |
| Arai, T | 3 |
| Okada, M | 1 |
| Nishibata, T | 1 |
| Sakai, N | 1 |
| Imagaki, K | 1 |
| Ohtani, J | 1 |
| Yoshizumi, T | 2 |
| Mizuarai, S | 1 |
| Iwasawa, Y | 1 |
| Dahlqvist, C | 1 |
| Fremault, A | 1 |
| Carrasco, J | 1 |
| Colinet, B | 1 |
| Aldulaymi, B | 1 |
| Christensen, IJ | 2 |
| Sölétormos, G | 1 |
| Jess, P | 1 |
| Nielsen, SE | 1 |
| Nielsen, HJ | 2 |
| Furumoto, K | 1 |
| Kojima, H | 1 |
| Takaya, H | 1 |
| Mizuno, R | 1 |
| Mori, T | 7 |
| Ito, D | 1 |
| Kogire, M | 1 |
| Ni, H | 1 |
| Bardia, A | 2 |
| Loprinzi, C | 2 |
| Nelson, G | 2 |
| Menon, S | 1 |
| Thome, S | 1 |
| Mukai, M | 1 |
| Vidaurreta, M | 1 |
| Sánchez-Muñoz, R | 1 |
| Veganzones, S | 1 |
| Rafael, S | 1 |
| Gutiérrez, M | 1 |
| de-la-Orden, V | 1 |
| Fernández, C | 1 |
| Arroyo, M | 1 |
| Cerdán, FJ | 1 |
| Maestro de las Casas, ML | 1 |
| Miyahira, T | 1 |
| Teruya, N | 1 |
| Matsuura, F | 1 |
| Murayama, S | 1 |
| Aka, H | 1 |
| Teruya, J | 1 |
| Hanashiro, N | 1 |
| Nishihara, M | 1 |
| Okushima, N | 1 |
| Toda, Y | 1 |
| Kiyuna, M | 1 |
| Rankin, C | 1 |
| Sonnenblick, A | 1 |
| Patel, BB | 2 |
| Gupta, D | 1 |
| Elliott, AA | 1 |
| Sengupta, V | 1 |
| Ishihara, Y | 1 |
| Hasegawa, G | 1 |
| Sato, A | 3 |
| Oukkal, M | 1 |
| Djilat, K | 1 |
| Hadjam, RM | 1 |
| Mahgoun, M | 1 |
| Bentabak, K | 1 |
| Graba, A | 1 |
| Smail, N | 1 |
| Kaci, NA | 1 |
| Ahmed, RB | 1 |
| Bouzid, K | 1 |
| Migali, C | 2 |
| Tsang, KY | 3 |
| Licchetta, A | 1 |
| Mannucci, S | 1 |
| Loiacono, L | 2 |
| Nardon, E | 1 |
| De Pellegrin, A | 1 |
| Decorti, G | 1 |
| Marra, M | 1 |
| Misso, G | 1 |
| Arcuri, FP | 1 |
| Carducci, A | 1 |
| Abbruzzese, A | 1 |
| Caraglia, M | 3 |
| Sumi, T | 2 |
| Tsuchida, A | 2 |
| Ishizaki, T | 1 |
| Shimazu, M | 1 |
| Aoki, T | 6 |
| Sato, J | 1 |
| Terui, K | 1 |
| Awatsu, A | 1 |
| Koyama, M | 1 |
| Itoh, J | 2 |
| Saijo, Y | 1 |
| Hayakari, M | 1 |
| Block, S | 1 |
| Promkan, M | 1 |
| Ridwelski, K | 2 |
| Bruch, HP | 1 |
| Gangadhar, T | 1 |
| Schilsky, RL | 2 |
| Wang, LX | 1 |
| Wang, RL | 1 |
| Fan, QX | 1 |
| Lu, SX | 1 |
| Figeac, M | 1 |
| Lecellier, CH | 1 |
| Lesuffleur, T | 5 |
| Dessein, R | 1 |
| Dejonghe, MJ | 1 |
| de Launoit, Y | 1 |
| Prévost, G | 1 |
| Porchet, N | 1 |
| Lledo, G | 4 |
| Adenis, A | 3 |
| Rebischung, C | 1 |
| Bergougnoux, L | 1 |
| Kockler, L | 1 |
| French, AJ | 2 |
| Kabat, B | 1 |
| Ribic, C | 1 |
| Moore, M | 1 |
| Sinicrope, F | 1 |
| Gallinger, S | 2 |
| Midgley, R | 1 |
| Nakanishi, H | 1 |
| Kodera, Y | 2 |
| Hirai, T | 1 |
| Nakao, A | 2 |
| Gallagher, DJ | 1 |
| Kemeny, N | 13 |
| Paduch, R | 1 |
| Kandefer-Szerszeń, M | 1 |
| Piersiak, T | 1 |
| Lai, JI | 1 |
| Wang, WS | 4 |
| Lai, YC | 1 |
| Lin, PC | 1 |
| Chang, SC | 1 |
| Okuda, T | 2 |
| Iwasaki, T | 3 |
| Tashiro, Y | 1 |
| Nagayasu, K | 1 |
| Ono, S | 1 |
| Hata, M | 1 |
| Sengoku, H | 1 |
| Tang, QL | 1 |
| Lang, N | 1 |
| Bi, F | 1 |
| Tsuno, NH | 2 |
| Tsurita, G | 1 |
| Okaji, Y | 1 |
| Nishikawa, T | 1 |
| Shuno, Y | 1 |
| Hongo, K | 2 |
| Hiyoshi, M | 2 |
| Kaneko, M | 4 |
| Kitayama, J | 6 |
| Nagawa, H | 8 |
| Son, JY | 1 |
| Shin, JW | 1 |
| Park, HJ | 1 |
| Raghavendran, HR | 1 |
| Son, CG | 1 |
| Okada, Y | 3 |
| Okura, Y | 1 |
| Matsukawa, S | 1 |
| Shiratori, T | 1 |
| Kugimiya, M | 1 |
| Matsuo, S | 3 |
| Kaji, S | 1 |
| Aoyama, Y | 1 |
| Regnier Denois, V | 1 |
| Poirson, J | 1 |
| Nourissat, A | 1 |
| Jacquin, JP | 1 |
| Guastalla, JP | 1 |
| Chauvin, F | 1 |
| Mounier-Boutoille, H | 1 |
| Boisdron-Celle, M | 3 |
| Cauchin, E | 1 |
| Galmiche, JP | 1 |
| Matysiak-Budnik, T | 1 |
| Fariña-Sarasqueta, A | 3 |
| van Lijnschoten, G | 1 |
| Rutten, HJ | 5 |
| Lavery, I | 2 |
| Watson, D | 1 |
| Baehner, FL | 1 |
| Baker, J | 1 |
| Cowens, JW | 1 |
| Kundu, S | 1 |
| Fan, K | 1 |
| Cao, M | 1 |
| Lindner, DJ | 1 |
| Tuthill, R | 1 |
| Gerson, S | 1 |
| Borden, E | 1 |
| Yi, T | 1 |
| Cao, XX | 1 |
| Jiang, HX | 1 |
| Zhao, XL | 1 |
| Lin, YH | 1 |
| Liu, QL | 1 |
| Jiang, B | 1 |
| Hu, CY | 2 |
| Delclos, GL | 1 |
| Shoji, H | 1 |
| Kuroki, M | 1 |
| Hiramoto, K | 1 |
| Miura, A | 1 |
| Hirakawa, H | 1 |
| Deng, YH | 1 |
| Pu, XX | 1 |
| Huang, MJ | 2 |
| Lin, TY | 1 |
| Lin, EH | 1 |
| Ohshimo, H | 2 |
| Nakagawa, F | 1 |
| Taguchi, T | 13 |
| Hiro, J | 5 |
| Inoue, Y | 8 |
| Yoshiyama, S | 2 |
| Mohri, Y | 1 |
| Morishita, A | 1 |
| Gong, J | 1 |
| Nomura, T | 1 |
| Izuishi, K | 1 |
| Kushida, Y | 1 |
| Haba, R | 1 |
| D'Armiento, J | 1 |
| Hosokawa, Y | 1 |
| Motoori, S | 1 |
| Miyazawa, T | 1 |
| Iwamoto, N | 1 |
| Kase, Y | 1 |
| Kitagawa, N | 1 |
| Saisho, H | 1 |
| Furuse, J | 1 |
| Kume, S | 1 |
| Torigoe, Y | 1 |
| Ikeda, O | 1 |
| Goto, Y | 1 |
| Tentes, IK | 1 |
| Mikulits, W | 1 |
| Kortsaris, A | 1 |
| Lesterhuis, WJ | 1 |
| de Vries, IJ | 1 |
| Aarntzen, EA | 1 |
| de Boer, A | 1 |
| Scharenborg, NM | 1 |
| van de Rakt, M | 1 |
| van Spronsen, DJ | 2 |
| Preijers, FW | 1 |
| Figdor, CG | 1 |
| Adema, GJ | 1 |
| Hirono, Y | 1 |
| Jiao, X | 1 |
| Shirley, LA | 1 |
| Elsaleh, H | 3 |
| Soutoglou, E | 1 |
| Knudsen, ES | 1 |
| Pestell, RG | 1 |
| López, R | 1 |
| Reboredo, M | 1 |
| Grande, C | 1 |
| Jorge, M | 1 |
| Romero, C | 2 |
| Quintero, G | 1 |
| Candamio, S | 1 |
| Nakajima, S | 1 |
| Sonoda, K | 2 |
| Egawa, H | 1 |
| van Lijnschoten, I | 2 |
| Slooter, GD | 2 |
| Emons, G | 1 |
| Kramer, F | 1 |
| Gaedcke, J | 1 |
| Rave-Fränk, M | 1 |
| Scharf, JG | 1 |
| Burfeind, P | 1 |
| Becker, H | 1 |
| Beissbarth, T | 1 |
| Ghadimi, BM | 1 |
| Ried, T | 1 |
| Grade, M | 1 |
| Schalhorn, A | 1 |
| Quietzsch, D | 1 |
| Maubach, PA | 1 |
| Lambertz, H | 1 |
| Oruzio, D | 1 |
| Schlag, R | 1 |
| Weigang-Köhler, K | 1 |
| Vehling-Kaiser, U | 1 |
| Schulze, M | 1 |
| Truckenbrodt, J | 1 |
| Goebeler, M | 1 |
| Mittermüller, J | 1 |
| Bosse, D | 1 |
| Szukics, B | 1 |
| Grundeis, M | 1 |
| Zwingers, T | 1 |
| Giessen, C | 1 |
| Na, YS | 1 |
| Kim, SM | 2 |
| Jung, KA | 1 |
| Yang, SJ | 1 |
| Ryu, MH | 1 |
| Ro, S | 1 |
| Cho, DH | 1 |
| Jin, DH | 1 |
| Biava, PM | 1 |
| Frati, L | 2 |
| Castillo-Fernández, O | 1 |
| Santibáñez, M | 1 |
| Bauza, A | 1 |
| Calderillo, G | 1 |
| Castro, C | 1 |
| Herrera, R | 1 |
| Serrano, A | 1 |
| Arrieta, O | 1 |
| Herrera, LA | 1 |
| Darsigny, M | 1 |
| Babeu, JP | 1 |
| Seidman, EG | 1 |
| Gendron, FP | 1 |
| Levy, E | 2 |
| Carrier, J | 1 |
| Perreault, N | 1 |
| Boudreau, F | 1 |
| Kaley, K | 1 |
| Satoh, T | 1 |
| Anwer, MK | 1 |
| Mowafy, HA | 1 |
| El-Bagory, IM | 1 |
| Bayomi, MA | 1 |
| Lambrechts, D | 1 |
| Prenen, H | 1 |
| Jain, RK | 1 |
| Carmeliet, P | 1 |
| Fossile, E | 2 |
| Scoppola, A | 1 |
| Graziani, G | 3 |
| Cappelletti, D | 2 |
| Cardillo, A | 2 |
| Concolino, F | 1 |
| D'Atri, S | 1 |
| Balduzzi, A | 2 |
| Caporaso, P | 1 |
| Greiner, JW | 2 |
| Bonmassar, E | 9 |
| Roselli, M | 1 |
| Lombardi, L | 1 |
| Morelli, F | 1 |
| Silvestris, N | 1 |
| Fazio, N | 1 |
| Orlando, L | 1 |
| Colucci, G | 4 |
| Paillas, S | 1 |
| Boissière, F | 1 |
| Denouel, A | 1 |
| Causse, A | 1 |
| Denis, V | 1 |
| Vezzio-Vié, N | 1 |
| Marzi, L | 1 |
| Cortijo, C | 1 |
| Ait-Arsa, I | 1 |
| Askari, N | 1 |
| Pourquier, P | 1 |
| Martineau, P | 1 |
| Del Rio, M | 1 |
| Gongora, C | 1 |
| Liu, LJ | 1 |
| Zhao, CH | 1 |
| Li, SS | 1 |
| Liu, JZ | 1 |
| Li, ZQ | 1 |
| Ihtiyar, E | 1 |
| Paşaoğlu, O | 1 |
| Erkasap, S | 1 |
| Karakaş, BR | 1 |
| Yaşar, FN | 1 |
| Ohana, P | 1 |
| Hochberg, A | 1 |
| Ratzenboeck, IE | 1 |
| Bartl, B | 1 |
| Forstner, B | 1 |
| Çalık, AN | 1 |
| Çeliker, E | 1 |
| Velibey, Y | 1 |
| Çağdaş, M | 1 |
| Güzelburç, Ö | 1 |
| Gil, T | 2 |
| Whenham, N | 1 |
| Van Hamme, J | 1 |
| Besse-Hammer, T | 1 |
| Brendel, E | 1 |
| Delesen, H | 1 |
| Joosten, MC | 1 |
| Lathia, CD | 1 |
| Loembé, BA | 1 |
| Piccart-Ghebart, M | 1 |
| Nagahama, T | 2 |
| Kurokawa, T | 1 |
| Hataji, K | 1 |
| Arai, K | 1 |
| Tei, S | 1 |
| Shimobayashi, T | 2 |
| Inatsugi, N | 2 |
| Yoshikawa, S | 2 |
| Uchida, H | 3 |
| Kuge, H | 2 |
| Yokotani, T | 2 |
| Yamaguchi, T | 5 |
| Kawaguchi, C | 2 |
| Yamaoka, K | 2 |
| Inagaki, M | 2 |
| Matsuoka, M | 2 |
| Saraya, T | 2 |
| Otsuji, T | 2 |
| Yamochi, Y | 2 |
| Yamanishi, K | 2 |
| Enomoto, Y | 2 |
| Nonomura, A | 2 |
| Sho, M | 2 |
| Nakajima, Y | 6 |
| Okada, N | 3 |
| Ohsawa, T | 4 |
| Sobajima, J | 3 |
| Kuwabara, K | 2 |
| Ishiguro, T | 2 |
| Amano, K | 2 |
| Hatano, S | 3 |
| Hokama, N | 1 |
| Ishii, M | 1 |
| Yamamoto, A | 2 |
| Kumamoto, K | 3 |
| Haga, N | 2 |
| Li, XH | 1 |
| Shi, YQ | 1 |
| He, Q | 1 |
| Ji, Q | 1 |
| Wang, RQ | 1 |
| Yang, SM | 1 |
| Fang, DC | 1 |
| Black, JM | 1 |
| Hodari, KT | 1 |
| Rogers, N | 1 |
| Farris, PK | 1 |
| Lewis, AT | 1 |
| Boh, EE | 1 |
| Gordon, VL | 1 |
| Harding, GA | 1 |
| Czaykowski, P | 1 |
| Moroz, MA | 1 |
| Kochetkov, T | 1 |
| Shamis, M | 1 |
| Nair, J | 1 |
| de Stanchina, E | 1 |
| Serganova, I | 1 |
| Schwartz, GK | 1 |
| Banerjee, D | 2 |
| Bertino, JR | 8 |
| Blasberg, RG | 1 |
| Papageorgis, P | 1 |
| Cheng, K | 1 |
| Ozturk, S | 1 |
| Gong, Y | 1 |
| Lambert, AW | 1 |
| Abdolmaleky, HM | 1 |
| Zhou, JR | 1 |
| Thiagalingam, S | 1 |
| Damaske, A | 1 |
| Ma, N | 1 |
| Williams, R | 2 |
| Basselin, C | 1 |
| Fontanges, T | 1 |
| Descotes, J | 1 |
| Chevalier, P | 1 |
| Bui-Xuan, B | 1 |
| Feinard, G | 1 |
| Timour, Q | 1 |
| Papadimitriou, CA | 1 |
| Papakostas, P | 1 |
| Karina, M | 1 |
| Malettou, L | 1 |
| Dimopoulos, MA | 1 |
| Pentheroudakis, G | 1 |
| Samantas, E | 2 |
| Bamias, A | 1 |
| Miliaras, D | 1 |
| Basdanis, G | 2 |
| Xiros, N | 1 |
| Klouvas, G | 2 |
| Bafaloukos, D | 1 |
| Kafiri, G | 1 |
| Papaspirou, I | 1 |
| Pectasides, D | 1 |
| Karanikiotis, C | 1 |
| Economopoulos, T | 1 |
| Efstratiou, I | 1 |
| Korantzis, I | 1 |
| Pisanidis, N | 1 |
| Makatsoris, T | 2 |
| Matsiakou, F | 1 |
| Aravantinos, G | 2 |
| Kalofonos, HP | 2 |
| Sánchez-Aragó, M | 2 |
| Cuezva, JM | 2 |
| Mariadason, JM | 3 |
| Kennecke, H | 1 |
| Komaki, C | 1 |
| Hanatate, F | 1 |
| Premkumar, L | 1 |
| He, XT | 1 |
| Fan, XM | 1 |
| Zha, XL | 1 |
| Precetti, FA | 1 |
| Prieto, Mde C | 1 |
| Pietrantonio, A | 1 |
| González, B | 1 |
| Gilberg, F | 2 |
| Delclos, GP | 1 |
| Dhawan, P | 1 |
| Ahmad, R | 1 |
| Chaturvedi, R | 1 |
| Smith, JJ | 1 |
| Midha, R | 1 |
| Mittal, MK | 1 |
| Krishnan, M | 1 |
| Eschrich, S | 1 |
| Yeatman, TJ | 1 |
| Harris, RC | 1 |
| Washington, MK | 1 |
| Wilson, KT | 1 |
| Beauchamp, RD | 1 |
| Singh, AB | 1 |
| Shigaki, N | 1 |
| Arima, N | 1 |
| Voisin, T | 1 |
| El Firar, A | 1 |
| Fasseu, M | 1 |
| Rouyer-Fessard, C | 1 |
| Descatoire, V | 1 |
| Walker, F | 1 |
| Paradis, V | 1 |
| Bedossa, P | 2 |
| Henin, D | 1 |
| Lehy, T | 1 |
| Laburthe, M | 1 |
| Miah, A | 1 |
| Sales, KM | 1 |
| Fuller, B | 1 |
| Seifalian, AM | 1 |
| Winslet, M | 2 |
| Gilbar, P | 1 |
| Sorour, N | 1 |
| Bae, WK | 1 |
| Park, MS | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Cho, SH | 1 |
| Guo, DD | 1 |
| Park, IK | 1 |
| Chung, IJ | 1 |
| Bai, J | 1 |
| Kleyser-Sugrue, K | 1 |
| Nerenstone, SR | 1 |
| Welch, JP | 2 |
| Katsifis, A | 1 |
| Hu, C | 1 |
| Huang, XF | 1 |
| He, JH | 1 |
| Zhang, XY | 1 |
| Wu, FY | 1 |
| Liao, XL | 1 |
| Jiang, JW | 1 |
| Shibata, M | 1 |
| Shimura, T | 1 |
| Nishina, Y | 1 |
| Gonda, K | 1 |
| Yajima, Y | 1 |
| Oh, PS | 1 |
| Patel, VB | 1 |
| Sanders, MA | 1 |
| Kanwar, SS | 1 |
| Nautiyal, J | 1 |
| Kim, GP | 1 |
| Moore, MJ | 2 |
| Winslet, MC | 1 |
| Mayes, PA | 1 |
| Dolloff, NG | 1 |
| Daniel, CJ | 1 |
| Liu, JJ | 1 |
| Jee, DI | 1 |
| Dorsey, JF | 1 |
| Liu, YY | 1 |
| Brown, JM | 1 |
| Furth, EE | 1 |
| Klein, PS | 1 |
| Sears, RC | 1 |
| Fan, X | 2 |
| Ouyang, N | 1 |
| Teng, H | 1 |
| Yao, H | 1 |
| Sporn, JC | 1 |
| Hothorn, T | 1 |
| Jung, B | 1 |
| Qureshi, A | 1 |
| Ross, P | 1 |
| Landau, D | 1 |
| Taiyoh, H | 1 |
| Matsumura, A | 1 |
| Murayama, Y | 1 |
| Ichikawa, D | 2 |
| Ochiai, T | 4 |
| Nakamura, T | 6 |
| Matsumoto, K | 3 |
| Abrams, TA | 1 |
| Brightly, R | 1 |
| Mao, J | 2 |
| Kirkner, G | 1 |
| Leite, D | 1 |
| Kater, FR | 1 |
| de Melo, JV | 1 |
| Vieira de Melo, MS | 1 |
| Abad, MH | 1 |
| Kabeya, M | 1 |
| Ina, K | 1 |
| Yuasa, S | 1 |
| Kikuchi, F | 1 |
| Tajiri, C | 1 |
| Hibi, S | 1 |
| Minagawa, Y | 1 |
| Furuta, R | 1 |
| Kayukawa, S | 1 |
| Grimminger, PP | 1 |
| Barrett, C | 1 |
| Lebwohl, D | 1 |
| Danenberg, KD | 1 |
| Brabender, J | 1 |
| Vigen, CL | 1 |
| Danenberg, PV | 2 |
| Jeppesen, JB | 1 |
| Østerlind, K | 1 |
| Duldulao, MP | 1 |
| Lee, W | 1 |
| Garcia-Aguilar, J | 1 |
| Bang, SM | 1 |
| Hsiao, FY | 2 |
| Klaver, YL | 1 |
| Hendriks, T | 1 |
| Lomme, RM | 1 |
| Bleichrodt, RP | 1 |
| de Hingh, IH | 1 |
| Watkins, J | 1 |
| Slade, JH | 1 |
| Phan, A | 1 |
| Weissferdt, A | 1 |
| Overman, MJ | 1 |
| Kuebler, JP | 4 |
| Weber, T | 1 |
| Santandreu, FM | 1 |
| Valle, A | 1 |
| Oliver, J | 1 |
| Roca, P | 1 |
| Al-Niaimi, F | 1 |
| Lyon, C | 1 |
| García, MA | 1 |
| Carrasco, E | 1 |
| Aguilera, M | 1 |
| Alvarez, P | 1 |
| Rivas, C | 1 |
| Campos, JM | 1 |
| Calleja, MA | 1 |
| Esteban, M | 1 |
| Marchal, JA | 1 |
| Van Hazel, G | 5 |
| Wong, A | 4 |
| Miyaki, Y | 1 |
| Suzuki, K | 3 |
| Koizumi, K | 1 |
| Kamiyama, H | 1 |
| Maeda, T | 2 |
| Shiya, N | 1 |
| Konishi, F | 1 |
| Zhuchenko, AP | 2 |
| Kalganov, ID | 2 |
| Filon, AF | 2 |
| Wilson, PM | 2 |
| Fujiwara, K | 1 |
| Nagayoshi, Y | 1 |
| Nakahara, C | 1 |
| Yamasaki, T | 1 |
| Iwashita, T | 1 |
| Oono, R | 1 |
| Enomoto, N | 1 |
| Hosoya, N | 1 |
| Ueda, Y | 2 |
| Otsuki, S | 1 |
| Motoyama, K | 1 |
| Tajik, R | 1 |
| Saadat, H | 1 |
| Taherkhani, M | 1 |
| Movahed, MR | 1 |
| McEvilly, M | 1 |
| Popelas, C | 1 |
| Tremmel, B | 1 |
| Chen, LC | 2 |
| Wu, YH | 2 |
| Liu, IH | 1 |
| Lee, WC | 1 |
| Lan, KL | 3 |
| Ting, G | 3 |
| Lee, TW | 3 |
| Shien, JH | 1 |
| Ogura, T | 1 |
| Niwa, Y | 2 |
| Kawai, H | 1 |
| Kondo, S | 2 |
| Sawaki, A | 1 |
| Mizuno, N | 1 |
| Hijioka, S | 1 |
| Higuchi, K | 1 |
| Goto, H | 1 |
| Yamao, K | 1 |
| Isozaki, Y | 1 |
| Yamanishi, M | 1 |
| Utsunomiya, S | 1 |
| Okita, M | 1 |
| Nagao, Y | 1 |
| Oyamada, H | 1 |
| Kokura, S | 1 |
| Naito, Y | 1 |
| Dignam, JJ | 1 |
| Blackstock, AW | 2 |
| Des, GG | 1 |
| Malka, D | 2 |
| Pandya, NB | 1 |
| Hong, SP | 1 |
| Cheon, JH | 1 |
| Kim, WH | 2 |
| Carpenter, W | 1 |
| Sanoff, H | 1 |
| Nie, J | 2 |
| Zheng, W | 1 |
| Du, X | 1 |
| Kuroda, T | 2 |
| Fuchs, BC | 2 |
| Supko, JG | 1 |
| Schmitt, A | 1 |
| McGinn, CM | 1 |
| Lanuti, M | 1 |
| Tanabe, KK | 2 |
| Clay, TD | 1 |
| Ashley, DA | 1 |
| Vieitez, JM | 1 |
| González-Flores, E | 1 |
| Grande, E | 1 |
| Pérez-Hoyos, T | 1 |
| Torres, E | 1 |
| Valero, M | 1 |
| Abu-Ghanem, S | 1 |
| Novik, EF | 1 |
| Abu-Ghanem, Y | 1 |
| Shelef, I | 1 |
| van Gils, CW | 1 |
| Redekop, WK | 1 |
| Uyl-de Groot, CA | 1 |
| Grunwald, MR | 1 |
| Howie, L | 1 |
| Diaz, LA | 1 |
| Shima, K | 1 |
| Hollis, D | 2 |
| Schaefer, P | 1 |
| Tajima, A | 1 |
| Iwaizumi, M | 1 |
| Tseng-Rogenski, S | 1 |
| Cabrera, BL | 1 |
| Carethers, JM | 1 |
| Adibe, OO | 1 |
| Sharp, RJ | 1 |
| Geng, L | 1 |
| Huehls, AM | 1 |
| Wagner, JM | 1 |
| Huntoon, CJ | 1 |
| Karnitz, LM | 1 |
| Kuwabara, H | 1 |
| Baba, H | 5 |
| Wakabayashi, M | 1 |
| Nakamura, H | 1 |
| Sanada, T | 1 |
| Nakajima, K | 1 |
| Goseki, N | 1 |
| Kikuchi, A | 1 |
| Ono, H | 1 |
| Kato, S | 4 |
| Kobayashi, H | 2 |
| Iida, S | 1 |
| Enomoto, M | 1 |
| Bruera, G | 1 |
| Cannita, K | 1 |
| Giuliante, F | 1 |
| Lanfiuti Baldi, P | 1 |
| Vicentini, R | 1 |
| Nuzzo, G | 1 |
| Antonucci, A | 1 |
| Ficorella, C | 3 |
| Ricevuto, E | 2 |
| Kang, HN | 1 |
| Yoo, YA | 1 |
| Emi, Y | 1 |
| Kakeji, Y | 1 |
| Saeki, H | 1 |
| Kitazono, M | 1 |
| Sakaguchi, Y | 1 |
| Morita, M | 1 |
| Samura, H | 1 |
| Akagi, Y | 2 |
| Natsugoe, S | 1 |
| Tokunaga, S | 1 |
| Sirzen, F | 2 |
| Choudhary, B | 1 |
| Hanski, ML | 1 |
| Zeitz, M | 1 |
| Hanski, C | 1 |
| Martin, CF | 1 |
| Fine, JP | 1 |
| Weeks, J | 1 |
| Niland, J | 1 |
| Kahn, KL | 1 |
| Schymura, MJ | 2 |
| Ruiz, MA | 1 |
| Caba, O | 2 |
| Luque, R | 1 |
| Segura, A | 1 |
| Freburger, J | 1 |
| Chen, K | 1 |
| Zullig, LL | 1 |
| Kim, SD | 1 |
| Shim, JW | 1 |
| Baek, SH | 1 |
| Zabel, BA | 1 |
| Bae, YS | 1 |
| Xin, Y | 2 |
| Cong, W | 1 |
| Zhou, N | 1 |
| Hong, DF | 1 |
| Cai, XJ | 1 |
| Feng, YH | 1 |
| Wu, CL | 1 |
| Shiau, AL | 1 |
| Lee, JC | 1 |
| Chang, JG | 1 |
| Lu, PJ | 1 |
| Tung, CL | 1 |
| Feng, LY | 1 |
| Huang, WT | 1 |
| Tsao, CJ | 1 |
| Ke, J | 1 |
| Lian, L | 1 |
| Lan, P | 1 |
| Chang, YY | 1 |
| Lin, JK | 5 |
| Jiang, JK | 3 |
| Shindo, J | 1 |
| Shiraki, A | 1 |
| Nakashima, H | 1 |
| Yukita, Y | 1 |
| Formentini, L | 1 |
| Sánchez-Cenizo, L | 1 |
| Mariggiò, MA | 1 |
| Galli, L | 1 |
| Passaro, D | 1 |
| Tikidzhieva, A | 1 |
| Michel, S | 1 |
| Dippold, W | 1 |
| von Knebel Doeberitz, M | 1 |
| Kurokawa, K | 1 |
| Tanahashi, T | 1 |
| Iima, T | 1 |
| Akaike, Y | 1 |
| Nishida, K | 1 |
| Masuda, K | 1 |
| Kuwano, Y | 1 |
| Murakami, Y | 1 |
| Rokutan, K | 1 |
| Agharbi, FZ | 1 |
| Meziane, M | 1 |
| Benhemmne, H | 1 |
| Daoudi, K | 1 |
| Elmesbahi, O | 1 |
| Mikou, O | 1 |
| Mernissi, FZ | 1 |
| Baehring, JM | 1 |
| Fukuda, M | 1 |
| Kubo, K | 1 |
| Une, Y | 2 |
| Setoguchi, Y | 1 |
| Hanada, K | 1 |
| Moriyama, S | 1 |
| Tani, M | 2 |
| Murakami, T | 1 |
| Okuchi, Y | 1 |
| Ogiso, S | 1 |
| Hata, H | 1 |
| Sakata, S | 1 |
| Otani, T | 1 |
| Yamato, T | 1 |
| Ikai, I | 1 |
| Qaqish, B | 1 |
| Weiner, BJ | 1 |
| Liang, BL | 1 |
| Chen, MW | 1 |
| Liu, HY | 1 |
| Gu, XF | 1 |
| Ito, I | 1 |
| Mizuno, M | 1 |
| Yasuda, K | 3 |
| Ozaki, T | 1 |
| Kosugi, T | 1 |
| Yasuda, Y | 1 |
| Sato, W | 1 |
| Tsuboi, N | 1 |
| Imai, E | 1 |
| Nair, S | 2 |
| Kao, WY | 1 |
| Tsai, SH | 1 |
| Deng, SM | 1 |
| Chen, SJ | 1 |
| Xue, P | 1 |
| Song, WF | 1 |
| Gu, HL | 1 |
| Yang, HY | 2 |
| Wang, LW | 1 |
| Hackl, C | 1 |
| Francia, G | 1 |
| Milsom, C | 1 |
| Xu, P | 1 |
| Kerbel, RS | 1 |
| Murono, K | 1 |
| Tada, N | 1 |
| Nirei, T | 1 |
| Sinha, VR | 1 |
| Ha, J | 1 |
| Yao, J | 1 |
| Zhu, BB | 1 |
| Lu, N | 1 |
| Ke, X | 1 |
| You, QD | 1 |
| Guo, QL | 1 |
| Lan, H | 1 |
| Han, N | 2 |
| Teng, L | 1 |
| Cao, F | 1 |
| Tursi, A | 1 |
| Michaelson, JS | 1 |
| Kelly, R | 2 |
| Wortham, K | 1 |
| Joseph, IB | 2 |
| Chen, FM | 1 |
| Fan, WC | 1 |
| Hsieh, JS | 1 |
| Zhao, T | 1 |
| He, B | 1 |
| Hirai, K | 1 |
| Toya, H | 1 |
| Totsuka, O | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 1 |
| Yoon, JS | 1 |
| Won, YW | 1 |
| Park, BB | 2 |
| Lee, YY | 1 |
| Kan, WL | 1 |
| Xu, HX | 1 |
| To, KK | 1 |
| Cho, CH | 1 |
| Rudd, JA | 1 |
| Lin, G | 1 |
| Carloni, V | 1 |
| Mazzocca, A | 1 |
| Mello, T | 1 |
| Galli, A | 1 |
| Capaccioli, S | 2 |
| Rick, FG | 2 |
| Buchholz, S | 2 |
| Schally, AV | 2 |
| Szalontay, L | 2 |
| Krishan, A | 2 |
| Datz, C | 2 |
| Stadlmayr, A | 2 |
| Aigner, E | 1 |
| Perez, R | 1 |
| Seitz, S | 2 |
| Block, NL | 2 |
| Hohla, F | 2 |
| Miller, R | 1 |
| Rama, AR | 1 |
| Rodríguez-Serrano, F | 1 |
| Boulaiz, H | 1 |
| Shimoishi, K | 1 |
| Asano, T | 1 |
| Negita, M | 1 |
| Uemura, T | 1 |
| Takagi, D | 1 |
| Hattori, M | 2 |
| Kamiya, I | 1 |
| Giráldez, MD | 1 |
| Lozano, JJ | 1 |
| Cuatrecasas, M | 1 |
| Alonso-Espinaco, V | 1 |
| Mármol, M | 1 |
| Hörndler, C | 1 |
| Ortego, J | 1 |
| Alonso, V | 1 |
| Escudero, P | 1 |
| Ramírez, G | 5 |
| Petry, C | 1 |
| Lasalvia, L | 1 |
| Bohmann, K | 1 |
| Wirtz, R | 1 |
| Mira, A | 1 |
| Castells, A | 1 |
| Krstovski, N | 1 |
| Dokmanovic, L | 1 |
| Lazic, J | 1 |
| Rodic, P | 1 |
| Paripovic, L | 1 |
| Janic, D | 1 |
| Shogbon, AO | 1 |
| Hap, J | 1 |
| Dretler, R | 1 |
| Dalvi, AG | 1 |
| Hayashi, R | 1 |
| Ochiai, H | 1 |
| Matsunaga, A | 1 |
| Kulcsár, G | 1 |
| Gaál, D | 1 |
| Kulcsár, PI | 1 |
| Schulcz, Á | 1 |
| Czömpöly, T | 1 |
| Chang, GJ | 1 |
| McCahill, LE | 1 |
| Lai, LL | 1 |
| Bechar, N | 1 |
| Giguere, JK | 2 |
| Wagman, LD | 1 |
| Granci, V | 1 |
| Cai, F | 1 |
| Lecumberri, E | 1 |
| Clerc, A | 1 |
| Andreis, F | 1 |
| Ferri, M | 1 |
| Mazzocchi, M | 1 |
| Meriggi, F | 2 |
| Rizzi, A | 1 |
| Rota, L | 1 |
| Di Biasi, B | 1 |
| Abeni, C | 1 |
| Codignola, C | 1 |
| Rozzini, R | 1 |
| Shivapurkar, N | 1 |
| Mikhail, S | 1 |
| Navarro, R | 1 |
| Hwang, J | 1 |
| Pishvaian, M | 1 |
| Wellstein, A | 1 |
| He, AR | 1 |
| Kitade, H | 2 |
| Shimasaki, T | 1 |
| Yoshimitsu, Y | 1 |
| Okuda, M | 1 |
| Hokkoku, K | 1 |
| Shintaku, K | 1 |
| Sakuma, H | 1 |
| Ueda, H | 3 |
| Nakai, M | 1 |
| Selvarajan, K | 1 |
| Hasan, MR | 1 |
| Chan, AP | 1 |
| Jin, C | 1 |
| Chan, SK | 1 |
| Le, ND | 1 |
| Teixeira, L | 1 |
| Stiefelhagen, P | 1 |
| Feng, JM | 1 |
| Miao, ZH | 1 |
| Li, JX | 1 |
| Tong, LJ | 1 |
| Huang, YR | 1 |
| Ding, J | 1 |
| Kwak, CH | 1 |
| Sir, JJ | 1 |
| Cho, WH | 1 |
| Choi, SK | 1 |
| Xiang, DB | 1 |
| Xiong, F | 1 |
| Li, TY | 1 |
| Wang, XL | 1 |
| Yoshimi, K | 1 |
| Hata, K | 2 |
| Serikawa, T | 1 |
| Maisano, R | 1 |
| Azzarello, D | 1 |
| Maisano, M | 1 |
| Mafodda, A | 1 |
| Bottari, M | 1 |
| Egitto, G | 1 |
| Nardi, M | 1 |
| Tenti, S | 1 |
| Conca, R | 1 |
| Pastina, P | 1 |
| Yoshida, R | 1 |
| Matsuura, T | 1 |
| Hijikawa, K | 1 |
| Yanagida, H | 1 |
| Takada, H | 1 |
| Kwon, AH | 1 |
| Hsu, CW | 2 |
| Chang, YJ | 2 |
| Yasuda, M | 1 |
| Yamanaka, N | 2 |
| Iimori, M | 1 |
| Utsumi, D | 1 |
| Kitahara, Y | 1 |
| Amagase, K | 1 |
| Horie, S | 1 |
| Takeuchi, K | 4 |
| Lin, P | 1 |
| Khan, AQ | 1 |
| Chachad, S | 1 |
| Purandare, S | 1 |
| Malhotra, G | 1 |
| Naidu, R | 1 |
| d'Ario, G | 1 |
| Staib, L | 5 |
| Wiegel, T | 1 |
| Kron, M | 4 |
| Cetin, B | 1 |
| Kaplan, MA | 1 |
| Berk, V | 1 |
| Tufan, G | 1 |
| Isikdogan, A | 1 |
| Can, G | 1 |
| Akpinar, B | 1 |
| Baran, Y | 1 |
| Zhivotovsky, B | 2 |
| Olsson, M | 2 |
| Hoeben, KW | 1 |
| van Steenbergen, LN | 1 |
| van de Wouw, AJ | 1 |
| Panchal, JM | 1 |
| Antoniou, E | 1 |
| Mantas, D | 1 |
| Paraskeva, P | 1 |
| Dimitroulis, D | 1 |
| Smyrnis, A | 1 |
| Nikitakis, N | 1 |
| Labadariou, A | 1 |
| Tsavaris, N | 3 |
| Vernicos, P | 1 |
| Kostakis, A | 1 |
| Ye, T | 1 |
| Xia, JL | 1 |
| Yang, BW | 1 |
| Ge, NL | 1 |
| Gan, YH | 1 |
| Ren, ZG | 1 |
| Clarke, S | 3 |
| Cartwright, TH | 1 |
| Hecht, JR | 1 |
| Maindrault-Goebel, F | 1 |
| Bajetta, E | 3 |
| Makrutzki, M | 1 |
| Shang, A | 1 |
| Jia, YB | 1 |
| Cai, CN | 1 |
| Guan, XD | 1 |
| Li, PP | 1 |
| Xie, YY | 1 |
| Zhang, BM | 1 |
| Ashwanikumar, N | 1 |
| Kumar, NA | 1 |
| Nair, SA | 1 |
| Kumar, GV | 1 |
| Wu, TT | 3 |
| Schmutz, JL | 1 |
| Trechot, P | 1 |
| Jang, NY | 1 |
| Lin, YL | 1 |
| Liau, JY | 1 |
| Yu, SC | 1 |
| Ou, DL | 1 |
| Lin, LI | 1 |
| Tseng, LH | 1 |
| Chang, YL | 1 |
| Chan, HY | 1 |
| Ng, CM | 1 |
| Tiu, SC | 1 |
| Chan, AO | 1 |
| Shek, CC | 1 |
| Jin, D | 1 |
| Visich, J | 1 |
| Allison, DE | 1 |
| Iwata, T | 1 |
| Chung, K | 1 |
| Hanada, S | 1 |
| Toda, M | 1 |
| Nakata, K | 1 |
| Mukai, T | 1 |
| Akiyoshi, T | 2 |
| Koga, R | 1 |
| Arita, J | 1 |
| Saiura, A | 1 |
| Ikeda, A | 1 |
| Nagasue, Y | 1 |
| Oikawa, Y | 1 |
| Yamakawa, K | 1 |
| Konishi, T | 1 |
| Fukunaga, Y | 1 |
| Yamamoto, C | 1 |
| Klingenbrunner, S | 1 |
| Bartsch, R | 1 |
| Dréanic, J | 1 |
| Mir, O | 1 |
| Boudou-Rouquette, P | 1 |
| Dhooge, M | 1 |
| Goldwasser, F | 2 |
| Miyake, Y | 3 |
| Ikeda, K | 3 |
| Osawa, H | 2 |
| Nagase, H | 1 |
| Hoshi, M | 1 |
| Doi, T | 3 |
| Makari, Y | 1 |
| Oshima, S | 1 |
| Iijima, S | 1 |
| Kurokawa, E | 1 |
| Kikkawa, N | 4 |
| Kumagai, Y | 1 |
| Makino, S | 1 |
| Murakami, M | 5 |
| Wada, Y | 3 |
| Nishigaki, T | 1 |
| Owada, Y | 1 |
| Yanagisawa, T | 1 |
| Ebisui, C | 1 |
| Yokouchi, H | 2 |
| Kinuta, M | 2 |
| Nakagomi, N | 1 |
| Tamai, M | 1 |
| Takeda, K | 1 |
| Shigematsu, T | 1 |
| Shirai, M | 1 |
| Yamagiwa, K | 1 |
| Amamori, K | 1 |
| Sunda, K | 1 |
| Yamanda, T | 1 |
| de Souza, JA | 1 |
| Perkins, M | 1 |
| Meropol, NJ | 2 |
| Ratain, MJ | 1 |
| Newcomer, LN | 1 |
| Alexander, GC | 1 |
| Öhrling, K | 1 |
| Hallström, M | 1 |
| Benson, A | 2 |
| Ayvaci, MU | 1 |
| Alagoz, O | 1 |
| Lubner, SJ | 1 |
| Srimuangwong, K | 1 |
| Tocharus, C | 1 |
| Tocharus, J | 1 |
| Suksamrarn, A | 1 |
| Chintana, PY | 1 |
| Arienti, C | 1 |
| Tesei, A | 3 |
| Verdecchia, GM | 1 |
| Framarini, M | 1 |
| Virzì, S | 1 |
| Grassi, A | 1 |
| Scarpi, E | 1 |
| Turci, L | 1 |
| Silvestrini, R | 1 |
| Zoli, W | 4 |
| Kashimoto, N | 1 |
| Ushijima, M | 1 |
| Tamura, K | 1 |
| Zhang, DQ | 1 |
| Guo, Q | 1 |
| Zhu, JH | 1 |
| Kulu, Y | 1 |
| Kawasaki, H | 1 |
| Donahue, JM | 1 |
| Kasuya, H | 1 |
| Cusack, JC | 1 |
| Choi, EW | 1 |
| Kuruppu, DK | 1 |
| Qu, JM | 1 |
| You, J | 1 |
| Huang, QD | 1 |
| Chapman, JW | 1 |
| O'Callaghan, CJ | 1 |
| Hu, N | 1 |
| Yothers, GA | 1 |
| Catalano, PJ | 7 |
| Gray, RG | 1 |
| Fanciullino, R | 1 |
| Mollard, S | 1 |
| Giacometti, S | 1 |
| Berda-Haddad, Y | 1 |
| Chefrour, M | 1 |
| Aubert, C | 3 |
| Iliadis, A | 1 |
| Cirillo, M | 1 |
| Musola, M | 1 |
| Cassandrini, PA | 1 |
| Lunardi, G | 1 |
| Venturini, M | 1 |
| Vigil, C | 1 |
| Russo, P | 2 |
| Malacarne, D | 1 |
| Falugi, C | 1 |
| Trombino, S | 1 |
| O'Connor, PM | 1 |
| Obama, K | 1 |
| Kawai, Y | 2 |
| Takabayashi, A | 1 |
| Raymond, E | 4 |
| Coudray, AM | 1 |
| Faivre, S | 1 |
| King, I | 1 |
| Bermudes, D | 1 |
| Lin, S | 1 |
| Belcourt, M | 1 |
| Pike, J | 1 |
| Troy, K | 1 |
| Le, T | 1 |
| Ittensohn, M | 1 |
| Lang, W | 1 |
| Runyan, JD | 1 |
| Zheng, LM | 1 |
| Codacci-Pisanelli, G | 4 |
| Van der Wilt, CL | 29 |
| Smid, K | 19 |
| Noordhuis, P | 12 |
| Voorn, D | 1 |
| Pinedo, HM | 33 |
| Ricciardiello, L | 1 |
| McCollum, AD | 1 |
| Macdonald, JS | 25 |
| Shimoyama, S | 1 |
| Mochizuki, Y | 1 |
| Kusada, O | 1 |
| Kaminishi, M | 1 |
| Brunetti, G | 1 |
| Delmastro, M | 1 |
| Poggi, G | 1 |
| Avanza, F | 1 |
| Bertoli, G | 1 |
| Rigas, A | 1 |
| Dervenis, C | 1 |
| Giannakou, N | 1 |
| Kozoni, V | 1 |
| Shiff, SJ | 1 |
| Rigas, B | 1 |
| Görgülü, S | 2 |
| Oğuz, E | 1 |
| Zor, A | 1 |
| Zor, U | 1 |
| Gürdoğan, M | 1 |
| Tezel, T | 2 |
| Iwashyna, TJ | 1 |
| Lamont, EB | 3 |
| Di Paolo, A | 2 |
| Ibrahim, T | 1 |
| Danesi, R | 2 |
| Maltoni, M | 1 |
| Vannozzi, F | 1 |
| Flamini, E | 1 |
| Del Tacca, M | 1 |
| Wetzig, T | 1 |
| Beckheinrich, P | 1 |
| Rytter, M | 1 |
| Haustein, UF | 1 |
| Rassu, PC | 1 |
| Cassinelli, G | 1 |
| Ronzitti, F | 1 |
| Bronzino, P | 1 |
| Stanizzi, T | 1 |
| Casaccia, M | 1 |
| Chen, XX | 1 |
| Lai, MD | 1 |
| Zhang, YL | 1 |
| Huang, Q | 1 |
| Naka, T | 1 |
| Sugamura, K | 1 |
| Hylander, BL | 1 |
| Widmer, MB | 1 |
| Rustum, YM | 22 |
| Repasky, EA | 1 |
| Celik, S | 1 |
| Tang, XM | 1 |
| Half, E | 1 |
| Kuo, MT | 1 |
| Dencausse, Y | 1 |
| Hartung, G | 1 |
| Sturm, J | 1 |
| Kopp-Schneider, A | 1 |
| Hagmüller, E | 1 |
| Wojatschek, C | 1 |
| Lindemann, H | 1 |
| Fritze, D | 3 |
| Queisser, W | 3 |
| Yang, TS | 3 |
| Hsu, KC | 3 |
| Chen, JS | 1 |
| Di Giacomo, A | 1 |
| Barratt, PL | 1 |
| Seymour, MT | 3 |
| Stenning, SP | 2 |
| Georgiades, I | 1 |
| Walker, C | 1 |
| Birbeck, K | 1 |
| Quirke, P | 1 |
| Copur, S | 2 |
| Ledakis, P | 1 |
| Novinski, D | 1 |
| Mleczko, KL | 1 |
| Frankforter, S | 1 |
| Bolton, M | 1 |
| Fruehling, RM | 1 |
| VanWie, E | 1 |
| Norvell, M | 1 |
| Muhvic, J | 1 |
| Saguchi, T | 1 |
| Makuuchi, H | 3 |
| Murayama, C | 2 |
| Agarwal, MR | 1 |
| Esmaeli, B | 1 |
| Burnstine, MA | 1 |
| Fuwa, N | 1 |
| Kodaira, T | 1 |
| Kamata, M | 1 |
| Matsumoto, A | 2 |
| Furutani, K | 2 |
| Tachibana, H | 1 |
| Azzariti, A | 1 |
| Tommasi, S | 1 |
| Lacalamita, R | 1 |
| Johnston, PG | 12 |
| Church, SW | 1 |
| Paradiso, A | 1 |
| Takeuchi, I | 1 |
| Nakada, H | 2 |
| Ishizuka, N | 1 |
| Inokuma, S | 1 |
| Yamada, H | 2 |
| Odaka, A | 1 |
| Hoshino, T | 1 |
| Murata, N | 1 |
| Hashimoto, D | 3 |
| Matsumoto, Y | 1 |
| Schneider, T | 1 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 1 |
| Scheuer, WV | 1 |
| Fan, YF | 1 |
| Huang, ZH | 1 |
| Parr, AL | 2 |
| Kirsch, I | 1 |
| Kim, G | 1 |
| Klein, P | 2 |
| Wieand, HS | 12 |
| Altuntas, F | 1 |
| Akbulut, KG | 1 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Unal, E | 1 |
| Icli, F | 1 |
| Heckelsmiller, K | 1 |
| Beck, S | 2 |
| Rall, K | 1 |
| Sipos, B | 1 |
| Schlamp, A | 1 |
| Tuma, E | 1 |
| Rothenfusser, S | 1 |
| Endres, S | 2 |
| Hartmann, G | 2 |
| Nyati, MK | 1 |
| DeRemer, S | 1 |
| Parsels, J | 1 |
| Rehemtulla, A | 2 |
| Ensminger, WD | 2 |
| Giuliani, A | 2 |
| Pellegrini, M | 1 |
| Micheli, L | 4 |
| Nencini, C | 4 |
| Petrioli, R | 4 |
| Giorgi, G | 5 |
| Arkenau, HT | 3 |
| Bermann, A | 2 |
| Rettig, K | 3 |
| Strohmeyer, G | 2 |
| Porschen, R | 6 |
| Yoshioka, T | 3 |
| Saitoh, S | 2 |
| Nakamura, A | 1 |
| Yamamichi, N | 1 |
| Sawada, M | 1 |
| Ono, Y | 1 |
| Chester, JD | 1 |
| Joel, SP | 1 |
| Cheeseman, SL | 1 |
| Hall, GD | 1 |
| Perry, J | 1 |
| Davis, T | 1 |
| Button, CJ | 1 |
| de Bruin, M | 2 |
| van Capel, T | 1 |
| Van der Born, K | 1 |
| Hoekman, K | 2 |
| Tomioka, H | 1 |
| Yamashita, S | 1 |
| Kato, F | 1 |
| Nakamura, R | 1 |
| Koyanagi, Y | 3 |
| Gorlick, R | 2 |
| Arora, A | 1 |
| Potter, J | 1 |
| Hosokawa, A | 1 |
| Akasu, T | 1 |
| Moriya, Y | 5 |
| Tai, CJ | 1 |
| Chen, WS | 3 |
| Yen, CC | 3 |
| Chiou, TJ | 3 |
| Chen, PM | 3 |
| Shinoura, N | 1 |
| Hamada, H | 3 |
| Rao, S | 1 |
| Apolone, G | 3 |
| Cavuto, S | 1 |
| la Vecchia, C | 1 |
| Okamoto, N | 1 |
| Maruta, M | 2 |
| Sato, H | 2 |
| Masumori, K | 2 |
| Sagawa, T | 3 |
| Takayanagi, N | 2 |
| Hirayama, Y | 1 |
| Sakamaki, S | 1 |
| Chiba, H | 2 |
| Iyama, S | 2 |
| Oku, T | 2 |
| Takayama, T | 6 |
| Niitsu, Y | 5 |
| Mazurchuk, R | 1 |
| Chaudhary, ND | 1 |
| Spernyak, J | 1 |
| Veith, J | 1 |
| Pera, P | 1 |
| Greco, W | 1 |
| Bernacki, RJ | 1 |
| Mayor, S | 1 |
| Shibata, T | 2 |
| Kikuchi, R | 1 |
| Oka, Y | 2 |
| Toyoda, H | 1 |
| Okada, S | 1 |
| Magagnoli, M | 1 |
| Masci, G | 2 |
| Carnaghi, C | 1 |
| Zucali, PA | 1 |
| Castagna, L | 1 |
| Morenghi, E | 1 |
| Gokel, Y | 1 |
| Bucaloiu, ID | 1 |
| Dubagunta, S | 1 |
| Pachipala, KK | 1 |
| Kamal, N | 1 |
| Fata, F | 2 |
| Moutardier, V | 1 |
| Tosini, F | 1 |
| Vlieghe, P | 1 |
| Cara, L | 1 |
| Delpero, JR | 1 |
| Clerc, T | 1 |
| Monz, BU | 1 |
| König, HH | 1 |
| Leidl, R | 1 |
| Sawabu, N | 1 |
| Pervez, H | 1 |
| Potti, A | 1 |
| Mehdi, SA | 1 |
| Wiebke, EA | 1 |
| Grieshop, NA | 1 |
| Loehrer, PJ | 3 |
| Eckert, GJ | 1 |
| Sidner, RA | 1 |
| Lamprecht, A | 1 |
| Melissas, J | 1 |
| Schoretsanitis, G | 1 |
| Daskalakis, M | 1 |
| Tsiftsis, DD | 1 |
| Grześk, G | 1 |
| Orzałkiewicz, Z | 1 |
| Polak, G | 1 |
| Przybył, R | 1 |
| Nartowicz, E | 1 |
| Szadujkis-Szadurski, L | 1 |
| Grabczewska, Z | 1 |
| Colin, P | 3 |
| Achille, E | 4 |
| Colbert, N | 2 |
| Boaziz, C | 3 |
| Piedbois, P | 7 |
| Tubiana-Mathieu, N | 4 |
| Boutan-Laroze, A | 4 |
| Flesch, M | 4 |
| Brickell, K | 1 |
| Porter, D | 1 |
| Thompson, P | 1 |
| Kamm, YJ | 3 |
| Hull, WE | 2 |
| Heerschap, A | 5 |
| Hashimoto, M | 1 |
| Umehara, A | 1 |
| Fujimoto, T | 3 |
| Iwasaki, K | 1 |
| Ogawa, K | 1 |
| Goloshchapov, RS | 1 |
| Kokov, LS | 1 |
| Vishnevskiĭ, VA | 1 |
| Ionkin, DA | 1 |
| Elagina, LV | 1 |
| Chen, ZH | 1 |
| Feng, B | 1 |
| Levin, M | 1 |
| Kim, DJ | 1 |
| Suh, JH | 1 |
| Cho, YS | 1 |
| Shin, SK | 1 |
| Kang, JK | 1 |
| Dogliotti, L | 3 |
| Lionetto, R | 1 |
| Bruzzi, P | 2 |
| Gallo, L | 2 |
| Conte, P | 1 |
| Comandone, A | 2 |
| Marzola, M | 1 |
| Folco, U | 1 |
| Pfanner, E | 1 |
| Mestriner, M | 1 |
| Galli, C | 1 |
| Tonato, M | 2 |
| Rosso, R | 12 |
| Gray, R | 4 |
| Jensen, AO | 1 |
| Mejer, J | 1 |
| Mathonnet, M | 1 |
| Fermeaux, V | 1 |
| CURRERI, AR | 5 |
| ANSFIELD, FJ | 8 |
| SHARP, GS | 1 |
| BENEFIEL, WW | 1 |
| SULLIVAN, RD | 3 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| BRINDLEY, CO | 1 |
| CHANG, WW | 1 |
| BUERGER, L | 1 |
| LANGDON, EA | 1 |
| OTTOMAN, RE | 1 |
| ROCHLIN, DB | 2 |
| SMART, CR | 2 |
| FIELD, JB | 1 |
| DALMAUCIRIA, M | 1 |
| KENNEDY, BJ | 2 |
| MOERTEL, CG | 26 |
| REITEMEIER, RJ | 5 |
| HAHN, RG | 9 |
| KABAKOW, B | 2 |
| ALBAUM, H | 1 |
| ANTOPOL, W | 1 |
| BLINICK, G | 1 |
| SUSSMAN, L | 1 |
| GINZBURG, L | 3 |
| HURLEY, JD | 1 |
| GOLDGRABER, MB | 1 |
| KIRSNER, JB | 2 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| ZUREK, WZ | 2 |
| NADLER, SH | 2 |
| MOORE, GE | 1 |
| WATSON, EC | 1 |
| CAMMACK, KV | 1 |
| HOLSTI, LR | 2 |
| SILVA, A | 1 |
| CHILDS, DS | 1 |
| HOLBROOK, MA | 1 |
| COLBY, MY | 1 |
| Kosmas, C | 1 |
| Giannakakis, T | 1 |
| Gouveris, P | 1 |
| Vadiaka, M | 2 |
| Dimitrakopoulos, A | 2 |
| Karadima, D | 1 |
| Rokana, S | 1 |
| Papalambros, E | 2 |
| Papastratis, G | 2 |
| Margaris, H | 2 |
| Tsipras, H | 2 |
| Polyzos, A | 2 |
| James, RD | 2 |
| Donaldson, D | 1 |
| Northover, JM | 1 |
| Taylor, I | 8 |
| Futamura, N | 1 |
| Matsutomo, M | 1 |
| Yasumura, M | 1 |
| Tateyama, K | 2 |
| Schwabe, W | 2 |
| Sträter, J | 1 |
| Polat, S | 1 |
| Kettner, E | 1 |
| Weiser, HF | 1 |
| Baumann, W | 2 |
| Schramm, H | 1 |
| Häusler, P | 2 |
| Ott, K | 1 |
| Behnke, D | 2 |
| Beger, HG | 2 |
| Brown, T | 1 |
| Sigurdson, E | 1 |
| Rogatko, A | 1 |
| Broccoli, D | 1 |
| Belhadj, N | 1 |
| Gargouri, D | 1 |
| Kharrat, J | 1 |
| Ben Hriz, F | 1 |
| Kochlef, A | 1 |
| Kilani, A | 1 |
| Romani, M | 1 |
| Ghorbel, A | 1 |
| Cherif, R | 1 |
| Khlifi, S | 1 |
| Ben Maamer, A | 1 |
| Letaief, A | 1 |
| Atalay, G | 1 |
| Cardoso, F | 1 |
| Mariani, G | 1 |
| Giaccon, G | 2 |
| Mastore, M | 1 |
| Sasaki, E | 1 |
| Matsunaga, N | 2 |
| Katsumoto, Y | 3 |
| Maruyama, KT | 1 |
| Furukawa, J | 3 |
| Maruyama, N | 1 |
| Tanaka, J | 2 |
| Ishigami, H | 1 |
| Matsuo, A | 2 |
| Kawaguchi, Y | 2 |
| Sugiyama, Y | 4 |
| Catalano, V | 4 |
| Piga, A | 1 |
| Marcellini, M | 1 |
| Pancotti, A | 1 |
| Bascioni, R | 1 |
| Torresi, U | 1 |
| Silva, RR | 1 |
| Pieroni, V | 1 |
| Giorgi, F | 1 |
| Catalano, G | 5 |
| Cellerino, R | 1 |
| Begbie, S | 1 |
| Borner, M | 1 |
| Burns, WI | 1 |
| Burris, HA | 1 |
| Jodrell, D | 2 |
| Koralewski, P | 2 |
| Levine, EL | 1 |
| Marschner, N | 2 |
| Tujakowski, J | 2 |
| Zaluski, J | 2 |
| Bezulier, K | 1 |
| Fina, F | 1 |
| Roussel, M | 1 |
| Martin, PM | 1 |
| Barra, Y | 1 |
| Sørbye, H | 3 |
| Tachimori, A | 1 |
| Nishiguchi, Y | 1 |
| Nishino, H | 2 |
| Matsuoka, K | 1 |
| Tsukuda, K | 1 |
| Suda, M | 1 |
| Ota, T | 1 |
| Okita, A | 1 |
| Suzuki, E | 1 |
| Doihara, H | 1 |
| Shimizu, N | 3 |
| Kaeser, MD | 1 |
| Pebernard, S | 1 |
| Iggo, RD | 1 |
| Jordan, A | 1 |
| Stein, J | 2 |
| Parikh, AA | 1 |
| Gentner, B | 1 |
| Curley, SA | 1 |
| Mahteme, H | 1 |
| Larsson, B | 1 |
| Sundin, A | 1 |
| Khamis, H | 1 |
| Graf, W | 3 |
| Dornstauder, E | 2 |
| Rizovski, B | 3 |
| Sedivy, R | 2 |
| Müller, MW | 1 |
| Geller, J | 1 |
| Petak, I | 3 |
| Szucs, KS | 1 |
| Nagy, K | 1 |
| Tillman, DM | 3 |
| Houghton, JA | 23 |
| Arango, D | 4 |
| Wilson, AJ | 1 |
| Corner, GA | 2 |
| Nicholas, C | 1 |
| Aranes, MJ | 1 |
| Lesser, M | 1 |
| Schwartz, EL | 9 |
| Augenlicht, LH | 5 |
| Yalcin, S | 2 |
| Tekuzman, G | 1 |
| Engin, H | 1 |
| Celik, I | 1 |
| Turker, A | 1 |
| Barista, I | 1 |
| Gullu, I | 1 |
| Guler, N | 1 |
| Altundag, K | 1 |
| Ozisik, Y | 1 |
| Kars, A | 1 |
| Iba, T | 3 |
| Kidokoro, A | 3 |
| Sugiyama, K | 1 |
| Fukunaga, T | 1 |
| Aihara, N | 1 |
| Jenkins, DE | 1 |
| Oei, Y | 1 |
| Hornig, YS | 1 |
| Yu, SF | 1 |
| Dusich, J | 1 |
| Purchio, T | 1 |
| Contag, PR | 1 |
| Kawashima, R | 2 |
| Haisa, M | 3 |
| Kimura, M | 2 |
| Takaoka, M | 1 |
| Shirakawa, Y | 1 |
| Takeda, H | 3 |
| Uetsuka, H | 1 |
| Gunduz, M | 1 |
| Nagai, N | 2 |
| Tanaka, N | 6 |
| Naomoto, Y | 3 |
| Yates, Z | 2 |
| Lucock, M | 2 |
| Saenger, J | 1 |
| Leible, M | 2 |
| Seelig, MH | 2 |
| Berger, MR | 2 |
| Atadja, P | 1 |
| Kwon, P | 1 |
| Trogani, N | 1 |
| Walker, H | 1 |
| Hsu, M | 1 |
| Yeleswarapu, L | 1 |
| Chandramouli, N | 1 |
| Perez, L | 1 |
| Versace, R | 1 |
| Wu, A | 1 |
| Sambucetti, L | 1 |
| Lassota, P | 1 |
| Cohen, D | 1 |
| Bair, K | 1 |
| Wood, A | 1 |
| Remiszewski, S | 1 |
| Tajima, T | 1 |
| Saitoh, T | 1 |
| Okushiba, S | 1 |
| Morikawa, T | 1 |
| Katoh, H | 1 |
| Burzykowski, T | 1 |
| Ohata, K | 1 |
| Saito, H | 4 |
| Fujisawa, K | 1 |
| Kasahara, Y | 1 |
| Mitsui, T | 1 |
| Miura, S | 1 |
| Simeoni, M | 1 |
| Magni, P | 1 |
| Cammia, C | 1 |
| De Nicolao, G | 1 |
| Croci, V | 1 |
| Pesenti, E | 1 |
| Germani, M | 1 |
| Poggesi, I | 1 |
| Rocchetti, M | 1 |
| de Vos tot Nederveen Cappel, WH | 1 |
| Meulenbeld, HJ | 1 |
| Kleibeuker, JH | 1 |
| Nagengast, FM | 1 |
| Menko, FH | 1 |
| Griffioen, G | 1 |
| Cats, A | 1 |
| Morreau, H | 1 |
| Gelderblom, H | 1 |
| Vasen, HF | 1 |
| Czito, BG | 1 |
| Hong, TJ | 1 |
| Cohen, DP | 1 |
| Tyler, DS | 1 |
| Lee, CG | 1 |
| Anscher, MS | 1 |
| Ludwig, KA | 1 |
| Seigler, HF | 1 |
| Mantyh, C | 1 |
| Morse, MA | 1 |
| Lockhart, AC | 1 |
| Petros, WP | 1 |
| Honeycutt, W | 1 |
| Spector, NL | 1 |
| Ertel, PJ | 1 |
| Mangum, SG | 1 |
| Kanellos, I | 2 |
| Mantzoros, I | 1 |
| Demetriades, H | 2 |
| Kalfadis, S | 1 |
| Kelpis, T | 1 |
| Sakkas, L | 1 |
| Betsis, D | 2 |
| Seeliger, H | 1 |
| Guba, M | 1 |
| Koehl, GE | 1 |
| Doenecke, A | 1 |
| Steinbauer, M | 1 |
| Bruns, CJ | 1 |
| Wagner, C | 1 |
| Frank, E | 1 |
| Jauch, KW | 1 |
| Geissler, EK | 1 |
| Liu, JM | 1 |
| Kho, PS | 1 |
| Zhuang, L | 1 |
| Chew, JL | 1 |
| Ng, HH | 1 |
| Liu, ET | 1 |
| Suresh, V | 1 |
| Khavandi, A | 1 |
| Hancock, H | 1 |
| van Zuylen, L | 1 |
| Sparreboom, A | 1 |
| Eskens, FA | 1 |
| de Bruijn, P | 1 |
| Sklenar, I | 1 |
| Planting, AS | 1 |
| Choi, L | 2 |
| Bootle, D | 1 |
| Mueller, C | 1 |
| Ledermann, JA | 1 |
| Verweij, J | 1 |
| Gmeiner, WH | 1 |
| Trump, E | 1 |
| Wei, C | 1 |
| Monden, M | 2 |
| Imamura, M | 1 |
| Ohtoshi, M | 1 |
| Ohhashi, S | 1 |
| Hioki, K | 3 |
| Yasutomi, M | 8 |
| Yamamura, T | 4 |
| Kameyama, M | 3 |
| Iwanaga, T | 2 |
| Mio, H | 1 |
| Sekiya, M | 1 |
| Kathou, T | 1 |
| Morishita, Y | 1 |
| Kasakura, Y | 1 |
| Fujii, M | 3 |
| Kochi, M | 1 |
| Yagyu, T | 2 |
| Aihara, T | 1 |
| Nakamura, E | 2 |
| Nozaki, H | 2 |
| Niida, M | 1 |
| Yasuoka, H | 1 |
| Nishimoto, Y | 2 |
| Syouda, S | 1 |
| Kouno, T | 1 |
| Fukuhara, A | 2 |
| Wan, JP | 1 |
| Lin, CS | 1 |
| Liu, CC | 1 |
| Thomé, SD | 1 |
| Benedetti, J | 1 |
| Shepherd, LE | 3 |
| Francois Seitz, J | 1 |
| Cha, SS | 2 |
| Heldebrant, MP | 1 |
| Sänger, J | 1 |
| Alauddin, MM | 1 |
| Shahinian, A | 1 |
| Park, R | 1 |
| Tohme, M | 1 |
| Fissekis, JD | 1 |
| Conti, PS | 1 |
| Clavijo, J | 1 |
| Gomez-de-Segura, IA | 1 |
| Gomez-García, L | 1 |
| Vallejo-Cremades, MT | 1 |
| Sanchez, M | 1 |
| de Miguel, E | 1 |
| Nishida, O | 1 |
| Kunii, Y | 5 |
| Kodaira, S | 13 |
| Hojyo, K | 1 |
| Niimoto, M | 3 |
| Kunitomo, K | 3 |
| Isomoto, H | 3 |
| De Angelis, PM | 2 |
| Kravik, KL | 2 |
| Tunheim, SH | 1 |
| Haug, T | 1 |
| Reichelt, WH | 1 |
| Davis, JJ | 2 |
| Jacob, DA | 1 |
| Chiao, P | 1 |
| Fang, B | 2 |
| Kondo, Y | 1 |
| Terashima, M | 3 |
| Pandya, KJ | 2 |
| Lefkopoulou, M | 2 |
| Vaughn, DJ | 2 |
| Smith, TJ | 1 |
| Harris, JE | 1 |
| El-Salhy, M | 3 |
| Zhang, YC | 1 |
| Ye, YJ | 1 |
| Cui, ZR | 1 |
| Fossati, R | 1 |
| Nitti, D | 5 |
| Boffi, L | 1 |
| Scatizzi, M | 1 |
| Tardio, B | 1 |
| Mastrodonato, N | 1 |
| Banducci, S | 1 |
| Consani, G | 1 |
| Pancera, G | 3 |
| Akaike, M | 1 |
| Shiraishi, R | 1 |
| Ozawa, Y | 1 |
| Miyazaki, T | 2 |
| Kasahara, A | 1 |
| Makino, T | 1 |
| Tamura, I | 1 |
| Rino, Y | 1 |
| Suganuma, T | 1 |
| Terauchi, R | 1 |
| Shikina, A | 1 |
| Aozasa, S | 1 |
| Utsunomiya, K | 1 |
| Fujino, K | 1 |
| Ito, H | 2 |
| Hase, K | 1 |
| Mounedji-Boudiaf, L | 2 |
| Zaninelli, M | 1 |
| Tabah-Fisch, I | 1 |
| Casale, F | 1 |
| Canaparo, R | 1 |
| Serpe, L | 1 |
| Muntoni, E | 1 |
| Pepa, CD | 1 |
| Costa, M | 1 |
| Mairone, L | 1 |
| Zara, GP | 1 |
| Fornari, G | 1 |
| Eandi, M | 1 |
| Brandi, G | 1 |
| Pantaleo, MA | 1 |
| Calabrese, C | 1 |
| Di Battista, M | 1 |
| Poggi, R | 1 |
| Biasco, G | 1 |
| Melisko, ME | 1 |
| Fox, R | 1 |
| De Marco, S | 1 |
| Squilloni, E | 1 |
| Vigna, L | 1 |
| Bertagnolio, MF | 1 |
| Sternberg, CN | 1 |
| Lim, KH | 1 |
| Lin, HC | 1 |
| Su, YW | 1 |
| Chang, YF | 1 |
| Lin, J | 1 |
| Chang, MC | 1 |
| Hsieh, RK | 2 |
| Patel, M | 1 |
| Agarwal, R | 1 |
| Ardalan, B | 6 |
| Goto, T | 1 |
| Tomizawa, N | 1 |
| Kobayashi, E | 1 |
| Fujimura, A | 1 |
| Jeon, E | 2 |
| Yu, ZW | 1 |
| Dong, XS | 1 |
| Tao, J | 1 |
| Yao, XQ | 1 |
| Yin, XH | 1 |
| Fu, SB | 1 |
| Steffens, F | 1 |
| Mai, KT | 1 |
| Carnat, T | 1 |
| Voboril, R | 1 |
| Hochwald, SN | 1 |
| Brank, A | 1 |
| Weberova, J | 1 |
| Wessels, F | 1 |
| Moldawer, LL | 1 |
| Camp, ER | 1 |
| MacKay, SL | 1 |
| Martenson, JA | 4 |
| Mailliard, JA | 4 |
| Donohue, JH | 3 |
| Gunderson, LL | 5 |
| Thomas, CR | 1 |
| Fisher, B | 6 |
| Myerson, R | 1 |
| Melen-Mucha, G | 1 |
| Balcerczak, E | 1 |
| Mucha, S | 1 |
| Panczyk, M | 1 |
| Lipa, S | 1 |
| Mirowski, M | 1 |
| Saio, M | 1 |
| Slevin, M | 3 |
| Payne, S | 1 |
| Leonard, GD | 1 |
| Wagner, MR | 1 |
| Quinn, MG | 1 |
| Takemura, M | 1 |
| Osugi, H | 2 |
| Fujiwara, Y | 1 |
| Nishizawa, S | 1 |
| Iwasaki, H | 1 |
| Ishiyama, T | 1 |
| Inazawa, K | 1 |
| Munakata, M | 2 |
| Kasai, M | 3 |
| Nozaki, T | 1 |
| Kawamura, S | 1 |
| Sawamura, N | 1 |
| Hiraga, H | 1 |
| Sakata, Y | 3 |
| Fukuda, Y | 2 |
| Fujio, N | 1 |
| Mayumi, K | 1 |
| Ihara, T | 1 |
| Terakura, M | 1 |
| Takatori, H | 1 |
| Tsukazaki, T | 1 |
| Tsukazaki, Y | 1 |
| Reddy, GK | 2 |
| Emura, T | 1 |
| Yamaguchi, M | 1 |
| Grem, J | 2 |
| Smith, RE | 6 |
| Colangelo, L | 6 |
| Begovic, M | 2 |
| Ninomiya, I | 1 |
| Terada, I | 1 |
| Takino, T | 1 |
| Morita, A | 2 |
| Fushida, S | 1 |
| Nishimura, G | 1 |
| Fujimura, T | 1 |
| Ohta, T | 2 |
| Harada, O | 1 |
| Sasamoto, M | 1 |
| Shimaya, S | 1 |
| Marsé, H | 1 |
| Valverde, S | 1 |
| Mueller, MW | 2 |
| Aksu, G | 1 |
| Fayda, M | 1 |
| Sakar, B | 1 |
| Kapran, Y | 1 |
| Eatock, M | 1 |
| Johnson, J | 1 |
| Morrison, R | 1 |
| Devlin, M | 1 |
| Blackey, R | 1 |
| Owen, S | 1 |
| Ito, R | 1 |
| Carnesecchi, S | 2 |
| Bras-Gonçalves, R | 1 |
| Bradaia, A | 1 |
| Zeisel, M | 1 |
| Gossé, F | 2 |
| Poupon, MF | 1 |
| Raul, F | 2 |
| Takanashi, K | 1 |
| Hayashi, T | 3 |
| Ishiwatari, H | 1 |
| Kogawa, T | 1 |
| Kikuchi, S | 1 |
| Shouda, S | 1 |
| Gupta, SK | 1 |
| Schiavon, G | 1 |
| Avvisati, G | 1 |
| Elmiger, R | 1 |
| Gerster, JC | 1 |
| Medinger, M | 1 |
| Steinbild, S | 1 |
| Mross, K | 2 |
| Lordick, F | 2 |
| Rosenberg, R | 1 |
| Stein, HJ | 1 |
| Peschel, C | 1 |
| Siewert, JR | 2 |
| Yu, ZG | 1 |
| Sun, JZ | 1 |
| Jia, HY | 1 |
| Wang, JX | 1 |
| Tanimoto, K | 1 |
| Shimokuni, T | 1 |
| Ukon, K | 1 |
| Tsujimoto, H | 2 |
| Kawahara, K | 1 |
| Hiyama, K | 1 |
| Nishiyama, M | 4 |
| Christodoulou, C | 1 |
| Anastasopoulos, D | 1 |
| Visvikis, A | 1 |
| Mellou, S | 1 |
| Detsi, I | 1 |
| Tsiakalos, G | 1 |
| Pateli, A | 1 |
| Papadimitriou, A | 1 |
| Skarlos, DV | 1 |
| Katona, C | 2 |
| Timár, F | 1 |
| Oláh, J | 1 |
| Bocsi, J | 1 |
| Budai, B | 1 |
| Otvös, L | 3 |
| Kralovánszky, J | 3 |
| Pop, C | 1 |
| Nica, R | 1 |
| Vlaicu, R | 1 |
| Vinereanu, D | 1 |
| Xu, SS | 1 |
| Shen, WL | 1 |
| Ouyang, SY | 1 |
| Huang, XW | 1 |
| Tang, ZY | 1 |
| Smirnakis, F | 1 |
| Moskovitz, DN | 1 |
| Novakovic, P | 1 |
| Plotnikov, A | 1 |
| Fishman, D | 1 |
| Tichler, T | 1 |
| Korenstein, R | 1 |
| Mochizuki, R | 1 |
| Gunji, Y | 1 |
| Makino, H | 1 |
| Matsushita, K | 1 |
| Miyauchi, H | 1 |
| Chiba, S | 1 |
| Doi, K | 1 |
| Ohchi, T | 1 |
| Ogata, K | 1 |
| Kikuchi, N | 1 |
| Ishimoto, T | 1 |
| Muranaka, T | 1 |
| Nakamura, Y | 5 |
| Sonoyama, T | 1 |
| Sakakura, C | 2 |
| Itoi, H | 1 |
| Hagiwara, A | 2 |
| Mitsuishi, Y | 1 |
| Kishida, T | 1 |
| Fakih, MG | 3 |
| Wang, GQ | 2 |
| Liao, H | 1 |
| Sando, K | 1 |
| Mikata, S | 1 |
| Nonaka, K | 1 |
| Ide, H | 1 |
| Michiura, T | 1 |
| Kainuma, S | 1 |
| Yamanaka, H | 1 |
| Mauritz, R | 3 |
| Beumer, IJ | 1 |
| Marsh, S | 1 |
| McLeod, HL | 1 |
| van Groeningen, CJ | 16 |
| Holwerda, U | 2 |
| Van Laar, JA | 10 |
| Bauer, W | 1 |
| Horvath, Z | 1 |
| Hoechtl, T | 1 |
| Illmer, C | 1 |
| Madlener, S | 1 |
| Schott, H | 1 |
| Alikhan, MA | 1 |
| Phooskooru, V | 1 |
| Kohli, M | 1 |
| Ishibashi, S | 1 |
| Nishimura, H | 1 |
| Mizusawa, H | 1 |
| Kamoshida, S | 1 |
| Matsuoka, H | 3 |
| Shimomura, R | 1 |
| Inada, K | 1 |
| Tsutsumi, Y | 1 |
| Blumenthal, RD | 5 |
| Osorio, L | 1 |
| Hayes, MK | 1 |
| Horak, ID | 1 |
| Hansen, HJ | 1 |
| Goldenberg, DM | 8 |
| Rahman, R | 1 |
| Latonen, L | 1 |
| Wiman, KG | 1 |
| Frassineti, G | 1 |
| Costanzo, FD | 1 |
| Miquel, C | 1 |
| Sabourin, JC | 2 |
| Elias, D | 7 |
| Grandjouan, S | 2 |
| Viguier, J | 1 |
| Duvillard, P | 1 |
| Cao, S | 3 |
| Durrani, FA | 1 |
| Harris, SM | 1 |
| Mistry, P | 1 |
| Freathy, C | 1 |
| Brown, JL | 1 |
| Charlton, PA | 1 |
| Aksoy, S | 1 |
| Comijn, EM | 1 |
| Bar-Yehuda, S | 1 |
| Madi, L | 1 |
| Silberman, D | 1 |
| Gery, S | 1 |
| Shkapenuk, M | 1 |
| Fishman, P | 1 |
| Stein, U | 1 |
| Bergmann, S | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 2 |
| Royer, HD | 1 |
| Schlag, PM | 3 |
| Walther, W | 1 |
| Morita, N | 1 |
| Kashihara, K | 1 |
| Tagashira, H | 1 |
| Otsuka, H | 1 |
| Yoneda, K | 1 |
| Murase, T | 1 |
| Tsujikawa, T | 1 |
| Furutani, S | 1 |
| Minato, M | 1 |
| Nishitani, H | 1 |
| Mitchell, P | 2 |
| Beale, P | 2 |
| Friedlander, M | 2 |
| White, S | 2 |
| Vega-Stromberg, T | 1 |
| Cao, X | 1 |
| Daniel, J | 1 |
| Smythe, WR | 1 |
| Hibi, K | 1 |
| Nakayama, G | 1 |
| Zou, W | 1 |
| Dang, Y | 1 |
| Qian, C | 1 |
| Qian, Q | 1 |
| Xu, C | 2 |
| Zhang, JS | 1 |
| Mo, Y | 1 |
| Tan, RX | 2 |
| Larina, IV | 1 |
| Evers, BM | 1 |
| Ashitkov, TV | 1 |
| Bartels, C | 1 |
| Larin, KV | 1 |
| Esenaliev, RO | 1 |
| Poplin, EA | 1 |
| Estes, NC | 3 |
| Weiss, GR | 2 |
| Rivkin, SE | 2 |
| Sciallero, S | 1 |
| Ueki, K | 1 |
| Ishizuka, D | 1 |
| Wakakuwa, R | 1 |
| Yamagami, T | 1 |
| Tanaka, O | 1 |
| Hirota, T | 2 |
| Dong, QM | 2 |
| Zhou, ZM | 1 |
| Xia, ZJ | 1 |
| Li, YY | 1 |
| Jung, MS | 1 |
| Davis, DA | 1 |
| Fugate, SE | 1 |
| Park, HY | 1 |
| Nam, JH | 1 |
| Chung, KO | 1 |
| Park, KY | 1 |
| Koo, JY | 1 |
| Ji, SH | 1 |
| Lim, DH | 1 |
| Park, KW | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Park, K | 1 |
| Klampfer, L | 1 |
| Swaby, LA | 1 |
| Sasazuki, T | 1 |
| Shirasawa, S | 1 |
| Augenlicht, L | 1 |
| Jagoditsch, M | 2 |
| Sorré, C | 1 |
| Hausmaninger, H | 1 |
| Mlineritsch, B | 1 |
| Mischinger, HJ | 1 |
| Holzberger, P | 1 |
| Jakesz, R | 3 |
| Hobday, TJ | 1 |
| Brivio, F | 1 |
| Fumagalli, L | 1 |
| Fattori, L | 1 |
| Nespoli, L | 1 |
| Denova, M | 1 |
| Sargenti, E | 1 |
| Nespoli, A | 1 |
| Grivicich, I | 4 |
| Regner, A | 3 |
| da Rocha, AB | 3 |
| Kayser, GB | 2 |
| Schunemann, DP | 1 |
| Grass, LB | 2 |
| Alves, PA | 2 |
| Henriques, JA | 3 |
| Schwartsmann, G | 4 |
| Dai, M | 1 |
| Owen, DA | 1 |
| Chen, LB | 1 |
| Aguiar, S | 1 |
| Lopes, A | 1 |
| Soares, FA | 1 |
| Rossi, BM | 1 |
| Ferreira, FO | 1 |
| Nakagawa, WT | 1 |
| Carvalho, AL | 1 |
| Filho, WJ | 1 |
| Doni, L | 1 |
| Hayakawa, K | 1 |
| Nishino, M | 1 |
| Morimoto, T | 2 |
| Mukaihara, S | 1 |
| Focan, C | 4 |
| Kreutz, F | 4 |
| Longrée, L | 2 |
| Graas, MP | 2 |
| Focan-Henrard, D | 4 |
| Moeneclaey, N | 2 |
| Biquet, JF | 1 |
| Materne, R | 1 |
| Weerts, J | 2 |
| Delforge, M | 1 |
| Bury, J | 1 |
| Matus, G | 1 |
| Izawa, H | 1 |
| Damdinsuren, B | 1 |
| Suzuki, R | 1 |
| Kitani, K | 1 |
| Seki, Y | 1 |
| Ikeda, M | 1 |
| Sekimoto, M | 1 |
| Monden, T | 1 |
| Yu, XQ | 1 |
| Deng, CS | 1 |
| Zhu, YQ | 2 |
| Cheng, FZ | 1 |
| Hoshino, S | 1 |
| Maekawa, T | 1 |
| Shirakusa, T | 1 |
| Rossi, L | 2 |
| Correale, PP | 1 |
| Baier, S | 1 |
| Tamburrelli, G | 1 |
| Hayashi, S | 1 |
| Shindo, H | 1 |
| Tonouchi, A | 1 |
| Yamamori, H | 1 |
| Ashktorab, H | 1 |
| Dawkins, FW | 1 |
| Mohamed, R | 1 |
| Larbi, D | 1 |
| Smoot, DT | 1 |
| Nowacki, MP | 2 |
| Abt, M | 1 |
| Burris, H | 1 |
| Fagerberg, J | 1 |
| Husseini, F | 2 |
| Pawlicki, M | 1 |
| Schüller, J | 1 |
| Stabuc, B | 1 |
| Dolnick, R | 1 |
| Wu, Q | 2 |
| Angelino, NJ | 1 |
| Stephanie, LV | 1 |
| Chow, KC | 1 |
| Sufrin, JR | 1 |
| Dolnick, BJ | 1 |
| Liberale, G | 1 |
| Sideris, L | 1 |
| Lasser, P | 6 |
| Prete, S | 1 |
| La Placa, M | 2 |
| Terrosi, C | 2 |
| Kitano, S | 2 |
| Inomata, M | 1 |
| Yoshimura, K | 1 |
| Brabham, JG | 1 |
| Munster, P | 1 |
| Fields, K | 1 |
| Zhao, RJ | 1 |
| Tjomsland, V | 2 |
| Westra, JL | 2 |
| Hollema, H | 2 |
| Schaapveld, M | 2 |
| Platteel, I | 1 |
| Oien, KA | 1 |
| Keith, WN | 1 |
| Buys, CH | 3 |
| Hofstra, RM | 3 |
| Plukker, JT | 6 |
| Janney, LM | 1 |
| Waterbury, NV | 1 |
| Redenbacher, M | 1 |
| Nikolic-Tomasevic, Z | 1 |
| Jelic, S | 2 |
| Filipovic-Ljeskovic, I | 1 |
| Tomasevic, Z | 1 |
| Chiba, N | 1 |
| Shibata, H | 2 |
| Sakayori, M | 1 |
| Otsuka, K | 1 |
| Kakudo, Y | 1 |
| Yamaura, G | 1 |
| Ishioka, C | 2 |
| Mitomi, T | 2 |
| Noto, T | 2 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 2 |
| Amano, T | 2 |
| Oki, S | 2 |
| Otani, Y | 2 |
| Oka, H | 1 |
| Takemiya, S | 2 |
| Nishiyama, K | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 6 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Hanyu, F | 1 |
| Shebzukhov, YV | 1 |
| Koroleva, EP | 1 |
| Khlgatian, SV | 1 |
| Lagarkova, MA | 1 |
| Meshcheryakov, AA | 1 |
| Lichinitser, MR | 1 |
| Karbach, J | 1 |
| Jager, E | 2 |
| Kuprash, DV | 1 |
| Nedospasov, SA | 1 |
| Marsili, S | 3 |
| Placa, ML | 1 |
| Intrivici, C | 1 |
| Ferrari, F | 1 |
| Ryoo, BY | 1 |
| Ahn, JS | 1 |
| Kang, YK | 1 |
| Gubanski, M | 1 |
| Naucler, G | 1 |
| Almerud, A | 1 |
| Lideståhl, A | 1 |
| Lind, PA | 1 |
| Hilding, L | 1 |
| Royson, H | 1 |
| de Boer, JP | 1 |
| Kraak, MM | 1 |
| de Jong, D | 1 |
| ter Elst, A | 1 |
| Mulder, NH | 6 |
| Jones, DH | 1 |
| Silberstein, PT | 1 |
| Lynch, H | 1 |
| Ternet, C | 1 |
| Allen, WL | 2 |
| Nakazato, H | 4 |
| Sorscher, SM | 1 |
| Hata, Y | 1 |
| Matsuoka, S | 1 |
| Nakajima, N | 1 |
| Yokoyama, R | 1 |
| Sano, F | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| von Borstel, R | 1 |
| Childs, RW | 1 |
| Di Genova, G | 1 |
| Savellini, GG | 1 |
| Vestri, M | 1 |
| Urso, R | 1 |
| Lemonnier, F | 1 |
| Kavgaci, H | 1 |
| Ozdemir, F | 1 |
| Ovali, E | 1 |
| Yavuz, A | 1 |
| Yavuz, M | 1 |
| Aydin, F | 1 |
| Kjellström, J | 1 |
| Kjellén, E | 1 |
| Johnsson, A | 1 |
| Matsuoka, T | 1 |
| Morikage, N | 1 |
| Kuga, T | 1 |
| Nakayama, T | 2 |
| Fujii, Y | 1 |
| Ribelles, N | 1 |
| Nishimoto, T | 1 |
| Kiriyama, K | 1 |
| Yabu, M | 1 |
| Himeno, S | 1 |
| Shirakawa, K | 1 |
| Lamberti, C | 1 |
| Sauerbruch, T | 1 |
| Glasmacher, A | 1 |
| Gul, M | 1 |
| Duzenli, A | 1 |
| Bircan, M | 1 |
| Cander, B | 1 |
| Kocak, S | 1 |
| Ozdemir, K | 1 |
| O'Rourke, MA | 1 |
| Frontiera, MS | 1 |
| Jackson, DV | 2 |
| Dietmaier, W | 1 |
| Bettstetter, M | 1 |
| Wild, PJ | 1 |
| Woenckhaus, M | 1 |
| Rümmele, P | 1 |
| Dechant, S | 1 |
| Blaszyk, H | 1 |
| Pauer, A | 1 |
| Jessup, JM | 1 |
| Stewart, A | 1 |
| Greene, FL | 1 |
| Minsky, BD | 4 |
| Costa, F | 1 |
| Guilloton, L | 1 |
| Michaud, A | 1 |
| Potier, V | 1 |
| Le Berre, J | 1 |
| Drouet, A | 1 |
| Felten, D | 1 |
| Kanazawa, T | 1 |
| Kazama, Y | 1 |
| Ishihara, S | 1 |
| Jiang, L | 1 |
| Xia, Q | 2 |
| Zhong, L | 1 |
| Horton, PJ | 1 |
| Chaudhury, PK | 1 |
| Znajda, TL | 1 |
| Martinie, JB | 1 |
| Rochon, C | 1 |
| Tzimas, GN | 1 |
| Metrakos, P | 1 |
| Yokoyama, N | 2 |
| Mitterer, G | 1 |
| Gerner, C | 1 |
| Yagüe, XH | 1 |
| Soy, E | 1 |
| Merino, BQ | 1 |
| Puig, J | 1 |
| Fabregat, MB | 1 |
| Colomer, R | 1 |
| Bourquin, C | 1 |
| Schreiber, S | 1 |
| Leichman, CG | 2 |
| Goffin, JR | 1 |
| Talavera, JR | 1 |
| Holen, KD | 1 |
| Ershler, WB | 1 |
| Alexandre, J | 1 |
| Nicco, C | 1 |
| Chéreau, C | 1 |
| Laurent, A | 1 |
| Weill, B | 1 |
| Batteux, F | 1 |
| Raoul, Y | 2 |
| Muron, T | 1 |
| Guérin Meyer, V | 1 |
| Maigre, M | 2 |
| Ganem, G | 2 |
| Mousseau, M | 4 |
| Kaliszewski, J | 1 |
| Marques, MB | 1 |
| Nabelle, L | 1 |
| Blank, J | 1 |
| McFarland, JG | 1 |
| Boyer, J | 1 |
| McLean, EG | 1 |
| McCulla, A | 1 |
| Moore, S | 1 |
| Caldas, C | 1 |
| Al Safarjalani, ON | 1 |
| Rais, R | 1 |
| Schinazi, RF | 1 |
| Naguib, FN | 2 |
| el Kouni, MH | 2 |
| Yau, K | 1 |
| Price, P | 1 |
| Pillai, RG | 1 |
| Aboagye, E | 1 |
| Miyazaki, K | 2 |
| Shibahara, T | 1 |
| Sato, D | 1 |
| Uchida, K | 1 |
| Yanaka, A | 1 |
| Nakahara, A | 1 |
| Matsuzaki, Y | 2 |
| Tuma, RS | 1 |
| Cilley, J | 1 |
| Matasar, M | 1 |
| McBride, R | 1 |
| Jacobson, JS | 2 |
| Tsai, WY | 1 |
| Grann, VR | 2 |
| McKendrick, JJ | 1 |
| Bustová, I | 1 |
| Lesniewski-Kmak, K | 1 |
| Coxon, F | 1 |
| Maughan, TS | 1 |
| Malzyner, A | 1 |
| Beham, A | 1 |
| Figer, A | 2 |
| Dufour, P | 2 |
| Patel, KK | 1 |
| Cowell, W | 1 |
| Garrison, LP | 1 |
| Alazmi, WM | 1 |
| McHenry, L | 1 |
| Watkins, JL | 1 |
| Fogel, EL | 1 |
| Schmidt, S | 1 |
| Sherman, S | 1 |
| Lehman, GL | 1 |
| Choi, W | 2 |
| Proctor, L | 1 |
| Gerner, EW | 1 |
| Chiao, PJ | 1 |
| Lembersky, BC | 5 |
| Marshall, ME | 1 |
| Jacobs, AD | 1 |
| Colman, LK | 3 |
| Soran, A | 2 |
| Leonetti, C | 3 |
| Scarsella, M | 1 |
| Zupi, G | 4 |
| Medri, L | 1 |
| Fabbri, F | 1 |
| Rosetti, M | 1 |
| Ulivi, P | 1 |
| Cecconetto, L | 1 |
| Bolla, M | 1 |
| Vakifahmetoglu, H | 1 |
| Orrenius, S | 1 |
| Halling, KC | 1 |
| La Plant, B | 1 |
| Laurie, JA | 8 |
| Witzig, TE | 1 |
| Miyata, Y | 1 |
| Mera, K | 1 |
| Yano, T | 1 |
| Tanigawara, Y | 1 |
| Zhang, ZG | 2 |
| Song, C | 1 |
| Wijesinghe, N | 2 |
| Thompson, PI | 1 |
| McAlister, H | 1 |
| Svendsrud, DH | 1 |
| Stokke, T | 1 |
| Kelder, W | 1 |
| Hospers, GA | 1 |
| Garassino, MC | 1 |
| Rahman, Z | 2 |
| Kohli, K | 2 |
| Khar, RK | 2 |
| Ali, M | 2 |
| Charoo, NA | 2 |
| Shamsher, AA | 2 |
| Norwood, AA | 2 |
| Tan, M | 1 |
| May, M | 1 |
| Tucci, M | 2 |
| Benghuzzi, H | 2 |
| Gambarota, G | 1 |
| Lok, J | 1 |
| Lammens, M | 1 |
| Kamm, YL | 1 |
| Wagener, T | 1 |
| van der Kogel, AJ | 1 |
| Hojo, K | 4 |
| Arai, Y | 6 |
| Uemura, N | 1 |
| Wu, XB | 1 |
| Zhang, JH | 1 |
| Chen, DD | 1 |
| Tan, ZM | 1 |
| Xiao, XZ | 1 |
| Segura, C | 1 |
| Afchain, P | 1 |
| Tempestini, A | 1 |
| Caciagli, B | 1 |
| Morganti, M | 1 |
| Witort, E | 1 |
| Nobili, S | 1 |
| Papucci, L | 1 |
| Schiavone, N | 1 |
| Donnini, M | 1 |
| Landini, I | 1 |
| Lapucci, A | 1 |
| Perna, F | 1 |
| Lulli, M | 1 |
| Mazzei, T | 2 |
| Shepherd, L | 2 |
| Krook, JE | 4 |
| Rayson, S | 1 |
| Morton, RF | 1 |
| Rowland, KM | 1 |
| Kugler, JW | 3 |
| Harlak, A | 1 |
| Wilson, JW | 1 |
| Nesbitt, L | 1 |
| Wienad, HS | 1 |
| Zhu, Q | 1 |
| Yang, CM | 1 |
| Xu, HW | 1 |
| Zhang, AZ | 1 |
| Wang, HB | 1 |
| Qin, CY | 1 |
| Li, YQ | 1 |
| Cogdell, D | 1 |
| Sun, YM | 1 |
| Zheng, ZX | 1 |
| Huang, CZ | 1 |
| Yuan, XH | 1 |
| Peng, YL | 1 |
| Gong, QF | 1 |
| Wand, ZQ | 1 |
| Jorgensen, TJ | 1 |
| Tian, H | 1 |
| Menon, K | 1 |
| Frost, D | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Deguchi, Y | 2 |
| Gundling, F | 1 |
| Fuchs, M | 1 |
| Nowak, L | 1 |
| Antoni, D | 1 |
| Hoffmann, E | 1 |
| Schepp, W | 1 |
| Lee, RA | 1 |
| Kim, HA | 1 |
| Kang, BY | 1 |
| Pasetto, LM | 1 |
| Monfardini, S | 1 |
| Zhou, AW | 1 |
| Fu, YC | 1 |
| Verma, UN | 1 |
| Tripathy, D | 1 |
| Frenkel, EP | 1 |
| Becerra, CR | 1 |
| Fujimoto-Ouchi, K | 1 |
| Onuma, E | 1 |
| Shirane, M | 1 |
| Mori, K | 2 |
| Nakatani, K | 1 |
| Nobori, T | 1 |
| Omura, K | 4 |
| Morita, S | 1 |
| Allen, JA | 1 |
| Adlakha, A | 1 |
| Bergethon, PR | 1 |
| Eggington, S | 2 |
| Tappenden, P | 2 |
| Pandor, A | 2 |
| Paisley, S | 2 |
| Seymour, M | 1 |
| Sutcliffe, P | 2 |
| Chilcott, J | 1 |
| Taverna, P | 1 |
| Rendahl, K | 1 |
| Jekic-McMullen, D | 1 |
| Shao, Y | 1 |
| Aardalen, K | 1 |
| Salangsang, F | 1 |
| Doyle, L | 1 |
| Moler, E | 1 |
| Hibner, B | 1 |
| Peramiquel, L | 1 |
| Dalmau, J | 1 |
| Puig, L | 1 |
| Roé, E | 1 |
| Fernández-Figueras, MT | 1 |
| Alomar, A | 1 |
| Moreira da Silva, IB | 1 |
| Aranha, MM | 1 |
| Albuquerque, C | 1 |
| Nobre Leitão, C | 1 |
| Steer, CJ | 1 |
| Yokoi, K | 1 |
| Ishikawa, N | 1 |
| Seya, T | 1 |
| Horiba, K | 1 |
| Kanazawa, Y | 1 |
| Shirakawa, T | 1 |
| Ohkawa, K | 1 |
| Kudoh, H | 1 |
| Koizumi, M | 1 |
| Yoshioka, M | 1 |
| Shinji, S | 1 |
| Yamashita, K | 2 |
| Oguro, A | 2 |
| Nanri, M | 1 |
| Miyamoto, Y | 1 |
| Ujiie, K | 1 |
| Iitaka, D | 1 |
| Koh, T | 1 |
| Kobayashi, S | 2 |
| Yamazaki, J | 1 |
| Gutermann, A | 1 |
| Mayer, E | 1 |
| von Dehn-Rothfelser, K | 1 |
| Breidenstein, C | 1 |
| Weber, M | 1 |
| Muench, M | 1 |
| Gungor, D | 1 |
| Suehnel, J | 1 |
| Moebius, U | 1 |
| Lechmann, M | 1 |
| Jiao, RH | 1 |
| Xu, S | 1 |
| Ge, HM | 1 |
| Ding, H | 1 |
| Zhu, HL | 1 |
| Werner, JM | 1 |
| Eger, K | 1 |
| Jürgen Steinfelder, H | 1 |
| Deng, Y | 2 |
| Tao, K | 1 |
| Prins, HJ | 1 |
| van Gelderop, E | 1 |
| Lim, R | 1 |
| Soler-Gonzalez, G | 1 |
| Abe, S | 2 |
| Araki, N | 1 |
| Okamoto, T | 1 |
| Nakahara, O | 1 |
| Beppu, T | 1 |
| Ishiko, T | 1 |
| Mizumoto, T | 1 |
| Takamori, H | 1 |
| Hirota, M | 1 |
| Platell, C | 3 |
| McCaul, K | 1 |
| Millward, M | 1 |
| Bayliss, E | 1 |
| Trotter, J | 1 |
| Ransom, D | 1 |
| Twelves, CJ | 2 |
| Kopec, JA | 2 |
| Ganz, PA | 2 |
| Land, SR | 2 |
| Cecchini, RS | 2 |
| Aballéa, S | 2 |
| Chancellor, JV | 1 |
| Raikou, M | 1 |
| Drummond, MF | 1 |
| Weinstein, MC | 1 |
| Jourdan, S | 1 |
| Wada, N | 1 |
| Yanagi, H | 2 |
| Fritschi, L | 1 |
| Tsushima, T | 1 |
| Ohura, K | 1 |
| Sumiyoshi, T | 1 |
| Yoshizaki, N | 1 |
| Jensen, SA | 1 |
| Vilmar, A | 1 |
| Sørensen, JB | 1 |
| Reddy, N | 1 |
| Jansen, G | 5 |
| Ougolkov, AV | 1 |
| Kitakata, H | 1 |
| Yasumoto, K | 2 |
| Omote, K | 2 |
| Mai, M | 1 |
| Minamoto, T | 2 |
| Kamoshita, N | 1 |
| Makita, F | 1 |
| Kabeya, K | 1 |
| Hou, S | 1 |
| Kou, G | 1 |
| Qian, W | 1 |
| Dai, J | 1 |
| Lin, B | 1 |
| Zhao, ZY | 1 |
| Wu, CP | 1 |
| Xu, LG | 1 |
| Zanoni, C | 1 |
| Correa, LP | 1 |
| Jotz, GP | 1 |
| Sameshima, S | 2 |
| Horikoshi, H | 1 |
| Motegi, K | 1 |
| Tomozawa, S | 1 |
| Hirayama, I | 1 |
| Sawada, T | 4 |
| Grau Cat, J | 1 |
| Navarro Ferrando, JT | 1 |
| Mate Sanz, JL | 1 |
| Ribera Santasusana, JM | 1 |
| Nehls, O | 1 |
| Okech, T | 1 |
| Hsieh, CJ | 1 |
| Enzinger, T | 1 |
| Sarbia, M | 1 |
| Borchard, F | 1 |
| Gruenagel, HH | 2 |
| Gaco, V | 1 |
| Hass, HG | 1 |
| Hartmann, JT | 1 |
| Gregor, M | 1 |
| Klump, B | 1 |
| Pascucci, A | 1 |
| Sciandivasci, A | 1 |
| Tassi, R | 1 |
| Civitelli, S | 2 |
| Tanzini, G | 2 |
| Lorenzi, M | 1 |
| Zou, K | 1 |
| Ju, JH | 1 |
| Li, YM | 1 |
| Yu, CH | 1 |
| Wang, SQ | 1 |
| Ji, F | 1 |
| Chen, CX | 1 |
| Larsen, AK | 1 |
| Tsuji, S | 1 |
| Yoshio, T | 1 |
| Ishii, S | 1 |
| Egawa, S | 1 |
| Kakiuchi, Y | 1 |
| Yasumaru, M | 1 |
| Murata, H | 1 |
| Kawano, S | 1 |
| Abbrederis, K | 1 |
| Kremer, M | 1 |
| Schuhmacher, C | 1 |
| Tang, XQ | 1 |
| Liu, HQ | 1 |
| Cao, JG | 1 |
| Lim, YJ | 1 |
| Rhee, JC | 1 |
| Bae, YM | 1 |
| Chun, WJ | 1 |
| Murphy, K | 1 |
| Needles, BM | 1 |
| Bearden, JD | 1 |
| Lanier, KS | 2 |
| Pajon, ER | 1 |
| Cella, D | 1 |
| Findlay, MP | 1 |
| Zapas, JL | 1 |
| Goodwin, JW | 2 |
| Ramanathan, RK | 1 |
| Conley, BA | 1 |
| Flynn, PJ | 1 |
| Soori, G | 1 |
| Levine, EA | 1 |
| Murakami, J | 1 |
| Kokeguchi, S | 1 |
| Tsujigiwa, H | 1 |
| Asaumi, J | 1 |
| Nagatsuka, H | 1 |
| Fukui, K | 1 |
| Kuroda, M | 1 |
| Matsubara, N | 1 |
| Tang, XY | 1 |
| Tao, WH | 1 |
| Wei, B | 1 |
| Lin, XL | 1 |
| Wisinski, KB | 1 |
| Mickle, M | 1 |
| Gupta, B | 1 |
| LeVea, C | 1 |
| Litwin, A | 1 |
| Prall, F | 1 |
| Ostwald, C | 1 |
| Schiffmann, L | 1 |
| Barten, M | 1 |
| Boler, A | 1 |
| Craig, A | 1 |
| Wasan, H | 1 |
| Sørensen, NM | 1 |
| Byström, P | 1 |
| Berglund, A | 1 |
| Muto, O | 1 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Hoshina, K | 1 |
| Kobayashi, I | 1 |
| Kurita, M | 1 |
| Miyashita, M | 1 |
| Zacharakis, E | 2 |
| Pramateftakis, MG | 1 |
| Lambrou, I | 1 |
| Zaraboukas, T | 1 |
| Koliakos, G | 1 |
| Schönau, KK | 1 |
| Thomas, JP | 1 |
| Fields, AL | 2 |
| Seki, H | 1 |
| Kurihara, E | 1 |
| Iwata, K | 1 |
| Saito, J | 1 |
| Mamiya, N | 1 |
| Kono, T | 1 |
| Mamiya, K | 1 |
| Satomi, M | 1 |
| Chisato, N | 1 |
| Ebisawa, Y | 1 |
| Evans, TR | 1 |
| Somanath, S | 1 |
| Schatzlein, A | 1 |
| Lévi, F | 3 |
| Karaboué, A | 1 |
| de la Valette, V | 1 |
| Baron, B | 1 |
| Giacchetti, S | 1 |
| Shi, YX | 1 |
| Faraoni, I | 1 |
| Press, OA | 1 |
| Haiman, CA | 1 |
| Yang, DY | 1 |
| Fazzone, W | 1 |
| Iqbal, S | 1 |
| Sherrod, AE | 1 |
| Quinaux, E | 1 |
| Debrix, I | 1 |
| Valdivia-Arenas, MA | 1 |
| Soriano, AO | 1 |
| Arteaga, RB | 1 |
| Stahtea, XN | 1 |
| Roussidis, AE | 1 |
| Kanakis, I | 1 |
| Tzanakakis, GN | 1 |
| Chalkiadakis, G | 1 |
| Kletsas, D | 1 |
| Karamanos, NK | 1 |
| Eguchi, T | 1 |
| Ojo-Amaize, EA | 1 |
| Cottam, HB | 1 |
| Oyemade, OA | 1 |
| Okogun, JI | 1 |
| Nchekwube, EJ | 1 |
| Coelho, V | 1 |
| Dernedde, J | 1 |
| Petrausch, U | 1 |
| Panjideh, H | 1 |
| Fuchs, H | 1 |
| Menzel, C | 1 |
| Dübel, S | 1 |
| Keilholz, U | 1 |
| Thiel, E | 2 |
| Deckert, PM | 1 |
| de Oca, J | 1 |
| Azuara, D | 1 |
| Sanchez-Santos, R | 1 |
| Capella, G | 1 |
| Moreno, V | 1 |
| Sola, A | 1 |
| Hotter, G | 1 |
| Biondo, S | 1 |
| Osorio, A | 1 |
| Martí-Ragué, J | 1 |
| Rafecas, A | 1 |
| Solano, JM | 1 |
| Bakri, SJ | 1 |
| Pulido, JS | 1 |
| Ishizu, K | 1 |
| Sunose, N | 1 |
| Tsuruo, T | 8 |
| Yamori, T | 3 |
| Nikaido, T | 1 |
| Jung, GR | 1 |
| Lee, TB | 1 |
| Han, SI | 1 |
| Han, HK | 1 |
| Lim, SC | 1 |
| Szöke, D | 1 |
| Györffy, A | 1 |
| Surowiak, P | 1 |
| Tulassay, Z | 1 |
| Dietel, M | 1 |
| Györffy, B | 1 |
| Argyriou, AA | 1 |
| Polychronopoulos, P | 1 |
| Iconomou, G | 1 |
| Koutras, A | 1 |
| Gerolymos, MK | 1 |
| Gourzis, P | 1 |
| Assimakopoulos, K | 1 |
| Chroni, E | 1 |
| Robinson, B | 1 |
| Czaykowski, PM | 1 |
| Siperstein, AE | 1 |
| Berber, E | 1 |
| Ballem, N | 1 |
| Parikh, RT | 1 |
| Thödtmann, R | 1 |
| Rabl, H | 1 |
| Wohlmuth, P | 1 |
| Fujita, H | 3 |
| Horii, J | 1 |
| Harada, K | 1 |
| Hiraoka, S | 1 |
| Shiraha, H | 1 |
| Sakaguchi, K | 1 |
| Shiratori, Y | 1 |
| Grothey, E | 1 |
| Tavares-Bello, R | 1 |
| Law, CC | 1 |
| Fu, YT | 1 |
| Chau, KK | 1 |
| Choy, TS | 1 |
| So, PF | 1 |
| Wong, KH | 1 |
| Hector, S | 1 |
| Tummala, R | 1 |
| Kisiel, ND | 1 |
| Diegelman, P | 1 |
| Vujcic, S | 1 |
| Clark, K | 1 |
| Kramer, DL | 1 |
| Porter, CW | 1 |
| Pendyala, L | 1 |
| Finch, R | 1 |
| Kweh, F | 1 |
| Massoll, NA | 1 |
| Campbell-Thompson, M | 1 |
| Wallace, MR | 1 |
| Young Kim, W | 1 |
| Noda, E | 1 |
| Fukunaga, S | 1 |
| Kaizaki, R | 1 |
| Shinto, O | 1 |
| Wada, K | 2 |
| Sakamoto, E | 1 |
| Tsukioka, S | 1 |
| Oie, S | 1 |
| Kobunai, T | 1 |
| Okayama, Y | 1 |
| Sugimoto, Y | 1 |
| Addeo, R | 1 |
| Montella, L | 1 |
| Cennamo, G | 1 |
| Guarrasi, R | 1 |
| Faiola, V | 1 |
| Del Prete, S | 1 |
| Szetela, AB | 1 |
| Gibson, DE | 1 |
| Alami, N | 1 |
| Paterson, J | 1 |
| Belanger, S | 1 |
| Juste, S | 1 |
| Grieshaber, CK | 1 |
| Leyland-Jones, B | 2 |
| Gong, ZJ | 1 |
| Ren, JQ | 1 |
| Kong, G | 1 |
| Qing, DJ | 1 |
| Liang, YQ | 1 |
| Guichard, SM | 1 |
| Macpherson, JS | 1 |
| Mayer, I | 1 |
| Reid, E | 1 |
| Muir, M | 1 |
| Dodds, M | 1 |
| Alexander, S | 1 |
| Jodrell, DI | 3 |
| Tilleul, P | 1 |
| Perrocheau, G | 1 |
| Maes, P | 1 |
| Lafuma, A | 1 |
| Baratta, A | 1 |
| Gorin, RJ | 1 |
| Costa, R | 1 |
| Theeraladanon, C | 1 |
| Togo, S | 2 |
| Milesi, L | 1 |
| Pessi, MA | 1 |
| Quadri, A | 1 |
| Belmonte-Montes, C | 1 |
| Cosme-Reyes, C | 1 |
| Puig, PL | 1 |
| Mailliez, A | 1 |
| Rigot, JM | 1 |
| Gamelin, L | 1 |
| Vanhuyse, M | 1 |
| Handolias, D | 1 |
| McLaughlin, S | 1 |
| Chapman, M | 1 |
| Johns, J | 1 |
| Faragher, I | 1 |
| Ette, C | 1 |
| Kreuser, ED | 2 |
| Rich, JN | 1 |
| Bao, S | 1 |
| Alea, MP | 1 |
| Di Stefano, AB | 1 |
| Cammareri, P | 1 |
| Vermeulen, L | 1 |
| Iovino, F | 1 |
| Tripodo, C | 1 |
| Gulotta, G | 1 |
| Medema, JP | 1 |
| Glen, H | 1 |
| Guan, Z | 1 |
| Sarkar, C | 1 |
| Chakroborty, D | 1 |
| Chowdhury, UR | 1 |
| Dasgupta, PS | 1 |
| Basu, S | 1 |
| Zhang, SQ | 1 |
| Tauseef, M | 1 |
| Mohammed, NN | 1 |
| Repka, MA | 1 |
| Yang, JL | 1 |
| Kohn, EC | 1 |
| Friedlander, ML | 1 |
| Bertoldi, I | 2 |
| Miracco, C | 1 |
| Campbell, ME | 1 |
| Iyomasa, S | 1 |
| Sawasaki, N | 1 |
| Kyokane, T | 1 |
| Phoo, MS | 1 |
| Clement, MV | 1 |
| Ahmed, NK | 1 |
| Balch, CM | 3 |
| Urist, MM | 2 |
| Mattes, P | 1 |
| Betzler, M | 1 |
| Hartenstein, R | 1 |
| Ehrhart, H | 1 |
| Possinger, K | 1 |
| Grage, TB | 5 |
| Moss, SE | 5 |
| Spears, CP | 7 |
| Shahinian, AH | 1 |
| Moran, RG | 4 |
| Heidelberger, C | 2 |
| Corbett, TH | 2 |
| Gustavsson, B | 8 |
| Hafström, L | 6 |
| Pant, KD | 1 |
| Shochat, D | 1 |
| Nelson, MO | 1 |
| Villacorte, D | 1 |
| Heck, D | 1 |
| Corbett, T | 1 |
| Arnott, SJ | 1 |
| Theodors, A | 1 |
| Bukowski, RM | 3 |
| Hewlett, JS | 1 |
| Livingston, RB | 1 |
| Buonocore, E | 1 |
| Gilbert, JM | 3 |
| Houghton, PJ | 18 |
| Heim, ME | 4 |
| Eberwein, S | 1 |
| Georgi, M | 1 |
| Benz, C | 4 |
| Choti, M | 2 |
| Newcomer, L | 1 |
| Cadman, E | 5 |
| Kemeny, NE | 2 |
| Ahmed, T | 3 |
| Michaelson, RA | 1 |
| Harper, HD | 1 |
| Yip, LC | 1 |
| Higgins, GA | 9 |
| Donaldson, RC | 2 |
| Rogers, LS | 2 |
| Juler, GL | 1 |
| Keehn, RJ | 3 |
| Markman, M | 3 |
| Au, JL | 5 |
| Ledesma, EJ | 1 |
| Mittelman, A | 16 |
| Creaven, PJ | 4 |
| Barone, RM | 3 |
| Byfield, JE | 5 |
| Goldfarb, PB | 1 |
| Frankel, S | 2 |
| Ginn, C | 1 |
| Greer, S | 1 |
| Togni, P | 1 |
| Sessa, C | 2 |
| Varini, M | 1 |
| Cavalli, F | 2 |
| Yagoda, A | 3 |
| Braun, D | 3 |
| Armstrong, RD | 1 |
| Presant, CA | 6 |
| Multhauf, P | 4 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 2 |
| Carr, BI | 2 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Oberfield, RA | 5 |
| Huberman, MS | 2 |
| Patt, YZ | 3 |
| Peters, RE | 2 |
| Chuang, VP | 2 |
| Wallace, S | 2 |
| Mavligit, G | 2 |
| Walker, JS | 1 |
| Rustum, Y | 5 |
| Weltz, MD | 1 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Brückner, R | 1 |
| Rothmund, M | 2 |
| Hinterberger, R | 1 |
| Stagg, RJ | 1 |
| Lewis, BJ | 1 |
| Friedman, MA | 3 |
| Ignoffo, RJ | 1 |
| Hohn, DC | 1 |
| Hara, Y | 1 |
| Kono, A | 1 |
| Manguso, L | 1 |
| Coraggio, F | 1 |
| Grimaldi, G | 1 |
| Zito, GA | 1 |
| Grimaldi, F | 1 |
| Vespoli, F | 1 |
| Gentile, B | 1 |
| Grieco, A | 2 |
| Lasorella, A | 1 |
| Astone, A | 2 |
| Vagliviello, L | 1 |
| Bartoloni, C | 1 |
| Trotter, GA | 1 |
| Morgan, GR | 1 |
| Goeting, N | 1 |
| Cooper, AJ | 1 |
| Zannini, G | 1 |
| Contieri, E | 1 |
| Young, D | 2 |
| Vine, E | 1 |
| Ghanbarpour, A | 1 |
| Shani, J | 2 |
| Siemsen, JK | 2 |
| Wolf, W | 3 |
| Avni, A | 1 |
| Haikin, H | 1 |
| Feuchtwanger, MM | 1 |
| Sacks, M | 1 |
| Naggan, L | 1 |
| Sarov, B | 1 |
| Sarov, I | 1 |
| Schwarzenberg, L | 5 |
| Tourani, JM | 2 |
| Michalski, B | 2 |
| Hayat, M | 2 |
| Dorval, T | 2 |
| Misset, JL | 7 |
| Delouche, C | 1 |
| Brochon, D | 1 |
| Fraioli, JP | 1 |
| Jasmin, C | 3 |
| Maral, R | 2 |
| Mathe, G | 4 |
| Murakami, N | 1 |
| Matsuka, Y | 1 |
| Ejiri, T | 1 |
| Asano, K | 1 |
| Willie, GR | 1 |
| Levy, SM | 1 |
| Michaels, RS | 1 |
| Zirkin, RM | 1 |
| Steele, G | 2 |
| Osteen, RT | 1 |
| Wilson, RE | 2 |
| Brooks, DC | 1 |
| Zamcheck, N | 1 |
| Ravikumar, TS | 1 |
| Futatsuki, K | 3 |
| Shimada, S | 1 |
| Kanda, Y | 2 |
| Ishibashi, I | 1 |
| Sendai, H | 1 |
| Akazawa, S | 6 |
| Herrmann, R | 6 |
| Spehn, J | 1 |
| Beyer, JH | 2 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 2 |
| Abel, U | 1 |
| Kopper, L | 2 |
| Magyarosy, E | 1 |
| Jeney, A | 2 |
| Lapis, K | 1 |
| Szabolcs, A | 2 |
| Madajewicz, S | 2 |
| Petrelli, N | 3 |
| Campbell, J | 1 |
| Herrera, L | 6 |
| Perry, A | 1 |
| House, AK | 2 |
| Maley, MA | 2 |
| Gough, IR | 2 |
| Furnival, CM | 1 |
| Smith, BJ | 1 |
| Ashford, RF | 1 |
| Bakowski, M | 1 |
| Hellman, K | 1 |
| Newton, K | 1 |
| Lambert, J | 1 |
| Jones, R | 1 |
| Peters, N | 1 |
| Evans, M | 1 |
| Amadeo, JH | 1 |
| McElhinney, J | 1 |
| McCaughan, JJ | 1 |
| Aigner, KR | 2 |
| Walther, H | 3 |
| Tonn, JC | 2 |
| Schoch, P | 1 |
| Schwemmle, K | 5 |
| Denes, AE | 1 |
| Bartolucci, AA | 1 |
| Hine, KR | 1 |
| Dykes, PW | 1 |
| Coates, AS | 1 |
| Tattersall, MH | 4 |
| Swanson, C | 2 |
| Hedley, D | 1 |
| Fox, RM | 1 |
| Raghavan, D | 2 |
| Komov, DV | 1 |
| Roshchin, EM | 1 |
| Chernova, MV | 1 |
| Dolgushin, BI | 1 |
| MacIntyre, JM | 4 |
| Klaassen, DJ | 4 |
| Xavier, AM | 1 |
| Kasimis, BS | 1 |
| Wu, SY | 1 |
| Kaneshiro, CA | 1 |
| Bedikian, AY | 6 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Bodey, GP | 9 |
| Tsunematsu, R | 1 |
| Bruckner, HW | 4 |
| Storch, JA | 1 |
| Goldberg, J | 1 |
| Chamberlin, K | 1 |
| Schutt, AJ | 9 |
| Rubin, J | 8 |
| Creagan, ET | 1 |
| Kajima, T | 1 |
| Takao, H | 2 |
| Ban, K | 1 |
| Ohashi, H | 1 |
| Kunieda, T | 1 |
| Kimoto, Y | 1 |
| Oota, J | 1 |
| Fujita, M | 8 |
| Falkson, G | 6 |
| Pretorius, HL | 1 |
| Falkson, HC | 5 |
| Schoeman, HS | 1 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Beck, TM | 2 |
| Curtis, PW | 1 |
| Woodard, DA | 2 |
| Hart, NE | 2 |
| Smith, CE | 2 |
| Okuyama, K | 1 |
| Isono, K | 1 |
| Satoh, H | 1 |
| Onoda, S | 1 |
| Tohnosu, N | 1 |
| Ryu, M | 1 |
| Koide, Y | 3 |
| Hanaoka, A | 1 |
| Hanatani, Y | 1 |
| Ibayashi, J | 1 |
| Lönn, U | 4 |
| Lönn, S | 4 |
| Maeta, M | 4 |
| Koga, S | 3 |
| Osaki, Y | 1 |
| Kanayama, H | 1 |
| Oda, M | 1 |
| Murakami, A | 3 |
| Hirooka, Y | 1 |
| Fujita, F | 2 |
| Tang, SG | 1 |
| Hornbeck, CL | 1 |
| Takashima, S | 3 |
| Kosaka, T | 1 |
| Miyazaki, I | 4 |
| Kameda, C | 1 |
| Shiomi, M | 1 |
| Saka, M | 1 |
| Katsu, K | 1 |
| Itoh, S | 1 |
| Laufman, LR | 2 |
| Nims, TA | 1 |
| Guy, JT | 1 |
| Guy, JF | 1 |
| Courter, S | 1 |
| Lagomarsino Caprino, MC | 1 |
| Popoli, P | 1 |
| Periti, P | 1 |
| Kimball, PM | 1 |
| Brattain, MG | 1 |
| Akao, S | 1 |
| Naganuma, K | 3 |
| Kawabata, H | 2 |
| Oh-Hara, T | 1 |
| Iida, H | 2 |
| Tsukagoshi, S | 4 |
| Sakurai, Y | 4 |
| Sternberg, A | 1 |
| Au, J | 1 |
| Creaven, P | 4 |
| Kvols, LK | 3 |
| Phillips, RK | 1 |
| Quill, DS | 1 |
| Dudley, HA | 1 |
| Finan, PJ | 3 |
| Koklitis, PA | 1 |
| Chisholm, EM | 3 |
| Giles, GR | 7 |
| Martin, F | 1 |
| Kao, AK | 1 |
| Muggia, FM | 7 |
| Dubin, N | 1 |
| Lerner, WA | 1 |
| Stark, R | 1 |
| Wernz, JC | 2 |
| Speyer, JL | 6 |
| Blum, RH | 1 |
| Rabinovich, MG | 2 |
| Perez, JE | 2 |
| Macchiavelli, M | 2 |
| Romero, A | 2 |
| Kremer, A | 1 |
| Leone, BA | 2 |
| Strauss, E | 2 |
| Finlay, GJ | 1 |
| Schlangen, J | 2 |
| Naus, A | 2 |
| Swoboda, M | 1 |
| Pahlke, W | 1 |
| Edler, L | 1 |
| Bicker, U | 1 |
| Danhauser, LL | 2 |
| Droz, JP | 2 |
| Kac, J | 1 |
| Spielmann, M | 1 |
| Crespon, B | 1 |
| Ley, G | 1 |
| Zimmermann, P | 1 |
| Theodore, C | 2 |
| Chavy, A | 1 |
| Danzi, M | 1 |
| Lewin, MR | 1 |
| Cruse, JP | 1 |
| Clark, CG | 2 |
| Shapiro, CM | 1 |
| Bitran, JD | 2 |
| Shapiro, RA | 1 |
| Kolarić, K | 1 |
| Scott, M | 3 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 2 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Schulz, A | 1 |
| Kracht, J | 1 |
| von Heyden, HW | 1 |
| Bartsch, HH | 1 |
| Klee, M | 1 |
| Nagel, GA | 1 |
| Schuster, R | 1 |
| von Romatowski, HJ | 1 |
| Bengmark, S | 5 |
| Nobin, A | 1 |
| Jeppsson, B | 4 |
| Tranberg, KG | 4 |
| Aigner, K | 2 |
| Tonn, J | 1 |
| Wenzl, A | 2 |
| Hechtel, R | 1 |
| Merker, G | 2 |
| Liberati, AM | 2 |
| Buzzi, F | 2 |
| Fatati, G | 2 |
| Biscottini, B | 2 |
| Ballatori, E | 1 |
| Falchi, R | 1 |
| Grignani, F | 2 |
| Brenner, HJ | 1 |
| Bibi, C | 1 |
| Chaitchik, S | 1 |
| Fleischer, I | 2 |
| Wainstein, R | 2 |
| de Gibson, AS | 1 |
| Garewal, HS | 1 |
| Ahmann, FR | 4 |
| Alberts, DS | 1 |
| Vanderlinden, B | 1 |
| Rozencweig, M | 2 |
| Nicaise, C | 1 |
| Van Rijmenant, M | 1 |
| Crespeigne, N | 1 |
| Kenis, Y | 2 |
| Kaye, SB | 2 |
| Sangster, G | 1 |
| Hutcheon, A | 1 |
| Habeshaw, T | 2 |
| Crossling, F | 1 |
| Ferguson, C | 1 |
| McArdle, C | 1 |
| George, WD | 1 |
| Calman, KC | 2 |
| Pratesi, G | 6 |
| Deschner, EE | 1 |
| Niederle, N | 3 |
| Kurschel, E | 2 |
| Schmidt, CG | 2 |
| Schlag, P | 5 |
| Flentje, D | 2 |
| Hori, K | 1 |
| Hardy, TG | 1 |
| Aguilar, PS | 1 |
| Plasencia, G | 1 |
| Rusan, MS | 1 |
| Hartmann, RF | 1 |
| Stewart, WR | 1 |
| Cavaleri, V | 1 |
| D'Avena, C | 1 |
| Mangialardi, N | 1 |
| Chirletti, P | 1 |
| Kikuchi, K | 5 |
| Drewinko, B | 2 |
| Yang, LY | 2 |
| Ho, DH | 1 |
| Benvenuto, J | 1 |
| Loo, TL | 2 |
| Freireich, EJ | 4 |
| Narisawa, T | 4 |
| Fujimoto, S | 3 |
| Kitsukawa, Y | 2 |
| Okui, K | 3 |
| Rainer, H | 2 |
| Kovats, E | 2 |
| Lehmann, HG | 1 |
| Micksche, M | 2 |
| Rauhs, R | 1 |
| Sedlacek, HH | 1 |
| Seidl, W | 1 |
| Schemper, M | 1 |
| Schiessel, R | 1 |
| Schweiger, B | 1 |
| Wunderlich, M | 1 |
| Mechl, Z | 1 |
| Conroy, JF | 3 |
| Roda, PI | 1 |
| Brodsky, I | 2 |
| Kahn, SB | 1 |
| Bulova, SI | 1 |
| Pequignot, E | 1 |
| Gisselbrecht, C | 1 |
| Belpomme, D | 1 |
| Mignot, L | 1 |
| Marty, M | 2 |
| Boiron, M | 1 |
| Cowan, JD | 1 |
| Easterbrock, J | 1 |
| Mills, GM | 1 |
| McCracken, JD | 4 |
| Wagner, I | 1 |
| Habs, M | 1 |
| Schmähl, D | 1 |
| Amberger, H | 1 |
| Bachmann, U | 1 |
| de Gibson, AM | 1 |
| Hamada, S | 1 |
| Kuwashima, T | 1 |
| Korematsu, H | 1 |
| Yoshikawa, H | 2 |
| Toyosaki, M | 1 |
| Komi, N | 2 |
| Douglass, HO | 10 |
| Muggia, F | 2 |
| Silverberg, M | 1 |
| DeLuca, SA | 1 |
| Castronovo, FP | 1 |
| Rhea, JT | 1 |
| Glazer, RI | 4 |
| Hartman, KD | 1 |
| Higi, M | 1 |
| Arndt, D | 1 |
| Schmidt, C | 1 |
| Schmitt, G | 1 |
| Thompson, EM | 1 |
| Slavin, G | 1 |
| Kark, AE | 1 |
| Goto, A | 1 |
| Moayeri, H | 2 |
| DiBenedetto, J | 2 |
| Donehower, RC | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Weinerman, B | 1 |
| Schacter, B | 1 |
| Schipper, H | 1 |
| Bowman, D | 1 |
| Levitt, M | 1 |
| Mavligit, GM | 8 |
| White, DR | 3 |
| Richards, F | 4 |
| Muss, HB | 3 |
| Cooper, MR | 3 |
| Spurr, CL | 3 |
| Chlebowski, RT | 4 |
| Silverberg, I | 1 |
| Pajak, T | 1 |
| Weiner, J | 2 |
| Kardinal, C | 1 |
| Bateman, JR | 4 |
| Valdivieso, M | 7 |
| Vogl, SE | 2 |
| Lanham, R | 2 |
| Kaplan, BH | 3 |
| Bonomi, PD | 1 |
| Chandra, G | 1 |
| Rossof, AH | 1 |
| Klaassen, D | 1 |
| Vaughn, CB | 3 |
| Chapman, JL | 1 |
| Garland, M | 2 |
| Pederson, B | 2 |
| Demitrish, MM | 2 |
| Chinn, B | 2 |
| Ward, D | 2 |
| Brady, PR | 1 |
| DeVita, VT | 5 |
| Henney, JE | 1 |
| Weiss, RB | 4 |
| Payne, JE | 2 |
| Pheils, MT | 2 |
| Chapuis, PH | 1 |
| MacPherson, JG | 2 |
| Bancewicz, J | 1 |
| Macpherson, SG | 1 |
| McArdle, CS | 4 |
| McVie, JG | 1 |
| Soukop, M | 1 |
| Cassell, PC | 1 |
| Ellis, H | 1 |
| Wastell, C | 1 |
| Hellmann, K | 2 |
| Evans, MG | 1 |
| Stoodley, BJ | 1 |
| Humphrey, EW | 1 |
| Shields, TW | 1 |
| Eriksson, S | 1 |
| Hugander, A | 1 |
| Kisner, DL | 1 |
| Solan, A | 1 |
| Berenzweig, M | 1 |
| Richard, J | 1 |
| Trux, F | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Sacks, H | 1 |
| Chalmers, TC | 2 |
| Smith, H | 1 |
| Manegold, C | 1 |
| Levine, AW | 1 |
| Donegan, WL | 4 |
| Irwin, M | 1 |
| Kies, MS | 1 |
| Navarra, S | 1 |
| Melita, P | 1 |
| Di Mauro, S | 1 |
| Kroener, JF | 1 |
| Saleh, F | 1 |
| Howell, SB | 1 |
| Quarles, JM | 1 |
| Morris, NG | 1 |
| Leibovitz, A | 1 |
| Schlesinger, T | 1 |
| Cantrell, JE | 2 |
| Brunet, R | 2 |
| Lagarde, C | 1 |
| Schein, PS | 8 |
| Smith, FP | 1 |
| Robinson, E | 2 |
| Bartal, A | 2 |
| Cohen, Y | 3 |
| Haim, N | 1 |
| Mohilever, J | 1 |
| Mekori, T | 2 |
| Cowen, DM | 1 |
| Siegerstetter, J | 1 |
| Janik, AC | 1 |
| Double, JA | 7 |
| Lloyd, LS | 1 |
| Sokolova, VD | 2 |
| Platinskiĭ, LV | 2 |
| Knysh, VI | 2 |
| Ozhiganov, EL | 3 |
| Chebotareva, LI | 1 |
| Granov, AM | 1 |
| Borisov, AE | 1 |
| Plotkin, LL | 1 |
| Zemlianoĭ, VP | 1 |
| Shelukhin, AP | 1 |
| Martin, DS | 5 |
| Stolfi, RL | 2 |
| Sawyer, RC | 1 |
| Spiegelman, S | 2 |
| Young, CW | 2 |
| Stroehlein, JR | 1 |
| Karlin, DA | 2 |
| Bennetts, RW | 1 |
| Calabro-Jones, PM | 1 |
| Ward, JF | 1 |
| Sharp, TR | 2 |
| Gota, CH | 1 |
| Chan, KK | 2 |
| Weiner, JM | 1 |
| Block, JB | 1 |
| Finck, SJ | 1 |
| Gupta, RK | 1 |
| Giuliano, AE | 1 |
| Morton, DL | 3 |
| Whitehouse, JM | 1 |
| Duncan, W | 1 |
| Sutton, JE | 1 |
| Roos, IA | 1 |
| Hillcoat, BL | 2 |
| Everson, LK | 3 |
| Cullinan, SA | 2 |
| Volberding, PA | 1 |
| Resser, KJ | 1 |
| Phillips, TL | 1 |
| Tice, AJ | 1 |
| Seifart, W | 2 |
| Marx, G | 2 |
| Krahl, M | 1 |
| Ariel, IM | 4 |
| Padula, G | 3 |
| Dworken, HJ | 1 |
| Botti, RE | 1 |
| Revazova, ES | 1 |
| Wolberg, WH | 2 |
| Morin, J | 1 |
| Aroney, RS | 1 |
| Dalley, DN | 1 |
| Chan, WK | 1 |
| Bell, DR | 1 |
| Levi, JA | 1 |
| Giuliani, FC | 1 |
| Zirvi, KA | 3 |
| Kaplan, NO | 1 |
| Goldin, A | 2 |
| Golbey, R | 2 |
| Wopfner, F | 1 |
| Schmitz, R | 4 |
| Hüper, J | 1 |
| Pichlmayr, R | 2 |
| Calabro-Jones, P | 1 |
| Thomas, TN | 1 |
| Haida, K | 1 |
| Haida, S | 1 |
| Prorokov, VV | 1 |
| Barsukov, IuA | 1 |
| Zaseev, VK | 1 |
| Helsper, JT | 1 |
| Lance, JS | 1 |
| Hall, TC | 3 |
| Bianucci, P | 1 |
| Pastorino, G | 1 |
| Lokich, J | 1 |
| Bothe, A | 1 |
| Fine, N | 1 |
| Perri, J | 1 |
| Joss, R | 2 |
| Goldhirsch, A | 2 |
| Tschopp, L | 1 |
| Brunner, K | 1 |
| Efimov, GA | 1 |
| Ushakov, IuM | 1 |
| Garelli, S | 1 |
| Valbonesi, M | 1 |
| Schieppati, G | 1 |
| Banfi, L | 1 |
| Antonelli, D | 1 |
| Beker, B | 1 |
| Barzilay, J | 1 |
| Kohno, KI | 1 |
| Nayak, R | 1 |
| Sawyer, R | 1 |
| Stolfi, R | 1 |
| Martin, D | 2 |
| Woodcock, TM | 1 |
| Damin, LA | 1 |
| Marangolo, M | 4 |
| Tarquini, A | 1 |
| Mascia, V | 1 |
| Chessa, PP | 1 |
| Pellegrini, A | 2 |
| Meyer, JH | 1 |
| Nelson, DS | 1 |
| Walls, RS | 1 |
| Bolanowska, W | 1 |
| Gessner, T | 1 |
| Van der Veer, LD | 1 |
| Balint, JA | 1 |
| Epenetos, AA | 1 |
| Amos, C | 1 |
| Collis, C | 1 |
| Rohatiner, A | 1 |
| Baille-Johnson, H | 1 |
| Pitts, J | 1 |
| Wrigley, PF | 1 |
| Schmitz, CA | 1 |
| Echtermeyer, V | 1 |
| Schoenberg, M | 1 |
| Siber, GR | 1 |
| Levin, MJ | 1 |
| Ichiki, AT | 1 |
| Krauss, S | 2 |
| Israelsen, KL | 1 |
| Sonoda, T | 2 |
| Collmann, IR | 1 |
| Maroda, SJ | 1 |
| Phillips, JO | 1 |
| Gamucci, T | 1 |
| Zampa, G | 1 |
| Collins, JM | 1 |
| Dedrick, RL | 1 |
| Brennan, MF | 1 |
| Buckpitt, AR | 1 |
| Londer, H | 1 |
| Myers, CE | 2 |
| Schuurman, B | 1 |
| Sirovich, I | 1 |
| Heuff, G | 1 |
| Beelen, RH | 1 |
| Meyer, S | 2 |
| Yuasa, C | 1 |
| Toko, T | 1 |
| Unemi, N | 2 |
| Klein, O | 2 |
| Wchter, B | 1 |
| Müller, B | 1 |
| Braun, U | 1 |
| Knuth, A | 2 |
| Rochlitz, CF | 1 |
| Carlsson, G | 4 |
| Frösing, R | 5 |
| Hafström, LO | 1 |
| Larsson, PA | 4 |
| Weissman, DE | 1 |
| Gedney, C | 1 |
| Stewart, RM | 2 |
| Betzing, KW | 1 |
| Kannan, K | 2 |
| Pizzorno, G | 6 |
| Davis, SJ | 1 |
| Hartigan, DJ | 1 |
| Russello, O | 4 |
| Ben-Josef, E | 1 |
| Court, WS | 1 |
| Jacquet, P | 1 |
| Averbach, AM | 1 |
| Stephens, AD | 1 |
| Koizumi, T | 1 |
| Osaku, M | 1 |
| Watahiki, Y | 1 |
| Hojyo, M | 1 |
| Kosaka, A | 2 |
| Maruo, H | 2 |
| Itani, K | 1 |
| Hiraoka, M | 1 |
| Noguchi, M | 1 |
| Franchi, F | 3 |
| Braakhuis, BJ | 6 |
| Hirschowitz, EA | 1 |
| Ohwada, A | 1 |
| Pascal, WR | 1 |
| Russi, TJ | 1 |
| Crystal, RG | 2 |
| Swaffar, DS | 1 |
| Ang, CY | 1 |
| Desai, PB | 1 |
| Rosenthal, GA | 1 |
| Thomas, DA | 1 |
| Crooks, PA | 1 |
| John, WJ | 3 |
| Schlangen, JT | 1 |
| Debets, JM | 1 |
| Wils, JA | 1 |
| Martí, V | 1 |
| García Picart, J | 1 |
| Guiteras, P | 1 |
| Augé, JM | 1 |
| Buchholz, DJ | 1 |
| Lepek, KJ | 1 |
| Rich, TA | 2 |
| Murray, D | 2 |
| Baptiste, N | 3 |
| Megati, S | 1 |
| Wadler, S | 12 |
| Otter, BA | 2 |
| Tayek, JA | 1 |
| Sutter, L | 1 |
| Manglik, S | 1 |
| Lillington, LB | 1 |
| Grosvenor, M | 1 |
| Furuya, Y | 1 |
| Kohno, N | 1 |
| Saitoh, Y | 1 |
| Jannot, MC | 1 |
| Yeaton, P | 1 |
| Pauwels, O | 1 |
| DePrez, C | 1 |
| Astruc, J | 1 |
| Chazottes, E | 1 |
| Kruczynski, A | 1 |
| Kiss, R | 1 |
| Molina Esquivel, J | 1 |
| Vargas Sandoval, G | 1 |
| Rodríguez del Rincón, E | 1 |
| Velázquez López, J | 1 |
| Makower, D | 2 |
| Sugarman, SM | 1 |
| Kano, N | 1 |
| Ishikawa, Y | 1 |
| Ohtaki, S | 1 |
| Fukuma, E | 1 |
| Miyajima, N | 2 |
| Kasugai, H | 1 |
| Hino, A | 2 |
| Rosen, H | 3 |
| Kornek, GV | 3 |
| Sebesta, C | 3 |
| Depisch, D | 5 |
| Le Bourgeois, JP | 1 |
| Takimoto, CH | 2 |
| Laupacis, A | 1 |
| Stathopoulos, GP | 1 |
| Stergiou, GS | 1 |
| Perrea-Kostarelis, DN | 1 |
| Dontas, IA | 1 |
| Karamanos, BG | 1 |
| Karayiannacos, PE | 1 |
| Sørensen, P | 2 |
| Edal, AL | 2 |
| Madsen, EL | 2 |
| Fenger, C | 2 |
| Poulsen, MR | 2 |
| Petersen, OF | 2 |
| Lerner-Tung, M | 1 |
| Chen, HX | 1 |
| Chang, CN | 1 |
| Zhu, JL | 1 |
| Chang, CP | 1 |
| Lin, TS | 1 |
| Cheng, YC | 1 |
| Fabian, C | 2 |
| Giri, S | 3 |
| Estes, N | 1 |
| Tangen, CM | 3 |
| Poplin, E | 3 |
| Vogel, S | 2 |
| Goodwin, W | 1 |
| Rivkin, S | 1 |
| Fleming, TR | 9 |
| Norman, A | 1 |
| Findlay, M | 2 |
| Nicolson, V | 1 |
| Hill, A | 1 |
| Iveson, A | 1 |
| Evans, C | 1 |
| Joffe, J | 1 |
| Nicolson, M | 1 |
| Aiba, K | 2 |
| Drake, JC | 5 |
| Su, J | 1 |
| Zhen, YC | 1 |
| Qi, CQ | 1 |
| Hu, JL | 1 |
| Voeller, DM | 2 |
| Enterline, DS | 1 |
| Davey, NC | 1 |
| Tien, RD | 1 |
| Mainwaring, P | 1 |
| Grygiel, JJ | 1 |
| Blomgren, H | 2 |
| Lundell, G | 2 |
| Magnusson, I | 1 |
| Sonnenfeld, T | 1 |
| Geoffroy, FJ | 1 |
| Sinha, B | 1 |
| Hughes-Davies, L | 1 |
| Rescigno, J | 1 |
| Kawano, K | 1 |
| Inokuchi, T | 1 |
| Fujihara, T | 1 |
| Mori, F | 1 |
| Yoshioka, Y | 1 |
| Tamura, Y | 2 |
| Kimoto, K | 1 |
| Sakuyama, T | 1 |
| Shimono, S | 1 |
| Takamura, S | 1 |
| Inomata, Y | 1 |
| Isshi, K | 1 |
| Chibai, M | 1 |
| Tadaoka, N | 1 |
| Ajao, OG | 1 |
| Grillo, IA | 1 |
| Malatani, T | 1 |
| al Shehri, MY | 1 |
| Satoh, Y | 1 |
| Fujisawa, J | 1 |
| Muranaga, S | 1 |
| Obara, M | 1 |
| Uchino, J | 1 |
| Ambrosini, G | 1 |
| Iirillo, A | 1 |
| Fiorentini, G | 1 |
| Duro, M | 1 |
| Piazza, E | 1 |
| Oliani, C | 1 |
| Kraus, TW | 1 |
| Eble, MJ | 1 |
| Raeth, U | 1 |
| Lin, DY | 1 |
| Ungerleider, JS | 3 |
| Emerson, WA | 3 |
| Tormey, DC | 4 |
| Glick, JH | 3 |
| Veeder, MH | 1 |
| Romani, R | 1 |
| Morris, DL | 4 |
| Rexroth, G | 1 |
| Scotland, V | 1 |
| Handschumacher, RE | 5 |
| Critchley, P | 1 |
| Abbott, R | 1 |
| Madden, FJ | 1 |
| Chen, MF | 1 |
| Boyce, HW | 1 |
| Laurent, PL | 1 |
| Tevaearai, HT | 1 |
| Eliason, JF | 1 |
| Givel, JC | 1 |
| Odartchenko, N | 1 |
| Chandrasekaran, B | 1 |
| Kute, TE | 1 |
| Duch, DS | 1 |
| Hinton, DR | 1 |
| Leichman, L | 2 |
| Atkinson, RD | 1 |
| Apuzzo, ML | 1 |
| Couldwell, WT | 1 |
| Weh, HJ | 3 |
| Dierlamm, J | 1 |
| Hossfeld, DK | 3 |
| Ilson, DH | 1 |
| Kelsen, DP | 2 |
| Cohen, AM | 6 |
| Yao, TJ | 2 |
| Enker, W | 1 |
| Tong, W | 1 |
| Tao, Y | 1 |
| Empereur, S | 1 |
| Fagot, D | 1 |
| Forgue-Lafitte, E | 1 |
| Chastre, E | 1 |
| Zimber, A | 1 |
| Mester, J | 3 |
| Hao, SN | 1 |
| Meijer, S | 5 |
| Tomita, K | 1 |
| Inaba, Y | 1 |
| Ohashi, K | 1 |
| Ariyoshi, Y | 2 |
| Hoshino, M | 1 |
| Igarashi, W | 1 |
| Ohtake, T | 1 |
| Ono, T | 1 |
| Hatakeyama, Y | 2 |
| Abe, R | 3 |
| Oster, W | 1 |
| Canney, PA | 2 |
| Yosef, H | 2 |
| Steward, WP | 1 |
| Civalleri, D | 2 |
| Pector, JC | 5 |
| Håkansson, L | 2 |
| Arnaud, JP | 2 |
| Duez, N | 3 |
| Chen, TB | 2 |
| Huzak, M | 1 |
| Macura, S | 2 |
| Vuk-Pavlović, S | 2 |
| Cerruti, A | 1 |
| Castello, G | 1 |
| Balleari, E | 1 |
| Bogliolo, G | 1 |
| Lerza, R | 1 |
| Pannacciulli, I | 1 |
| Remmenga, SW | 1 |
| Colcher, D | 1 |
| Gansow, O | 1 |
| Pippen, CG | 1 |
| Raubitschek, A | 1 |
| Ozawa, T | 1 |
| Mezger, J | 1 |
| Bravard, A | 1 |
| Beaumatin, J | 3 |
| Dussaulx, E | 4 |
| Zweibaum, A | 3 |
| Luccioni, C | 3 |
| Klostergaard, J | 2 |
| Leroux, ME | 2 |
| Tomasovic, SP | 1 |
| Sagaster, P | 1 |
| Essl, R | 1 |
| Teich, G | 1 |
| Fritz, E | 1 |
| Wasilewski, M | 1 |
| Umek, H | 1 |
| Dünser, E | 1 |
| Mascher, H | 1 |
| Davis, MA | 2 |
| Maybaum, J | 2 |
| Frasci, G | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Westlin, JE | 1 |
| Påhlman, L | 3 |
| Motoyama, M | 1 |
| Imaoka, T | 1 |
| Ichihara, N | 1 |
| Miyauchi, S | 1 |
| Kwan, W | 1 |
| Bjarnason, GA | 1 |
| Hamilton, P | 1 |
| Yit, CC | 1 |
| Das, NP | 1 |
| Scarfe, MA | 1 |
| Israel, MK | 1 |
| Kamm, VJ | 1 |
| Rietjens, IM | 2 |
| Vervoort, J | 2 |
| Rosenbusch, G | 2 |
| Hofs, HP | 1 |
| Wagener, DJ | 3 |
| Prentice, RL | 1 |
| Pepe, MS | 1 |
| Glidden, D | 1 |
| Shibata, J | 3 |
| Minowa, S | 1 |
| Horikoshi, N | 2 |
| Fabri, MC | 1 |
| Miyauchi, T | 1 |
| Yamada, A | 1 |
| Fuji, N | 1 |
| Sollitto, RB | 1 |
| Frank, W | 1 |
| Palko, MJ | 1 |
| Rogers, GS | 1 |
| Forman, WB | 1 |
| Brown, ML | 2 |
| Nayfield, SG | 1 |
| Shibley, LM | 1 |
| O'Connor, CJ | 2 |
| Tangen, C | 1 |
| Lorenzini, L | 1 |
| Mancini, S | 1 |
| Armenio, S | 1 |
| Marzocca, G | 1 |
| Prat, F | 2 |
| Sibille, A | 1 |
| Pansu, D | 1 |
| Chapelon, JY | 2 |
| Ponchon, T | 2 |
| Cathignol, D | 2 |
| Hurwitz, BS | 2 |
| Kornek, G | 2 |
| Pidlich, J | 1 |
| Karall, M | 2 |
| Prochaska, M | 1 |
| Ernst, A | 1 |
| Eckhardt, S | 2 |
| Manda, T | 1 |
| Mukumoto, S | 1 |
| Nishigaki, F | 1 |
| Kawamura, I | 1 |
| Fine, S | 4 |
| Adkins, DA | 3 |
| Saijo, N | 2 |
| Sugirnoto, Y | 1 |
| Mayer, RS | 1 |
| Spread, C | 1 |
| Berkel, H | 1 |
| Jewell, L | 1 |
| Jenkins, H | 1 |
| Yakimets, W | 1 |
| Köhne-Wömpner, CH | 3 |
| Schöffski, P | 2 |
| Tagawa, Y | 3 |
| Kawazoe, N | 2 |
| Lu, Z | 1 |
| Aschele, C | 9 |
| Guglielmi, AP | 2 |
| Mori, AM | 2 |
| Melioli, GG | 1 |
| Ichiki, Y | 1 |
| Nakano, S | 4 |
| Hirata, Y | 1 |
| Kanaya, S | 1 |
| Niho, Y | 3 |
| Neefe, JR | 1 |
| Cantrell, J | 1 |
| Smith, M | 1 |
| Mao, X | 1 |
| Bajaj, R | 1 |
| Hallam, S | 2 |
| Baccanari, DP | 2 |
| Davis, ST | 2 |
| Knick, VC | 1 |
| Spector, T | 2 |
| Taal, BG | 3 |
| Ten Bokkel Huinink, WW | 1 |
| Rodenhuis, S | 1 |
| Sharkey, RM | 3 |
| Natale, AM | 1 |
| Kashi, R | 2 |
| Wong, G | 2 |
| Farthmann, E | 1 |
| Herfarth, C | 3 |
| Laffer, U | 3 |
| Harder, F | 1 |
| Wilke, H | 4 |
| Rustamov, IR | 1 |
| Dzhulbekov, KI | 1 |
| de Jong, M | 2 |
| Nord, LD | 1 |
| Giovanella, BC | 1 |
| el Fadil, FA | 1 |
| Theillère, Y | 1 |
| Imaizumi, M | 3 |
| Kondo, T | 7 |
| Hattori, T | 7 |
| Abe, O | 6 |
| Kitano, M | 2 |
| Wakui, A | 7 |
| McAtee, N | 2 |
| Balis, F | 1 |
| Murphy, R | 1 |
| Venzon, D | 1 |
| Kramer, B | 1 |
| Goldspiel, B | 1 |
| Begley, M | 1 |
| Wang, FS | 1 |
| Chang, YM | 2 |
| Eda, H | 3 |
| Fujimoto, K | 3 |
| Watanabe, S | 2 |
| Ura, M | 2 |
| Ishitsuka, H | 6 |
| Nolè, F | 1 |
| Biganzoli, L | 1 |
| Ishida, F | 2 |
| Yamamitsu, S | 5 |
| Shirasaka, T | 5 |
| Rodriguez-Bigas, M | 1 |
| de'Clari, F | 1 |
| Kurman, MR | 1 |
| Morton, CL | 3 |
| Rahman, A | 3 |
| Su, JQ | 1 |
| Wei, LJ | 1 |
| Kase, S | 5 |
| Takahara, T | 2 |
| Teramoto, T | 4 |
| Ishibiki, K | 5 |
| Yoshida, Y | 3 |
| Kosaki, G | 1 |
| Kurihara, M | 1 |
| Tamaki, Y | 1 |
| Takatsuka, Y | 1 |
| Koyama, H | 1 |
| Masuyama, M | 1 |
| Koishi, Y | 1 |
| Miyata, K | 2 |
| Hidaka, K | 1 |
| Mashima, H | 1 |
| Katano, M | 1 |
| Kishikawa, T | 1 |
| Hisatsugu, T | 2 |
| Murotani, M | 1 |
| Takami, M | 1 |
| Takada, T | 1 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Okumura, Y | 1 |
| Aoki, F | 1 |
| Moriyama, Y | 1 |
| Shiiba, K | 1 |
| Ouchi, A | 1 |
| Momono, S | 1 |
| Muto, I | 1 |
| Mashiko, H | 1 |
| Inada, T | 2 |
| Ozawa, I | 1 |
| Hishinuma, S | 1 |
| Kotake, K | 1 |
| Ikeda, T | 2 |
| Najjar, TA | 1 |
| Slomiany, BL | 1 |
| Rockette, H | 5 |
| Wickerham, DL | 6 |
| Redmond, C | 3 |
| Fisher, ER | 4 |
| Jones, J | 6 |
| Mamounas, EP | 5 |
| Ore, L | 1 |
| Neu, IS | 1 |
| Pazdur, R | 4 |
| Ajani, JA | 3 |
| Gomez, J | 1 |
| Bready, B | 1 |
| Levin, B | 8 |
| Mackarel, AJ | 1 |
| Wallace, HM | 1 |
| Inutsuka, S | 1 |
| Kohnoe, S | 1 |
| Sugimachi, K | 6 |
| Ota, K | 4 |
| Yura, J | 1 |
| Inagaki, J | 1 |
| Hoshino, A | 1 |
| Kimmel, DW | 2 |
| Graffner, HO | 1 |
| Milsom, JW | 1 |
| Chaudry, IH | 1 |
| Bobbio-Pallavicini, E | 1 |
| Porta, C | 2 |
| Moroni, M | 2 |
| Spaghi, A | 1 |
| Casagranda, I | 1 |
| Nastasi, G | 2 |
| Malmberg, M | 1 |
| Yin, MB | 2 |
| Slocum, HK | 3 |
| Kuo, TH | 3 |
| Tanino, H | 2 |
| Saikawa, Y | 3 |
| Fujiki, T | 1 |
| Amemiya, K | 1 |
| Uchida, N | 1 |
| Oishi, T | 1 |
| Sakakibara, N | 1 |
| Iida, A | 1 |
| Komatsu, T | 1 |
| Ookubo, K | 1 |
| Ikeda, N | 1 |
| Smith, RD | 1 |
| Hall, J | 1 |
| Gurney, H | 1 |
| Harnett, PR | 1 |
| Koeller, DM | 2 |
| Zinn, S | 3 |
| Djordjevic, B | 2 |
| Lange, CS | 2 |
| Allison, RR | 1 |
| Rotman, M | 3 |
| Ohiwa, T | 1 |
| Tatsuno, K | 1 |
| Fung, CY | 1 |
| Kaufman, DS | 1 |
| Efird, J | 1 |
| Shellito, PC | 1 |
| Pouillart, P | 2 |
| Bittner, S | 1 |
| Hoffknecht, M | 1 |
| Alghisi, A | 1 |
| Marini, G | 2 |
| Hsu, HA | 1 |
| Hsi, BP | 1 |
| Siddik, ZH | 1 |
| Tomasovi, SP | 1 |
| Tausch-Treml, R | 1 |
| Baumgart, F | 1 |
| Ziessow, D | 1 |
| Köpf-Maier, P | 1 |
| Marcell, A | 1 |
| Kwasny, W | 1 |
| Cersosimo, RJ | 1 |
| Lee, JM | 1 |
| Atkins, CD | 1 |
| Heck, DE | 1 |
| DeGeorge, G | 1 |
| Laskin, JD | 1 |
| Epis, O | 1 |
| Sundaram, SG | 1 |
| Milner, JA | 1 |
| Doroshow, JH | 5 |
| Savarese, DM | 1 |
| Gordon, J | 1 |
| Smith, TW | 1 |
| Litofsky, NS | 1 |
| Licho, R | 1 |
| Ragland, R | 1 |
| Recht, L | 1 |
| Raskov, HH | 2 |
| Babu, KG | 1 |
| Raud, C | 1 |
| Kumaraswamy, SV | 1 |
| Lalitha, N | 1 |
| Garrido, C | 1 |
| Mehlen, P | 1 |
| Fromentin, A | 1 |
| Hammann, A | 1 |
| Assem, M | 1 |
| Arrigo, AP | 1 |
| Chauffert, B | 2 |
| Takechi, T | 1 |
| Uchida, J | 1 |
| Fujioka, A | 1 |
| Oyama, K | 1 |
| Lokich, JJ | 10 |
| Moore, CL | 2 |
| Anderson, NR | 2 |
| Sakabe, T | 1 |
| Brown, TD | 1 |
| Komissarov, A | 1 |
| Kok, M | 1 |
| Van Groeningen, V | 1 |
| McElhinney, RS | 5 |
| McCormick, JE | 5 |
| Bibby, MC | 5 |
| Radacic, M | 4 |
| Asanuma, F | 1 |
| Kawamura, E | 2 |
| Haas, NB | 1 |
| Schilder, RJ | 1 |
| Nash, S | 1 |
| Catalano, RC | 1 |
| Ozols, RF | 1 |
| Buecher, B | 1 |
| Blanc, JF | 1 |
| Magnien, F | 1 |
| Bechade, D | 1 |
| Lapprand, M | 1 |
| Oddes, B | 1 |
| Blijham, GH | 2 |
| Saletti, P | 1 |
| Pagani, O | 1 |
| Visser, GW | 4 |
| Wedzinga, R | 1 |
| Herscheid, JD | 3 |
| Werner, A | 1 |
| Bender, E | 1 |
| Mahaffey, W | 1 |
| McKeating, J | 1 |
| Marrangoni, A | 1 |
| Katoh, A | 1 |
| Kano, Y | 2 |
| Akutsu, M | 2 |
| Tsunoda, S | 2 |
| Ando, J | 1 |
| Matsui, J | 1 |
| Adachi, K | 1 |
| Zoboli, A | 1 |
| Barbieri, F | 1 |
| Crisi, G | 1 |
| Piccinini, L | 1 |
| Silingardi, V | 1 |
| Zalupski, M | 1 |
| Garcia, Y | 1 |
| Grant, A | 1 |
| Angeles, A | 1 |
| DeJong, L | 1 |
| Galassi, G | 1 |
| Tassone, G | 1 |
| Sintini, M | 1 |
| Spagnoli, M | 1 |
| Bertolani, L | 1 |
| Mavilla, L | 1 |
| Yuasa, N | 1 |
| Fukata, S | 1 |
| Kamei, K | 1 |
| Kurumiya, Y | 1 |
| Ichikawa, W | 1 |
| Nihei, Z | 1 |
| Kawamura, N | 1 |
| Sawai, S | 1 |
| Miyanaga, T | 2 |
| Hirayama, R | 1 |
| Mishima, Y | 1 |
| Kosmidis, PA | 1 |
| Skarlos, D | 2 |
| Theocharis, D | 1 |
| Pavlidis, N | 2 |
| Briassoulis, E | 2 |
| Kahn, MJ | 2 |
| Amos, EH | 1 |
| Mendenhall, WM | 1 |
| McCarty, PJ | 1 |
| Gage, JO | 1 |
| Emlet, JL | 1 |
| Lowrey, GC | 1 |
| Peterson, CA | 1 |
| Amos, WR | 1 |
| Shiomi, S | 1 |
| Kuroki, T | 1 |
| Hasegawa, I | 1 |
| Nishio, H | 1 |
| Ochi, H | 1 |
| Findenig, G | 1 |
| Parmar, MK | 1 |
| Ungerleider, RS | 1 |
| Simon, R | 1 |
| Yamato, A | 1 |
| Djelloul, S | 2 |
| Buquet-Fagot, C | 2 |
| Nelson, H | 5 |
| Cha, S | 2 |
| Haddock, M | 2 |
| Devine, R | 2 |
| Fieck, JM | 2 |
| Wolff, B | 2 |
| Dozois, R | 2 |
| Cooper, RA | 1 |
| Taylor, KJ | 1 |
| Muto, A | 1 |
| Ashino, Y | 1 |
| Kanno, A | 2 |
| Moriyama, A | 1 |
| Hiraga, M | 1 |
| Kuiper, CM | 5 |
| Culine, S | 1 |
| Suc, E | 1 |
| Brunet, P | 1 |
| Extra, JM | 1 |
| Bonneterre, J | 1 |
| Namer, M | 3 |
| Negrier, S | 2 |
| Merrouche, Y | 1 |
| Burki, F | 1 |
| Herait, P | 1 |
| Mahjoubi, M | 2 |
| Geoffrey, F | 1 |
| Drake, J | 1 |
| Voeller, D | 1 |
| Joffe, JK | 1 |
| Perren, TJ | 1 |
| Bradley, C | 1 |
| Primrose, J | 1 |
| Ward, U | 1 |
| Illingworth, JM | 1 |
| Selby, PJ | 1 |
| Asano, M | 2 |
| Yasuno, M | 1 |
| Takasaki, S | 1 |
| Masumoto, N | 2 |
| Tabata, H | 1 |
| Cleary, JF | 1 |
| Arzoomanian, R | 1 |
| Alberti, D | 1 |
| Feierabend, C | 1 |
| Storer, B | 1 |
| Witt, P | 1 |
| Carbone, P | 2 |
| Wilding, G | 1 |
| Ikuta, Y | 1 |
| Anakura, T | 1 |
| Kasimis, B | 1 |
| Schein, P | 1 |
| Capizzi, R | 1 |
| Kurman, M | 1 |
| Nakashio, T | 1 |
| Takagi, H | 4 |
| Narita, T | 1 |
| Mitsuoka, C | 1 |
| Kannagi, R | 1 |
| Swaminathan, R | 1 |
| Burch, PA | 1 |
| Santala, RG | 1 |
| Schroeder, G | 1 |
| Pitot, HC | 2 |
| Wright, K | 1 |
| Stella, PJ | 1 |
| Garton, GR | 1 |
| Corner, G | 1 |
| Richards, C | 1 |
| Ryan, L | 1 |
| Multani, AS | 1 |
| Pathak, S | 1 |
| Heerdt, BG | 1 |
| Vignoud, J | 1 |
| Varette, C | 2 |
| Moreau, S | 1 |
| Le Bail, N | 1 |
| Krulik, M | 1 |
| Aherne, GW | 2 |
| Ratkin, GA | 2 |
| Ren, Q | 1 |
| Hardcastle, A | 1 |
| Geoffroy, F | 1 |
| Okabo, S | 1 |
| Murase, N | 2 |
| Endo, M | 1 |
| Shimoju, K | 1 |
| Sakurazawa, K | 1 |
| Maruyama, M | 3 |
| Yabata, E | 1 |
| Kawasaki, T | 2 |
| Hess, P | 1 |
| Heinicke, JM | 1 |
| Laffer, UT | 1 |
| Barendswaard, E | 1 |
| Old, LJ | 1 |
| Welt, S | 1 |
| Piazza, GA | 1 |
| Rahm, AK | 1 |
| Finn, TS | 1 |
| Fryer, BH | 1 |
| Stoumen, AL | 1 |
| Pamukcu, R | 1 |
| Ahnen, DJ | 1 |
| Nosaka, S | 1 |
| Takeshita, S | 1 |
| Kiyozumi, Y | 1 |
| Sagara, K | 1 |
| Takamura, K | 1 |
| Kurano, R | 1 |
| Brashear, A | 1 |
| Siemers, E | 1 |
| Denno, R | 1 |
| Oikawa, I | 1 |
| Mukaiya, M | 1 |
| Hiraike, N | 1 |
| Yagihashi, A | 1 |
| Takasaka, H | 1 |
| Katsuramaki, T | 1 |
| Yamashiro, K | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Posner, MR | 2 |
| Perry, LJ | 2 |
| Stuart, KE | 2 |
| Maroun, JA | 1 |
| Cripps, C | 1 |
| Goel, R | 1 |
| Dahrouge, S | 1 |
| Boisvert, D | 1 |
| Lohwasser, S | 1 |
| Ernst, H | 1 |
| Hahn, EG | 3 |
| Gossner, L | 1 |
| Ell, C | 1 |
| Tokunaga, Y | 1 |
| Nishitai, R | 1 |
| Kaganoi, J | 1 |
| Nanbu, H | 1 |
| Ohsumi, K | 1 |
| Murray, CL | 1 |
| Ford, WJ | 1 |
| Swenson, KK | 1 |
| Heros, D | 1 |
| Sperduto, PW | 1 |
| Sahmoud, T | 2 |
| Curran, D | 2 |
| Couvreur, ML | 2 |
| Lise, M | 3 |
| Rauschecker, H | 2 |
| dos Santos, JG | 1 |
| Stremmel, W | 2 |
| Roelofsen, F | 1 |
| Cohen, A | 2 |
| De Luca, A | 1 |
| Selvam, MP | 1 |
| Sandomenico, C | 1 |
| Pepe, S | 2 |
| Bianco, AR | 2 |
| Salomon, DS | 1 |
| Nemunaitis, J | 1 |
| Cox, J | 1 |
| Meyer, W | 1 |
| Courtney, A | 1 |
| Mues, G | 1 |
| Ichihashi, H | 4 |
| Tamada, R | 2 |
| Sides, K | 1 |
| Stein, R | 1 |
| Yasuoka, Y | 1 |
| Hatano, H | 1 |
| Orita, K | 2 |
| Maeshiro, T | 2 |
| Miyamoto, S | 2 |
| Awane, Y | 2 |
| Yasuda, T | 1 |
| Ohigashi, H | 1 |
| Hiratsuka, M | 1 |
| Ishikawa, O | 1 |
| Furukawa, H | 1 |
| Imaoka, S | 1 |
| Koshiji, M | 1 |
| Adachi, Y | 3 |
| Taketani, S | 1 |
| Ikehara, S | 2 |
| Cordel, S | 3 |
| Heymann, MF | 1 |
| Boisteau, O | 1 |
| Oliver, L | 2 |
| Le Pendu, J | 2 |
| Grégoire, M | 2 |
| Meflah, K | 3 |
| Holland, SK | 1 |
| Bergman, AM | 1 |
| Adams, ER | 1 |
| Cvitkovic, E | 3 |
| Allain, P | 1 |
| O'Hagan, S | 1 |
| Diamond, T | 1 |
| Sieder, AE | 1 |
| Braun, J | 1 |
| Streit, M | 1 |
| Jaehde, U | 1 |
| Stremetzne, S | 1 |
| Kerz, H | 1 |
| Strohbach, F | 1 |
| Hohenberger, P | 3 |
| Zwiebel, FM | 1 |
| Hebart, H | 1 |
| Böthig, R | 1 |
| Kairies, M | 1 |
| Zillig, D | 1 |
| Schuchmann, S | 1 |
| Warnecke, S | 1 |
| Fitzgibbons, RJ | 1 |
| Kocha, WI | 1 |
| Vukov, AM | 1 |
| Figueredo, A | 4 |
| Skylstad, D | 1 |
| Småland, R | 1 |
| Yasue, M | 1 |
| Lin, TC | 2 |
| Fan, FS | 2 |
| Longo, GS | 1 |
| Izzo, J | 1 |
| Tong, WP | 1 |
| Zielinski, Z | 1 |
| Chou, TC | 1 |
| Bergman, PJ | 1 |
| Gravitt, KR | 1 |
| Ward, NE | 1 |
| Beltran, P | 1 |
| Gupta, KP | 1 |
| O'Brian, CA | 2 |
| Delva, R | 2 |
| Regimbeau, C | 1 |
| Cailleux, PE | 1 |
| Alleaume, C | 1 |
| Maillet, ML | 1 |
| Goudier, MJ | 1 |
| Sire, M | 1 |
| Person-Joly, MC | 1 |
| Maillart, P | 1 |
| Fety, R | 1 |
| Burtin, P | 2 |
| Lortholary, A | 1 |
| Dumesnil, Y | 1 |
| Picon, L | 1 |
| Geslin, J | 1 |
| Gesta, P | 1 |
| Danquechin-Dorval, E | 1 |
| Larra, F | 1 |
| Robert, J | 1 |
| Sawada, N | 1 |
| Fukase, Y | 1 |
| Nishida, M | 1 |
| Yoshikubo, T | 1 |
| Adachi, W | 1 |
| Yazawa, K | 1 |
| Koide, N | 1 |
| Koike, S | 1 |
| Mihara, M | 1 |
| Kajikawa, S | 1 |
| Amano, J | 1 |
| Marczell, A | 1 |
| Karner, J | 1 |
| Salem, G | 1 |
| Greiner, R | 1 |
| Burger, D | 1 |
| Stöger, F | 1 |
| Ritschel, J | 1 |
| Vischer, HM | 1 |
| Schneeweiss, B | 1 |
| Yamane, N | 1 |
| Makino, M | 1 |
| Taniguchi, T | 1 |
| Kurayoshi, K | 1 |
| Kaibara, N | 2 |
| Tortora, G | 1 |
| Caputo, R | 1 |
| Damiano, V | 1 |
| Bianco, R | 1 |
| Pomatico, G | 1 |
| Veerman, G | 2 |
| Inaba, M | 2 |
| Sawada, H | 2 |
| Mosconi, P | 1 |
| Grilli, R | 1 |
| Cifani, S | 1 |
| Tinazzi, A | 1 |
| Topf, N | 1 |
| Worgall, S | 1 |
| Hackett, NR | 1 |
| Kikot', VA | 1 |
| Iugrinov, OG | 1 |
| Galakhin, KA | 1 |
| Sorokin, BV | 1 |
| Priĭmak, VV | 1 |
| Tarasova, TA | 1 |
| Meli, M | 1 |
| Danova, M | 1 |
| Bernardo, G | 1 |
| Leonardi, V | 1 |
| Dastoli, G | 1 |
| Rausa, L | 2 |
| Palmieri, G | 1 |
| Della Vittoria Scarpati, M | 1 |
| Lo Russo, V | 1 |
| Di Lauro, L | 1 |
| Bruni, G | 1 |
| Piazzi, M | 1 |
| Gebbia, N | 1 |
| Spada, S | 1 |
| Shirasu, M | 1 |
| Yamasaki, J | 1 |
| Togawa, T | 1 |
| Muranishi, S | 1 |
| Hyon, S | 1 |
| Ikada, Y | 1 |
| Stein, ME | 1 |
| Drumea, K | 1 |
| Yarnitsky, D | 1 |
| Benny, A | 1 |
| Tzuk-Shina, T | 1 |
| Gerard, B | 1 |
| Van Daele, D | 1 |
| Di Leo, A | 1 |
| Fernez, B | 1 |
| Brienza, S | 2 |
| Bozec, L | 1 |
| Bierling, P | 1 |
| Fromont, P | 1 |
| Debat, P | 1 |
| Wein, A | 2 |
| Riedel, C | 2 |
| Wakker, R | 1 |
| Reingruber, B | 2 |
| Teichmann, W | 1 |
| Kohnen, R | 1 |
| Hohenberger, W | 2 |
| Bours, V | 2 |
| Jerusalem, G | 2 |
| Fillet, G | 2 |
| Mackean, MJ | 1 |
| Reed, NS | 1 |
| Robertson, AG | 1 |
| McInnes, A | 1 |
| McCann, J | 1 |
| Ishi, K | 1 |
| Koyatsu, J | 1 |
| Hara, A | 1 |
| Chung, YS | 1 |
| Matsubara, T | 1 |
| Satake, K | 1 |
| Miyazaki, H | 1 |
| Okabe, S | 2 |
| Miwa, M | 4 |
| Kojima, T | 2 |
| Naruse, T | 2 |
| Shimoda, K | 1 |
| Shiraishi, N | 1 |
| Doci, R | 1 |
| De Waele, B | 1 |
| Hejna, M | 1 |
| Raderer, M | 1 |
| Brodowicz, T | 1 |
| Fiebiger, WC | 1 |
| Walker-Dilks, C | 2 |
| Germond, C | 2 |
| Browman, G | 1 |
| Dubé, P | 1 |
| Harstrick, A | 2 |
| Gonzales, A | 1 |
| Schleucher, N | 1 |
| Vanhoefer, U | 1 |
| Formento, JL | 3 |
| Seeber, S | 1 |
| Maeda, M | 1 |
| Koike, H | 1 |
| Kasai, H | 1 |
| Nita, ME | 4 |
| Tominaga, O | 2 |
| Tsuno, N | 3 |
| Fujii, S | 2 |
| Fu, CG | 1 |
| Takenoue, T | 4 |
| Muto, T | 4 |
| De Filippi, R | 1 |
| Takeda, J | 1 |
| Iwamoto, M | 1 |
| Kawabata, S | 1 |
| Yunoki T Miwa, K | 1 |
| Iwakuma, N | 1 |
| Nicolini, A | 1 |
| Carpi, A | 1 |
| Ferrari, P | 1 |
| Sagripanti, A | 1 |
| Anselmi, L | 1 |
| Colofiore, JR | 1 |
| Chazal, M | 3 |
| Cheradame, S | 1 |
| Francoual, M | 2 |
| Formento, P | 6 |
| Etienne, MC | 5 |
| Richelme, H | 1 |
| Letoublon, C | 2 |
| Pezet, D | 1 |
| Cure, H | 1 |
| Haynes, H | 1 |
| Cheshire, PJ | 4 |
| Stewart, CF | 1 |
| Guglielmi, A | 2 |
| Mori, A | 1 |
| Baldo, C | 2 |
| Debernardis, D | 4 |
| Valenti, M | 1 |
| Bruno, S | 1 |
| Taverna, M | 1 |
| Tixi, LM | 1 |
| Bolli, EA | 1 |
| Mammoliti, S | 1 |
| Rollandi, GA | 1 |
| Bertoglio, S | 1 |
| Hallman, JD | 1 |
| Lutz, L | 1 |
| Yang, B | 1 |
| Eshleman, JR | 1 |
| Berger, NA | 1 |
| Markowitz, SD | 1 |
| Pavillard, V | 1 |
| Rostagno, P | 3 |
| Fischel, JL | 5 |
| Bryant, J | 1 |
| Smith, R | 2 |
| Hyams, D | 1 |
| Atkins, J | 1 |
| Dimitrov, N | 1 |
| Oishi, R | 1 |
| Prager, D | 1 |
| Romond, E | 1 |
| Bygrave, HA | 1 |
| Geh, JI | 1 |
| Jani, Y | 1 |
| Glynne-Jones, R | 1 |
| Kuzu, MA | 1 |
| Kuzu, I | 1 |
| Köksoy, C | 1 |
| Akyol, FH | 1 |
| Uzal, D | 1 |
| Kale, IT | 1 |
| Orhan, D | 1 |
| Terzi, C | 1 |
| Kuzu, J | 1 |
| Bulkley, GB | 1 |
| Aziz, SA | 1 |
| Tramboo, NA | 1 |
| Mohi-ud-Din, K | 1 |
| Iqbal, K | 1 |
| Jalal, S | 1 |
| Ahmad, M | 1 |
| Slevin, ML | 3 |
| Au, E | 2 |
| Ang, PT | 1 |
| Seow-Choen, F | 1 |
| Soo, KC | 1 |
| Low, CH | 1 |
| Chng, HC | 1 |
| Ng, BK | 1 |
| Evrard, A | 2 |
| Cuq, P | 2 |
| Robert, B | 1 |
| Vian, L | 1 |
| Pèlegrin, A | 2 |
| Cano, JP | 1 |
| Fezza, JP | 1 |
| Wesley, RE | 1 |
| Klippenstein, KA | 1 |
| Schwartz, MS | 1 |
| Shinkai, K | 1 |
| Kida, H | 1 |
| Hisano, H | 1 |
| Shibasaki, S | 1 |
| Yano, H | 1 |
| Nomura, M | 1 |
| Nakanishi, K | 1 |
| Ueno, Y | 1 |
| Nakamura, N | 1 |
| Tanihata, H | 1 |
| Masuda, M | 1 |
| Terada, M | 1 |
| Satoh, M | 1 |
| Okamoto, E | 1 |
| Mabuchi, K | 2 |
| Kitaoka, H | 2 |
| Hirata, N | 1 |
| Kitaoka, U | 1 |
| Sauter, C | 1 |
| Britten, CD | 1 |
| Hilsenbeck, SG | 1 |
| Eckhardt, SG | 1 |
| Marty, J | 1 |
| Mangold, G | 1 |
| MacDonald, JR | 1 |
| Rowinsky, EK | 1 |
| Von Hoff, DD | 3 |
| Weitman, S | 1 |
| Duan, C | 1 |
| Leng, A | 1 |
| Horowitz, R | 1 |
| Zhang, HY | 1 |
| Moiseenko, VM | 1 |
| Orlova, RV | 1 |
| Gebbia, V | 2 |
| Giuliani, F | 1 |
| Serravezza, G | 1 |
| Lelli, G | 1 |
| Leo, S | 1 |
| Nicolella, G | 1 |
| Brandi, M | 1 |
| Sugano, N | 1 |
| Ebuchi, M | 2 |
| Shehata, N | 1 |
| Pater, A | 1 |
| Tang, SC | 1 |
| van Triest, B | 2 |
| van Hensbergen, Y | 1 |
| Telleman, F | 1 |
| Schoenmakers, PS | 1 |
| Kievit, E | 1 |
| Bershad, E | 1 |
| Ng, E | 1 |
| Sethna, P | 1 |
| Dev, I | 1 |
| Yamashita, T | 1 |
| Mariko, Y | 1 |
| Nosaka, Y | 1 |
| Tsuchiya, K | 1 |
| Nakanishi, O | 1 |
| Sabaawy, HE | 1 |
| Farley, T | 1 |
| Feldman, E | 2 |
| Abraham, NG | 2 |
| Juturi, JV | 1 |
| Francis, B | 1 |
| Koontz, PW | 1 |
| Wilkes, JD | 1 |
| Benoit, L | 1 |
| Duvillard, C | 1 |
| L'Helgouarc'h, JL | 1 |
| Momose, F | 1 |
| Fuse, S | 1 |
| Nagakari, K | 1 |
| Harrington, DP | 1 |
| Mamounas, E | 2 |
| Wieand, S | 3 |
| Bear, HD | 2 |
| Timmerman, D | 1 |
| Sabaawy, HM | 1 |
| Quan, S | 1 |
| Kancherla, R | 1 |
| Harper, P | 1 |
| Lobelle, JP | 1 |
| Adam, R | 1 |
| Dallemagne, B | 1 |
| Jehaes, C | 1 |
| Markiewicz, S | 1 |
| Bismuth, H | 1 |
| Funahashi, Y | 2 |
| Koyanagi, N | 2 |
| Sonoda, J | 1 |
| Kitoh, K | 2 |
| Yee, LK | 1 |
| Venzon, DJ | 1 |
| Schuler, B | 1 |
| Grollman, F | 1 |
| Chabuk, C | 1 |
| Hamilton, JM | 3 |
| Chen, AP | 1 |
| Kronborg, O | 1 |
| Wiboltt, K | 1 |
| Bajzer, Z | 1 |
| Satomoto, K | 1 |
| Yamatuji, T | 1 |
| Bunz, F | 1 |
| Hwang, PM | 1 |
| Torrance, C | 1 |
| Waldman, T | 1 |
| Dillehay, L | 1 |
| Williams, J | 1 |
| Lengauer, C | 1 |
| Nabai, H | 1 |
| Mohindra, R | 1 |
| Mehregan, D | 1 |
| Maghfoor, I | 1 |
| Wisotzkey, JD | 1 |
| Toman, J | 1 |
| Bell, T | 1 |
| Monk, JS | 1 |
| Jones, D | 1 |
| Iwata, R | 1 |
| Ido, T | 1 |
| Murakawa, Y | 1 |
| Gamo, M | 1 |
| Kanamaru, R | 4 |
| Bernhard, J | 2 |
| Hürny, C | 2 |
| Maibach, R | 2 |
| Tunesi, G | 2 |
| Staccioli, MP | 3 |
| Brenna, A | 2 |
| Muretto, P | 3 |
| Agarwal, B | 1 |
| Bhendwal, S | 1 |
| Halmos, B | 1 |
| Moss, SF | 1 |
| Ramey, WG | 1 |
| Holt, PR | 1 |
| Lim, WT | 1 |
| Koo, WH | 1 |
| Khoo, KS | 1 |
| Sakukawa, R | 1 |
| Hashimoto, A | 2 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| King, DW | 1 |
| Kitchens, ME | 1 |
| Forsthoefel, AM | 1 |
| Barbour, KW | 1 |
| Spencer, HT | 1 |
| Berger, FG | 2 |
| Wildner, O | 1 |
| Blaese, RM | 1 |
| Candotti, F | 1 |
| Kinuya, S | 1 |
| Yokoyama, K | 1 |
| Tega, H | 1 |
| Hiramatsu, T | 1 |
| Konishi, S | 1 |
| Shuke, N | 1 |
| Aburano, T | 1 |
| Michigishi, T | 1 |
| Tonami, N | 1 |
| Dimitrov, NV | 1 |
| Glass, AG | 1 |
| Kimura, H | 1 |
| Hata, F | 1 |
| Kusaba, H | 1 |
| Mitsugi, K | 1 |
| Ueyama, T | 1 |
| Fukui, H | 2 |
| Eshraghi, N | 1 |
| Swanstrom, LL | 1 |
| Bax, T | 1 |
| Jobe, B | 1 |
| Horvath, K | 1 |
| Sheppard, B | 1 |
| Deveney, C | 1 |
| Masui, H | 1 |
| Miya, K | 1 |
| Fukada, D | 1 |
| Umemoto, T | 1 |
| Kunieda, K | 1 |
| Utsumi, T | 1 |
| Matsumoto, M | 1 |
| Senda, K | 1 |
| Ishihara, O | 1 |
| Yoshioka, S | 1 |
| Shingai, T | 2 |
| Azama, T | 2 |
| Okajima, S | 2 |
| Sue, F | 2 |
| Akaishi, O | 1 |
| Tsukikawa, S | 1 |
| Yabe, K | 1 |
| Higashi, S | 1 |
| Kato, C | 1 |
| Sakumoto, H | 1 |
| Sumiyoshi, K | 1 |
| Takahahsi, T | 1 |
| Kane, T | 1 |
| Sakoda, M | 1 |
| Hosono, Y | 1 |
| Kure, M | 1 |
| Wakahara, M | 1 |
| Tanemura, H | 1 |
| Ooshita, H | 1 |
| Hiraoka, T | 1 |
| Suhara, T | 1 |
| Nakata, T | 1 |
| Saitou, S | 1 |
| Foon, KA | 1 |
| Chakraborty, M | 1 |
| Teitelbaum, A | 1 |
| Garrison, J | 1 |
| Kashala, O | 1 |
| Chatterjee, SK | 1 |
| Bhattacharya-Chatterjee, M | 1 |
| Bonnay, M | 1 |
| Bexon, A | 1 |
| Armand, JP | 1 |
| Méry-Mignard, D | 1 |
| Pierrefite-Carle, V | 3 |
| Baqué, P | 3 |
| Gavelli, A | 3 |
| Mala, M | 1 |
| Gugenheim, J | 1 |
| Bourgeon, A | 3 |
| Staccini, P | 3 |
| Rossi, B | 3 |
| Goupille, C | 1 |
| Hallouin, F | 1 |
| Sekiguchi, R | 1 |
| Haruno, M | 1 |
| Moriyama, N | 1 |
| Pandi, E | 1 |
| Erdélyi-Tóth, V | 1 |
| Kovács, P | 1 |
| Danikas, D | 1 |
| Theodorou, SJ | 1 |
| Arvanitis, ML | 1 |
| Zinterhofer, LM | 1 |
| Rienzo, AA | 1 |
| Jacobson, J | 1 |
| Betzing, KS | 1 |
| Lorenz, M | 1 |
| Müller, HH | 1 |
| Powell, B | 1 |
| Soontrapornchai, P | 1 |
| Joseph, D | 1 |
| Goria, F | 1 |
| Spry, N | 1 |
| Jackman, AL | 2 |
| Kimbell, R | 1 |
| Ford, HE | 1 |
| Mans, DR | 1 |
| Modrak, DE | 2 |
| Lew, W | 2 |
| Blumenthal, R | 1 |
| Lin, X | 1 |
| Parsels, LA | 1 |
| Maley, GF | 1 |
| Maley, F | 2 |
| Tansik, RL | 1 |
| Porter, DJ | 1 |
| Ukarapol, N | 1 |
| Wongsawasdi, L | 1 |
| Singhavejsakul, J | 1 |
| Prasad, S | 1 |
| Kamath, GG | 1 |
| Phillips, RP | 1 |
| Yanagida, T | 1 |
| Ohya, M | 1 |
| Feleszko, W | 1 |
| Jakóbisiak, M | 1 |
| Daly, JM | 3 |
| Vaillant, JC | 1 |
| Deuffic, S | 1 |
| Pelissier, E | 1 |
| Favre, JP | 1 |
| Jaeck, D | 1 |
| Fourtanier, G | 1 |
| Grandjean, JP | 1 |
| Marre, P | 1 |
| Israel, ZH | 1 |
| Lossos, A | 1 |
| Soffer, D | 1 |
| Siegal, T | 1 |
| Zisiadis, A | 1 |
| Konstantaras, C | 1 |
| Hatzitheoharis, G | 1 |
| Papavramidis, S | 1 |
| Bousoulegas, A | 1 |
| Giannoulis, E | 1 |
| Dokmetzioglou, J | 1 |
| Katsohis, C | 1 |
| Nenopoulou, E | 1 |
| Karvounis, N | 1 |
| Kosmidis, P | 1 |
| Block, A | 1 |
| Freund, CT | 1 |
| Chen, SH | 1 |
| Nguyen, KP | 1 |
| Finegold, M | 1 |
| Windler, E | 1 |
| Woo, SL | 1 |
| Araki, S | 1 |
| Kaihara, J | 1 |
| Yasunaga, M | 1 |
| Hayashi, K | 1 |
| Yatsugi, H | 1 |
| Yamauchi, K | 1 |
| Yang, SH | 1 |
| Wang, HS | 1 |
| Peillard, L | 1 |
| Catalin, J | 2 |
| Bergmann-Leitner, ES | 2 |
| Abrams, SI | 2 |
| Backus, HH | 5 |
| Toge, T | 4 |
| Sowa, M | 1 |
| Hatano, K | 2 |
| Soori, GS | 1 |
| Oldham, RK | 2 |
| Dobbs, TW | 1 |
| Bury, MJ | 1 |
| Church, CK | 1 |
| DePriest, C | 1 |
| Kawamura, K | 1 |
| Tasaki, K | 1 |
| Takenaga, K | 1 |
| Sakiyama, S | 1 |
| Tagawa, M | 1 |
| Takei, Y | 1 |
| Umetani, N | 1 |
| Horák, D | 1 |
| Guseinov, E | 1 |
| Vishnevskii, V | 1 |
| Adamyan, A | 1 |
| Kokov, L | 1 |
| Tsvirkun, V | 1 |
| Tchjao, A | 1 |
| Titova, M | 1 |
| Skuba, N | 1 |
| Trostenyuk, N | 1 |
| Gumargalieva, K | 1 |
| Palermo, JA | 1 |
| Lohman, KK | 1 |
| Lovelace, JV | 1 |
| Atkinson, J | 1 |
| Case, LD | 2 |
| Seigner, C | 1 |
| Giovannini, M | 1 |
| Sauvan, R | 1 |
| Reggio, H | 1 |
| Kleeberg, UR | 2 |
| Schumacher, K | 1 |
| De Lucia, L | 1 |
| Casaretti, R | 1 |
| Orditura, M | 1 |
| Rivellini, F | 1 |
| Comella, G | 1 |
| Horvath, CM | 1 |
| Waxman, S | 1 |
| Rashidi, B | 1 |
| An, Z | 1 |
| Sun, FX | 1 |
| Moossa, AR | 1 |
| Kamata, T | 1 |
| Nakamoto, A | 1 |
| Onishi, I | 1 |
| Koyasaki, N | 1 |
| Kanno, M | 1 |
| Chang, TC | 1 |
| Oh, CM | 1 |
| Bleeker, WA | 3 |
| Hermans, J | 4 |
| Otter, R | 2 |
| Ladner, RD | 1 |
| Lynch, FJ | 1 |
| Xiong, YP | 1 |
| Sherrod, A | 1 |
| Caradonna, SJ | 1 |
| Stoehlmacher, J | 1 |
| McCart, JA | 1 |
| Puhlmann, M | 1 |
| Libutti, SK | 1 |
| Alexander, HR | 1 |
| Bartlett, DL | 1 |
| Abramson, RG | 1 |
| Rosen, MP | 1 |
| Brophy, DP | 1 |
| Raeburn, SL | 1 |
| Alektiar, KM | 1 |
| Zelefsky, MJ | 1 |
| Paty, PB | 1 |
| Guillem, J | 1 |
| Tokuda, C | 1 |
| Miyama, Y | 1 |
| Ezekiel, G | 1 |
| Walfisch, S | 1 |
| Wouters, D | 4 |
| Padrón, JM | 1 |
| Molders, N | 1 |
| Guerquin-Kern, JL | 1 |
| Volk, A | 1 |
| Chenu, E | 1 |
| Lougerstay-Madec, R | 1 |
| Monneret, C | 1 |
| Florent, JC | 1 |
| Carrez, D | 1 |
| Croisy, A | 1 |
| Ono-Nita, SK | 1 |
| Ohkuma, K | 1 |
| Hisano, C | 1 |
| Maruyama, T | 1 |
| Kaji, Y | 1 |
| Schmiegel, W | 1 |
| Nakahara, H | 1 |
| Okajima, M | 1 |
| Nakahara, M | 1 |
| Yano, M | 1 |
| Asahara, T | 1 |
| Bandelloni, R | 1 |
| Baldelli, AM | 2 |
| Valenti, A | 1 |
| Perer, ES | 1 |
| Madan, AK | 1 |
| Shurin, A | 1 |
| Zakris, E | 1 |
| Romeguera, K | 1 |
| Pang, Y | 1 |
| Beech, DJ | 1 |
| Hemminki, A | 1 |
| Mecklin, JP | 1 |
| Järvinen, H | 1 |
| Aaltonen, LA | 1 |
| Joensuu, H | 1 |
| Pestieau, SR | 1 |
| Funaki, M | 1 |
| Gouchi, A | 1 |
| Iwagaki, H | 2 |
| Morimoto, Y | 1 |
| Ariki, N | 1 |
| Unno, M | 1 |
| Matsuno, S | 1 |
| Yamazaki, H | 2 |
| Satoh, K | 1 |
| Katoh, M | 1 |
| Koninkx, J | 1 |
| Schumacher, U | 1 |
| Ukei, T | 1 |
| Touno, T | 1 |
| Masutani, S | 1 |
| Oozato, H | 1 |
| Tamamori, Y | 1 |
| Yukawa, M | 1 |
| Takekuni, K | 1 |
| Koyama, F | 1 |
| Hirao, T | 1 |
| Harboe, K | 1 |
| Todnem, K | 1 |
| Zotova, L | 1 |
| Lind, A | 1 |
| Ogreid, D | 1 |
| Daniele, B | 2 |
| Perrone, F | 2 |
| Gallo, C | 2 |
| Pignata, S | 1 |
| De Martino, S | 1 |
| De Vivo, R | 1 |
| Barletta, E | 1 |
| Tambaro, R | 1 |
| Abbiati, R | 1 |
| D'Agostino, L | 1 |
| Sawa, H | 1 |
| Morikawa, J | 1 |
| Shiku, H | 1 |
| Fey, MF | 1 |
| Ricotti, L | 1 |
| De Paola, F | 1 |
| Casini-Raggi, C | 1 |
| Barzanti, F | 1 |
| van Kuilenburg, AB | 2 |
| Haasjes, J | 1 |
| Richel, DJ | 1 |
| Zoetekouw, L | 1 |
| Van Lenthe, H | 1 |
| De Abreu, RA | 1 |
| Maring, JG | 1 |
| Vreken, P | 1 |
| van Gennip, AH | 2 |
| Behr, TM | 1 |
| Memtsoudis, S | 1 |
| Gratz, S | 1 |
| Becker, W | 1 |
| Milovica, V | 1 |
| Turchanowa, L | 1 |
| Khomutov, AR | 1 |
| Khomutov, RM | 1 |
| Caspary, WF | 1 |
| Adeyemo, D | 1 |
| Imtiaz, F | 1 |
| Toffa, S | 1 |
| Lowdell, M | 1 |
| Wickremasinghe, RG | 1 |
| Kumar, SK | 1 |
| Goda, F | 1 |
| Maeba, T | 1 |
| Mori, S | 1 |
| Okano, K | 1 |
| Usuki, H | 1 |
| Mihara, T | 1 |
| Okada, H | 1 |
| Ohkawa, M | 1 |
| Maeta, H | 1 |
| Senda, S | 1 |
| Dubreuil, A | 2 |
| Yazawa, Y | 1 |
| Löffler, T | 1 |
| Haack, G | 1 |
| Anger, Y | 1 |
| Brückl, W | 1 |
| Kastl, S | 1 |
| Astrow, AB | 1 |
| Ishizaki, M | 1 |
| Akiyama, N | 1 |
| Motegi, M | 1 |
| Sasamoto, H | 1 |
| Wada, W | 1 |
| Billiau, V | 1 |
| Gramont, A | 1 |
| Mak, W | 1 |
| Cheng, PW | 1 |
| Cheung, RT | 1 |
| Haddock, MG | 2 |
| Devine, RM | 2 |
| Dozois, RR | 1 |
| Wolff, BG | 1 |
| Hayes, VM | 1 |
| Karrenbeld, A | 1 |
| Verlind, E | 1 |
| Poppema, S | 1 |
| Valentini, M | 1 |
| Rossi, C | 1 |
| Grianti, C | 1 |
| Satriano, R | 1 |
| Semsek, D | 1 |
| Comijn, L | 1 |
| Voorn, DA | 1 |
| Priest, DG | 2 |
| Bunni, MA | 2 |
| Mitchell, F | 1 |
| Zori Comba, A | 1 |
| Blajman, C | 1 |
| Richardet, E | 1 |
| Bella, S | 1 |
| Vilanova, M | 1 |
| Cóppola, F | 1 |
| Van Kooten, M | 1 |
| Rodger, J | 1 |
| Giglio, R | 1 |
| Balbiani, L | 1 |
| Perazzo, F | 1 |
| Montiel, M | 1 |
| Chacón, M | 1 |
| Pujol, F | 1 |
| Mickiewicz, E | 1 |
| Cazap, E | 1 |
| Recondo, G | 1 |
| Lastiri, F | 1 |
| Simon, J | 1 |
| Wasserman, E | 1 |
| Schmilovich, A | 1 |
| Gibbs, JF | 1 |
| Shim, KY | 1 |
| Jeung, HC | 1 |
| Rha, SY | 1 |
| Yoo, NC | 1 |
| Min, JS | 1 |
| Murayama, N | 1 |
| Ohno, Y | 1 |
| Sawada , J | 1 |
| Nozoe, Y | 2 |
| Sasatomi, T | 2 |
| Miyagi, Y | 2 |
| Mahyar-Roemer, M | 1 |
| Meyers, M | 1 |
| Wagner, MW | 1 |
| Hwang, HS | 1 |
| Kinsella, TJ | 1 |
| Boothman, DA | 1 |
| Soeth, E | 1 |
| Wirth, T | 1 |
| List, HJ | 1 |
| Kumbhani, S | 1 |
| Petersen, A | 1 |
| Neumaier, M | 1 |
| Czubayko, F | 1 |
| Juhl, H | 1 |
| Wilson, RH | 1 |
| Harold, N | 1 |
| Keith, B | 1 |
| Dougherty, DS | 1 |
| Barth, G | 1 |
| Basten, O | 1 |
| Rüschoff, J | 1 |
| Rompel, R | 1 |
| Xin, M | 1 |
| Sekikawa, K | 1 |
| Anzai, K | 1 |
| Yamaki, T | 1 |
| Ando, Y | 1 |
| Sassa, M | 1 |
| Endo, Y | 1 |
| Kimijima, I | 1 |
| Marchetti, S | 1 |
| Kuranaga, N | 1 |
| Shinomiya, N | 1 |
| Mochizuki, H | 1 |
| Lowy, A | 1 |
| Raida, M | 1 |
| Höffken, K | 1 |
| Inoue, F | 1 |
| Mutoh, T | 1 |
| Tatematsu, H | 1 |
| Yamataka, K | 1 |
| Sakurai, T | 1 |
| Kawahara, H | 1 |
| Jacobson, SD | 1 |
| Pitini, V | 1 |
| Arrigo, C | 1 |
| Aloi, G | 1 |
| Righi, M | 1 |
| Falduto, M | 1 |
| Teti, D | 1 |
| Griffiths, JR | 1 |
| McIntyre, DJ | 1 |
| Howe, FA | 1 |
| McSheehy, PM | 1 |
| Rodrigues, LM | 1 |
| Wadsworth, P | 1 |
| Price, NM | 1 |
| Lofts, F | 1 |
| Nicholson, G | 1 |
| Stubbs, M | 1 |
| Habara, K | 2 |
| Ajiki, T | 1 |
| Kamigaki, T | 2 |
| Kuroda, Y | 4 |
| Chung-Faye, GA | 1 |
| Chen, MJ | 1 |
| Green, NK | 1 |
| Burton, A | 1 |
| Anderson, D | 1 |
| Mautner, V | 1 |
| Searle, PF | 1 |
| Kunimoto, Y | 1 |
| Fukumoto, S | 1 |
| Ku, Y | 1 |
| Coudert, B | 1 |
| Pierga, JY | 1 |
| Provençal, J | 1 |
| Rixe, O | 1 |
| Krisch, C | 1 |
| Germa, C | 1 |
| Bekradda, M | 1 |
| Mignard, D | 1 |
| Zoetmulder, FA | 1 |
| Gilbar, PJ | 1 |
| Brodribb, TR | 1 |
| Yamada, F | 1 |
| Tsukamoto, Y | 1 |
| Kato, Y | 1 |
| Horii, I | 1 |
| Sabatino, M | 1 |
| Pozzessere, D | 1 |
| Sanguedolce, R | 1 |
| Caliò, E | 1 |
| Seminara, P | 1 |
| Aronne, T | 1 |
| Sbaffi, E | 1 |
| Pagani Guazzugli Bonaiuti, V | 1 |
| Gargano, L | 1 |
| Rodriguez, MD | 1 |
| Tomiak, A | 1 |
| Earle, CC | 1 |
| Kocha, W | 1 |
| Eidus, L | 1 |
| Whiston, F | 1 |
| Stitt, L | 1 |
| Araki, Y | 1 |
| Xing, TH | 1 |
| Qiu, GQ | 1 |
| Tang, HM | 1 |
| Brossette, N | 2 |
| Benchimol, D | 2 |
| Saint Paul, MC | 1 |
| Rengelshausen, J | 1 |
| Schwenger, V | 1 |
| Göggelmann, C | 1 |
| Walter-Sack, I | 1 |
| Bommer, J | 1 |
| Green, RJ | 1 |
| Metlay, JP | 1 |
| Propert, K | 1 |
| Warren, JL | 1 |
| Nauta, RJ | 2 |
| Zhu, K | 1 |
| Shan, H | 1 |
| Bruserud, Y | 1 |
| Lazaris, AC | 1 |
| Kavantzas, NG | 1 |
| Zorzos, HS | 1 |
| Tsavaris, NV | 1 |
| Davaris, PS | 1 |
| Sundararajan, V | 1 |
| Mitra, N | 1 |
| Heitjan, DF | 1 |
| Lauderdale, DS | 1 |
| Christakis, NA | 1 |
| Taylor, WE | 1 |
| Nagorney, DM | 1 |
| Larson, DR | 1 |
| Wang, HM | 1 |
| Lin, YC | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Wierzba, K | 1 |
| Boyer, CR | 1 |
| Karjian, PL | 1 |
| Wahl, GM | 1 |
| Pegram, M | 1 |
| Neuteboom, ST | 1 |
| Petit, T | 1 |
| Davidson, KK | 1 |
| Cerna, C | 1 |
| Lawrence, RA | 1 |
| Heise, C | 1 |
| Kirn, D | 1 |
| Izbicka, E | 1 |
| Nagata, T | 1 |
| Nakamori, M | 1 |
| Iwahashi, M | 1 |
| Yamaue, H | 1 |
| Kouniavsky, G | 1 |
| Khaikin, M | 1 |
| Zvibel, I | 1 |
| Zippel, D | 1 |
| Brill, S | 1 |
| Halpern, Z | 1 |
| Papa, M | 1 |
| Wold, LE | 1 |
| Johnston, P | 1 |
| Behan, K | 1 |
| Levitt, R | 1 |
| Tria Tirona, M | 1 |
| Violette, S | 1 |
| Poulain, L | 1 |
| Pepin, D | 1 |
| Faussat, AM | 1 |
| Chambaz, J | 1 |
| Lacorte, JM | 1 |
| Staedel, C | 1 |
| Mirza, A | 1 |
| Craig, G | 1 |
| Law, A | 1 |
| Gallagher, J | 1 |
| Ellison, N | 1 |
| Bernath, A | 1 |
| Craipeau, C | 1 |
| Baars, A | 1 |
| Claessen, AM | 1 |
| Wagstaff, J | 1 |
| Giaccone, G | 1 |
| Schakel, MJ | 1 |
| Gall, HE | 1 |
| Meijer, CJ | 1 |
| Vermorken, JB | 1 |
| van den Eertwegh, AJ | 1 |
| Langley, K | 1 |
| Exinger, F | 1 |
| Barbieux, I | 1 |
| LeCabellec, MT | 1 |
| Vallette, FM | 1 |
| Saint-Paul, MC | 1 |
| Benchalal, M | 1 |
| Yahchouchy-Chouillard, E | 1 |
| Fouere, S | 1 |
| Fingerhut, A | 1 |
| Tsavaris, NB | 1 |
| Gennatas, K | 1 |
| Kosmas, Ch | 1 |
| Macheras, A | 1 |
| Giannopoulos, A | 1 |
| Koufos, Ch | 1 |
| Kawasaki, M | 1 |
| Schreml, W | 1 |
| Bergevin, PR | 2 |
| Patwardhan, VC | 1 |
| Weissman, J | 1 |
| Wallack, MK | 1 |
| Rosato, FE | 1 |
| Brown, AS | 1 |
| Rosato, EF | 1 |
| Gutterman, JU | 6 |
| Burgess, MA | 7 |
| Khankhanian, N | 2 |
| Seibert, GB | 2 |
| Speer, JF | 2 |
| Jubert, AV | 4 |
| Martin, RC | 2 |
| McBride, CM | 4 |
| Copeland, EM | 3 |
| Gehan, EA | 2 |
| Hersh, EM | 5 |
| Hsu, LY | 1 |
| David, K | 1 |
| Serotkin, AV | 1 |
| Godmilov, L | 1 |
| Hirschhorn, K | 1 |
| Horton, J | 3 |
| Brickner, TJ | 1 |
| Illig, WP | 1 |
| Self, J | 1 |
| Thompson, CT | 1 |
| Winkler, R | 1 |
| Rauchenberger, B | 1 |
| Barrett, A | 1 |
| Gazet, JC | 1 |
| Bradbeer, JW | 1 |
| Peckham, MJ | 1 |
| Hartwich, G | 1 |
| Neidhardt, B | 1 |
| Mayr, AC | 1 |
| Kubanek, B | 1 |
| Tisman, G | 1 |
| Wu, SJ | 1 |
| Hill, GJ | 4 |
| Cornell, GN | 2 |
| Frelick, RW | 2 |
| Chevrel, JP | 1 |
| Damsin, JP | 1 |
| Lebhar, E | 1 |
| Tutton, PJ | 1 |
| Barkla, DH | 1 |
| Cagetti, M | 1 |
| Casula, G | 1 |
| Uccheddu, A | 1 |
| Woolley, PV | 4 |
| Buroker, T | 5 |
| Samson, M | 2 |
| Correa, J | 2 |
| Fraile, R | 1 |
| Vaitkevicius, VK | 7 |
| Brockman, RW | 1 |
| Shaddix, SC | 1 |
| Rose, LM | 1 |
| Danhauser, L | 1 |
| Bland, KI | 1 |
| Garrison, RN | 1 |
| Knutson, CO | 1 |
| Polio, J | 1 |
| Clouse, ME | 1 |
| Hamilton, T | 1 |
| Ramming, KP | 1 |
| Sparks, FC | 2 |
| Eilber, FR | 1 |
| Holmes, EC | 1 |
| Pratt, CB | 1 |
| Rivera, G | 1 |
| Shanks, E | 1 |
| Johnson, WW | 1 |
| Howarth, C | 1 |
| Terrell, W | 1 |
| Kumar, AP | 1 |
| Shimosato, Y | 1 |
| Möschl, P | 1 |
| Lubec, G | 1 |
| Bolton, PM | 2 |
| Clunie, GJ | 1 |
| Burnett, W | 1 |
| Louie, AC | 1 |
| DeBeer, R | 1 |
| Karrer, K | 1 |
| Denck, H | 1 |
| Pridun, N | 1 |
| Petrek, JA | 1 |
| Minton, JP | 2 |
| Ansfield, F | 1 |
| Klotz, J | 1 |
| Nealon, T | 1 |
| Minton, J | 1 |
| Hill, G | 1 |
| Wilson, W | 1 |
| Davis, H | 1 |
| Cornell, G | 1 |
| Heal, JM | 1 |
| Grossi, CE | 7 |
| Wolff, WI | 2 |
| Nealon, TF | 3 |
| Pasternack, B | 2 |
| Rousselot, LM | 7 |
| Bedikian, A | 3 |
| Rodriguez, V | 2 |
| Miller, A | 2 |
| Baker, L | 3 |
| McKenzie, M | 1 |
| Diggs, CH | 1 |
| Wiernik, PH | 1 |
| Smyth, AC | 1 |
| Brooman, P | 1 |
| Rowling, JT | 1 |
| Lawrence, W | 3 |
| Terz, JJ | 3 |
| Horsley, JS | 2 |
| Brown, PW | 2 |
| Berman, R | 1 |
| Malhotra, A | 2 |
| Bird, GG | 2 |
| Gajjar, PD | 1 |
| Bunch, GA | 2 |
| Hall, R | 2 |
| Ratkin, G | 1 |
| Klahr, C | 2 |
| Smith, LF | 1 |
| Wojtaszak, B | 1 |
| Dindogru, A | 1 |
| DeMattia, M | 1 |
| Groth, C | 1 |
| Shioda, R | 1 |
| Taylor, SG | 1 |
| Desai, SA | 1 |
| DeWys, WD | 1 |
| Kim, PN | 1 |
| Groppe, C | 2 |
| McCracken, J | 2 |
| O'Bryan, R | 1 |
| Panettiere, F | 1 |
| Coltman, C | 1 |
| Bottomley, R | 1 |
| Wilson, H | 1 |
| Bonnet, J | 2 |
| Thigpen, T | 1 |
| Hoogstraten, B | 2 |
| Heilbrun, L | 2 |
| Staab, R | 1 |
| Livingston, R | 1 |
| Lavin, PT | 2 |
| Woll, J | 2 |
| Vogel, SJ | 1 |
| Padilla, F | 1 |
| Guy, G | 1 |
| Quagliana, J | 1 |
| Sokova, OI | 1 |
| Volgareva, GM | 1 |
| Milstein, D | 1 |
| Belt, RJ | 1 |
| Stephens, R | 2 |
| Vassilopoulos, PP | 1 |
| Shingleton, WW | 3 |
| Elias, EG | 4 |
| Aust, JB | 2 |
| Kessinger, MA | 1 |
| Foley, JF | 2 |
| Lemon, HM | 2 |
| Dionne, LJ | 1 |
| Kibrite, A | 1 |
| Martin, M | 1 |
| Mandel, HG | 2 |
| Klubes, P | 2 |
| Fernandes, DJ | 1 |
| Luporini, G | 2 |
| Mangiarotti, F | 1 |
| Fraschini, P | 1 |
| Tassi, GC | 1 |
| De Barbieri, A | 1 |
| Zeitoun, P | 1 |
| Salas, H | 1 |
| Solomon, A | 1 |
| White, LA | 1 |
| Perry, MC | 1 |
| Kardinal, CG | 1 |
| Carey, RW | 2 |
| Lee, YT | 1 |
| Griswold, DP | 1 |
| Wolpert, MK | 1 |
| Venditti, JM | 1 |
| Schabel, FM | 1 |
| Danjoux, CE | 1 |
| Catton, GE | 1 |
| Hartman, HA | 1 |
| Kessinger, A | 1 |
| Scanni, A | 1 |
| Tomirotti, M | 1 |
| Licciardello, L | 1 |
| Annibali, E | 1 |
| Biraghi, M | 1 |
| Trovato, M | 1 |
| Fittipaldi, M | 1 |
| Adamoli, P | 1 |
| Curtarelli, G | 1 |
| Brutti, A | 1 |
| Sini, S | 1 |
| Barzi, AM | 1 |
| Stone, SP | 1 |
| Marcuello Gaspar, E | 1 |
| Germa Lluch, JR | 1 |
| Abad Esteve, A | 1 |
| Badia Canto, A | 1 |
| Kelly, JP | 1 |
| Hannam, TW | 1 |
| Rowling, J | 1 |
| Windle, R | 3 |
| Macpherson, S | 1 |
| Bell, PR | 2 |
| Joss, RA | 1 |
| Goldberg, RS | 1 |
| Yates, JW | 1 |
| Cifuentes de Castro, L | 1 |
| Lee, PW | 1 |
| Li, MC | 3 |
| Ecnow, B | 1 |
| Gold, BH | 1 |
| Sadove, M | 1 |
| Skarin, AT | 4 |
| Frei, E | 2 |
| Himori, T | 1 |
| Haidak, DJ | 1 |
| Yeung, KY | 1 |
| Krein, BM | 1 |
| Palangie, T | 1 |
| Jouve, M | 1 |
| Langlois, A | 1 |
| Garcia-Giralt, E | 1 |
| Regensberg, C | 1 |
| Blic, V | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Baron, A | 1 |
| Fischetti, MR | 1 |
| Weitzman, SA | 1 |
| Kaufman, S | 1 |
| Kelley, RM | 1 |
| Sohier, WD | 1 |
| Obrecht, JP | 1 |
| Cerna, I | 1 |
| Connelly, K | 1 |
| Geelhoed, GW | 1 |
| Evans, JT | 1 |
| Greco, FA | 1 |
| Richardson, RL | 1 |
| Shulman, SF | 1 |
| Christophidis, N | 1 |
| Lucas, I | 1 |
| Vajda, FJ | 1 |
| Louis, WJ | 1 |
| Kane, RC | 1 |
| Cashdollar, MR | 1 |
| Bernath, AM | 1 |
| Davis, S | 2 |
| Park, YK | 1 |
| Baughman, BB | 1 |
| Buscaglia, MD | 1 |
| Lakings, DB | 1 |
| Adamson, RH | 1 |
| Schreiber, MM | 1 |
| McCulloch, PB | 1 |
| Figueredo, AT | 1 |
| Ehsan, MH | 1 |
| Rosenfeld, JM | 1 |
| Lawton, JO | 1 |
| Kisner, D | 1 |
| Cedermark, BJ | 2 |
| Didolkar, MS | 2 |
| Carter, SK | 2 |
| Bullen, BR | 1 |
| Brown, GJ | 1 |
| Souchon, EA | 1 |
| Watson, P | 1 |
| Dudrick, SJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 2 |
| Wilson, WL | 1 |
| Davis, HL | 3 |
| Grage, T | 1 |
| Fletcher, WS | 4 |
| Golomb, FM | 1 |
| Cruz, AB | 2 |
| Grage, TD | 1 |
| Metter, GE | 2 |
| Strawitz, JG | 1 |
| Gormican, A | 1 |
| Nystrom, JS | 2 |
| Falk, RE | 2 |
| MacGregor, AB | 2 |
| Ambus, U | 2 |
| Landi, S | 2 |
| Miller, AB | 1 |
| Samuel, ES | 1 |
| Langer, B | 2 |
| Kaufman, JH | 1 |
| Viola, MV | 1 |
| Bixenman, WW | 1 |
| Nicholls, JV | 1 |
| Warwick, OH | 1 |
| Malahy, MA | 1 |
| Jubert, A | 1 |
| Posey, LE | 1 |
| Morgan, LR | 2 |
| Greenwald, ES | 2 |
| Ross, ST | 1 |
| von Eyben, FE | 1 |
| Larsen, V | 3 |
| Pedersen, H | 3 |
| Kisner, DF | 1 |
| Smythe, T | 1 |
| Smith, L | 1 |
| Almersjö, O | 5 |
| Hansen, RM | 5 |
| Stein, RS | 1 |
| Fischerman, K | 1 |
| Petersen, CF | 1 |
| Jensen, SL | 1 |
| Christensen, KC | 1 |
| Efsen, F | 1 |
| Blumenshein, G | 1 |
| Welch, CE | 1 |
| Mosher, MB | 1 |
| Hallauer, WC | 1 |
| Silverstein, MJ | 1 |
| Rangel, D | 1 |
| Passaro, E | 1 |
| Horsley, S | 1 |
| Donaldson, M | 1 |
| Lovett, WL | 1 |
| Ruffner, BW | 1 |
| Regelson, W | 1 |
| Ansell, BF | 1 |
| Steel, GG | 1 |
| Roseti, A | 1 |
| Pajak, TL | 1 |
| Tropé, C | 1 |
| Dencker, H | 1 |
| Seifert, P | 1 |
| Baker, LH | 1 |
| Reed, ML | 2 |
| Vongtama, V | 1 |
| Moore, RH | 1 |
| Holyoke, ED | 2 |
| Webster, JH | 1 |
| Pitman, SW | 1 |
| Samuels, MS | 1 |
| Thomas, W | 1 |
| Krementz, ET | 1 |
| Meeker, W | 1 |
| Reed, RC | 1 |
| Schulman, S | 1 |
| Thorp, GW | 1 |
| Rosenberg, IH | 1 |
| Nitter, L | 1 |
| Yamada, K | 2 |
| Nichols, M | 1 |
| Vyas, AC | 1 |
| Hamilin, R | 1 |
| Ohtsubo, T | 1 |
| Fujieda, S | 1 |
| Kovach, JS | 1 |
| Svingen, PA | 1 |
| Schaid, DJ | 1 |
| Smith, FW | 1 |
| Heys, SD | 1 |
| Evans, NT | 1 |
| Roeda, D | 1 |
| Gvozdanovic, D | 1 |
| Eremin, O | 1 |
| Mallard, JR | 1 |
| Gyergyay, F | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Rivoire, M | 1 |
| Iigo, M | 7 |
| Nishikata, K | 2 |
| Hoshi, A | 3 |
| Daemen, T | 1 |
| Regts, J | 1 |
| Morselt, H | 1 |
| Scherphof, GL | 1 |
| Pyrhönen, SO | 1 |
| Kouri, MO | 1 |
| Williams, LG | 5 |
| Loftin, SK | 1 |
| Dayan, A | 1 |
| Jolivet, J | 2 |
| Kawamura, H | 1 |
| Maesawa, C | 1 |
| Takiyama, I | 1 |
| Yoshinari, H | 1 |
| Koeda, K | 1 |
| Arima, S | 2 |
| Ohsato, K | 2 |
| Ohkuma, R | 2 |
| Fukuyama, N | 1 |
| Yamanouchi, A | 1 |
| Bugnon, PY | 1 |
| Elhage, A | 1 |
| Bounoua, F | 1 |
| Gautier-Benoît, C | 1 |
| Berruti, A | 1 |
| Gorzegno, G | 1 |
| Vitetta, G | 1 |
| Yateman, NA | 1 |
| Skene, AM | 1 |
| Wilmanns, C | 1 |
| Fan, D | 2 |
| Bucana, CD | 1 |
| Fidler, IJ | 3 |
| Madden, M | 1 |
| Werner, ID | 1 |
| Geddes, C | 1 |
| Lim Kok Hooi, A | 1 |
| Ebina, T | 1 |
| Alberto, P | 3 |
| Kubota, Y | 1 |
| Ooya, M | 1 |
| Shinozaki, M | 1 |
| Uchiyama, M | 1 |
| Sakaguchi, M | 1 |
| Hasegawa, E | 1 |
| Ohmura, G | 1 |
| Hirakawa, S | 1 |
| Momose, K | 1 |
| Faderan, MA | 1 |
| Cloos, J | 2 |
| Hoffman, M | 1 |
| Wiegand, RA | 1 |
| Lentz, SK | 1 |
| Platz, D | 1 |
| Braumann, D | 1 |
| Buggisch, P | 1 |
| Schmiegel, WH | 1 |
| Drescher, S | 1 |
| Müllerleile, U | 1 |
| Crone-Münzebrock, W | 1 |
| Hoffman, R | 1 |
| Hiddemann, W | 1 |
| Knipp, H | 1 |
| Bodenstein, H | 1 |
| Lohrmann, HP | 1 |
| Preiss, J | 2 |
| Bernhard, H | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Boarman, D | 2 |
| Balis, FM | 1 |
| Murphy, RF | 1 |
| Richter, EI | 1 |
| Schultheis, KH | 1 |
| Gebhardt, C | 1 |
| Wurzer, W | 1 |
| Hirano, T | 1 |
| Nakagoe, T | 1 |
| Kusano, H | 2 |
| Ifuku, M | 1 |
| Doden, K | 1 |
| Gray, BN | 2 |
| Anderson, JE | 1 |
| Burton, MA | 1 |
| Codde, J | 1 |
| Morgan, C | 1 |
| Klemp, P | 1 |
| Schmittgen, TD | 1 |
| Koolemans-Beynen, A | 1 |
| Webb, TE | 1 |
| Rosol, TJ | 1 |
| Bennamoun, M | 1 |
| Demuynck, B | 1 |
| Cady, J | 1 |
| Delfau, S | 1 |
| Grangé, JD | 1 |
| Chazouillères, O | 1 |
| Zylberait, D | 1 |
| Zhen, YS | 1 |
| Taniki, T | 1 |
| Weber, G | 2 |
| Sinnige, HA | 1 |
| Wajima, T | 1 |
| Mukhopadhyay, P | 1 |
| Fujikawa, T | 1 |
| Tanabe, A | 1 |
| Sakurai, K | 1 |
| Warlters, A | 1 |
| Cameron-Strange, A | 1 |
| Lynch, W | 1 |
| Utsunomiya, J | 2 |
| Fukuda, I | 1 |
| Van Ginckel, R | 1 |
| Distelmans, W | 1 |
| De Brabander, M | 1 |
| Callens, M | 1 |
| Janssens, B | 1 |
| Jagers, E | 1 |
| Wouters, L | 1 |
| De Coster, R | 1 |
| Janssen, PA | 1 |
| Ueo, H | 1 |
| Hook, CC | 1 |
| Scheithauer, BW | 1 |
| Forsyth, PA | 1 |
| Rodriguez, M | 1 |
| Hughes, LL | 1 |
| Luengas, J | 1 |
| Trepel, J | 1 |
| Berlion, M | 1 |
| Berille, J | 1 |
| Gioanni, J | 1 |
| Bizzari, JP | 1 |
| Altermatt, HJ | 1 |
| Gebbers, JO | 1 |
| Laissue, JA | 1 |
| Wersto, R | 1 |
| Weinberg, V | 1 |
| Thompson, D | 1 |
| Jamis-Dow, CA | 1 |
| Yeh, GC | 1 |
| Laurensse, EJ | 5 |
| Kröger, N | 1 |
| Frenzel, H | 1 |
| Anderson, JH | 1 |
| Setanoians, A | 1 |
| Cooke, TG | 1 |
| Fleischer, AB | 1 |
| Rosenthal, DI | 1 |
| Bernard, SA | 1 |
| O'Keefe, EJ | 1 |
| Stetson, PL | 1 |
| Kraal, I | 1 |
| Keller, F | 1 |
| Gallkowski, U | 1 |
| Boese-Landgraf, J | 1 |
| Sakamoto, S | 1 |
| Kudo, H | 1 |
| Kuwa, K | 1 |
| Kasahara, N | 1 |
| Okamoto, R | 1 |
| Marinelli, A | 1 |
| Nozue, M | 1 |
| Todoroki, T | 1 |
| Fukuda, S | 1 |
| Iwasaki, Y | 1 |
| Stringer, I | 1 |
| Miyamoto, T | 1 |
| Mochinaga, N | 1 |
| Tsunoda, T | 1 |
| Maas, IW | 1 |
| Boven, E | 1 |
| Schlüper, HM | 1 |
| Haisma, HJ | 1 |
| Scanlon, KL | 1 |
| Jordá, E | 1 |
| Galan, A | 1 |
| Betlloch, I | 1 |
| Ramon, D | 1 |
| Revert, A | 1 |
| Torres, V | 1 |
| Pignon, JP | 1 |
| Tigaud, JM | 1 |
| Lumbroso, J | 3 |
| Ruffie, P | 1 |
| Lasser, PH | 1 |
| Ridolfi, R | 1 |
| Amaducci, L | 1 |
| Derni, S | 1 |
| Fabbri, L | 1 |
| Innocenti, MP | 1 |
| Vignutelli, P | 1 |
| Panis, Y | 1 |
| Puts, JP | 1 |
| Herve, JP | 1 |
| Delelo, R | 1 |
| Ballet, F | 1 |
| Pflüger, KH | 1 |
| Havemann, K | 1 |
| Konovalova, NP | 1 |
| Diatchkovskaya, RF | 1 |
| Ganieva, LKh | 1 |
| Volkova, LM | 1 |
| Lapshin, IM | 1 |
| Shapiro, AB | 1 |
| Jinushi, K | 3 |
| Sawamura, A | 1 |
| Aogi, K | 1 |
| Crown, J | 1 |
| Jakubowski, A | 1 |
| Gordon, M | 1 |
| Gasparetto, C | 1 |
| Sheridan, C | 1 |
| Toner, G | 1 |
| Meisenberg, B | 1 |
| Botet, J | 2 |
| Kuramoto, S | 1 |
| Ihara, O | 1 |
| Oohara, T | 1 |
| Atabek, U | 1 |
| Port, RE | 2 |
| Daniel, B | 1 |
| Ding, RW | 1 |
| Tetsuya, T | 1 |
| Tetsuro, K | 1 |
| Hiroshi, Y | 1 |
| Touru, T | 1 |
| Toshiharu, F | 1 |
| Suguru, K | 1 |
| Susumu, K | 1 |
| Kyuya, I | 1 |
| Osahiko, A | 1 |
| Hirokazu, Y | 1 |
| Josui, K | 1 |
| Arisawa, Y | 2 |
| Suto, A | 2 |
| Satta, T | 1 |
| Isobe, K | 1 |
| Nakashima, I | 1 |
| Itou, K | 1 |
| Sakanoue, Y | 1 |
| Shoji, Y | 1 |
| Motwani, BT | 1 |
| Kornowski, A | 2 |
| Muleris, M | 1 |
| Barbat, A | 2 |
| Dutrillaux, B | 1 |
| Augeron, C | 1 |
| Laboisse, C | 1 |
| Taiana, A | 1 |
| Liberati, A | 1 |
| Clarke, M | 1 |
| Agrez, MV | 1 |
| Chua, FK | 1 |
| Fagan, K | 1 |
| Heath, JW | 1 |
| Ferguson, NW | 1 |
| Cathcart-Rake, WF | 1 |
| Mowery, WE | 1 |
| Skillings, JR | 1 |
| Levine, M | 1 |
| Rayner, HL | 1 |
| Eisenhauer, E | 1 |
| Kerr, I | 1 |
| Lofters, W | 1 |
| Smalley, SR | 1 |
| Kimler, BF | 1 |
| Evans, RG | 1 |
| Bagshawe, KD | 1 |
| Sharma, K | 1 |
| Southall, PJ | 1 |
| Boden, JA | 1 |
| Boxer, GM | 1 |
| Patridge, TA | 1 |
| Antoniw, P | 1 |
| Pedley, RB | 1 |
| Newman, EM | 1 |
| Mutch, RS | 1 |
| Hutson, PR | 1 |
| Arancia, G | 2 |
| Malorni, W | 2 |
| Greco, C | 2 |
| Fonte, CE | 1 |
| Cardello, F | 1 |
| Schöber, C | 1 |
| Poliwoda, H | 1 |
| Gorbunova, VA | 1 |
| Shatikhin, VA | 1 |
| Kusuyama, T | 3 |
| Okuyama, Y | 1 |
| Landy, D | 1 |
| Jaffe, G | 1 |
| Pascal, R | 1 |
| Fukuzumi, S | 1 |
| Makuuchi, M | 1 |
| Terui, S | 1 |
| Yoshikawa, K | 2 |
| Amemiya, A | 1 |
| Emoto, T | 1 |
| Itou, A | 1 |
| Tsujimura, T | 1 |
| Suga, T | 1 |
| Asai, T | 1 |
| Sawaguchi, K | 1 |
| Kusama, K | 1 |
| Nakajima, A | 1 |
| Eiraku, H | 1 |
| Serizawa, H | 1 |
| Ebihara, Y | 1 |
| Hirabayashi, N | 1 |
| Kirihara, Y | 2 |
| Takagami, S | 2 |
| Ryuji, K | 1 |
| Yorishima, T | 1 |
| Noso, Y | 1 |
| Szinai, I | 1 |
| Veres, Z | 1 |
| De Clercq, E | 2 |
| Nobile, MT | 4 |
| Nyce, J | 1 |
| Klann, RC | 1 |
| Holbrook, CT | 1 |
| Kido, C | 4 |
| Cheson, BD | 2 |
| Mitsuhashi, J | 1 |
| Hikishima, H | 1 |
| Hayashi, H | 1 |
| Adachi, I | 1 |
| Douden, K | 1 |
| Iwa, T | 2 |
| Bruso, CE | 1 |
| Shewach, DS | 1 |
| Izumi, R | 1 |
| Shimizu, K | 1 |
| Matsui, O | 1 |
| Persson, BG | 1 |
| Ekberg, H | 3 |
| Lundstedt, C | 2 |
| Sznol, M | 1 |
| Cortesi, E | 2 |
| Aschelter, AM | 1 |
| Gioacchini, N | 1 |
| Mazzei, N | 1 |
| Potvin, M | 1 |
| Davies, RJ | 2 |
| Robidoux, A | 1 |
| Cosset, JM | 1 |
| Glass, LL | 1 |
| Chesser, MR | 1 |
| Araki, E | 2 |
| Saito, D | 2 |
| Tajiri, H | 2 |
| Treat, J | 1 |
| Joseph, RR | 1 |
| Gröhn, P | 1 |
| Heinonen, E | 1 |
| Kumpulainen, E | 1 |
| Länsimies, H | 1 |
| Lantto, A | 1 |
| Salmi, R | 1 |
| Pyrhönen, S | 1 |
| Numminen, S | 1 |
| Shouji, I | 1 |
| Terasima, K | 1 |
| Igari, H | 1 |
| Akuzawa, K | 1 |
| Ueki, Y | 1 |
| Cleton, FJ | 1 |
| Welvaart, K | 1 |
| Zwaveling, A | 2 |
| Servis, KL | 1 |
| el-Tahtawy, A | 1 |
| Albright, MJ | 1 |
| Barker, PB | 1 |
| Ring, R | 1 |
| Atkinson, D | 1 |
| Ong, R | 1 |
| King, M | 1 |
| Goodman, PJ | 2 |
| Archer, SG | 1 |
| Laudonio, N | 2 |
| Erba, E | 1 |
| Greenhalgh, DA | 2 |
| Parish, JH | 2 |
| Kerr, HD | 1 |
| Kupchik, HZ | 1 |
| Collins, EA | 1 |
| O'Brien, MJ | 1 |
| McCaffrey, RP | 1 |
| Radparvar, S | 4 |
| Germain, G | 2 |
| Pennington, J | 1 |
| Fabian, CJ | 2 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Misset, B | 1 |
| Escudier, B | 1 |
| Leclercq, B | 1 |
| Rivara, D | 1 |
| Nitenberg, G | 2 |
| Wainer, IW | 2 |
| Jadaud, P | 1 |
| Brunetti, I | 1 |
| Calabresi, P | 2 |
| Goulette, FA | 1 |
| Darnowski, JW | 2 |
| Gorree, GC | 2 |
| Fiorentino, MV | 1 |
| Fornasiero, A | 1 |
| Daniele, O | 1 |
| Ichikawa, S | 1 |
| Nagai, M | 1 |
| Natsumeda, Y | 1 |
| Archer, S | 1 |
| Gray, B | 1 |
| Israel, K | 1 |
| Chapman, D | 1 |
| Minsky, B | 1 |
| Vinciguerra, V | 1 |
| Rosenbluth, R | 1 |
| Bosselli, B | 1 |
| Cochran, C | 1 |
| Leong, L | 3 |
| Margolin, K | 3 |
| Litchfield, T | 1 |
| Akman, S | 2 |
| Carr, B | 2 |
| Bertrand, M | 3 |
| Goldberg, D | 3 |
| Blayney, D | 2 |
| Kato, N | 1 |
| Leith, JT | 1 |
| Leite, DV | 1 |
| Glicksman, AS | 1 |
| Burke, P | 1 |
| Stulc, J | 1 |
| Emrich, LJ | 1 |
| Trave, F | 5 |
| Zakrzewski, SF | 1 |
| Arbuck, SG | 1 |
| Molzahn, E | 1 |
| Freund, U | 1 |
| Gross, D | 1 |
| Colozza, M | 1 |
| Belsanti, V | 1 |
| Mosconi, AM | 1 |
| Fiorucci, S | 1 |
| Gernini, I | 1 |
| Rambotti, P | 1 |
| Mulcahy, RT | 1 |
| Miller, EM | 1 |
| Fischer, PH | 4 |
| Smith, RA | 1 |
| Stubblefield, GC | 1 |
| Reagan, MT | 1 |
| Saitoh, H | 1 |
| Shinohara, Y | 1 |
| Aoki, Y | 1 |
| Takagi, S | 1 |
| Morikawa, K | 2 |
| Denkins, YM | 1 |
| Walker, SM | 1 |
| Romanini, A | 2 |
| Nicolin, A | 2 |
| Smith, DE | 1 |
| Muff, NS | 1 |
| Shetabi, H | 1 |
| Stutz, FH | 1 |
| Eiesland, H | 1 |
| Sinmyo, K | 1 |
| Hosoi, H | 1 |
| Kitagawa, M | 1 |
| Susaki, H | 1 |
| Rios, AA | 1 |
| Ende, K | 1 |
| Abbruzzese, JL | 1 |
| Edwards, C | 1 |
| Faintuch, JS | 1 |
| Saks, S | 1 |
| Gustavsson, BG | 4 |
| Nio, Y | 1 |
| Imai, S | 1 |
| Ohgaki, K | 1 |
| Tobe, T | 1 |
| Morioka, Y | 1 |
| Kusama, S | 1 |
| Kimura, T | 2 |
| Tomiyama, J | 1 |
| Nylen, U | 1 |
| Winblad, G | 1 |
| de Bruijn, EA | 2 |
| van Walsum, M | 1 |
| Ogasawara, H | 1 |
| Itoh, T | 1 |
| Furukohri, N | 1 |
| Tsushima, K | 1 |
| Munakata, A | 1 |
| Zanea-Wangler, E | 1 |
| Kesseler, J | 1 |
| Ploss, HJ | 1 |
| Ohkawa, T | 1 |
| Scanlon, KJ | 1 |
| Kashani-Sabet, M | 1 |
| Sowers, LC | 1 |
| Soga, K | 1 |
| Turuya, T | 1 |
| Toshima, M | 1 |
| Shibasaki, K | 1 |
| Matugi, H | 1 |
| Kawai, C | 1 |
| Asakura, H | 1 |
| Cohen, MB | 1 |
| Marquet, RL | 1 |
| Jeekel, J | 1 |
| Ernstoff, MS | 1 |
| Kirkwood, JM | 1 |
| Hazelton, BJ | 1 |
| Pezzuoli, G | 1 |
| Marubini, E | 1 |
| Boracchi, P | 1 |
| Cocconi, G | 1 |
| Cunsolo, A | 1 |
| Garcea, D | 1 |
| Germiniani, R | 1 |
| Strauss, LG | 1 |
| Clorius, JH | 1 |
| Nunziata, C | 1 |
| Ricci, F | 1 |
| Cucchiara, G | 1 |
| Picconi, A | 1 |
| Bonmassar, G | 1 |
| Lagomarsino Caprino, M | 1 |
| Blöchl, H | 1 |
| Schröder, U | 1 |
| Osieka, R | 1 |
| Glatte, P | 1 |
| Marx, JL | 1 |
| Atassi, G | 3 |
| Rembiesa, BM | 1 |
| Sahovic, E | 1 |
| Stuart, R | 1 |
| Nadal, JC | 3 |
| Smigel, K | 1 |
| Kern, K | 1 |
| Lack, E | 1 |
| Ralston, M | 1 |
| Penny, R | 1 |
| Hayes, J | 1 |
| San Martín, S | 1 |
| Oddó, D | 1 |
| Paredes, H | 1 |
| Arraztoa, J | 1 |
| Ahlgren, JD | 1 |
| Gullo, JJ | 1 |
| Philips, JA | 1 |
| Fryer, JG | 1 |
| Buroker, TR | 1 |
| Marschke, RF | 1 |
| Ridge, JA | 2 |
| Stephens, FO | 1 |
| Crea, P | 1 |
| Walker, PJ | 1 |
| Ottery, FD | 1 |
| Scupham, RK | 1 |
| Weese, JL | 1 |
| Woodhouse, L | 2 |
| Holl, E | 1 |
| Zänker, KS | 1 |
| Lange, J | 1 |
| Malet-Martino, MC | 1 |
| Faure, F | 1 |
| Vialaneix, JP | 1 |
| Palevody, C | 1 |
| Hollande, E | 1 |
| Martino, R | 1 |
| van Dijk, J | 2 |
| van Groeningen, C | 1 |
| Leyva, A | 2 |
| Lankelma, J | 3 |
| Flentje, M | 1 |
| Canobbio, L | 3 |
| Mouroux, J | 1 |
| Deixonne, B | 1 |
| Eledjam, JJ | 1 |
| Baumel, H | 1 |
| Inaba, H | 1 |
| Monk, MR | 1 |
| Sanchez, JD | 1 |
| Phelps, CD | 1 |
| Miller, DM | 1 |
| Sidibe, S | 1 |
| Valone, FH | 2 |
| Kohler, M | 1 |
| Fisher, K | 1 |
| Hannigan, J | 2 |
| Flam, M | 1 |
| Gandara, D | 1 |
| Hendrickson, C | 1 |
| Richman, E | 1 |
| Yu, KP | 1 |
| Reichman, B | 1 |
| Geller, N | 1 |
| Hollander, P | 1 |
| Schroy, PC | 1 |
| Winawer, SJ | 1 |
| Friedman, EA | 1 |
| Mermillod, B | 2 |
| Germano, G | 1 |
| Kaplan, S | 1 |
| Weber, W | 1 |
| Spati, B | 1 |
| Martz, G | 1 |
| Choong, YS | 1 |
| Lee, SP | 1 |
| Alley, PA | 1 |
| Koks, CH | 1 |
| Brouwers, JR | 1 |
| Sleijfer, DT | 1 |
| Peschau, K | 1 |
| Warthona, M | 1 |
| Berne, M | 3 |
| Spears, P | 1 |
| Sundström, E | 1 |
| Margreiter, R | 1 |
| Schmid, T | 1 |
| Steiner, E | 1 |
| Aigner, F | 1 |
| Then, P | 1 |
| Pernthaler, H | 1 |
| Fosså, SD | 3 |
| Hoel, R | 1 |
| Heier, M | 1 |
| Loeb, M | 1 |
| Marymont, JV | 1 |
| Travers, H | 1 |
| Housholder, DF | 1 |
| Schwartz, PM | 1 |
| Moir, RD | 1 |
| Hyde, CM | 1 |
| Turek, PJ | 1 |
| Claghorn, L | 1 |
| Weiss, KD | 1 |
| Torrance, PM | 3 |
| Order, SE | 1 |
| Klein, JL | 1 |
| Leichner, PK | 1 |
| Ettinger, DS | 1 |
| Kopher, K | 1 |
| Finney, K | 1 |
| Surdyke, M | 1 |
| Leibel, SA | 1 |
| Imajo, K | 1 |
| Mukaiyama, T | 1 |
| Miyaoka, K | 1 |
| Friedrich, M | 1 |
| Berger, T | 1 |
| Böse-Landgraf, J | 1 |
| La Ciura, P | 1 |
| La Grotta, G | 1 |
| Nigra, E | 1 |
| Grecchi, G | 1 |
| Leria, G | 1 |
| Calciati, A | 1 |
| Bolton, JS | 1 |
| Sauter, ER | 1 |
| Wittlinger, PS | 1 |
| Flam, MS | 1 |
| Drakes, T | 1 |
| Eisenberg, PD | 1 |
| Schaeffer, N | 1 |
| Higgins, J | 1 |
| Qazi, R | 1 |
| Rubins, J | 1 |
| Asbury, R | 1 |
| Konno, K | 1 |
| Nakai, Y | 1 |
| Koie, H | 1 |
| Masuda, H | 3 |
| Terabe, K | 1 |
| Bjerkeset, T | 1 |
| Fjøsne, HE | 1 |
| Chapman, J | 1 |
| Enochs, K | 1 |
| Groshko, G | 1 |
| Rocchio, R | 1 |
| Futami, K | 1 |
| Shigeta, M | 1 |
| Kinashi, M | 1 |
| Shimura, H | 1 |
| Claycomb, CL | 1 |
| Berkovic, M | 1 |
| Inokuchi, K | 2 |
| Anai, H | 3 |
| Kusumoto, H | 3 |
| Orikasa, H | 1 |
| Usugane, M | 1 |
| Metzger, U | 2 |
| Aeberhard, P | 1 |
| Gloor, F | 1 |
| Bissat, A | 1 |
| Egeli, R | 1 |
| Martinoli, S | 1 |
| Mueller, W | 1 |
| Schroeder, R | 1 |
| Rieck, B | 1 |
| Grace, RH | 1 |
| Scott, KW | 1 |
| Ikeda, Y | 1 |
| Kiuchi, T | 1 |
| Fukuzumi, N | 1 |
| Kaga, F | 1 |
| Sakata, A | 1 |
| Kusumoto, T | 2 |
| Miyamoto, K | 1 |
| Fukuchi, K | 1 |
| Kairaluoma, MI | 1 |
| Leinonen, A | 1 |
| Niemelä, R | 1 |
| Kiviniemi, H | 1 |
| Siniluoto, T | 1 |
| Ståhlberg, M | 1 |
| Calabet, J | 1 |
| Andersen, E | 1 |
| Weder, W | 1 |
| Roethlin, M | 1 |
| Largiadèr, F | 1 |
| Saeki, T | 1 |
| Niimi, K | 1 |
| Kim, R | 1 |
| Nitta, A | 1 |
| Saitou, T | 1 |
| Gerard, A | 4 |
| Fuchimoto, S | 1 |
| Shiiki, S | 1 |
| Kaufman, SD | 1 |
| Wood, WC | 1 |
| Manzotti, C | 2 |
| Damia, G | 1 |
| Cantwell, BM | 1 |
| Harris, AL | 1 |
| Bernstein, L | 1 |
| Hayes, AA | 1 |
| Iosi, F | 1 |
| Reddy, E | 1 |
| Jewell, W | 1 |
| Trowbridge, AA | 1 |
| McCracken, D | 1 |
| Yoshimori, M | 1 |
| Ookura, H | 1 |
| Okazaki, N | 1 |
| Schwarz, V | 1 |
| Hines, JD | 1 |
| Zakem, MH | 1 |
| Adelstein, DJ | 1 |
| Mortimer, JE | 1 |
| Higano, C | 1 |
| Bartolucci, R | 1 |
| Padalino, D | 1 |
| Brugia, M | 1 |
| Frank, C | 1 |
| deGraaf, SS | 1 |
| Rodman, JR | 1 |
| Glass, A | 1 |
| Lerner, H | 1 |
| Stevens, L | 1 |
| Datena, S | 1 |
| Graffis, R | 1 |
| Elhakim, T | 1 |
| Turner, S | 1 |
| Kubilis, P | 1 |
| Hui, S | 1 |
| Ansari, R | 1 |
| Stephens, D | 1 |
| Woodburn, R | 1 |
| Panettiere, FJ | 1 |
| Costanzi, JJ | 1 |
| Brownlee, RW | 1 |
| Laufman, L | 1 |
| Stephens, RL | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Banerjee, TK | 1 |
| Zaentz, SD | 1 |
| Schiferl, EA | 1 |
| Ousley, JL | 1 |
| Pogodzinski, AE | 1 |
| Trump, DL | 1 |
| Mackintosh, J | 2 |
| Coates, A | 1 |
| Thomas, PR | 1 |
| Stablein, DM | 1 |
| Steinberg, SM | 1 |
| Barkin, JS | 1 |
| Shaw, D | 1 |
| Boublil, JL | 2 |
| Khater, R | 2 |
| Frenay, M | 1 |
| Thyss, A | 2 |
| Bourry, J | 2 |
| Philip, C | 2 |
| Renée, N | 2 |
| Bruneton, JN | 2 |
| Belliveau, JF | 1 |
| Weitberg, AB | 1 |
| Sabbath, K | 1 |
| Wiemann, MC | 1 |
| Cummings, FJ | 1 |
| Hryniuk, WM | 1 |
| Goodyear, M | 1 |
| Hoth, DF | 1 |
| King, SA | 1 |
| Miller, RL | 1 |
| Andresen, S | 1 |
| Gahbauer, R | 1 |
| Domergue, J | 1 |
| Ismail, M | 1 |
| Astre, C | 1 |
| Saint-Aubert, B | 1 |
| Joyeux, H | 1 |
| Solassol, C | 1 |
| Pujol, H | 1 |
| de Brauw, LM | 1 |
| van de Velde, CJ | 1 |
| Tjaden, UR | 1 |
| Bell, AV | 1 |
| Miyata, T | 1 |
| Saeki, K | 1 |
| Torisu, M | 1 |
| Shimoyama, T | 1 |
| Makiyama, T | 1 |
| Kawaguchi, A | 1 |
| Kajiwara, K | 1 |
| Mine, Y | 1 |
| Persson, B | 1 |
| Nilsson, LG | 1 |
| Gustafson, T | 1 |
| Andersson, KE | 1 |
| Laurensse, E | 1 |
| Goldberg, JA | 2 |
| Willmott, N | 1 |
| McKillop, JH | 1 |
| Gianni, L | 1 |
| Zunino, F | 1 |
| Silberman, H | 1 |
| Hamazoe, R | 2 |
| Sawata, T | 1 |
| Jakubowski, AA | 1 |
| Lieberman, DP | 1 |
| Dalesio, O | 2 |
| Delvaux, G | 2 |
| Willems, G | 2 |
| Depadt, G | 1 |
| Gilbert, J | 1 |
| Kuzuoka, M | 1 |
| Takabayashi, T | 1 |
| Chia, KB | 1 |
| Chua, EJ | 1 |
| Khor, TH | 1 |
| Tan, BC | 1 |
| Tan, TM | 1 |
| Durrant, LG | 1 |
| Garnett, MC | 1 |
| Armitage, NC | 1 |
| Ballantyne, KC | 1 |
| Marksman, RA | 1 |
| Hardcastle, JD | 1 |
| Baldwin, RW | 1 |
| Pagana, TJ | 1 |
| Bresadola, F | 1 |
| Virdis, A | 1 |
| Spissu, M | 1 |
| Soro, P | 1 |
| Masia, S | 1 |
| Trignano, M | 1 |
| Ginman, C | 1 |
| Graffman, S | 1 |
| Ståhle, E | 1 |
| Blayney, DW | 1 |
| Cecchi, G | 1 |
| Ritch, PS | 2 |
| Anderson, T | 2 |
| Quebbeman, EJ | 1 |
| Frick, J | 1 |
| Krzeczowski, KA | 1 |
| Roach, R | 1 |
| Segal, M | 1 |
| Shoemaker, DD | 1 |
| Garufi, C | 1 |
| Cavallaro, A | 1 |
| Netri, G | 1 |
| Rossi, S | 1 |
| Cassano, A | 1 |
| Noviello, MR | 1 |
| Wanderås, EH | 1 |
| Flokkmann, A | 1 |
| Newman, E | 1 |
| Chollet, P | 3 |
| Metzger, G | 2 |
| Zittoun, J | 2 |
| Benavides, M | 1 |
| Marquet, J | 2 |
| Vandenbulcke, JM | 2 |
| Zekan, P | 1 |
| Cruz, J | 1 |
| Stuart, JJ | 1 |
| Fourtillan, JB | 1 |
| Gianola, FJ | 6 |
| Barofsky, I | 4 |
| Hancock, SL | 1 |
| Wesley, R | 3 |
| Satou, H | 1 |
| Kamano, T | 1 |
| Izumi, T | 1 |
| Yoshida, M | 1 |
| Irvin, T | 1 |
| Vowles, KD | 1 |
| Golby, MG | 1 |
| Budd, GT | 1 |
| O'Bryan, RM | 1 |
| Balcerzak, SP | 1 |
| Sertoli, MR | 2 |
| Guarneri, D | 1 |
| Rubagotti, A | 2 |
| Porcile, G | 1 |
| Hart, RD | 1 |
| Taylor, RF | 1 |
| Harvey, JH | 1 |
| Gayral, F | 1 |
| Edouard, D | 1 |
| Dinh, A | 1 |
| Paoli, D | 1 |
| Larrieu, H | 1 |
| Hunt, TM | 1 |
| Neijt, JP | 1 |
| Veenhof, CH | 1 |
| Clark, PI | 2 |
| Reznek, RH | 1 |
| Cedermark, B | 1 |
| Fallenius, A | 1 |
| Ohman, U | 1 |
| Burger, AJ | 1 |
| Mannino, S | 1 |
| Schaaf, LJ | 1 |
| Dobbs, BR | 1 |
| Edwards, IR | 1 |
| Perrier, DG | 1 |
| Lelcuk, S | 1 |
| Klausner, JM | 1 |
| Inbar, M | 1 |
| Kaplan, O | 1 |
| Merhav, A | 1 |
| Rozin, RR | 1 |
| Ozawa, H | 1 |
| Wicks, LJ | 1 |
| Galligioni, E | 1 |
| Figoli, F | 1 |
| Fassio, T | 1 |
| Frustaci, S | 1 |
| Crivellari, D | 1 |
| Vaccher, E | 1 |
| Lo Re, G | 1 |
| Gasparini, G | 1 |
| Veronesi, A | 1 |
| Feil, H | 1 |
| Ruoff, G | 1 |
| Hölting, T | 1 |
| Buhl, K | 1 |
| Nakatsu, T | 1 |
| Furue, H | 2 |
| Waldenström, J | 1 |
| Sigurdson, ER | 1 |
| Honda, H | 1 |
| Agishi, T | 1 |
| Nakazawa, H | 1 |
| Teraoka, S | 1 |
| Fuchinoue, S | 1 |
| Nakagawa, Y | 1 |
| Dy, C | 1 |
| Algarra, SM | 1 |
| Aparicio, LA | 1 |
| Calvo, F | 1 |
| Herranz, P | 1 |
| Berne, MH | 1 |
| Spears, PC | 1 |
| Thirlwell, MP | 1 |
| Hollingsworth, LM | 1 |
| Herba, MJ | 1 |
| Boileau, G | 2 |
| Boos, G | 1 |
| MacFarlane, JK | 1 |
| Okutani, T | 1 |
| Ukawa, K | 1 |
| Nomura, H | 1 |
| Ootsu, K | 1 |
| Kozai, Y | 1 |
| Kurihara, H | 1 |
| Hanff, G | 1 |
| Ranstam, J | 1 |
| Garewal, H | 2 |
| Planting, A | 1 |
| Hillen, H | 1 |
| Papaioannou, AN | 1 |
| Polychronis, AP | 1 |
| Kozonis, JA | 1 |
| Nomicos, J | 1 |
| Tsamouri, M | 1 |
| Plataniotis, GA | 1 |
| Papageorgiou, JK | 1 |
| White, DE | 1 |
| Meyers, CE | 2 |
| Büyükünal, E | 1 |
| Berkarda, N | 1 |
| Serdengeçti, S | 1 |
| Derman, U | 1 |
| Berkarda, B | 1 |
| Zambruni, A | 1 |
| Marpicati, P | 1 |
| Gorni, F | 1 |
| Simoncini, E | 1 |
| Ragni, F | 1 |
| Bardakji, Z | 1 |
| Langelier, Y | 1 |
| Besner, JG | 1 |
| Ayoub, J | 1 |
| Kuruvilla, AM | 1 |
| Choi, K | 1 |
| Bhutiani, I | 1 |
| Aziz, H | 1 |
| Rosenthal, J | 1 |
| Braverman, A | 1 |
| Marti, J | 1 |
| Brandys, M | 1 |
| Camacho, FJ | 1 |
| Green, MD | 1 |
| Clark, JL | 1 |
| Berger, SH | 1 |
| Asbury, RF | 1 |
| Boros, L | 1 |
| Brower, M | 1 |
| Chang, A | 1 |
| Bennett, J | 1 |
| Caruso, U | 1 |
| Elli, M | 1 |
| Cravotto, E | 1 |
| Tisone, G | 1 |
| Lombardo, PA | 1 |
| Silvaroli, M | 1 |
| Casciani, CU | 1 |
| Vanden-Bulcke, JM | 1 |
| Rudenstam, CM | 1 |
| Domellöf, L | 1 |
| Machin, D | 1 |
| Mullee, M | 1 |
| Trotter, G | 1 |
| Cooke, T | 1 |
| Adson, MA | 1 |
| Ilstrup, DM | 1 |
| Speyer, JC | 1 |
| Itoh, I | 1 |
| Jewell, LD | 1 |
| Murray, CJ | 1 |
| Thomson, AB | 1 |
| Abe, F | 1 |
| Shibuya, K | 1 |
| Ashizawa, J | 1 |
| Horinishi, H | 1 |
| Ishizuka, M | 1 |
| Umezawa, H | 1 |
| Higuchi, M | 1 |
| Sako, T | 1 |
| Koyama, K | 1 |
| Weber-Stadelmann, W | 1 |
| Kinami, Y | 2 |
| Arizuka, S | 1 |
| Ashida, Y | 1 |
| Quebbeman, E | 1 |
| Ausman, R | 1 |
| Becker, T | 1 |
| Caballero, G | 1 |
| Ritch, P | 1 |
| Jenkins, D | 1 |
| Blake, D | 1 |
| Tangen, L | 1 |
| Schulte, W | 1 |
| Zimmerman, RJ | 1 |
| VanWinkle, TJ | 1 |
| Mantel, N | 1 |
| Goller, DA | 1 |
| Weidema, WF | 1 |
| Greenberg, BR | 1 |
| Mancuso, L | 1 |
| Bondì, F | 1 |
| Marchì, S | 1 |
| Iacona, MA | 1 |
| Di Gregorio, L | 1 |
| Klecker, RW | 1 |
| Zorzitto, ML | 1 |
| Myers, R | 1 |
| Bazos, MJ | 1 |
| Shepherd, FA | 1 |
| Evans, WK | 1 |
| Kiriyama, M | 1 |
| Tomita, F | 1 |
| Ardizzoni, A | 1 |
| Tatarek, R | 1 |
| Weatherall, TJ | 1 |
| Oishi, N | 1 |
| Janaki, L | 1 |
| Boyer, C | 1 |
| Pelikán, A | 1 |
| Kawaura, Y | 1 |
| Ohmura, K | 1 |
| Hashizume, Y | 1 |
| Takayama, K | 1 |
| Sakatoku, M | 1 |
| Hirano, M | 1 |
| August, DA | 1 |
| Ottow, RT | 1 |
| Schneider, PD | 1 |
| Goldberg, DA | 1 |
| Miner, PJ | 1 |
| Lynch, G | 1 |
| Chun, H | 1 |
| Young, C | 1 |
| Ellison, NM | 1 |
| Servi, RJ | 1 |
| Dias Wickramanayake, P | 1 |
| Klein, HO | 1 |
| Pape, S | 1 |
| Meyer-Hofmann, H | 1 |
| Fischer, HP | 1 |
| Kaalhus, O | 1 |
| Whitley, NO | 1 |
| Keramati, B | 1 |
| Jackson, AJ | 1 |
| Hebel, RJ | 1 |
| Jordan, TE | 1 |
| Kanojia, MD | 1 |
| Korinek, JK | 1 |
| Stein, SH | 1 |
| Espinoza, EG | 1 |
| Chiuten, DF | 2 |
| Panasci, L | 1 |
| Ford, J | 1 |
| Margolese, R | 1 |
| Shepard, KV | 1 |
| Faintuch, J | 1 |
| Sweet, DL | 1 |
| Robin, E | 1 |
| Kok, RM | 1 |
| de Jong, AP | 1 |
| Einhorn, LH | 1 |
| Williams, SD | 1 |
| Hui, SL | 1 |
| Pennington, K | 1 |
| Bruzzone, M | 1 |
| Tagarelli, G | 1 |
| Benvenuto, JA | 1 |
| Gottlieb, JA | 2 |
| Luce, JK | 1 |
| Massey, WH | 2 |
| Judkins, MP | 1 |
| Dennis, DL | 2 |
| Dwight, RW | 1 |
| Smith, JV | 1 |
| Knock, FE | 1 |
| Galt, RM | 1 |
| Oester, YT | 1 |
| Sylvester, R | 1 |
| Leone, LA | 1 |
| Leissner, KH | 1 |
| Rosengren, K | 1 |
| Wedel, N | 1 |
| Pettavel, J | 1 |
| Morgenthaler, F | 1 |
| Mackman, S | 5 |
| Nordman, E | 1 |
| Witte, S | 1 |
| Hindringer, B | 1 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Muller, CJ | 1 |
| Harris, HS | 2 |
| Murray-Lyon, IM | 1 |
| Parsons, VA | 1 |
| Blendis, LM | 1 |
| Dawson, JL | 1 |
| Rake, MO | 1 |
| Laws, JW | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| Meyza, J | 1 |
| Lipton, A | 1 |
| Ratner, LH | 1 |
| Weiner, MJ | 1 |
| Cohen, SM | 1 |
| Greenspan, EM | 1 |
| Krakoff, IH | 1 |
| Cady, B | 1 |
| Bessot, M | 2 |
| Duprez, A | 2 |
| Kühböck, J | 1 |
| Pokorny, D | 1 |
| Steinbach, K | 1 |
| Eggerth, G | 1 |
| Ferguson, E | 1 |
| Obi, LJ | 1 |
| Donaldson, MH | 2 |
| Taylor, P | 1 |
| Rawitscher, R | 1 |
| Sewell, JB | 1 |
| Wood, DC | 1 |
| Ricci, JA | 1 |
| Sanford, RG | 1 |
| Brown, RB | 1 |
| Silvernail, WI | 1 |
| Stehlin, JS | 1 |
| Greeff, PJ | 1 |
| Majima, S | 1 |
| Matsushige, H | 1 |
| Gailani, S | 2 |
| Leone, L | 2 |
| Hacker, CB | 1 |
| Cunningham, TJ | 1 |
| Sponzo, RW | 1 |
| Raventos, A | 1 |
| Pettigrew, RT | 1 |
| Galt, JM | 1 |
| Ludgate, CM | 1 |
| Smith, AN | 1 |
| Andrews, JT | 1 |
| Cox, KR | 1 |
| Hare, WS | 1 |
| McConchie, IH | 1 |
| Carbone, PP | 1 |
| McElwain, TJ | 1 |
| van Eden, EB | 2 |
| Donaldson, GA | 1 |
| Wassif, SB | 1 |
| Holland, JF | 1 |
| Burningham, R | 1 |
| Larsen, RR | 1 |
| Priestman, TJ | 1 |
| Hanham, IW | 1 |
| Lapsa, RKh | 1 |
| Bevan, PG | 1 |
| Van der Merwe, AM | 1 |
| Van Dyk, JJ | 1 |
| Tully, TE | 1 |
| Shafer, RB | 1 |
| Weiss, AJ | 1 |
| Mastrangelo, MJ | 1 |
| Kissel, P | 1 |
| Olson, K | 1 |
| Schwartz, GF | 1 |
| Green, HL | 1 |
| Bendon, ML | 1 |
| Graham, WP | 1 |
| Blakemore, WS | 1 |
| Johnston, GS | 1 |
| Jones, AE | 1 |
| al-Sarraf, M | 1 |
| Vaitkevicious, VK | 1 |
| Blokhina, NG | 1 |
| Vozny, EK | 1 |
| Garin, AM | 1 |
| Ishida, M | 2 |
| From, P | 1 |
| Morrissey, WJ | 1 |
| Sams, J | 1 |
| Lahiri, SR | 1 |
| Freckman, HA | 1 |
| Cole, DR | 4 |
| Conte, AJ | 3 |
| Gonzalez, EM | 3 |
| Rowe-Jones, DC | 1 |
| Rall, DP | 1 |
| Korbitz, BC | 1 |
| Van Way, CW | 1 |
| Reynolds, VH | 1 |
| Rapoport, AH | 1 |
| Burleson, RL | 1 |
| Mansfield, CM | 1 |
| Kramer, S | 1 |
| Southard, ME | 1 |
| Yamada, E | 1 |
| Miyaishi, S | 1 |
| Kuroyanagi, Y | 1 |
| Mitchell, MS | 1 |
| DeConti, RC | 1 |
| Eras, P | 1 |
| Sherlock, P | 1 |
| Wisborg, K | 1 |
| Edwards, AJ | 1 |
| Rowland, GF | 1 |
| Sumner, MR | 1 |
| Hurd, CM | 1 |
| Neubauer, HW | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Pasternack, BS | 1 |
| Henderson, IW | 1 |
| Lipowska, B | 1 |
| Lougheed, MN | 1 |
| Rowe, DS | 1 |
| Benabderrahmane, M | 1 |
| Spratt, JS | 1 |
| Topolnicki, W | 1 |
| Slattery, J | 1 |
| Shook, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours[NCT03256981] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2017-11-27 | Active, not recruiting | ||
| Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression[NCT03808662] | Phase 2 | 107 participants (Actual) | Interventional | 2019-01-16 | Active, not recruiting | ||
| Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial[NCT02756793] | 90 participants (Actual) | Interventional | 2016-10-31 | Active, not recruiting | |||
| TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.[NCT03644303] | 84 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | |||
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma[NCT03775525] | Phase 1 | 127 participants (Anticipated) | Interventional | 2019-03-01 | Active, not recruiting | ||
| Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer[NCT03925662] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma[NCT03068455] | Phase 3 | 1,844 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Observation of MRD Detection for Preoperative Sensitivity and Postoperative Positive Rate in Common Risk Stage II Colorectal Cancer[NCT05795010] | 60 participants (Anticipated) | Observational | 2023-03-30 | Not yet recruiting | |||
| Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients With Locally Advanced Cholangiocarcinoma and Discovery of Biomarkers[NCT05677217] | 100 participants (Anticipated) | Observational | 2023-03-20 | Recruiting | |||
| A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer[NCT01092481] | Phase 3 | 1,580 participants (Actual) | Interventional | 2010-01-26 | Active, not recruiting | ||
| Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab[NCT03368859] | Phase 2 | 70 participants (Actual) | Interventional | 2018-03-20 | Terminated (stopped due to Study may continue) | ||
| Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT01249638] | Phase 3 | 516 participants (Anticipated) | Interventional | 2010-12-31 | Recruiting | ||
| Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer[NCT00275210] | Phase 3 | 2,246 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Randomized Trial Investigating the Role of FOLFOX-4 Regimen Duration (3 Versus 6 Months) and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer[NCT00646607] | Phase 3 | 3,756 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer[NCT00749450] | Phase 3 | 6,088 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| "An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (XELOX) Versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients Who Have Undergone Surgery for Colon Carcinoma, AJCC/UICC[NCT00069121] | Phase 3 | 1,886 participants (Actual) | Interventional | 2003-04-18 | Completed | ||
| A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274] | Phase 3 | 3,397 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer[NCT01308086] | Phase 3 | 2,000 participants (Actual) | Interventional | 2010-10-31 | Active, not recruiting | ||
| A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regime[NCT00112918] | Phase 3 | 3,451 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer[NCT00958737] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2009-05-12 | Active, not recruiting | ||
| A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer[NCT01150045] | Phase 3 | 2,527 participants (Actual) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case[NCT01991873] | Phase 2 | 387 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study[NCT06119347] | 1,581 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen[NCT01882868] | Phase 2 | 62 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment: an Ancillary Study of IDEA France Study[NCT03422601] | 1,122 participants (Actual) | Observational | 2017-07-13 | Active, not recruiting | |||
| Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of [NCT02792842] | Phase 2 | 79 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma[NCT02228668] | 1,636 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620] | 100 participants (Anticipated) | Interventional | 2023-06-20 | Not yet recruiting | |||
| A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278] | Phase 3 | 2,710 participants (Actual) | Interventional | 2004-09-15 | Completed | ||
| PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer[NCT01675999] | Phase 2 | 186 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Association of the C677T and A1298C MTHFR Polymorphisms With Chemotherapy Effectiveness Among Patients With Metastatic Colorectal Cancer[NCT03852290] | 65 participants (Anticipated) | Observational | 2019-01-16 | Active, not recruiting | |||
| A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780] | Phase 3 | 1,072 participants (Actual) | Interventional | 2010-12-02 | Completed | ||
| Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024] | 856 participants (Actual) | Observational | 2005-11-30 | Completed | |||
| An In Depth Study Evaluating Patterns in the Colon Cancer Patients Clinical Trials[NCT05715905] | 500 participants (Anticipated) | Observational | 2024-02-29 | Not yet recruiting | |||
| Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer[NCT00026273] | Phase 3 | 0 participants | Interventional | 2001-01-31 | Completed | ||
| A Pilot, Randomized, Double Blind, Placebo Controlled Study to Evaluate an Immune System Modulator Nutritional Supplement for the Prevention of Infections in Cancer Patients Receiving Oncologic Treatment During the COVID-19 Pandemia.[NCT05080920] | 109 participants (Actual) | Interventional | 2020-10-28 | Completed | |||
| Clinical Study to Evaluate the Effectiveness and Safety of the Consumption of a Food Supplement in a Group of Healthy People[NCT03492086] | 60 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial[NCT00994864] | 235 participants (Actual) | Interventional | 2009-11-30 | Completed | |||
| A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer[NCT01975454] | Phase 1/Phase 2 | 62 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study[NCT03127111] | 300 participants (Anticipated) | Observational | 2022-12-01 | Not yet recruiting | |||
| Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer Patients as Predictive Factors for Systemic Therapy Outcome[NCT04543019] | 50 participants (Anticipated) | Observational | 2020-12-31 | Not yet recruiting | |||
| Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer[NCT00003835] | Phase 3 | 1,260 participants (Anticipated) | Interventional | 1999-05-31 | Completed | ||
| A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT01099449] | Phase 3 | 362 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004] | 40 participants (Actual) | Observational | 2018-01-22 | Completed | |||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684] | Phase 3 | 1,808 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study[NCT04567459] | 100 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | |||
| Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.[NCT03429296] | 120 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity[NCT00316914] | Phase 3 | 104 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.[NCT01972503] | Phase 4 | 300 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi[NCT02355379] | Phase 3 | 774 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)[NCT02256800] | 213 participants (Actual) | Interventional | 2014-08-13 | Completed | |||
| Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan[NCT04223479] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2020-01-15 | Completed | ||
| Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence[NCT00005979] | Phase 3 | 0 participants | Interventional | 1998-07-22 | Completed | ||
| The Effect of ATP-Binding Cassette C2 (ABCC2) Transporter Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin -Based Chemotherapy[NCT05494320] | 120 participants (Anticipated) | Observational | 2021-08-15 | Recruiting | |||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer[NCT00427570] | Phase 3 | 0 participants | Interventional | 1977-09-30 | Completed | ||
| A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon[NCT00427310] | Phase 3 | 1,158 participants (Actual) | Interventional | 1984-03-31 | Completed | ||
| From the Model to the Adaptation of a Therapeutic Education Program in Cancer Research: the Case of Renal Cancer Patients Treated by Oral Treatments, Multidisciplinary Approach[NCT02896790] | 24 participants (Actual) | Observational | 2015-03-09 | Completed | |||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152] | Phase 3 | 2,151 participants (Actual) | Interventional | 1989-07-31 | Completed | ||
| Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer[NCT00002593] | Phase 3 | 1,135 participants (Actual) | Interventional | 1994-12-31 | Completed | ||
| Evaluation of Computed Tomography and Magnetic Diffusion Resonance Imaging in the Preoperative Staging of Colon Cancer[NCT05727007] | 120 participants (Actual) | Interventional | 2019-01-23 | Completed | |||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946] | 46 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| Phase I Study of Gemcitabine With Antiangiogenic Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 Derived From VEGFR2 in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer[NCT00622622] | Phase 1 | 21 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer[NCT00624182] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Suspended | ||
| Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)[NCT02942238] | 582 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | |||
| A Local Feasibility Study on Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Patients Operated Upon Colon Cancer Stage Dukes' C[NCT00671996] | Phase 2 | 14 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer[NCT00497107] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon[NCT00378716] | Phase 3 | 1,608 participants (Actual) | Interventional | 1997-02-28 | Completed | ||
| Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052] | Phase 3 | 240 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors[NCT00001579] | Phase 1 | 50 participants | Interventional | 1997-06-30 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Phase I Trial of Romidepsin Given on Days One, Three, and Five in Patients With Thyroid and Other Advanced Cancers[NCT00048334] | Phase 1 | 28 participants (Actual) | Interventional | 2002-10-26 | Completed | ||
| Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma[NCT01445340] | Phase 1 | 6 participants (Actual) | Interventional | 2007-04-21 | Terminated | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer[NCT02004769] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Leas[NCT00510627] | Phase 4 | 0 participants (Actual) | Interventional | 2007-08-31 | Withdrawn (stopped due to Boston Scientific has decided to close the Study.) | ||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients[NCT01819233] | 38 participants (Actual) | Interventional | 2013-03-08 | Completed | |||
| Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial[NCT00772824] | Phase 4 | 23 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis[NCT00001569] | Phase 1 | 74 participants | Interventional | 1997-01-31 | Completed | ||
| MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171] | 180 participants (Anticipated) | Observational | 2022-10-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates. (NCT03068455)
Timeframe: From randomization to date of death (up to approximately 45 months)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | NA |
| Arm B: Nivo | NA |
OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates. (NCT03068455)
Timeframe: From randomization to date of death (up to approximately 45 months)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | NA |
| Arm B: Nivo | NA |
PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death. (NCT03068455)
Timeframe: From randomization to progression event (up to approximately 45 months)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | NA |
| Arm B: Nivo | NA |
PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death. (NCT03068455)
Timeframe: From randomization to progression event (up to approximately 45 months)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | NA |
| Arm B: Nivo | NA |
"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median values based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Primary Completion Date (up to approximately 3 years)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | NA |
| Arm B: Nivo | NA |
"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Primary Completion Date (up to approximately 3 years)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | 33.15 |
| Arm B: Nivo | 27.63 |
Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment. (NCT03068455)
Timeframe: From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | 4.60 |
| Arm B: Nivo | 4.80 |
Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment. (NCT03068455)
Timeframe: From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)
| Intervention | Months (Median) |
|---|---|
| Arm A: Nivo + Ipi | 4.44 |
| Arm B: Nivo | 5.04 |
"RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.~Median based on Kaplan-Meier Estimates." (NCT03068455)
Timeframe: From randomization to Study Completion Date (up to approximately 45 months)
| Intervention | Months (Median) | ||||
|---|---|---|---|---|---|
| < 1% Tumor PD-L1 Expression | ≥ 1% Tumor PD-L1 Expression | ≥ 5% Tumor PD-L1 Expression | < 5% Tumor PD-L1 Expression | Non-quantifiable Tumor PD-L1 Expression | |
| Arm A: Nivo + Ipi | 33.18 | NA | NA | NA | NA |
| Arm B: Nivo | 25.33 | NA | NA | NA | NA |
"Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.~Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date." (NCT03068455)
Timeframe: From randomization to start of next therapy or second next therapy (up to approximately 45 months)
| Intervention | Months (Median) | |
|---|---|---|
| Time to next therapy | Time to second next therapy | |
| Arm A: Nivo + Ipi | NA | NA |
| Arm B: Nivo | NA | NA |
"Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.~Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date" (NCT03068455)
Timeframe: From randomization to start of next therapy or second next therapy (up to approximately 45 months)
| Intervention | Months (Median) | |
|---|---|---|
| Time to next therapy | Time to second next therapy | |
| Arm A: Nivo + Ipi | NA | NA |
| Arm B: Nivo | NA | NA |
ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR) as determined by a investigator assessment based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. (NCT03368859)
Timeframe: From randomization up to 30 days after last dose of study drug; median time on follow-up was 25.6 (0.3 - 64.4) and 37.6 (0.3 - 66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab plus FOLFIRI, respectively
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-165 Plus FOLFIRI | 5.6 |
| Bevacizumab Plus FOLFIRI | 14.7 |
OS is defined as the time from randomization until death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively
| Intervention | Months (Median) |
|---|---|
| ABT-165 Plus FOLFIRI | 7.95 |
| Bevacizumab Plus FOLFIRI | NA |
PFS is defined as the time from randomization until the first occurrence of radiographic progression determined by investigator assessment or death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively
| Intervention | Months (Median) |
|---|---|
| ABT-165 Plus FOLFIRI | 3.78 |
| Bevacizumab Plus FOLFIRI | 7.36 |
Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations. (NCT00069121)
Timeframe: Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).
| Intervention | months (Median) |
|---|---|
| 5-FU/LV | NA |
| XELOX | 88.6 |
Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations. (NCT00069121)
Timeframe: Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).
| Intervention | months (Median) |
|---|---|
| 5-FU/LV | NA |
| XELOX | NA |
A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations. (NCT00069121)
Timeframe: Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).
| Intervention | months (Median) |
|---|---|
| 5-FU/LV | NA |
| XELOX | 88.6 |
Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. (NCT00069121)
Timeframe: Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients with Event | Patients without Events | |
| 5-FU/LV | 379 | 563 |
| XELOX | 320 | 624 |
"The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms severe and serious are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details." (NCT00069121)
Timeframe: From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Mild AEs | Moderate AEs | Severe AEs | Life-Threatening | |
| 5-FU/LV MAYO CLINIC | 557 | 493 | 299 | 83 |
| 5-FU/LV ROSWELL PARK | 256 | 217 | 146 | 21 |
| XELOX | 855 | 792 | 548 | 63 |
Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. (NCT00069121)
Timeframe: Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients With Event | Patients Without Events | |
| 5-FU/LV | 286 | 656 |
| XELOX | 242 | 702 |
A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. (NCT00069121)
Timeframe: Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients With Event | Patients Without Events | |
| 5-FU/LV | 356 | 586 |
| XELOX | 290 | 654 |
"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 67.1 |
| Mutant KRAS Arm D | 65.0 |
"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 74.6 |
| Wild-type KRAS Arm D | 71.5 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 87.9 |
| Mutant KRAS Arm D | 82.7 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 87.3 |
| Wild-type KRAS Arm D | 85.6 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Mutant KRAS Arm A | 55.6 |
| Mutant KRAS Arm D | 72.3 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Wild-type KRAS Arm A | 51.1 |
| Wild-type KRAS Arm D | 73.3 |
Disease-free survival (DFS) was defined as the time from the date of randomization to the time of a recurrence, a new occurrence of colorectal cancer or death due to any cause, whichever occurred first. Patients without an event were censored at the last date the patient was known to be disease-free. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Patients with no tumor assessments after baseline but still alive at the time of the clinical cut-off were censored at day 1. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the analysis were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
Overall survival was defined as the time between date of randomization and date of death due to any cause. Patients not reported as having died at the time of the clinical cut-off date (30 June 2012) were censored at the date they were last known to be alive. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
| Intervention | months (Median) |
|---|---|
| FOLFOX4 | NA |
| FOLFOX4 + Bv | NA |
| XELOX+Bv | NA |
A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer. (NCT00112918)
Timeframe: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Patients with a DFS event | Recurrence | New Occurrence | Death | Patients without events | |
| FOLFOX4 | 237 | 219 | 3 | 17 | 718 |
| FOLFOX4 + Bv | 280 | 253 | 8 | 21 | 680 |
| XELOX+Bv | 253 | 223 | 6 | 25 | 699 |
An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the clinical data cut-off date of 30 June 2010 (36 months after the last patient randomized).
| Intervention | participants (Number) | |
|---|---|---|
| Patients with events | Patients without events | |
| FOLFOX4 | 115 | 840 |
| FOLFOX4 + Bv | 151 | 809 |
| XELOX+Bv | 145 | 807 |
An overall survival event was death due to any cause. (NCT00112918)
Timeframe: From first patient randomized until the final data cut-off date of 30 June 2012 (5 years after the last patient randomized).
| Intervention | participants (Number) | |
|---|---|---|
| Patients with events | Patients without events | |
| FOLFOX4 | 161 | 794 |
| FOLFOX4 + Bv | 202 | 758 |
| XELOX+Bv | 182 | 770 |
Disease-Free Survival (DFS) is defined as the time of randomization until documented progression or death from any cause. The endpoint of this trial is to compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive and disease free after 3 years are reported here. A log-rank test stratified with the stratification factors was used to compare disease-free survival (celecoxib vs placebo) (NCT01150045)
Timeframe: At 3 years of follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| FOLFOX and Placebo (Arms A +C) | 73.4 |
| FOLFOX Plus Celecoxib Daily (Arms B + D) | 76.3 |
Overall Survival (DFS) is defined as the time of randomization until documented death from any cause. The endpoint is to compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 5 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive after 3 years are reported here. (NCT01150045)
Timeframe: up to 3 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| FOLFOX and Placebo (Arms A +C) | 81.6 |
| FOLFOX Plus Celecoxib Daily (Arms B + D) | 84.3 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non - compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ratio (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 0.0313 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | mcg*day/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 304.6 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg*day/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 355 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | mcg*day/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 246.9 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of 5-FU in combination with aflibercept and irinotecan in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 2.5, 21 and 45 hours post 5-FU infusion on Day 1 of Cycle 1
| Intervention | liter/hour (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 122 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed pharmacokinetic (PK) analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | mcg/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 73.19 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on--treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment. (NCT01882868)
Timeframe: First dose (Day 1 of Cycle 1) of study treatment up to end of treatment visit (30 days after last dose of study treatment) (maximum duration: 77 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI | 62 |
OS was defined as the time interval from the date of first study drug administration to the date of death due to any cause. If death was not observed, the participant was censored at the last date the participant was known to be alive or the study cut-off date, whichever was first. OS was estimated by Kaplan-Meier estimates. (NCT01882868)
Timeframe: Baseline up to death or study cut--off (maximum duration: 24.7 months)
| Intervention | months (Median) |
|---|---|
| Aflibercept + FOLFIRI | 15.59 |
Overall response in participants was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) assessed by an independent radiological review committee (IRRC) according to response evaluation criteria in solid tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions; any lymph node (target or non-target) must have reduction in the short axis to <10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants with overall response and the 95% confidence interval (CI) were provided. The 95% CI was calculated using normal approximation. (NCT01882868)
Timeframe: Baseline and every 6 weeks until DP (maximum duration: 16.4 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Aflibercept + FOLFIRI | 8.3 |
PFS was defined as the time interval from the date of first study drug administration to the date of first observation of DP or death due to any cause, whichever came first. If death or progression was not observed, the participant was censored at the date of participant's last valid progression-free tumor assessment prior to the study cut-off date. DP for PFS was assessed by the IRRC based on tumor imaging according to RECIST 1.1. Progression in disease was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study with absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated by Kaplan-Meier estimates. (NCT01882868)
Timeframe: Baseline and every 6 weeks until DP or death, due to any cause (maximum duration: 16.4 months)
| Intervention | months (Median) |
|---|---|
| Aflibercept + FOLFIRI | 5.42 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of 5-FU in combination with aflibercept and irinotecan in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 2.5, 21 and 45 hours post 5-FU infusion on Day 1 of Cycle 1
| Intervention | ng/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 930 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | days (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 4.47 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | liter/day (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 0.8053 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | liter/day (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 0.716 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | liter/hour (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 18.3 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | liters (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 6.197 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | liters (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 3.53 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | liter (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 92.5 |
Blood samples of participants were analyzed by using a titer-based, bridging immunoassay developed and validated to detect aflibercept ADA in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative, competitive ligand binding assay to detect NAb. (NCT01882868)
Timeframe: Baseline, at any time post baseline and 90 days after the last dose of aflibercept
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At baseline in the ADA assay (n=62) | At any time post-baseline in the ADA assay (n=62) | At any time post-baseline in the NAb assay (n=62) | At 90 days after last dose in the ADA assay (n=50) | At 90 days after last dose in NAb assay (n=50) | |
| Aflibercept + FOLFIRI | 1 | 0 | 0 | 0 | 0 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ng*h/mL (Mean) | |
|---|---|---|
| Plasma Irinotecan (n=10) | Plasma SN-38 (n=4) | |
| Aflibercept + FOLFIRI | 17700 | 341 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg*day/mL (Mean) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=5) | |
| Aflibercept + FOLFIRI | 312 | 23.3 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg*day/mL (Mean) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=8) | |
| Aflibercept + FOLFIRI | 321 | 24.4 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ng*h/mL (Mean) | |
|---|---|---|
| Plasma Irinotecan | Plasma SN-38 | |
| Aflibercept + FOLFIRI | 16900 | 344 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg/mL (Mean) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=8) | |
| Aflibercept + FOLFIRI | 90.8 | 2.83 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Plasma Irinotecan | Plasma SN-38 | |
| Aflibercept + FOLFIRI | 2220 | 32.2 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | hours (Mean) | |
|---|---|---|
| Plasma Irinotecan (n=10) | Plasma SN-38 (n=5) | |
| Aflibercept + FOLFIRI | 5.19 | 10.3 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | days (Median) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=8) | |
| Aflibercept + FOLFIRI | 0.07 | 13.97 |
Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil | 75.5 |
| Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 77.4 |
Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (mFOLFOX6) | 77.6 |
| Arm II (Bevacizumab, mFOLFOX6) | 78.7 |
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | 4.0 |
| Placebo + FOLFIRI | 6.6 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | -0.097 |
| Placebo + FOLFIRI | -0.103 |
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 13.3 |
| Placebo + FOLFIRI | 11.7 |
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab + FOLFIRI | 13.4 |
| Placebo + FOLFIRI | 12.5 |
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 5.7 |
| Placebo + FOLFIRI | 4.5 |
(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17
| Intervention | micrograms/milliliter (ug/mL) (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cmin Dose 3 (n=248) | Cmin Dose 5 (n=154) | Cmin Dose 9 (n=27) | Cmin Dose 13 (n=11) | Cmin Dose 17 (n=5) | Cmax Dose 3 (n=88) | Cmax Dose 5 (n=51) | Cmax Dose 9 (n=18) | Cmax Dose 13 (n=12) | Cmax Dose 17 (n=7) | |
| Ramucirumab + FOLFIRI | 46.3 | 65.1 | 77.9 | 75.9 | 72.0 | 221.0 | 243.0 | 262.0 | 307.0 | 253.0 |
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Immunogenicity Any Time During Study (n=516, 512) | Immunogenicity Post-Treatment (n=477, 473) | |
| Placebo + FOLFIRI | 5.5 | 3.8 |
| Ramucirumab + FOLFIRI | 5.6 | 3.1 |
The oxaliplatin-induced motor neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) motor neuropathy subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN motor neuropathy subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 motor neuropathy subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 motor neuropathy subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 Months
| Intervention | AUC QLQ-CIPN20 Motor Neuropathy Score (Mean) |
|---|---|
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 94.1 |
| Placebo (Pre and Post) | 93.3 |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 91.6 |
The oxaliplatin-induced autonomic neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) autonomic subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN autonomic subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 autonomic subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 autonomic subscale as the endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | score on a scale (Mean) |
|---|---|
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 89.8 |
| Placebo (Pre and Post) | 86.7 |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 84.5 |
A patient has a dose-limiting chronic neurotoxicity when they discontinue oxaliplatin-based chemotherapy because of neurotoxicity. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | Doses (Mean) |
|---|---|
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 8.1 |
| Placebo (Pre and Post) | 8.4 |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 8.0 |
(NCT01099449)
Timeframe: Up to 18 months
| Intervention | Number of reported Adverse Events (Number) |
|---|---|
| Arm I | 290 |
| Arm II | 259 |
| Arm III | 296 |
(NCT01099449)
Timeframe: Up to 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 34.7 |
| Placebo (Pre and Post) | 27.7 |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 30.5 |
The oxaliplatin-induced sensory neuropathy as repeatedly measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) sensory subscale during the chemotherapy. This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the CIPN20 sensory subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) of CIPN20 sensory subscale as the primary endpoint. This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | score on a scale (Mean) |
|---|---|
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 89.2 |
| Placebo (Pre and Post) | 88.3 |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 87.1 |
This is a multivariate repeated measurement of CIPN with possibly variable cycles for every patient. The supplemental quality of life (QOL) subscale will be calculated by standard scoring algorithm and converted to 0-100 scale, where higher scores represent a higher quality of life. Rather than choosing the subscale at a fixed cycle of chemotherapy, we will adopt a summary measure, area under the curve (AUC) . This AUC will be prorated by the number of chemotherapy cycles patients received. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Diarrhea | Constipation | Stomach Cramping | Bowel Problems | Swallowing | Numbness in finger and toes | Tingling in finger and toes | |
| Arm I | 86.7 | 90.1 | 92.8 | 89.1 | 91.2 | 83.4 | 78.9 |
| Arm II | 86.2 | 88.8 | 90.6 | 88.5 | 87.6 | 81.8 | 76.5 |
| Arm III | 84.5 | 88.0 | 89.4 | 84.6 | 86.7 | 80.0 | 76.3 |
Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | percentage of patients (Number) | |
|---|---|---|
| grade 2+ | grade 3+ | |
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 42.7 | 7.7 |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 46.1 | 7.8 |
| Placebo (Pre and Post) | 44.8 | 7.8 |
This is the percent of patients who scored >=50 in all sequences of all cycles by arm for side effect Q1: Sensitivity to touching cold. This is a> repeated measurement of CIPN with possibly variable cycles for every patient. The CIPN subscale will be calculated by standard scoring algorithm and converted to 0-100 scale. Where 0 is no sensitivity and 100 is as bad as it can be. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | percentage of patients (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | Cycle 7 | Cycle 8 | Cycle 9 | Cycle 10 | Cycle 11 | Cycle 12 | |
| Arm I | 10 | 24 | 32 | 34 | 34 | 31 | 35 | 32 | 34 | 29 | 28 | 27 |
| Arm II | 13 | 27 | 33 | 37 | 33 | 37 | 34 | 34 | 37 | 39 | 39 | 45 |
| Arm III | 14 | 28 | 32 | 36 | 39 | 33 | 34 | 33 | 32 | 30 | 33 | 32 |
Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity, the duration of the chronic cumulative neurotoxicity during and after the adjuvant oxaliplatin-based chemotherapy. Grades are determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.0) and oxaliplatin-specific neurotoxicity scale, during and after chemotherapy. Higher grades symbolize greater severity of the adverse event. (NCT01099449)
Timeframe: Up to 18 months
| Intervention | Days (Median) | |
|---|---|---|
| Time to Grade 2 Neuropathy | Time to Grade 3 Neuropathy | |
| Calcium Gluconate + Magnesium Sulfate (Pre and Post) | 171 | NA |
| Calcium Gluconate + Magnesium Sulfate (Pre), Placebo (Post) | 171 | NA |
| Placebo (Pre and Post) | 173 | 208 |
Neuropathic adverse events were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | days (Median) |
|---|---|
| Ca/Mg | 81 |
| Placebo | 72 |
Neurotoxicity were assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ca/Mg | 46 |
| Placebo | 55.8 |
Acute neuropathic toxicities were measured using the Symptom Experience Diary and supplemental quality of life questions in the scale of 0 (no symptom) to 10 (worst symptom). The item score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Any score greater than 0 was considered having acute neuropathy. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Ca/Mg | 88 |
| Placebo | 90 |
Neuropathic adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Neurotoxicity evaluation grade: loss of deep tendon reflexes or paresthesia, including tingling, but not interfering with function (Grade 1); objective sensory alteration or paresthesia, including tingling, interfering with function, but not with activities of daily living (Grade 2); sensory alteration or paresthesia interfering with activities of daily living (Grade 3); permanent sensory losses that are disabling (Grade 4) (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Ca/Mg | 22 |
| Placebo | 41 |
Neurotoxicity were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Days (Median) |
|---|---|
| Ca/Mg | NA |
| Placebo | 18.1 |
Neurotoxicity was assessed by CTCAE v3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Days (Median) |
|---|---|
| Ca/Mg | NA |
| Placebo | NA |
Fatigue was measured by Brief Fatigue Inventory in the scale of 0 (no fatigue) to 10 (fatigue as bad as you can imagine). The item score was reversed and transformed into 0 (low quality of life (QOL)) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Fatigue NOW | Fatigue USUAL | Fatigue WORST | |
| Ca/Mg | 1.0 | 3.1 | 0.0 |
| Placebo | -2.8 | -1.6 | -1.6 |
Quality of Life (QOL) were measured using the Symptom Experience Diary and supplemental quality of life questions. Item score range: 0 (no symptom) to 10 (worst symptom). The score was reversed and transformed into 0 (low QOL) to 100 (best QOL) scale for analysis. Change: score at one month minus score at baseline. (NCT00316914)
Timeframe: Baseline and One month
| Intervention | Units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue WORST | Walking | Buttoning Shirt or Tying Laces | Diarrhea | Constipation | Abdominal Cramping | Bowel Problems with Normal Activity | Shortness of Breath (Week 2 - Baseline) | Swallowing (Week 2 - Baseline) | Numbness in Fingers, Toes (Week 2 - Baseline) | Tingling in Fingers, Toes (Week 2 - Baseline) | |
| Ca/Mg | 0.0 | -2.5 | -2.0 | -7.1 | -2.9 | -2.5 | -3.2 | -0.7 | -7.5 | -8.3 | -14.8 |
| Placebo | -1.6 | 0.2 | 0.4 | -10.4 | 0.4 | 1.3 | -9.1 | 2.1 | 2.1 | -9.6 | -20.4 |
Adverse Events were measured using CTCAE V3.0. (NCT00316914)
Timeframe: 127 days
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal Infection | Acne NOS | Anemia | Anorexia | Clostridial Infection | Constipation | Dehydration | Diarrhea-No Colostom | Dry Skin | Erythema Multiforme | Fatigue | Hypercalcemia | Hyperglycemia | Hypermagnesemia | Hypersensitivity | Hypokalemia | Hypomagnesemia | Hyponatremia | Infection | Ischemia-Cerebral | Ischemia/Infarction | Laryngeal Discomfort | Leukopenia | Muscle Weakness | Myalgia | Nausea | Neuro-motor | Neuro-sensory | Neutropenia | Oral cavity MS CE | Pain-Abdominal | Pain-Chest | Pain-Headache | Rash/Desquamation | Skin Rxn-Hand/Foot | Stomatitis | Taste | Thrombocytopenia | Thrombosis | Urticaria | Vasc Access Complication | Vomiting | |
| Ca/Mg | 2 | 2 | 4 | 4 | 0 | 42 | 2 | 68 | 0 | 4 | 10 | 0 | 2 | 14 | 6 | 4 | 0 | 4 | 0 | 0 | 2 | 0 | 6 | 2 | 4 | 60 | 4 | 2 | 18 | 2 | 0 | 0 | 0 | 4 | 4 | 2 | 2 | 2 | 6 | 0 | 2 | 34 |
| Placebo | 0 | 2 | 4 | 2 | 2 | 47 | 6 | 73 | 2 | 0 | 25 | 2 | 0 | 18 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 10 | 0 | 0 | 71 | 4 | 12 | 33 | 0 | 8 | 2 | 4 | 0 | 2 | 2 | 2 | 2 | 4 | 2 | 0 | 33 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in body fat (Mean) |
|---|---|
| Behavioral Dietary Intervention | -3.1 |
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in BMI (Mean) |
|---|---|
| Behavioral Dietary Intervention | -1.2 |
Assessed via mixed-effects regression. (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | beats per minute (Mean) |
|---|---|
| Behavioral Dietary Intervention | 67.3 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%. (NCT01819233)
Timeframe: Up to week 12
| Intervention | participants (Number) |
|---|---|
| Behavioral Dietary Intervention | 28 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much) (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | score on a scale (Mean) |
|---|---|
| Behavioral Dietary Intervention | 0.8 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
258 reviews available for fluorouracil and Cancer of Colon
| Article | Year |
|---|---|
Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; | 2022 |
Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2021 |
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Colonic Neo | 2022 |
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 2022 |
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Melaton | 2023 |
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Clinical Tria | 2023 |
Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature.
Topics: Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Liver Cirrhosis; Liver Diseases; Portal Vein; Po | 2023 |
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colonic Neoplasm | 2023 |
Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Colon | 2023 |
Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature.
Topics: Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colonic Neoplasms; Disease Progression; Elec | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tu | 2020 |
Controversies in the treatment of RAS wild-type metastatic colorectal cancer.
Topics: Advisory Committees; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colo | 2021 |
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem.
Topics: ATP-Binding Cassette Transporters; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug R | 2020 |
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Medical Oncology; Oxaliplatin; United States; United States | 2020 |
Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2020 |
Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2021 |
Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Disease | 2021 |
Randomized Clinical Trials in Colon and Rectal Cancer.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Neoadjuvant Therapy; Randomized Con | 2017 |
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
[A Case of Hyperammonemia Induced by Chemotherapy with 5-Fluorouracil for Metastatic Colon Cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Hyperam | 2018 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; | 2018 |
The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2018 |
[A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Chemotherapy, Adjuvant; Colon, Ascen | 2018 |
[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplas | 2019 |
Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemo | 2019 |
[A case of recurrent colon cancer involved in multiple organs maintaining complete response over the long-term after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluor | 2013 |
Applications of oral fluoropyrimidines in colon cancer: their role and new directions.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Co | 2003 |
Managing choices for older patients with colon cancer: adjuvant therapy.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy | 2013 |
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehy | 2013 |
[Early diagnosis of capecitabine-induced acute leukoencephalopathy by using diffusion-weighted MRI].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diff | 2014 |
TroVax in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines | 2014 |
[A case of juvenile colon cancer with peritoneal dissemination treated effectively by use of resection and chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colostomy; C | 2014 |
Hypersensitivity reaction caused by folinic acid administration: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Hypersensitivity; Fluorourac | 2016 |
[Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplas | 2015 |
Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2016 |
[Five-Year Recurrence-Free Survival after mFOLFOX6 Administration, Right Hemicolectomy, and Lymphadenectomy for Portal Venous Tumor Thromboembolism].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Ascending; Colonic Neoplasms | 2015 |
[A Case of Drug-Induced Thrombocytopenia Resulting from Sensitivity to Oxaliplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colon, Tran | 2015 |
[A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothe | 2016 |
Colon cancer targeting using conjugates biomaterial 5-flurouracil.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Colonic Neoplasms; Drug Delivery Systems; F | 2016 |
Motility patterns in mouse colon: gastrointestinal dysfunction induced by anticancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Colon; Colonic Neoplasms; Enteric Nervous System; Fluorouracil; Gast | 2016 |
Synchronous quintuple primary gastrointestinal tract malignancies: Case report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer | 2017 |
[A Case of Intussusception Caused by Descending Colon Cancer].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Desce | 2016 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy P | 2008 |
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-F | 2008 |
Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; CpG Islands; DNA Methylation; Fluorouracil; Huma | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary | 2009 |
[Case of indwelling catheter dislocation into the duodenum during hepatic arterial infusion chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colonic Neoplasms; Duodenum; Fluorour | 2009 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr | 2009 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
[A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2009 |
[The current status of adjuvant chemotherapy of colonic cancer].
Topics: Antimetabolites, Antineoplastic; Carnitine O-Palmitoyltransferase; Chemotherapy, Adjuvant; Colonic N | 2009 |
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Blood Glucose; Capecitabine; Colonic Neoplasms; Deoxycytidine; Feno | 2009 |
[Neoadjuvant chemotherapy and pancreatoduodenectomy for locally advanced colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Flu | 2009 |
Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
Topics: Acidosis, Renal Tubular; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
[Adjuvant therapy in colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical | 2010 |
Molecular markers to individualize adjuvant therapy for colon cancer.
Topics: Adjuvants, Immunologic; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 2010 |
Metastatic colorectal cancer: from improved survival to potential cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Catheter Ablation; | 2010 |
[Difference of colon cancer and rectal cancer-from the view of an oncological physician].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chromosomal In | 2010 |
Adjuvant colon cancer chemotherapy: where we are and where we'll go.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic N | 2010 |
[Advances in research on capecitabine as adjuvant treatment for colon cancer after radical resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2010 |
[A surgical (pancreatoduodenectomy) case of lymph node metastatic recurrence of colon cancer after chemotherapy].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Duoden | 2010 |
Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2011 |
Colorectal cancer treatment.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Ob | 2010 |
Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Huma | 2011 |
[Multimodal therapy for colon cancer: state of the art].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Angina induced by 5-fluorouracil infusion in a patient with normal coronaries.
Topics: Adult; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Angiography; Co | 2010 |
[Recurrent autoimmune hemolytic anemia induced by XELOX chemotherapy for colon cancer].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Mid | 2012 |
[Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; DNA-Binding Proteins; Endonucleas | 2011 |
[A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 2012 |
Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2012 |
The role of genomic instabilities in affecting treatment responses of colorectal cancer.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Hum | 2002 |
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother | 2002 |
Chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 2002 |
Adjuvant chemotherapy in colon cancer: what is the evidence?
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Evidence-B | 2003 |
Older patients with colon cancer: is adjuvant chemotherapy safe and effective?
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Leuco | 2003 |
Adjuvant therapy for colon cancer in the new millenium.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetaboli | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxe | 2003 |
Sigmoidoduodenal fistula as a rare complication of colonic carcinoma: report of a case.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Duodenal Diseases; Fluorouracil; Hu | 2003 |
[Colon cancer in pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cesarean Section; C | 2003 |
Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxy | 2003 |
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2004 |
An overview of adjuvant systemic chemotherapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2004 |
Customizing chemotherapy for colon cancer: the potential of gene expression profiling.
Topics: Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Humans; Progn | 2004 |
Adjuvant therapy for stage II colon cancer: an elephant in the living room?
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Leucovorin; Lymph No | 2004 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic | 2004 |
[Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
[Adjuvant therapy for colon cancer].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murin | 2004 |
Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2004 |
Advances in colon cancer chemotheapy: nursing implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
An overview of approaches to adjuvant therapy for colorectal cancer in the United States.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
[Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Combined | 2004 |
Adjuvant therapy in colon cancer: which treatment in 2005?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Ch | 2005 |
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarke | 2005 |
An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Digestive System Surgical Procedur | 2005 |
[Progression of adjuvant chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2005 |
Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Histor | 2006 |
Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; DNA; DNA Topoiso | 2006 |
Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical T | 2006 |
Adjuvant therapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2006 |
Effects of 5-fluorouracil adjuvant treatment of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2006 |
[FOLFIRI regimen for metastatic or recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capeci | 2006 |
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2006 |
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Cost-Benefi | 2006 |
Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colonic Neoplasms; Cost-Ben | 2006 |
[Up to date chemotherapy for colon cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
[Standard chemotherapy for colonic neoplasms].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
Adjuvant treatment of colon cancer: past, present and future.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2007 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Circadi | 2007 |
The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2007 |
How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neopl | 2007 |
The role of adjuvant chemotherapy in colon cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2007 |
Chemotherapy in alimentary tract malignomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cytarabine; Doxor | 1981 |
Intraarterial hepatic infusion chemotherapy in metastatic liver cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1983 |
Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.
Topics: Antineoplastic Agents; Catheterization; Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; F | 1983 |
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridin | 1984 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
An analysis of chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1984 |
[Treatment of metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1984 |
Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines.
Topics: Cell Line; Cell Survival; Colonic Neoplasms; Culture Media; Drug Evaluation, Preclinical; Fluorourac | 1980 |
Systemic adjuvant therapy with BCG versus BCG + 5FU in colorectal cancer Dukes' Class C: updated critical analysis.
Topics: Aged; BCG Vaccine; Carcinoembryonic Antigen; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1980 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Advances in the multimodal primary management of cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphami | 1980 |
Studies on the treatment and prevention of colorectal liver metastases.
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Hemodynamics; Humans; Liv | 1981 |
Large bowel cancer: an overview.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Femal | 1982 |
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es | 1982 |
Adjuvant chemotherapy for colon and rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1995 |
Role of adjuvant therapy in surgically resected colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1995 |
[Chemotherapy in cancers of the colon].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemotherapy, | 1993 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neopla | 1993 |
[Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 1994 |
[Adjuvant chemotherapy in cancers of the colon and rectum].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; Rectal Neoplasms | 1994 |
Adjuvant postoperative therapy of gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
[Adjuvant therapy in colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
[Adjuvant chemotherapy in colonic cancers].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Heparin; Humans; | 1994 |
The role of chemotherapy and adjuvant therapy in the management of colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 1994 |
[Adjuvant systemic chemo- or immunotherapy of colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
An overview of adjuvant treatment of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1993 |
Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Adjuvant; | 1994 |
The chemotherapy of colon cancer can no longer be ignored.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1993 |
Enhancement of thymidylate synthase inhibition.
Topics: Animals; Colonic Neoplasms; Fluorouracil; Humans; Thymidylate Synthase | 1993 |
Recent clinical trials with levamisole.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; | 1993 |
Adjuvant radiation therapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Disease-Free Survival | 1995 |
Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasms; Floxuridine; Fluo | 1996 |
[Adjuvant systemic chemotherapy in colon cancer].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Adjuvant therapy of colon cancer: towards a new consensus.
Topics: Antinematodal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1996 |
Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Leukoencephalopathy, Progre | 1996 |
[Analysis of clinical effects of a concurrent CDDP/5-FU therapy on inoperable colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colonic Neoplas | 1996 |
The role of adjuvant radiation therapy in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms | 1997 |
The role of adjuvant chemotherapy in the treatment of colorectal cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
[The current status of postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colect | 1997 |
Adjuvant therapy of colorectal cancer.
Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemother | 1997 |
[Surgery and multidisciplinary treatment for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1998 |
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Division; Cisplatin; Colonic Neopl | 1998 |
[Adjuvant treatment for colon carcinoma. Results and perspectives].
Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic | 1998 |
Colorectal cancer: treatment of advanced disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1998 |
[Treatment of peritoneal carcinosis of colorectal origin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemothe | 1997 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
[Adjuvant therapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuvant; Colonic Neo | 1998 |
Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1999 |
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Topics: Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Middle Aged; Nerv | 1999 |
Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.
Topics: Age Factors; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 1999 |
External beam radiotherapy for pelvic node recurrence after curative resection of colon cancer: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colectomy; Colonic Neopla | 1999 |
[Treatment with cytostatic agents should be considered in colorectal cancer. It improves prognosis and quality of life].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1999 |
Which 5-fluorouracil regimen?--the great debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1999 |
[Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
Intraperitoneal chemotherapy in the management of colon cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, | 1999 |
[Theoretical basis for low-dose CDDP/5-FU therapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1999 |
[Problems and prospects for combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; Fluor | 1999 |
[Is portal infusion chemotherapy uneffective for hepatic recurrence after resection for colorectal cancer?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1999 |
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Human | 1999 |
Colonic carcinoma: a case report in a child and review literature.
Topics: Abdominal Pain; Adenocarcinoma; Biopsy, Needle; Child; Colectomy; Colonic Neoplasms; Fluorouracil; F | 2000 |
Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy.
Topics: Aged; Carcinoma; Colectomy; Colonic Neoplasms; Dacryocystorhinostomy; Female; Fluorouracil; Humans; | 2000 |
Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression.
Topics: Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biopsy; Blotting, Western; Colon; Col | 2000 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
[Capecitabine--a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Che | 2000 |
Adjuvant therapy in high-risk colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 2000 |
Treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Colorectal Ne | 2000 |
[New drugs in the treatment of advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
[Adjuvant therapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2000 |
Adjuvant chemotherapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2001 |
Adjuvant therapy of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2001 |
Future directions in adjuvant therapy for stage III colon carcinoma.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Forecasting; Humans; | 2001 |
[Chemotherapy of colonic carcinoma in the year 2001].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic | 2002 |
Adjuvant chemotherapy for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 2002 |
Progress in treatment of cancer of the large bowel.
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Intestinal Obstru | 1976 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
[Current trends of complementary therapy in radical surgery of colo-rectal cancer].
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Postoperative Care; P | 1979 |
Chemotherapy of colorectal carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Drug Administration Sche | 1976 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Chemotherapy of gastrointestinal cancer.
Topics: Apudoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Hum | 1978 |
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Evaluation Stud | 1979 |
[Symposium on carcinoma of colon and rectum: 4. The role of adjuvant therapy with surgery in cancers of the colon and rectum].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunosuppressive Agents; Neoplasm Metastasis; Nitrosourea | 1978 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Abdominal surgery (second of three parts).
Topics: Abdomen; Acute Disease; Anus Diseases; Appendectomy; Appendicitis; Appendix; Carcinoembryonic Antige | 1975 |
Accomplishments in surgical adjuvant therapy for large bowel cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Drug T | 1992 |
Adjuvant and palliative treatments of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1992 |
Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience.
Topics: Colonic Neoplasms; Deoxyuridine; Dipyridamole; DNA Damage; DNA, Neoplasm; Drug Interactions; Fluorou | 1992 |
Chemotherapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1992 |
Advances in adjuvant chemotherapy for colon cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 1992 |
[Biochemical modulation of 5-FU with interferon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Admini | 1992 |
[Combined therapy with 5-FU and levamisole].
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1992 |
Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Hy | 1992 |
Colorectal cancer. Recent developments and continuing controversies.
Topics: Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Levamisol | 1992 |
Skin reactions to radiotherapy--a spectrum resembling erythema multiforme: case report and review of the literature.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Erythema Multiforme; Female; Flu | 1992 |
Adjuvant therapy of colon cancer: lessons while looking for breakthroughs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1991 |
Adjuvant treatment of node-positive colon carcinoma with levamisole and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; | 1991 |
[Adjuvant therapy in colonic carcinoma].
Topics: Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Levamisole; Neoplasm | 1991 |
Chemotherapy of advanced cancer of the colon and rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Huma | 1991 |
Current treatment approaches in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neop | 1991 |
The role of immunotherapy in colorectal cancer.
Topics: Antibodies, Monoclonal; Colonic Neoplasms; Fluorouracil; Humans; Immunologic Factors; Immunotherapy; | 1991 |
Levamisole in the adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1991 |
Modulation of cytotoxic drug activity by dipyridamole.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1990 |
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Clinical; Colonic Neoplas | 1990 |
Management of colorectal cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu | 1990 |
[Adjuvant chemotherapy in colonic cancer].
Topics: Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Levamisole; Postoper | 1990 |
Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Transplantation; Thymidyl | 1989 |
Treatment of colorectal hepatic metastases.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; F | 1985 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
Colorectal cancer: surgical management of recurrent and metastatic disease.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Rectal Neoplas | 1988 |
In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Femal | 1988 |
Colon cancer: medical therapy.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Interleukin-2; Pyrimidines | 1988 |
Hepatic artery ligation or embolization and locoregional chemotherapy of liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1988 |
[Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Dru | 1988 |
Evaluation and treatment of hepatic metastasis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1988 |
Adjuvant therapy of colorectal cancer. Why we still don't know.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neopla | 1988 |
Role of chemotherapy in the treatment of colorectal carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1987 |
Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Fluorou | 1987 |
Biochemical modulation of fluorouracil therapy in advanced colorectal cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Interactions; F | 1987 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
[Chemotherapy of cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms | 1985 |
Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion?
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi | 1985 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
[Chemotherapy of cancer of the rectum and the colon].
Topics: Antimetabolites; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Injections, I | 1970 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Chemotherapy in colorectal cancer.
Topics: Carmustine; Chlorambucil; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorourac | 1973 |
Management of cancer of the colon.
Topics: Colitis, Ulcerative; Colon; Colonic Diseases; Colonic Neoplasms; Diagnostic Errors; Fluorouracil; Hu | 1974 |
Predictive tests in cancer. Tuesday 9 April 1974.
Topics: Age Factors; Breast Neoplasms; Cell Movement; Clinical Enzyme Tests; Colonic Neoplasms; Cytarabine; | 1974 |
578 trials available for fluorouracil and Cancer of Colon
| Article | Year |
|---|---|
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2022 |
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as | 2022 |
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2022 |
The Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients With Colon Cancer (JCOG1006): A Multicenter, Open-label, Randomized, Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dipeptides; Fluorouraci | 2022 |
Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2022 |
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neopla | 2022 |
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chromosome Deletion; Chromosomes; Colon | 2022 |
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2022 |
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adju | 2022 |
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bevacizumab; Camptothecin; Cetuximab; | 2022 |
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell-Free Nucleic Acids; Colonic Neopl | 2022 |
[The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tu | 2022 |
Oxaliplatin (3 months
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2022 |
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2022 |
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Bevacizumab; C | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2022 |
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2023 |
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2023 |
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Circulating Tumor DNA; Clinical Trials | 2022 |
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2023 |
Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2023 |
Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2023 |
Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2023 |
Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Personalizing neoadjuvant chemotherapy for locally advanced colon cancer: protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase | 2023 |
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colonic Neoplasms; Colorect | 2023 |
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorourac | 2023 |
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2023 |
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Female; Flu | 2023 |
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2023 |
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C | 2023 |
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2023 |
Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2023 |
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Capecitabine; Che | 2019 |
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2019 |
Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2020 |
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2020 |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Colonic Neoplas | 2020 |
"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Chemotherapy, Adjuvant; Circulating Tumor DNA; Colonic N | 2020 |
Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2020 |
Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leuco | 2020 |
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv | 2020 |
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv | 2020 |
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv | 2020 |
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv | 2020 |
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2021 |
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Drug Eruptions; Female | 2021 |
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2021 |
Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 2021 |
Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colectomy; C | 2021 |
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Chemotherapy, Adjuvant; Col | 2021 |
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2021 |
Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer.
Topics: Benzydamine; Colonic Neoplasms; Fluorouracil; Glutamine; Humans; Mouthwashes; Pain; Prospective Stud | 2023 |
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease-F | 2017 |
Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
Topics: Biomarkers, Tumor; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovori | 2018 |
Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal | 2017 |
Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2018 |
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2018 |
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2018 |
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2018 |
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2018 |
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2018 |
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2018 |
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2018 |
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2018 |
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; CpG | 2018 |
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diabetes Mellitus, Type 2; F | 2019 |
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).
Topics: Aged; Cetuximab; Colonic Neoplasms; Disease-Free Survival; Fatty Acids, Omega-3; Female; Fish Oils; | 2019 |
A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; DN | 2019 |
Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colectomy; Colonic Neoplasms | 2020 |
Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2013 |
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
[Neoadjuvant chemotherapy and radiation therapy of resectable cancer recti of distal localization].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Surviv | 2013 |
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2013 |
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2013 |
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2013 |
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cold Tem | 2014 |
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Nucleus; Chem | 2015 |
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; | 2014 |
MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coloni | 2014 |
A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Colon | 2015 |
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2015 |
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col | 2014 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2014 |
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2015 |
Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms | 2015 |
Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Chronic Disease; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2015 |
TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colonic Neoplasms; Disease-Free Survi | 2015 |
Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem | 2016 |
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2015 |
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2015 |
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2015 |
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2015 |
Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Agents; Colectomy; Colonic Neoplasms; Delayed-Action Preparations; Disease-Free Survi | 2015 |
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil De | 2016 |
PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chem | 2016 |
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluoro | 2016 |
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; | 2016 |
[Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2016 |
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2016 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemotherapy | 2017 |
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2017 |
Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Haplotypes; Humans; Male; Methy | 2017 |
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2008 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2008 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2009 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free | 2009 |
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Antirheumatic Agents; Chemotherapy, | 2009 |
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2009 |
Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colonic Neoplasms; Di | 2009 |
Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2009 |
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2009 |
Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuv | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; | 2009 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Ther | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2011 |
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2011 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclon | 2010 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Topics: Alanine; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Mouthwashes; Pilo | 2011 |
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy | 2012 |
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2011 |
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2011 |
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2011 |
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2011 |
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2012 |
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic | 2012 |
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarke | 2012 |
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capeci | 2013 |
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemot | 2012 |
Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2013 |
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant; Colonic Neo | 2013 |
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
Topics: Antimetabolites, Antineoplastic; Black People; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorourac | 2002 |
Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2002 |
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorourac | 2002 |
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2002 |
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colectomy; Colonic Neoplasms; Com | 2003 |
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2003 |
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2003 |
Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogeni | 2003 |
[Cytoreductive surgery with intraperitoneal chemotherapy in patients with colon cancer and peritoneal carcinomatosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined | 2003 |
Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Cos | 2003 |
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Chemotherapy, Adjuvant | 2003 |
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-S | 2003 |
Results of a randomized trial with or without 5-FU-based preoperative chemotherapy followed by postoperative chemotherapy in resected colon and rectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2003 |
Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2003 |
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 2003 |
The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2003 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 2003 |
Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chi-Square Distribution; Colectomy; Colonic Neoplasms; | 2004 |
[Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diseas | 2004 |
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adult; Aged; Amidines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Coloni | 2004 |
Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-flu
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplas | 2004 |
Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Disease Progression; D | 2004 |
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
[An institution-randomized trial of 5-fluorouracil and l-leucovorin therapy given monthly versus every two months to patients with advanced colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Case-Control Studies; Colo | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
Topics: Adult; Aged; Area Under Curve; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Adminis | 2004 |
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2005 |
Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasm | 2005 |
Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2004 |
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2005 |
Calcium pectinate capsules for colon-specific drug delivery.
Topics: Administration, Oral; Adult; Animals; Antineoplastic Agents; Capsules; Cecum; Colon; Colonic Neoplas | 2005 |
Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2005 |
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Diseas | 2005 |
[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronob | 2005 |
[Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronobiology Phenomena; C | 2005 |
Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA, Neoplasm; Drug Administrati | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Capecitabine as adjuvant treatment for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2005 |
Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2005 |
Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2005 |
Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distributi | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2005 |
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemot | 2005 |
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2006 |
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2006 |
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2006 |
Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Com | 2006 |
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2006 |
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2006 |
Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Colonic Neoplasms; Diverticulum, Colon; | 2006 |
[The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Complement C3; Compl | 2006 |
Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2006 |
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2007 |
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2007 |
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2007 |
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2007 |
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2007 |
Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic beta-catenin activation.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; beta Catenin; Colonic Neoplasms; Drug | 2007 |
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2006 |
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose- | 2008 |
[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2007 |
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2007 |
An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Bene | 2007 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic An | 2007 |
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 2007 |
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2007 |
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neoplasms; Electrophys | 2007 |
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Colonic Neop | 2007 |
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Ch | 2007 |
Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2008 |
[Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2007 |
Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr | 2008 |
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow | 2008 |
Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Neo | 1981 |
Adjuvant chemotherapy of large bowel cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Floxu | 1982 |
Chemotherapy after palliative resection of colorectal cancer. Yorkshire Gastrointestinal Tumour Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1984 |
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; | 1984 |
Newer techniques in cancer chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bleomycin; Bone Marrow Transplantation; Carcinoma; Ce | 1984 |
Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1983 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
Current status of adjuvant therapy in the treatment of large bowel cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Human | 1983 |
High-dose intermittent iv 5-FU and melphalan in advanced colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug The | 1983 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedu | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1984 |
Adjuvant therapy for colo-rectal cancer.
Topics: Adjuvants, Immunologic; BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality | 1983 |
An analysis of chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1984 |
Adjuvant therapy of colon cancer--results of a prospectively randomized trial.
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Drug Therapy, C | 1984 |
Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Female; Fluorour | 1984 |
[Adjuvant therapy in colonic cancer].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Leukemia; Prospect | 1984 |
Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Clinical Trials as Topic; | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Combination chemotherapy with 5-fluorouracil, CCNU, and vincristine in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections, | 1983 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
[Evaluation of preoperative administration of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) suppository in surgical adjuvant chemotherapy for large bowel cancer].
Topics: Adult; Colonic Neoplasms; Colostomy; Female; Fluorouracil; Humans; Male; Middle Aged; Preoperative C | 1984 |
Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Ne | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Herpes Labialis; Humans; Hypotension | 1984 |
[Antiblastic therapy of nonadvanced colorectal cancer: preliminary results of a randomized therapeutic trial].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1982 |
[Clinical evaluation of combination chemotherapy of aclacinomycin A (ACM) and 5-fluorouracil (5-FU) for advanced carcinoma of gastrointestinal tract].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Clinical Trials as Topic; Colonic Neo | 1982 |
Methyl-CCNU and ftorafur in treatment of rectosigmoidal tumors and ftorafur capsules in treatment of colorectal tumors.
Topics: Capsules; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Huma | 1981 |
Adjuvant chemotherapy of colorectal carcinoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neo | 1982 |
Combination chemotherapy containing semustine (MeCCNU) in patients with advanced colorectal cancer previously treated with 5-fluorouracil (5-Fu).
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; | 1983 |
Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells.
Topics: Animals; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug The | 1983 |
Systemic adjuvant therapy with BCG versus BCG + 5FU in colorectal cancer Dukes' Class C: updated critical analysis.
Topics: Aged; BCG Vaccine; Carcinoembryonic Antigen; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1980 |
Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide | 1980 |
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap | 1980 |
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, C | 1980 |
MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; F | 1980 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1981 |
Advances in the multimodal primary management of cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphami | 1980 |
The effect of fluorouracil on survival in metastatic colorectal cancer fluorouracil response improves survival.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; R | 1981 |
Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Immuno | 1980 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea (FIVB) in colon cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1981 |
A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Piperazines; Razoxane; Rectal Neo | 1981 |
Adjuvant therapy for large bowel cancer: update of Veterans Administration Surgical Oncology Group Trials.
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1981 |
[Background and experience of adjuvant cytostatic therapy in gastrointestinal cancer (author's transl)].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1981 |
Adjuvant chemotherapy in colon and gastric cancer.
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; F | 1982 |
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration | 1982 |
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; Drug Therapy, Combination; Fluo | 1982 |
Large bowel cancer: an overview.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Femal | 1982 |
Combined adjuvant therapy of radically operated colorectal cancer patients. (chemotherapy, radiotherapy, and MER-BCG).
Topics: Adult; Aged; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Male; Midd | 1982 |
High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug The | 1995 |
[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1995 |
[A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1995 |
Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1995 |
Cimetidine and survival with colorectal cancer.
Topics: CD8-Positive T-Lymphocytes; Cimetidine; Colonic Neoplasms; Combined Modality Therapy; Disease-Free S | 1995 |
Altered metabolism and mortality in patients with colon cancer receiving chemotherapy.
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Colonic Neoplasms; Drug | 1995 |
[Is radiotherapy necessary in the control of colorectal cancer?].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic | 1995 |
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1993 |
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
Topics: Adenocarcinoma; Colonic Neoplasms; Fatty Liver; Female; Fluorouracil; Humans; Interferon alpha-2; In | 1995 |
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedu | 1995 |
Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study.
Topics: Abdominal Pain; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Stu | 1995 |
Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sc | 1995 |
[Usefulness of 5-FU high-dose continuous therapy at home in patients with recurrent gastric and colon cancer].
Topics: Adult; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Services, Ho | 1994 |
[Effect of continuous infusion of 5-fluorouracil and daily low-dose cisplatin for inoperable recurrent cancer of the stomach and colon].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasm | 1995 |
Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; | 1994 |
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1995 |
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; F | 1995 |
Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1994 |
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1994 |
Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorodeoxyu | 1994 |
[Evaluation of cases of metastatic liver tumors resected following intra-arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colonic Neo | 1994 |
[The value of hepatic arterial infusion chemotherapy for liver metastases--discussion from viewpoints of prevention of hepatic death and QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Fl | 1994 |
[Efficacy of intrahepatic arterial chemotherapy to prevent recurrence of residual liver in metastatic liver cancer patients after hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Epirubicin; Female; Fluorou | 1994 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neop | 1994 |
[A study of various complications in arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Catheters, Indwelling; | 1994 |
[Adjuvant therapy in colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Par | 1994 |
Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1994 |
Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovor | 1994 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
Rationale for the combination therapy of 5FU and CDDP.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Col | 1993 |
Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dose-Resp | 1993 |
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin | 1993 |
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induced Liver Injury; Chem | 1993 |
A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-Resp | 1993 |
Recent clinical trials with levamisole.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; | 1993 |
Nonparametric estimation for the difference or ratio of median failure times.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Mathematics; Models, Statistical; Rectal Neoplasms; Surviva | 1993 |
[The efficacy of intra-arterial infusion chemotherapy in patients with non-resectable liver metastasis from colorectal cancer--a randomized study comparing FAM versus FEM].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ad | 1993 |
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Life Tables; Ma | 1993 |
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F | 1993 |
[Phase I study of 5-fluorouracil and l-leucovorin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1993 |
Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema | 1993 |
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1995 |
[Possible effect of administration methods on pharmacological action. Study of cytostatic therapy in advanced cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 1995 |
Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Col | 1995 |
5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
[Adjuvant systemic chemotherapy in colon cancer].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1996 |
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Sche | 1995 |
A pilot trial of continuous infusion 5-fluorouracil with levamisole for adjuvant therapy of colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Ad | 1996 |
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-F | 1996 |
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 1997 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon | 1997 |
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neop | 1997 |
[Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coloni | 1997 |
A phase I study of 5-fluorouracil, leucovorin and levamisole.
Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 1997 |
[Reversible liver steatosis in patients treated with 5-fluorouracil and interferon-alpha].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fatty Liver; Female; Fluo | 1997 |
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic N | 1997 |
Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.
Topics: Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Gene Amplificatio | 1997 |
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1997 |
[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer].
Topics: Adenocarcinoma; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
[The importance of adjuvant chemotherapy in the treatment of colonic carcinoma: SAKK Study 40/93 (Swiss Work Group for Clinical Cancer Research)].
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites | 1997 |
Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites, A | 1997 |
[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1997 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: a preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1997 |
Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Can
Topics: Adult; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neopla | 1997 |
Association between blood transfusion and survival in a randomised multicentre trial of perioperative adjuvant portal chemotherapy in patients with colorectal cancer. The Swiss Group for Clinical Cancer Research (SAKK).
Topics: Aged; Antimetabolites, Antineoplastic; Blood Transfusion; Chemotherapy, Adjuvant; Colonic Neoplasms; | 1997 |
[Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1997 |
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Sche | 1997 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colon | 1998 |
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neopla | 1998 |
GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in O
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1998 |
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 1998 |
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1998 |
Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studie | 1998 |
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 1998 |
[Clinical evaluation as palliative therapy of combination chemotherapy with continuous infusional 5-fluorouracil and consecutive low-dose cisplatin in unresectable gastrointestinal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1998 |
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Inte | 1998 |
Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-F | 1995 |
Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1996 |
Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1998 |
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antidotes; Antineoplastic Combined Chemotherapy P | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C | 1999 |
[Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1999 |
Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1999 |
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administrat | 1999 |
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 1999 |
[Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1999 |
[Clinical evaluation of intermittent hepatic arterial infusion therapy with CDDP and 5-FU for liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1999 |
[Weekly hepatic arterial infusion of high dose 5-fluorouracil for liver metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorourac | 1999 |
[Evaluation of intermittent hepatic arterial infusion chemotherapy for multiple liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Femal | 1999 |
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 1999 |
Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1999 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 2000 |
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Coloni | 2000 |
Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chi-Square Distribution; Colonic Neoplasms; Female; Fluo | 2000 |
Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2000 |
Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2000 |
Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease-Free Survival; Female; Fluo | 2000 |
[Comparison of fluorouracil + folinic acid, fluorouracil + levamisole and fluorouracil + folinic acid + levamisole in Dukes' B and C colon cancer: NSABP Trial C-04].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Survival; Fluorourac | 2000 |
Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Dose-Resp | 2000 |
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
[Adjuvant therapy of colon cancer stage C MAC. Adverse effects and efficacy in the Department of Oncology, Soroka Medical Center in the years 1991-1994].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 1999 |
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonic Neoplasms; F | 2000 |
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic N | 2000 |
UFT/leucovorin vs 5-FU/leucovorin in colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2000 |
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Diarrhea; Dou | 2001 |
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2001 |
Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neopl | 2001 |
Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy, Combinatio | 2001 |
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admini | 2001 |
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2001 |
Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration S | 2001 |
[Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Colo | 1998 |
Response shift in the perception of health for utility evaluation. an explorative investigation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Attitude to Health; | 2001 |
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2001 |
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2001 |
Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer: dose adjusted according to its toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 2001 |
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Hypersensitivi | 2002 |
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cost-Benefit Analys | 2002 |
Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil.
Topics: Administration, Oral; BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Fol | 1976 |
Adjuvant chemotherapy in large-bowel cancer: demonstration of effectiveness of single agent chemotherapy in a prospectively controlled,, randomized trial.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Palliative Care; Prognosis; Rando | 1978 |
Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Injection | 1976 |
Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Topics: Bacterial Vaccines; Colonic Neoplasms; Corynebacterium; Dacarbazine; Female; Fluorouracil; Humans; I | 1978 |
[Initial experiences with a nation-wide Austrian study of adjuvant chemo- and immunotherapy of colorectal cancer following radical surgery].
Topics: Antineoplastic Agents; Austria; Colectomy; Colonic Neoplasms; Drug Therapy, Combination; Fluorouraci | 1979 |
A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.
Topics: Administration, Oral; Aged; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Admi | 1977 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Intraluminal fluorouracil chemotherapy adjunct to surgical procedures for respectable carcinoma of the colon and rectum.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; H | 1977 |
Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; England; Female; Fluorouracil; Follow-Up Studies; | 1977 |
Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Eval | 1978 |
Randomized trial of melphalan plus 5-fluorouracil (5-FU) versus methyl-CCNU plus 5-FU in patients with advanced colorectal cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Phase II trial of 5-fluorouracil plus melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinat | 1978 |
Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Blood Cell Count; Clinical Trials as Topic; Colonic Neoplasms; Doxorubi | 1978 |
Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Ther | 1978 |
Phase II trial of a combination of cyclosphamide, vincristine, and methotrexate in advanced colorectal carcinoma.
Topics: Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, | 1978 |
5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Huma | 1978 |
Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Eva | 1978 |
Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neopl | 1978 |
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1978 |
A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; D | 1979 |
Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1979 |
The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Colonic N | 1979 |
Adjuvant therapy in colorectal cancer. (A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with the methanol extraction residue of BCG, MER).
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluor | 1979 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study.
Topics: Adenocarcinoma; Catheterization; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; | 1979 |
Adjuvant chemotherapy for large bowel cancer: an optimistic appraisal.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Postoperati | 1979 |
Adriamycin, mitomycin C, and 5-fluorouracil in combination for advanced colorectal adenocarcinoma previously treated with 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Dru | 1979 |
Adjuvant cytotoxic liver perfusion for colorectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; England; Female; | 1979 |
Cytotoxic perfusion for colorectal liver metastases.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Evaluation Studies as Topi | 1978 |
[Non resectable colonic cancer. Results from a test of chemotherapy with simultaneous prescription of VM26, methyl-CCNU and 5 fluoro-uracile (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1978 |
Special problems in the evaluation of results in adjuvant trials of cancer treatment.
Topics: Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Humans; Neoplasms; Prognosis; Statisti | 1978 |
Chemotherapy of large intestinal carcinoma. Current results and future prospects.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms | 1975 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1976 |
Fluorouracil, methyl-CCNU and vincristine in cancer of the colon.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neopla | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Randomized comparison of melphalan and 5-fluorouracil in the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Biliary Tract Diseases; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; F | 1976 |
Adjuvant chemotherapy with 5-fluorouracil after surgical resection of colorectal carcinoma (COG protocol 7041). A preliminary report.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Prospective Studies; Rectal N | 1977 |
Combined treatment with BCG and chemotherapy for metastatic gastrointestinal cancer.
Topics: BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Neoplasm | 1977 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.
Topics: Arylsulfatases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1977 |
A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studie | 1975 |
Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.
Topics: Antineoplastic Agents; Colonic Neoplasms; Cyclohexanes; Evaluation Studies as Topic; Female; Fluorou | 1975 |
Chemotherapy as an adjuvant to surgery for colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Postoperative Care; P | 1975 |
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administratio | 1975 |
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 1992 |
[Multicenter cooperative study of pre- and post-operative adjuvant chemotherapy in the treatment of colorectal cancer. North Kyushu Co-operative Study Group for Cancer Chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1992 |
Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1992 |
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1992 |
Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1992 |
Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1992 |
[Methionine-deprived amino acid solution-induced biochemical modulation of 5-FU and augmentation of the antitumor activity].
Topics: Amino Acids; Colonic Neoplasms; Fluorouracil; Humans; Methionine; Parenteral Nutrition, Total; Retin | 1992 |
A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intra | 1992 |
Is a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review?
Topics: Breast Neoplasms; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Inform | 1991 |
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
Topics: Adult; Aged; Blood Glucose; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinati | 1991 |
Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast | 1991 |
Combined 5-fluorouracil and recombinant alpha-2a-interferon vs. 5-fluorouracil alone in metastatic colorectal carcinoma: a multicenter randomized study.
Topics: Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; In | 1991 |
Adjuvant therapy with hepatic irradiation plus fluorouracil in colon carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver; Male | 1991 |
Levamisole in the adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1991 |
Adjuvant therapy for cancer of the colon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1991 |
[Requirements for the randomized trial of i.a. vs. i.v. administration to reveal the impact of hepatic arterial infusion on survival in the treatment of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Floxuri | 1990 |
Efficacy and toxicity of 5-fluorouracil and folates in advanced colon cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucov | 1990 |
Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; In | 1990 |
[Adjuvant treatment of colonic cancer. An important progress?].
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Fluorou | 1990 |
Dose-dependent leucovorin efficacy with an intermittent high-dose 5-fluorouracil schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; | 1990 |
[Adjuvant chemotherapy improves chances of survival in curative surgery of colon cancer, Dukes' stage C].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1990 |
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
[Concepts in the prevention and treatment of liver metastases of colorectal cancer by regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colonic Ne | 1988 |
[Outcome of adjuvant mifurol chemotherapy in patients with resected colonic carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1989 |
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1989 |
Levamisole with fluorouracil for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1989 |
[Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; | 1988 |
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1989 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
Systemic infusional chemotherapy for liver metastasis: an improved schedule for 5-fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Fluorouracil | 1986 |
A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuri
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Drug Administration Sc | 1987 |
Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1988 |
A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxurid | 1988 |
Regional infusion of fluoropyrimidines for hepatic metastases of colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu | 1988 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; | 1988 |
A northern California Oncology Group randomized trial of single agent 5-FU vs. high-dose folinic acid + 5-FU vs. methotrexate + 5-FU + folinic acid in patients with disseminated measurable large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1988 |
Adjuvant therapy for colorectal cancer: the NSABP clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1988 |
[Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1986 |
[Prospective adjuvant chemotherapy, with mitomycin C plus long-term carmofur in colorectal cancer].
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; D | 1986 |
Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum.
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1986 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorourac | 1987 |
Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1987 |
Mitomycin C plus carmofur (HCFU) adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma (interim report).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1987 |
Superselective intra-arterial chemotherapy with mitomycin C in liver and gallbladder cancer.
Topics: Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Gallbladder Neoplasms; Humans; I | 1988 |
Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Blood Platelets; Colonic Neoplasms; Female; Fluorouracil; Humans; | 1987 |
[Prospective adjuvant chemotherapy of mitomycin C plus HCFU for colorectal cancer (2d report)--6-year survival after surgery: Tokai Cooperative Study Group of Surgical Adjuvant Chemotherapy].
Topics: Adjuvants, Immunologic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colect | 1988 |
Pilot study on the regional treatment of colorectal liver metastases by intermittent arterial ischaemia with degradable starch microspheres and arterial and portal infusion with mitomycin C plus 5-fluorouracil--a clinical trial led by the Gastrointestinal
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Emboliz | 1988 |
Phase I-II pilot of whole abdominal radiation and concomitant 5-FU as an adjuvant in colon cancer: a Southwest Oncology Group Study.
Topics: Abdomen; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Middle Age | 1988 |
Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; Colonic | 1988 |
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1988 |
Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine | 1988 |
Adjuvant therapy of colorectal cancer. Why we still don't know.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neopla | 1988 |
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
Systemic therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colonic Neoplas | 1988 |
Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Female; | 1987 |
The effects of liver directed radiotherapy and chemotherapy on liver function tests and hematological parameters in patients with surgically resected colon cancer: findings from the Gastrointestinal Tumor Study Group.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bone Marrow; Carcinoma; Clinical Trials as Topic; | 1987 |
A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1987 |
Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukocyte M | 1987 |
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin | 1987 |
Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1987 |
Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colonic | 1987 |
Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Fluorou | 1987 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Biological Availability; Colonic Neoplasms; Fluorouracil; Hematopoiesis; Humans; Inf | 1987 |
Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms; Dose-Respon | 1987 |
Cytotoxic intracavitary chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheterization; Cisplatin; Clinical Tr | 1986 |
Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1986 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1986 |
5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule | 1986 |
Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Hepatic arterial ligation and portal vein infusion: a clinical trial by the Gastrointestinal Tract Cancer Group of the European Organization for Research and Treatment of Cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arter | 1986 |
[Comparative clinical study of MF(mitomycin and 5-fluorouracil) and MF.BH-AC therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1986 |
Fluorouracil in chemoprophylaxis of colorectal cancer. Results of a controlled clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; | 1986 |
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1987 |
Adjuvant immunochemotherapy in colorectal cancer Dukes C.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fema | 1987 |
Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical | 1987 |
Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sched | 1987 |
Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.
Topics: Adult; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Half-Life; Humans; | 1987 |
Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Humans | 1986 |
A randomized trial of oral 5-fluorouracil versus placebo as adjuvant therapy in colorectal cancer Dukes' B and C: results after 5 years observation time.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Double-Blind Method; Fluorou | 1985 |
A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1985 |
Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer.
Topics: Adult; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorourac | 1985 |
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Adult; Catheters, Indwelling; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colo | 1985 |
Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion?
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi | 1985 |
[Results of phase III study of lentinan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
The need for pilot studies and surgery-only controls in adjuvant therapy trials for large-bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1985 |
Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Colonic Neoplasms; Combined Modality Therapy; F | 1985 |
Fluorouracil as an adjuvant to surgery in carcinoma of the colon.
Topics: Adult; Age Factors; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Inject | 1971 |
Clinical effects of whole-body hyperthermia in adnanced malignancy.
Topics: Adult; Body Temperature; Breast Neoplasms; Child; Colonic Neoplasms; Cyclophosphamide; Female; Fluor | 1974 |
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: clinical trials.
Topics: Antineoplastic Agents; Blood Platelets; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1972 |
Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma.
Topics: Adult; Aged; Anemia, Aplastic; Blood Cell Count; Carcinoma; Clinical Trials as Topic; Colonic Neopla | 1972 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr | 1974 |
A pilot study for the evaluation of a new regime of combined therapy for the radical treatment of marginally operable rectal (or colo-rectal) cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluor | 1974 |
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar | 1972 |
Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease.
Topics: Antibiotics, Antineoplastic; Azo Compounds; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; D | 1970 |
Remission induction in childhood leukemia with second course vincristine (NSC-67574) and prednisone (NSC-10023) therapy.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Clinical Trials as Topic; Colonic | 1970 |
Comparison of antimetabolites in the treatment of breast and colon cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites; Breast Neoplasms; Child; Clinical Trials a | 1967 |
Intraluminal chemotherapy (HN2 or 5-FU) adjuvant to operation for cancer of the colon and rectum. II. Follow-up report of 97 cases.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Humans; M | 1967 |
A five year progress report on the effectiveness of intraluminal chemotherapy (5-fluorouracil) adjuvant to surgery for colorectal cancer.
Topics: Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Mechloret | 1968 |
[Tolerance of 5-fluorouracil in intensive treatment with high doses: 4 or 24-hour perfusions?].
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intraven | 1968 |
2825 other studies available for fluorouracil and Cancer of Colon
| Article | Year |
|---|---|
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
Topics: Acetates; Adenocarcinoma; Animals; Chemical Phenomena; Chemistry; Chlorine; Colonic Neoplasms; Hydro | 1989 |
Eleven novel diarylheptanoids and two unusual diarylheptanoid derivatives from the seeds of Alpinia blepharocalyx.
Topics: Animals; Antineoplastic Agents; China; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fibrosar | 2001 |
New spirostanol steroids and steroidal saponins from roots and rhizomes of Dracaena angustifolia and their antiproliferative activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Doxorubicin; Fibrosarcoma; Humans; Li | 2001 |
Constituents of Chinese propolis and their antiproliferative activities.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Caffeic Acids; China; Chromatography, Thin Layer | 2002 |
Three new C-14 oxygenated taxanes from the wood of Taxus yunnanensis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Survival; Colonic Neoplasms | 2002 |
Scaffold targeting drug-resistant colon cancers.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Depsipeptides; Drug Resistance, Neoplasm | 2007 |
Synthesis of new pyrrolo[2,3-d]pyrimidine derivatives and evaluation of their activities against human colon cancer cell lines.
Topics: Apoptosis; Colonic Neoplasms; Dose-Response Relationship, Drug; HCT116 Cells; Humans; Inhibitory Con | 2010 |
Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Ehrlich Tumor; Cell C | 2011 |
Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Biological Assay; Breast Neoplasms; Cell L | 2012 |
Mitochondrial dysfunction contributes to the cytotoxicity of some 3,5-bis(benzylidene)-4-piperidone derivatives in colon HCT-116 cells.
Topics: Animals; Colonic Neoplasms; Glutathione; HCT116 Cells; Humans; Membrane Potential, Mitochondrial; Mi | 2013 |
Novel 3,5-bis(arylidene)-4-piperidone dimers: potent cytotoxins against colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Dimerization; D | 2013 |
6-Acetonyldihydrochelerythrine Is a Potent Inducer of Apoptosis in HCT116 and SW620 Colon Cancer Cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Colon; Colonic Neoplasms; Drug Screening Assays, Antitu | 2014 |
Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer.
Topics: Amino Acids; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Colon | 2015 |
Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
Topics: Angiogenesis Inhibitors; Animals; Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, S | 2015 |
Monoterpene indole alkaloid hydrazone derivatives with apoptosis inducing activity in human HCT116 colon and HepG2 liver carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Colon; Colonic Neoplasms; HCT116 Cells; Hep G2 Cells; | 2015 |
Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Cycle Check | 2016 |
Vobasinyl-Iboga Alkaloids from Tabernaemontana elegans: Cell Cycle Arrest and Apoptosis-Inducing Activity in HCT116 Colon Cancer Cells.
Topics: Africa; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Cycle; Cell Cycle Checkpoints; | 2016 |
Cytotoxic pterosins from Pteris multifida roots against HCT116 human colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Caspase 9; Cell Proliferation; Circular Dichroism; Colonic Neopla | 2017 |
3,5-Bis(3-dimethylaminomethyl-4-hydroxybenzylidene)-4-piperidone and related compounds induce glutathione oxidation and mitochondria-mediated cell death in HCT-116 colon cancer cells.
Topics: Apoptosis; Cell Line; Colonic Neoplasms; Curcumin; Glutathione; HCT116 Cells; Humans; Membrane Poten | 2017 |
Nature-inspired development of unnatural meroterpenoids as the non-toxic anti-colon cancer agents.
Topics: Antineoplastic Agents; Biological Products; Cell Cycle Checkpoints; Cell Death; Cell Proliferation; | 2018 |
Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, D | 2019 |
From tryptophan to novel mitochondria-disruptive agent, synthesis and biological evaluation of 1,2,3,6-tetrasubstituted carbazoles.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carbazoles; Cell Line, Tumor; Cell Proliferation; | 2022 |
Discovery of dual inhibitors of topoisomerase I and Cyclooxygenase-2 for colon cancer therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; DN | 2022 |
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorourac | 2021 |
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2022 |
Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2022 |
LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis.
Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucose; Humans; MicroRNAs; | 2022 |
Prevotella contributes to individual response of FOLFOX in colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Diseas | 2021 |
CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cholesterol; | 2021 |
Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.
Topics: Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Hum | 2022 |
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neopl | 2022 |
Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell | 2021 |
EGF-functionalized lipid-polymer hybrid nanoparticles of 5-fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma.
Topics: Biological Availability; Carcinoma; Cell Survival; Colonic Neoplasms; Drug Carriers; Drug Delivery S | 2022 |
Fraxetin induces cell death in colon cancer cells via mitochondria dysfunction and enhances therapeutic effects in 5-fluorouracil resistant cells.
Topics: Cell Death; Colonic Neoplasms; Coumarins; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; HT2 | 2022 |
Vesicular IFN-γ as a cooperative attacker to enhance anti-cancer effect of 5-fluorouracil via thymidine phosphorylase upregulation and tumor microenvironment normalization.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Interferon-gamma; Thymidine Phosphorylase; Tumor Microenvir | 2022 |
Manuka honey in combination with 5-Fluorouracil decreases physical parameters of colonspheres enriched with cancer stem-like cells and reduces their resistance to apoptosis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Honey; Humans | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals.
Topics: Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Fluorouracil; Hospit | 2021 |
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Cetuximab; Colonic Neoplasm | 2022 |
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
Panitumumab Associated Acute Pancreatitis.
Topics: Acute Disease; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2022 |
[A Case of Colon Cancer with Suspected DPD Deficiency Causing Severe Adverse Effects following Adjuvant Chemotherapy with Capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2021 |
Ceftazidime and cefepime antagonize 5-fluorouracil's effect in colon cancer cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2022 |
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
UHMK1-dependent phosphorylation of Cajal body protein coilin alters 5-FU sensitivity in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Coiled Bodies; Colonic Neoplasms; Fluorouracil; Humans; Intracellul | 2022 |
The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo | 2023 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoembryonic Antigen; | 2022 |
Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease- | 2022 |
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CDX2 Transcription Factor; | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3.
Topics: Aldo-Keto Reductase Family 1 Member C3; Cell Line, Tumor; Colonic Neoplasms; DNA-Binding Proteins; D | 2022 |
Influence of extremely low-frequency magnetic field on chemotherapy and electrochemotherapy efficacy in human Caco-2 colon cancer cells.
Topics: Caco-2 Cells; Colonic Neoplasms; Electrochemotherapy; Electromagnetic Fields; Fluorouracil; Humans; | 2022 |
Mechanisms of GZ17-6.02 resistance.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Colonic Neoplas | 2022 |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2022 |
ARHGAP17 enhances 5-Fluorouracil-induced apoptosis in colon cancer cells by suppressing Rac1.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Ge | 2022 |
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndr | 2022 |
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions.
Topics: Aged, 80 and over; Capecitabine; Colonic Neoplasms; Conjunctivitis; Fluorouracil; Humans; Male; Rect | 2022 |
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chem | 2022 |
Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis.
Topics: Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neopla | 2022 |
[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2022 |
5-fluorouracil and curcumin with pectin coating as a treatment regimen for titanium dioxide with dimethylhydrazine-induced colon cancer model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Curcumin; Dimethylhydrazines; Fluorouracil; | 2022 |
Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy.
Topics: Animals; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Macrop | 2022 |
Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Flu | 2022 |
Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5‑FU by promoting the SDF‑1/CXCR4/Akt axis.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic | 2022 |
Deoxyelephantopin Induces Apoptosis and Enhances Chemosensitivity of Colon Cancer via miR-205/Bcl2 Axis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasm | 2022 |
Cross talk between acetylation and methylation regulators reveals histone modifier expression patterns posing prognostic and therapeutic implications on patients with colon cancer.
Topics: Acetylation; Biomarkers, Tumor; Colonic Neoplasms; DNA Methylation; Fluorouracil; Gene Expression Re | 2022 |
The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Colonic Neoplasms; Colorectal Neoplasms; DNA; Epige | 2023 |
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Ne | 2022 |
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Topics: Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Dihydropyrimidine De | 2022 |
The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer.
Topics: Adiposity; Cohort Studies; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, | 2022 |
The Effects of Ovalbumin on Proliferation, Migration, and Stemness Properties of Chemoresistant SW480 Colon Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Humans; Neoplastic Stem Cells | 2022 |
VMP1 promotes exosome secretion and enhances 5-FU resistance in colon cancer cells.
Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Exosomes; Fluorouracil; HT29 Cel | 2022 |
Curcumae longae Rhizoma (Jianghuang) extract reverses the 5-Fluoruracil resistance in colorectal cancer cells via TLR4/PI3K/Akt/mTOR pathway.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neop | 2022 |
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
A different approach to immunochemotherapy for colon Cancer: Development of nanoplexes of cyclodextrins and Interleukin-2 loaded with 5-FU.
Topics: Animals; Colonic Neoplasms; Cyclodextrins; Fluorouracil; Immunotherapy; Interleukin-2; Mice; Nanopar | 2022 |
5-Fluorouracil Treatment of CT26 Colon Cancer Is Compromised by Combined Therapy with IMMODIN.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Co | 2022 |
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
Early-stage colon cancer with high MALAT1 expression is associated with the 5-Fluorouracil resistance and future metastasis.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Ge | 2022 |
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon a
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; | 2022 |
Expression of Long Nonencoding Ribonucleic Acid SNHG20 in Colon Cancer Tissue in Its Influences on Chemotherapeutic Sensitivity of Colon Cancer Cells.
Topics: Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorourac | 2022 |
Second Cancer After Additive Chemotherapy in Patients With Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2022 |
Effect of long noncoding RNA CCAT2 on drug sensitivity to 5-fluorouracil of breast cancer cells through microRNA-145 meditated by p53.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
FKBP4 regulates 5-fluorouracil sensitivity in colon cancer by controlling mitochondrial respiration.
Topics: Adenocarcinoma; Carrier Proteins; Colonic Neoplasms; Copper; Electron Transport Complex IV; Fluorour | 2022 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorect | 2022 |
Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells.
Topics: Apoptosis; Autophagy; Cadherins; Cell Line, Tumor; Cell Proliferation; Claudin-3; Colonic Neoplasms; | 2022 |
Tenglong Buzhong granules inhibits the growth of SW620 human colon cancer.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinases; Cyclins; Fluorouracil; Human | 2022 |
The treatment efficacy of three-layered functional polymer materials as drug carrier for orthotopic colon cancer.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Endothelial Cells; Fluorouracil; Humans | 2022 |
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine; | 2022 |
A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
Topics: Biomarkers, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gene Expression Profiling; | 2022 |
Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional
Topics: Catenins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal N | 2022 |
Folate decorated lipid chitosan hybrid nanoparticles of 5-fluorouracil for enhanced anticancer efficacy against colon cancer.
Topics: Cell Line, Tumor; Chitosan; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; F | 2022 |
Sulforaphane has an additive anticancer effect to FOLFOX in highly metastatic human colon carcinoma cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic | 2022 |
Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid preparation protocol.
Topics: Adenocarcinoma; Cell Line, Tumor; Colonic Neoplasms; Cytostatic Agents; Fluorouracil; Humans; Irinot | 2022 |
Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2023 |
Characterization of the Molecular Alterations Induced by the Prolonged Exposure of Normal Colon Mucosa and Colon Cancer Cells to Low-Dose Bisphenol A.
Topics: Agar; Benzhydryl Compounds; beta Catenin; Colonic Neoplasms; Fluorouracil; HCT116 Cells; HSP27 Heat- | 2022 |
New Oxazolo[5,4-
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Prolifera | 2022 |
The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Evening primrose seed extract rich in polyphenols modulates the invasiveness of colon cancer cells by regulating the TYMS expression.
Topics: Animals; Colonic Neoplasms; Fluorouracil; Mice; Oenothera biennis; Plant Extracts; Polyphenols; Thym | 2022 |
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor | 2023 |
Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Topics: Adenosine Diphosphate; Antimalarials; Antineoplastic Agents; Artesunate; ATP Binding Cassette Transp | 2022 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2023 |
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coloni | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Modulating the activity of fluoropyrimidines against colorectal cancer by Vitamin D and its analogs.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Vitamin D | 2022 |
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Capecitabine; Chemotherapy, Adjuvant; Coloni | 2022 |
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.
Topics: Bevacizumab; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hu | 2022 |
Expression pattern of secretory-cell-related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes.
Topics: Adenocarcinoma; Cluster Analysis; Colonic Neoplasms; Fluorouracil; Humans; Tumor Microenvironment | 2023 |
Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA | 2022 |
2'-Fucosyllactose Suppresses Angiogenesis and Alleviates Toxic Effects of 5-Fu in a HCT116 Colon Tumor-Bearing Model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil; HCT116 Ce | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
Topics: Antineoplastic Agents; Colonic Neoplasms; Computer Simulation; Fluorouracil; Humans | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.
Topics: Apoptosis; Colonic Neoplasms; Estradiol; Female; Fluorouracil; HT29 Cells; Humans; Male | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Mitochondrial Factor C20orf7 Facilitates the EMT-Mediated Cancer Cell Migration and the Proliferation of Colon Cancer In Vitro and In Vivo.
Topics: Animals; Cell Movement; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Epithelial-Me | 2022 |
Dioscin reduced chemoresistance for colon cancer and analysis of sensitizing targets.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Oxa | 2023 |
Dioscin reduced chemoresistance for colon cancer and analysis of sensitizing targets.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Oxa | 2023 |
Dioscin reduced chemoresistance for colon cancer and analysis of sensitizing targets.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Oxa | 2023 |
Dioscin reduced chemoresistance for colon cancer and analysis of sensitizing targets.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Oxa | 2023 |
A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice.
Topics: Animals; Arginase; Arginine; Colonic Neoplasms; Cyclophosphamide; Dietary Supplements; Fluorouracil; | 2022 |
A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice.
Topics: Animals; Arginase; Arginine; Colonic Neoplasms; Cyclophosphamide; Dietary Supplements; Fluorouracil; | 2022 |
A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice.
Topics: Animals; Arginase; Arginine; Colonic Neoplasms; Cyclophosphamide; Dietary Supplements; Fluorouracil; | 2022 |
A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice.
Topics: Animals; Arginase; Arginine; Colonic Neoplasms; Cyclophosphamide; Dietary Supplements; Fluorouracil; | 2022 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
microRNA-143 interferes the EGFR-stimulated glucose metabolism to re-sensitize 5-FU resistant colon cancer cells via targeting hexokinase 2.
Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplas | 2023 |
Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Colonic Neoplasms; Fl | 2023 |
High therapeutic efficacy of 5-Fluorouracil-loaded exosomes against colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Exosomes; Fluorouracil; Human | 2023 |
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating MicroRNA; Colonic Neoplasm | 2023 |
Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinases; Flu | 2023 |
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
[Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv | 2022 |
Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?
Topics: Adrenergic beta-Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Ne | 2023 |
The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B.
Topics: Animals; B7-H1 Antigen; Carcinogenesis; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gastr | 2023 |
[A Case of Rhabdomyolysis Caused by Oxaliplatin during Postoperative Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2023 |
[Two Cases of Transfusion-Free Hepatectomy Following Chemotherapy for H3 Grade of Simultaneous Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Femal | 2023 |
Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drugs, Chinese Herbal; Fluorouracil; Humans; JNK Mitogen | 2023 |
DNA groove binder and significant cytotoxic activity on human colon cancer cells: Potential of a dimeric zinc (II) phthalocyanine derivative.
Topics: Antineoplastic Agents; Circular Dichroism; Cisplatin; Colonic Neoplasms; DNA; Ethidium; Fluorouracil | 2023 |
Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report.
Topics: Aged; Colonic Neoplasms; Fluorouracil; Humans; Leukoencephalopathies; Male; Neuroleptic Malignant Sy | 2023 |
Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids.
Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Colonic Neopl | 2023 |
Colorectal Cancer Bioengineered Microtissues as a Model to Replicate Tumor-ECM Crosstalk and Assess Drug Delivery Systems In Vitro.
Topics: Colonic Neoplasms; Drug Delivery Systems; Extracellular Matrix; Fluorouracil; Humans; Tumor Microenv | 2023 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Imm | 2023 |
Development of the new pH-driven carrier from alginate/carboxymethyl starch bio-coated co-drugs@COF-OH for controlled and concomitant colon cancer treatment.
Topics: Alginates; Colonic Neoplasms; Curcumin; Drug Carriers; Excipients; Fluorouracil; Humans; Hydrogen-Io | 2023 |
5-Fluorouracil Combined with Rutaecarpine Synergistically Suppresses the Growth of Colon Cancer Cells by Inhibiting STAT3.
Topics: Animals; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Ki-67 Antigen; Mice; | 2023 |
Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Cetuximab; Colonic | 2023 |
Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Mismatch Repair; Fluorouracil; Humans; Neoplasm Stagi | 2023 |
The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2023 |
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; | 2023 |
Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic N | 2023 |
Improvement of the In Vitro Cytotoxic Effect on HT-29 Colon Cancer Cells by Combining 5-Fluorouacil and Fluphenazine with Green, Red or Brown Propolis.
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Fluphenazine; HT29 Cells; Humans; Phenols; P | 2023 |
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Euonymus; Fluorouracil; Humans; | 2023 |
Dihydropyrimidine Dehydrogenase (DPD) as a Bridge between the Immune Microenvironment of Colon Cancers and 5-FU Resistance.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colonic Neoplasms; Dihydrouracil Dehydrogenase ( | 2023 |
Potential Anti-Inflammatory and Growth Inhibitory Effect of Cyrtopodion scabrum Extract on Colon Cancer; An in vivo Study.
Topics: Animals; Anti-Inflammatory Agents; Colonic Neoplasms; Female; Fluorouracil; Lizards; Mice; Mice, Inb | 2023 |
FOSL1 transcriptionally regulates PHLDA2 to promote 5-FU resistance in colon cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Computational Biology; Drug Resi | 2023 |
Multidimensional controllable fabrication of tumor spheroids based on a microfluidic device.
Topics: Animals; Capsules; Cell Line, Tumor; Chromatography, Liquid; Colonic Neoplasms; Fluorouracil; Humans | 2023 |
ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.
Topics: Activating Transcription Factor 2; Ataxia Telangiectasia Mutated Proteins; Checkpoint Kinase 1; Colo | 2023 |
FOXM1/NCAPH activates glycolysis to promote colon adenocarcinoma stemness and 5-FU resistance.
Topics: Adenocarcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluoro | 2023 |
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic N | 2023 |
Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Misma | 2023 |
Folic Acid-Functionalized Albumin/Graphene Oxide Nanocomposite to Simultaneously Deliver Curcumin and 5-Fluorouracil into Human Colorectal Cancer Cells: An
Topics: Albumins; Colonic Neoplasms; Curcumin; Excipients; Fluorouracil; Folic Acid; Graphite; Humans | 2023 |
Ferroptosis-associated gene CISD2 suppresses colon cancer development by regulating tumor immune microenvironment.
Topics: Adenocarcinoma; Cell Cycle; Colonic Neoplasms; Ferroptosis; Fluorouracil; Humans; Tumor Microenviron | 2023 |
Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2023 |
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Topics: Abdominal Pain; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Human | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Can the phenolic compounds of Manuka honey chemosensitize colon cancer stem cells? A deep insight into the effect on chemoresistance and self-renewal.
Topics: Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Honey; Humans; Neoplastic Stem Cells; Ph | 2023 |
KLF4 targets RAB26 and decreases 5-FU resistance through inhibiting autophagy in colon cancer.
Topics: Animals; Autophagosomes; Autophagy; Colonic Neoplasms; Disease Models, Animal; Fluorouracil; Humans; | 2023 |
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta | 2023 |
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
[Bletilla striata polysaccharide improves toxic and side effects induced by 5-FU: an untargeted metabolomics study].
Topics: Animals; Colonic Neoplasms; Diarrhea; Fluorouracil; Hormones; Male; Metabolomics; Mice; Mice, Inbred | 2023 |
Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; F | 2023 |
The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuv | 2023 |
New Schiff bases derived from dimethylpyridine-1,2,4-triazole hybrid as cytotoxic agents targeting gastrointestinal cancers: Design, synthesis, biological evaluation and molecular docking studies.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neopla | 2023 |
Blockade of chemo-resistance to 5-FU by a CK2-targeted combination via attenuating AhR-TLS-promoted genomic instability in human colon cancer cells.
Topics: Casein Kinase II; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Resistance, Neoplasm; Fluorouracil; | 2023 |
Quercetin reverses 5-fluorouracil resistance in colon cancer cells by modulating the NRF2/HO-1 pathway.
Topics: Apoptosis; Colonic Neoplasms; Fluorouracil; Heme Oxygenase-1; Humans; NF-E2-Related Factor 2; Oxidat | 2023 |
Changes in Prescribing Patterns in Stage III Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2023 |
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Col | 2023 |
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Prod | 2023 |
Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic N | 2023 |
TRIM69: a marker of metastasis and potential sensitizer to 5-Fluorouracil and PD-1 blockers in colon adenocarcinoma.
Topics: Adenocarcinoma; Algorithms; Colonic Neoplasms; Fluorouracil; Humans; Programmed Cell Death 1 Recepto | 2023 |
Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; F | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
[Astragalus polysaccharide inhibits IDO1 expression in colon tumor microenvironment to increase intratumoral CD8~+ T cell infiltration].
Topics: Animals; CD8-Positive T-Lymphocytes; Colonic Neoplasms; Fluorouracil; Mice; Polysaccharides; RNA, Me | 2023 |
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Col | 2023 |
[Modulation of Expression of Drug Metabolizing Enzymes and Augmentation of Anti-cancer Drug Effects: Through Epigenetics and Three-dimensional Cancer Cell Culture Systems].
Topics: Antineoplastic Agents; Cell Culture Techniques; Colonic Neoplasms; Cytochrome P-450 CYP1A2; Decitabi | 2023 |
Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2019 |
An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy.
Topics: Acrylic Resins; Administration, Oral; Animals; Chitosan; Colonic Neoplasms; Contrast Media; Delayed- | 2019 |
Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance?
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Co | 2019 |
Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2019 |
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2020 |
miR-210-3p mediates metabolic adaptation and sustains DNA damage repair of resistant colon cancer cells to treatment with 5-fluorouracil.
Topics: Adaptation, Physiological; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; DNA Da | 2019 |
E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, | 2019 |
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2020 |
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Camptothecin; Colon | 2019 |
Inhibition of hydrogen sulfide synthesis reverses acquired resistance to 5-FU through miR-215-5p-EREG/TYMS axis in colon cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Cystathionine beta- | 2019 |
Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Chromatin; Colonic Neoplasms; D | 2020 |
Adjuvant therapy with γ-tocopherol-induce apoptosis in HT-29 colon cancer via cyclin-dependent cell cycle arrest mechanism.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Cell Proliferation; Chemotherapy, Adj | 2019 |
Objectively measured physical activity during chemotherapy in colon cancer patients.
Topics: Accelerometry; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2020 |
BH3 profiling discriminates the anti‑apoptotic status of 5‑fluorouracil‑resistant colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; bcl-X Protein; Cell Proliferation; | 2019 |
PHBV/PLGA nanoparticles for enhanced delivery of 5-fluorouracil as promising treatment of colon cancer.
Topics: Animals; Calorimetry, Differential Scanning; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Dru | 2020 |
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Topics: Adenomatous Polyposis Coli Protein; Animals; Carcinogenesis; Cell Cycle Checkpoints; Cell Proliferat | 2019 |
Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Colonic Neoplasms; Dose-Response Re | 2019 |
Gercumin synergizes the action of 5-fluorouracil and oxaliplatin against chemoresistant human cancer colon cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; | 2020 |
Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carbon-S | 2019 |
Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2020 |
Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Colonic Neoplas | 2021 |
P-mapa, a promisor immunomodulator against tumor cells of colonic tissues: An investigation of the action mechanism over the TLR4 signaling pathway.
Topics: Aberrant Crypt Foci; Animals; Antineoplastic Agents; Biopolymers; Colonic Neoplasms; Enzyme-Linked I | 2020 |
[Successful Management of Deep Vein Thromboembolism and Pulmonary Embolism by Edoxaban for Long-Term 5-FU-Based Chemotherapy for Colon Cancer-A Case Report].
Topics: Aged; Anticoagulants; Colonic Neoplasms; Fluorouracil; Humans; Pulmonary Embolism; Pyridines; Thiazo | 2019 |
Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; | 2020 |
Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Resist | 2020 |
Topics: Adaptive Immunity; Animals; Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Flu | 2019 |
Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Decision-Making; Co | 2020 |
Fluorouracil-Induced Hyperpigmentation.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Hand; Humans; Hyperpigmentation; Male; Midd | 2020 |
Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Drug T | 2020 |
Overexpressing microRNA-34a overcomes ABCG2-mediated drug resistance to 5-FU in side population cells from colon cancer via suppressing DLL1.
Topics: 3' Untranslated Regions; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Calcium-B | 2020 |
IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; | 2020 |
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell | 2020 |
Dicoumarol suppresses HMGA2-mediated oncogenic capacities and inhibits cell proliferation by inducing apoptosis in colon cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2020 |
Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
Topics: Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin | 2020 |
Long non-coding RNA POU6F2-AS2 promotes cell proliferation and drug resistance in colon cancer by regulating miR-377/BRD4.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplas | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytid | 2020 |
[Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2019 |
Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Canada; Chemotherapy, Adjuvant; Colonic N | 2020 |
Data Mining the Prognostic Biomarkers: miRNAs Targeting the Chemotherapeutic Agent 5-Fluorouracil in Colon Cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colonic Neoplasms; Data Mining; Fluorouracil; Hu | 2020 |
Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Asian People; Case-Control Studies; Chemotherapy, Adjuvant; | 2020 |
Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Chemotherapy, Adjuvant; Col | 2020 |
Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line; Cell Proliferation; Cell Survival; C | 2020 |
Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis.
Topics: Adjuvants, Pharmaceutic; Animals; Apoptosis; beta Catenin; Cadherins; Carcinogenesis; Cell Adhesion | 2020 |
Multi-Domain Photopatterned 3D Tumor Constructs in a Micro-Physiological System for Analysis, Quantification, and Isolation of Infiltrating Cells.
Topics: Caco-2 Cells; Cell Separation; Colonic Neoplasms; Fluorouracil; HCT116 Cells; Humans; Hydrogels; Hyd | 2020 |
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Colonic Neop | 2020 |
Cost Effective Use of a Thiosulfinate-Enriched
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cost-Bene | 2020 |
Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colonic Neoplasms; Drug Car | 2020 |
The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers; Cetuximab; Colonic | 2020 |
[A Case of Ascending Colon Cancer with Synchronous Unresectable Liver Metastasis Maintaining a Long-Term Stable Disease State after Discontinuing Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colonic Neoplasms; Female; F | 2020 |
[A Case of Complete Pathological Response in a Patient with Advanced Ascending Colon Cancer That Invaded the Liver and Duodenum after FOLFOXIRI plus Bevacizumab Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Ascending; C | 2020 |
6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Catechols; Cell Hypoxia; Cell Line, Tumor; Colonic Neop | 2020 |
Challenges in Reirradiation of Intrahepatic Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2020 |
Functionalized layer-by-layer assembled film with directional 5-fluorouracil release to target colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Capsules; Cell Line, Tumor; Cell Proliferati | 2020 |
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2020 |
How we treat left-sided vs right-sided colon cancer.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2020 |
[Transverse Colon Cancer with Peritoneal Metastasis Successfully Treated with mFOLFOX6 plus Bevacizumab-A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colon, Transverse; C | 2020 |
Different effects of lysophosphatidic acid receptor-2 (LPA
Topics: Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Kn | 2021 |
Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2021 |
Biofilm-encapsulated nano drug delivery system for the treatment of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Bacterial Outer Membrane; Cell Line, Tumor; Colonic Neopla | 2020 |
Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2020 |
Immunogenic chemotherapy in two mouse colon cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumo | 2020 |
Significance of expression of pyrimidine metabolizing genes in colon cancer.
Topics: Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Pyrimidines; Thymidylat | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Single-Cell Transcriptome Analysis of Colon Cancer Cell Response to 5-Fluorouracil-Induced DNA Damage.
Topics: Colonic Neoplasms; DNA Damage; Fluorouracil; Humans; Single-Cell Analysis; Transcriptome | 2020 |
Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Calcium-Binding Proteins; Cell Movement; Cell Proli | 2020 |
A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE Study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2022 |
Ginsenoside Rg3 enhances the anticancer effect of 5‑FU in colon cancer cells via the PI3K/AKT pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Fluorou | 2020 |
Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2020 |
Robotic Complete Mesocolic Excision After Neoadjuvant Chemotherapy for Advanced Ascending Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colon, Ascending; | 2020 |
Apoptosis pathway in the combined treatment of x-ray and 5-FU-loaded triblock copolymer-coated magnetic nanoparticles.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Human | 2020 |
Role of PrP
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Colon; Colonic Neoplasms; Drug Resistance, Neop | 2020 |
An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Mice; Oxa | 2020 |
Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colitis; Colon; Colonic Neoplasm | 2021 |
Angiogenesis is promoted by exosomal DPP4 derived from 5-fluorouracil-resistant colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell P | 2021 |
Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin | 2021 |
[A Case of Neoadjuvant Chemotherapy with Modified FOLFOXIRI plus Bevacizumab for Transverse Colon Cancer with Invasion of the Gastric Antrum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Transverse; | 2020 |
Colon-specific tablets containing 5-fluorouracil microsponges for colon cancer targeting.
Topics: Colon; Colonic Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Tablets; Tablets, Enteric-Coa | 2020 |
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Microsatell | 2022 |
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2020 |
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; C | 2020 |
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical | 2020 |
Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2021 |
Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease Progression; Drug Resista | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Microsatellite Instability; Neoplasm Staging; | 2021 |
Mechanical characterization of bio composite films as a novel drug carrier platform for sustained release of 5-fluorouracil for colon cancer: Methodological investigation.
Topics: Colonic Neoplasms; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Fluorouracil; Humans | 2021 |
Home-based chemotherapy for stage III colon cancer patients in Thailand: Cost-utility and budget impact analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Cost-Benefit Analysi | 2021 |
Elucidation of underlying molecular mechanism of 5-Fluorouracil chemoresistance and its restoration using fish oil in experimental colon carcinoma.
Topics: 1,2-Dimethylhydrazine; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding | 2021 |
Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasm | 2021 |
FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Bioma | 2021 |
[A Case of Colon Cancer with Synchronous Multiple Metastases Successfully Treated with Combined Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Fluorouracil; Hu | 2021 |
Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Diet; DNA Damage; Drug Resistance | 2021 |
Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therap | 2021 |
Pluronic-Coated Biogenic Gold Nanoparticles for Colon Delivery of 5-Fluorouracil: In vitro and Ex vivo Studies.
Topics: Animals; Colonic Neoplasms; Drug Compounding; Drug Delivery Systems; Drug Liberation; Fluorouracil; | 2021 |
Staging Paradox and Discrepancy in Adjuvant Chemotherapy in Patients with T4N0, T1-2N1, and T3N1 Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Dox | 2021 |
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2021 |
[Construction of artificial neural network model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2021 |
Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2021 |
[Curcumin mediates IL-6/STAT3 signaling pathway to repair intestinal mucosal injury induced by 5-FU chemotherapy for colon cancer].
Topics: Animals; Colonic Neoplasms; Curcumin; Fluorouracil; Interleukin-6; Intestinal Mucosa; Rats; Rats, Sp | 2021 |
Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2021 |
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caco-2 Cel | 2021 |
Exosome-Mediated Transfer of circ_0000338 Enhances 5-Fluorouracil Resistance in Colorectal Cancer through Regulating MicroRNA 217 (miR-217) and miR-485-3p.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neop | 2021 |
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2021 |
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2021 |
Inhibition of Heat-shock Protein 27 Reduces 5-Fluorouracil-acquired Resistance in Human Colon Cancer Cells.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HSP27 Heat-Shock Prote | 2021 |
miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal transition in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Col | 2021 |
Upregulation of NOX-2 and Nrf-2 Promotes 5-Fluorouracil Resistance of Human Colon Carcinoma (HCT-116) Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2021 |
Gamma radiation synthesis of a novel amphiphilic terpolymer hydrogel pH-responsive based chitosan for colon cancer drug delivery.
Topics: Acrylamides; Acrylates; Alkanesulfonates; Antimetabolites, Antineoplastic; Chitosan; Colonic Neoplas | 2021 |
Chemotherapy of metastatic colon cancer in France: A population-based study.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2021 |
Endogenous hydrogen sulfide regulates xCT stability through persulfidation of OTUB1 at cysteine 91 in colon cancer cells.
Topics: Amino Acid Transport System y+; Animals; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Deubiquitina | 2021 |
Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloni | 2021 |
Ganoderic acid alleviates chemotherapy-induced fatigue in mice bearing colon tumor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Cytokines; Energy Metabolism; F | 2021 |
Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2021 |
Hospitalizations among early-stage colon cancer patients receiving adjuvant chemotherapy: a real-world study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2021 |
Synergistic Interaction between 5-FU and an Analog of Sulforaphane-2-Oxohexyl Isothiocyanate-In an In Vitro Colon Cancer Model.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms | 2021 |
C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer.
Topics: Case-Control Studies; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition | 2021 |
Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bacterial Proteins; Cell Movement; Cell Prolife | 2021 |
Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study.
Topics: Aged; Biomarkers, Tumor; Cell-Free Nucleic Acids; Colonic Neoplasms; DNA, Neoplasm; Female; Fluorour | 2021 |
The role of SIRT5 and p53 proteins in the sensitivity of colon cancer cells to chemotherapeutic agent 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Colonic Neoplas | 2021 |
Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Flu | 2022 |
Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Apoptosis; Breast Neoplasms; C | 2021 |
Sulfonamide-Functionalized Polymeric Nanoparticles for Enhanced In Vivo Colorectal Cancer Therapy.
Topics: Chemical and Drug Induced Liver Injury; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Flu | 2022 |
The Early Impact of the IDEA Collaboration Results: How the Results Changed Prescribing Practice.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical | 2021 |
Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II - III elderly patients with colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2022 |
Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2021 |
Eudragit S-100 Surface Engineered Nanostructured Lipid Carriers for Colon Targeting of 5-Fluorouracil: Optimization and In Vitro and In Vivo Characterization.
Topics: Animals; Caco-2 Cells; Colon; Colonic Neoplasms; Drug Carriers; Fluorouracil; Humans; Lipids; Nanost | 2021 |
Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Colonic Neoplasms; DNA Damage; DNA M | 2021 |
Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neopla | 2021 |
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as | 2021 |
Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post-metastatic liver biochip modeling.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; | 2021 |
Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Apoptosis mediated chemosensitization of tumor cells to 5-fluorouracil on supplementation of fish oil in experimental colon carcinoma.
Topics: Animals; Apoptosis; Carcinoma; Cell Proliferation; Colonic Neoplasms; Dextran Sulfate; DNA Damage; D | 2017 |
Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2017 |
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 2017 |
Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Creatinine; Disseminated In | 2017 |
Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil.
Topics: Aged; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Female; Fluo | 2017 |
Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevaci | 2017 |
Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism.
Topics: Cellular Reprogramming; Colonic Neoplasms; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistan | 2017 |
[A Case of Advanced Transverse Colon Cancer with Nephrotic Syndrome Treated with Curative Resection and Complete Adjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2017 |
Enhanced Susceptibility to 5-Fluorouracil in Human Colon Cancer Cells by Silencing of GRP78.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Su | 2017 |
In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tum | 2017 |
Treatment of colon cancer cells with 5-fluorouracil can improve the effectiveness of RNA-transfected antitumor dendritic cell vaccine.
Topics: Antigen Presentation; Antimetabolites, Antineoplastic; Cancer Vaccines; Cell Proliferation; Colonic | 2017 |
Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy.
Topics: Antineoplastic Agents; Bioreactors; Cells, Cultured; Colon; Colonic Neoplasms; Drug Discovery; Drug | 2017 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Surviv | 2017 |
Prognostic relevance of Src activation in stage II-III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis.
Topics: Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Down-Regulati | 2017 |
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonic Neoplasms; F | 2017 |
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Exons; Fluorouracil; Humans | 2017 |
Novel Gold(I) Thiolate Derivatives Synergistic with 5-Fluorouracil as Potential Selective Anticancer Agents in Colon Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Auranofin; Caco-2 Cells; Cattle; Cell Cycle; Colonic Neop | 2017 |
Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coh | 2018 |
Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2017 |
Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2017 |
Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2017 |
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Brain Dise | 2017 |
Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2018 |
Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Anima | 2017 |
The novel gene HA117 promotes in vitro and in vivo drug resistance in mouse colon tumor cells.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Models, A | 2017 |
Development of biomedical 5-fluorouracil nanoplatforms for colon cancer chemotherapy: Influence of process and formulation parameters.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Fluorouracil; Humans; Lactic Acid; Nanoparticles | 2017 |
The Allosteric Hemoglobin Effector ITPP Inhibits Metastatic Colon Cancer in Mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
[Prognostic value of chemotherapy-induced neutropenia in metastatic colon cancer patients undergoing first-line chemotherapy with FOLFOX].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; | 2017 |
Mesoporous silica nanoparticles (MSNs)-based organic/inorganic hybrid nanocarriers loading 5-Fluorouracil for the treatment of colon cancer with improved anticancer efficacy.
Topics: Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Hyd | 2017 |
Anticancer effects of seaweed compounds fucoxanthin and phloroglucinol, alone and in combination with 5-fluorouracil in colon cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Survival; Colon; Col | 2017 |
GRP78 Regulates Apoptosis, Cell Survival and Proliferation in 5-Fluorouracil-resistant SNUC5 Colon Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dr | 2017 |
Subcutaneous Draining of Lower Extremity Edema in a Patient With Advanced Cancer Relieves Scrotal Swelling and Improves Mobility.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drainage; Edema; Fluoroura | 2018 |
miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorourac | 2017 |
Pressure responsive nanogel base on Alginate-Cyclodextrin with enhanced apoptosis mechanism for colon cancer delivery.
Topics: Alginates; Apoptosis; Calorimetry, Differential Scanning; Colonic Neoplasms; Cross-Linking Reagents; | 2018 |
Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Line, T | 2017 |
MACC1 facilitates chemoresistance and cancer stem cell‑like properties of colon cancer cells through the PI3K/AKT signaling pathway.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Gene | 2017 |
Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Delayed-Action Preparations; Drug Carri | 2018 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colec | 2017 |
Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Capecitabine; Colonic Neoplasms | 2017 |
Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.
Topics: Antineoplastic Agents; Cellular Senescence; Colonic Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; | 2018 |
Novel mouse models of hepatic artery infusion.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; Hepatic A | 2017 |
MicroRNA-195 desensitizes HCT116 human colon cancer cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Cycle Proteins; Checkpoint Kinase 1; Colonic Neopl | 2018 |
Overexpression of lamin B1 induces mitotic catastrophe in colon cancer LoVo cells and is associated with worse clinical outcomes.
Topics: Actin Cytoskeleton; Actins; Antimetabolites, Antineoplastic; beta Catenin; Cell Cycle; Cell Death; C | 2018 |
Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Survival; Drug | 2018 |
Potentiation of treatment efficacy against colon cancer of dopamine via elevating KLF2 expression in tumor vascular endothelial cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Dopamine; Drug Scree | 2017 |
DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase.
Topics: Animals; Antineoplastic Agents; Arabidopsis Proteins; Cell Cycle; Cell Line, Tumor; Colonic Neoplasm | 2018 |
Chemotherapy diminishes lipid storage capacity of adipose tissue in a preclinical model of colon cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2017 |
Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopt | 2017 |
Transferrin targeted liposomal 5-fluorouracil induced apoptosis via mitochondria signaling pathway in cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Colonic Neoplasms; Drug Delivery Systems; Flu | 2018 |
Deciding the Duration of Adjuvant Chemotherapy in a Patient With Stage III Colon Cancer: When Can Less Be More?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fl | 2017 |
Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2017 |
A case of severe stenosis of hepatic veins and inferior vena cava with stomal variceal bleeding induced by oxaliplatin-based chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic N | 2018 |
Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Colonic | 2018 |
RETRACTED: Schizandrin A enhances chemosensitivity of colon carcinoma cells to 5-fluorouracil through up-regulation of miR-195.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclooctanes; Dru | 2018 |
[A Case of Ascending Colon Cancer with Lynch Syndrome Who Underwent XELOX Adjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colon, | 2018 |
Formyl peptide receptor 2 mediated chemotherapeutics drug resistance in colon cancer cells.
Topics: Adult; Aged; Carrier Proteins; Cell Line, Tumor; Cell Survival; Chemotactic Factors; Colonic Neoplas | 2018 |
Effects of LPA
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cisplatin; Colonic Neoplasms; Fluorouracil; | 2018 |
[A Case of Effective Neoadjuvant Chemotherapy for Transverse Colon Cancer with Extensive Abdominal Wall Invasion].
Topics: Abdominal Wall; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms | 2017 |
Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway.
Topics: Animals; Apoptosis; Cell Line; Cell Proliferation; Chromatography, High Pressure Liquid; Colonic Neo | 2018 |
Hyaluronidase Enzyme-responsive Targeted Nanoparticles for Effective Delivery of 5-Fluorouracil in Colon Cancer.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; Drug Com | 2018 |
Targeting PRPK Function Blocks Colon Cancer Metastasis.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic N | 2018 |
Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2018 |
Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2018 |
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet | 2018 |
Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Dipeptides; Drug The | 2018 |
Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.
Topics: Adenocarcinoma; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diag | 2018 |
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec | 2018 |
Novel 1,3,4-thiadiazoles inhibit colorectal cancer via blockade of IL-6/COX-2 mediated JAK2/STAT3 signals as evidenced through data-based mathematical modeling.
Topics: Animals; Colonic Neoplasms; Cyclooxygenase 2; Fluorouracil; Interleukin-6; Janus Kinase 2; Male; Met | 2019 |
Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Ethanol; | 2018 |
Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin | 2018 |
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemot | 2018 |
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2019 |
Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase Inhibitors; Caspases; Cell | 2018 |
A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2018 |
Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon; Colonic Neoplasms; Fl | 2018 |
DUOX2-mediated production of reactive oxygen species induces epithelial mesenchymal transition in 5-fluorouracil resistant human colon cancer cells.
Topics: Acetylcysteine; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Dual Oxidases; Epith | 2018 |
Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neopl | 2018 |
Selenium Nanoparticles Induce the Chemo-Sensitivity of Fluorouracil Nanoparticles in Breast and Colon Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; | 2019 |
Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell Movement; Cisplatin; Colon; Colonic Neoplas | 2018 |
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2018 |
Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drugs, Chinese Herbal; Fluorour | 2018 |
Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction.
Topics: Antimetabolites, Antineoplastic; Biglycan; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2018 |
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial | 2018 |
Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Lin | 2018 |
Predicting events in clinical trials using two time-to-event outcomes.
Topics: Biometry; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; Models, Sta | 2018 |
Acute coronary syndrome in the oncology patient: An avoidable event?
Topics: Acute Coronary Syndrome; Angioplasty; Antineoplastic Agents; Colonic Neoplasms; Duodenal Neoplasms; | 2018 |
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2018 |
Enhancement of 5-Fluorouracil Cytotoxicity by Pyridoxal 5'-Phosphate and Folinic Acid in Tandem.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Fluorouracil; | 2018 |
Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Eso | 2018 |
Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy.
Topics: Allografts; alpha-Tocopherol; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neop | 2018 |
Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorour | 2019 |
Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cells, | 2018 |
Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2018 |
[Five-Year Survival of Two Patients with Para-Aortic Lymph Node Metastasis Treated with Four FOLFOX6and Four FOLFIRI Courses in Combination with Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2018 |
Effective sustained release of 5-FU-loaded PLGA implant for improving therapeutic index of 5-FU in colon tumor.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Delayed-Action Prepar | 2018 |
Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability.
Topics: Apoptosis; Cell Movement; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Fluorouracil; Gene | 2018 |
Chemosensitivity of human colon cancer cells is influenced by a p53-dependent enhancement of ceramide synthase 5 and induction of autophagy.
Topics: Autophagy; Colonic Neoplasms; Down-Regulation; Fluorouracil; Gene Expression Regulation, Neoplastic; | 2018 |
Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle | 2018 |
Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regulating cellular prion protein-Oct4 axis.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Autophagy; Colon; Colonic Neoplasms; | 2018 |
Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Colonic Neop | 2018 |
Co-delivery of 5-fluorouracil and oxaliplatin in novel poly(3-hydroxybutyrate-co-3-hydroxyvalerate acid)/poly(lactic-co-glycolic acid) nanoparticles for colon cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic N | 2019 |
Estimation and identification issues in the promotion time cure model when the same covariates influence long- and short-term survival.
Topics: Biostatistics; Colonic Neoplasms; Fluorouracil; Humans; Models, Statistical; Multivariate Analysis; | 2019 |
[A Case of Neuroendocrine Carcinoma of the Ascending Colon That Responded Completely to Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Neuroendocrine; Colectomy; C | 2018 |
Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer.
Topics: Benzodiazepinones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chec | 2018 |
The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuv | 2018 |
E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Agents; Cadherins; Colonic Neoplasms; Drug Resistance, | 2019 |
Palladium concave nanocrystals with high-index facets accelerate ascorbate oxidation in cancer treatment.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Catalysis; Colonic Neoplasms; Female; Fluorouracil; H | 2018 |
Silibinin, A Natural Blend In Polytherapy Formulation For Targeting Cd44v6 Expressing Colon Cancer Stem Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Colonic Neoplasms; Fluorouracil; G1 Phase; HCT116 Cell | 2018 |
Beta-Hydroxybutyrate Promotes Proliferation, Migration and Stemness in a Subpopulation of 5FU Treated SW480 Cells: Evidence for Metabolic Plasticity in Colon Cancer
Topics: 3-Hydroxybutyric Acid; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation | 2018 |
Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic N | 2019 |
Case of purpuric drug eruption probably induced by panitumumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Colonic Neoplasms; Drug Erupti | 2019 |
Neutrophilic eccrine hidradenitis in a patient with FOLFOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hidradenitis | 2018 |
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2018 |
[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2018 |
[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic | 2018 |
Dihomo-γ-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cap | 2018 |
Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor | 2019 |
The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; D | 2019 |
Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic | 2019 |
BET Inhibitors Potentiate Chemotherapy and Killing of
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azepines; Cell Cycle Proteins; Cell Proliferati | 2019 |
In vitro and in vivo evaluation of colon cancer targeted epichlorohydrin crosslinked Portulaca-alginate beads.
Topics: Administration, Oral; Alginates; Animals; Antineoplastic Agents; Colon; Colonic Neoplasms; Epichloro | 2018 |
Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chemical Phenomena; Colonic Neoplasms; Disease Models, Ani | 2019 |
[A Case of Recurrent Colon Cancer with Long-Term Complete Response Treated with FOLFOX Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Flu | 2018 |
[A Super-Elderly Patient with Recurrent Colon Cancer with Metastasis Effectively Treated with Capecitabine plus Bevacizumab Chemotherapy-A Case Report].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2018 |
[A Case of Long-Term Survival in a Patient with Ascending Colon Cancer and Synchronous Multiple Liver Metastases after Multimodality Therapy Including Multiple Hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colonic Neoplasms; Female; F | 2018 |
Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2019 |
uMUC1-Targeting Magnetic Resonance Imaging of Therapeutic Response in an Orthotropic Mouse Model of Colon Cancer.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Fluorouracil; Glycosylation; M | 2019 |
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota.
Topics: Animals; Azoxymethane; Colitis; Colon; Colonic Neoplasms; Colorectal Neoplasms; Dextran Sulfate; Dis | 2019 |
Activation of the PERK-ATF4 pathway promotes chemo-resistance in colon cancer cells.
Topics: Activating Transcription Factor 4; Animals; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug | 2019 |
FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2019 |
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
Topics: Apoptosis; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; R | 2019 |
MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27.
Topics: 3' Untranslated Regions; Base Sequence; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Enzyme Activ | 2019 |
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; F | 2019 |
Identification of Nrf2/STAT3 axis in induction of apoptosis through sub-G
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Proliferation; Cell Survival; Colonic Neo | 2019 |
Partial response after treatment with Conversion chemotherapy: A case report of a patient with colon cancer and unresectable hepatic metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms | 2019 |
Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
Topics: Animals; Aptamers, Nucleotide; Biomarkers, Pharmacological; Carcinoembryonic Antigen; Cell Adhesion; | 2019 |
Downregulation of lncRNA CCAT1 enhances 5-fluorouracil sensitivity in human colon cancer cells.
Topics: Animals; Apoptosis; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Drug Resistance, Neoplas | 2019 |
Clinical Evaluation of Preoperative Radiotherapy Combined with FOLFOX Chemotherapy on Patients with Locally Advanced Colon Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherap | 2019 |
To Take or Not to Take a Side: That Is the Question.
Topics: Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin | 2019 |
TGF-β1 protects colon tumor cells from apoptosis through XAF1 suppression.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival | 2019 |
Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Female | 2019 |
Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Descending; Colonic Neoplasms; Female; | 2019 |
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2019 |
Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cross-Sectional Stud | 2020 |
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colonic Neoplasms; Dr | 2020 |
[Long-Term Effectiveness of Chemotherapy Containing mFOLFOX6 plus Panitumumab and 5-FU/l-LV plus Panitumumab after Primary Tumor Resection in a Case of Ascending Colon Carcinoma and Multiple Hepatic Metastases].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colo | 2019 |
An acellular tissue matrix-based drug carriers with dual chemo-agents for colon cancer growth suppression.
Topics: Acellular Dermis; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ap | 2019 |
Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory P | 2020 |
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2019 |
Optimal duration of adjuvant therapy for stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chem | 2019 |
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (I
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2019 |
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (I
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2019 |
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (I
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2019 |
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (I
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2019 |
[Intussusception Caused by Colon Cancer in Pregnancy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscop | 2019 |
Cytotoxic activity of the seaweed compound fucosterol, alone and in combination with 5-fluorouracil, in colon cells using 2D and 3D culturing.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Colonic Neoplasms; Fibroblasts; Fluorourac | 2019 |
Sesquiterpenes α-humulene and β-caryophyllene oxide enhance the efficacy of 5-fluorouracil and oxaliplatin in colon cancer cells.
Topics: Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Humans; Membran | 2019 |
Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; | 2019 |
Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm In | 2019 |
Atypical PRES with diffusion restriction or neurotoxicity- ? part of same spectrum-after oxaliplatin (FOLFOX-4 regimen) for colonic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura | 2019 |
Polymeric Microsphere Formulation for Colon Targeted Delivery of 5-Fluorouracil Using Biocompatible Natural Gum Katira.
Topics: Animals; Antimetabolites, Antineoplastic; Biocompatible Materials; Colonic Neoplasms; Drug Carriers; | 2019 |
Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles.
Topics: Animals; Apoptosis; Catechin; Colonic Neoplasms; Fluorouracil; HT29 Cells; Humans; Mice; Nanoconjuga | 2019 |
Anticancer activity of "Trigno M", extract of Prunus spinosa drupes, against in vitro 3D and in vivo colon cancer models.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Coloni | 2019 |
Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Animals; Colonic Neoplasms; Female; Fluorine Radioisotopes; Fluorour | 2013 |
The combination therapy of α-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Cytotoxicity, Immunologic; Drug Synergism; Female; Flu | 2013 |
Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2013 |
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Colonic Neoplasms; Female; Fluorouracil; | 2013 |
Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, | 2013 |
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; beta Catenin; Biomarkers, Tumor; CD8 Antigens | 2013 |
Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines.
Topics: Adenosine; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclic AMP; Cyclic AMP-Dependent Pr | 2013 |
ALPPS procedure with the use of pneumoperitoneum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic | 2013 |
The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2013 |
The effects of 5-fluorouracil on the proteome of colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Fluorouracil; | 2013 |
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2013 |
Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemistry, Pharmaceutical; Colonic Neoplas | 2013 |
Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Colonic | 2013 |
[Study of tolerability of capecitabine in postoperative adjuvant chemotherapy in colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deox | 2013 |
Impact of dihydropyrrol derivative on the normal colonic mucosa of DMH-induced colon cancer rats compared with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Cell Proliferation; Cell Transformation, Neoplastic; | 2013 |
Predictive value of baseline plasma D-dimers for chemotherapy- induced thrombocytopenia in patients with stage III colon cancer: a pilot study.
Topics: Adult; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curv | 2013 |
Wheat germ agglutinin-functionalised crosslinked polyelectrolyte microparticles for local colon delivery of 5-FU: in vitro efficacy and in vivo gastrointestinal distribution.
Topics: Alginates; Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Chitosan; Colon; Colonic Neoplasm | 2013 |
The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, | 2013 |
Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; | 2013 |
Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; | 2013 |
Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; | 2013 |
Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; | 2013 |
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Chemotherapy, Adjuvant; Colonic Neoplasms; Cyclin D1; Femal | 2014 |
Update: NCCN colon and rectal cancer clinical practice guidelines.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2004 |
Selecting regimens in advanced colon cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2004 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms | 2013 |
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Belgium; Chemotherapy, Adjuvant; Col | 2013 |
MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Casset | 2013 |
Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Delayed-Action Pr | 2013 |
Teaching NeuroImages: 5-FU-induced acute leukoencephalopathy.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; | 2013 |
Analysis of saliva samples from oncological patients treated with 5-fluorouracil and leucovorin calcium by scanning electron microscopy with energy dispersive system.
Topics: Administration, Intravenous; Adult; Antimetabolites, Antineoplastic; Calcium; Carcinoma; Colonic Neo | 2013 |
Induction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Colonic Neoplasms; Culture Media; DNA Methylation; Down-Regulat | 2013 |
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzofurans; Camptothecin; Cell Death; | 2013 |
Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; DNA Damage; Drug Resistance, | 2013 |
Cytotoxic withanolides from the leaves of Moroccan Withania frutescens.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Chromatography, High P | 2013 |
Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2013 |
Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances anticancer effects of 5--Fluorouracil in CT26 colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Caspases; Cell | 2013 |
Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Coculture Techniques; Colonic Neoplasms; Cytotoxic | 2013 |
Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease Models, Animal; | 2013 |
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2013 |
Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2013 |
Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Colonic Neoplasms; Ethnicity; Female; Fluorouracil; Humans; | 2014 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; | 2013 |
[A case of relapsed colon cancer successfully treated by capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouraci | 2013 |
[A case of recurrent colon cancer developed thrombosis in superior mesenteric vein after chemotherapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; | 2013 |
Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2013 |
Potential anti-tumor effects of Mugil cephalus processed roe extracts on colon cancer cells.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Survival; Cholesterol; Colonic Neoplasms; Dietary | 2013 |
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Lym | 2013 |
[A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Benzimidazoles; Colonic N | 2013 |
Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson's disease worsened after capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnostic Errors; | 2013 |
γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line | 2013 |
Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; DNA-Bi | 2014 |
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryoni | 2013 |
Paraneoplastic optic neuropathy and retinopathy associated with colon adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscopy; Comb | 2013 |
Nicotine increases survival in human colon cancer cells treated with chemotherapeutic drugs.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Camptotheci | 2013 |
Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells.
Topics: Analgesics, Opioid; Antimetabolites, Antineoplastic; Cell Proliferation; Colonic Neoplasms; Drug Int | 2014 |
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Topics: Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fl | 2013 |
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Hum | 2013 |
Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neopl | 2014 |
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF‑κB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Berberine; Camptothe | 2014 |
Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
[A case study of stable disease after hepatic arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable hepatic metastases of colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Resistance, Neoplasm; | 2013 |
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2013 |
A preclinical murine model for the detection of circulating human tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Disease | 2013 |
[A case wherein bevacizumab/XELOX combination therapy was remarkably effective for the treatment of extensive dissemination in advanced colon cancer, and the primary lesion could be resected].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptotic Protease-Activating Factor 1; B | 2014 |
[Enhanced anticancer effects of 5'-DFUR on colorectal cancer cell lines SW480 and LOVO by transfection with thymidine phosphorylase cDNA].
Topics: Cell Line, Tumor; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Thymidine Phosphorylase; Tra | 2013 |
1,3-Bis(2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carmustine | 2013 |
Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Cell Cycle; Cell Proliferation; Chemoradiotherapy | 2014 |
High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxyuracil Nucleotides; DNA Rep | 2014 |
siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Dow | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyr | 2014 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Drug resistance mediated changes in lymphendothelial tumor cell intravasation.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Endothelium, Lymphatic; Epithelial-M | 2014 |
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Cycle Proteins; Cel | 2014 |
CD133 and CD133-regulated nucleophosmin linked to 5-fluorouracil susceptibility in human colon cancer cell line SW620.
Topics: AC133 Antigen; Antigens, CD; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Electro | 2014 |
A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Coloni | 2013 |
The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Hum | 2014 |
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N | 2014 |
[A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Ch | 2014 |
[A case of preoperative "bridge to chemotherapy" expandable metallic stent insertion and neoadjuvant therapy for obstructive colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human | 2013 |
[A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
[A case of a recurrent hepatic metastasis occurred after curative resection of ascending colon cancer and a hepatic metastasis responding completely to capecitabine plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
pH dependent poly[2-(methacryloyloxyethyl)trimetylammonium chloride-co-methacrylic acid]hydrogels for enhanced targeted delivery of 5-fluorouracil in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biocompatible Materials; Cell Line; Colonic Neoplasms; Drug Carrie | 2014 |
Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures.
Topics: Antineoplastic Agents; Apoptosis; Cell Count; Cell Line, Tumor; Colonic Neoplasms; Curcumin; DNA Mis | 2014 |
Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Caspase 7; Cell Line, Tumor; Colonic Neoplasms; Cont | 2014 |
Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dose | 2014 |
[Compliance with FOLFOX4 for Stage III colon cancer in the adjuvant setting].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2014 |
[A case of endocrine cell carcinoma of the ascending colon with liver metastasis treated with hepatectomy after excision of the primary lesion and systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Transport; Cell Survival; Colonic Neopla | 2015 |
Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Colonic Neoplasms; Cytoplasm; Down-Re | 2014 |
Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU).
Topics: Animals; Antimetabolites, Antineoplastic; Chitosan; Colonic Neoplasms; Delayed-Action Preparations; | 2013 |
Colon carcinoma treated with oxaliplatin and capecitabine in a 12-year-old child.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Colonic Neoplas | 2014 |
Metformin: a potential therapeutic agent for recurrent colon cancer.
Topics: Animals; Cell Movement; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; M | 2014 |
Irinotecan-induced immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Col | 2014 |
3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
Topics: Animals; Colonic Neoplasms; Dideoxynucleosides; Disease Models, Animal; Fluorouracil; Heterografts; | 2014 |
The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caco-2 Cells; Campto | 2013 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo | 2014 |
Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cognition; Cognition D | 2014 |
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Syn | 2014 |
Expression of phosphoenolpyruvate carboxykinase linked to chemoradiation susceptibility of human colon cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Chemoradiotherapy; Colonic Neoplasms; Down-Regulat | 2014 |
Colon cancer cells treated with 5‑fluorouracil exhibit changes in polylactosamine‑type N‑glycans.
Topics: Amino Sugars; Antimetabolites, Antineoplastic; Apoptosis; Basigin; Cell Cycle Checkpoints; Cell Line | 2014 |
[Label-free monitoring 5-FU induced SW 620 cells apoptosis using FTIR microspectroscopy].
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Spectroscopy, Fourier Transfor | 2013 |
CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2014 |
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neopla | 2014 |
Diterpenoid C of Radix Curcumae: an inhibitor of proliferation and inducer of apoptosis in human colon adenocarcinoma cells acting via inhibiting MAPK signaling pathway.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cel | 2014 |
To treat or not to treat: who should decide?
Topics: Aged; Capecitabine; Colonic Neoplasms; Decision Making; Deoxycytidine; Fluorouracil; Humans; Male; O | 2014 |
Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment.
Topics: Aberrant Crypt Foci; Adenocarcinoma; Adenoma; Administration, Oral; Animals; Antimetabolites, Antine | 2014 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2014 |
13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13).
Topics: Animals; Apoptosis; CD13 Antigens; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Female; | 2014 |
JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy.
Topics: Anthracenes; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; A | 2014 |
The mechanisms of 5-FU-PLA-O-CMC-NPS-mediated inhibition of the proliferation of colorectal cancer cell line SW480.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloni | 2014 |
Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation.
Topics: Animals; Biocatalysis; Cell Line, Tumor; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltransferases; DN | 2014 |
Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Cycle; Cell | 2014 |
AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells.
Topics: Aquaporin 5; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Colonic Neoplasms; | 2014 |
NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Models, Animal; Female; F | 2014 |
In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Blood Coagulation; Cell Cycle; Cell Line; Cell Lin | 2014 |
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytid | 2013 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2015 |
Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems | 2014 |
Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Base Sequence; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms | 2014 |
Low molecular weight procyanidins from grape seeds enhance the impact of 5-Fluorouracil chemotherapy on Caco-2 human colon cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Biflavonoids; Caco-2 Cells; Catechin; Cell Survival; Colonic Ne | 2014 |
A new magnetic nanocapsule containing 5-fluorouracil: in vivo drug release, anti-tumor, and pro-apoptotic effects on CT26 cells allograft model.
Topics: Allografts; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Delayed- | 2014 |
Supplementation of fish oil augments efficacy and attenuates toxicity of 5-fluorouracil in 1,2-dimethylhydrazine dihydrochloride/dextran sulfate sodium-induced colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Antimetabolites, Antineoplastic; Carcinogens; Cell Cycle; Cell Proli | 2014 |
[Effective chemotherapy with bevacizumab/FOLFOX4 for neuroendocrine carcinoma of the ascending colon - a case study].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2014 |
Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Calcitriol; Cell Cycle; Colonic Neoplasms; Dihydroxycholec | 2014 |
Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neo | 2014 |
Protein kinase C ζ regulates survivin expression and inhibits apoptosis in colon cancer.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic | 2014 |
Characterization of side population cells isolated from the colon cancer cell line SW480.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Resistance, Neop | 2014 |
The wide gulf between stage III and stage IV colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer.
Topics: Adenocarcinoma; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cell Shape; Cobalt; Colonic Neoplasms | 2014 |
Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment.
Topics: Animals; Biological Availability; Cell Cycle; Cell Line, Tumor; Chitosan; Colonic Neoplasms; Curcumi | 2014 |
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 2014 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, | 2015 |
Colon cancer, version 3.2014.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Co | 2014 |
Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
Induction of cancer stem cell properties in colon cancer cells by defined factors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; D | 2014 |
Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
The impact of pyrvinium pamoate on colon cancer cell viability.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell L | 2014 |
A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells.
Topics: Cell Cycle; Cell Death; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; D | 2014 |
Antioxidant value and antiproliferative efficacy of mitragynine and a silane reduced analogue.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antioxidants | 2014 |
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
Piper betle leaf extract enhances the cytotoxicity effect of 5-fluorouracil in inhibiting the growth of HT29 and HCT116 colon cancer cells.
Topics: Apoptosis; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; HC | 2014 |
Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Becaplermin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colon | 2014 |
5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Col | 2015 |
Free radical derivatives formed from cyclooxygenase-catalyzed dihomo-γ-linolenic acid peroxidation can attenuate colon cancer cell growth and enhance 5-fluorouracil's cytotoxicity.
Topics: 8,11,14-Eicosatrienoic Acid; Antineoplastic Agents; Apoptosis; Biocatalysis; Cell Cycle; Cell Line, | 2014 |
Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Erlotinib Hydrochloride; F | 2014 |
The impact of inflammatory lipid mediators on colon cancer-initiating cells.
Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Dinoprostone; Disease Progression; Drug | 2015 |
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Ch | 2015 |
Suppressive effect of sinomenine combined with 5-fluorouracil on colon carcinoma cell growth.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2014 |
Ablation of experimental colon cancer by intratumoral 224Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy.
Topics: Ablation Techniques; Alpha Particles; Animals; Antineoplastic Agents; Brachytherapy; Cell Line, Tumo | 2015 |
Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.
Topics: Animals; Anticarcinogenic Agents; beta Catenin; Biomarkers, Tumor; Cell Line, Tumor; Colon; Colonic | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resi | 2014 |
Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT.
Topics: Coculture Techniques; Colonic Neoplasms; Curcumin; Epithelial-Mesenchymal Transition; Fibroblasts; F | 2014 |
Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Topics: Aged; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Female; Fluorouracil; | 2015 |
Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.
Topics: Adult; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Coronary Angiography; Coronary Thromb | 2014 |
[Survey of the current status of capecitabine-induced hypertriglyceridemia].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deo | 2014 |
[Two cases of Wernicke´s encephalopathy that developed during total parenteral nutrition in colon cancer patients treated with 5-fluorouracil-based chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Brain; Colonic Neoplasms; Fluorouracil; Humans; Magnetic Res | 2014 |
Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
[Capecitabine-induced subacute cutaneous lupus: a case report].
Topics: Adverse Drug Reaction Reporting Systems; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neop | 2014 |
Conditioned media from human macrophages of M1 phenotype attenuate the cytotoxic effect of 5‑fluorouracil on the HT‑29 colon cancer cell line.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Cycle; Cell Survival; Colonic Neoplasms; Culture | 2015 |
5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53‑mutated colon cancer cells.
Topics: Alkaloids; Antineoplastic Agents; Cell Cycle; Checkpoint Kinase 1; Colonic Neoplasms; Drug Resistanc | 2015 |
Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2015 |
Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil.
Topics: 3' Untranslated Regions; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Survival; Colonic Neop | 2015 |
Colon cancer: the new chronic disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chronic Disease; Clinical Trials, Phase III | 2014 |
DPYD variants to predict 5-FU toxicity: the ultimate proof.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 2014 |
A Cancer Reprogramming Method Using MicroRNAs as a Novel Therapeutic Approach against Colon Cancer: Research for Reprogramming of Cancer Cells by MicroRNAs.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Differentiation; Cell L | 2015 |
[Neoadjuvant chemotherapy for colon cancer based on evidence-based medicine].
Topics: Colonic Neoplasms; Evidence-Based Medicine; Fluorouracil; Humans; Neoadjuvant Therapy | 2014 |
PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy.
Topics: Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Survival; Colonic N | 2015 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemother | 2015 |
Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disseminated Intravascular Coagul | 2015 |
miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Cell Cycle; Cell Movement; Cell Proliferation; Ch | 2015 |
5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway.
Topics: Adenomatous Polyposis Coli Protein; Amino Acid Sequence; Antimetabolites, Antineoplastic; Cell Line, | 2014 |
Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2015 |
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; | 2015 |
Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Vessels; Camptoth | 2015 |
Fourier transform infrared microspectroscopy monitoring of 5-fluorouracil-induced apoptosis in SW620 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neopla | 2015 |
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.
Topics: Aberrant Crypt Foci; Animals; Antibodies, Blocking; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
MicroRNA profiling in human colon cancer cells during 5-fluorouracil-induced autophagy.
Topics: Apoptosis; Autophagy; Colonic Neoplasms; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; MicroRNAs; | 2014 |
Prognostic factors of overall survival for patients with stage II colon cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic | 2014 |
Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinica | 2014 |
Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Ca | 2015 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
[Blindness and symmetrical neurological deficit in a patient with colon cancer receiving adjuvant chemotherapy: is it always cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Neoplasms; Capecitabine; Chemothera | 2014 |
Chemopreventive potential of alpha lipoic acid in the treatment of colon and cervix cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Caco-2 Cells; Cell Proliferation; Chem | 2014 |
Optimization of the tissue source, malignancy, and initial substrate of tumor cell-derived matrices to increase cancer cell chemoresistance against 5-fluorouracil.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Drug Discov | 2015 |
Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Camptothecin; Capecitabine; Co | 2015 |
[Systemic chemotherapy and surgery for recurrent metachronous liver metastases with peritoneal dissemination from triple colon cancers-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined Moda | 2014 |
[Preoperative chemotherapy with modified FOLFOX + panitumumab for the treatment of descending colon cancer with multiple liver metastases - a case study].
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colectomy; Co | 2015 |
[Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 2014 |
Factors derived from Escherichia coli Nissle 1917, grown in different growth media, enhance cell death in a model of 5-fluorouracil-induced Caco-2 intestinal epithelial cell damage.
Topics: Caco-2 Cells; Cell Death; Cell Membrane Permeability; Cell Survival; Colonic Neoplasms; Culture Medi | 2015 |
Protopanaxadiol, an active ginseng metabolite, significantly enhances the effects of fluorouracil on colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2015 |
Maltese mushroom (Cynomorium coccineum L.) as source of oil with potential anticancer activity.
Topics: Agaricales; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colonic N | 2015 |
Observational study of adjuvant therapy with capecitabine in colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; | 2015 |
The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells.
Topics: Aged; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subf | 2015 |
[Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2014 |
[A case of descending colon cancer with multiple liver metastases effectively treated with capecitabine/oxaliplatin (CapeOX) and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col | 2014 |
[A case of early gastric cancer completely responding to adjuvant chemotherapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2014 |
[Establishment and biological characterization of 5-fluorouracil-resistant human colon cancer HT-29/5-FU cell line].
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dr | 2015 |
The ellagic acid derivative 4,4'-di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16.
Topics: Anticarcinogenic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, N | 2015 |
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.
Topics: Animals; Apoptosis; Benzophenones; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2015 |
Use of vinegar to relieve persistent hiccups in an advanced cancer patient.
Topics: Acetic Acid; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hiccup | 2015 |
Liver-Tumor Hybrid Organoids for Modeling Tumor Growth and Drug Response In Vitro.
Topics: Coculture Techniques; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; Hep G2 Cell | 2015 |
The anticancer effect of (1S,2S,3E,7E,11E)-3,7,11, 15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer cells.
Topics: Animals; Anthozoa; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Diterpenes; Down-Regulation; | 2015 |
[The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Adjuvant chemotherapy and prognostic factors in stage II colon cancer--Izmir Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2015 |
[Management for adverse events associated with FOLFIRI plus cetuximab or panitumumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2015 |
Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Endothelial Cells; Fluorouracil; Hom | 2015 |
Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner.
Topics: Acid Ceramidase; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; | 2015 |
[Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2015 |
The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacteria; Caco-2 Cells; Cell Cycle; Colonic Neoplasms; Coumarins; | 2015 |
MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colo | 2015 |
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2015 |
T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carci | 2015 |
Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; C | 2015 |
LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
5-Fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection.
Topics: Adult; Antimetabolites, Antineoplastic; Calcium Channel Blockers; Cardiotoxicity; Colonic Neoplasms; | 2015 |
Role of iron oxide core of polymeric nanoparticles in the thermosensitivity of colon cancer cell line HT-29.
Topics: Colonic Neoplasms; Comet Assay; Drug Carriers; Ferric Compounds; Fever; Fluorouracil; HT29 Cells; Hu | 2015 |
[A case of polymyositis associated with transverse colon cancer that responded to tumor resection and chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Transverse; Colonic Neoplasm | 2015 |
PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Prolif | 2015 |
Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression.
Topics: AC133 Antigen; Antigens, CD; Antimetabolites, Antineoplastic; Caco-2 Cells; Colon; Colonic Neoplasms | 2015 |
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Hypoxia; Cell | 2015 |
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; | 2015 |
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, Adjuv | 2015 |
NECTIN-4 increased the 5-FU resistance in colon cancer cells by inducing the PI3K-AKT cascade.
Topics: Antimetabolites, Antineoplastic; Cell Adhesion Molecules; Cell Line, Tumor; Colonic Neoplasms; Drug | 2015 |
Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Ch | 2015 |
An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Cachexia; Cell Line, Tumor; Colon; Colonic Neoplasms; | 2015 |
H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; DNA Methylation; Dr | 2015 |
Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Camptothecin; Colonic Neoplasms; Disease-Free Survival; | 2015 |
Organizing pneumonia with fatal outcome after adjuvant chemotherapy with FOLFOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2015 |
A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Cy | 2015 |
SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Adhesion; Cell Count; Cell Line, Tumor; Cell Proliferation | 2015 |
Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Comparative Effectiveness Researc | 2015 |
Vitamin D3 enhances the tumouricidal effects of 5-Fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer.
Topics: Animals; beta Catenin; Cholecalciferol; Colonic Neoplasms; Disease Models, Animal; Fluorouracil; Hum | 2015 |
Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colonic Neoplasms; Down-Regulati | 2015 |
[Rapidly Growing Interval Colon Cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats.
Topics: Aberrant Crypt Foci; Animals; Antioxidants; Apoptosis; Azoxymethane; Chemoprevention; Colonic Neopla | 2015 |
Inhibition of human 67-kDa laminin receptor sensitizes multidrug resistance colon cancer cell line SW480 for apoptosis induction.
Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Dru | 2016 |
An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
Topics: Acyltransferases; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; California; Chemotherapy | 2016 |
Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2015 |
Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug | 2015 |
[Drug resistance of colon cancer cells to 5-fluorouracil mediated by microRNA-21].
Topics: Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Su | 2015 |
Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
Topics: Biomarkers, Tumor; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mutation; Tumor Suppressor | 2015 |
Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Adhesion Molecules; Colonic Ne | 2015 |
Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2015 |
Pterostilbine, an active component of blueberries, sensitizes colon cancer cells to 5-fluorouracil cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Blueberry Plants; Caco-2 Cells; Catalytic Domain; C | 2015 |
Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Drug Delivery Syst | 2015 |
[A Case of Advanced Gastric Cancer Presenting as Multiple Colonic Lymphoid Hyperplasia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil | 2015 |
Synergistic therapeutic effects of Schiff's base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferat | 2016 |
Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Extr | 2015 |
Effects of 5-Amyno-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrol-3-one Intake on Digestive System in a Rat Model of Colon Cancer.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Colon; Colonic Neoplasms; Digestive System; Disease | 2015 |
Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Calcitriol; Cell Self Renewal; Cell Survival; Colonic Neoplasms; Di | 2016 |
Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2016 |
Unilateral Capecitabine-related Hand-foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon | 2015 |
Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Colonic Neoplasms; | 2016 |
Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; British Columbia; Capecitabine; Chemotherapy, Adjuva | 2016 |
5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2015 |
Subacute cutaneous lupus erythematosus induced by capecitabine: 5-FU was innocent.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Female; Fluorouracil; Humans; Lupus Er | 2016 |
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Lineage; Cell Movement; Chemokine CXCL12; Colonic Neopla | 2015 |
Combination of ultrasound and newly synthesized magnetic nanocapsules affects the temperature profile of CT26 tumors in BALB/c mice.
Topics: Animals; Antimetabolites, Antineoplastic; Body Temperature; Colonic Neoplasms; Drug Delivery Systems | 2015 |
Primary Adenocarcinoma with Focal Choriocarcinomatous Differentiation in the Sigmoid Colon.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2015 |
Preparation and in vitro evaluation of 5-fluorouracil-loaded PCL nanoparticles for colon cancer treatment.
Topics: Caco-2 Cells; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Nanopar | 2017 |
Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Col | 2015 |
Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2014 |
Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Fluo | 2016 |
Optimization of chitosan nanoparticles for colon tumors using experimental design methodology.
Topics: Animals; Chitosan; Colonic Neoplasms; Fluorouracil; Humans; Models, Biological; Nanoparticles | 2016 |
Lin28A enhances chemosensitivity of colon cancer cells to 5-FU by promoting apoptosis in a let-7 independent manner.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; DNA Repa | 2016 |
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2016 |
[Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 2015 |
Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2016 |
Paradoxical E-cadherin increase in 5FU-resistant colon cancer is unaffected during mesenchymal-epithelial reversion induced by γ-secretase inhibition.
Topics: Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; | 2016 |
Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mes | 2016 |
Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Topics: Aminopyridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neo | 2015 |
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Decision-Making; Colonic Neoplasms; Co | 2016 |
[Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; | 2015 |
[A Case of Liver Metastasis of Descending Colon Cancer with a Pathological Complete Response to mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Descending; Col | 2016 |
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Databases | 2016 |
Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surfac | 2016 |
Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway.
Topics: Apoptosis; Axin Protein; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colonic Neop | 2016 |
Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Culture Techniques; Chemo | 2016 |
Inhibition of Growth and Metastasis of Colon Cancer by Delivering 5-Fluorouracil-loaded Pluronic P85 Copolymer Micelles.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; D | 2016 |
A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Combined Modality The | 2016 |
DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; | 2016 |
Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.
Topics: Animals; Biomarkers, Tumor; Colonic Neoplasms; Dextran Sulfate; Drug Resistance, Neoplasm; Female; F | 2016 |
Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combi | 2016 |
Impact of multicellular tumor spheroids as an in vivo‑like tumor model on anticancer drug response.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorour | 2016 |
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; DNA Methylation; Fem | 2016 |
[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; | 2016 |
[Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dru | 2016 |
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2016 |
NFκB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Drug Resi | 2016 |
[Benefit of adjuvant 5-fluorouracil based chemotherapy for colon cancer: a retrospective cohort study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2.
Topics: 8,11,14-Eicosatrienoic Acid; Arachidonic Acid; Caprylates; Caspase 9; Cell Proliferation; Colonic Ne | 2016 |
5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Dihydrouracil Dehyd | 2017 |
Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2016 |
Too little benefit for too much toxicity: rethinking the adjuvant development model in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic N | 2016 |
MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzodiazepinone | 2016 |
Endoplasmic reticulum stress induces 5-fluorouracil resistance in human colon cancer cells.
Topics: Activating Transcription Factor 6; Antimetabolites, Antineoplastic; Calcium; Cell Line, Tumor; Cell | 2016 |
RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2016 |
Potent in vivo anticancer activity and stability of liposomes encapsulated with semi-purified Job's tear (Coix lacryma-jobi Linn.) extracts on human colon adenocarcinoma (HT-29) xenografted mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Coix; Colon; Colonic Neoplasms; Dr | 2016 |
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Topics: Camptothecin; Cell Line, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cohort Studies; Co | 2016 |
Folic Acid Supplementation Adversely Affects Chemosensitivity of Colon Cancer Cells to 5-fluorouracil.
Topics: Animals; Cell Proliferation; Colonic Neoplasms; Dietary Supplements; Disease Models, Animal; Drug In | 2016 |
l-carnosine dipeptide overcomes acquired resistance to 5-fluorouracil in HT29 human colon cancer cells via downregulation of HIF1-alpha and induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy | 2016 |
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regula | 2016 |
Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetux | 2016 |
Butyrate-mediated acquisition of chemoresistance by human colon cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter | 2016 |
Spontaneous ileostomy closure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2016 |
Randomized Controlled Trial of the Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2017 |
Women at a Disadvantage in Fluorouracil Treatment.
Topics: Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Polymorph | 2016 |
Women at a Disadvantage in Fluorouracil Treatment-Reply.
Topics: Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Polymorph | 2016 |
Response to RE: Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2016 |
The Effect of Analogues of 1α,25-Dihydroxyvitamin D₂ on the Regrowth and Gene Expression of Human Colon Cancer Cells Refractory to 5-Fluorouracil.
Topics: Antineoplastic Agents; Calcitriol; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Drug Resi | 2016 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2016 |
Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3β.
Topics: Apoptosis; Cell Survival; Colonic Neoplasms; Epithelial-Mesenchymal Transition; Extracellular Signal | 2016 |
5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lacking p53.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Line, Tumor; | 2016 |
Primary cultures of human colon cancer as a model to study cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms | 2016 |
Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5-fluorouracil.
Topics: Cell Proliferation; Colonic Neoplasms; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Express | 2016 |
Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats.
Topics: Animals; Anticarcinogenic Agents; Benzoquinones; Carcinogenesis; Cell Proliferation; Colonic Neoplas | 2016 |
Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasms; Disease Model | 2016 |
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasm | 2017 |
Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Colon; Coloni | 2016 |
Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Caspase 7; Colonic Neoplasms; | 2016 |
Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Topics: Adaptor Proteins, Signal Transducing; Aged; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2016 |
Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Hypoxia; Cell | 2016 |
Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.
Topics: Adenoviruses, Human; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; | 2016 |
Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Chemotherapy, A | 2017 |
Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Prolif | 2016 |
Bevacizumab in colorectal cancer: it should have worked.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2016 |
Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Robotic Right Colectomy with Modified Complete Mesocolic Excision: Long-Term Oncologic Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Ch | 2016 |
[A Case of Stage IV Colon Cancer Relapsed 10 Years after Curative Resection with Adjuvant Chemotherapy Using Long-Term, Low-Dose Leucovorin and 5-Fluorouracil(LV/5-FU)].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Hu | 2016 |
Comparison of the expression and function of Lin28A and Lin28B in colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Prol | 2016 |
c-Myc is regulated by HIF-2α in chronic hypoxia and influences sensitivity to 5-FU in colon cancer.
Topics: Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle Proteins; | 2016 |
Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coloni | 2016 |
Antitumor efficacy of combined gene and radiotherapy in animals.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Combi | 2016 |
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Topics: Aged; Biomarkers, Tumor; Colonic Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female | 2017 |
Late-stage inhibition of autophagy enhances calreticulin surface exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein-1 Homolog; Becl | 2016 |
Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Chemistry, Pharmaceutical; Colonic Neoplasms; Dr | 2017 |
Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Colonic N | 2016 |
Hyperthermic carbon dioxide pneumoperitoneum reinforces the inhibition of 5-FU on the proliferation and invasion of colon cancer.
Topics: Animals; Carbon Dioxide; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality | 2017 |
Annexin A1 is involved in resistance to 5-FU in colon cancer cells.
Topics: Annexin A1; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, N | 2017 |
MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells.
Topics: Apoptosis; Cell Death; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouraci | 2017 |
Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2017 |
Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tu | 2017 |
miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer.
Topics: ADAM Proteins; Adult; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Drug Resistan | 2017 |
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Self Renewal; Colonic Ne | 2016 |
Synthesis and bio-evaluation of xylan-5-fluorouracil-1-acetic acid conjugates as prodrugs for colon cancer treatment.
Topics: Acetic Acid; Animals; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems; Fluorouracil; Huma | 2017 |
Lysophosphatidic acid (LPA) signaling via LPA
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Fluorouracil; H | 2017 |
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; | 2017 |
REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Sur | 2017 |
Reduction of carcinomatosis risk using icodextrin as a carrier solution of intraperitoneal oxaliplatin chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cell Movement; | 2017 |
[A Case of Aortoesophageal Fistula Rupture Due to Descending Thoracic Aortic Dissection with Recurrent Colon Cancer during Chemotherapy Containing Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aortic Diseases; Bevacizumab; Capecitabine; Co | 2016 |
[A Case Report of Clinical Complete Response with Chemotherapy for Descending Colon Cancer Complicated with Severe Pulmonary Dysfunction].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Descending; Colonic Neopl | 2016 |
Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe | 2017 |
Resistance of mitochondrial p53 to dominant inhibition.
Topics: Alpha-Amanitin; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Cyclin-Depe | 2008 |
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2008 |
Adjuvant systemic chemotherapy with 5-fluorouracil and leucovorin in colon cancer: a monoinstitutional institutional experience.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant | 2008 |
Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy.
Topics: Antineoplastic Agents; Carcinoembryonic Antigen; Cell Line, Tumor; Colonic Neoplasms; Flow Cytometry | 2008 |
Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Down- | 2008 |
Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Fluorouracil; High | 2008 |
Calcium and calcium sensing receptor modulates the expression of thymidylate synthase, NAD(P)H:quinone oxidoreductase 1 and survivin in human colon carcinoma cells: promotion of cytotoxic response to mitomycin C and fluorouracil.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blotting, Western; Calcium; Calcium Si | 2009 |
Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cannabinoid Receptor Antagonists; Can | 2009 |
Proteomic analysis of the basic proteins in 5-fluorouracil resistance of human colon cancer cell line using the radical-free and highly reducing method of two-dimensional polyacrylamide gel electrophoresis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Electrophores | 2008 |
[Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Endostatins; Fluorouracil; Hu | 2008 |
Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; DNA, Neoplasm; Female; Fl | 2008 |
In vino, curationis?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Colonic Neoplasms; Do | 2008 |
Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; Col | 2008 |
Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Enzyme Activation; Fluor | 2008 |
A simple colostomy implantation model for evaluating colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Colostomy; Disease Mo | 2009 |
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2008 |
Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Prognostic impact of bim, puma, and noxa expression in human colon carcinomas.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonis | 2008 |
In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Chitosan; Colon; Colonic Neop | 2008 |
Advances in defective mismatch repair colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Combined Chemotherap | 2008 |
Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; Drug Resist | 2008 |
Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Colonic Neoplasms; Fluorouracil; Gallic | 2009 |
Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capec | 2008 |
'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 2008 |
[Relative dose intensity of FOLFOX4 regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 2008 |
[Super-elderly colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy--report of a case].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic | 2008 |
[Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2008 |
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2009 |
Estrone and progesterone inhibit the growth of murine MC38 colon cancer line.
Topics: Animals; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Estrone; Fluoro | 2009 |
Small-vessel vasculitis following treatment with combination 5-fluorouracil/folinic acid and oxaliplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leuco | 2009 |
Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA M | 2009 |
Sequential or combination chemotherapy for a patient with mCRC?
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabo | 2008 |
Reduction of Orc6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin.
Topics: Cell Line, Tumor; Cell Nucleus; Cisplatin; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; | 2008 |
Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Blott | 2009 |
Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo.
Topics: Animals; Apoptosis; Calcium Phosphates; Carcinoembryonic Antigen; Cell Line, Tumor; Colonic Neoplasm | 2009 |
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therap | 2009 |
Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses.
Topics: Anastomosis, Surgical; Animals; Antineoplastic Agents; Colonic Neoplasms; Disease Models, Animal; Fe | 2009 |
Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Antimetabolites; Apoptosis; Cell Cycle Pr | 2009 |
Chemotherapy side-effect management using mobile phones.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Capecitabine; Cell Phone; Colonic Neoplasms; Deoxycyt | 2008 |
Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangitis, Sclerosing; Col | 2009 |
Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Hypoxia; Cell Proliferation; Coloni | 2009 |
Colon cancer in a 16-year-old girl: signet-ring cell carcinoma without microsatellite instability--an unusual suspect.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Colonic Neo | 2009 |
Molecular mechanisms of drug resistance.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Colon | 2009 |
Oxaliplatin-mediated autoimmune thrombocytopenia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fema | 2009 |
Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Colonic | 2010 |
Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 2009 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined M | 2009 |
[A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; | 2009 |
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Caspase 3; Caspase 7; Cell Line, Tumor; Colo | 2009 |
Adjuvant therapy for colorectal cancer: increasingly complex as patients age.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical | 2009 |
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2009 |
Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Benzofurans; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Ce | 2009 |
A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; beta-Galactosidase; | 2009 |
Assessing software impact on clinical workflow and resource utilization.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Efficiency, Organiz | 2009 |
5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels.
Topics: Adult; Aged; Angiotensin II; Brachial Artery; Cardiovascular Diseases; Colonic Neoplasms; Female; Fl | 2010 |
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colon; Colonic Neoplasms; Drug Resist | 2009 |
Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Female; Fluorouraci | 2008 |
Interstitial lung disease associated with oxaliplatin: description of two cases.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemot | 2009 |
[A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabolic; Colonic Neoplasms; | 2009 |
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolife | 2009 |
Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Fl | 2009 |
Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Pro | 2009 |
Mirk regulates the exit of colon cancer cells from quiescence.
Topics: Antimetabolites; Cell Cycle; Cell Line; Colonic Neoplasms; Cyclin D; Cyclin-Dependent Kinase Inhibit | 2009 |
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2009 |
Acute renal failure related to oxaliplatin-induced intravascular hemolysis.
Topics: Acute Kidney Injury; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combi | 2010 |
Wheat germ agglutinin-conjugated chitosan-Ca-alginate microparticles for local colon delivery of 5-FU: development and in vitro characterization.
Topics: Adsorption; Alginates; Animals; Antimetabolites, Antineoplastic; Buffers; Calcium; Chelating Agents; | 2009 |
Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic | 2009 |
Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report.
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neop | 2009 |
Spontaneous and 5-fluorouracil-induced centrosome amplification lowers the threshold to resveratrol-evoked apoptosis in colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 6; Centrosome; Colonic Neoplasms; | 2010 |
Enhanced chemotherapy sensitivity of human colon cancer cells to 5-fluorouracil by siRNA recombinant expression vector targeting survivin gene.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorourac | 2009 |
[A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2009 |
Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Cell Division; Cell Line, | 2010 |
Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Highlights from: The 45th Annual Meeting of the American Society of Clinical Oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; | 2009 |
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum | 2009 |
New targeted-colon delivery system: in vitro and in vivo evaluation using X-ray imaging.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Chemistry, Pharmaceutical; Chitosan; | 2010 |
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2009 |
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Autophagic cell death induced by 5-FU in Bax or PUMA deficient human colon cancer cell.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated | 2010 |
Scutellarin sensitizes drug-evoked colon cancer cell apoptosis through enhanced caspase-6 activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Blotting, Western; Caspase 6; C | 2009 |
Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2009 |
Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cloning, Molecular; Colonic Neoplasms; Down-Regulation; Drug S | 2010 |
Cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fema | 2009 |
The necessity of chemotherapy in T3N0M0 colon cancer without risk factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2009 |
[Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2009 |
[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Combined M | 2009 |
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Cell Cycle; Cell Proliferation; Colonic Neoplasms; | 2009 |
Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Combined M | 2009 |
[A case of simultaneous bilateral metastatic ovarian tumor of colon cancer followed by FOLFOX4 Regimen and oral tegafur/uracil+oral leucovorin after R0 operation].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colectomy; C | 2009 |
Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Cop | 2010 |
MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Co | 2009 |
Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Black or African American; Chemotherapy, A | 2009 |
NCCN guideline updates: colon and rectal cancers, version 1.2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Caspases; Cathepsin B; Cel | 2010 |
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2010 |
Glutathione modulation reverses the growth-promoting effect of growth factors, improving the 5-fluorouracil antitumour response in WiDr colon cancer cells.
Topics: Buthionine Sulfoximine; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Epidermal Growth | 2009 |
Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX).
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2009 |
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Hist | 2009 |
Chemotherapy: Adding oxaliplatin to the equation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as | 2009 |
[Limited 5-fluorouracil-induced systemic scleroderma].
Topics: Adult; Antimetabolites, Antineoplastic; Calcium Channel Blockers; Colectomy; Colonic Neoplasms; Fema | 2009 |
The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; DNA-Binding Proteins; Drug Synergism; Elli | 2009 |
Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2010 |
5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug S | 2010 |
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
Topics: Adenocarcinoma; Aged; Apoptosis; Cell Division; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 2010 |
Sickle cell crisis in a patient receiving capecitabine chemotherapy.
Topics: Adenocarcinoma; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Capecitabine; Colonic Neopla | 2010 |
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
[A case of duodenal penetration by indwelling catheter during hepatic arterial infusion chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Catheters, In | 2009 |
[A case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Female; Fluorour | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
[Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Transverse; Colonic Neoplasms; | 2009 |
[Ovarian metastasis after complete response of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
[A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Esopha | 2009 |
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasm | 2009 |
En bloc resection for right colon cancer directly invading duodenum or pancreatic head.
Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodena | 2009 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytog | 2010 |
[Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy].
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoth | 2010 |
Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2010 |
[A case of advanced ascending colon cancer, curatively resected after complete response in left supraclavicular and paraaortic lymph nodes and liver metastases to FOLFOX4 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonic Neoplasms; Combined Modality Therapy | 2010 |
Livin gene plays a role in drug resistance of colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line | 2010 |
Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2010 |
Significance of occult neoplastic cells on tumor metastasis: a case report of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Signet Ring Cell; Cell Differentiation; Chemothe | 2010 |
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
[A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen | 2010 |
Obesity is an independent prognostic variable in colon cancer survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body | 2010 |
Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model.
Topics: Adenine; AMP-Activated Protein Kinase Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplas | 2010 |
Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferat | 2010 |
The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neo | 2010 |
[Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv | 2011 |
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Ant | 2010 |
Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor | 2010 |
[Survey on the compliance of patients with continuous infusion of 5-fluorouracil via portable infusion pumps].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouraci | 2010 |
[Chemotherapy of colonic cancer].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; C | 2010 |
[Insulin induces anticancer cytotoxicity of 5-Fu to two human colon cancer cell lines].
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms | 2010 |
Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
Topics: Animals; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Pr | 2010 |
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Chemotherapy, Adjuvant; Colonic Neoplasms; Combin | 2010 |
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?
Topics: Antimetabolites, Antineoplastic; Biomarkers; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Mismatch | 2010 |
Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug C | 2010 |
The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coculture Techniques; | 2010 |
Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Camptothecin; Cell Growth Pr | 2010 |
Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.
Topics: Acute Disease; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
[A case of gastric carcinoma with lung and liver metastasis successfully treated by mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colectomy; Colonic Neoplasms; Female; | 2010 |
[A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Topics: AC133 Antigen; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Antineopl | 2010 |
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells.
Topics: Antimalarials; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apop | 2010 |
Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cisplatin; Colonic Ne | 2011 |
[Two cases of unstable angina in patients treated with bevacizumab].
Topics: Aged; Angina, Unstable; Angiogenesis Inhibitors; Angiography; Antibodies, Monoclonal; Antibodies, Mo | 2010 |
[A recurrence after surgery for colon cancer with metastases of the liver and periaortic lymph nodes, with CR achieved by using bevacizumab+mFOLFOX6].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine | 2011 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Disea | 2010 |
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasm | 2010 |
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasm | 2010 |
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasm | 2010 |
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasm | 2010 |
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2010 |
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colo | 2010 |
Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; | 2011 |
[A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Comb | 2010 |
5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells.
Topics: AC133 Antigen; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Prol | 2010 |
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting | 2010 |
Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer.
Topics: Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluorouracil | 2010 |
The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
Topics: Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Ch | 2010 |
[Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU].
Topics: Aged; Bilirubin; Colonic Neoplasms; Female; Fluorouracil; Hemolysis; Humans; Iron; Male; Middle Aged | 2010 |
[A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; | 2010 |
Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620.
Topics: AC133 Antigen; Antigens, CD; Azacitidine; beta Catenin; Cadherins; Cell Adhesion; Cell Death; Cell L | 2010 |
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
Topics: Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cancer Vacc | 2010 |
Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Inhibito | 2010 |
Alternative cyclin D1 splice forms differentially regulate the DNA damage response.
Topics: Alternative Splicing; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neoplasms; | 2010 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
[A case of high CEA colon cancer responding to neoadjuvant chemotherapy with FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colonic Neop | 2010 |
TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Fluo | 2010 |
A gene expression signature for chemoradiosensitivity of colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Surviv | 2010 |
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2010 |
Zebrafish stem cell differentiation stage factors suppress Bcl-xL release and enhance 5-Fu-mediated apoptosis in colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; C | 2011 |
Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Progression; Female; Fluoro | 2010 |
Hepatocyte nuclear factor-4alpha promotes gut neoplasia in mice and protects against the production of reactive oxygen species.
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Gene Exp | 2010 |
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Col | 2010 |
Does 1 year adjuvant chemotherapy with oral 5-FUs in colon cancer reduce the peak of recurrence in 1 year and provide long-term OS benefit?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Ne | 2011 |
A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cecum; Cell Proliferation; Colonic Neoplas | 2011 |
Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Chromatography, High P | 2010 |
Lessons from the adjuvant bevacizumab trial on colon cancer: what next?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarker | 2010 |
Chemotherapy: Failure of bevacizumab in early-stage colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2011 |
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2011 |
Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Colon, Transverse; | 2010 |
Suicide activation in a 5-fluorouracil resistant colon cancer model in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cytosine Deamin | 2011 |
Cross-resistance of 5-fluorouracil-resistant colon carcinoma in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resistance | 2011 |
Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Angiogra | 2012 |
[An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
[A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
[Clinical path for mFOLFOX6 describing criteria for reduction and suspension of drugs].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2010 |
CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2011 |
Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Capecitabine-induced, nonneutropenic enterocolitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Chemotherapy, Adjuva | 2011 |
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dideoxynucleosides; Fluorine Ra | 2011 |
Smad4 inactivation promotes malignancy and drug resistance of colon cancer.
Topics: Cell Hypoxia; Cell Movement; Cell Transformation, Neoplastic; Colonic Neoplasms; Drug Resistance, Ne | 2011 |
Leucovorin-induced hypersensitivity reaction.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
5-Fluorouracil-induced Tako-Tsubo-like syndrome.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Takotsu | 2011 |
The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil.
Topics: Adenosine Triphosphate; Blotting, Western; Cell Death; Colonic Neoplasms; Energy Metabolism; Fluorou | 2011 |
Biomarkers of 5-FU response in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colonic Neoplasms; Fluorouracil; Gene E | 2011 |
Scan? Cure? Sure!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2011 |
Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online.
Topics: Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Disease-Free Survival; Fe | 2011 |
[A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Nifedipine synergizes with calcium in activating the calcium sensing receptor, suppressing the expression of thymidylate synthase and survivin and promoting sensitivity to fluorouracil in human colon carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Calcium; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; D | 2011 |
Ghrelin inhibits 5-fluorouracil-induced apoptosis in colonic cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Biomarkers, Tumor; Blotting, Western; Caspase 3; Cell Prolife | 2011 |
[Mixed carcinoid-adenocarcinoma in transverse colon].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoid Tumor; Colon, Transverse; Colonic N | 2010 |
Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2012 |
Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation.
Topics: Animals; Caco-2 Cells; Cell Division; Claudins; Colonic Neoplasms; Epidermal Growth Factor; ErbB Rec | 2011 |
[A resected case of gastric regional lymph node metastasis from ascending colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colon, Ascending; Colonic Neoplasms; Combined M | 2011 |
Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis.
Topics: Adenocarcinoma; Animals; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Drug Resistan | 2011 |
Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment.
Topics: Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Caspases; Cell Death; Cell Line, Tumor; | 2011 |
Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
Enhanced anti-cancer effect of 5-fluorouracil loaded into thermo-responsive conjugated linoleic acid-incorporated poloxamer hydrogel on metastatic colon cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Drug Deli | 2011 |
Synchronous colonic adenocarcinoma and pelvic schwannoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carcinoembryoni | 2011 |
Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents; Cell Survival; Chromones; Colonic Neoplasms; Cycloheximide; Dose-Response Rel | 2011 |
[Knock-down of apollon gene by antisense oligodeoxynucleotide inhibits the proliferation of Lovo cells and enhances chemo-sensitivity].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colon | 2011 |
[PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
Topics: Agaricales; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Co | 2011 |
Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antineoplastic Combined Chemotherapy P | 2011 |
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Va | 2011 |
Dual role of autophagy in colon cancer cell survival.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Colonic Neoplasms; Fluorouracil; Hum | 2011 |
TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
Topics: 5' Untranslated Regions; Age Distribution; Aged; Biomarkers, Tumor; Colonic Neoplasms; Female; Fluor | 2011 |
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; CD | 2011 |
Isolation and characterization of spheroid cells from the HT29 colon cancer cell line.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Biological Assay; Cell Adhesion; Cell | 2011 |
BARD1 expression predicts outcome in colon cancer.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Wes | 2011 |
NK4 gene expression enhances 5-fluorouracil-induced apoptosis of murine colon cancer cells.
Topics: Animals; Apoptosis; Cisplatin; Colonic Neoplasms; Combined Modality Therapy; Cricetinae; Cricetulus; | 2011 |
Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2011 |
Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2011 |
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; D | 2012 |
Gene expression variations in microsatellite stable and unstable colon cancer cells.
Topics: Colonic Neoplasms; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression | 2012 |
Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, | 2011 |
Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic | 2012 |
Fatal diffuse alveolar damage associated with oxaliplatin administration.
Topics: Acute Lung Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fatal Ou | 2011 |
Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Lipid Peroxidation | 2011 |
Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2012 |
The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; eIF-2 Kinase | 2011 |
Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Caco-2 Cells; Camptothecin; Case- | 2012 |
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; | 2011 |
[Intraabdominal chemotherapy of prevailing forms of colon cancer].
Topics: Abdominal Cavity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Fluo | 2011 |
Common cancer stem cell gene variants predict colon cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2011 |
[A case of undifferentiated colon cancer responding to FOLFIRI therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fatal Outcome | 2011 |
[Pancreatoduodenectomy for locally advanced ascending colon cancer after neoadjuvant chemotherapy (mFOLFOX6)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2011 |
Use of uridine triacetate for the management of fluorouracil overdose.
Topics: Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Coloni | 2011 |
Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Colonic Neoplasms; Fluorourac | 2012 |
[A case of disseminated carcinomatosis of bone marrow with disseminated intravascular coagulation caused by advanced colon cancer treated by mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Colonic Neoplasms; Disseminat | 2011 |
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2012 |
The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colonic Neoplasms; Female; Fluorouracil; Humans; | 2012 |
Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Topics: Aged; Antineoplastic Agents; Black or African American; Chemotherapy, Adjuvant; Cohort Studies; Colo | 2012 |
microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin D1; Disease Progression; | 2012 |
Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chlorocebus aethiops; Colonic Neoplasms; | 2012 |
Acute pain associated with oxaliplatin infusion: case report and literature review.
Topics: Acute Pain; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; | 2012 |
Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothe | 2011 |
Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dia | 2011 |
Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2012 |
Both hMutSα and hMutSß DNA mismatch repair complexes participate in 5-fluorouracil cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Baculoviridae; Cell Line, Tumor; Colonic Neo | 2011 |
Colon cancer with microsatellite instability in a 13-year-old Hispanic male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; DNA-Binding Proteins; | 2012 |
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumo | 2011 |
[mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2011 |
[A case of colonic neuroendocrine carcinoma with severe liver dysfunction by multiple liver metastases successfully treated with hepatic arterial infusion].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Neuroendocrine; Colonic Neoplasms; Combined Modality The | 2011 |
Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Cell Prolif | 2012 |
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidi | 2013 |
Proliferation rate but not mismatch repair affects the long-term response of colon carcinoma cells to 5FU treatment.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Cell Growth Proces | 2012 |
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli | 2012 |
5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2012 |
Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2012 |
A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Apoptosis; Cancer Vaccines; | 2012 |
[RAD001 reverses radio-resistance and exerts synergistic tumor inhibition with 5-fluorouracil].
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Everolimus; Fluorouracil; Humans; Thymidine Phosphoryl | 2011 |
MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation; Colonic Neoplasms; Fluorouracil; | 2012 |
A subpopulation of CD24⁺ cells in colon cancer cell lines possess stem cell characteristics.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; CD24 Antigen; Ce | 2012 |
Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2012 |
The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response.
Topics: ATPase Inhibitory Protein; bcl-X Protein; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2012 |
Quantitative shape analysis of chemoresistant colon cancer cells: correlation between morphotype and phenotype.
Topics: Algorithms; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Shape; Colo | 2012 |
Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Flu | 2012 |
[Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Follo | 2012 |
Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dihydropy | 2012 |
[Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2012 |
Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Chemoradiotherapy, Adjuvant; Colonic Neo | 2012 |
Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Genetic Therapy; Humans; | 2012 |
A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.
Topics: Acute Kidney Injury; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Nonspecific but significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Signet Ring Cell; Colonic Neop | 2012 |
Early evaluation for treatment efficacy of 5-fluorouracil and hyperthermia on HCT-116 colon cancer cells by fluorine-18-fluorodeoxyglucose uptake.
Topics: Apoptosis; Cell Proliferation; Colonic Neoplasms; Fever; Fluorodeoxyglucose F18; Fluorouracil; HCT11 | 2012 |
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Prot | 2013 |
Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2012 |
Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxyge | 2012 |
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma | 2012 |
Onset of segmental colitis associated with diverticulosis after treatment with bevacizumab for metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Co | 2012 |
Laparoscopic management for acute malignant colonic obstruction.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colo | 2012 |
[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Colonic Neoplas | 2012 |
[A case of advanced colon cancer with peritoneal dissemination effectively treated with modified FOLFOX6 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fatal Outcome; Female; Fluorourac | 2012 |
Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration.
Topics: Antimalarials; Antimetabolites, Antineoplastic; Autophagy; Blotting, Western; Cell Cycle; Cell Line, | 2012 |
Antitumor effects of novel compound, guttiferone K, on colon cancer by p21Waf1/Cip1-mediated G(0) /G(1) cell cycle arrest and apoptosis.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Benzophenones; Caspase 3; Caspase 8; Caspase | 2013 |
Cell fusion promotes chemoresistance in metastatic colon carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cell Fusion; Colonic Neoplasms; Drug Resistance, N | 2013 |
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Topics: Animals; Antineoplastic Agents; Bombesin; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Co | 2012 |
Auraptene and its effects on the re-emergence of colon cancer stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Colonic Neoplasms; Coumarins; Drug | 2013 |
Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Camptothecin; Cell Survival; Colonic Neoplasms; | 2012 |
[The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human | 2012 |
[A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Co | 2012 |
Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fem | 2013 |
Colon carcinoma in a child treated with oxaliplatin and antiangiogenic treatment regimens.
Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Cryptogenic organizing pneumonia during adjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Cry | 2013 |
Suppression of heat shock protein 27 expression promotes 5-fluorouracil sensitivity in colon cancer cells in a xenograft model.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Colonic Neoplasms; Dihydrouracil Dehydrogen | 2012 |
A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Topics: Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase | 2013 |
Challenge of primary tumor management in patients with stage IV colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Lin | 2013 |
Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cognition; Cogn | 2013 |
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluo | 2013 |
[A case of colon cancer with chronic renal dysfunction responding to effective retreatment with FOLFIRI].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; | 2012 |
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Aspirin; ATP Binding Cassette Transporter, S | 2012 |
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Tre
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2012 |
[Therapy traces on hands and feet in a patient with colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diagnosis, Di | 2012 |
Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line.
Topics: AC133 Antigen; Animals; Antigens, CD; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Colonic Neop | 2012 |
Current stages of adjuvant treatment of colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
A case of severe coronary spasm associated with 5-fluorouracil chemotherapy.
Topics: Aged, 80 and over; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel | 2012 |
Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Basic Helix-Loop-Helix Leucine Zipper Transcription | 2012 |
Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Animals; Antimetabolites, Antineoplastic; Azoxym | 2012 |
Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.
Topics: Activities of Daily Living; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineopla | 2012 |
Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
Topics: Adjuvants, Immunologic; Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Proto | 2012 |
Isolation and characterization of calcium sensing receptor null cells: a highly malignant and drug resistant phenotype of colon cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Calcium; Cell Adhe | 2013 |
[A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI(5-FU/LV/irinotecan)therapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic | 2012 |
Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Fluorouracil; Humans; Liposome | 2012 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; | 2013 |
The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell L | 2013 |
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colon | 2012 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells.
Topics: Apoptosis; Calcium; Calcium Signaling; Calmodulin; Carcinoma; Caspases; Cell Line, Tumor; Colonic Ne | 2013 |
Treatment and complications in elderly stage III colon cancer patients in the Netherlands.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2013 |
Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coh | 2013 |
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj | 2012 |
[Evaluation of the efficacy and prognostic factors for colorectal liver metastases treated with transcatheter arterial chemoembolization].
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; | 2012 |
[Predicting value of dynamic alteration of blood neutrophil/lymphocyte ratio on recurrence-free survival in patients with advanced colon cancer after operation and chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2012 |
Methacrylic-based nanogels for the pH-sensitive delivery of 5-fluorouracil in the colon.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Delayed-Action | 2012 |
Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptos | 2013 |
[Resolution of actinic keratosis with capecetabin].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorou | 2012 |
Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Che | 2013 |
KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; | 2012 |
Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxy | 2012 |
Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; | 2013 |
Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2013 |
Solitary bulky mediastinal lymph node metastasis from colon cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Differentiation; Chemother | 2013 |
[A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
NF-κB addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model.
Topics: Antimetabolites, Antineoplastic; Cell Death; Colonic Neoplasms; Dose-Response Relationship, Drug; Dr | 2013 |
Cervical extravasation of bevacizumab.
Topics: Adenocarcinoma; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antin | 2013 |
[Fluoropyrimidines with oxaliplatin(L-OHP) as an adjuvant chemotherapy for Stage III colon cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
[Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
[Liver damage detected after a hepatectomy for liver metastasis after 12 courses of mFOLFOX6 therapy as an adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemical and Drug Induced Liver Injury; C | 2012 |
[Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; F | 2012 |
Unsupported off-label chemotherapy in metastatic colon cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2012 |
A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA | 2013 |
Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; | 2013 |
Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 2013 |
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic Neoplasms; Curcumin; Cyc | 2012 |
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonic Neoplasms; D | 2013 |
Effects of a water-soluble extract of Ganoderma lucidum mycelia on aberrant crypt foci induced by azoxymethane and small-intestinal injury by 5-FU in F344 rats.
Topics: Aberrant Crypt Foci; Animals; Azoxymethane; Colonic Neoplasms; Culture Media; Fluorouracil; Intestin | 2013 |
Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2013 |
Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.
Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Herpesvi | 2013 |
[Effect of 5-fluorouracil on the expression of ATP-binding cassette superfamily G member 2 in human colon cancer cell SW480].
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Lin | 2013 |
Innovative estimation of survival using log-normal survival modelling on ACCENT database.
Topics: Aged; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Combined Modality Therapy; Databases a | 2013 |
In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Cell Line, Tumor; Colon; Colonic | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2012 |
Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53.
Topics: Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Cell Cycle; Colonic Neoplasms; Enzyme | 2002 |
Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle Proteins; Cell Division; Colonic Neop | 2002 |
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Survival; | 2002 |
Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.
Topics: Animals; Antineoplastic Agents; Biotransformation; Colonic Neoplasms; Cytosine Deaminase; Escherichi | 2002 |
High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil | 2002 |
Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Cell Division; Cell S | 2002 |
Sudden improvement of respiratory failure in a woman with carcinoma of the colon.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Bronchial Neoplasms; Colonic Neopla | 2002 |
Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Division; Colon | 2002 |
A case of myocardial ischaemia induced by 5-fluorouracil.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Electrocardiogr | 2002 |
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2002 |
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
Topics: Aged; Analysis of Variance; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluoroura | 2002 |
Erosion of psoriatic plaques: an uncommon side-effect of neoadjuvant 5-fluorouracil treatment of colon cancer.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Eruptions; Fluorouracil | 2002 |
Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2002 |
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regula | 2002 |
A case of coronary spasm induced by 5-fluorouracil.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Chest Pain; Colonic Neoplasms; Coronary Angiography; | 2002 |
Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caspase Inhibitors; Caspases; Colonic Neoplasms; | 2002 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 2002 |
Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Sq | 2001 |
[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Col | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2002 |
Squamous metaplasia of the canaliculi associated with 5-fluorouracil: a clinicopathologic case report.
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dacryocystorhinostomy; Epithelial Cells; F | 2002 |
Performing phase III clinical trials: never an easy task.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colonic Neoplas | 2002 |
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Colonic Neoplasms; Dose-Re | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
[Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer].
Topics: Animals; Body Weight; Cell Division; Colonic Neoplasms; Cyclohexanes; Disease Models, Animal; Drug C | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Co | 2002 |
Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; | 2003 |
Oxaliplatin (Eloxatin) for advanced colon cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseas | 2003 |
Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoembryonic Antigen; Colonic Neoplasms; Cyto | 2003 |
[A case of advanced colon cancer responding to treatment with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Admini | 2003 |
Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Gene Expression R | 2003 |
Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens.
Topics: Aged; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Fluoroura | 2003 |
Fluoropyrimidine resistance in colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Colonic Neoplasms; Drug Resistan | 2002 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Adminis | 2003 |
5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Caspase 8; Caspase 9; Caspases; | 2003 |
Effectiveness of adjuvant fluorouracil in elderly colon cancer patients: the internal and external validity of nonrandomized research design.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2003 |
[Clinical outcome of intra-hepatic arterial infusion therapy for multiple liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; C | 2003 |
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Division; Colonic Neoplasms; Cytosine; Deox | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colo | 2003 |
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2003 |
Chronic myeloid leukemia in a patient with colon adenocarcinoma.
Topics: Adenocarcinoma; Cisplatin; Colonic Neoplasms; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic, | 2002 |
Small-cell cancers, and an unusual reaction to chemotherapy: Case 4. Fluorouracil-related small bowel vasculitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Ileal | 2003 |
Colloidal anticancer drugs bioavailabilities in oral administration models.
Topics: Animals; Antineoplastic Agents; Biological Availability; Biological Transport; Caco-2 Cells; Colloid | 2003 |
Adjuvant therapy of colon cancer in idiopathic leukopenia.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middl | 2003 |
Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Colonic Neoplasms; DNA; Dose-Response Re | 2003 |
Microsphere design for the colonic delivery of 5-fluorouracil.
Topics: Acrylic Resins; Adjuvants, Pharmaceutic; Administration, Oral; Antineoplastic Agents; Chemistry, Pha | 2003 |
[Coronary artery stenting in the treatment of 5-fluorouracil-induced unstable angina].
Topics: Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Angiography; Dose-Resp | 2003 |
Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Breast | 2003 |
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma.
Topics: Administration, Inhalation; Animals; Antimetabolites, Antineoplastic; Carbon Dioxide; Colonic Neopla | 2003 |
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2003 |
[Regional arterial chemoembolisation and chemoimmunoembolisation in combined treatment of colon cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Doxoru | 2003 |
[Effect of the change of caspase-3 activity on the neoadjuvant chemotherapy-induced apoptosis of large-intestinal carcinoma cells].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin | 2003 |
Advances in colon cancer.
Topics: Camptothecin; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum | 2003 |
5'fluorouracil (FU) and folinic acid (FA) in either the weekly 'Roswell Park' or the 4-weekly 'Mayo' regimen should be standard chemotherapy for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; | 2003 |
Remission of methotrexate-resistant rheumatoid arthritis after receiving 5-fluorouracil for colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antirheumatic Agents; Arthritis, Rheumatoid; Colonic Neoplasm | 2003 |
Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in the treatment of far-advanced breast and colon lesions.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Deoxyuridine; Fluorouracil; Humans; Nucl | 1962 |
5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Rectum; | 1962 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
DISSEMINATED GEOTRICHOSIS; CASE REPORT.
Topics: Adenocarcinoma; Aged; Colitis; Colonic Neoplasms; Fluorouracil; Geotrichosis; Humans; Mycoses; Patho | 1964 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
5-FLUOROURACIL (NSC-19893) TREATMENT OF ADVANCED CANCER IN AMBULATORY PATIENTS.
Topics: Ampulla of Vater; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Ne | 1963 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
CHEMOTHERAPY OF COLON CANCER.
Topics: Androgens; Colonic Neoplasms; Cortisone; Floxuridine; Fluorouracil; Hydrochlorothiazide; Pyrimidines | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
CARCINOMA OF THE COLON IN ULCERATIVE COLITIS.
Topics: Aged; Aging; Cell Biology; Colitis; Colitis, Ulcerative; Colonic Neoplasms; Fluorouracil; Humans; Me | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
FLUOROURACIL COLON-RECTUM ADJUVANT CHEMOTHERAPY.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy; Fluorouracil; Humans; Infusions, Parenteral | 1964 |
5-FLUOURACIL IN THE TREATMENT OF DISSEMINATED COLON AND RECTAL CARCINOMA.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Geriatrics; Neoplasm Metastasis; Pharmacology; Rect | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
COMBINED SPLIT-COURSE THERAPY WITH 5-FLUOROURACIL AND MEGAVOLTAGE IRRADIATION.
Topics: Colonic Neoplasms; Drug Therapy; Fluorouracil; Lung Neoplasms; Neoplasms; Radiography, Thoracic; Rad | 1964 |
CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT.
Topics: Antineoplastic Agents; Carcinoid Tumor; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Gastroint | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
COMPARISON OF 5-FLUOROURACIL (NSC-19893) AND 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) IN TREATMENT OF PATIENTS WITH ADVANCED ADENOCARCINOMA OF COLON OR RECTUM.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Deoxyuridine; Drug Therapy; Fluorouracil; | 1965 |
[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2003 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Dihydrouracil Dehy | 2003 |
Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line.
Topics: Analysis of Variance; Blotting, Southern; Colonic Neoplasms; Fluorouracil; HT29 Cells; Humans; Rever | 2003 |
[A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases].
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluor | 2003 |
Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy.
Topics: Acute Disease; Adenocarcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary Angiography; Coro | 2003 |
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Cyclooxyg | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo | 2003 |
[Relation between p53 expression of human colon cancer cell lines and induction of apoptosis by anticancer drugs].
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Colonic Neoplasms; Drug Synergism; Fluorouracil; Humans | 2003 |
Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; DNA, Complementary; Fas | 2003 |
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2003 |
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line, Tumor; Cell Movem | 2004 |
The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Cell Survival; Colonic Ne | 2004 |
Regulation of p53 stability and function in HCT116 colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; DNA Damage; Doxorubicin; Drug Stabilit | 2004 |
Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Cycle; Cell Division; Colonic Neoplas | 2003 |
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Fluo | 2003 |
Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Autoradiography; Colonic Neoplasms; Female | 2004 |
Gene expression profiling of colon cancer reveals a broad molecular repertoire in 5-fluorouracil resistance.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Ex | 2003 |
Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspase 3; Caspase 7; Caspase 8; Caspases; Caspases | 2003 |
Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Base Pair Mismatch; Camptothecin | 2003 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2003 |
[Effect and mechanism of orally administered leucovorin/5-fluorouracil on colon cancer].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colonic | 2003 |
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Image Interpretation, Computer-A | 2003 |
Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Collagen; Colonic Neop | 2004 |
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.
Topics: Alanine; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neoplasms; Cell Line, T | 2004 |
Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2004 |
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Enzy | 2004 |
Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoem | 2004 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Flu | 2004 |
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms, Hered | 2004 |
Healing of colon anastomoses covered with fibrin glue after immediate postoperative intraperitoneal administration of 5-fluorouracil.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Colon; Colonic Neoplasms; Fibrin Ti | 2004 |
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Aorta, Thoracic; Colonic Neoplasms; Deoxyr | 2004 |
Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2004 |
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis.
Topics: Apoptosis; Base Sequence; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Colonic Neopla | 2004 |
5-flurouracil induced coronary artery vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Vasospasm; Electrocardiography; | 2004 |
Enhanced DNA-directed effects of FdUMP[10] compared to 5FU.
Topics: Colonic Neoplasms; DNA; Fluorodeoxyuridylate; Fluorouracil; HT29 Cells; Humans | 2004 |
[Analysis of microsatellite instability and p53 LOH in advanced colorectal cancers--first report of the No. 3 protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 2004 |
[A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Colonic Neoplasms; | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dru | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Coloni | 2004 |
Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Calorimet | 2004 |
Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic | 2004 |
Synthesis of 2'-deoxy-2'-[18F]fluoro-5-bromo-1-beta-D-arabinofuranosyluracil ([18F]-FBAU) and 2'-deoxy-2'-[18F]fluoro-5-chloro-1-beta-D-arabinofuranosyl-uracil ([18F]-FCAU), and their biological evaluation as markers for gene expression.
Topics: Animals; Arabinofuranosyluracil; Biomarkers, Tumor; Bromouracil; Colonic Neoplasms; Fluorouracil; Ge | 2004 |
Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bacterial Translocation; Body W | 2004 |
Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Colonic Neoplasms; Dose-Response | 2004 |
Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associ | 2004 |
Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; C | 2004 |
[Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2; C | 2004 |
Mature results of adjuvant colon cancer trials from the fluorouracil-only era.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colo | 2004 |
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxy | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fl | 2004 |
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Ca | 2004 |
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Desen | 2004 |
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam | 2004 |
A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Body Weight; Cathe | 2004 |
Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line.
Topics: Amino Acids; Aminobutyrates; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Weste | 2004 |
Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Sub | 2004 |
[Mitomycin-induced hemolytic uremia syndrome].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Do | 2004 |
Mucinous and immunohistochemical changes of colonic adenocarcinoma secondary to chemo-radiotherapy.
Topics: Adenocarcinoma, Mucinous; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; H | 2004 |
Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line, Tumor; Colonic N | 2004 |
Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2004 |
p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cisplatin | 2004 |
New treatments for colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetux | 2004 |
Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disa | 2004 |
[Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female | 2004 |
[A case of advanced colon cancer responding to l-LV+5-FU as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; C | 2004 |
[Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Benzimidazoles; Colectomy; Colonic Neoplasms; | 2004 |
[A case of advanced descending colon cancer with peritoneal dissemination responding to weekly high-dose l-leucovorin/5-fluorouracil combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respon | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
Adjuvant therapy for colon cancer: a historical perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2004 |
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorourac | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2004 |
Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling.
Topics: Antimetabolites, Antineoplastic; Calcium-Binding Proteins; Cell Adhesion; Collagen; Colonic Neoplasm | 2004 |
Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2003 |
[Comparative study on human colonic-cancer cell line, DLD-1 and the 5-FU resistant cell line].
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Drug Res | 2004 |
Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.
Topics: Acyclic Monoterpenes; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA; Drug Therapy | 2004 |
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Division; Colonic Neop | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwe | 2004 |
[A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Col | 2004 |
Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia.
Topics: Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Comorbidity; Confidence Intervals; Dementia; Female | 2004 |
Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Flu | 2004 |
[Bilateral shoulder-hand syndrome revealing hypothyroidism and colon carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Diagnosi | 2004 |
[Relationship between expression of thymidylate synthase and colorectal carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Femal | 2004 |
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq | 2004 |
Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Guillain-Barre Syndrome; Hum | 2004 |
[Potentiation of 5-fluorouracil efficacy. Molecular mechanisms playing a role in the cytotoxic action of 5-fluorouracil and 5-ethyl-2'-deoxyuridine (EUdR) combination].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; | 2004 |
Vasospastic angina caused by 5-fluorouracil. A case report.
Topics: Adenocarcinoma; Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary | 2003 |
[Adjuvant therapy of colonic carcinoma--soon in tablet form].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytid | 2004 |
Inhibition of transfected PTEN on human colon cancer.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Division; Colonic Neoplasms; Fluorouracil; Gene Express | 2004 |
5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Galactosidase; Carcinoma, | 2005 |
Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Division; Cell Survival; Colonic Neoplasms; Do | 2004 |
Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti-tumour immunity.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 2004 |
[A case of the 5-year survivor of ascending colon cancer associated with synchronous multiple liver metastasis and peritoneal dissemination successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colonic Neoplasms; Embolization, Therapeutic | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
[A case of unresectable multiple liver metastases from colon cancer successfully treated by hepatic arterial infusion chemotherapy and systemic immunotherapy (IFNANK) followed by hepatic resection].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2004 |
5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Huma | 2004 |
[Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
[A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy; | 2004 |
Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Flu | 2004 |
A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Screening A | 2004 |
Cytotoxic and apoptotic effects of novel heterodinucleoside phosphates consisting of 5-fluorodeoxyuridine and Ara-C in human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bisbenzimidazole; Cell Line, Tumor; Colonic Neoplasms; C | 2004 |
5-FU-induced acute leukoencephalopathy.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Diseases; Colonic Neoplasms; F | 2004 |
Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; C | 2004 |
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemo | 2005 |
hTERT antagonizes p53-induced apoptosis independently of telomerase activity.
Topics: Apoptosis; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA-Bind | 2005 |
An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Carcinoid Tumor; Chemotherapy, Adjuva | 2004 |
Adjuvant portal vein cytotoxic infusion for curatively resected colon cancer--is it obsolete?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 2005 |
Re: Pooled analysis of fluorouracil-based adjuvant therapy of stage II and III colon cancer: who benefits and by how much?
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2005 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2005 |
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2005 |
Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Vasospasm | 2005 |
Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA; Fluorouracil; Humans; Lung | 2005 |
CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Antimetabolites, Antineoplastic; Cell Proliferat | 2005 |
YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA-Binding Proteins; Drug Resistance, Multiple; | 2005 |
Two cases of retroperitoneal hematoma caused by combination of anticoagulant therapy and 5-fluorouracil.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Interactions; Esophag | 2005 |
Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2005 |
Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Blotting, Western; Cell Line, T | 2005 |
Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Screeni | 2005 |
Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.
Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Colonic | 2005 |
Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Drug Deliver | 2005 |
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months?
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Rando | 2005 |
[Three cases of multiple colorectal liver metastases responding to hepatic arterial infusion chemotherapy undergoing liver resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Sigmoid; Colonic Neoplasms; | 2005 |
Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Catheters, Indwe | 2005 |
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dihydroura | 2005 |
Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance.
Topics: Antimetabolites, Antineoplastic; Aurovertins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasm | 2005 |
Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy.
Topics: Adenocarcinoma; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Synergism; | 2005 |
[The inhibitory effect of curcumin on the growth of human colon cancer cells (HT-29, WiDr) in vitro].
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Curcumin; Flow Cytometry; | 2005 |
Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis.
Topics: Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Dru | 2005 |
The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Synergism; Electrophoresis, | 2005 |
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, | 2005 |
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2005 |
Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square | 2005 |
Effects of p21cip1/waf1 overexpression on growth, apoptosis and differentiation in human colon carcinoma cells.
Topics: Agar; Alkaline Phosphatase; Apoptosis; Blotting, Western; Butyrates; Carcinoma; Cell Cycle Proteins; | 2005 |
[Effects of expression of thymidine phosphorylase induced by gamma-interferon on regulation of antineoplastic activity of fluorouracil on colonic cancer].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Interferon-gamma; Thymidin | 2005 |
Combined effects of protein kinase inhibitors and 5-fluorouracil on CEA expression in human colon cancer cells.
Topics: Carcinoembryonic Antigen; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Dru | 2005 |
[A case of metastatic submandibular lymphnode treated successfully with palliative oral (5-FU + PSK) chemotherapy in the elderly].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2005 |
Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Line, Tu | 2005 |
Adjuvant therapy for colon cancer--the pace quickens.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytid | 2005 |
Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
Topics: 4-Butyrolactone; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Cell Line, Tu | 2005 |
Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Tech | 2005 |
Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplasti | 2005 |
Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Line, Tumor; C | 2005 |
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Topics: Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuv | 2005 |
Capecitabine-warfarin interaction.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dru | 2005 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.
Topics: Antibodies; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colonic Neoplasms; Fluorouracil; Hum | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell | 2005 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2005 |
Predicting recurrence risk for synchronous primary colon cancers.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cecal N | 2004 |
[Adjuvant therapy of colon cancer soon in tablet form].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2005 |
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Topics: Acetates; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2006 |
Cytotoxins and cancer immunotherapy: the dance of the macabre?
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cancer Vaccines; Colonic Neoplasms; Female; Fluor | 2005 |
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2005 |
Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell L | 2005 |
In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line.
Topics: Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; Fluorouraci | 2005 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Looking for the right drug for the right patient: a tale of old drugs and new pathways.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; | 2005 |
[A case of sclerosing cholangitis trigered by 5-FU/leucovorine combination therapy and rapidly deteriorated].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis, Sclerosing; Colonic Neoplasms; Co | 2005 |
[Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dihydrouracil Dehydr | 2005 |
Cardiotoxicity resembling myocardial infarction that occurs during chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Chest Pain; Colonic Neoplasms; Diagnosis, Differential; Electrocardiography; | 2005 |
Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Colo | 2006 |
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.
Topics: Adjuvants, Immunologic; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Black | 2005 |
Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2005 |
[Ataxia and confusion after treatment with 5 Fluorouracile].
Topics: Antimetabolites, Antineoplastic; Ataxia; Colonic Neoplasms; Confusion; Fluorouracil; Humans; Wernick | 2005 |
TP53 mutation and microsatellite instability status for the prediction of survival in adjuvant-treated colon cancer patients.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; D | 2005 |
Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29.
Topics: Cell Proliferation; Colonic Neoplasms; Curcumin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug | 2006 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2006 |
5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Topics: Aged; Antimetabolites, Antineoplastic; beta-Alanine; Cardiovascular Diseases; Colonic Neoplasms; Dru | 2005 |
Proteomic analysis of chemoresistance to 5-fluorouracil in colon cancer in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Flu | 2005 |
Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chemothera | 2005 |
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; CpG Island | 2006 |
Overstated conclusions of a pooled analysis of bevacizumab in colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catalase; Cell Line, Tumor; Cell Survival; | 2006 |
[Adjuvant treatment of colon cancer MOSAIC study's main results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2006 |
Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase | 2005 |
Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bone M | 2006 |
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; | 2006 |
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Topics: Adenocarcinoma; Biological Transport, Active; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Ne | 2006 |
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cisplatin; | 2006 |
Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Gene Expression | 2006 |
Accrual delayed in adjuvant bevacizumab trial.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplas | 2006 |
Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreat | 2006 |
Inactivation of IkappaB contributes to transcriptional activation of spermidine/spermine N(1)-acetyltransferase.
Topics: Acetyltransferases; Antineoplastic Agents; Colonic Neoplasms; Cycloheximide; Dactinomycin; Fluoroura | 2006 |
Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Survival; Col | 2006 |
Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage.
Topics: Apoptosis; Base Sequence; Caspase 2; Caspases; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA | 2006 |
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Genomic In | 2006 |
[Treatment efficacy of surgical management for liver metastasis from colorectal cancer--a report of 198 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2006 |
Acute coronary syndrome induced by capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Angiography; Coronary Dis | 2006 |
Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Fluorou | 2006 |
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therap | 2006 |
New strategies in colon cancer adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2006 |
Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2006 |
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therap | 2006 |
[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2006 |
Characterization of 5-fluorouracil microspheres for colonic delivery.
Topics: Antineoplastic Agents; Colon; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation, Precl | 2006 |
Comparison of potential chemotherapeutic agents, 5-fluoruracil, green tea, and thymoquinone on colon cancer cells.
Topics: Antineoplastic Agents; Benzoquinones; Catechin; Cell Proliferation; Cell Survival; Colonic Neoplasms | 2006 |
Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon Dioxide; Cell Line, Tumor; Colonic Neoplasms; Disea | 2006 |
[Double sites short hairpin RNAs targeting epidermal growth factor receptor to promote colon cancer cells apoptosis and enhance 5-fluorouracil chemotherapy effect].
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; ErbB Receptors; Fluoroura | 2006 |
[CoCl2-induced chemotherapy resistance in SW480 cells and its mechanism].
Topics: Antimutagenic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cobalt; Colonic Neoplasms; | 2006 |
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2005 |
Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cisplatin; Coculture Techniques; Colonic Neopl | 2006 |
Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway.
Topics: Adenocarcinoma; Carboxylesterase; Cell Line, Tumor; Chromatin; Colonic Neoplasms; Consensus Sequence | 2006 |
[Effects of hyperthermic chemotherapy on gastrointestinal cancer cells in vitro].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cispl | 2006 |
Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Topics: Animals; Antimitotic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 2007 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
["Iatrogenic acute coronary syndrome"--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Neoplasms; Fluoro | 2006 |
Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Colonic Neoplas | 2006 |
Is acute dyspnea related to oxaliplatin administration?
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2006 |
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferati | 2006 |
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercal | 2007 |
Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Floxu | 2006 |
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; DNA; DNA Damage; Floxuridine; Fluorou | 2007 |
Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2006 |
Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Line, Tumor; | 2007 |
[Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenas | 2006 |
[Partial response of liver metastasis from colon cancer following intermittent oral administration of TS-1 after intra-hepatic arterial single injection of CDDP, doxorubicin and 5-FU].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2006 |
Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluo | 2006 |
Chaetominine, a cytotoxic alkaloid produced by endophytic Chaetomium sp. IFB-E015.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Campanulaceae; Cell Line, Tumor; Chaet | 2006 |
Comparison of the rapid pro-apoptotic effect of trans-beta-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Li | 2007 |
Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; | 2007 |
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Topics: Administration, Oral; Animals; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Colonic Neopla | 2007 |
[Anaphylactic reaction to oxaliplatin--a case of colon cancer].
Topics: Adenocarcinoma; Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2006 |
[A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2006 |
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.
Topics: Adult; Age Distribution; Age Factors; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2006 |
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2007 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2006 |
Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy.
Topics: Age Factors; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neopl | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.
Topics: Adenoviridae; Adoptive Transfer; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Carcinoma, H | 2007 |
Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Rel | 2007 |
Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters.
Topics: Aged; Angiography; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Car | 2007 |
[Acute promyelocytic leukemia in a patient with colon adenocarcinoma treated with fluorouracil].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Leukemia, | 2007 |
Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
Topics: Aged; Apoptosis; bcl-2-Associated X Protein; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluo | 2007 |
Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neo | 2007 |
[The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dihydrouracil Dehydr | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colonic Neoplasms; Cyclooxygenas | 2007 |
[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Topics: Anastomosis, Surgical; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.
Topics: Anilides; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; | 2007 |
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo | 2007 |
The hope for today--the promise for tomorrow: will oncologists meet the challenge?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2007 |
A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzoquinones; Catechin; Cell Proliferation; Cell Survival; C | 2007 |
Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neo | 2007 |
Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Carcin | 2007 |
Bevacizumab in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2007 |
Panitumumab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 2007 |
Liver resection after FOLFOX with bevacizumab.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2007 |
Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 2007 |
Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells.
Topics: Acetylation; Actins; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Fluoroura | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
[A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
Effect of IGF-I on healing of colonic anastomoses in rats under 5-FU treatment.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Collagen; Colon; Colonic Neoplasms; | 2008 |
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2007 |
Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coculture Techniques; Colonic Neoplasms; Dru | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethi | 2007 |
[A case of local recurrence of colon cancer responding to chemotherapy with low-dose oxaliplatin, 5-FU and l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; C | 2007 |
[A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.
Topics: Blotting, Western; Carcinoembryonic Antigen; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplas | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Gene Expressio | 2007 |
Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Geno | 2007 |
Constrictive bronchiolitis after treatment of colon cancer with 5-fluorouracil.
Topics: Adult; Bronchiolitis; Colonic Neoplasms; Female; Fluorouracil; Humans; Tomography Scanners, X-Ray Co | 2007 |
Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Adm | 2007 |
Hypoestoxide inhibits tumor growth in the mouse CT26 colon tumor model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cel | 2007 |
Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Topics: Antibodies, Monoclonal; Antibody Specificity; Artificial Gene Fusion; Chromatography, Affinity; Clon | 2007 |
Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tum | 2008 |
Regression of radiation-induced macular edema after systemic bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab | 2007 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2007 |
Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
Topics: Adenocarcinoma; Amyotrophic Lateral Sclerosis; Antineoplastic Combined Chemotherapy Protocols; Campt | 2007 |
Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; bcl-Associated Death Protein; Bet | 2007 |
Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil | 2007 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; | 2007 |
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2007 |
Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine.
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tu | 2008 |
p53 regulates FAK expression in human tumor cells.
Topics: Adenoviridae; Animals; Base Sequence; Blotting, Western; Breast Neoplasms; Cells, Cultured; Chromati | 2008 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, | 2007 |
[Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopla | 2007 |
Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; D | 2008 |
Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eruptions; Fluorouraci | 2007 |
Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Camptothecin; Capecitabine; Cell Line, Tumor; Cell P | 2007 |
Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Colo | 2008 |
Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
Topics: Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluor | 2007 |
Sister Mary Joseph nodule: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo | 2007 |
Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions.
Topics: Animals; Colonic Neoplasms; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorouracil; I | 2008 |
Capecitabine-related cardiotoxicity: recognition and management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deo | 2008 |
A case of late-onset severe cardiotoxicity from 5-fluorouracil therapy resulting in death.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2007 |
[Treatment of colonic cancer and follow up].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colon; Colonic Neoplasms; Colost | 2007 |
Recurrent priapism related to oxaliplatin infusion.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Colo | 2008 |
Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neo | 2008 |
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Stud | 2008 |
Chemotherapy and cancer stem cells.
Topics: Animals; Antineoplastic Agents; Cell Death; Colonic Neoplasms; Fluorouracil; Humans; Interleukin-4; | 2007 |
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.
Topics: AC133 Antigen; Aged; Animals; Antigens, CD; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Col | 2007 |
Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2008 |
Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neopla | 2008 |
Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capillary Permeability; Cell Line, Tumor; Cell Pro | 2008 |
In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil.
Topics: 1,2-Dimethylhydrazine; Alginates; Animals; Antimetabolites, Antineoplastic; Cecum; Colon; Colonic Ne | 2008 |
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; | 2008 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Colonic Neopla | 2008 |
[Patient of advanced age with synclonus liver metastases from colon cancer effectively treated with intraarterial chemotherapy of 5-FU].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Hepatic Artery; | 2008 |
Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 6; Cell Survi | 2008 |
Mechanism of resistance to chemoradiation in p53 mutant human colon cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Blotting, Western; Colonic Neoplasms; Combined Moda | 2008 |
Enzymes of the de novo and salvage pathways for pyrimidine biosynthesis in normal colon, colon carcinoma, and xenografts.
Topics: Adenocarcinoma; Animals; Carboxy-Lyases; Colon; Colonic Neoplasms; Fluorouracil; Humans; Intestinal | 1984 |
[Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxoru | 1984 |
[Therapeutic measures in liver metastases].
Topics: Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms | 1980 |
[Current status of chemotherapy of gastric and colorectal cancer].
Topics: Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Invasivene | 1981 |
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Inj | 1982 |
Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Humans; Liver | 1981 |
Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Antigens, Neoplasm; Carcinoembryonic Antigen; Colonic Neoplasms; Epitopes; | 1982 |
Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Resistance; Fluorouracil; Leukemia P388; Mice; Neop | 1982 |
Colorectal cancer. Radiotherapy.
Topics: Animals; Carcinoembryonic Antigen; Colonic Neoplasms; Dose-Response Relationship, Radiation; Fluorou | 1982 |
Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study.
Topics: Adult; Aged; Catheterization; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; | 1982 |
Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Female; Fluorouracil; Humans; Hypoxanthines | 1983 |
Palliative therapy of pelvic tumors by intra-arterial infusion of cytotoxic drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Doxorubicin; Fe | 1983 |
Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma.
Topics: Cells, Cultured; Colonic Neoplasms; Drug Interactions; Flow Cytometry; Fluorouracil; Humans; Kinetic | 1984 |
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; Fluorouracil; Humans; Infusions, Parenter | 1982 |
Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Drug Admin | 1982 |
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine; | 1983 |
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Effective retreatment of patients with colorectal cancer and liver metastases.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Resistan | 1983 |
Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dimethylhydrazines; Female; Floxur | 1983 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1983 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
[Local infusion therapy in liver metastases of colorectal cancers. Results of a phase-II study].
Topics: Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1984 |
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1984 |
[Measurement of 5'-deoxy-5-fluorouridine (5'-DFUR) by high-performance liquid chromatography and studies on pharmacokinetics of 5'-DFUR and 5-fluorouracil by oral and intravenous administration].
Topics: Administration, Oral; Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuri | 1984 |
[Up-date of the chemotherapy of carcinoma of the colo-rectum: our experience with 5-fluorouracil and folinic acid in high doses].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leu | 1984 |
[Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). A non-controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ev | 1984 |
Prognostic factors and in vitro cytotoxic sensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; Floxuridine | 1984 |
[Hormone receptors in colonic cancer].
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Lomustine; Male; Medroxyprogesterone; Prognosis; Re | 1982 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Antibody pattern to human cytomegalovirus in patients with adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Viral; Colonic Neoplasms; Cytomegalovirus; Fluorouracil; He | 1981 |
[Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1982 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
[Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Colonic Neoplasms; Drug Synergism; Dru | 1983 |
Hemolytic-uremic syndrome in a patient receiving mitomycin C and 5-fluorouracil.
Topics: Adenocarcinoma, Mucinous; Aged; Colonic Neoplasms; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; | 1983 |
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Colonic Neoplasms; Combined Modali | 1984 |
[Clinical trial on the effect of tegafur (SF-SP)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Capsules; Carcinoma, Intraductal, Noninfiltrating | 1984 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Coloni | 1984 |
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Mid | 1984 |
Immune capability of rats with colorectal carcinoma treated by resection with or without 5-fluorouracil or levamisole.
Topics: Animals; B-Lymphocytes; Cell Migration Inhibition; Colonic Neoplasms; Cytotoxicity, Immunologic; Flu | 1984 |
[Isolated liver perfusion in advanced metastases of colorectal cancers].
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; | 1984 |
Continuous intravenous administration of 1-(2-tetrahydrofuryl)-5-fluorouracil [FT] by intravenous hyperalimentation (IVH)--stability of FT in IVH solution and tumor levels of 5-fluorouracil (5-FU).
Topics: Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Parenteral Nutrition, Tot | 1983 |
Phase II trial of combination chemotherapy of colonic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
Topics: Altretamine; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Drug Eval | 1983 |
Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1983 |
[A study on postoperative long-term continuous immuno-chemotherapy with PSK and 5-FUDS for advanced gastric and colo-rectal cancers].
Topics: Aged; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Human | 1983 |
[Intra-arterial infusion chemotherapy for metastatic hepatic tumor of colo-rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1983 |
Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dacarbazine; Female; | 1983 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1984 |
[Basic and clinical studies on metastatic cancer--with special reference of multidisciplinary treatment of gastric and colorectal cancer patients with hepatic metastasis].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Ar | 1983 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Aphidicolin; Cell Line; Colonic Neoplasms; Diterpenes; | 1984 |
[Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer].
Topics: Adult; Aged; Carcinoembryonic Antigen; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; F | 1984 |
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1984 |
Enhanced accumulation of 5-fluorouracil in human tumors in athymic mice by co-administration of Ftorafur and uracil.
Topics: Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Mice; Mice, Nude; Neopl | 1984 |
[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
Topics: Administration, Oral; Adult; Aged; Capsules; Colonic Neoplasms; Delayed-Action Preparations; Drug Ev | 1984 |
Hepatic artery ligation and portal vein infusion for liver metastases from colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Hepat | 1984 |
On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.
Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate | 1980 |
Isolation of a cellular subpopulation from a human colonic carcinoma cell line.
Topics: Animals; Carcinoembryonic Antigen; Cell Division; Cell Line; Cells, Cultured; Colonic Neoplasms; Dru | 1980 |
Studies on surgical adjuvant chemotherapy for colorectal cancer and administration of neocarzinostatin into the lumen of the colon or rectum using a double balloon catheter and iontophoresis.
Topics: Animals; Antibiotics, Antineoplastic; Catheterization; Colonic Neoplasms; Dogs; Fluorouracil; Humans | 1981 |
Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; Lymphatic Met | 1984 |
Adjuvant therapy for carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; L | 1984 |
A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colonic Neoplasms; Drug Sy | 1984 |
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Ataxia; Colonic Neoplasm | 1984 |
Experimental colon neoplasia enhanced by extract of sperm (protamine).
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Colonic Polyps; Dimethylhydrazines; Female; Fluorouracil | 1984 |
Comparative levels of tissue enzymes concerned in the early metabolism of 5-fluorouracil in normal and malignant human colorectal tissue.
Topics: Aged; Colon; Colonic Neoplasms; Epithelium; Female; Fluorouracil; Humans; Male; Middle Aged; Pentosy | 1984 |
[Adjuvant chemotherapy in cancers of the stomach, pancreas and intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1984 |
Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; | 1984 |
Sequential combination chemotherapy with methotrexate and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1984 |
The use of human cancer cell lines as a primary screening system for antineoplastic compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Cytarabine; Dr | 1984 |
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; | 1984 |
Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 1984 |
Chemotherapeutic efficacy of 5-fluorouracil with concurrent thymidine infusion against transplantable colon tumors in rodents.
Topics: Animals; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Male; Mice; Mice, Inbre | 1984 |
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo | 1983 |
[Evaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancers].
Topics: Adolescent; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; | 1983 |
Combination chemotherapy with 5-fluorouracil (5FU) and 1,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) prolongs survival of rats with dimethylhydrazine-induced colon cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carmust | 1983 |
Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model.
Topics: Animals; Colonic Neoplasms; Combined Modality Therapy; Disease Models, Animal; Fluorouracil; Levamis | 1983 |
Remission of metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Intestinal Poly | 1983 |
[A clinical study (phase II) of a combination of 5-fluorouracil, vincristine and methyl CCNU in patients with advanced carcinoma of the large intestine].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; | 1983 |
First histologic findings in metastases of colorectal carcinoma following isolated liver perfusion with cytostatics.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; L | 1983 |
Intra-arterial perfusion therapy with 5-fluorouracil in patients with metastatic colorectal carcinoma and intractable pelvic pain.
Topics: Adult; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluor | 1983 |
Transient repeated dearterialization combined with intra-arterial infusion of oncolytic drugs in the treatment of liver tumors.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Cyclophosphamide; Duod | 1983 |
First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary.
Topics: Animals; Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic N | 1983 |
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Hyd | 1983 |
Adjuvant therapy for Dukes C adenocarcinoma of colon.
Topics: Abdomen; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle | 1983 |
[Treatment of advanced cancer of the colon and rectum with the combination of 5-fluorouracil, imidazolecarboxamide and vincristine].
Topics: Aged; Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1983 |
Lack of inhibition by oxipurinol of 5-FU toxicity against human tumor cell lines.
Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Fem | 1983 |
[Preliminary study of a combination of fluorouracil and cisplatin in the treatment of tumors of the colon].
Topics: Adult; Aged; Cisplatin; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1983 |
Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation | 1984 |
The antitumoral activity of 4'-deoxydoxorubicin compared to doxorubicin and 5-fluorouracil on methylazoxymethanol acetate-induced colon tumors in CF1 mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Female; Flu | 1984 |
Chemosensitivity testing of human neoplasms using the soft agar colony assay.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Cell Division; Colonic Neoplasms; Colony-Forming Un | 1984 |
Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors.
Topics: Adenocarcinoma; Age Factors; Animals; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Fluorou | 1984 |
Adjuvant intrahepatic cytotoxic liver infusion for colon cancer. Catheter placement technique.
Topics: Catheterization; Colonic Neoplasms; Fluorouracil; Heparin; Humans; Liver Neoplasms; Portal System | 1984 |
Chemoprevention of development of colonic adenomatosis and carcinomatosis with 5-fluorouracil and ftorafur on animal model.
Topics: Adenoma; Animals; Carcinoma; Colon; Colonic Neoplasms; Female; Fluorouracil; Methylnitrosourea; Neop | 1980 |
Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1981 |
Effectiveness of postoperative adjuvant therapy with cytotoxic chemotherapy (cytosine arabinoside, mitomycin C, 5-fluorouracil) or immunotherapy (neuraminidase-modified allogeneic cells) in the prevention of recurrence of Duke's B and C colon cancer.
Topics: Aged; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans; Immunotherapy; Male; Middle Aged; | 1981 |
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; | 1981 |
Chemotherapy of carcinomas of the digestive tract.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Esop | 1982 |
Intrahepatic artery 5-fluorouracil and mitomycin-C in previously untreated patients with hepatic metastases from colorectal carcinoma.
Topics: Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Mitomyci | 1982 |
Chemotherapeutic studies on N-nitrosoacetoxymethyl-methylamine-and 1,2-dimethylhydrazine-induced colonic tumors in rats: monotherapy with 5-fluorouracil, ftorafur, CGP 6809, and CGP 15'720A.
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Agents; Carcinogens; Colonic Neoplasms; Dimethylhydra | 1982 |
[Adjuvant treatment in surgery of colon and rectal cancer].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Prognosis; Rectal Neoplasms; Thiotepa | 1982 |
[Anticancer effect of levamisole and tegafur on 1,2-dimethylhydrazine (DMH)-induced colonic cancers in rats].
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Agents; Colonic Neoplasms; Dimethylhydrazines; Fluoro | 1982 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study.
Topics: Breast Neoplasms; Colonic Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Colonic Neoplasms; Diphosphon | 1983 |
In vitro translation of messenger RNA following exposure of human colon carcinoma cells in culture to 5-fluorouracil and 5-fluorouridine.
Topics: Cell Line; Centrifugation, Density Gradient; Colonic Neoplasms; Electrophoresis, Polyacrylamide Gel; | 1983 |
[Gastrointestinal tumors: chemotherapeutic preparations].
Topics: Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gast | 1983 |
[Treatment of cancers of the colon and rectum].
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Rectal Ne | 1983 |
[Analysis of morbidity from simultaneous 5-fluorouracil therapy and radiation therapy in advanced gastrointestinal tumors. Report of results].
Topics: Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Radiothera | 1983 |
Chemotherapy of chemically-induced colorectal tumours.
Topics: Animals; Colonic Neoplasms; Dimethylhydrazines; Disease Models, Animal; Female; Fluorouracil; Neopla | 1983 |
Sequence-dependent synergism between dichloromethotrexate and 5-fluorouracil in a human colon carcinoma cell line.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluo | 1983 |
Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Indomethacin; M | 1983 |
Metastatic colorectal cancer. Combination chemotherapy in patients previously treated with 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middl | 1980 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Sequential methotrexate and 5-FU in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Follow-Up | 1982 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointesti | 1982 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
Randomized versus historical controls for clinical trials.
Topics: Abortion, Habitual; Anticoagulants; BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Corona | 1982 |
[Sequential methotrexate and fluorouracil in metastasizing colorectal carcinomas. Results of a phase II pilot study (author's transl)].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Life Expectancy; Male; Methotrexate; M | 1982 |
Adenocarcinoma of the colon with hepatic metastases. Fifteen-year survival.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Prognosis; | 1982 |
Fluorouracil for colorectal cancer: a sobering look.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Rectal Neoplasms | 1982 |
[Immunotherapy in the treatment of colorectal cancers in the aged].
Topics: Aged; Aging; BCG Vaccine; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle | 1982 |
5-FU and allopurinol: toxicity modulation and phase II results in colon cancer.
Topics: Allopurinol; Brain; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Hum | 1982 |
Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Hu | 1982 |
Ex vivo hemodialysis culture system for assessing the activity of cancer chemotherapeutic agents.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dogs; Drug Eval | 1982 |
Dosimetry and preliminary human studies of 18F-5-fluorouracil.
Topics: Animals; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Fluorine; Fluorouracil; Half-Life; Hu | 1982 |
Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Fluorou | 1982 |
The assessment of response of murine transplantable colon tumors to combination chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Cell Line; Colonic Neoplasms; Dimethylhy | 1982 |
Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture.
Topics: Cell Nucleus; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Humans | 1982 |
[Chemotherapy of colorectal cancer].
Topics: Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1982 |
[Vascular isolation and perfusion of the liver in clinical practice].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colonic Neop | 1982 |
High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
Topics: Animals; Colonic Neoplasms; Fluorouracil; Kinetics; Leukopenia; Mice; Mice, Inbred BALB C; Neoplasms | 1982 |
Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; F | 1982 |
Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro.
Topics: Adenocarcinoma; Cell Line; Cell Survival; Clone Cells; Colonic Neoplasms; Dose-Response Relationship | 1982 |
Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Kinetic | 1982 |
Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Colonic Neoplasms; Complement Fixation Tests; Female; Fluorouracil; | 1982 |
Colorectal cancer. Chemotherapy.
Topics: Adjuvants, Pharmaceutic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; | 1982 |
Colorectal cancer. Prospects in management.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Colonic Neoplasms; Fluorouracil; Humans; Postoperat | 1982 |
Combined actions of 5-fluorouracil and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on human colonic carcinoma cells in vitro.
Topics: Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Thera | 1982 |
Combination chemotherapy in patients with advanced colorectal carcinoma previously treated with 5-FU.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nitrosourea Compou | 1982 |
Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate.
Topics: Aged; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver | 1982 |
The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Methotr | 1982 |
[Results of surgical and complex treatment of colonic and rectal cancer].
Topics: Colectomy; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Lomustine; Neoplasm Staging; P | 1982 |
[Isolated liver perfusion with 5-fluorouracil (5-FU) in the human].
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neo | 1982 |
[Phase II study of carmofur (HCFU) fine granules].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Child, Preschool; Colonic N | 1982 |
Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Colonic Neoplasms; Drug Therapy, Combinatio | 1982 |
Angina and anemia with marked valvular stenosis.
Topics: Adenocarcinoma; Aged; Anemia, Hypochromic; Angina Pectoris; Aortic Valve Stenosis; Colon; Colonic Ne | 1982 |
[Effect of chemotherapy on the growth of human gastrointestinal tumor strains].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms, Experimental; Mic | 1980 |
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
Topics: Adenocarcinoma; Colon; Colonic Neoplasms; Deoxyuracil Nucleotides; Dose-Response Relationship, Drug; | 1981 |
Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1981 |
Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs: 5-fluorouracil and 1-3-bis-(-2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives: 4'deoxydoxorubicin and 4'-O-methyldoxorubicin.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Fluorouracil; Humans; Mice; Mic | 1981 |
Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil vincristine and streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorourac | 1980 |
[Treatment of inoperable liver metastases: preliminary results with intrahepatic chemotherapy via a new type of indwelling catheter (author's transl)].
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1981 |
Studies in an animal model on the effectiveness of adjuvant chemotherapy with 5-FU and BCNU in cases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluoroura | 1981 |
Surgical adjuvant therapy in colon carcinoma: a human tumor spheroid model for evaluating radiation sensitizing agents.
Topics: Allopurinol; Cell Count; Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Ra | 1981 |
[Intra-arterial injection of antineoplastic agents in colorectal neoplasms].
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Mitomyci | 1981 |
[Diagnosis and treatment of colonic neoplasms (the data from Moscow municipal oncological dispensary)].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Moscow | 1981 |
Transfemoral hepatic artery infusion for metastatic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Female; Femoral Artery; Fluorour | 1981 |
[Immunochemotherapeutic treatment of gastrointestinal neoplasms].
Topics: Adjuvants, Immunologic; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Prognos | 1981 |
Phase I study of protracted venous infusion of 5-fluorouracil.
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Admini | 1981 |
[Gastrointestinal tumors. Prognostic factors and chemotherapy of today].
Topics: Carmustine; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1981 |
[Remote results of the treatment of colon cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Mal | 1981 |
Defective function of granulocytes in patients with cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Femal | 1981 |
[Early cardiotoxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Myocarditis; Pericarditi | 1981 |
Chemoprevention of development of colonic adenomatosis and carcinomatosis with intrarectal dose of 5-FU on animal model.
Topics: Adenoma; Animals; Colonic Neoplasms; Female; Fluorouracil; Injections, Intraperitoneal; Methylnitros | 1980 |
Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.
Topics: Animals; Colonic Neoplasms; DNA, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; | 1980 |
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.
Topics: Adult; Aged; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1980 |
[Evaluation of the 1st trials of adjuvant treatment. Future prospects].
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal | 1980 |
[Current aspects of precautional therapy of colorectal neoplasms].
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Postoper | 1980 |
The value of lymphocyte transformation in carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Lymphocyte Activa | 1980 |
Drug interactions with acetaminophen: effects of phenobarbital, prednisone and 5-fluorouracil in normal and tumor-bearing rats.
Topics: Acetaminophen; Animals; Colonic Neoplasms; Drug Interactions; Female; Fluorouracil; Galactosamine; I | 1980 |
Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; In Vitro Techniques | 1980 |
5-Fluorouracil in combination with hypoxathine and allopurinol: toxicity and metabolism in xenografts of human colonic carcinomas in mice.
Topics: Allopurinol; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Hypoxanthi | 1980 |
Chemotherapy for gastrointestinal malignancy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Fluoroura | 1980 |
Comparison of two combination chemotherapy regimens in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorourac | 1980 |
[Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 1. Experiments to test the feasibility of combined chemotherapy with VCR and 5-FU (author's transl)].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Mice; M | 1980 |
Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma; Cell Line; Colonic Neoplasms; Drug Administration Sched | 1980 |
Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma.
Topics: Colonic Neoplasms; Feces; Fluorouracil; Humans; Intestinal Absorption; Povidone; Time Factors; Tobra | 1980 |
Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil | 1981 |
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; M | 1981 |
Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Me | 1981 |
Cardiotoxicity of 5-fluorouracil.
Topics: Angina Pectoris; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lomusti | 1980 |
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Inje | 1980 |
The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Analysis of Variance; Animals; Cell Separation; Cells, Cultu | 1995 |
[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopla | 1995 |
[Adjuvant treatment of colonic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1995 |
Antitumour effects of pure diastereoisomers of 5-formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Divis | 1995 |
The style of early clinical research reporting: what are we saying and how do we say it?
Topics: Abstracting and Indexing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car | 1993 |
Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; CD56 Antigen; Chemotherapy, Adjuvant; Colonic | 1994 |
Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Synergism; Female; Fluorou | 1994 |
Whole abdominal radiotherapy and concomitant 5-fluorouracil as adjuvant therapy in advanced colon cancer.
Topics: Abdomen; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hum | 1995 |
Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Laparosco | 1995 |
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Topics: Animals; Carcinoma, Squamous Cell; Circadian Rhythm; Colonic Neoplasms; Delayed-Action Preparations; | 1995 |
In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Topics: Adenoviridae; Animals; Antineoplastic Agents; beta-Galactosidase; Cell Division; Cell Line; Colonic | 1995 |
Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Canavanine; Colonic Neoplasms; Dose-Respons | 1995 |
The 'pinch-off phenomenon': a radiological symptom for potential fracture of an implanted permanent subclavian catheter system.
Topics: Antimetabolites, Antineoplastic; Catheterization, Central Venous; Colonic Neoplasms; Fluorouracil; H | 1995 |
[Fracture and intravascular migration of a catheter implanted for venous access].
Topics: Adult; Catheters, Indwelling; Colectomy; Colonic Neoplasms; Equipment Failure; Female; Fluorouracil; | 1995 |
5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Cycle; Cell Division; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; R | 1995 |
5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Division; Colonic Neoplasms; Deoxyuridine; | 1995 |
Serum concentrations of 5-fluorouracil achieved with nocturnal constant-rate infusion in patients with disseminated cancer.
Topics: Adult; Aged; Breast Neoplasms; Circadian Rhythm; Colonic Neoplasms; Drug Administration Schedule; Fe | 1995 |
Chemotherapy-induced nuclear alterations of morphologic and genomic characteristics in a human colon cancer grafted onto nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Nucleus; Chromatin; Colonic Neopl | 1995 |
Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Interferon-alpha; Thymidine Phosphorylase; Transfection; Tu | 1995 |
Comparison of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase.
Topics: Animals; Biotransformation; Cell Line; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate; | 1994 |
[Tissue concentration of 5-FU after intra-operative arterial infusion].
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Lymph Nodes; Male; Posto | 1995 |
Enigma of fluorouracil and levamisole.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamiso | 1995 |
Research by collaboration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1995 |
Influence of 5-fluorouracil on serum lipids.
Topics: Aged; Animals; Breast Neoplasms; Cholesterol; Cholesterol, HDL; Colonic Neoplasms; Female; Fluoroura | 1995 |
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as | 1995 |
5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Topics: Administration, Oral; Aldehyde Oxidase; Aldehyde Oxidoreductases; Animals; Biological Availability; | 1995 |
Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1995 |
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
Topics: Cell Division; Cell Line; Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Gene Ampl | 1995 |
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzofurans; Biological Transport; Carc | 1995 |
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line; Colonic Neoplasms; Dose-Response Relationship, Drug; | 1995 |
Neuroradiology case of the day. Multifocal inflammatory leukoencephalopathy due to treatment with 5-fluorouracil and levamisole.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colonic Neoplasms; Demyelinating Dis | 1995 |
Interaction of 5-fluorouracil with folates.
Topics: Aged; Colonic Neoplasms; Drug Interactions; Drug Therapy, Combination; Female; Fluorouracil; Folic A | 1995 |
Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Topics: Biotransformation; Cell Division; Colonic Neoplasms; DNA, Neoplasm; Drug Synergism; Fluorouracil; Hu | 1994 |
Fluorouracil and folinic acid in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 1995 |
Fluorouracil and folinic acid in colon cancer. IMPACT Investigators.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 1995 |
[Home infusion chemotherapy in patients with relapsed or recurred stomach and colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Home Care Servic | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-1)].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1994 |
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Fatal | 1995 |
Colo-rectal carcinoma in a tropical African population: an overview report.
Topics: Adenocarcinoma; Administration, Rectal; Adolescent; Adult; Aged; Anus Neoplasms; Ascites; Colonic Ne | 1994 |
Adjuvant treatment for cancer of the colon and rectum.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Rectal N | 1994 |
Cox regression analysis of multivariate failure time data: the marginal approach.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bias; Clinical Trials as Topic; Cluster | 1994 |
SMS 201.995 (Sandostatin) enhances in-vitro effects of 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Carcinoma; Colonic Neoplasms; Colorimetry; Drug Synergism; Fluorouracil; Humans; Oct | 1995 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden | 1994 |
Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines.
Topics: Cell Division; Colonic Neoplasms; Drug Resistance; Fluorouracil; Humans; Orotate Phosphoribosyltrans | 1995 |
Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil.
Topics: Cell Cycle; Colonic Neoplasms; DNA; Drug Interactions; Fluorouracil; Humans; Leucovorin; S Phase; Th | 1995 |
Multifocal inflammatory leukoencephalopathy developing in a patient receiving 5-fluorouracil and levamisole.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Chemotherapy, Adjuvant; Colonic Neopla | 1994 |
Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells.
Topics: Adenocarcinoma; Biological Transport; Colonic Neoplasms; Drug Administration Schedule; Drug Synergis | 1995 |
Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Floxuridine; Fluoroura | 1994 |
Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Cell Survival; Colonic Neoplasms; | 1995 |
Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report.
Topics: Aged; Cerebral Cortex; Chemotherapy, Adjuvant; Colonic Neoplasms; Cytokines; Female; Fluorouracil; H | 1994 |
The arotinoid Ro 40-8757 has antiproliferative effects in drug-resistant human colon and breast cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Division; Colonic Neoplasms; Doxorubic | 1994 |
Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Topics: Animals; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NAD+); Drug Synergism; Female; Fluorouracil | 1994 |
Treatment of patients with irresectable liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver | 1994 |
Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids.
Topics: Adenocarcinoma; Amino Acid Sequence; Cell Cycle; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug | 1994 |
Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin.
Topics: Aged; Colonic Neoplasms; Erythropoiesis; Erythropoietin; Female; Fluorouracil; Humans; Leucovorin; M | 1994 |
Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft.
Topics: Adenocarcinoma, Mucinous; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Fluorouracil; Humans; | 1994 |
Modifications of the anti-oxidant metabolism during proliferation and differentiation of colon tumor cell lines.
Topics: Antioxidants; Catalase; Cell Differentiation; Cell Division; Colonic Neoplasms; Drug Resistance; Flu | 1994 |
[Study of in vitro cancer sensitivity of anticancer drugs by SDI (succinate dehydrogenase inhibition test)].
Topics: Cisplatin; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fibroblasts; Fluorouracil; Humans; M | 1994 |
Clonogenic survival studies of human colon tumor cell lines in vitro: combined hyperthermia, 5-fluorouracil/leucovorin, carboplatin and tumor necrosis factor.
Topics: Carboplatin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Human | 1995 |
Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; Fluorour | 1994 |
Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects.
Topics: Cell Cycle; Colonic Neoplasms; DNA; Fluorouracil; Humans; Radiation-Sensitizing Agents; Thymidine; T | 1994 |
[Effect of BOF-A2 on experimental and spontaneous metastasis model of mouse colon 26].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Chemotherapy, Adjuvant; Colonic Neoplas | 1994 |
Adjuvant therapy with fluorouracil and levamisole and liver ultrasound mimicking liver metastases.
Topics: Adult; Colonic Neoplasms; Diagnosis, Differential; Fatty Liver; Female; Fluorouracil; Humans; Levami | 1994 |
Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation.
Topics: Adenocarcinoma; Cell Division; Chalcone; Chalcones; Colonic Neoplasms; Flavonoids; Fluorouracil; Hum | 1994 |
Possible drug interaction between warfarin and combination of levamisole and fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Interactions; Fluorour | 1994 |
Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Interferon-alpha; Leucovo | 1994 |
[Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Resistance; Fluorouracil; Humans; Polymerase Chain Reaction; | 1994 |
Adjuvant treatment of colon cancer. A plea for a large-scale European trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
[The concentration of FT in peripheral blood and portal blood after oral, intravenous or rectal administration].
Topics: Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplas | 1994 |
An oncology patient with an erythematous papulosquamous eruption in sun-exposed areas. Inflamed actinic keratoses due to systemic chemotherapy (fluorouracil and, possibly, interferon alfa).
Topics: Colonic Neoplasms; Erythema; Fluorouracil; Humans; Interferon-alpha; Keratosis; Male; Middle Aged; S | 1994 |
Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Computer | 1994 |
Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxyribonucleosides; Drug Synerg | 1994 |
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer.
Topics: Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit | 1993 |
Increased chemocytotoxicity to colon cancer cells by shock wave-induced cavitation.
Topics: Air; Carcinoma; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Deoxyuridin | 1994 |
Cicatricial ectropion: a complication of systemic fluorouracil.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cicatrix; Colonic Neoplasms; Dexamethasone; Ectropion; Fe | 1993 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
Enhanced cytotoxicity of 5-fluorouracil combined with [6RS]leucovorin and recombinant human interferon-alpha 2a in colon carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Drug Synergism; Fl | 1993 |
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Fluorodeoxyuridyla | 1993 |
Comparison of continuous infusions and bolus injections of 5-fluorouracil with or without leucovorin: implications for inhibition of thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Infusions, | 1993 |
Colon carcinoid tumors. A population-based study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemothera | 1994 |
Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1994 |
[Relationship between the Ki-67 nuclear antigen content and cell-cycle perturbation on WiDr cells treated with 5-FU].
Topics: Cell Cycle; Colonic Neoplasms; Flow Cytometry; Fluorouracil; Humans; Ki-67 Antigen; Neoplasm Protein | 1993 |
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluoro | 1993 |
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Cycle; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug S | 1993 |
[A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura | 1993 |
N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Base | 1993 |
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Topics: Administration, Oral; Animals; Biological Availability; Colonic Neoplasms; Dihydrouracil Dehydrogena | 1993 |
Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1993 |
Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
Topics: Animals; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; | 1994 |
[Is adjuvant chemotherapy of colon cancers (Dukes C; TxN+) regarded as standard today?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1993 |
[Local use of a drug combination consisting of fluorouracil, cyclophosphamide and silicone sorbent in patients with colonic cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Topical; Antineoplastic Combined Chemother | 1993 |
The interval between methotrexate and leucovorin determines the efficacy of 5-fluorouracil modulation in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; Colonic Neoplasms | 1993 |
Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent.
Topics: Binding Sites; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Syner | 1993 |
New perspectives in colon cancer chemotherapy.
Topics: Animals; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplan | 1994 |
In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Moda | 1993 |
A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; Doxoru | 1993 |
A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms | 1993 |
Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance.
Topics: Adenocarcinoma; Base Sequence; Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Huma | 1993 |
Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.
Topics: Antineoplastic Agents; Blotting, Northern; Cell Division; Colonic Neoplasms; Cytokines; Depression, | 1993 |
Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
[A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 1993 |
Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diar | 1993 |
[An accelerated appearance of a multifocal leukoencephalopathy caused by fluorouracil and ranitidine].
Topics: Adjuvants, Pharmaceutic; Colonic Neoplasms; Female; Fluorouracil; Humans; Leukoencephalopathy, Progr | 1993 |
Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells.
Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug Synergism; Fluorou | 1993 |
The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, | 1993 |
Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Drug | 1993 |
[Complications of intra-arterial chemo-infusion using implantable vascular access system].
Topics: Breast Neoplasms; Colonic Neoplasms; Equipment Failure; Evaluation Studies as Topic; Female; Fluorou | 1993 |
[Intermittent intra-arterial infusion chemotherapy of 5-FU and carboplatin for unresectable liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Drug Administration | 1993 |
[Clinical study on the effect of continuous transarterial infusion chemotherapy of CDDP for metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Admi | 1993 |
[Evaluation of subselective intraarterial infusion chemotherapy in far advanced gastric and colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1993 |
[Two cases of intrahepatic biloma during hepatic arterial infusion chemotherapy proved by CT-Scan].
Topics: Adult; Bile; Bile Duct Diseases; Bile Ducts, Intrahepatic; Colonic Neoplasms; Female; Fluorouracil; | 1993 |
Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106.
Topics: Antibodies, Monoclonal; Blotting, Western; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Hu | 1993 |
A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans; | 1993 |
Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Doxorubicin; Female; | 1993 |
Multifocal inflammatory leukencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 1993 |
Effect of 5-fluorouracil on polyamine excretion in human colonic cancer cells.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Polyamines; Spermidine; Tumor Cells, Cultured | 1993 |
[Experimental and clinical study in vitro chemosensitivity test for succinate dehydrogenase inhibition test].
Topics: Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopla | 1993 |
Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum | 1993 |
Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1993 |
Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Drug Resistance; Floxuridine; Flu | 1993 |
Experimental cancer chemotherapy using a liver metastatic model of human colon cancer transplanted into the spleen of severe combined immunodeficient mice.
Topics: Animals; Colonic Neoplasms; Fluorouracil; Humans; Isoenzymes; L-Lactate Dehydrogenase; Liver; Liver | 1993 |
[A new sequential chemotherapy of methotrexate with 5-fluorouracil against advanced colo-rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; D | 1993 |
[Evaluation of long-term administration of oral anti-cancer agent].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1993 |
[A case of advance colon cancer responding to sequential methotrexate and 5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1993 |
A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms | 1993 |
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Topics: Colonic Neoplasms; Drug Synergism; Enzyme Induction; Enzyme Stability; Fluorouracil; Gene Expression | 1993 |
Response of primary colon cancer cells in hybrid spheroids to 5-fluorouracil.
Topics: Cell Survival; Colonic Neoplasms; Drug Resistance; Drug Screening Assays, Antitumor; Feasibility Stu | 1993 |
Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine.
Topics: Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Cytokines; Dose-Response Relations | 1993 |
Postoperative radiation therapy for high-risk colon carcinoma.
Topics: Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Lymphatic Metastas | 1993 |
[Medical treatment of colorectal cancers: evaluation].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 1993 |
Neurotoxicity following weekly therapy with folinic acid and high-dose 5-fluorouracil 24-h infusion in patients with gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Epilepsy, Complex Partial; Female | 1993 |
5-fluorouracil by protracted subcutaneous infusion. A pilot study.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Injectio | 1995 |
Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro.
Topics: Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbop | 1996 |
5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Fluorine Radioisotopes; Fluo | 1996 |
Creatine kinase elevation associated with 5-fluorouracil and levamisole therapy for carcinoma of the colon. A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Co | 1996 |
Inflammatory bowel disease associated with levamisole and fluorouracil chemotherapy for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Inflammator | 1996 |
5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Interfe | 1996 |
Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice.
Topics: Administration, Oral; Allyl Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemo | 1996 |
Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Brain Diseases; Colonic Neoplasms; Demyelinati | 1996 |
Carcinoma colon with mandible and liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1996 |
Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27.
Topics: Cell Survival; Cisplatin; Colonic Neoplasms; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistan | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1996 |
Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alky | 1996 |
Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alky | 1996 |
Chemotherapy in stage II/Duke's B2 colon cancer: tolerable but necessary?
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 1996 |
Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Gas Chromatography-Mass S | 1995 |
Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Ethylnitrosourea; Fluorouracil; Mammary Neoplasms | 1996 |
Thymidylate synthase in advanced gastrointestinal and breast cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Colonic Neoplasms; Fem | 1996 |
[Studies on the in vivo and in vitro chemosensitivity tests using human tumor xenografts].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, An | 1995 |
Dual modulation by l-leucovorin and recombinant human interferon alpha 2a of 5-fluorouracil antitumor activity against the human colon carcinoma xenograft Co-4.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Synergism; Fluorour | 1995 |
[Severe myalgias: an unusual undesirable effect of levamisole combined with 5-fluorouracil].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined | 1996 |
Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration.
Topics: Adenocarcinoma; Central Nervous System Diseases; Colonic Neoplasms; Drug Interactions; Female; Fluor | 1996 |
18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results.
Topics: Animals; Cell Line; Colonic Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyuridylate; Fluorou | 1996 |
Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineopl | 1996 |
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 1996 |
5-Fluorouracil- and levamisole-associated multifocal leukoencephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; F | 1996 |
[Two cases of multiple liver metastases (H3) from colon cancer treated by home hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Fluorouracil; Hepati | 1995 |
Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colonic Neoplasms; Female; Fluorouracil; | 1996 |
Comparison by carcinoembryonic antigen doubling time of hepatic injection and infusion for unresectable hepatic metastasis from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Female; F | 1995 |
Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 1996 |
5-Fluorouracil metabolite patterns in viable and necrotic tumor areas of murine colon carcinoma determined by 19F NMR spectroscopy.
Topics: Animals; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectroscopy; | 1996 |
Postoperative radiotherapy for locally advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 1996 |
Accumulation of Tc-99m HMDP in hepatic metastasis from colon carcinoma without detectable calcification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Calcinosis; Cisplatin; Colonic Neopl | 1996 |
Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance; Drug Synergism; Fluorouracil; H | 1996 |
Assessing whether to perform a confirmatory randomized clinical trial.
Topics: Adjuvants, Immunologic; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Combined M | 1996 |
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic | 1996 |
Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Female; | 1996 |
Cardiac perforation associated with continuous infusional chemotherapy.
Topics: Antineoplastic Agents; Catheterization, Central Venous; Colonic Neoplasms; Fluorouracil; Heart Injur | 1996 |
[Should adjuvant chemotherapy be also used in Dukes stage B2 colon cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1996 |
[Trial of home anti-cancer chemotherapy with infusion of 5-FU and low-dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Colonic Neopla | 1996 |
Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
Topics: Adenocarcinoma; Animals; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1996 |
The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Division; Cisplatin; Colonic | 1996 |
[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colectomy; Colonic Neop | 1997 |
[A case of advanced colon cancer with marked response to combination chemotherapy with 5-FU, low dose CDDP, and leucovorin].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1997 |
[Effects of carcinostatic agents in the hematogenous metastasis of cancer].
Topics: Animals; Cell Adhesion; Cisplatin; Colonic Neoplasms; Doxorubicin; E-Selectin; Endothelium; Fluorour | 1997 |
Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1997 |
Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Fluorourac | 1997 |
Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug Synergi | 1997 |
Adjuvant therapy for colon and rectal cancer.
Topics: Algorithms; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Mod | 1997 |
Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Topics: Cell Division; Cell Survival; Colonic Neoplasms; Deoxyribonucleotides; Deoxyuracil Nucleotides; DNA | 1997 |
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Topics: 16,16-Dimethylprostaglandin E2; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; | 1997 |
[Case of acute immune hemolytic anemia developing during fluorouracil administration following surgery of colonic cancer].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Co | 1997 |
Focal dystonia after chemotherapy: a case series.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dyst | 1997 |
Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[Morphological changes in human colon carcinoma after chemotherapy with 5-fluorouracil--a study in the nude mouse model].
Topics: Adenocarcinoma, Papillary; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasm | 1997 |
Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Brain; Chemotherapy, Adjuva | 1997 |
Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Cell Division; Cisplatin; Colonic Neoplasms; DNA, Neoplasm; Dox | 1997 |
[Adjuvant treatment in operable colonic and rectal cancer. A new possibility].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1997 |
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy | 1997 |
Future directions in the adjuvant treatment of colon cancer.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms | 1997 |
Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.
Topics: Animals; Antibodies, Bispecific; Antidotes; Antimetabolites, Antineoplastic; Capillary Permeability; | 1997 |
Apoptosis in cultured human colon cancer cells induced by combined treatments with 5-fluorouracil, tumor necrosis factor-alpha and interferon-alpha.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1997 |
[Evaluation of hepatic resection and hepatic arterial infusion chemotherapy for multiple liver metastases from colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1997 |
[A case of huge liver metastasis from colon cancer successfully treated by hepatic intraarterial infusion of low-dose 5-FU].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil | 1997 |
[Liver abscess caused by hepatic artery infusion chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatec | 1997 |
Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Caspase 1; Colonic Neoplasms; Cysteine Endope | 1997 |
5-Fluorouracil-resistant colonic tumors are highly responsive to sodium butyrate/interleukin-2 bitherapy in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Butyrates; | 1997 |
19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Topics: Animals; Colonic Neoplasms; Enzyme Inhibitors; Fluorine Radioisotopes; Fluorouracil; Magnetic Resona | 1997 |
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Colonic Neo | 1997 |
Cutaneous metastasis as a complication of hepatic intra-arterial chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1997 |
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA; Drug Resistance, Neoplasm; Fluorouracil; Hu | 1997 |
[Palliative treatment with cytostatics of metastatic colorectal cancer in general practice. A model].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Administration | 1997 |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1998 |
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colonic Neoplasms; Dose- | 1998 |
Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 1997 |
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytid | 1998 |
[Continuous intraportal chemotherapy for prevention of metachronous hepatic metastasis in colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 1998 |
[Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern].
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Female; Flow Cytometry; Flu | 1998 |
Dihydropyrimidine dehydrogenase in livers from mouse and rat, and in human liver, colon tumors, and mucosa in relation to anabolism of 5-fluorouracil.
Topics: Animals; Biological Availability; Biotransformation; Colonic Neoplasms; Dihydrouracil Dehydrogenase | 1998 |
The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil.
Topics: Animals; Cell Line; Colonic Neoplasms; Cytosol; Female; Fluorouracil; Mice; Mice, Inbred BALB C; Mit | 1998 |
Increased sensitivity to long-term 5-fluorouracil exposure of human colon cancer HT-29 cells resistant to short-term exposure.
Topics: Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HT29 Cells; Humans; Thymidylate Synthase | 1998 |
Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Topics: Adenoviridae; Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1998 |
[Immediate and early results of combined treatment of colonic cancer using neoadjuvant selective intra-arterial polychemotherapy].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice.
Topics: Animals; Biocompatible Materials; Colonic Neoplasms; Fluorouracil; Injections, Intraperitoneal; Lact | 1998 |
A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Demyelinating Diseases; Female; | 1998 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B | 1998 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1998 |
[The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluoro | 1998 |
[5-fluorouracil and low-dose leucovorin as surgical adjuvant therapy from viewpoint of long-term outcome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1998 |
[p53 expression and response to hepatic intraarterial infusion chemotherapy in patients with colorectal cancer metastasis to liver].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1998 |
[Serum factors in cancer patients affecting the antitumor effect of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Tumor Cells, Cultured | 1998 |
Low-dose cisplatin-5-fluorouracil prevents postoperative suppression of natural killer cell activity in patients with gastrointestinal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colectomy; | 1998 |
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Progression; Fem | 1998 |
Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Levamisole; Neoplasm St | 1997 |
Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Immunoth | 1997 |
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Resistanc | 1998 |
Alcohol consumption enhances liver metastasis in colorectal carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Analysis of Variance; Antineoplastic Agents; Blood | 1998 |
5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.
Topics: Apoptosis; Base Sequence; bcl-2-Associated X Protein; bcl-X Protein; Colonic Neoplasms; Drug Resista | 1998 |
Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
Topics: Animals; B7-1 Antigen; Blotting, Western; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluor | 1998 |
Modulation of 5-fluorouracil in mice using uridine diphosphoglucose.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Ne | 1997 |
Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Colonic Neoplasms; Col | 1997 |
Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
Topics: Antineoplastic Agents; Blood Platelets; Clinical Trials as Topic; Colonic Neoplasms; Endothelial Gro | 1997 |
Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Female; Fluoro | 1995 |
In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Drug A | 1995 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 1996 |
Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Death; Colonic Neoplasms; Fluorouracil; Humans; Isopropyl Thi | 1996 |
Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridyla | 1996 |
Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Screening Assa | 1998 |
Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Brain; Bulbar Palsy, Progressive; Colonic Neoplasms; Esophageal Neo | 1998 |
Histological evaluation of colonic anastomotic healing in the rat following preoperative 5-fluorouracil, fractionated irradiation, and combined treatment.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon; Colo | 1998 |
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr | 1998 |
Is there a standard adjuvant treatment for colon cancer?
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Protocol | 1998 |
Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; | 1998 |
Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Colonic Neoplasms; Drug Synergism; Floxuridine; | 1999 |
A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.
Topics: Cell Division; Colonic Neoplasms; Drug Synergism; Fas Ligand Protein; fas Receptor; Fluorouracil; HT | 1999 |
The treatment of punctal and canalicular stenosis in patients on systemic 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms | 1999 |
Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Cyclooxygenase In | 1998 |
[Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic N | 1999 |
[Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Colonic Ne | 1999 |
[A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neopla | 1999 |
[Photosensitization caused by 5-fluorouracil (5-FU)].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Diagnosis, Differential; Drug Eruptions; F | 1999 |
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 1999 |
[Neoplasm-inhibiting effect and sensitivity-promoting effect of indomethacin in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Co | 1997 |
Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.
Topics: Cell Cycle; Cell Division; Colonic Neoplasms; Deoxyribonucleotides; Fluorouracil; G1 Phase; Gene Exp | 1998 |
[Experimental study on intraperitoneal administration of 5-fluorouracil for liver metastasis in comparison with intravenous administration].
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Infusions, Intravenous; I | 1999 |
Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Binding Sites; Biological Transport; Blotting, Western; Catalysis; | 1999 |
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.
Topics: Animals; Bacteria; Colonic Neoplasms; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Cell Cycle; Cell Survival; Colonic Neoplasms; | 1999 |
Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Colonic Neoplasms | 1999 |
[Intratumoral chemotherapy in an experimental animal model: another therapeutic possibility in cancerology].
Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Ag | 1999 |
[Comparison between continuous intravenous and oral administration of 5-FU with LV].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dr | 1999 |
The tea leaves of small trials.
Topics: Antidotes; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; L | 1999 |
Positive results achieved with new oral chemotherapy agent.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deox | 1999 |
Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer.
Topics: 3T3 Cells; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Northern; | 1999 |
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic | 1999 |
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colonic Neoplasms; Digestive System Neo | 1999 |
[Palliative chemotherapy in colorectal cancer--can we afford it?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Denmark; Drug Costs; Fluorouracil | 1999 |
Differences in metabolism of 5-fluorouracil and 5-fluorouridine and regulation by glucosamine in human colon cancer multicell tumor spheroids.
Topics: Body Fluid Compartments; Colonic Neoplasms; Fluorouracil; Glucosamine; Humans; Kinetics; Magnetic Re | 1999 |
Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line.
Topics: Antimetabolites, Antineoplastic; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Cycle; Colonic Neopla | 1999 |
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; | 1999 |
Selective inflammatory effect of systemic fluorouracil in actinic keratosis.
Topics: Adenocarcinoma; Administration, Topical; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; F | 1999 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1999. Neurologic disorder in a 65-year-old man after treatment of colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Cogniti | 1999 |
Colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1999 |
MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Le | 1999 |
FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 1999 |
Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Division; Cisplatin; Colonic Neop | 1999 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Be | 1999 |
Drug-company decision to end cancer trial.
Topics: Advisory Committees; Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colonic N | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Topics: Amino Acid Substitution; Antineoplastic Agents; Cell Line; Colonic Neoplasms; Drug Resistance, Neopl | 1999 |
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
Topics: Antiviral Agents; Bromodeoxyuridine; Colonic Neoplasms; Combined Modality Therapy; Enzyme Inhibitors | 1999 |
Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Blood Cell Count; Colonic Neoplasms; Combined Modality Therapy; Dos | 1999 |
[Anti-tumor effects of carmofur on human 5-FU resistant cells].
Topics: Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; | 1999 |
Topical treatments of laparoscopic port sites can decrease the incidence of incision metastasis.
Topics: Administration, Topical; Animals; Colectomy; Colonic Neoplasms; Female; Fluorouracil; Laparoscopy; M | 1999 |
[Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1999 |
[Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
Topics: Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Fluorouracil; Infusions, | 1999 |
[Long partial response (PR) in a case of multiple liver metastasis from colon cancer effectively treated by continuous hepatic intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1999 |
Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Topics: Adjuvants, Immunologic; Aluminum Hydroxide; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclo | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 1999 |
Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.
Topics: Animals; Antifungal Agents; Antimetabolites; Antineoplastic Agents; Cancer Vaccines; Colonic Neoplas | 1999 |
Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dru | 2000 |
Optimal injection protocol for CT evaluation during hepatic arterial infusion chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouraci | 1999 |
5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Deoxyuridine; Dose-Re | 1999 |
Malar metastasis from rectal carcinoma: a case report.
Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fatal Outcome; Female | 1999 |
p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 2000 |
Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Colonic Neoplasms; DNA | 1999 |
Sphingomyelin potentiates chemotherapy of human cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; | 2000 |
Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA.
Topics: Binding Sites; Colonic Neoplasms; Fluorouracil; Gene Expression Regulation; Genes, Reporter; Humans; | 2000 |
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; beta-Alanine; Colonic Neoplasms; Colorectal Neoplasms; Dru | 2000 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Colonic Neoplasms; Drug Synerg | 2000 |
Intraperitoneal chemotherapy: biologic implications for clinical outcome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, | 2000 |
Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dementia, Vascula | 2000 |
Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase.
Topics: Adenoviridae; Animals; Bacterial Proteins; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Rela | 2000 |
[Dihydropyrimidine dehydrogenase and thymidylate synthase activities in colonic cancer tissue and sensitivity to 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resista | 1999 |
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Age Factors; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoembryonic | 2000 |
Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Divis | 2000 |
Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunolog | 2000 |
Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Wes | 2000 |
[Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cispla | 2000 |
Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colo | 1999 |
Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity.
Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Escherichia coli; Fluorouracil; Lymphoma; | 2000 |
Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles.
Topics: Anticoagulants; Carcinoid Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Dalteparin; Doxo | 2000 |
[Clinical importance of the determination of the hydrophobic forms of serum carcinoembryonic antigen (CEA) in metastatic cancer of the colon].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Female; F | 1995 |
[Plasma and salivary pharmacokinetics of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Saliva | 2000 |
Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma.
Topics: Administration, Inhalation; Animals; Antimetabolites, Antineoplastic; Carbon Dioxide; Colonic Neopla | 2000 |
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting | 2000 |
Antimetastatic intraoperative chemotherapy of human colon tumors in the livers of nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorou | 2000 |
Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2000 |
Perfusion of the oesophagus and stomach during hepatic artery chemotherapy via an aberrant gastric artery.
Topics: Adenocarcinoma; Angiography; Antimetabolites, Antineoplastic; Catheterization; Colonic Neoplasms; Em | 1999 |
dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Colon; Colonic Neoplasms; Colorectal | 2000 |
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Relationship, Drug; Dr | 2000 |
Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benchmarking; C | 2000 |
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Colonic Neopla | 2000 |
[Antitumor activity of 1-hexylcarbamoyluracil which is carmofur substituted fluorine for hydrogen].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Mice; Mice, Inbred BALB C; | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Direct in vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Glucuronidase; Hu | 2000 |
Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Colonic Neoplasms; Drug I | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
[A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2000 |
The optimal 5-fluorouracil regimen for the adjuvant therapy of colon cancer: where to from here?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells.
Topics: Antibodies, Monoclonal; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; H | 2000 |
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; | 2000 |
Biochemical modulation of 5-fluorouracil with a streptococcal preparation, OK-432, against murine colon-26 carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorodeoxyuridylate; Fl | 2000 |
[A study of liver metastasis from colorectal cancer in which hepatic resection was performed after hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modalit | 2000 |
Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Colonic Neoplasms; Dehydroepiandrosterone; Dose-Resp | 2000 |
Heat shock protein expression in human tumours grown in severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Femal | 2000 |
[Intra-arterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neop | 2000 |
[Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; Hepati | 2000 |
[Repetitive chemo-embolization with degradable starch microspheres (DSM) to each left and replaced right hepatic artery in a patient with multiple liver metastases of colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colonic Neoplasms; E | 2000 |
Adjuvant chemotherapy for stage II colon cancer: the time has come.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-F | 2000 |
Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Escherichia coli; Fluorou | 2000 |
p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase Inhibitors; Cell Cycle; Colonic Neoplasms; DNA D | 2000 |
Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cisplatin; Coloni | 2000 |
Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study.
Topics: Antineoplastic Agents; Cell Cycle; Cell Survival; Colonic Neoplasms; Drug Interactions; Drug Screeni | 2000 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Dihydrou | 2000 |
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2000 |
Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Carci | 2000 |
Hydroxylamine-containing inhibitors of polyamine biosynthesis and impairment of colon cancer cell growth.
Topics: Adenosylmethionine Decarboxylase; Antineoplastic Agents; Caco-2 Cells; Cell Division; Colonic Neopla | 2001 |
Antioxidants enhance the susceptibility of colon carcinoma cells to 5-fluorouracil by augmenting the induction of the bax protein.
Topics: Acetylcysteine; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; bcl-2-Associated X Protein | 2001 |
[Outcomes of home anti-cancer chemotherapy--estimation of hepatic arterial infusion chemotherapy for patients with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluorouracil; He | 2000 |
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; | 2000 |
Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2001 |
[Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2001 |
Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor.
Topics: Aminophenols; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Liver Neoplas | 2001 |
Fourth International Conference on Colorectal Cancer: adjuvant treatment of colon cancer--introduction.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Therap | 2001 |
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; F | 2001 |
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptoth | 2001 |
5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Clinical Trials | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, A | 2001 |
Leukoencephalopathy following chemotherapy for colonic carcinoma.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Co | 2001 |
Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluor | 2001 |
Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Codon; Colonic | 2001 |
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Resist | 2001 |
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chr | 2001 |
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Diet; Dose-Response Rela | 2001 |
Image analysis for quantitation of solid tumor drug sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dose-Response Relations | 1999 |
Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur.
Topics: Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Cell Division; Colonic Neoplasms; Co | 2001 |
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Combinations; Drug Screening Assays, Antitum | 2001 |
c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Chemotherapy, Adjuvant; Clinical Trials, | 2001 |
Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Colonic Neoplasms; DNA Damage; DNA, Neoplasm | 2000 |
p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents.
Topics: Adenocarcinoma; Alleles; Amino Acid Chloromethyl Ketones; Anticarcinogenic Agents; Antineoplastic Ag | 2001 |
Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Ce | 2001 |
Controlled ribozyme targeting demonstrates an antiapoptotic effect of carcinoembryonic antigen in HT29 colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoembryonic Antigen; Cell Count; Cell Cyc | 2001 |
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Colonic Neoplasms; Dihydrouracil | 2001 |
[Clinical and histopathological characteristics of early Leser-Trélat syndrome].
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colon; Colonic Neoplasms; Colonosco | 2001 |
[Intermittent administration of 5-FU and isovorin to patients with advanced and recurrent colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2001 |
Effects of short term treatment with pentagastrin, proglumide, tamoxifen given separately or together with 5-fluorouracil on the growth in the murine transplantable Colon 38 cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bromodeoxyuridine; Cell Division | 2001 |
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Floxuridine; | 2001 |
Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study.
Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Division; Cisplatin; Clone Cells; Colo | 2001 |
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla | 2001 |
[A case of intra-peritoneal recurrence of colon carcinoma that responded remarkably to combined therapy of low-dose leucovorin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2001 |
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Europe; Fluorouracil; Hu | 2001 |
Clinical response to fluorouracil and p53.
Topics: Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Genes, myc; Genes, p53; | 2001 |
Older age--not a barrier to cancer treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2001 |
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Le | 2001 |
Serum factors attenuating the anti-tumor activity of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Cytokines; DNA, Neoplasm; Drug Interactions; Dru | 2001 |
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb | 2001 |
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Topics: Biliary Tract Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relati | 2001 |
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
Topics: Adenoviridae; Analysis of Variance; Animals; Artificial Gene Fusion; Bystander Effect; Colonic Neopl | 2001 |
[Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administ | 2001 |
Phenytoin and fluorouracil interaction.
Topics: Aged; Anticonvulsants; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Interacti | 2001 |
[Basic study on the sensitivity test for inhibiting fibroblast proliferation (II)].
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; | 2001 |
Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue b
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colo | 2001 |
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.
Topics: Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma; Cell Line; Colonic Neoplasms; Drug Resi | 2001 |
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; CD8-Positiv | 2001 |
Thymidylate synthase inhibition induces p53 dependent and independent cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Colonic Neoplasms; DNA Damage; Enzy | 2000 |
In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cisplatin; Colonic Neopl | 2001 |
Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cisplatin; Colonic | 2002 |
Thymidylate synthase expression in stage II and III colon cancer: a retrospective review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Colectomy; | 2001 |
[Efficacy of postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2002 |
Relationship between Fas/FasL expression and apoptosis of colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2001 |
Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Bystander Effect; Colonic Neoplasms; Cytosine Deaminase; D | 2002 |
Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colonic Neoplasms; | 2002 |
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
Topics: Adenoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Colonic Neoplasms; | 2002 |
Chemotherapy in the elderly.
Topics: Age Factors; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Fluorouracil; H | 2002 |
Chemotherapy in the elderly.
Topics: Age Factors; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Middle Aged; Neo | 2002 |
Chemotherapy in the elderly.
Topics: Age Factors; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Staging | 2002 |
[Implanted percutaneous continuous hepatic arterial infusion system for nonresectable liver metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 2001 |
Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Colonic Ne | 2001 |
Markers of drug resistance in relapsing colon cancer.
Topics: Aneuploidy; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette | 2002 |
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon | 2002 |
Summary for patients. Survival of elderly patients with colon cancer treated with chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon | 2002 |
Construct validity of medicare chemotherapy claims: the case of 5FU.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chi-Square Distribution; Colonic Neoplasms; D | 2002 |
The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Combined Modality Therap | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bromodeoxyuridine; Carrier | 2002 |
Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Colonic Neoplasms; Combined Modality T | 2002 |
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Combined | 2002 |
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Pr | 2002 |
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2002 |
Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status.
Topics: Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Colon | 2002 |
Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Membrane; Colonic Neoplasms; DNA Da | 2002 |
Geraniol, a component of plant essential oils, sensitizes human colonic cancer cells to 5-Fluorouracil treatment.
Topics: Acyclic Monoterpenes; Antimetabolites, Antineoplastic; Biological Transport; Caco-2 Cells; Cell Deat | 2002 |
Resistance to apoptosis is increased during metastatic dissemination of colon cancer.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; bcl | 2002 |
Naked DNA injection for liver metastases treatment in rats.
Topics: Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Disease Models, Animal; Flucytosine | 2002 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2002 |
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemot | 2002 |
[Adjuvant therapy following curative surgery of colon cancer].
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Neoplasm | 1979 |
Letter: Neurotoxicity of 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Male; Parkin | 1975 |
Cancer of the colon and rectum. A review.
Topics: Barium Sulfate; Carcinoembryonic Antigen; Colonic Neoplasms; Cystadenoma; Electrocoagulation; Fiber | 1975 |
Letter: Immunotherapy for colorectal cancer.
Topics: BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Humans; Rectal Neoplasms | 1976 |
[Incurable colorectal cancer. Possibilities and limits of differentiated therapy (author's transl)].
Topics: Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Palliative Care; Recta | 1977 |
Failure of methyl-C.C.N.U. and 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1978 |
[Chemotherapy of colorectal carcinomas].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Palli | 1978 |
[Incurable colon cancer. 2. Limits and possibilities of palliative drug- and radiotherapy].
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Palliativ | 1979 |
Allopurinol modulation of high-dose fluorouracil toxicity.
Topics: Allopurinol; Colon; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans | 1979 |
[The state of chemotherapy of colorectal neoplasms].
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine | 1978 |
Human gastrointestinal cancer grown in nude mice used to test new chemotherapeutic agents.
Topics: Abrin; Ancitabine; Animals; Colonic Neoplasms; Cytarabine; Drug Evaluation, Preclinical; Female; Flu | 1979 |
[Chemotherapy for digestive carcinomas. Results of a phase II clinical trial (author's transl)].
Topics: Bile Duct Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Esophageal Neopl | 1979 |
Cell proliferation in dimethylhydrazine-induced colonic adenocarcinomata following cytotoxic drug treatment.
Topics: 5,7-Dihydroxytryptamine; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cimetidine; | 1978 |
Biochemical aspects of chemotherapy of mouse colon carcinoma: fluoropyrimidines and pyrazofurin.
Topics: Amidophosphoribosyltransferase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcino | 1977 |
Selectivity of action of 5-FU: biochemical basis.
Topics: Animals; Colonic Neoplasms; Drug Resistance; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Humans | 1979 |
Colorectal carcinoma: overview of management techniques.
Topics: BCG Vaccine; Carcinoembryonic Antigen; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Radioth | 1979 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusi | 1979 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Colect | 1976 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Colorectal carcinoma in adolescents implications regarding etiology.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Child; Colonic Neoplasms; Female; Fluorouracil; Humans; | 1977 |
Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice.
Topics: Adenocarcinoma, Mucinous; Animals; Colonic Neoplasms; Female; Fluorouracil; Humans; Mice; Mice, Nude | 1978 |
[5-fluorouracil inhibits the collagenolytic activity of invasive colonic adenocarcinomas in vitro].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Microbial Colla | 1978 |
Current trends and prospects in surgical adjuvant trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Dianhydroga | 1978 |
Anaphylactoid reaction. Associated with intravenous administration of 5-fluorouracil.
Topics: Anaphylaxis; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged | 1979 |
Treatment of hepatic metastases by percutaneous hepatic arterial infusion.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastroint | 1979 |
Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole.
Topics: BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamisole; Lomusti | 1977 |
Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Re | 1977 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
Chemoimmunotherapy with BCG and FT 207 (II).
Topics: BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Tegafur | 1978 |
Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Central Nervous System; Colonic Neoplasms; Drug Evaluation; Female; Flu | 1979 |
[Effect of ftorafur and 5-fluorouracil on the chromosomes of human tumor cell cultures].
Topics: Cells, Cultured; Chromosome Deletion; Chromosomes, Human; Colonic Neoplasms; Fluorouracil; Humans; K | 1979 |
Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Colonic Neoplasms; Digestive System; Drug Evaluation; Drug | 1979 |
Studies of the antitumor action of 5-fluorouracil (FU).
Topics: Animals; Antineoplastic Agents; Bone Marrow; Carcinoma 256, Walker; Colonic Neoplasms; Deoxyuridine; | 1979 |
Determinants of 5-fluorouracil sensitivity in human tumors.
Topics: Biopsy, Needle; Breast Neoplasms; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridylate; | 1979 |
[Importance of the analysis of the carcinoembryonic antigen in clinical oncology].
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1979 |
[Nonsurgical treatments of colonic cancers: chemotherapy, immunotherapy, radiotherapy].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Human | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1979 |
Effect of preoperative intralesional BCG and postoperative 5-FU chemotherapy in three adenocarcinoma lines in rats.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Male; Mammary Neoplas | 1979 |
Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.
Topics: Animals; Antineoplastic Agents; Carmustine; Cisplatin; Colonic Neoplasms; Drug Evaluation, Preclinic | 1979 |
Delayed complications in colo-rectal carcinoma treated by combination radiotherapy and 5-fluorouracil--Eastern Cooperative Oncology Group (E.C.O.G.) pilot study.
Topics: Aged; Colonic Diseases; Colonic Neoplasms; Connective Tissue; Constriction, Pathologic; Female; Fluo | 1979 |
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus | 1979 |
Variations in serum copper and ceruloplasmin levels in advanced gastrointestinal cancer treated with polychemotherapy.
Topics: Aged; Antineoplastic Agents; Ceruloplasmin; Colonic Neoplasms; Copper; Cyclophosphamide; Drug Admini | 1979 |
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cells; Colonic Neoplasms; Drug Administration Schedule; Dr | 1979 |
Basal cell nevus syndrome and adenocarcinoma of the colon. Response to systemic fluorouracil.
Topics: Adenocarcinoma; Adult; Carcinoma, Basal Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Nevus | 1979 |
[Experience with weekly intravenous 5-fluorouracil in advanced colonic and rectal neoplasms].
Topics: Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Int | 1979 |
The cytocidal action of metronidazole in combination with other antineoplastic agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Colonic Neoplasms; D | 1979 |
Combination infusional 5-fluorouracil and radiation therapy for the treatment of metastatic carcinoma of the colon to the liver.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Liver Neo | 1979 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil vs. intravenous 5-fluorouracil in patients with hepatic metastases from colo-rectal cancer: a Central Oncology Group Study (COG 7032).
Topics: Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Hepatic Artery; Humans; Infusions, Int | 1979 |
Neutropenia associated with metronidazole.
Topics: Agranulocytosis; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Metronidazole; | 1979 |
Combination chemotherapy of colorectal cancer with 5-fluorouracil, methyl-1,3-cis(2-chloroethyl)-1-nitrosourea, and vincristine.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluoro | 1979 |
[Combined drug therapy in transplanted colonic mice tumors].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation, Preclinical; Drug The | 1979 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Middle Aged; Postoperative Care; Rectal Neopla | 1977 |
Fluorouracil and colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Solubility | 1977 |
Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1977 |
Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A, and prednisolone.
Topics: Adenocarcinoma; Breast Neoplasms; Chromomycins; Colonic Neoplasms; Drug Therapy, Combination; Evalua | 1977 |
Chemotherapy, immunotherapy and chemoimmunotherapy of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Lomustine; Methotrexate; Mitomycins; Rectal | 1977 |
Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil.
Topics: Breast Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Lacrimal Apparatus Diseases | 1978 |
Chemotherapy of colorectal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Rectal Ne | 1978 |
Sequential 5-fluorouracil and hydroxyurea therapy for metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Hydroxyurea; Neoplasm Metastasis; Rectal Ne | 1978 |
Evaluation of single-agent therapy in human colorectal tumour xenografts.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mice; Neoplas | 1978 |
Treatment of advanced colorectal cancer with a combination of 5-fluorouracil and methyl-CCNU.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Nitrosourea Comp | 1978 |
[Current state of therapy for gastrointestinal tumors].
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; | 1978 |
Effects of 5-fluorouracil on human colon carcinoma and solid rat Walker 256 carcinosarcoma: evaluation as in vitro predictors of clinical response.
Topics: Animals; Carcinoma 256, Walker; Colonic Neoplasms; Deoxyuridine; DNA, Neoplasm; Fluorodeoxyuridylate | 1978 |
Phase II study of melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1978 |
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Catheters, Indwelling; Colonic Neoplasms; Femoral Artery; Fluorouracil; Hepatic Artery; Humans; Infu | 1978 |
Lacrimation and 5-fluorouracil.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Lacrimal Apparatus Diseases; Tears | 1978 |
Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combin | 1978 |
Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Doxorubicin; Drug Therapy, Com | 1978 |
Cancer of the large bowel with special reference to incidence and etiology.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; Rectal N | 1978 |
Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; DNA, Neoplasm; Fluorodeoxyuridy | 1978 |
Quantitative analysis of 5-fluorouracil in human serum by selected ion monitoring gas chromatography--mass spectrometry.
Topics: Chromatography, Gas; Colonic Neoplasms; Fluorouracil; Mass Spectrometry | 1978 |
Systemic fluorouracil photosensitivity.
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Keratosis; Photosensitivity Disorders | 1978 |
Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Pare | 1978 |
Chemotherapy for known residual disease after resection of gastric and colorectal cancer.
Topics: Carcinoembryonic Antigen; Carmustine; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; H | 1978 |
Ongoing trials in the surgical adjuvant management of colorectal cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; F | 1978 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Digestive System; Fluorouracil; Humans; Male; Neoplasms; | 1975 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Taste acuity and food attitudes of selected patients with cancer.
Topics: Adult; Aged; Attitude to Health; Breast Neoplasms; Colonic Neoplasms; Diet; Female; Fluorouracil; Fo | 1977 |
Adjuvant treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Rectal Neoplasms | 1977 |
Adjuvant treatment of cancer I. Large bowel cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunity, Cellular; Immunotherapy; Rectal Neoplasms | 1977 |
Oculomotor disturbances associated with 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Adult; Brain Stem; Cerebellar Diseases; Colonic Neoplasms; Eye Movements; Female; Fl | 1977 |
Surgical adjuvant therapy for colon cancer: a plea for restraint.
Topics: Colonic Neoplasms; Fluorouracil; Humans | 1977 |
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C): prolongation of disease-free interval and survival.
Topics: BCG Vaccine; Carcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm | 1977 |
Letter: Organic mental changes with fluorouracil therapy.
Topics: Aged; Cognition Disorders; Colonic Neoplasms; Consciousness Disorders; Female; Fluorouracil; Humans; | 1976 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
Chemoprophylaxis for patients with colorectal cancer. Prospective study with five-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Follow-Up Stu | 1976 |
Editorial: Progress in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Rectal Neoplasms | 1976 |
Editorial: Adjuvant chemotherapy in colorectal cancer.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Neoplasm Metastasis; Rectal Neoplasms | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery; the breakthrough that never was.
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Middle Aged; Postoperative Care; Rectal Neopla | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Postoperative Care; Rectal Neoplasms | 1976 |
5-Fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combin | 1976 |
5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combina | 1976 |
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infu | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Rectal Neoplasms | 1976 |
Survival among patients with liver metastases from cancer of the colon and rectum.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Bilirubin; Colonic Neoplasms; F | 1976 |
Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
Topics: BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Doxorubicin; Female; Fluorouracil; Hu | 1976 |
Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: clinical and pathophysiological results.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Carbon Dioxide; Colonic Neoplasms; Female; Fluorouracil; | 1975 |
The effectiveness of 5-fluorouracil administered orally.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1975 |
The therapeutic response of three human tumor lines maintained in immune-suppressed mice.
Topics: Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma; Cell Line; Chromosomes; Colonic Neop | 1975 |
[Chemotherapy with 5 Fu as subsidiary to the surgical treatment of colonic neoplasms].
Topics: Colonic Neoplasms; Fluorouracil; Humans | 1975 |
Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma.
Topics: Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouraci | 1975 |
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Melphala | 1975 |
End results of radiation therapy, alone and combination with 5-fluorouracil in colorectal cancers.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Perineum; Radiotherapy; Radiothe | 1975 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |
Arylsulfatse B in colorectal cancer.
Topics: Adult; Aged; Chondro-4-Sulfatase; Colonic Neoplasms; Female; Fluorouracil; Humans; Isoenzymes; Male; | 1975 |
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical results.
Topics: BCG Vaccine; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms | 1975 |
The gasteointestinal oncology clinic. A multidisciplinary approach to cancer diagnosis and management at a University Medical Center.
Topics: Adenocarcinoma; Colitis, Ulcerative; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; | 1976 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
[Chemotherapy in gastrointestinal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Meth | 1976 |
Intraluminal, lymph node, hepatic, and serum levels after intraluminal and intramural injection of 5-fluorouracil in the dog colon.
Topics: Animals; Carbon Radioisotopes; Colon; Colonic Neoplasms; Dogs; Fluorouracil; Injections; Injections, | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
Topics: Adenocarcinoma; Aged; Ataxia; Blood-Brain Barrier; Cerebellar Ataxia; Colonic Neoplasms; Fluorouraci | 1976 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase.
Topics: Breast Neoplasms; Colonic Neoplasms; Drug Synergism; Ethers, Cyclic; Fluorouracil; Humans; Levamisol | 1992 |
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; | 1992 |
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inb | 1992 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne | 1992 |
[Cancers of the colon and the rectum: news in 1992].
Topics: Amifostine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusio | 1992 |
In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cell Div | 1992 |
The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity, Immunol | 1992 |
Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1992 |
[Experimental study of biochemical modulation of 5-fluorouracil with l-leucovorin against human esophageal cancer].
Topics: Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Fluoroura | 1992 |
[5-FU cardiotoxicity in adjuvant chemotherapy for colonic cancer letter)].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Myocardial Isc | 1992 |
Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Res | 1992 |
Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo | 1992 |
Sample sizes for proportional hazards survival studies with arbitrary patient entry and loss to follow-up distributions.
Topics: Colonic Neoplasms; Data Collection; Fluorouracil; Follow-Up Studies; Humans; Linear Models; Proporti | 1992 |
Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil.
Topics: Animals; Colonic Neoplasms; Doxorubicin; Drug Resistance; Fluorouracil; Male; Mice; Mice, Inbred BAL | 1992 |
Adjuvant therapy after surgery for cancer of the colon.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans | 1992 |
Adjuvant chemotherapy and radiotherapy in the management of colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Mal | 1992 |
Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors.
Topics: Animals; Colonic Neoplasms; Drug Synergism; Fluorouracil; Leucovorin; Mice; Thymidylate Synthase; Ti | 1992 |
Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 1992 |
[Serum concentration of HCFU and 5-FU after oral administration of HCFU in postoperative digestive cancer patients].
Topics: Administration, Oral; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans; S | 1992 |
Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorodeoxy | 1992 |
[Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer].
Topics: Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps; Infusions, In | 1992 |
[Intraperitoneal chemotherapy of metastatic ovarian cancer].
Topics: Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; | 1992 |
Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
Topics: Cell Line; Cell Survival; Colonic Neoplasms; Drug Resistance; Floxuridine; Fluorouracil; Humans; Kin | 1992 |
Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
Topics: Animals; Colonic Neoplasms; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Leucovo | 1992 |
Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells.
Topics: Adenosine; Biotransformation; Cell Line; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Humans; Int | 1992 |
Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; | 1992 |
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Fluorourac | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[Indication for chemoembolization of liver tumors. An interdisciplinary concept and initial results].
Topics: Adult; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Fluorouracil; Germany, West; Human | 1992 |
[Pharmacokinetic study of tegafur in the hepatic tissue obtained from the patients with liver cancer].
Topics: Aged; Colonic Neoplasms; Fluorouracil; Humans; Liver; Liver Neoplasms; Middle Aged; Stomach Neoplasm | 1992 |
[Treatment of advanced cancer of the alimentary tract with cisplatin and 5-fluorouracil (UFT)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1992 |
Regression of liver metastases following treatment with yttrium-90 microspheres.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Col | 1992 |
Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.
Topics: Animals; Cell Division; Colonic Neoplasms; Drug Synergism; Drug Therapy, Combination; Female; Fluoro | 1992 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: a 3-day/3-week schedule. Group d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; F | 1992 |
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replic | 1992 |
[Cytokines as immunotherapy in cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Interferon | 1992 |
Possible interactions between warfarin and 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Drug Interactions; Fluorouracil; Humans; Male; Warfarin | 1992 |
[Modulation by recombinant alpha-2a-interfer on the activity and site of action of 5-fluorouracil on xenografted human colon cancer in nude mice: preliminary report].
Topics: Animals; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Immunologic Fac | 1992 |
Effect of electrohydraulic and extracorporeal shock waves on gastrointestinal cancer cells and their response to cytotoxic agents.
Topics: Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Mitosis; Stomach Neoplasms; Tumor Cells, Cul | 1992 |
[Potentiation of thymidylate synthetase (TS) inhibition by combined administration of HCFU and dipyridamole: preliminary report. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dipyridamole; Female; Fluor | 1992 |
Levamisole plus 5-fluorouracil inhibits the growth of human colorectal xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1992 |
Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response.
Topics: Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Liver Neoplasms; Rectal Neoplasms; Re | 1992 |
Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Biopsy; Brain; Chemoth | 1992 |
Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery.
Topics: Adenocarcinoma; Cell Survival; Cesium Radioisotopes; Colonic Neoplasms; DNA Repair; Dose-Response Re | 1992 |
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Topics: Antibodies, Monoclonal; Antibody Specificity; Blotting, Western; Breast Neoplasms; Colonic Neoplasms | 1992 |
Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1991 |
Heavy water enhances the antineoplastic effect of 5-fluoro-uracil and bleomycin in nude mice bearing human carcinoma.
Topics: Adenocarcinoma; Animals; Bleomycin; Carcinoma, Squamous Cell; Colonic Neoplasms; Deuterium; Drug Syn | 1990 |
Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.
Topics: Cell Cycle; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Fluo | 1990 |
Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; Drug Interactions; Drug Resistance; Fluorodeo | 1990 |
Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Topics: Blotting, Southern; Breast Neoplasms; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Dose-Response | 1991 |
Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Division; Cell Line; Cell Nucleus; | 1991 |
[Inhibitory effect of bleomycin A6 on human colon cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cecal Neoplasms; Colonic Neoplasms; Female; Fluorouracil; | 1990 |
A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Colon; Colonic Neoplasms; Fluorodeoxyuridylate; Flu | 1991 |
[Adjuvant therapy in colonic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; | 1992 |
Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells.
Topics: Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Humans; Idoxuridine; In Vitro Techniques | 1992 |
Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Collagen; Colonic Neoplasms; Culture Media; Doxoru | 1992 |
In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Colonic Neoplasms; Drug Administration Schedule; | 1992 |
[Adjuvant treatment of resected colon cancers using a 5-fluorouracil-levamisole combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1991 |
Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy.
Topics: Colonic Neoplasms; Female; Fluorouracil; Hemofiltration; Hemoperfusion; Humans; Infusions, Intra-Art | 1991 |
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eva | 1991 |
Isolated liver perfusion versus hepatic artery infusion with 5-fluorouracil in a rat model; effects on thymidylate synthase.
Topics: Animals; Binding Sites; Bone Marrow; Cell Line; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouraci | 1991 |
Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in patients with colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leu | 1991 |
Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; DNA Damage; Dose-Response Relationship, Drug; | 1991 |
[5-fluorouracil concentration in gastroenterological tumor tissues, in adjacent normal tissues, and in serum after preoperative oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Colonic Neoplasms; Floxuridine; Fluorouracil; Gallbladder Neoplasms; Humans; S | 1991 |
In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides.
Topics: Colonic Neoplasms; Deoxyuridine; DNA; Fluorouracil; Head and Neck Neoplasms; Humans; Mitosis; Stereo | 1991 |
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop | 1991 |
The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines.
Topics: Antibodies, Monoclonal; Carcinoembryonic Antigen; Cell Division; Cell Line; Colonic Neoplasms; Drug | 1991 |
Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.
Topics: Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 1991 |
Painful, red hands. A side effect of 5-fluorouracil by continuous perfusion.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans; Mi | 1991 |
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hep | 1991 |
Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoid Tumor; | 1991 |
Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Animals; Azoxymethane; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dise | 1991 |
Subrenal capsule assay of human tumor chemosensitivity.
Topics: Aclarubicin; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neop | 1991 |
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Folic Acid; Interfer | 1991 |
[Loco-regional cancer therapy for hepatic metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamid | 1991 |
[Evaluation of continuous intra-arterial infusion chemotherapy after hepatic resection of liver metastases in colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
[Classification of DNA histogram perturbed with 5-FU and its clinical application].
Topics: Aneuploidy; Cell Division; Colonic Neoplasms; Diploidy; DNA Damage; DNA, Neoplasm; Flow Cytometry; F | 1991 |
In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Do | 1991 |
[Growth chamber assay, a novel chemosensitivity test which eliminates normal stromal cells].
Topics: Animals; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitum | 1991 |
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Enzyme Activation; Flu | 1991 |
Establishment of drug resistance in human gastric and colon carcinoma xenograft lines.
Topics: Animals; Blotting, Northern; Cell Line; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Resistance; | 1991 |
Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Brachytherapy; Colonic Neoplasms; Colonoscopy; Combined | 1991 |
Colon cancer, some progress at last.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Levamisole | 1991 |
[Establishment of transplantable human colon cancer cell lines, chemosensitivity of colon carcinomas and the serially transplantable strains with MTT assay].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, An | 1991 |
Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation.
Topics: Blotting, Northern; Blotting, Southern; Cell Differentiation; Cell Division; Colonic Neoplasms; Drug | 1991 |
Increased growth adaptability to 5-fluorouracil and methotrexate of HT-29 sub-populations selected for their commitment to differentiation.
Topics: Cell Differentiation; Cell Division; Colonic Neoplasms; Drug Resistance; Fluorescent Antibody Techni | 1991 |
Efficacy of intraportal infusion for colon cancer: a fair assessment?
Topics: Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Levamisole; Portal Vein | 1991 |
A human colon cancer cell line established from collagen matrix cultures transplanted into nude mice.
Topics: Animals; Carcinoembryonic Antigen; Cell Line; Chromosome Aberrations; Chromosome Disorders; Collagen | 1991 |
Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter.
Topics: Adenocarcinoma; Arrhythmias, Cardiac; Catheterization, Central Venous; Colonic Neoplasms; Female; Fl | 1991 |
Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Levamisole; Postoperative Period; Randomized Controlled Tri | 1991 |
5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorour | 1991 |
Selective uptake of toxic nucleoside (125IUdR) by resistant cancer.
Topics: Adenocarcinoma; Animals; Cell Line; Choriocarcinoma; Colon; Colonic Neoplasms; Cytarabine; Drug Resi | 1991 |
Fluoropyrimidine biochemical modulation in colon cancer: pharmacology relevant in both the laboratory and the clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; | 1991 |
[Adjuvant chemotherapy in colonic carcinoma?].
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon | 1991 |
[Treatment of colorectal cancers. Recommendations of the French Foundation of Digestive Cancerology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Digestive System Neoplasms; Fluor | 1991 |
Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1991 |
Chest pain in a cancer patient on chemotherapy.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Male; Myocardial Infarction; Strepto | 1991 |
[Intrahepatic arterial infusion chemotherapy in primary and metastatic cancer of the liver].
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatic Artery; | 1990 |
[Experimental studies on subrenal capsule assay using cyclosporin A treated mice--the optimal treatment schedules of CsA and anticancer agents (mitomycin C and 5-fluorouracil)].
Topics: Animals; Body Weight; Breast Neoplasms; Colonic Neoplasms; Cyclosporins; Female; Fluorouracil; Human | 1990 |
Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colonic Neoplasm | 1990 |
[Methodological aspects on the histological evaluation of subrenal capsule assay (SRCA)].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyclophosphamide; Cyclosporins; Female; Fluoroura | 1990 |
Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrogra | 1990 |
[Tissue UFT distribution and histological changes following UFT administration in metastatic liver cancer cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human | 1990 |
[Long-term arterial infusion chemotherapy to the cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Doxorubic | 1990 |
[An unresectable colon cancer with a diffuse metastases that turned resectable following thermotherapy with chemoimmunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1990 |
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Scree | 1990 |
Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Floxuridine; Fluorouracil; Humans; Ki | 1990 |
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas | 1990 |
Resistance to 5-fluorouracil and 5-fluoro-2'-deoxyuridine mechanisms and clinical implications.
Topics: Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance; Floxuridine; Fluorouracil; Hum | 1990 |
Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Carbon Radioisotopes; Colonic Neoplasms; Dehydroepiandrosterone; Fluorouracil; Human | 1990 |
Clinical trials referral resource. Adjuvant therapy for colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colo | 1990 |
Pros and cons of infusional 5-FU as adjuvant therapy for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Drug A | 1990 |
Levamisole receives FDA imprimatur for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; | 1990 |
Kinetic analysis of 5-fluorouracil action against various cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Colonic Neoplasms; Dose-Response Relationship, Drug; Flo | 1990 |
[A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; F | 1990 |
Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells.
Topics: Cell Survival; Colonic Neoplasms; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Floxurid | 1990 |
[Intra-hepato-arterial infusion chemotherapy using catheter inserted and placed in hepatic artery via the left radial artery on liver malignancy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1990 |
Repeated dearterialization of hepatic tumors with an implantable occluder.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization; Catheters, Indwelling; Colonic Neoplasms; E | 1990 |
Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Fluorouracil; Humans; | 1990 |
New findings in treatment of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; | 1990 |
Levamisole approved for use in adjuvant regimen for colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole | 1990 |
Oral carmofur in advanced gastrointestinal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Admini | 1990 |
[A case of early gastric carcinoma which disappeared with treatment of low dose 5-FU].
Topics: Administration, Oral; Colectomy; Colonic Neoplasms; Fluorouracil; Gastroscopy; Humans; Male; Middle | 1990 |
[Adjuvant treatment of colon and rectum carcinoma: one step ahead].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Fluorou | 1990 |
Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic N | 1990 |
Does adjuvant therapy work in colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Ther | 1990 |
Comparison of portal vein chemotherapy with hepatic artery chemotherapy in the treatment of liver micrometastases.
Topics: Animals; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Infusions, I | 1990 |
Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasm | 1990 |
Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Nucleolus; Cell Survival; Colonic Neoplasms; Fl | 1990 |
Superior vena cava syndrome associated with a Hickman catheter.
Topics: Catheterization, Central Venous; Catheters, Indwelling; Colonic Neoplasms; Fluorouracil; Humans; Inf | 1990 |
Chemotherapy screening assay using 3-dimensional cell culture.
Topics: Alginates; Cell Survival; Clone Cells; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorour | 1990 |
Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; Cytosol; Fluorouracil; Humans; Kinetics; Thymidine | 1990 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |
Acute myocardiotoxicity during 5-fluorouracil therapy.
Topics: Adult; Cardiomyopathies; Colonic Neoplasms; Fluorouracil; Hemodynamics; Humans; Infusions, Intraveno | 1990 |
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; | 1990 |
5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies.
Topics: Animals; Cell Division; Colonic Neoplasms; DNA, Neoplasm; Drug Administration Schedule; Drug Synergi | 1990 |
Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.
Topics: Animals; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorine Radioisoto | 1990 |
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
Topics: Colonic Neoplasms; Combined Modality Therapy; Drug Synergism; Drug Therapy, Combination; Fluorouraci | 1990 |
Modulating fluorouracil with different drugs: the Padua experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Synergism; Fluoro | 1990 |
Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells.
Topics: Animals; Cell Line; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Humans; Kinetics | 1990 |
[Current status of chemotherapy for colonic, rectal and anal carcinoma].
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colonic Neoplasms; Combi | 1990 |
Is portal-vein fluorouracil hepatic infusion effective colon cancer surgical adjuvant therapy?
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Portal V | 1990 |
Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases.
Topics: Animals; Catheterization; Colonic Neoplasms; Fluorouracil; Liver Neoplasms; Male; Neoplasm Transplan | 1990 |
[Chemotherapy and total body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colonic Neoplasms; Combined Mo | 1985 |
Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon.
Topics: Animals; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Drug Interactions; Drug Therap | 1985 |
Enhanced X ray sensitivity of human colon tumor cells by combination of N-methylformamide with chemotherapeutic agents.
Topics: Antineoplastic Agents; Bleomycin; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Fo | 1986 |
Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.
Topics: Animals; Biotransformation; Cell Division; Colonic Neoplasms; DNA; Drug Synergism; Fluorouracil; Fol | 1987 |
5-Fluorouracil and isoprinosine in the treatment of advanced colorectal cancer. A limited phase I, II evaluation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fl | 1988 |
Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line.
Topics: Cell Survival; Colonic Neoplasms; Deoxyuracil Nucleotides; Deoxyuridine; Dipyridamole; DNA; DNA Dama | 1989 |
Effective palliation of metastatic adenocarcinoma to the liver: a case report.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, | 1988 |
A case of carmofur-induced leukoencephalopathy--MR images and CT findings.
Topics: Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Leukoencephalopathy, P | 1989 |
Mechanisms of combined effects of gamma-interferon and 5-fluorouracil on human colon cancers implanted into nude mice.
Topics: Animals; Cell Line; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Interferon-g | 1989 |
Continuous low-dose infusion of fluorouracil: is the benefit worth the cost?
Topics: Colonic Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Infusions, Intravenous; Injections, | 1989 |
Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasms; Drug Interactions; Flu | 1989 |
Postoperative adjuvant chemotherapy and radiotherapy for cancer of the large bowel and rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cecal Neoplasms; Colonic Neop | 1989 |
[Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Biotransformation; Colonic Neop | 1989 |
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neop | 1989 |
Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasms; Dose-Response Relation | 1989 |
Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration.
Topics: Aged; Biotransformation; Colonic Neoplasms; Cytosol; Drug Interactions; Female; Fluorodeoxyuridylate | 1989 |
[Anti-tumor effect of fluoropyrimidines on human tumor cell lines transplanted in nude mice with CCl4-induced liver dysfunction].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Tetrachloride; Cell Line; Colonic Ne | 1989 |
Adjuvant therapy for colon carcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Interfer | 1989 |
5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
Topics: Adenocarcinoma; Colonic Neoplasms; Dipyridamole; DNA; DNA Damage; Floxuridine; Fluorouracil; Humans; | 1989 |
Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Drug Resistance; Female; Floxuridine; | 1989 |
Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Chrom | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
MTX-5-FU combination therapy compared to FUDR monotherapy in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; | 1989 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Un | 1989 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Combined Modality Th | 1989 |
Fluoropyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Head and Ne | 1989 |
Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine.
Topics: Cell Line; Cisplatin; Colonic Neoplasms; DNA Polymerase I; DNA Polymerase II; DNA Repair; DNA Replic | 1989 |
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N | 1989 |
Clinical trials referral resource. Adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; | 1989 |
Cytotoxicity and the inhibition of ribosomal RNA processing in human colon carcinoma cells.
Topics: Azacitidine; Azaguanine; Cell Survival; Cells, Cultured; Colonic Neoplasms; Fluorouracil; Humans; Pr | 1985 |
Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1985 |
Antagonistic effect of polyinosinic-polycytidylic acid on the cell lethality produced by 5-fluorouracil in human colon carcinoma cells in vitro.
Topics: Cell Survival; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Interferons; P | 1985 |
Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1989 |
Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells.
Topics: Carcinoma; Cell Line; Cell Survival; Colonic Neoplasms; DNA Probes; Dose-Response Relationship, Drug | 1989 |
The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-Response | 1989 |
In vitro and in vivo inhibition of thymidylate synthase of human colon cancer by 5-fluorouracil.
Topics: Colonic Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Liver Neoplasms; Thymidylate Synthase | 1989 |
[Positron emission tomography following brief infusion of 5-[18F]uracil: linear model for the kinetics of 18F radioactivity in tumors].
Topics: Colonic Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neoplasms; Tomography, Emissi | 1989 |
Immunochemotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. 1. Toxicological studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1989 |
Human-alpha-interferon on xenotransplanted human colonic adenocarcinomas in nude mice.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Interferon Typ | 1989 |
Response of human colon carcinoma xenografts to recombinant human tumor necrosis factor (TNF).
Topics: Animals; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Male; Mice; Mice, Nude; Neoplasm Trans | 1989 |
Drug availability is an issue for cancer patients, too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; | 1989 |
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Dr | 1989 |
An optimized synthesis of 18F-labelled 5-fluorouracil and a reevaluation of its use as a prognostic agent.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Mice; Mice, Nude | 1989 |
Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells.
Topics: Clone Cells; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; | 1989 |
[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Flu | 1989 |
[Antitumor effects of 5-fluorouracil-bound organic silicon compound].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Ethyla | 1989 |
Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Sche | 1989 |
Accumulation of tetrahydrofolates in human plasma after leucovorin administration.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1989 |
Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.
Topics: Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combinat | 1989 |
Adjuvant therapy benefits Dukes' C colon cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Levamisole | 1989 |
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry; Colonic Neo | 1989 |
Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment.
Topics: Adenocarcinoma, Mucinous; Adult; Colonic Neoplasms; Combined Modality Therapy; Drug Therapy, Combina | 1987 |
Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma.
Topics: Adenocarcinoma, Mucinous; Biopsy; Colonic Neoplasms; Fluorouracil; Glomerulonephritis; Humans; Immun | 1987 |
Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Carcinoembryonic Antigen; | 1987 |
[Signet ring cell carcinoma of the colon].
Topics: Adenocarcinoma, Mucinous; Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Postoperative Care | 1988 |
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Combinations; Drug Evaluation, Preclinical; Fluorou | 1989 |
Hepatic artery infusion chemotherapy for colorectal metastases: a personal experience.
Topics: Adult; Aged; Carcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans | 1985 |
The implantable "Infusaid" infusion pump. The Sydney experience using 5-fluorouracil.
Topics: Australia; Colonic Neoplasms; Floxuridine; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Infusi | 1986 |
Chemical cholecystitis after intrahepatic chemotherapy. The case for prophylactic cholecystectomy during pump placement.
Topics: Adult; Cholecystectomy; Cholecystitis; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1986 |
Incorporation of intermediary products of 5-FU anabolism into colorectal cancer.
Topics: Aged; Colon; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Intestinal Mucosa; Male; | 1986 |
Implantable vascular access devices in the treatment of colorectal liver metastases.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arter | 1986 |
On the differential affinities of two anticancer analogues to their target.
Topics: Adenocarcinoma; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuridine; Fluoro | 1985 |
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac | 1986 |
Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine.
Topics: Animals; Body Temperature Regulation; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug | 1986 |
Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.
Topics: Cells, Cultured; Colonic Neoplasms; Deoxyuracil Nucleotides; Deoxyuridine; Dipyridamole; DNA; Floxur | 1986 |
Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA).
Topics: Colonic Neoplasms; Colony-Forming Units Assay; Culture Techniques; Dose-Response Relationship, Drug; | 1986 |
Role of administration route in the therapeutic efficacy of doxifluridine.
Topics: Administration, Oral; Animals; Biological Availability; Colonic Neoplasms; Female; Floxuridine; Fluo | 1987 |
[Chemoprophylaxis of liver metastasis of colonic and rectal cancers].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Portal Vein; Rectal N | 1986 |
[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Colon; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Kineti | 1987 |
Regional and systemic chemotherapy for colorectal metastases to the liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans | 1987 |
Myocardial ischemia with fluorouracil and floxuridine therapy.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Coronary Disease; Electrocardiography; Floxuridine; Fluorou | 1987 |
[Locoregional chemotherapy of hepatic metastases of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Infusion Pumps; I | 1987 |
New chemotherapeutic drug sensitivity assay for colon carcinomas in monolayer culture.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Culture Techniques; Drug Resistance; Drug Scree | 1988 |
[Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouraci | 1988 |
Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats.
Topics: Animals; Body Weight; Colonic Neoplasms; Drug Therapy; Female; Floxuridine; Fluorouracil; Prodrugs; | 1987 |
Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues.
Topics: Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Pentosyltransferases; Pro | 1988 |
Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma.
Topics: Adenocarcinoma; Aphidicolin; Cell Line; Cell Survival; Colonic Neoplasms; Diterpenes; DNA; DNA Damag | 1988 |
Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells.
Topics: Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Floxuridine; Fluorour | 1988 |
Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat.
Topics: Animals; Carcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Male | 1988 |
[Our therapy concept in nonresectable liver metastases].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Com | 1988 |
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
Topics: Angina Pectoris; Brain Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Evaluation; Elect | 1985 |
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch | 1985 |
Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Topics: Animals; Bone Marrow; Colonic Neoplasms; Diphosphates; Female; Fluorouracil; Kinetics; Mice; Mice, I | 1985 |
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C | 1985 |
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
Topics: Adenocarcinoma; Adenosine Monophosphate; Animals; Cell Line; Colonic Neoplasms; Deoxyuracil Nucleoti | 1986 |
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C | 1986 |
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 1986 |
[Angiographic and computed tomographic findings in intra-arterial cytostasis of colorectal liver metastases].
Topics: Angiography; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arteri | 1986 |
Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Fluorouracil; Follow- | 1986 |
Combination chemotherapy for advanced colorectal cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
An aggressive, sequential combination chemotherapy regimen in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 1986 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
[Surgery and adjuvant therapy of cancer of the large intestine].
Topics: BCG Vaccine; Colonic Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule | 1986 |
[5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Male; Rats | 1986 |
Microangiopathic hemolytic anemia, noncardiac pulmonary edema, and renal failure after treatment of metastatic adenocarcinoma of the colon with 5-fluorouracil and mitomycin-C: report of a case.
Topics: Adenocarcinoma; Anemia, Hemolytic; Colonic Neoplasms; Female; Fluorouracil; Humans; Kidney Failure, | 1986 |
[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Fluor | 1987 |
[A model for the sensitivity determination of anticancer agents against human cancer using nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Line; Cisplatin; Colonic Neoplas | 1987 |
[Subrenal capsule assay for chemosensitivity testing].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Colony-Forming Units Assay; Cyclophosphamide; Dox | 1987 |
Rationale and indications for perfusion in liver tumors: current data.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1987 |
Successful treatment of multiple liver metastases by liver perfusion.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Heparin; | 1987 |
[The effect of tegafur suppository and glutathione in patients with gastric and colonic cancer with special reference to the histopathological anticancer effect].
Topics: Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Glutathione; Humans; Stomach Neoplasms; | 1987 |
[Subrenal capsule assay as a chemosensitivity test (V)--Experimental chemotherapy of cyclosporin A-treated mice and nude mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Cy | 1988 |
[Human colorectal carcinoma is more sensitive to HCFU than 5-FU and tegafur in in vitro and in vivo drug sensitivity tests].
Topics: Animals; Colonic Neoplasms; Fluorouracil; Humans; Mice; Rectal Neoplasms; Subrenal Capsule Assay; Te | 1988 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |
[Intra-arterial chemotherapy of colorectal liver metastases with 5-fluorouracil (5-FU) and mitomycin C (MMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1987 |
Colorectal carcinoma in vitro is more sensitive to 1-hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, Adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil.
Topics: Aclarubicin; Antineoplastic Agents; Carbazilquinone; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug | 1988 |
[Combined effects of interferon alpha-A/D with fluoropyrimidine derivatives in the subrenal capsule assay].
Topics: Animals; Colonic Neoplasms; Drug Synergism; Fluorouracil; Interferon Type I; Male; Mice; Mice, Nude; | 1988 |
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1988 |
[Results of intra-arterial infusion chemotherapy in colorectal cancer patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Colonic Neoplasms; Combined Modality Th | 1988 |
A mechanism for the potentiation of the cytotoxic effects of antimetabolites drugs (FT-207, 5FU) by hyperthermia.
Topics: Cell Line; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Cytosol; Fluorouracil; Hot T | 1988 |
Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Floxuridine; Fluorour | 1985 |
Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512).
Topics: Animals; Antineoplastic Agents; Carcinogens; Colonic Neoplasms; Female; Flavonoids; Fluorouracil; Ki | 1988 |
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo | 1988 |
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Resistance; Fluor | 1988 |
Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Cy | 1988 |
[Continuous infusion of anti-cancer drug with balloon infusors].
Topics: Aged; Breast Neoplasms; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluorouracil; Humans | 1988 |
[Intra-arterial 5-fluorouracil chemotherapy in liver metastases of colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arter | 1988 |
Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1988 |
Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1988 |
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Gastr | 1988 |
Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Colonic Neopla | 1988 |
Pharmacodynamics of 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Animals; Bone Marrow; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridyla | 1988 |
Selectivity of CF and 5-fluorouracil: critical role of polyglutamylation.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorouracil; Folic Acid; Humans; Leucovorin; | 1988 |
Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.
Topics: Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorouracil; Humans; Kin | 1987 |
Phase II evaluation of sequential hepatic artery infusion of 5-fluorouracil and hepatic irradiation in metastatic colorectal carcinoma.
Topics: Colonic Neoplasms; Combined Modality Therapy; Drug Evaluation; Female; Fluorouracil; Humans; Infusio | 1988 |
Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients.
Topics: Adenocarcinoma; Adult; Age Factors; Colonic Neoplasms; Female; Fluorouracil; France; Humans; Male; R | 1988 |
In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue.
Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Chromatography, High Pressure Liquid; Colonic Neo | 1988 |
[Prevention of immunodeficiency induced by cancer chemotherapy with BCG].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Neoplasms; Cytarabine; Fe | 1988 |
[Studies of 5-FU concentrations associated with microangiography in colorectal cancer tissue].
Topics: Adult; Aged; Angiography; Colonic Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Male; Midd | 1988 |
Intraperitoneal infusion of 5-FU in liver metastases from colorectal cancer.
Topics: Abdomen; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Liver Neoplasms; Mal | 1988 |
In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
Topics: Animals; Bone Marrow; Colonic Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Intestinal | 1988 |
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
Topics: Albumins; Angiotensin II; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Injections, Intra | 1988 |
Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administ | 1988 |
Colorectal cancer chemotherapy: meta-analysis or large-scale trials?
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Rectal | 1988 |
[Clinical results and problems of total-body thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Ther | 1988 |
Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
Topics: Adult; Cisplatin; Colonic Neoplasms; Echocardiography; Electrocardiography; Female; Fluorouracil; He | 1988 |
Salvage of blocked hepatic artery infusion catheters for regional therapy of metastatic liver disease.
Topics: Arterial Occlusive Diseases; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Coloni | 1988 |
Hepatic arterial ligation with and without portal infusion in metastatic colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Hum | 1988 |
MOF as control arm for NSABP adjuvant chemotherapy trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1988 |
[Transcatheter arterial chemoembolization and selective hepatic arterial infusion using totally implantable reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Embolization, Therap | 1988 |
Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1988 |
Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma; Colonic Neoplasms; Co | 1987 |
Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; | 1987 |
Nucleoside analogues. 5. Molecular combination of anti-cancer drugs: activity of 5-fluorouracil/nitrosourea combinations against mouse colon tumours.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; E | 1986 |
[Delayed post-transfusional hemolysis, leukemoid syndrome, autoimmune hemolytic anemia. Coordinating Committee for the Specific Study of Anemias under the chairmanship of H. Rochant].
Topics: Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Colonic Neoplasms; Female; Flu | 1987 |
A new technique for hepatic infusional chemotherapy.
Topics: Catheterization, Peripheral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1986 |
[Prevention of hepatic metastasis in patients operated on for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Epirubicin; Fluorour | 1987 |
Sequential methotrexate--5-FU--leucovorin (MFL) in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1986 |
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1986 |
[Chemotherapy of advanced and recurrent colorectal cancer].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1986 |
Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema | 1986 |
Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
[Biochemical modulation with sequential methotrexate (MTX)-5-fluorouracil (5-FU) treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 1987 |
Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1987 |
Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea | 1987 |
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fl | 1987 |
Sequential 5-fluorouracil and methotrexate. Negative experience in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Fem | 1987 |
Biologic modulation of 5-fluorouracil with high-dose leucovorin and combination chemotherapy of 5-fluorouracil and cisplatin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-R | 1987 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Gas | 1987 |
[Response to hepatic intra-arterial chemotherapy for metastases of colorectal cancer. Anatomo-pathological evaluation apropos of 3 cases of secondary hepatic excision].
Topics: Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intra-Arteria | 1987 |
Cannulation of the portal vein for cytotoxic liver perfusion in colorectal carcinomas: an alternative approach.
Topics: Adenocarcinoma; Antineoplastic Agents; Catheterization; Colonic Neoplasms; Fluorouracil; Humans; Liv | 1987 |
[Treatment of colonic carcinoma with cytostatic agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1987 |
Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil.
Topics: Adenocarcinoma; Charcoal; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Thymidylate | 1987 |
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Inf | 1987 |
5-Fluorouracil-induced coronary vasospasm.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Coronary Vasospas | 1987 |
[Preliminary results of a phase II study of 5-FU, adriamycin, and mitomycin C (FAM) in combined hepatic infusion in patients with non-resectable metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dr | 1987 |
Gastrointestinal anastomotic healing during treatment with perioperative 5-fluorouracil.
Topics: Aged; Colonic Neoplasms; Colostomy; Drug Evaluation; Female; Fluorouracil; Gallbladder; Gastrectomy; | 1987 |
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; | 1987 |
[The effect and CT imaging of FAM hepatic infusion chemotherapy in patients with liver metastasis from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil | 1987 |
Treatment modalities for colorectal cancer.
Topics: Colonic Neoplasms; Colostomy; Combined Modality Therapy; Fluorouracil; Humans; Rectal Neoplasms | 1986 |
Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1987 |
[Home treatment of cancer: experiences with ambulatory intra-arterial chemotherapy of liver metastases].
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Home Care Services; Hum | 1987 |
[Phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Group].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; | 1987 |
Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; Female; Fluorodeox | 1987 |
Tumor and liver drug uptake following hepatic artery and portal vein infusion.
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; In | 1987 |
[Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump].
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arterial; In | 1987 |
Survival following self-administered chemotherapy for liver metastases.
Topics: Catheters, Indwelling; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Prognosis; Self Adm | 1987 |
Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Eval | 1986 |
Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Interactions; Female; Fluo | 1986 |
Ambulatory hepatic artery infusion chemotherapy for cancer of the liver.
Topics: Adult; Aged; Ambulatory Care; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Gastro | 1986 |
Synthesis and antitumor activity of 5-fluoro-4-(furfurylideneaminooxy)hexahydro-2,6-dioxo-5-pyrim idinecarb oxylates.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Drug Evaluation, P | 1986 |
[Clinical study of clonogenic assays--with reference to adjuvant cancer chemotherapy after operation].
Topics: Antineoplastic Agents; Colonic Neoplasms; Colony-Forming Units Assay; Combined Modality Therapy; Flu | 1986 |
Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: a multivariate analysis.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
Phase II-study vindesine + 5-Fluoro-Uracil combination chemotherapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fluorouracil; Hu | 1986 |
Chemotherapy with or without anticoagulation as initial management of patients with operable colorectal cancer: a prospective study with at least 5 years follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1986 |
Modulation of fluorouracil metabolism and cytotoxicity by nitrothiobenzylinosine.
Topics: Cell Line; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Inosine; Thioinosine; Thymidine | 1986 |
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Parenter | 1986 |
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ev | 1986 |
Chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1986 |
Treatment of advanced colorectal and gastric cancer with cisplatinum and 5-fluorouracil. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Femal | 1986 |
Response of colo-rectal hepatic metastases to concomitant radiotherapy and intravenous infusion 5 fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1986 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.
Topics: Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Gene Amplification; Humans; Male; M | 1987 |
5-Fluorouracil and high-dose folic acid treatment for metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; F | 1987 |
Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage.
Topics: Adenocarcinoma; Animals; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Isoenzym | 1987 |
Colorectal cancer (Duke's group B2, C1, C2): adjuvant chemotherapy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced | 1985 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 1985 |
Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Ki | 1985 |
Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy.
Topics: Adenocarcinoma; Aluminum; Cimetidine; Colonic Neoplasms; Fluorouracil; Gastric Mucosa; Humans; Infus | 1985 |
Enhancement of antitumor effect of cytotoxic agents by bestatin.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neop | 1985 |
Long-term survivors of colorectal cancer with unresectable hepatic metastases.
Topics: Administration, Oral; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Human | 1985 |
[Colony assay for clinical application].
Topics: Adult; Agar; Aged; Antineoplastic Agents; Cell Count; Cell Division; Cells, Cultured; Colonic Neopla | 1985 |
[A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Colonic Neoplasms; Fluor | 1985 |
[Intra-arterial continuous infusion in patients with advanced and recurrent cancer of the digestive system].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1985 |
[Multimodality therapy of colorectal cancer].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Emboliz | 1985 |
Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 1985 |
5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; | 1986 |
Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neopl | 1986 |
The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil.
Topics: Adenocarcinoma; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Dru | 1986 |
Transmural electrical potential difference as an early marker in colon cancer.
Topics: Animals; Cholic Acids; Colon; Colonic Neoplasms; Diet; Female; Fluorouracil; In Vitro Techniques; In | 1986 |
Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Ev | 1986 |
Cardiac toxicity of 5-fluorouracil. Report of a case of spontaneous angina.
Topics: Angina Pectoris; Colonic Neoplasms; Electrocardiography; Fluorouracil; Humans; Liver Neoplasms; Male | 1986 |
Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution.
Topics: Ascitic Fluid; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intraperitoneal; Time Factors | 1986 |
Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1986 |
[Distribution of 1-hexycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal | 1986 |
Phase II study of sequential methotrexate and 5-FU combination in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1985 |
[Adjuvant chemotherapy in colorectal carcinoma].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Rectal Neoplasms | 1985 |
[Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer].
Topics: Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Injections, In | 1985 |
Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modal | 1985 |
Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1985 |
Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic N | 1985 |
[Chemotherapy protocol for metastasizing colorectal carcinoma. Methotrexate, 5-fluorouracil and cytarabine].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cytarabine; Drug Adm | 1985 |
[Therapy-induced tumor regression. Morphological findings in malignant primary and secondary liver tumors following intensive regional cytostatic treatment].
Topics: Adenocarcinoma; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Doxoru | 1985 |
[Radiotherapy. Locally advanced colorectal cancer with and without 5-fluorouracil].
Topics: Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; | 1985 |
[Risk-related surgical treatment of colorectal tumors].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Post | 1985 |
Unresectable hepatic metastases from carcinoma of the colon and rectum.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Carcinoembryon | 1985 |
Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1985 |
[Experimental studies with the use of metastatic clones isolated from mouse tumors].
Topics: Adenocarcinoma; Animals; Clone Cells; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; | 1985 |
Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
Topics: Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; Dose-Response Relationship | 1985 |
Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Hepatic Artery; Hum | 1985 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Ev | 1985 |
Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.
Topics: Allopurinol; Colonic Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mouth Mucosa; Mouthwashes; | 1985 |
Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1985 |
Colorectal cancer: speculations on the role of intraperitoneal therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Coloni | 1985 |
The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies.
Topics: Ascitic Fluid; Catheterization; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1985 |
Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
Topics: Animals; Colonic Neoplasms; Female; Fluorouracil; Lethal Dose 50; Mice; Mice, Inbred C57BL; Uracil; | 1985 |
Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry.
Topics: Alkylation; Bromouracil; Colonic Neoplasms; Fluorouracil; Gas Chromatography-Mass Spectrometry; Huma | 1985 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Cellular basis for the inefficacy of 5-FU in human colon carcinoma.
Topics: Cell Count; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Colony-Forming Units Assay; | 1985 |
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |
Cerebellar ataxia with weekly 5-fluorouracil administration.
Topics: Adenocarcinoma; Cerebellar Ataxia; Colonic Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neo | 1971 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
Inhibition of DNA polymerases and neoplastic cells by selected SH inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenicals; Benzoates; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Ch | 1972 |
The chemotherapy of colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, | 1974 |
[Attack on liver cancer--what's the value of diagnosis and treatment?].
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Middle | 1974 |
Prolonged intra-aortic infusion therapy with anti-tumor agents for advanced cancer of the stomach, colon and rectum.
Topics: Adult; Aged; Antineoplastic Agents; Aorta; Bleomycin; Catheterization; Colonic Neoplasms; Cytarabine | 1971 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
Reoperation in carcinoma of the colon following resection and adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurr | 1966 |
The value of radiotherapy in the treatment of carcinoma of the colon.
Topics: Abdominal Neoplasms; Colonic Neoplasms; Denmark; Female; Finland; Fluorouracil; Humans; Male; Neopla | 1966 |
The second look operation for carcinoma of the colon after administration of 5-fluorouracil.
Topics: Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; | 1968 |
[Method and results of experimental chemotherapy of a human colonic carcinoma (H.Ad.No. 1) in the cheek pouch of the golden hamster].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aziridines; Cheek; Colonic Neoplasms; Cricetinae; Cy | 1969 |
[Palliative radiotherapy of cancer in the Karl Bremer Hospital, 1963-1968].
Topics: Black People; Cobalt Isotopes; Colonic Neoplasms; Esophageal Neoplasms; Fluorouracil; Humans; Neopla | 1969 |
Metastatic colorectal carcinoma. Response to hepatic infusion. A review.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms | 1970 |
Second-look operation for colon carcinoma after fluorouracil therapy.
Topics: Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Palli | 1970 |
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Angiography; Aortography; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perf | 1970 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
Chemotherapy of cancer of the colon and rectum.
Topics: Antineoplastic Agents; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; | 1972 |
Practical aspects of investigation and treatment of colorectal cancer.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Parenteral; Liver Function | 1972 |
Chemotherapy of colon and rectal cancer.
Topics: Administration, Oral; Antigens, Neoplasm; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasm | 1972 |
Effect of resection of the primary neoplasm on responsiveness to chemotherapy of patients with large bowel cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; Rectal | 1972 |
Chemotherapy of gastrointestinal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Esophageal Neoplasms; Floxuridine; Fluorouracil; Gastroint | 1972 |
Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon.
Topics: Age Factors; Aspartate Aminotransferases; Catheterization; Chemotherapy, Cancer, Regional Perfusion; | 1974 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
[Polychemotherapy of malignant tumors and hemoblastoses].
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom | 1968 |
Carcinoma of the colon and rectum in patients up to 25 years of age.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Age Factors; Colonic Neoplasms; Female; | 1971 |
Colon carcinoma in childhood.
Topics: Adenocarcinoma, Mucinous; Adolescent; Age Factors; Barium Sulfate; Child; Colonic Neoplasms; Female; | 1971 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
Long term survivor in metastatic colonic carcinoma to the brain.
Topics: Adenocarcinoma, Mucinous; Brain Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Age | 1973 |
Experience with infusion and resection in cancer of the liver.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Female | 1974 |
Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man.
Topics: Administration, Oral; Bile; Carbon Radioisotopes; Carcinoma, Hepatocellular; Chromatography, Thin La | 1974 |
Studies on the mechanism and prevention of local recurrence of carcinoma at the suture line after colonic resection.
Topics: Animals; Carcinoma, Hepatocellular; Colon; Colonic Neoplasms; Fluorouracil; Intestinal Mucosa; Liver | 1971 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
The chemotherapy of large-bowel cancer. Present status and future prospects.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cricetinae; Culture Techniques; Cyclohexanes; Cyc | 1974 |
Section meeting on reexamination of the old and prospects for new approaches to therapy.
Topics: Colectomy; Colonic Neoplasms; Cyclohexanes; Cyclophosphamide; Drug Therapy, Combination; Fluorouraci | 1974 |
A second look at the second operation in colonic cancer after the administration of fluorouracil.
Topics: Biopsy; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphat | 1974 |
Intraluminal and intravenous 5-FU chemotherapy adjuvant to surgery for resectable colorectal cancer.
Topics: Administration, Topical; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Postopera | 1974 |
Systemic 5-fluorouracil in hepatic metastases from primary colon or rectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Hepatic metastases from rectal and colon cancers. Treatment by infusion of 5-fluorouracil into umbilical vein.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Liver scanning for the detection of metastases following colo-rectal cancer surgery.
Topics: Adenocarcinoma; Adult; Celiac Artery; Colonic Neoplasms; Female; Fluorouracil; Gold Isotopes; Hepate | 1973 |
Adjuvant chemotherapy in resectable cancer of the colon and rectum.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Postoperative Complications; Rectal Neoplasms; Thiotepa | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Results of 27 cases with hepatic metastases treated by combination chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; | 1972 |
[The reactivity of the RES in cancer of the gastrointestinal tract and during treatment with fluorofur].
Topics: Achlorhydria; Adult; Aged; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Furans; Go | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
Cytotoxic perfusion of the liver via the umbilical vein for liver metastases in carcinoma of the colon.
Topics: Aged; Blood Sedimentation; Cholestasis; Colonic Neoplasms; Diarrhea; Fluorouracil; Humans; Leukocyte | 1973 |
FIVB--a new combination of drugs in the treatment of cancer.
Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi | 1973 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
Advanced cancer: New concepts of medical therapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Choriocarcinoma; Colonic Neopl | 1973 |
Serial liver scanning. Metastatic disease.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injectio | 1974 |
[Attempts at in vivo synchronization of the synthesis of DNA in human malignant cell by 5-fluorouracil. Autohistoradiographic study].
Topics: Autoradiography; Colonic Neoplasms; DNA, Neoplasm; Fluorouracil; Humans; Stomach Neoplasms | 1966 |
[Are combinations more effective than monotherapy in the matter of antiocancer chemotherapy?].
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Synergism; Female; Fluorouracil; Fl | 1968 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
Sequential liver scanning.
Topics: Adult; Breast Neoplasms; Chloroquine; Colonic Neoplasms; Dactinomycin; Emetine; Estrogens; Female; F | 1969 |
Chemotherapy of colorectal cancer.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Results of treatment of malignant tumors with ftorafur.
Topics: Antimetabolites; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Deoxyr | 1972 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |
[Local intra-arterial infusion chemotherapy of malignant tumor--successful treatment by intra-arterial infusion of 5-fluorouracil and mitomycin C in cases of unresectable cancer of the liver, stomach, colon and rectum].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infant; Injections, Intra-Arterial; Li | 1971 |
Circulating cancer cells: pre- and post-chemotherapy observations.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Female; Filtration; Fluorouracil; Humans; Male; | 1971 |
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth.
Topics: Administration, Oral; Aged; Bone Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver C | 1971 |
Chemotherapy for metastatic colorectal liver carcinoma by intra-aortic infusion.
Topics: Antineoplastic Agents; Aorta, Abdominal; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Cytotoxic penetration and concentration in human malignant tumours.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections | 1969 |
New approaches in administration of anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Female; Fluorouracil; Humans | 1969 |
Comparative study of monthly courses versus weekly doses of 5-fluorouracil (NSC-19893).
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplas | 1969 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |
Survival of patients treated with systemic fluorouracil for hepatic metastases.
Topics: Adult; Age Factors; Aged; Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1970 |
The influence of treatment on the survival of patients with hepatic metastases diagnosed by liver scanning.
Topics: Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Hepatectomy; Humans; | 1970 |
One-shot infusion of non-surgically administered mitomycin C in the celiac artery for liver metastases. Clinical effects.
Topics: Adult; Aged; Angiography; Blood Cell Count; Blood Platelets; Celiac Artery; Colonic Neoplasms; Femal | 1970 |
Immunosuppression by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antigens; Blood Bactericidal Activity; Blood Platel | 1970 |
Hepatic coma secondary to metastatic liver disease.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Breast Neoplasms; Colonic Neoplasms; Fluorouracil | 1971 |
[Chemotherapy of solid tumors in the intestins].
Topics: Colonic Neoplasms; Cytarabine; Drug Synergism; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1971 |
Differential effects of anti-tumour drugs on human tumour and spleen DNA synthesis in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Culture Techniques; Disease Model | 1971 |
[The possibilities of drug therapy in metastazing carcinoma of the large intestine].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Rectal Neoplasms | 1967 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
[Surgical use of 5-FU--with special reference to changes in tumor tissues].
Topics: Adult; Aged; Colon; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Male; | 1967 |
Clinical evaluation of combined radiation and chemotherapy in gastrointestinal malignancies.
Topics: Bone Marrow; Bone Marrow Cells; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1968 |
Carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic | 1968 |
The role of chemotherapy in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
Prolonged continuous hepatic infusion. Results with fluorouracil for primary and metastatic cancer in the liver.
Topics: Adult; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorou | 1969 |
Response of recurrent carcinoma of the colon to combined deep x-ray therapy and chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans | 1969 |
Intraluminal chemotherapy adjuvant (HN2 or 5-FU) to operation for cancer of the colon and rectum. Follow-up report of 83 cases.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Mechlorethamine; Middle | 1965 |
Gardners syndrome.
Topics: Adult; Colonic Diseases; Colonic Neoplasms; Female; Fluorouracil; Humans; Polyps | 1965 |
Chemotherapy for liver cancer by protracted ambulatory infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans | 1965 |
Adjuvant intraluminal chemotherapy with 5-fluorouracil in simulated colon cancer in the rat.
Topics: Animals; Carcinoma 256, Walker; Colonic Neoplasms; Fluorouracil; Rats | 1966 |